Glioma	O
tumor	O
stem	O
-	O
like	O
cells	O
promote	O
tumor	O
angiogenesis	O
and	O
vasculogenesis	O
via	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
stromal	O
-	O
derived	O
factor	O
1	O
.	O

Cancer	O
stem	O
cells	O
(	O
CSC	O
)	O
are	O
predicted	O
to	O
be	O
critical	O
drivers	O
of	O
tumor	O
progression	O
due	O
to	O
their	O
self	O
-	O
renewal	O
capacity	O
and	O
limitless	O
proliferative	O
potential	O
.	O

An	O
emerging	O
area	O
of	O
research	O
suggests	O
that	O
CSC	O
may	O
also	O
support	O
tumor	O
progression	O
by	O
promoting	O
tumor	O
angiogenesis	O
.	O

To	O
investigate	O
how	O
CSC	O
contribute	O
to	O
tumor	O
vascular	O
development	O
,	O
we	O
used	O
an	O
approach	O
comparing	O
tumor	O
xenografts	O
of	O
the	O
C6	B
glioma	O
cell	O
line	O
containing	O
either	O
a	O
low	O
or	O
a	O
high	O
fraction	O
of	O
CSC	O
.	O

Compared	O
with	O
CSC	O
-	O
low	O
tumors	O
,	O
CSC	O
-	O
high	O
tumors	O
exhibited	O
increased	O
microvessel	O
density	O
and	O
blood	O
perfusion	O
and	O
induced	O
increased	O
mobilization	O
and	O
tumor	O
recruitment	O
of	O
bone	O
marrow	O
-	O
derived	O
endothelial	O
progenitor	O
cells	O
(	O
EPC	O
)	O
.	O

CSC	O
-	O
high	O
C6	B
cell	O
cultures	O
also	O
induced	O
higher	O
levels	O
of	O
endothelial	O
cell	O
proliferation	O
and	O
tubule	O
organization	O
in	O
vitro	O
compared	O
with	O
CSC	O
-	O
low	O
cultures	O
.	O

CSC	O
-	O
high	O
cultures	O
and	O
tumors	O
expressed	O
increased	O
levels	O
of	O
the	O
proangiogenic	O
factors	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
stromal	O
-	O
derived	O
factor	O
1	O
,	O
and	O
when	O
signaling	O
by	O
either	O
factor	O
was	O
blocked	O
,	O
all	O
aspects	O
of	O
angiogenesis	O
observed	O
in	O
CSC	O
-	O
high	O
cultures	O
and	O
tumors	O
,	O
including	O
microvessel	O
density	O
,	O
perfusion	O
,	O
EPC	O
mobilization	O
/	O
recruitment	O
,	O
and	O
stimulation	O
of	O
endothelial	O
cell	O
activity	O
,	O
were	O
reduced	O
to	O
levels	O
comparable	O
with	O
those	O
observed	O
in	O
CSC	O
-	O
low	O
cultures	O
/	O
tumors	O
.	O

These	O
results	O
suggest	O
that	O
CSC	O
contribute	O
to	O
tumor	O
angiogenesis	O
by	O
promoting	O
both	O
local	O
endothelial	O
cell	O
activity	O
and	O
systemic	O
angiogenic	O
processes	O
involving	O
bone	O
marrow	O
-	O
derived	O
EPC	O
in	O
a	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
dependent	O
and	O
stromal	O
-	O
derived	O
factor	O
1	O
-	O
dependent	O
manner	O
.	O

Islet	O
endothelial	O
activation	O
and	O
oxidative	O
stress	O
gene	O
expression	O
is	O
reduced	O
by	O
IL	O
-	O
1Ra	O
treatment	O
in	O
the	O
type	O
2	O
diabetic	O
GK	O
rat	O
.	O

BACKGROUND	O
:	O
Inflammation	O
followed	O
by	O
fibrosis	O
is	O
a	O
component	O
of	O
islet	O
dysfunction	O
in	O
both	O
rodent	O
and	O
human	O
type	O
2	O
diabetes	O
.	O

Because	O
islet	O
inflammation	O
may	O
originate	O
from	O
endothelial	O
cells	O
,	O
we	O
assessed	O
the	O
expression	O
of	O
selected	O
genes	O
involved	O
in	O
endothelial	O
cell	O
activation	O
in	O
islets	O
from	O
a	O
spontaneous	O
model	O
of	O
type	O
2	O
diabetes	O
,	O
the	O
Goto	O
-	O
Kakizaki	O
(	O
GK	O
)	O
rat	O
.	O

We	O
also	O
examined	O
islet	O
endotheliuml	O
/	O
oxidative	O
stress	O
(	O
OS	O
)	O
/	O
inflammation	O
-	O
related	O
gene	O
expression	O
,	O
islet	O
vascularization	O
and	O
fibrosis	O
after	O
treatment	O
with	O
the	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
receptor	O
antagonist	O
(	O
IL	O
-	O
1Ra	O
)	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Gene	O
expression	O
was	O
analyzed	O
by	O
quantitative	O
RT	O
-	O
PCR	O
on	O
islets	O
isolated	O
from	O
10	O
-	O
week	O
-	O
old	O
diabetic	O
GK	O
and	O
control	O
Wistar	O
rats	O
.	O

Furthermore	O
,	O
GK	O
rats	O
were	O
treated	O
s	O
.	O
c	O
twice	O
daily	O
with	O
IL	O
-	O
1Ra	O
(	O
Kineret	O
,	O
Amgen	O
,	O
100	O
mg	O
/	O
kg	O
/	O
day	O
)	O
or	O
saline	O
,	O
from	O
4	O
weeks	O
of	O
age	O
onwards	O
(	O
onset	O
of	O
diabetes	O
)	O
.	O

Four	O
weeks	O
later	O
,	O
islet	O
gene	O
analysis	O
and	O
pancreas	O
immunochemistry	O
were	O
performed	O
.	O

Thirty	O
-	O
two	O
genes	O
were	O
selected	O
encoding	O
molecules	O
involved	O
in	O
endothelial	O
cell	O
activation	O
,	O
particularly	O
fibrinolysis	O
,	O
vascular	O
tone	O
,	O
OS	O
,	O
angiogenesis	O
and	O
also	O
inflammation	O
.	O

All	O
genes	O
except	O
those	O
encoding	O
angiotensinogen	O
and	O
epoxide	O
hydrolase	O
(	O
that	O
were	O
decreased	O
)	O
,	O
and	O
12	O
-	O
lipoxygenase	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
that	O
showed	O
no	O
change	O
)	O
,	O
were	O
significantly	O
up	O
-	O
regulated	O
in	O
GK	O
islets	O
.	O

After	O
IL	O
-	O
1Ra	O
treatment	O
of	O
GK	O
rats	O
in	O
vivo	O
,	O
most	O
selected	O
genes	O
implied	O
in	O
endothelium	O
/	O
OS	O
/	O
immune	O
cells	O
/	O
fibrosis	O
were	O
significantly	O
down	O
-	O
regulated	O
.	O

IL	O
-	O
1Ra	O
also	O
improved	O
islet	O
vascularization	O
,	O
reduced	O
fibrosis	O
and	O
ameliorated	O
glycemia	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
GK	O
rat	O
islets	O
have	O
increased	O
mRNA	O
expression	O
of	O
markers	O
of	O
early	O
islet	O
endothelial	O
cell	O
activation	O
,	O
possibly	O
triggered	O
by	O
several	O
metabolic	O
factors	O
,	O
and	O
also	O
some	O
defense	O
mechanisms	O
.	O

The	O
beneficial	O
effect	O
of	O
IL	O
-	O
1Ra	O
on	O
most	O
islet	O
endothelial	O
/	O
OS	O
/	O
immune	O
cells	O
/	O
fibrosis	O
parameters	O
analyzed	O
highlights	O
a	O
major	O
endothelial	O
-	O
related	O
role	O
for	O
IL	O
-	O
1	O
in	O
GK	O
islet	O
alterations	O
.	O

Thus	O
,	O
metabolically	O
-	O
altered	O
islet	O
endothelium	O
might	O
affect	O
the	O
beta	O
-	O
cell	O
microenvironment	O
and	O
contribute	O
to	O
progressive	O
type	O
2	O
diabetic	O
beta	O
-	O
cell	O
dysfunction	O
in	O
GK	O
rats	O
.	O

Counteracting	O
islet	O
endothelial	O
cell	O
inflammation	O
might	O
be	O
one	O
way	O
to	O
ameliorate	O
/	O
prevent	O
beta	O
-	O
cell	O
dysfunction	O
in	O
type	O
2	O
diabetes	O
.	O

Cognitive	O
function	O
and	O
number	O
of	O
teeth	O
in	O
a	O
community	O
-	O
dwelling	O
elderly	O
population	O
without	O
dementia	O
.	O

Although	O
the	O
number	O
of	O
sound	O
or	O
decayed	O
teeth	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
cognitive	O
function	O
in	O
elderly	O
populations	O
with	O
dementia	O
,	O
little	O
is	O
known	O
about	O
this	O
association	O
in	O
elderly	O
populations	O
without	O
dementia	O
.	O

We	O
evaluated	O
this	O
relationship	O
,	O
with	O
adjustment	O
for	O
confounding	O
factors	O
,	O
in	O
Japanese	O
populations	O
of	O
60	O
-	O
year	O
-	O
old	O
(	O
n	O
=	O
270	O
;	O
120	O
males	O
and	O
150	O
females	O
)	O
and	O
65	O
-	O
year	O
-	O
old	O
(	O
n	O
=	O
123	O
;	O
57	O
males	O
and	O
66	O
females	O
)	O
individuals	O
residing	O
in	O
Fukuoka	O
Prefecture	O
of	O
Japan	O
.	O

Dental	O
examinations	O
were	O
performed	O
in	O
all	O
subjects	O
,	O
along	O
with	O
the	O
Mini	O
-	O
mental	O
state	O
examination	O
(	O
MMSE	O
)	O
for	O
assessing	O
cognitive	O
function	O
.	O

Among	O
the	O
total	O
of	O
393	O
subjects	O
,	O
the	O
mean	O
MMSE	O
score	O
was	O
27	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
9	O
,	O
and	O
391	O
subjects	O
scored	O
24	O
or	O
higher	O
.	O

The	O
mean	O
numbers	O
of	O
sound	O
and	O
decayed	O
teeth	O
were	O
12	O
.	O
0	O
+	O
/	O
-	O
6	O
.	O
3	O
and	O
0	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
2	O
,	O
respectively	O
.	O

Associations	O
were	O
found	O
between	O
the	O
numbers	O
of	O
sound	O
and	O
decayed	O
teeth	O
and	O
MMSE	O
in	O
total	O
subjects	O
and	O
males	O
,	O
but	O
not	O
in	O
females	O
,	O
by	O
multiple	O
regression	O
analysis	O
adjusted	O
for	O
gender	O
,	O
age	O
,	O
level	O
of	O
education	O
,	O
marital	O
status	O
,	O
smoking	O
,	O
alcohol	O
drinking	O
,	O
working	O
status	O
,	O
systolic	O
blood	O
pressure	O
and	O
blood	O
glucose	O
.	O

An	O
association	O
was	O
also	O
found	O
between	O
MMSE	O
and	O
the	O
number	O
of	O
sound	O
teeth	O
in	O
a	O
logistic	O
regression	O
analysis	O
.	O

In	O
conclusion	O
,	O
associations	O
were	O
found	O
between	O
normal	O
-	O
range	O
cognitive	O
function	O
and	O
the	O
numbers	O
of	O
sound	O
and	O
decayed	O
teeth	O
,	O
after	O
adjustment	O
for	O
various	O
confounding	O
factors	O
,	O
in	O
an	O
elderly	O
Japanese	O
population	O
.	O

Magnesium	O
for	O
treatment	O
of	O
asthma	O
in	O
children	O
.	O

QUESTION	O
:	O
Magnesium	O
is	O
considered	O
adjuvant	O
therapy	O
for	O
moderate	O
to	O
severe	O
asthma	O
exacerbations	O
in	O
adults	O
,	O
but	O
can	O
it	O
be	O
used	O
to	O
treat	O
children	O
?	O

ANSWER	O
:	O
Magnesium	O
seems	O
to	O
be	O
beneficial	O
in	O
the	O
treatment	O
of	O
moderate	O
to	O
severe	O
asthma	O
in	O
children	O
.	O

It	O
is	O
a	O
safe	O
drug	O
to	O
administer	O
,	O
but	O
there	O
have	O
been	O
minor	O
side	O
effects	O
reported	O
,	O
such	O
as	O
epigastric	O
or	O
facial	O
warmth	O
,	O
flushing	O
,	O
pain	O
and	O
numbness	O
at	O
the	O
infusion	O
site	O
,	O
dry	O
mouth	O
,	O
malaise	O
,	O
and	O
hypotension	O
.	O

Owing	O
to	O
its	O
bronchodilating	O
and	O
anti	O
-	O
inflammatory	O
effects	O
,	O
magnesium	O
is	O
an	O
encouraging	O
adjuvant	O
therapy	O
for	O
pediatric	O
patients	O
who	O
do	O
not	O
respond	O
to	O
conventional	O
treatment	O
in	O
acute	O
severe	O
exacerbations	O
.	O

Future	O
studies	O
should	O
focus	O
on	O
establishing	O
the	O
optimal	O
dosage	O
for	O
maximal	O
benefits	O
and	O
the	O
best	O
route	O
of	O
administration	O
.	O

Magnesium	O
should	O
also	O
be	O
considered	O
as	O
a	O
prophylactic	O
treatment	O
.	O

AVE8062	O
:	O
a	O
new	O
combretastatin	O
derivative	O
vascular	O
disrupting	O
agent	O
.	O

Angiogenesis	O
has	O
an	O
essential	O
role	O
in	O
promoting	O
and	O
supporting	O
tumor	O
growth	O
and	O
it	O
is	O
an	O
important	O
therapeutic	O
target	O
.	O

The	O
tumor	O
vascular	O
network	O
is	O
the	O
result	O
of	O
pro	O
-	O
angiogenic	O
and	O
inhibitory	O
factors	O
as	O
well	O
as	O
of	O
the	O
interaction	O
between	O
endothelial	O
cells	O
and	O
extracellular	O
matrix	O
.	O

Different	O
antiangiogenic	O
therapeutics	O
have	O
been	O
developed	O
to	O
improve	O
tumor	O
control	O
through	O
vascular	O
-	O
targeting	O
agents	O
(	O
VTA	O
)	O
.	O

VTAs	O
can	O
be	O
divided	O
into	O
two	O
groups	O
:	O
antiangiogenic	O
agents	O
and	O
vascular	O
-	O
disrupting	O
agents	O
(	O
VDAs	O
)	O
.	O

VTAs	O
inhibit	O
specific	O
factors	O
required	O
to	O
induce	O
and	O
direct	O
the	O
angiogenic	O
process	O
,	O
with	O
major	O
activity	O
against	O
small	O
tumor	O
masses	O
and	O
at	O
the	O
tumor	O
periphery	O
,	O
encompassing	O
monoclonal	O
antibodies	O
and	O
small	O
molecules	O
inhibitors	O
of	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
VEGF	O
receptor	O
.	O

VDAs	O
specifically	O
target	O
and	O
destroy	O
well	O
-	O
established	O
tumor	O
vessels	O
with	O
ischemia	O
and	O
destruction	O
of	O
large	O
masses	O
with	O
central	O
hemorrhagic	O
necrosis	O
and	O
survival	O
of	O
a	O
thin	O
peripheral	O
tumor	O
layer	O
.	O

VDAs	O
can	O
be	O
divided	O
into	O
biologics	O
,	O
such	O
as	O
ligand	O
-	O
based	O
,	O
and	O
small	O
-	O
molecule	O
agents	O
;	O
this	O
second	O
group	O
includes	O
small	O
-	O
molecule	O
VDAs	O
like	O
flavonoids	O
,	O
such	O
as	O
5	O
,	O
6	O
-	O
dimethylxanthenone	O
-	O
4	O
-	O
acetic	O
acid	O
(	O
DMXAA	O
)	O
,	O
and	O
microtubule	O
-	O
destabilizing	O
agents	O
.	O

In	O
this	O
review	O
we	O
will	O
discuss	O
the	O
mechanism	O
of	O
action	O
,	O
as	O
well	O
as	O
the	O
preclinical	O
and	O
clinical	O
results	O
,	O
of	O
one	O
of	O
the	O
most	O
promising	O
antitubulin	O
agents	O
:	O
the	O
combretastatin	O
A4	O
-	O
phosphate	O
derivative	O
,	O
AVE8062A	O
.	O

Targeting	O
TNF	O
for	O
Treatment	O
of	O
Cancer	O
and	O
Autoimmunity	O
.	O

Tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
was	O
first	O
isolated	O
two	O
decades	O
ago	O
as	O
a	O
macrophageproduced	O
protein	O
that	O
can	O
effectively	O
kill	O
tumor	O
cells	O
.	O

TNF	O
-	O
alpha	O
is	O
also	O
an	O
essential	O
component	O
of	O
the	O
immune	O
system	O
and	O
is	O
required	O
for	O
hematopoiesis	O
,	O
for	O
protection	O
from	O
bacterial	O
infection	O
and	O
for	O
immune	O
cell	O
-	O
mediated	O
cytotoxicity	O
.	O

Extensive	O
research	O
,	O
however	O
,	O
has	O
revealed	O
that	O
TNF	O
-	O
alpha	O
is	O
one	O
of	O
the	O
major	O
players	O
in	O
tumor	O
initiation	O
,	O
proliferation	O
,	O
invasion	O
,	O
angiogenesis	O
and	O
metastasis	O
.	O

The	O
proinflammatory	O
activities	O
link	O
TNF	O
-	O
alpha	O
with	O
a	O
wide	O
variety	O
of	O
autoimmune	O
diseases	O
,	O
including	O
psoriasis	O
,	O
inflammatory	O
bowel	O
disease	O
,	O
rheumatoid	O
arthritis	O
,	O
systemic	O
sclerosis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
multiple	O
sclerosis	O
,	O
diabetes	O
and	O
ankylosing	O
spondylitis	O
.	O

Systemic	O
inhibitors	O
of	O
TNF	O
such	O
as	O
etanercept	O
(	O
Enbrel	O
)	O
(	O
a	O
soluble	O
TNF	O
receptor	O
)	O
and	O
infliximab	O
(	O
Remicade	O
)	O
and	O
adalimumab	O
(	O
Humira	O
)	O
(	O
anti	O
-	O
TNF	O
antibodies	O
)	O
have	O
been	O
approved	O
for	O
the	O
treatment	O
inflammatory	O
bowel	O
disease	O
,	O
psoriasis	O
and	O
rheumatoid	O
arthritis	O
.	O

These	O
drugs	O
,	O
however	O
,	O
exhibit	O
severe	O
side	O
effects	O
and	O
are	O
expensive	O
.	O

Hence	O
orally	O
active	O
blockers	O
of	O
TNF	O
-	O
alpha	O
that	O
are	O
safe	O
,	O
efficacious	O
and	O
inexpensive	O
are	O
urgently	O
needed	O
.	O

Numerous	O
products	O
from	O
fruits	O
,	O
vegetable	O
and	O
traditional	O
medicinal	O
plants	O
have	O
been	O
described	O
which	O
can	O
suppress	O
TNF	O
expression	O
and	O
TNF	O
signaling	O
but	O
their	O
clinical	O
potential	O
is	O
yet	O
uncertain	O
.	O

[	O
Prognostic	O
significance	O
of	O
cellular	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
in	O
the	O
course	O
of	O
chronic	O
myeloid	O
leukaemia	O
]	O

INTRODUCTION	O
:	O
Increased	O
angiogenesis	O
in	O
bone	O
marrow	O
is	O
one	O
of	O
the	O
characteristics	O
of	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
,	O
a	O
clonal	O
myeloproliferative	O
disorder	O
that	O
expresses	O
a	O
chimeric	O
bcr	O
/	O
abl	O
protein	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
one	O
of	O
the	O
most	O
potent	O
and	O
a	O
specific	O
regulator	O
of	O
angiogenesis	O
which	O
principally	O
targets	O
endothelial	O
cells	O
and	O
regulates	O
several	O
of	O
their	O
functions	O
,	O
including	O
mitogenesis	O
,	O
permeability	O
and	O
migration	O
.	O

The	O
impact	O
of	O
elevated	O
VEGF	O
expression	O
on	O
the	O
course	O
of	O
chronic	O
myeloid	O
leukaemia	O
is	O
unknown	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
the	O
follow	O
-	O
up	O
of	O
VEGF	O
expression	O
during	O
the	O
course	O
of	O
CML	O
.	O

METHODS	O
:	O
We	O
studied	O
VEGF	O
expression	O
of	O
85	O
CML	O
patients	O
(	O
median	O
age	O
50	O
years	O
,	O
range	O
16	O
-	O
75	O
years	O
)	O
.	O

At	O
the	O
commencement	O
of	O
the	O
study	O
,	O
29	O
patients	O
were	O
in	O
chronic	O
phase	O
(	O
CP	O
)	O
,	O
25	O
in	O
an	O
accelerated	O
phase	O
(	O
AP	O
)	O
,	O
and	O
31	O
in	O
the	O
blast	O
crisis	O
(	O
BC	O
)	O
.	O

The	O
temporal	O
expression	O
(	O
percentage	O
positivity	O
per	O
1000	O
analysed	O
cells	O
)	O
VEGF	O
proteins	O
over	O
the	O
course	O
of	O
CML	O
were	O
studied	O
using	O
the	O
immunohistochemical	O
technique	O
utilizing	O
relevant	O
monoclonal	O
antibodies	O
.	O

It	O
was	O
correlated	O
with	O
the	O
laboratory	O
(	O
Hb	O
,	O
WBC	O
and	O
platelet	O
counts	O
,	O
and	O
the	O
percentage	O
of	O
blasts	O
)	O
and	O
clinical	O
parameters	O
(	O
organomegaly	O
,	O
duration	O
of	O
CP	O
,	O
AP	O
,	O
and	O
BC	O
)	O
of	O
disease	O
progression	O
.	O

RESULTS	O
:	O
The	O
expression	O
ofVEGF	O
protein	O
was	O
most	O
pronounced	O
in	O
AP	O
(	O
ANOVA	O
,	O
p	O
=	O
0	O
.	O
033	O
)	O
.	O

The	O
level	O
of	O
VEGF	O
expression	O
correlated	O
inversely	O
with	O
the	O
degree	O
of	O
splenomegaly	O
(	O
Pearson	O
,	O
r	O
=	O
-	O
0	O
.	O
400	O
,	O
p	O
=	O
0	O
.	O
011	O
)	O
.	O

High	O
expression	O
of	O
VEGF	O
correlated	O
with	O
a	O
shorter	O
overall	O
survival	O
(	O
log	O
rank	O
,	O
p	O
=	O
0	O
.	O
042	O
)	O
.	O

CONCLUSION	O
:	O
Immunohistochemically	O
confirmed	O
significance	O
of	O
the	O
expression	O
of	O
VEGF	O
in	O
dependence	O
of	O
the	O
CML	O
stage	O
could	O
be	O
of	O
clinical	O
importance	O
in	O
deciding	O
on	O
the	O
timing	O
therapy	O
.	O

These	O
data	O
suggest	O
that	O
VEGF	O
plays	O
a	O
role	O
in	O
the	O
biology	O
of	O
CML	O
and	O
that	O
VEGF	O
inhibitors	O
should	O
be	O
investigated	O
in	O
CML	O
.	O

Pbx1	O
is	O
a	O
downstream	O
target	O
of	O
Evi	O
-	O
1	O
in	O
hematopoietic	O
stem	O
/	O
progenitors	O
and	O
leukemic	O
cells	O
.	O

Ecotropic	O
viral	O
integration	O
site	O
-	O
1	O
(	O
Evi	O
-	O
1	O
)	O
is	O
a	O
nuclear	O
transcription	O
factor	O
,	O
which	O
is	O
essential	O
for	O
the	O
proliferation	O
/	O
maintenance	O
of	O
hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
)	O
.	O

Aberrant	O
expression	O
of	O
Evi	O
-	O
1	O
has	O
been	O
frequently	O
found	O
in	O
myeloid	O
leukemia	O
,	O
and	O
is	O
associated	O
with	O
a	O
poor	O
patient	O
survival	O
.	O

Recently	O
,	O
we	O
reported	O
candidate	O
target	O
genes	O
of	O
Evi	O
-	O
1	O
shared	O
in	O
HSCs	O
and	O
leukemic	O
cells	O
using	O
gene	O
expression	O
profiling	O
analysis	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
Pbx1	O
,	O
a	O
proto	O
-	O
oncogene	O
in	O
hematopoietic	O
malignancy	O
,	O
as	O
a	O
target	O
gene	O
of	O
Evi	O
-	O
1	O
.	O

Overexpression	O
of	O
Evi	O
-	O
1	O
increased	O
Pbx1	O
expression	O
in	O
hematopoietic	O
stem	O
/	O
progenitor	O
cells	O
.	O

An	O
analysis	O
of	O
the	O
Pbx1	O
promoter	O
region	O
revealed	O
that	O
Evi	O
-	O
1	O
upregulates	O
Pbx1	O
transcription	O
.	O

Furthermore	O
,	O
reduction	O
of	O
Pbx1	O
levels	O
through	O
RNAi	O
-	O
mediated	O
knockdown	O
significantly	O
inhibited	O
Evi	O
-	O
1	O
-	O
induced	O
transformation	O
.	O

In	O
contrast	O
,	O
knockdown	O
of	O
Pbx1	O
did	O
not	O
impair	O
bone	O
marrow	O
transformation	O
by	O
E2A	O
/	O
HLF	O
or	O
AML1	O
/	O
ETO	O
,	O
suggesting	O
that	O
Pbx1	O
is	O
specifically	O
required	O
for	O
the	O
maintenance	O
of	O
bone	O
marrow	O
transformation	O
mediated	O
by	O
Evi	O
-	O
1	O
.	O

These	O
results	O
indicate	O
that	O
Pbx1	O
is	O
a	O
target	O
gene	O
of	O
Evi	O
-	O
1	O
involved	O
in	O
Evi	O
-	O
1	O
-	O
mediated	O
leukemogenesis	O
.	O

Inducible	O
nitric	O
oxide	O
synthase	O
modulates	O
angiogenesis	O
in	O
ischemic	O
hindlimb	O
of	O
rat	O
.	O

BACKGROUND	O
:	O
Angiogenesis	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
adequate	O
oxygen	O
delivery	O
,	O
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
is	O
a	O
potential	O
regulator	O
of	O
angiogenesis	O
.	O

NO	O
is	O
synthesized	O
through	O
three	O
isoforms	O
of	O
NO	O
synthase	O
(	O
NOS	O
)	O
.	O

It	O
is	O
hypothesized	O
that	O
the	O
NO	O
derived	O
from	O
inducible	O
NOS	O
(	O
iNOS	O
)	O
may	O
promote	O
survival	O
of	O
ischemic	O
tissue	O
through	O
angiogenesis	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
iNOS	O
deficiency	O
(	O
by	O
L	O
-	O
NIL	O
)	O
on	O
angiogenesis	O
in	O
a	O
hindlimb	O
ischemia	O
model	O
.	O

METHODS	O
:	O
Thirty	O
-	O
two	O
male	O
wistar	O
rats	O
randomly	O
divided	O
into	O
four	O
groups	O
.	O

In	O
groups	O
1	O
&	O
2	O
,	O
hindlimb	O
ischemia	O
was	O
induced	O
by	O
ligation	O
of	O
femoral	O
artery	O
and	O
they	O
received	O
L	O
-	O
NIL	O
and	O
saline	O
respectively	O
.	O

The	O
animals	O
in	O
groups	O
3	O
and	O
4	O
also	O
received	O
L	O
-	O
NIL	O
and	O
saline	O
respectively	O
without	O
surgical	O
procedure	O
.	O

After	O
21	O
days	O
,	O
the	O
serum	O
concentration	O
of	O
nitrite	O
,	O
capillary	O
density	O
and	O
expression	O
of	O
HIF1alpha	O
were	O
determined	O
.	O

RESULTS	O
:	O
Serum	O
nitrite	O
levels	O
were	O
significantly	O
lower	O
in	O
L	O
-	O
NIL	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
capillary	O
density	O
in	O
group	O
1	O
(	O
ischemia	O
+	O
L	O
-	O
NIL	O
)	O
was	O
significantly	O
different	O
from	O
group	O
2	O
(	O
ischemia	O
+	O
saline	O
)	O
;	O
group	O
1	O
:	O
360	O
.	O
33	O
+	O
/	O
-	O
77	O
.	O
02	O
,	O
group	O
2	O
:	O
549	O
+	O
/	O
-	O
81	O
.	O
85	O
/	O
mm2	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
In	O
addition	O
,	O
expression	O
of	O
HIF1alpha	O
was	O
significantly	O
increased	O
in	O
ischemic	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
Selective	O
inhibition	O
of	O
iNOS	O
by	O
L	O
-	O
NIL	O
inhibits	O
angiogenesis	O
in	O
a	O
hindlimb	O
ischemic	O
rat	O
model	O
.	O

In	O
addition	O
,	O
ischemia	O
induces	O
expression	O
of	O
HIF1alpha	O
in	O
hypoxic	O
tissue	O
.	O

Tumor	O
Angiogenesis	O
:	O
Initiation	O
and	O
Targeting	O
-	O
Therapeutic	O
Targeting	O
of	O
an	O
FGF	O
-	O
Binding	O
Protein	O
,	O
an	O
Angiogenic	O
Switch	O
Molecule	O
,	O
and	O
Indicator	O
of	O
Early	O
Stages	O
of	O
Gastrointestinal	O
Adenocarcinomas	O
-	O
.	O

Tumor	O
angiogenesis	O
has	O
been	O
related	O
to	O
the	O
initiation	O
as	O
well	O
as	O
progression	O
toward	O
more	O
aggressive	O
behavior	O
of	O
human	O
tumors	O
.	O

In	O
particular	O
,	O
the	O
activity	O
of	O
angiogenic	O
factors	O
is	O
crucial	O
for	O
tumor	O
progression	O
.	O

We	O
previously	O
characterized	O
a	O
secreted	O
fibroblast	O
growth	O
factor	O
-	O
binding	O
protein	O
(	O
FGF	O
-	O
BP	O
)	O
as	O
a	O
chaperone	O
molecule	O
,	O
which	O
binds	O
to	O
various	O
FGFs	O
,	O
enhances	O
FGF	O
-	O
mediated	O
biochemical	O
and	O
biologic	O
events	O
and	O
importantly	O
is	O
a	O
crucial	O
rate	O
-	O
limiting	O
factor	O
for	O
tumor	O
-	O
dependent	O
angiogenesis	O
.	O

We	O
generated	O
monoclonal	O
antibodies	O
that	O
target	O
FGF	O
-	O
BP	O
protein	O
and	O
used	O
them	O
as	O
a	O
tool	O
to	O
evaluate	O
frequency	O
and	O
pattern	O
of	O
FGF	O
-	O
BP	O
expression	O
during	O
the	O
malignant	O
progression	O
of	O
pancreas	O
and	O
colorectal	O
carcinoma	O
in	O
archival	O
tissue	O
samples	O
.	O

We	O
found	O
that	O
FGF	O
-	O
BP	O
is	O
dramatically	O
upregulated	O
during	O
the	O
initiation	O
of	O
colorectal	O
and	O
pancreatic	O
adenocarcinoma	O
.	O

Crucial	O
genetic	O
events	O
underlying	O
the	O
initiation	O
and	O
progression	O
of	O
colorectal	O
and	O
pancreatic	O
adenocarcinoma	O
with	O
a	O
particular	O
focus	O
on	O
the	O
modulation	O
of	O
angiogenesis	O
and	O
antiangiogenic	O
therapies	O
are	O
discussed	O
.	O

We	O
propose	O
that	O
the	O
upregulation	O
of	O
the	O
secreted	O
FGF	O
-	O
BP	O
protein	O
during	O
early	O
phases	O
of	O
pancreas	O
and	O
colon	O
cancer	O
could	O
make	O
this	O
protein	O
a	O
possible	O
serum	O
marker	O
indicating	O
the	O
presence	O
of	O
high	O
-	O
risk	O
premalignant	O
lesions	O
.	O

Furthermore	O
,	O
the	O
biological	O
activity	O
of	O
FGF	O
-	O
BP	O
is	O
neutralized	O
by	O
monoclonal	O
antibodies	O
suggesting	O
the	O
potential	O
for	O
antibody	O
-	O
based	O
therapeutic	O
targeting	O
.	O

Range	O
of	O
motion	O
limitation	O
after	O
rotator	O
cuff	O
repair	O
.	O

HYPOTHESIS	O
:	O

This	O
study	O
was	O
conducted	O
to	O
identify	O
preoperative	O
factors	O
correlating	O
with	O
limited	O
motion	O
after	O
rotator	O
cuff	O
repair	O
(	O
RCR	O
)	O
and	O
to	O
evaluate	O
the	O
affect	O
of	O
loss	O
of	O
motion	O
on	O
outcome	O
.	O

We	O
hypothesized	O
that	O
patients	O
with	O
preoperative	O
ROM	O
loss	O
,	O
diabetes	O
,	O
and	O
workman	O
'	O
s	O
compensation	O
claims	O
would	O
exhibit	O
postoperative	O
ROM	O
loss	O
at	O
3	O
months	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O

Preoperative	O
and	O
postoperative	O
evaluations	O
,	O
including	O
outcomes	O
assessment	O
and	O
physical	O
examination	O
parameters	O
,	O
were	O
reviewed	O
for	O
345	O
patients	O
who	O
underwent	O
RCR	O
.	O

Correlations	O
between	O
demographic	O
,	O
physical	O
examination	O
,	O
and	O
surgical	O
variables	O
and	O
postoperative	O
limitation	O
of	O
motion	O
and	O
need	O
for	O
capsular	O
release	O
were	O
determined	O
.	O

RESULTS	O
:	O

At	O
3	O
-	O
month	O
follow	O
-	O
up	O
,	O
mean	O
active	O
forward	O
elevation	O
(	O
AFE	O
)	O
,	O
active	O
external	O
rotation	O
(	O
AER	O
)	O
,	O
and	O
passive	O
internal	O
rotation	O
(	O
PIR	O
)	O
were	O
90	O
%	O
,	O
78	O
%	O
,	O
and	O
80	O
%	O
of	O
the	O
contralateral	O
side	O
.	O

Limitation	O
of	O
preoperative	O
motion	O
correlated	O
with	O
limitation	O
of	O
postoperative	O
AFE	O
,	O
AER	O
,	O
and	O
PIR	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

Forty	O
-	O
seven	O
patients	O
considered	O
clinically	O
stiff	O
were	O
followed	O
at	O
1	O
year	O
postoperatively	O
.	O

Three	O
patients	O
required	O
arthroscopic	O
capsular	O
release	O
for	O
persistent	O
range	O
of	O
motion	O
loss	O
.	O

CONCLUSION	O
:	O

Early	O
postoperative	O
limitation	O
of	O
motion	O
after	O
RCR	O
is	O
associated	O
with	O
restricted	O
preoperative	O
motion	O
.	O

Other	O
factors	O
,	O
including	O
diabetes	O
mellitus	O
and	O
worker	O
'	O
s	O
compensation	O
claim	O
,	O
are	O
also	O
associated	O
with	O
range	O
of	O
motion	O
loss	O
.	O

Most	O
shoulders	O
with	O
early	O
motion	O
loss	O
recover	O
motion	O
and	O
rarely	O
require	O
capsular	O
release	O
.	O

[	O
Effect	O
of	O
osteopontin	O
silencing	O
by	O
lentivirus	O
-	O
mediated	O
delivery	O
of	O
siRNA	O
on	O
glioma	O
cell	O
invasion	O
and	O
apoptosis	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
osteopontin	O
silencing	O
on	O
the	O
invasion	O
and	O
apoptosis	O
of	O
U251	B
cells	O
.	O

METHODS	O
:	O
The	O
invasion	O
,	O
apoptosis	O
and	O
levels	O
of	O
uPA	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
were	O
determined	O
by	O
invasion	O
assay	O
,	O
flow	O
cytometry	O
,	O
Western	O
blot	O
and	O
real	O
-	O
time	O
fluorescence	O
quantitative	O
PCR	O
respectively	O
.	O

RESULTS	O
:	O
Osteopontin	O
small	O
interference	O
RNA	O
(	O
siRNA	O
)	O
inhibited	O
osteopontin	O
expression	O
and	O
cell	O
invasion	O
,	O
promoted	O
apoptosis	O
in	O
U251	B
cells	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
Bcl	O
-	O
2	O
,	O
uPA	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
was	O
decreased	O
,	O
while	O
Bax	O
level	O
was	O
elevated	O
.	O

CONCLUSION	O
:	O
Osteopontin	O
siRNA	O
can	O
inhibit	O
U251	B
cells	O
invasion	O
via	O
the	O
down	O
-	O
regulation	O
of	O
uPA	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
levels	O
,	O
and	O
promote	O
apoptosis	O
through	O
induction	O
of	O
Bax	O
expression	O
and	O
inhibition	O
of	O
Bcl	O
2	O
level	O
.	O

It	O
suggests	O
that	O
osteopontin	O
plays	O
an	O
important	O
role	O
in	O
human	O
glioma	O
progression	O
.	O

The	O
role	O
of	O
hypoxia	O
in	O
2	O
-	O
butoxyethanol	O
-	O
induced	O
hemangiosarcoma	O
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
compound	O
-	O
induced	O
hemangiosarcomas	O
in	O
mice	O
,	O
and	O
therefore	O
,	O
their	O
human	O
relevance	O
,	O
a	O
systems	O
biology	O
approach	O
was	O
undertaken	O
using	O
transcriptomics	O
and	O
Causal	O
Network	O
Modeling	O
from	O
mice	O
treated	O
with	O
2	O
-	O
butoxyethanol	O
(	O
2	O
-	O
BE	O
)	O
.	O

2	O
-	O
BE	O
is	O
a	O
hemolytic	O
agent	O
that	O
induces	O
hemangiosarcomas	O
in	O
mice	O
.	O

We	O
hypothesized	O
that	O
the	O
hemolysis	O
induced	O
by	O
2	O
-	O
BE	O
would	O
result	O
in	O
local	O
tissue	O
hypoxia	O
,	O
a	O
well	O
-	O
documented	O
trigger	O
for	O
endothelial	O
cell	O
proliferation	O
leading	O
to	O
hemangiosarcoma	O
.	O

Gene	O
expression	O
data	O
from	O
bone	O
marrow	O
(	O
BM	O
)	O
,	O
liver	O
,	O
and	O
spleen	O
of	O
mice	O
exposed	O
to	O
a	O
single	O
dose	O
(	O
4	O
h	O
)	O
or	O
seven	O
daily	O
doses	O
of	O
2	O
-	O
BE	O
were	O
used	O
to	O
develop	O
a	O
mechanistic	O
model	O
of	O
hemangiosarcoma	O
.	O

The	O
resulting	O
mechanistic	O
model	O
confirms	O
previous	O
work	O
proposing	O
that	O
2	O
-	O
BE	O
induces	O
macrophage	O
activation	O
and	O
inflammation	O
in	O
the	O
liver	O
.	O

In	O
addition	O
,	O
the	O
model	O
supports	O
local	O
tissue	O
hypoxia	O
in	O
the	O
liver	O
and	O
spleen	O
,	O
coupled	O
with	O
increased	O
erythropoeitin	O
signaling	O
and	O
erythropoiesis	O
in	O
the	O
spleen	O
and	O
BM	O
,	O
and	O
suppression	O
of	O
mechanisms	O
that	O
contribute	O
to	O
genomic	O
stability	O
,	O
events	O
that	O
could	O
be	O
contributing	O
factors	O
to	O
hemangiosarcoma	O
formation	O
.	O

Finally	O
,	O
an	O
immunohistochemistry	O
method	O
(	O
Hypoxyprobe	O
)	O
demonstrated	O
that	O
tissue	O
hypoxia	O
was	O
present	O
in	O
the	O
spleen	O
and	O
BM	O
.	O

Together	O
,	O
the	O
results	O
of	O
this	O
study	O
identify	O
molecular	O
mechanisms	O
that	O
initiate	O
hemangiosarcoma	O
,	O
a	O
key	O
step	O
in	O
understanding	O
safety	O
concerns	O
that	O
can	O
impact	O
drug	O
decision	O
processes	O
,	O
and	O
identified	O
hypoxia	O
as	O
a	O
possible	O
contributing	O
factor	O
for	O
2	O
-	O
BE	O
-	O
induced	O
hemangiosarcoma	O
in	O
mice	O
.	O

Magnitude	O
of	O
malate	O
-	O
aspartate	O
reduced	O
nicotinamide	O
adenine	O
dinucleotide	O
shuttle	O
activity	O
in	O
intact	O
respiring	O
tumor	O
cells	O
.	O

Measurements	O
of	O
respiration	O
,	O
CO2	O
and	O
lactate	O
production	O
,	O
and	O
changes	O
in	O
the	O
levels	O
of	O
various	O
key	O
metabolites	O
of	O
the	O
glycolytic	O
sequence	O
and	O
tricarboxylic	O
acid	O
cycle	O
were	O
made	O
on	O
five	O
lines	O
of	O
rodent	O
ascites	O
tumor	O
cells	O
(	O
two	O
strains	O
of	O
Ehrlich	O
ascites	O
tumor	O
cells	O
,	O
Krebs	B
II	I
carcinoma	O
,	O
AS	B
-	I
30D	I
carcinoma	O
,	O
and	O
L1210	B
cells	O
)	O
incubated	O
aerobically	O
in	O
the	O
presence	O
of	O
uniformly	O
labeled	O
D	O
-	O
[	O
14C	O
]	O
glucose	O
.	O

From	O
these	O
data	O
,	O
as	O
well	O
as	O
earlier	O
evidence	O
demonstrating	O
that	O
the	O
reduced	O
nicotinamide	O
adenine	O
dinucleotide	O
(	O
NADH	O
)	O
shuttle	O
in	O
these	O
cells	O
requires	O
a	O
transaminase	O
step	O
and	O
is	O
thus	O
identified	O
as	O
the	O
malate	O
-	O
aspartate	O
shuttle	O
(	O
W	O
.	O
V	O
.	O
V	O
.	O
Greenhouse	O
and	O
A	O
.	O
L	O
.	O
Lehninger	O
,	O
Cancer	O
Res	O
.	O
,	O
36	O
:	O
1392	O
-	O
1396	O
,	O
1976	O
)	O
,	O
metabolic	O
flux	O
diagrams	O
were	O
constructed	O
for	O
the	O
five	O
cell	O
lines	O
.	O

These	O
diagrams	O
show	O
the	O
relative	O
rates	O
of	O
glycolysis	O
,	O
the	O
tricarboxylic	O
acid	O
cycle	O
,	O
electron	O
transport	O
,	O
and	O
the	O
malate	O
-	O
aspartate	O
shuttle	O
in	O
these	O
tumors	O
.	O

Large	O
amounts	O
of	O
cytosolic	O
NADH	O
were	O
oxidized	O
by	O
the	O
mitochondrial	O
respiratory	O
chain	O
via	O
the	O
NADH	O
shuttle	O
,	O
comprising	O
anywhere	O
from	O
about	O
20	O
to	O
80	O
%	O
of	O
the	O
total	O
flow	O
of	O
reducing	O
equivalents	O
to	O
oxygen	O
in	O
these	O
tumors	O
.	O

Calculations	O
of	O
the	O
sources	O
of	O
energy	O
for	O
adenosine	O
triphosphate	O
synthesis	O
indicated	O
that	O
on	O
the	O
average	O
about	O
one	O
-	O
third	O
of	O
the	O
respiratory	O
adenosine	O
triphosphate	O
is	O
generated	O
by	O
electron	O
flow	O
originating	O
from	O
cytosolic	O
NADH	O
via	O
the	O
malate	O
-	O
aspartate	O
shuttle	O
.	O

AKT2	O
is	O
a	O
downstream	O
target	O
of	O
metabotropic	O
glutamate	O
receptor	O
1	O
(	O
Grm1	O
)	O
.	O

We	O
reported	O
earlier	O
on	O
the	O
oncogenic	O
properties	O
of	O
Grm1	O
by	O
demonstrating	O
that	O
stable	O
Grm1	O
-	O
mouse	O
-	O
melanocytic	O
clones	O
proliferate	O
in	O
the	O
absence	O
of	O
growth	O
supplement	O
and	O
anchorage	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
these	O
clones	O
also	O
exhibit	O
aggressive	O
tumorigenic	O
phenotypes	O
in	O
vivo	O
with	O
short	O
latency	O
in	O
tumor	O
formation	O
in	O
both	O
immunodeficient	O
and	O
syngeneic	O
mice	O
.	O

We	O
also	O
detected	O
strong	O
activation	O
of	O
AKT	O
in	O
allograft	O
tumors	O
specifically	O
AKT2	O
as	O
the	O
predominant	O
isoform	O
involved	O
.	O

In	O
parallel	O
,	O
we	O
assessed	O
several	O
human	O
melanoma	O
biopsy	O
samples	O
and	O
found	O
again	O
that	O
AKT2	O
was	O
the	O
predominantly	O
activated	O
AKT	O
in	O
these	O
human	O
melanoma	O
biopsies	O
.	O

In	O
cultured	O
stable	O
Grm1	O
-	O
mouse	O
-	O
melanocytic	O
clones	O
,	O
as	O
well	O
as	O
an	O
metabotropic	O
glutamate	O
receptor	O
1	O
(	O
Grm1	O
)	O
expressing	O
human	O
melanoma	O
cell	O
line	O
,	O
C8161	B
,	O
stimulation	O
of	O
Grm1	O
by	O
its	O
agonist	O
led	O
to	O
the	O
activation	O
of	O
AKT	O
,	O
while	O
preincubation	O
with	O
Grm1	O
-	O
antagonist	O
abolished	O
Grm1	O
-	O
agonist	O
-	O
induced	O
AKT	O
activation	O
.	O

In	O
addition	O
,	O
a	O
reduction	O
in	O
tumor	O
volume	O
of	O
Grm1	O
-	O
mouse	O
-	O
melanocytic	O
-	O
allografts	O
was	O
detected	O
in	O
the	O
presence	O
of	O
small	O
interfering	O
AKT2	O
RNA	O
(	O
siAKT2	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
showed	O
that	O
,	O
in	O
addition	O
to	O
the	O
MAPK	O
pathway	O
previously	O
reported	O
being	O
a	O
downstream	O
target	O
of	O
stimulated	O
Grm1	O
,	O
AKT2	O
is	O
another	O
downstream	O
target	O
in	O
Grm1	O
mediated	O
melanocyte	O
transformation	O
.	O

Pancreatic	O
endocrine	O
tumors	O
:	O
expression	O
profiling	O
evidences	O
a	O
role	O
for	O
AKT	O
-	O
mTOR	O
pathway	O
.	O

PURPOSE	O
:	O
We	O
investigated	O
the	O
global	O
gene	O
expression	O
in	O
a	O
large	O
panel	O
of	O
pancreatic	O
endocrine	O
tumors	O
(	O
PETs	O
)	O
aimed	O
at	O
identifying	O
new	O
potential	O
targets	O
for	O
therapy	O
and	O
biomarkers	O
to	O
predict	O
patient	O
outcome	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Using	O
a	O
custom	O
microarray	O
,	O
we	O
analyzed	O
72	O
primary	O
PETs	O
,	O
seven	O
matched	O
metastases	O
,	O
and	O
10	O
normal	O
pancreatic	O
samples	O
.	O

Relevant	O
differentially	O
expressed	O
genes	O
were	O
validated	O
by	O
either	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
or	O
immunohistochemistry	O
on	O
tissue	O
microarrays	O
.	O

RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
:	O
tuberous	O
sclerosis	O
2	O
(	O
TSC2	O
)	O
and	O
phosphatase	O
and	O
tensin	O
homolog	O
(	O
PTEN	O
)	O
were	O
downregulated	O
in	O
most	O
of	O
the	O
primary	O
tumors	O
,	O
and	O
their	O
low	O
expression	O
was	O
significantly	O
associated	O
with	O
shorter	O
disease	O
-	O
free	O
and	O
overall	O
survival	O
;	O
somatostatin	O
receptor	O
2	O
(	O
SSTR2	O
)	O
was	O
absent	O
or	O
very	O
low	O
in	O
insulinomas	O
compared	O
with	O
nonfunctioning	O
tumors	O
;	O
and	O
expression	O
of	O
fibroblast	O
growth	O
factor	O
13	O
(	O
FGF13	O
)	O
gene	O
was	O
significantly	O
associated	O
with	O
the	O
occurrence	O
of	O
liver	O
metastasis	O
and	O
shorter	O
disease	O
-	O
free	O
survival	O
.	O

TSC2	O
and	O
PTEN	O
are	O
two	O
key	O
inhibitors	O
of	O
the	O
Akt	O
/	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
pathway	O
and	O
the	O
specific	O
inhibition	O
of	O
mTOR	O
with	O
rapamycin	O
or	O
RAD001	O
inhibited	O
cell	O
proliferation	O
of	O
PET	O
cell	O
lines	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
strongly	O
support	O
a	O
role	O
for	O
PI3	O
K	O
/	O
Akt	O
/	O
mTOR	O
pathway	O
in	O
PET	O
,	O
which	O
ties	O
in	O
with	O
the	O
fact	O
that	O
mTOR	O
inhibitors	O
have	O
reached	O
phase	O
III	O
trials	O
in	O
neuroendocrine	O
tumors	O
.	O

The	O
finding	O
of	O
differential	O
SSTR	O
expression	O
raises	O
the	O
potential	O
for	O
SSTR	O
expression	O
to	O
be	O
evaluated	O
as	O
a	O
marker	O
of	O
response	O
to	O
somatostatin	O
analogs	O
.	O

Finally	O
,	O
we	O
identified	O
FGF13	O
as	O
a	O
new	O
prognostic	O
marker	O
that	O
predicted	O
poorer	O
outcome	O
in	O
patients	O
who	O
were	O
clinically	O
considered	O
free	O
from	O
disease	O
.	O

Neural	O
network	O
analysis	O
of	O
spectroscopic	O
data	O
of	O
lycopene	O
and	O
beta	O
-	O
carotene	O
content	O
in	O
food	O
samples	O
compared	O
to	O
HPLC	O
-	O
UV	O
-	O
vis	O
.	O

In	O
this	O
study	O
a	O
neural	O
network	O
(	O
NN	O
)	O
model	O
was	O
designed	O
to	O
predict	O
lycopene	O
and	O
beta	O
-	O
carotene	O
concentrations	O
in	O
food	O
samples	O
,	O
combined	O
with	O
a	O
simple	O
and	O
fast	O
technique	O
,	O
such	O
as	O
UV	O
-	O
vis	O
spectroscopy	O
.	O

The	O
measurement	O
of	O
the	O
absorbance	O
at	O
446	O
and	O
502	O
nm	O
of	O
different	O
beta	O
-	O
carotene	O
and	O
lycopene	O
standard	O
mixtures	O
was	O
used	O
to	O
optimize	O
a	O
neural	O
network	O
based	O
on	O
a	O
multilayer	O
perceptron	O
(	O
MLP	O
)	O
(	O
learning	O
and	O
verification	O
process	O
)	O
.	O

Then	O
,	O
for	O
validation	O
purposes	O
,	O
the	O
optimized	O
NN	O
has	O
been	O
applied	O
to	O
determine	O
the	O
concentration	O
of	O
both	O
compounds	O
in	O
food	O
samples	O
(	O
fresh	O
tomato	O
,	O
tomato	O
concentrate	O
,	O
tomato	O
sauce	O
,	O
ketchup	O
,	O
tomato	O
juice	O
,	O
watermelon	O
,	O
medlar	O
,	O
green	O
pepper	O
,	O
and	O
carrots	O
)	O
,	O
comparing	O
the	O
NN	O
results	O
with	O
the	O
known	O
values	O
of	O
these	O
compounds	O
obtained	O
by	O
analytical	O
techniques	O
(	O
UV	O
-	O
vis	O
and	O
HPLC	O
)	O
.	O

It	O
was	O
concluded	O
that	O
when	O
the	O
MLP	O
-	O
NN	O
is	O
used	O
within	O
the	O
range	O
studied	O
,	O
the	O
optimized	O
NN	O
is	O
able	O
to	O
estimate	O
the	O
beta	O
-	O
carotene	O
and	O
lycopene	O
concentrations	O
in	O
food	O
samples	O
with	O
an	O
adequate	O
accuracy	O
,	O
solving	O
the	O
UV	O
-	O
vis	O
interference	O
of	O
beta	O
-	O
carotene	O
and	O
lycopene	O
.	O

Effectiveness	O
of	O
different	O
approaches	O
for	O
establishing	O
cisplatin	O
-	O
induced	O
cochlear	O
lesions	O
in	O
mice	O
.	O

CONCLUSIONS	O
:	O

Mouse	O
cochleae	O
are	O
highly	O
resistant	O
to	O
systemically	O
administered	O
cisplatin	O
.	O

However	O
,	O
cochlear	O
lesions	O
can	O
be	O
produced	O
effectively	O
in	O
mice	O
when	O
cisplatin	O
is	O
applied	O
locally	O
through	O
the	O
round	O
window	O
niche	O
or	O
tympanum	O
.	O

OBJECTIVE	O
:	O

To	O
explore	O
the	O
optimal	O
approach	O
for	O
creating	O
cisplatin	O
-	O
induced	O
cochlear	O
lesions	O
in	O
mice	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O

Cisplatin	O
was	O
administered	O
to	O
adult	O
C57BL	O
/	O
6J	O
mice	O
via	O
four	O
approaches	O
:	O
(	O
1	O
)	O
transtympanic	O
injection	O
,	O
(	O
2	O
)	O
round	O
window	O
niche	O
injection	O
,	O
(	O
3	O
)	O
intraperitoneal	O
injection	O
(	O
i	O
.	O
p	O
.	O
)	O
at	O
4	O
mg	O
/	O
kg	O
/	O
day	O
for	O
4	O
consecutive	O
days	O
,	O
and	O
(	O
4	O
)	O
one	O
15	O
mg	O
/	O
kg	O
dose	O
i	O
.	O
p	O
.	O

The	O
hearing	O
was	O
monitored	O
using	O
frequency	O
-	O
specific	O
auditory	O
brainstem	O
responses	O
(	O
ABRs	O
)	O
and	O
distortion	O
-	O
product	O
otoacoustic	O
emissions	O
(	O
DPOAEs	O
)	O
.	O

Cochlear	O
pathology	O
was	O
observed	O
in	O
cochleograms	O
with	O
Harris	O
'	O
hematoxylin	O
staining	O
.	O

RESULTS	O
:	O

Cisplatin	O
applied	O
systemically	O
did	O
not	O
cause	O
any	O
significant	O
ABR	O
threshold	O
elevation	O
across	O
the	O
frequencies	O
tested	O
(	O
2	O
-	O
32	O
kHz	O
)	O
,	O
whereas	O
local	O
application	O
of	O
cisplatin	O
through	O
the	O
round	O
window	O
niche	O
or	O
tympanum	O
resulted	O
in	O
significant	O
ABR	O
threshold	O
elevations	O
from	O
high	O
to	O
medium	O
frequencies	O
.	O

The	O
functional	O
changes	O
were	O
consistent	O
with	O
the	O
cochlear	O
pathology	O
across	O
groups	O
.	O

[	O
Reconstruction	O
of	O
hepatic	O
artery	O
in	O
adult	O
to	O
adult	O
living	O
donor	O
liver	O
transplantation	O
in	O
104	O
patients	O
]	O
.	O

OBJECTIVE	O
:	O

To	O
report	O
the	O
experience	O
of	O
hepatic	O
artery	O
reconstruction	O
with	O
adult	O
-	O
to	O
-	O
adult	O
living	O
donor	O
liver	O
transplantation	O
(	O
ALDLT	O
)	O
using	O
right	O
lobe	O
liver	O
grafts	O
.	O

METHODS	O
:	O

From	O
January	O
2002	O
to	O
August	O
2007	O
,	O
104	O
patients	O
underwent	O
ALDLT	O
using	O
right	O
lobe	O
grafts	O
.	O

Hepatic	O
arteries	O
of	O
donors	O
and	O
recipients	O
were	O
assessed	O
carefully	O
with	O
spiral	O
CT	O
angiography	O
and	O
DSA	O
before	O
ALDLT	O
.	O

All	O
patients	O
underwent	O
reconstruction	O
of	O
hepatic	O
artery	O
between	O
right	O
lobe	O
liver	O
grafts	O
of	O
donor	O
and	O
recipient	O
which	O
included	O
the	O
anastomosis	O
between	O
right	O
hepatic	O
artery	O
of	O
donors	O
and	O
recipients	O
;	O
the	O
reconstruction	O
of	O
right	O
hepatic	O
artery	O
between	O
donor	O
grafts	O
and	O
left	O
hepatic	O
artery	O
of	O
recipients	O
;	O
interpositional	O
bypass	O
using	O
autogenous	O
saphenous	O
vein	O
and	O
cryopreserved	O
iliac	O
artery	O
between	O
right	O
hepatic	O
artery	O
of	O
donors	O
and	O
hepatic	O
artery	O
,	O
common	O
hepatic	O
artery	O
and	O
abdominal	O
aorta	O
of	O
recipients	O
.	O

The	O
microsurgical	O
technique	O
was	O
employed	O
under	O
the	O
magnification	O
of	O
3	O
.	O
5	O
times	O
and	O
operative	O
microscope	O
of	O
5	O
-	O
10	O
times	O
.	O

RESULTS	O
:	O

In	O
these	O
series	O
,	O
HAT	O
occurred	O
in	O
2	O
recipients	O
at	O
Days	O
1	O
and	O
7	O
post	O
-	O
ALDLT	O
(	O
1	O
.	O
9	O
%	O
)	O
.	O

Both	O
were	O
revascularized	O
with	O
autogenous	O
saphenous	O
vein	O
between	O
right	O
hepatic	O
artery	O
of	O
donor	O
and	O
abdominal	O
aorta	O
of	O
recipient	O
.	O

HAT	O
occurred	O
in	O
1	O
recipient	O
at	O
Days	O
90	O
post	O
-	O
ALDLT	O
,	O
but	O
no	O
symptom	O
was	O
presented	O
.	O

There	O
was	O
no	O
severe	O
complication	O
and	O
mortality	O
related	O
to	O
hepatic	O
artery	O
reconstruction	O
in	O
recipients	O
.	O

No	O
HAT	O
,	O
hepatic	O
artery	O
stenosis	O
and	O
aneurysm	O
occurred	O
during	O
the	O
follow	O
-	O
up	O
period	O
of	O
2	O
-	O
60	O
months	O
.	O

The	O
1	O
,	O
2	O
and	O
3	O
-	O
year	O
survival	O
rates	O
were	O
89	O
.	O
3	O
%	O
,	O
76	O
.	O
0	O
%	O
and	O
69	O
.	O
3	O
%	O
respectively	O
.	O

CONCLUSION	O
:	O

Careful	O
evaluation	O
of	O
hepatic	O
artery	O
condition	O
and	O
using	O
microsurgical	O
techniques	O
are	O
important	O
for	O
safer	O
arterial	O
reconstruction	O
and	O
a	O
long	O
-	O
term	O
patency	O
of	O
hepatic	O
artery	O
in	O
living	O
donor	O
liver	O
transplantation	O
in	O
adults	O
using	O
right	O
lobe	O
liver	O
grafts	O
.	O

ICAM	O
-	O
3	O
enhances	O
the	O
migratory	O
and	O
invasive	O
potential	O
of	O
human	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
cells	O
by	O
inducing	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
via	O
Akt	O
and	O
CREB	O
.	O

We	O
have	O
previously	O
reported	O
that	O
intercellular	O
adhesion	O
molecule	O
-	O
3	O
(	O
ICAM	O
-	O
3	O
)	O
is	O
associated	O
with	O
an	O
increase	O
of	O
cellular	O
radio	O
-	O
resistance	O
and	O
cancer	O
cell	O
proliferation	O
.	O

In	O
this	O
study	O
,	O
we	O
hypothesized	O
that	O
ICAM	O
-	O
3	O
has	O
an	O
additional	O
effect	O
on	O
cancer	O
cell	O
migration	O
and	O
invasion	O
because	O
molecules	O
induced	O
by	O
ICAM	O
-	O
3	O
are	O
known	O
as	O
regulators	O
of	O
cell	O
migration	O
and	O
invasion	O
.	O

To	O
examine	O
this	O
hypothesis	O
,	O
we	O
used	O
NCI	B
-	I
H1299	I
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
cell	O
line	O
(	O
p53	O
and	O
PTEN	O
null	O
cell	O
)	O
and	O
constructed	O
an	O
ICAM	O
-	O
3	O
-	O
over	O
-	O
expressing	O
stable	O
transfectant	O
,	O
which	O
exhibited	O
increased	O
cell	O
migration	O
and	O
invasion	O
.	O

The	O
increased	O
migration	O
and	O
invasion	O
resulted	O
from	O
up	O
-	O
regulation	O
of	O
expression	O
and	O
activities	O
of	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
.	O

ICAM	O
-	O
3	O
also	O
increased	O
Akt	O
phosphorylation	O
,	O
which	O
caused	O
an	O
increase	O
in	O
cellular	O
migration	O
/	O
invasion	O
and	O
MMP	O
activities	O
.	O

Activity	O
of	O
several	O
transcriptional	O
factors	O
located	O
downstream	O
in	O
the	O
Akt	O
pathway	O
was	O
also	O
tested	O
,	O
and	O
constitutive	O
activation	O
of	O
adenosine	O
3	O
'	O
,	O
5	O
'	O
-	O
monophosphate	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
by	O
ICAM	O
-	O
3	O
was	O
detected	O
.	O

Blockage	O
of	O
the	O
Akt	O
pathway	O
attenuated	O
CREB	O
activation	O
,	O
and	O
a	O
decrease	O
in	O
CREB	O
expression	O
reduced	O
cellular	O
migration	O
/	O
invasion	O
and	O
activity	O
of	O
MMPs	O
.	O

This	O
result	O
indicates	O
that	O
CREB	O
functions	O
in	O
the	O
signaling	O
pathway	O
between	O
Akt	O
and	O
MMP	O
.	O

We	O
also	O
showed	O
ICAM	O
-	O
3	O
-	O
induced	O
cell	O
migration	O
and	O
invasion	O
in	O
NCI	B
-	I
H460	I
NSCLC	O
cells	O
(	O
wild	O
-	O
type	O
p53	O
and	O
PTEN	O
cell	O
)	O
through	O
the	O
same	O
signaling	O
pathway	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
ICAM	O
-	O
3	O
stimulates	O
cancer	O
cell	O
migration	O
/	O
invasion	O
via	O
ICAM	O
-	O
3	O
/	O
Akt	O
/	O
CREB	O
/	O
MMP	O
pathway	O
regardless	O
of	O
p53	O
and	O
PTEN	O
status	O
,	O
and	O
this	O
reflects	O
the	O
possibility	O
that	O
ICAM	O
-	O
3	O
could	O
be	O
considered	O
as	O
a	O
candidate	O
for	O
anti	O
-	O
cancer	O
drug	O
development	O
and	O
as	O
a	O
cancer	O
diagnostic	O
marker	O
.	O

Phenolic	O
fraction	O
of	O
tobacco	O
smoke	O
condensate	O
potentiates	O
benzo	O
[	O
a	O
]	O
pyerene	O
diol	O
epoxide	O
-	O
induced	O
cell	O
transformation	O
:	O
role	O
of	O
protein	O
kinase	O
C	O
.	O

In	O
this	O
study	O
we	O
separated	O
weakly	O
acidic	O
phenolic	O
components	O
from	O
other	O
neutral	O
,	O
acidic	O
and	O
basic	O
components	O
of	O
tobacco	O
smoke	O
condensate	O
(	O
TSC	O
)	O
and	O
observed	O
that	O
phenolic	O
fraction	O
of	O
TSC	O
significantly	O
increased	O
the	O
number	O
of	O
colonies	O
of	O
promotion	O
-	O
sensitive	O
JB6	B
Cl41	I
cells	O
that	O
showed	O
anchorage	O
-	O
independent	O
growth	O
on	O
soft	O
agar	O
in	O
response	O
to	O
BPDE	O
(	O
an	O
ultimate	O
carcinogen	O
produced	O
by	O
metabolic	O
activation	O
of	O
the	O
PAH	O
benzo	O
[	O
a	O
]	O
pyrene	O
)	O
.	O

Anchorage	O
-	O
independent	O
cell	O
growth	O
is	O
indicative	O
of	O
cell	O
transformation	O
resulting	O
in	O
acquisition	O
of	O
tumorigenic	O
potential	O
.	O

In	O
order	O
to	O
understand	O
the	O
underlying	O
mechanism	O
by	O
which	O
TSC	O
phenolic	O
fraction	O
potentiates	O
BPDE	O
-	O
induced	O
tumorigenicity	O
,	O
we	O
examined	O
its	O
effect	O
on	O
the	O
activation	O
of	O
two	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
which	O
are	O
known	O
to	O
be	O
influenced	O
by	O
established	O
tumor	O
promoter	O
TPA	O
.	O

BPDE	O
treatment	O
caused	O
induction	O
of	O
both	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
activity	O
as	O
determined	O
by	O
luciferase	O
reporter	O
assay	O
and	O
only	O
NF	O
-	O
kappaB	O
induction	O
in	O
response	O
to	O
BPDE	O
was	O
significantly	O
attenuated	O
by	O
TSC	O
phenolic	O
fraction	O
whereas	O
AP	O
-	O
1	O
induction	O
remains	O
unaltered	O
.	O

Attenuation	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
TSC	O
phenolic	O
fraction	O
was	O
associated	O
with	O
significant	O
decrease	O
of	O
intracellular	O
PKC	O
substrate	O
phosphorylation	O
in	O
BPDE	O
treated	O
cells	O
.	O

Non	O
-	O
specific	O
PKC	O
inhibitors	O
staurosporine	O
and	O
bisindolylmaleimide	O
II	O
as	O
well	O
as	O
inhibitors	O
specific	O
to	O
conventional	O
PKCs	O
(	O
Go6976	O
)	O
and	O
PKC	O
-	O
delta	O
(	O
rottlerin	O
)	O
attenuated	O
NF	O
-	O
kappaB	O
activation	O
in	O
BPDE	O
treated	O
cells	O
to	O
a	O
varying	O
degree	O
indicating	O
a	O
possible	O
link	O
between	O
PKC	O
down	O
-	O
regulation	O
and	O
the	O
attenuation	O
of	O
NF	O
-	O
kappaB	O
activity	O
by	O
TSC	O
phenolic	O
fraction	O
.	O

Treatment	O
of	O
cells	O
with	O
PKC	O
inhibitors	O
also	O
potentiated	O
anchorage	O
-	O
independent	O
growth	O
of	O
BPDE	O
treated	O
cells	O
on	O
soft	O
agar	O
.	O

Our	O
data	O
suggest	O
a	O
possible	O
role	O
of	O
PKC	O
down	O
-	O
regulation	O
in	O
potentiation	O
of	O
BPDE	O
-	O
induced	O
tumorogenicity	O
by	O
TSC	O
phenolic	O
fraction	O
.	O

Costs	O
of	O
hip	O
fracture	O
.	O

Rehabilitation	O
of	O
180	O
patients	O
in	O
primary	O
health	O
care	O
.	O

Costs	O
related	O
to	O
functional	O
status	O
were	O
calculated	O
for	O
180	O
consecutive	O
hip	O
fracture	O
patients	O
(	O
mean	O
age	O
78	O
years	O
)	O
who	O
were	O
admitted	O
from	O
their	O
own	O
home	O
and	O
rehabilitated	O
in	O
primary	O
health	O
care	O
.	O

Within	O
4	O
months	O
after	O
the	O
fracture	O
,	O
75	O
percent	O
of	O
the	O
patients	O
had	O
been	O
discharged	O
to	O
their	O
own	O
home	O
,	O
9	O
percent	O
were	O
dead	O
,	O
and	O
the	O
short	O
-	O
term	O
medical	O
treatment	O
costs	O
per	O
patient	O
were	O
SEK	O
43	O
,	O
000	O
,	O
whereas	O
the	O
total	O
costs	O
including	O
communal	O
help	O
and	O
costs	O
for	O
living	O
accommodations	O
after	O
discharge	O
were	O
twice	O
as	O
high	O
.	O

The	O
total	O
costs	O
per	O
patient	O
for	O
long	O
-	O
term	O
medical	O
treatment	O
(	O
from	O
4	O
months	O
up	O
to	O
3	O
years	O
after	O
fracture	O
)	O
were	O
7	O
percent	O
of	O
the	O
short	O
-	O
term	O
medical	O
treatment	O
costs	O
.	O

Patients	O
with	O
a	O
cervical	O
fracture	O
discharged	O
to	O
their	O
own	O
home	O
and	O
with	O
good	O
functional	O
status	O
consumed	O
only	O
one	O
fifth	O
of	O
the	O
resources	O
that	O
patients	O
with	O
a	O
trochanteric	O
fracture	O
discharged	O
to	O
institutional	O
care	O
and	O
who	O
had	O
reduced	O
functional	O
status	O
consumed	O
.	O

A	O
substantial	O
part	O
of	O
the	O
costs	O
can	O
be	O
saved	O
by	O
improved	O
organization	O
of	O
rehabilitation	O
after	O
discharge	O
from	O
the	O
hospital	O
.	O

A	O
further	O
cost	O
reduction	O
would	O
require	O
a	O
combination	O
of	O
technologic	O
,	O
social	O
,	O
and	O
organizational	O
changes	O
aimed	O
at	O
early	O
discharge	O
and	O
continued	O
follow	O
-	O
up	O
in	O
primary	O
health	O
care	O
.	O

The	O
role	O
of	O
p53	O
in	O
glucose	O
metabolism	O
.	O

The	O
p53	O
protein	O
functions	O
to	O
prevent	O
tumour	O
development	O
by	O
inhibiting	O
the	O
outgrowth	O
of	O
stressed	O
or	O
damaged	O
cells	O
.	O

In	O
addition	O
to	O
well	O
established	O
functions	O
to	O
block	O
cell	O
proliferation	O
,	O
recent	O
studies	O
have	O
revealed	O
a	O
role	O
for	O
p53	O
in	O
the	O
regulation	O
of	O
pathways	O
involved	O
in	O
glucose	O
metabolism	O
.	O

The	O
metabolic	O
functions	O
of	O
p53	O
resist	O
the	O
shift	O
to	O
glycolysis	O
that	O
is	O
characteristically	O
seen	O
in	O
cancers	O
,	O
and	O
also	O
help	O
cells	O
adapt	O
to	O
and	O
survive	O
limited	O
periods	O
of	O
metabolic	O
stress	O
.	O

Such	O
activities	O
of	O
p53	O
would	O
not	O
only	O
help	O
to	O
prevent	O
cancer	O
development	O
,	O
but	O
might	O
also	O
contribute	O
to	O
non	O
-	O
tumour	O
related	O
roles	O
for	O
p53	O
,	O
such	O
as	O
in	O
the	O
regulation	O
of	O
longevity	O
.	O

These	O
new	O
functions	O
of	O
p53	O
are	O
providing	O
interesting	O
possibilities	O
for	O
the	O
development	O
of	O
novel	O
therapies	O
.	O

14	O
-	O
3	O
-	O
3zeta	O
Overexpression	O
and	O
abnormal	O
beta	O
-	O
catenin	O
expression	O
are	O
associated	O
with	O
poor	O
differentiation	O
and	O
progression	O
in	O
stage	O
I	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
14	O
-	O
3	O
-	O
3zeta	O
interacted	O
with	O
other	O
key	O
cellular	O
proteins	O
involved	O
in	O
the	O
tumor	O
development	O
and	O
progression	O
.	O

Knowledge	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
and	O
beta	O
-	O
catenin	O
expression	O
and	O
clinical	O
significance	O
in	O
the	O
same	O
tumor	O
tissues	O
is	O
limited	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
expression	O
and	O
significance	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
and	O
beta	O
-	O
catenin	O
in	O
stage	O
I	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

Specimens	O
of	O
NSCLC	O
and	O
adjacent	O
normal	O
lung	O
tissues	O
were	O
collected	O
from	O
110	O
patients	O
.	O

The	O
expressions	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
and	O
beta	O
-	O
catenin	O
were	O
detected	O
by	O
western	O
blotting	O
,	O
double	O
labeling	O
immunofluorescence	O
,	O
confocal	O
laser	O
scanning	O
microscopy	O
and	O
immunohistochemistry	O
.	O

The	O
expression	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
was	O
upregulated	O
in	O
stage	O
I	O
NSCLC	O
.	O

Further	O
,	O
the	O
overexpression	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
correlated	O
with	O
histological	O
grades	O
,	O
lymph	O
node	O
metastasis	O
and	O
poor	O
clinical	O
outcome	O
.	O

Abnormal	O
expression	O
of	O
beta	O
-	O
catenin	O
was	O
significantly	O
correlated	O
with	O
poor	O
differentiation	O
and	O
lymph	O
node	O
metastasis	O
.	O

Abnormal	O
beta	O
-	O
catenin	O
expression	O
was	O
associated	O
significantly	O
with	O
positive	O
14	O
-	O
3	O
-	O
3zeta	O
expression	O
.	O

In	O
conclusion	O
,	O
14	O
-	O
3	O
-	O
3zeta	O
and	O
beta	O
-	O
catenin	O
might	O
have	O
an	O
important	O
role	O
in	O
development	O
,	O
progression	O
and	O
metastatic	O
process	O
of	O
NSCLC	O
.	O

14	O
-	O
3	O
-	O
3zeta	O
might	O
be	O
used	O
as	O
prognostic	O
biomarkers	O
for	O
NSCLC	O
.	O

A	O
randomized	O
pilot	O
study	O
of	O
the	O
Engaging	O
Moms	O
Program	O
for	O
family	O
drug	O
court	O
.	O

In	O
response	O
to	O
the	O
need	O
for	O
effective	O
drug	O
court	O
interventions	O
,	O
the	O
effectiveness	O
of	O
the	O
Engaging	O
Moms	O
Program	O
(	O
EMP	O
)	O
versus	O
Intensive	O
Case	O
Management	O
Services	O
(	O
ICMS	O
)	O
on	O
multiple	O
outcomes	O
for	O
mothers	O
enrolled	O
in	O
family	O
drug	O
court	O
was	O
investigated	O
.	O

In	O
this	O
intent	O
-	O
to	O
-	O
treat	O
study	O
,	O
mothers	O
(	O
N	O
=	O
62	O
)	O
were	O
randomly	O
assigned	O
to	O
either	O
usual	O
drug	O
court	O
care	O
or	O
the	O
Engaging	O
Moms	O
drug	O
court	O
program	O
.	O

Mothers	O
were	O
assessed	O
at	O
intake	O
and	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
months	O
following	O
intake	O
.	O

Results	O
indicated	O
that	O
at	O
18	O
months	O
post	O
drug	O
court	O
enrollment	O
,	O
77	O
%	O
of	O
mothers	O
assigned	O
to	O
EMP	O
versus	O
55	O
%	O
of	O
mothers	O
assigned	O
to	O
ICMS	O
had	O
positive	O
child	O
welfare	O
dispositions	O
.	O

There	O
were	O
statistically	O
significant	O
time	O
effects	O
for	O
both	O
intervention	O
groups	O
on	O
multiple	O
outcomes	O
including	O
substance	O
use	O
,	O
mental	O
health	O
,	O
parenting	O
practices	O
,	O
and	O
family	O
functioning	O
.	O

EMP	O
showed	O
equal	O
or	O
better	O
improvement	O
than	O
ICMS	O
on	O
all	O
outcomes	O
.	O

The	O
results	O
suggest	O
that	O
EMP	O
in	O
family	O
drug	O
court	O
is	O
a	O
viable	O
and	O
promising	O
intervention	O
approach	O
to	O
reduce	O
maternal	O
addiction	O
and	O
child	O
maltreatment	O
.	O

Hormonal	O
regulation	O
and	O
distinct	O
functions	O
of	O
semaphorin	O
-	O
3B	O
and	O
semaphorin	O
-	O
3F	O
in	O
ovarian	O
cancer	O
.	O

Semaphorins	O
comprise	O
a	O
family	O
of	O
molecules	O
that	O
influence	O
neuronal	O
growth	O
and	O
guidance	O
.	O

Class	O
-	O
3	O
semaphorins	O
,	O
semaphorin	O
-	O
3B	O
(	O
SEMA3B	O
)	O
and	O
semaphorin	O
-	O
3F	O
(	O
SEMA3F	O
)	O
,	O
illustrate	O
their	O
effects	O
by	O
forming	O
a	O
complex	O
with	O
neuropilins	O
(	O
NP	O
-	O
1	O
or	O
NP	O
-	O
2	O
)	O
and	O
plexins	O
.	O

We	O
examined	O
the	O
status	O
and	O
regulation	O
of	O
semaphorins	O
and	O
their	O
receptors	O
in	O
human	O
ovarian	O
cancer	O
cells	O
.	O

A	O
significantly	O
reduced	O
expression	O
of	O
SEMA3B	O
(	O
83	O
kDa	O
)	O
,	O
SEMA3F	O
(	O
90	O
kDa	O
)	O
,	O
and	O
plexin	O
-	O
A3	O
was	O
observed	O
in	O
ovarian	O
cancer	O
cell	O
lines	O
when	O
compared	O
with	O
normal	O
human	O
ovarian	O
surface	O
epithelial	O
cells	O
.	O

The	O
expression	O
of	O
NP	O
-	O
1	O
,	O
NP	O
-	O
2	O
,	O
and	O
plexin	O
-	O
A1	O
was	O
not	O
altered	O
in	O
human	O
ovarian	O
surface	O
epithelial	O
and	O
ovarian	O
cancer	O
cells	O
.	O

The	O
decreased	O
expression	O
of	O
SEMA3B	O
,	O
SEMA3F	O
,	O
and	O
plexin	O
-	O
A3	O
was	O
confirmed	O
in	O
stage	O
3	O
ovarian	O
tumors	O
.	O

The	O
treatment	O
of	O
ovarian	O
cancer	O
cells	O
with	O
luteinizing	O
hormone	O
,	O
follicle	O
-	O
stimulating	O
hormone	O
,	O
and	O
estrogen	O
induced	O
a	O
significant	O
upregulation	O
of	O
SEMA3B	O
,	O
whereas	O
SEMA3F	O
was	O
upregulated	O
only	O
by	O
estrogen	O
.	O

Cotreatment	O
of	O
cell	O
lines	O
with	O
a	O
hormone	O
and	O
its	O
specific	O
antagonist	O
blocked	O
the	O
effect	O
of	O
the	O
hormone	O
.	O

Ectopic	O
expression	O
of	O
SEMA3B	O
or	O
SEMA3F	O
reduced	O
soft	O
-	O
agar	O
colony	O
formation	O
,	O
adhesion	O
,	O
and	O
cell	O
invasion	O
of	O
ovarian	O
cancer	O
cell	O
cultures	O
.	O

Forced	O
expression	O
of	O
SEMA3B	O
,	O
but	O
not	O
SEMA3F	O
,	O
inhibited	O
viability	O
of	O
ovarian	O
cancer	O
cells	O
.	O

Overexpression	O
of	O
SEMA3B	O
and	O
SEMA3F	O
reduced	O
focal	O
adhesion	O
kinase	O
phosphorylation	O
and	O
matrix	O
metalloproteinase	O
-	O
2	O
and	O
matrix	O
metalloproteinase	O
-	O
9	O
expression	O
in	O
ovarian	O
cancer	O
cells	O
.	O

Forced	O
expression	O
of	O
SEMA3F	O
,	O
but	O
not	O
SEMA3B	O
in	O
ovarian	O
cancer	O
cells	O
,	O
significantly	O
inhibited	O
endothelial	O
cell	O
tube	O
formation	O
.	O

Collectively	O
,	O
our	O
results	O
suggest	O
that	O
the	O
loss	O
of	O
SEMA3	O
expression	O
could	O
be	O
a	O
hallmark	O
of	O
cancer	O
progression	O
.	O

Furthermore	O
,	O
gonadotropin	O
-	O
and	O
/	O
or	O
estrogen	O
-	O
mediated	O
maintenance	O
of	O
SEMA3	O
expression	O
could	O
control	O
ovarian	O
cancer	O
angiogenesis	O
and	O
metastasis	O
.	O

Tobacco	O
smoke	O
promotes	O
lung	O
tumorigenesis	O
by	O
triggering	O
IKKbeta	O
-	O
and	O
JNK1	O
-	O
dependent	O
inflammation	O
.	O

Chronic	O
exposure	O
to	O
tobacco	O
smoke	O
,	O
which	O
contains	O
over	O
60	O
tumor	O
-	O
initiating	O
carcinogens	O
,	O
is	O
the	O
major	O
risk	O
factor	O
for	O
development	O
of	O
lung	O
cancer	O
,	O
accounting	O
for	O
a	O
large	O
portion	O
of	O
cancer	O
-	O
related	O
deaths	O
worldwide	O
.	O

It	O
is	O
well	O
established	O
that	O
tobacco	O
smoke	O
is	O
a	O
tumor	O
initiator	O
,	O
but	O
we	O
asked	O
whether	O
it	O
also	O
acts	O
as	O
a	O
tumor	O
promoter	O
once	O
malignant	O
initiation	O
,	O
such	O
as	O
caused	O
by	O
K	O
-	O
ras	O
activation	O
,	O
has	O
taken	O
place	O
.	O

Here	O
we	O
demonstrate	O
that	O
repetitive	O
exposure	O
to	O
tobacco	O
smoke	O
promotes	O
tumor	O
development	O
both	O
in	O
carcinogen	O
-	O
treated	O
mice	O
and	O
in	O
transgenic	O
mice	O
undergoing	O
sporadic	O
K	O
-	O
ras	O
activation	O
in	O
lung	O
epithelial	O
cells	O
.	O

Tumor	O
promotion	O
is	O
due	O
to	O
induction	O
of	O
inflammation	O
that	O
results	O
in	O
enhanced	O
pneumocyte	O
proliferation	O
and	O
is	O
abrogated	O
by	O
IKKbeta	O
ablation	O
in	O
myeloid	O
cells	O
or	O
inactivation	O
of	O
JNK1	O
.	O

Killing	O
tumor	O
cells	O
through	O
their	O
surface	O
beta	O
(	O
2	O
)	O
-	O
microglobulin	O
or	O
major	O
histocompatibility	O
complex	O
class	O
I	O
molecules	O
.	O

Targeted	O
antibody	O
-	O
based	O
therapy	O
has	O
been	O
used	O
successfully	O
to	O
treat	O
cancers	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
tumor	O
cells	O
treated	O
with	O
antibodies	O
specific	O
for	O
beta	O
(	O
2	O
)	O
-	O
microglobulin	O
(	O
beta	O
(	O
2	O
)	O
M	O
)	O
or	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
molecules	O
undergo	O
apoptosis	O
in	O
vitro	O
and	O
in	O
vivo	O
(	O
mouse	O
models	O
)	O
.	O

Antibodies	O
against	O
beta	O
(	O
2	O
)	O
M	O
or	O
MHC	O
class	O
I	O
induce	O
tumor	O
cell	O
apoptosis	O
by	O
1	O
)	O
recruiting	O
MHC	O
class	O
I	O
molecules	O
to	O
lipid	O
rafts	O
and	O
activating	O
LYN	O
kinase	O
and	O
the	O
signal	O
-	O
transducing	O
enzyme	O
phospholipase	O
C	O
-	O
gamma2	O
-	O
dependent	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
signaling	O
pathway	O
and	O
2	O
)	O
expelling	O
interleukin	O
6	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
receptors	O
out	O
of	O
lipid	O
rafts	O
and	O
inhibiting	O
the	O
growth	O
and	O
survival	O
factor	O
-	O
induced	O
activation	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
/	O
Akt	O
and	O
extracellular	O
signal	O
-	O
related	O
kinase	O
pathways	O
.	O

Consequently	O
,	O
mitochondrial	O
integrity	O
is	O
compromised	O
,	O
and	O
the	O
caspase	O
-	O
9	O
-	O
dependent	O
cascade	O
is	O
activated	O
in	O
treated	O
tumor	O
cells	O
.	O

However	O
,	O
although	O
beta	O
(	O
2	O
)	O
M	O
and	O
MHC	O
class	O
I	O
are	O
expressed	O
on	O
normal	O
hematopoietic	O
cells	O
,	O
which	O
is	O
a	O
potential	O
safety	O
concern	O
,	O
the	O
monoclonal	O
antibodies	O
were	O
selective	O
to	O
tumor	O
cells	O
and	O
did	O
not	O
damage	O
normal	O
cells	O
in	O
vitro	O
or	O
in	O
human	O
-	O
like	O
mouse	O
models	O
.	O

These	O
findings	O
suggest	O
that	O
targeting	O
beta	O
(	O
2	O
)	O
M	O
or	O
MHC	O
class	O
I	O
by	O
using	O
antibodies	O
or	O
other	O
agents	O
offers	O
a	O
potential	O
therapeutic	O
approach	O
for	O
beta	O
(	O
2	O
)	O
M	O
/	O
MHC	O
class	O
I	O
-	O
expressing	O
malignancies	O
.	O

Cancer	O
2010	O
.	O

(	O
c	O
)	O
2010	O
American	O
Cancer	O
Society	O
.	O

Further	O
Characterization	O
of	O
Activin	O
A	O
-	O
induced	O
IgA	O
Response	O
in	O
Murine	O
B	O
Lymphocytes	O
.	O

We	O
have	O
recently	O
shown	O
that	O
activin	O
A	O
,	O
a	O
member	O
of	O
TGF	O
-	O
beta	O
superfamily	O
,	O
stimulates	O
mouse	O
B	O
cells	O
to	O
express	O
IgA	O
isotype	O
but	O
other	O
isotypes	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
further	O
characterized	O
effects	O
of	O
activin	O
A	O
on	O
B	O
cell	O
growth	O
and	O
IgA	O
expression	O
.	O

We	O
found	O
that	O
activin	O
A	O
did	O
not	O
have	O
effect	O
on	O
LPS	O
-	O
stimulated	O
cell	O
viability	O
.	O

In	O
parallel	O
,	O
CFSE	O
staining	O
analysis	O
revealed	O
that	O
activin	O
A	O
did	O
not	O
alter	O
cell	O
division	O
.	O

An	O
increase	O
of	O
IgA	O
secretion	O
by	O
activin	O
A	O
was	O
completely	O
abrogated	O
by	O
anti	O
-	O
activin	O
A	O
Ab	O
but	O
not	O
by	O
anti	O
-	O
TGFbeta1	O
Ab	O
.	O

In	O
the	O
same	O
conditions	O
,	O
no	O
other	O
isotypes	O
are	O
significantly	O
affected	O
by	O
each	O
antibody	O
treatment	O
.	O

Finally	O
,	O
activin	O
A	O
,	O
as	O
similar	O
to	O
TGF	O
-	O
beta1	O
,	O
increased	O
IgA	O
secretion	O
by	O
mesenteric	O
lymph	O
node	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
activin	O
A	O
can	O
specifically	O
stimulate	O
IgA	O
response	O
,	O
independent	O
of	O
TGF	O
-	O
beta	O
in	O
the	O
gut	O
.	O

Posterior	O
stabilization	O
of	O
the	O
cervical	O
spine	O
with	O
hook	O
plates	O
.	O

Hook	O
-	O
plate	O
fixation	O
is	O
designed	O
for	O
posterior	O
cervical	O
stabilization	O
from	O
C2	O
to	O
C7	O
.	O

Indications	O
remain	O
the	O
same	O
as	O
for	O
standard	O
posterior	O
fixations	O
.	O

The	O
prime	O
indications	O
are	O
discoligamentous	O
injuries	O
.	O

The	O
plates	O
are	O
hooked	O
under	O
the	O
lower	O
laminas	O
and	O
attached	O
to	O
the	O
articular	O
masses	O
of	O
the	O
upper	O
vertebra	O
by	O
oblique	O
screws	O
.	O

An	O
H	O
-	O
graft	O
is	O
placed	O
between	O
the	O
spinous	O
processes	O
.	O

The	O
vertebrae	O
are	O
compressed	O
together	O
by	O
the	O
plates	O
at	O
three	O
points	O
,	O
the	O
facet	O
joints	O
,	O
and	O
graft	O
.	O

The	O
resulting	O
pre	O
-	O
stressed	O
system	O
is	O
stable	O
in	O
all	O
directions	O
.	O

A	O
protocol	O
for	O
safe	O
reduction	O
of	O
cervical	O
dislocations	O
is	O
observed	O
.	O

Of	O
70	O
patients	O
treated	O
from	O
1979	O
to	O
1986	O
,	O
51	O
were	O
examined	O
12	O
-	O
54	O
months	O
after	O
surgery	O
.	O

All	O
fusions	O
consolidated	O
.	O

Two	O
neurologic	O
complications	O
not	O
attributable	O
to	O
the	O
fixation	O
occurred	O
.	O

Other	O
major	O
complications	O
were	O
not	O
seen	O
.	O

Comment	O
on	O
""""	O
Why	O
reduced	O
-	O
form	O
regression	O
models	O
of	O
health	O
effects	O
versus	O
exposures	O
should	O
not	O
replace	O
QRA	O
:	O
livestock	O
production	O
and	O
infant	O
mortality	O
as	O
an	O
example	O
,	O
""""	O
by	O
Louis	O
Anthony	O
(	O
Tony	O
)	O
Cox	O
,	O
Jr	O
.	O
,	O
Risk	O
Analysis	O
2009	O
,	O
Vol	O
.	O

29	O
,	O
No	O
.	O
12	O
.	O

While	O
a	O
recent	O
paper	O
by	O
Cox	O
in	O
this	O
journal	O
uses	O
as	O
its	O
motivating	O
factor	O
the	O
benefits	O
of	O
quantitative	O
risk	O
assessment	O
,	O
its	O
content	O
is	O
entirely	O
devoted	O
to	O
critiquing	O
Sneeringer	O
'	O
s	O
article	O
in	O
the	O
American	O
Journal	O
of	O
Agricultural	O
Economics	O
.	O

Cox	O
'	O
s	O
two	O
main	O
critiques	O
of	O
Sneeringer	O
are	O
fundamentally	O
flawed	O
and	O
misrepresent	O
the	O
original	O
article	O
.	O

Cox	O
posits	O
that	O
Sneeringer	O
did	O
A	O
and	O
B	O
,	O
and	O
then	O
argues	O
why	O
A	O
and	O
B	O
are	O
incorrect	O
.	O

However	O
,	O
Sneeringer	O
in	O
fact	O
did	O
C	O
and	O
D	O
;	O
thus	O
critiques	O
of	O
A	O
and	O
B	O
are	O
not	O
applicable	O
to	O
Sneeringer	O
'	O
s	O
analysis	O
.	O

Dose	O
-	O
and	O
time	O
-	O
dependent	O
effects	O
of	O
doxorubicin	O
on	O
cytotoxicity	O
,	O
cell	O
cycle	O
and	O
apoptotic	O
cell	O
death	O
in	O
human	O
colon	O
cancer	O
cells	O
.	O

The	O
cytostatic	O
drug	O
doxorubicin	O
is	O
a	O
well	O
-	O
known	O
chemotherapeutic	O
agent	O
which	O
is	O
used	O
in	O
treatment	O
of	O
a	O
wide	O
variety	O
of	O
cancers	O
.	O

A	O
key	O
factor	O
in	O
the	O
response	O
of	O
cancer	O
cells	O
to	O
chemotherapeutic	O
drugs	O
is	O
the	O
activation	O
of	O
the	O
apoptotic	O
pathway	O
,	O
a	O
pathway	O
that	O
is	O
often	O
impaired	O
in	O
chemoresistant	O
colon	O
cancer	O
cells	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
doxorubicin	O
in	O
Hct	B
-	I
116	I
human	O
colon	O
carcinoma	O
cells	O
in	O
order	O
to	O
clarify	O
if	O
a	O
time	O
/	O
concentration	O
range	O
for	O
optimal	O
doxorubicin	O
-	O
induced	O
apoptosis	O
exists	O
.	O

We	O
compared	O
a	O
treatment	O
schedule	O
were	O
cells	O
were	O
bolus	O
incubated	O
for	O
3h	O
with	O
doxorubicin	O
followed	O
by	O
24h	O
in	O
drug	O
-	O
free	O
medium	O
,	O
with	O
a	O
continuous	O
doxorubicin	O
treatment	O
schedule	O
for	O
24h	O
.	O

Bolus	O
incubation	O
was	O
carried	O
out	O
to	O
determine	O
effects	O
of	O
doxorubicin	O
accumulated	O
during	O
the	O
first	O
3h	O
,	O
whereas	O
continuous	O
incubation	O
allowed	O
further	O
(	O
continuous	O
)	O
exposure	O
to	O
doxorubicin	O
.	O

We	O
found	O
that	O
bolus	O
(	O
3h	O
)	O
treatment	O
with	O
doxorubicin	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
decrease	O
of	O
viable	O
cells	O
and	O
concomitant	O
increase	O
of	O
apoptosis	O
.	O

Additionally	O
,	O
bolus	O
(	O
3h	O
)	O
doxorubicin	O
incubation	O
led	O
to	O
phosphorylation	O
of	O
p53	O
at	O
serine	O
392	O
,	O
induction	O
of	O
p21	O
,	O
G2	O
arrest	O
and	O
increase	O
of	O
proapoptotic	O
protein	O
Bax	O
.	O

In	O
contrast	O
,	O
continuous	O
(	O
24h	O
)	O
treatment	O
with	O
doxorubicin	O
reduced	O
the	O
number	O
of	O
living	O
cells	O
with	O
no	O
parallel	O
raise	O
in	O
the	O
amount	O
of	O
dead	O
cells	O
.	O

Continuous	O
(	O
24h	O
)	O
treatment	O
with	O
5	O
microM	O
doxorubicin	O
resulted	O
in	O
cell	O
cycle	O
arrest	O
in	O
G0	O
/	O
G1	O
phase	O
that	O
was	O
neither	O
accompanied	O
by	O
phosphorylation	O
and	O
activation	O
of	O
p53	O
nor	O
enhanced	O
expression	O
of	O
p21	O
.	O

These	O
results	O
suggest	O
that	O
doxorubicin	O
is	O
able	O
to	O
induce	O
cell	O
death	O
by	O
apoptosis	O
only	O
at	O
particular	O
dose	O
and	O
treatment	O
conditions	O
and	O
imply	O
a	O
completely	O
different	O
cellular	O
response	O
following	O
bolus	O
or	O
continuous	O
exposure	O
to	O
doxorubicin	O
.	O

p24	O
family	O
type	O
1	O
transmembrane	O
proteins	O
are	O
required	O
for	O
insulin	O
biosynthesis	O
and	O
secretion	O
in	O
pancreatic	O
beta	O
-	O
cells	O
.	O

The	O
p24	O
protein	O
family	O
have	O
multiple	O
functions	O
in	O
protein	O
transport	O
in	O
the	O
early	O
secretory	O
pathway	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
role	O
of	O
p24	O
proteins	O
in	O
insulin	O
transport	O
.	O

Several	O
members	O
were	O
detected	O
in	O
insulinoma	O
cell	O
lines	O
and	O
rat	O
islets	O
and	O
expression	O
levels	O
positively	O
correlated	O
with	O
insulin	O
abundance	O
,	O
particularly	O
for	O
p24delta1	O
and	O
p24beta1	O
.	O

Knocking	O
down	O
p24delta1	O
in	O
insulinoma	O
cell	O
lines	O
,	O
which	O
also	O
resulted	O
in	O
the	O
concomitant	O
knock	O
-	O
down	O
of	O
other	O
family	O
members	O
,	O
impaired	O
glucose	O
-	O
stimulated	O
insulin	O
secretion	O
,	O
decreased	O
total	O
cellular	O
insulin	O
content	O
and	O
reduced	O
proinsulin	O
biosynthesis	O
.	O

There	O
was	O
no	O
effect	O
on	O
overall	O
protein	O
biosynthesis	O
or	O
ER	O
stress	O
.	O

These	O
results	O
suggest	O
that	O
p24delta1	O
and	O
possibly	O
other	O
p24	O
family	O
proteins	O
are	O
required	O
for	O
normal	O
insulin	O
biosynthesis	O
and	O
subsequent	O
secretion	O
in	O
pancreatic	O
beta	O
-	O
cells	O
.	O

Absence	O
of	O
microbiota	O
(	O
germ	O
-	O
free	O
conditions	O
)	O
accelerates	O
the	O
atherosclerosis	O
in	O
ApoE	O
-	O
deficient	O
mice	O
fed	O
standard	O
low	O
cholesterol	O
diet	O
.	O

AIM	O
:	O

The	O
aim	O
of	O
our	O
work	O
was	O
to	O
determine	O
the	O
influence	O
of	O
intestinal	O
bacteria	O
on	O
the	O
development	O
of	O
atherosclerotic	O
lesions	O
using	O
apolipoprotein	O
E	O
(	O
ApoE	O
)	O
-	O
deficient	O
knockout	O
mice	O
.	O

METHODS	O
:	O

The	O
experiments	O
were	O
performed	O
on	O
ApoE	O
-	O
/	O
-	O
-	O
deficient	O
mouse	O
strain	O
C57BL	O
/	O
6	O
,	O
bred	O
under	O
germ	O
-	O
free	O
(	O
GF	O
)	O
conditions	O
for	O
two	O
generations	O
or	O
under	O
conventional	O
conditions	O
with	O
defined	O
microflora	O
(	O
CV	O
)	O
.	O

The	O
mice	O
were	O
fed	O
a	O
standard	O
low	O
cholesterol	O
diet	O
or	O
cholesterol	O
-	O
rich	O
diet	O
for	O
3	O
-	O
4	O
months	O
.	O

We	O
studied	O
the	O
development	O
of	O
advanced	O
lesions	O
in	O
the	O
thoracic	O
and	O
abdominal	O
aorta	O
by	O
histological	O
,	O
morphometric	O
and	O
immunohistological	O
methods	O
.	O

RESULTS	O
:	O

Conventionally	O
reared	O
ApoE	O
-	O
/	O
-	O
mice	O
(	O
containing	O
no	O
pathogenic	O
intestinal	O
microbiota	O
)	O
and	O
fed	O
a	O
standard	O
low	O
cholesterol	O
diet	O
in	O
contrast	O
to	O
a	O
high	O
cholesterol	O
diet	O
did	O
not	O
develop	O
atherosclerotic	O
aortic	O
plaques	O
.	O

In	O
contrast	O
,	O
ApoE	O
-	O
/	O
-	O
mice	O
reared	O
under	O
germfree	O
conditions	O
for	O
2	O
generations	O
and	O
fed	O
a	O
low	O
cholesterol	O
diet	O
exhibited	O
atherosclerotic	O
plaques	O
in	O
the	O
aorta	O
.	O

Characteristic	O
lipid	O
deposition	O
with	O
foam	O
cells	O
and	O
macrophages	O
was	O
found	O
in	O
their	O
arterial	O
walls	O
.	O

CONCLUSION	O
:	O

In	O
contrast	O
to	O
the	O
absence	O
of	O
atherosclerotic	O
plaques	O
in	O
conventionally	O
reared	O
ApoE	O
-	O
deficient	O
mice	O
,	O
germ	O
-	O
free	O
ApoE	O
-	O
/	O
-	O
mice	O
consuming	O
the	O
same	O
low	O
cholesterol	O
standard	O
diet	O
developed	O
atherosclerotic	O
plaques	O
in	O
the	O
aorta	O
.	O

Differences	O
in	O
atherosclerotic	O
plaques	O
between	O
GF	O
and	O
CV	O
ApoE	O
-	O
/	O
-	O
mice	O
are	O
not	O
so	O
apparent	O
when	O
mice	O
are	O
fed	O
a	O
high	O
cholesterol	O
diet	O
.	O

Our	O
findings	O
thus	O
document	O
the	O
protective	O
effect	O
of	O
microbiota	O
(	O
commensal	O
bacteria	O
)	O
on	O
atherosclerosis	O
development	O
.	O

Lactate	O
-	O
dehydrogenase	O
5	O
is	O
overexpressed	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
correlates	O
with	O
the	O
expression	O
of	O
the	O
transketolase	O
-	O
like	O
protein	O
1	O
.	O

AIMS	O
:	O
As	O
one	O
of	O
the	O
five	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
isoenzymes	O
,	O
LDH5	O
has	O
the	O
highest	O
efficiency	O
to	O
catalyze	O
pyruvate	O
transformation	O
to	O
lactate	O
.	O

LDH5	O
overexpression	O
in	O
cancer	O
cells	O
induces	O
an	O
upregulated	O
glycolytic	O
metabolism	O
and	O
reduced	O
dependence	O
on	O
the	O
presence	O
of	O
oxygen	O
.	O

Here	O
we	O
analyzed	O
LDH5	O
protein	O
expression	O
in	O
a	O
well	O
characterized	O
large	O
cohort	O
of	O
primary	O
lung	O
cancers	O
in	O
correlation	O
to	O
clinico	O
-	O
pathological	O
data	O
and	O
its	O
possible	O
impact	O
on	O
patient	O
survival	O
.	O

METHODS	O
:	O
Primary	O
lung	O
cancers	O
(	O
n	O
=	O
269	O
)	O
and	O
non	O
neoplastic	O
lung	O
tissue	O
(	O
n	O
=	O
35	O
)	O
were	O
tested	O
for	O
LDH5	O
expression	O
by	O
immunohistochemistry	O
using	O
a	O
polyclonal	O
LDH5	O
antibody	O
(	O
ab53010	O
)	O
.	O

The	O
results	O
of	O
LDH5	O
expression	O
were	O
correlated	O
to	O
clinico	O
-	O
pathological	O
data	O
as	O
well	O
as	O
to	O
patient	O
'	O
s	O
survival	O
.	O

In	O
addition	O
,	O
the	O
results	O
of	O
the	O
previously	O
tested	O
transketolase	O
like	O
1	O
protein	O
(	O
TKTL1	O
)	O
expression	O
were	O
correlated	O
to	O
LDH5	O
expression	O
.	O

RESULTS	O
:	O
89	O
.	O
5	O
%	O
(	O
n	O
=	O
238	O
)	O
of	O
NSCLC	O
revealed	O
LDH5	O
expression	O
whereas	O
LDH5	O
expression	O
was	O
not	O
detected	O
in	O
non	O
neoplastic	O
lung	O
tissues	O
(	O
n	O
=	O
34	O
)	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

LDH5	O
overexpression	O
was	O
associated	O
with	O
histological	O
type	O
(	O
adenocarcinoma	O
=	O
57	O
%	O
,	O
squamous	O
cell	O
carcinoma	O
=	O
45	O
%	O
,	O
large	O
cell	O
carcinoma	O
=	O
46	O
%	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

No	O
significant	O
correlation	O
could	O
be	O
detected	O
with	O
regard	O
to	O
TNM	O
-	O
stage	O
,	O
grading	O
or	O
survival	O
.	O

A	O
two	O
sided	O
correlation	O
between	O
the	O
expression	O
of	O
TKTL1	O
and	O
LDH5	O
could	O
be	O
shown	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
within	O
the	O
overall	O
cohort	O
as	O
well	O
as	O
for	O
each	O
grading	O
and	O
pN	O
group	O
.	O

A	O
significant	O
correlation	O
between	O
LDH5	O
and	O
TKTL1	O
within	O
each	O
histologic	O
tumortype	O
could	O
not	O
be	O
revealed	O
.	O

CONCLUSIONS	O
:	O
LDH5	O
is	O
overexpressed	O
in	O
NSCLC	O
and	O
could	O
hence	O
serve	O
as	O
an	O
additional	O
marker	O
for	O
malignancy	O
.	O

Furthermore	O
,	O
LDH5	O
correlates	O
positively	O
with	O
the	O
prognostic	O
marker	O
TKTL1	O
.	O

Our	O
results	O
confirm	O
a	O
close	O
link	O
between	O
the	O
two	O
metabolic	O
enzymes	O
and	O
indicate	O
an	O
alteration	O
in	O
the	O
glucose	O
metabolism	O
in	O
the	O
process	O
of	O
malignant	O
transformation	O
.	O

Expression	O
of	O
KISS1	O
and	O
MMP	O
-	O
9	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
their	O
relations	O
to	O
metastasis	O
and	O
survival	O
.	O

KISS1	O
and	O
matrix	O
metalloproteinase	O
-	O
9	O
(	O
MMP	O
-	O
9	O
)	O
may	O
play	O
important	O
roles	O
as	O
metastasis	O
suppressor	O
and	O
metastasis	O
promoter	O
genes	O
,	O
respectively	O
,	O
in	O
a	O
variety	O
of	O
malignancies	O
.	O

However	O
,	O
there	O
is	O
little	O
information	O
about	O
their	O
possible	O
roles	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

The	O
goals	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
mRNA	O
and	O
protein	O
expressions	O
of	O
KISS1	O
and	O
MMP	O
-	O
9	O
in	O
NSCLC	O
and	O
their	O
relations	O
to	O
metastasis	O
and	O
prognosis	O
.	O

The	O
mRNA	O
and	O
protein	O
expressions	O
of	O
KISS1	O
and	O
of	O
MMP	O
-	O
9	O
protein	O
were	O
detected	O
by	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
respectively	O
in	O
85	O
cases	O
of	O
NSCLC	O
,	O
and	O
their	O
matched	O
lymph	O
node	O
metastases	O
.	O

Expressions	O
of	O
KISS1	O
mRNA	O
and	O
protein	O
were	O
significantly	O
higher	O
in	O
low	O
TNM	O
stages	O
of	O
NSCLC	O
(	O
I	O
-	O
II	O
)	O
compared	O
to	O
more	O
advanced	O
stages	O
(	O
III	O
-	O
IV	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Moreover	O
,	O
in	O
advanced	O
TNM	O
stages	O
,	O
cases	O
without	O
metastasis	O
had	O
higher	O
KISS1	O
gene	O
expression	O
compared	O
to	O
those	O
with	O
lymph	O
node	O
metastasis	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
contrast	O
,	O
MMP	O
-	O
9	O
expression	O
was	O
higher	O
in	O
stage	O
III	O
-	O
IV	O
NSCLC	O
cases	O
compared	O
to	O
stage	O
I	O
-	O
II	O
tumors	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
higher	O
in	O
NSCLC	O
cases	O
with	O
metastasis	O
than	O
those	O
without	O
metastasis	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
negative	O
correction	O
between	O
KISS1	O
and	O
MMP	O
-	O
9	O
protein	O
expression	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
5	O
-	O
year	O
survival	O
rate	O
in	O
cases	O
with	O
higher	O
KISS1	O
protein	O
expression	O
was	O
significantly	O
higher	O
than	O
in	O
those	O
with	O
low	O
expression	O
(	O
20	O
.	O
9	O
vs	O
.	O
2	O
.	O
4	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

However	O
,	O
the	O
5	O
-	O
year	O
survival	O
rate	O
of	O
patients	O
with	O
high	O
MMP	O
-	O
9	O
protein	O
expression	O
were	O
lower	O
than	O
those	O
with	O
low	O
expression	O
(	O
19	O
vs	O
.	O
4	O
.	O
7	O
%	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
KISS1	O
and	O
MMP	O
-	O
9	O
may	O
serve	O
as	O
potential	O
prognostic	O
and	O
therapeutic	O
markers	O
in	O
lung	O
cancer	O
.	O

Is	O
the	O
elimination	O
of	O
HIV	O
infection	O
within	O
reach	O
in	O
the	O
United	O
States	O
?	O

Lessons	O
from	O
an	O
epidemiologic	O
transmission	O
model	O
.	O

Recent	O
estimates	O
show	O
that	O
the	O
transmission	O
rate	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
in	O
the	O
U	O
.	O
S	O
.	O
has	O
substantially	O
decreased	O
.	O

This	O
raises	O
the	O
question	O
,	O
is	O
elimination	O
of	O
HIV	O
infection	O
in	O
the	O
nation	O
feasible	O
in	O
the	O
foreseeable	O
future	O
?	O

We	O
demonstrate	O
that	O
if	O
the	O
HIV	O
transmission	O
rate	O
were	O
reduced	O
by	O
50	O
%	O
,	O
then	O
the	O
reproductive	O
rate	O
of	O
HIV	O
infection	O
would	O
drop	O
below	O
unity	O
and	O
lead	O
to	O
eventual	O
elimination	O
of	O
infection	O
.	O

In	O
recent	O
congressional	O
testimony	O
,	O
the	O
director	O
of	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
and	O
others	O
asserted	O
that	O
the	O
HIV	O
transmission	O
rate	O
can	O
be	O
halved	O
by	O
2020	O
,	O
if	O
not	O
earlier	O
,	O
provided	O
sufficient	O
investment	O
is	O
made	O
toward	O
achieving	O
this	O
goal	O
.	O

We	O
assert	O
that	O
if	O
adequate	O
investment	O
is	O
made	O
and	O
the	O
transmission	O
rate	O
is	O
in	O
fact	O
lowered	O
by	O
50	O
%	O
,	O
then	O
the	O
HIV	O
reproductive	O
rate	O
would	O
fall	O
below	O
unity	O
,	O
setting	O
the	O
stage	O
for	O
eventual	O
elimination	O
of	O
HIV	O
infection	O
in	O
the	O
U	O
.	O
S	O
.	O

Loss	O
of	O
CDC4	O
/	O
FBXW7	O
in	O
gastric	O
carcinoma	O
.	O

BACKGROUND	O
:	O
CDC4	O
/	O
FBXW7	O
,	O
encoding	O
a	O
ubiquitin	O
ligase	O
,	O
maps	O
to	O
4q32	O
and	O
has	O
been	O
implicated	O
as	O
a	O
tumor	O
suppressor	O
gene	O
and	O
therapeutic	O
target	O
in	O
many	O
tumor	O
types	O
.	O

Mutations	O
in	O
colonic	O
adenomas	O
,	O
and	O
the	O
frequent	O
losses	O
on	O
4q	O
described	O
in	O
gastric	O
cancer	O
prompt	O
speculation	O
about	O
the	O
role	O
of	O
CDC4	O
/	O
FBXW7	O
in	O
gastric	O
carcinogenesis	O
.	O

METHODS	O
:	O
We	O
assessed	O
the	O
role	O
of	O
CDC4	O
/	O
FBXW7	O
in	O
gastric	O
cancer	O
,	O
through	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
on	O
47	O
flow	O
-	O
sorted	O
gastric	O
carcinomas	O
including	O
early	O
-	O
onset	O
gastric	O
cancers	O
(	O
EOGC	O
)	O
and	O
xenografted	O
conventional	O
gastric	O
carcinomas	O
.	O

Ploidy	O
analysis	O
was	O
carried	O
out	O
on	O
39	O
EOGCs	O
and	O
immunohistochemistry	O
of	O
CDC4	O
/	O
FBXW7	O
and	O
its	O
substrates	O
c	O
-	O
myc	O
,	O
c	O
-	O
jun	O
,	O
Notch	O
and	O
cyclin	O
E	O
was	O
performed	O
on	O
204	O
gastric	O
carcinomas	O
using	O
tissue	O
microarrays	O
(	O
TMAs	O
)	O
.	O

Sequence	O
analysis	O
of	O
CDC4	O
/	O
FBXW7	O
was	O
carried	O
out	O
on	O
gastric	O
carcinoma	O
cell	O
lines	O
and	O
xenografts	O
.	O

RESULTS	O
:	O
Loss	O
of	O
heterozygosity	O
of	O
CDC4	O
/	O
FBXW7	O
occurred	O
in	O
32	O
%	O
of	O
EOGCs	O
,	O
and	O
correlated	O
with	O
loss	O
of	O
expression	O
in	O
26	O
%	O
.	O

Loss	O
of	O
expression	O
was	O
frequent	O
in	O
both	O
EOGC	O
and	O
conventional	O
gastric	O
cancers	O
.	O

No	O
CDC4	O
/	O
FBXW7	O
mutations	O
were	O
found	O
and	O
loss	O
of	O
CDC4	O
/	O
FBXW7	O
did	O
not	O
correlate	O
with	O
ploidy	O
status	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
loss	O
of	O
CDC4	O
/	O
FBXW7	O
expression	O
and	O
upregulation	O
of	O
c	O
-	O
myc	O
.	O

CONCLUSION	O
:	O
Loss	O
of	O
CDC4	O
/	O
FBXW7	O
appears	O
to	O
play	O
a	O
role	O
in	O
both	O
EOGC	O
and	O
conventional	O
gastric	O
carcinogenesis	O
,	O
and	O
c	O
-	O
myc	O
overexpression	O
is	O
likely	O
to	O
be	O
an	O
important	O
oncogenic	O
consequence	O
of	O
CDC4	O
/	O
FBXW7	O
loss	O
.	O

Pain	O
assessment	O
by	O
continuous	O
EEG	O
:	O
association	O
between	O
subjective	O
perception	O
of	O
tonic	O
pain	O
and	O
peak	O
frequency	O
of	O
alpha	O
oscillations	O
during	O
stimulation	O
and	O
at	O
rest	O
.	O

Recordings	O
of	O
neurophysiological	O
brain	O
responses	O
to	O
noxious	O
stimuli	O
have	O
been	O
traditionally	O
based	O
on	O
short	O
stimuli	O
,	O
in	O
the	O
order	O
of	O
milliseconds	O
,	O
which	O
induce	O
distinct	O
event	O
-	O
related	O
potentials	O
(	O
ERPs	O
)	O
.	O

However	O
,	O
using	O
such	O
stimuli	O
in	O
the	O
experimental	O
setting	O
is	O
disadvantageous	O
as	O
they	O
are	O
too	O
brief	O
to	O
faithfully	O
simulate	O
clinical	O
pain	O
.	O

We	O
aimed	O
at	O
utilizing	O
continuous	O
EEG	O
to	O
investigate	O
the	O
properties	O
of	O
peak	O
alpha	O
frequency	O
(	O
PAF	O
)	O
as	O
an	O
objective	O
cortical	O
measure	O
associated	O
with	O
subjective	O
perception	O
of	O
tonic	O
pain	O
.	O

Five	O
minute	O
long	O
continuous	O
EEG	O
was	O
recorded	O
in	O
18	O
healthy	O
volunteers	O
under	O
:	O
(	O
i	O
)	O
resting	O
-	O
state	O
;	O
(	O
ii	O
)	O
innocuous	O
temperature	O
;	O
and	O
(	O
iii	O
)	O
psychophysically	O
-	O
anchored	O
noxious	O
temperature	O
.	O

Numerical	O
pain	O
scores	O
(	O
NPSs	O
)	O
collected	O
during	O
the	O
application	O
of	O
tonic	O
noxious	O
stimuli	O
were	O
tested	O
for	O
correlation	O
with	O
peak	O
frequencies	O
of	O
alpha	O
power	O
-	O
curves	O
derived	O
from	O
central	O
,	O
temporal	O
and	O
frontal	O
electrodes	O
.	O

NPSs	O
and	O
PAFs	O
remained	O
stable	O
throughout	O
the	O
recording	O
conditions	O
(	O
RM	O
-	O
ANOVAs	O
;	O
Ps	O
>	O
0	O
.	O
51	O
)	O
.	O

In	O
the	O
noxious	O
condition	O
,	O
PAFs	O
obtained	O
at	O
the	O
bilateral	O
temporal	O
scalp	O
were	O
correlated	O
with	O
NPSs	O
(	O
Ps	O
<	O
0	O
.	O
001	O
)	O
.	O

Moreover	O
,	O
resting	O
-	O
state	O
PAFs	O
recorded	O
at	O
the	O
bilateral	O
temporal	O
scalp	O
were	O
correlated	O
with	O
NPSs	O
reported	O
during	O
the	O
noxious	O
condition	O
(	O
Ps	O
<	O
0	O
.	O
01	O
)	O
.	O

These	O
psychophysical	O
-	O
neurophysiological	O
relations	O
attest	O
to	O
the	O
properties	O
of	O
PAF	O
as	O
a	O
novel	O
cortical	O
objective	O
measure	O
of	O
subjective	O
perception	O
of	O
tonic	O
pain	O
.	O

Moreover	O
,	O
resting	O
-	O
state	O
PAFs	O
might	O
hold	O
inherent	O
pain	O
modulation	O
attributes	O
,	O
possibly	O
enabling	O
the	O
prediction	O
of	O
individual	O
responsiveness	O
to	O
prolonged	O
pain	O
.	O

The	O
relevance	O
of	O
PAF	O
to	O
the	O
neural	O
processing	O
of	O
tonic	O
pain	O
may	O
indicate	O
its	O
potential	O
to	O
advance	O
pain	O
research	O
as	O
well	O
as	O
clinical	O
pain	O
characterization	O
.	O

Acoustic	O
trauma	O
evokes	O
hyperactivity	O
and	O
changes	O
in	O
gene	O
expression	O
in	O
guinea	O
-	O
pig	O
auditory	O
brainstem	O
.	O

Hearing	O
loss	O
from	O
acoustic	O
trauma	O
is	O
a	O
risk	O
factor	O
for	O
tinnitus	O
.	O

Animal	O
models	O
using	O
acoustic	O
trauma	O
have	O
demonstrated	O
hyperactivity	O
in	O
central	O
auditory	O
pathways	O
,	O
which	O
has	O
been	O
suggested	O
as	O
a	O
substrate	O
for	O
tinnitus	O
.	O

We	O
used	O
a	O
guinea	O
-	O
pig	O
model	O
of	O
unilateral	O
acoustic	O
trauma	O
.	O

Within	O
the	O
same	O
animals	O
,	O
measurements	O
of	O
peripheral	O
hearing	O
loss	O
,	O
spontaneous	O
activity	O
of	O
single	O
neurons	O
in	O
the	O
inferior	O
colliculus	O
and	O
gene	O
expression	O
in	O
cochlear	O
nucleus	O
and	O
inferior	O
colliculus	O
were	O
combined	O
,	O
acutely	O
and	O
after	O
recovery	O
from	O
acoustic	O
trauma	O
.	O

Genes	O
investigated	O
related	O
to	O
inhibitory	O
(	O
GABA	O
-	O
A	O
receptor	O
subunit	O
alpha	O
1	O
;	O
glycine	O
receptor	O
subunit	O
alpha	O
1	O
)	O
and	O
excitatory	O
neurotransmission	O
(	O
glutamate	O
decarboxylase	O
1	O
;	O
glutamate	O
receptor	O
AMPA	O
subunit	O
alpha	O
2	O
;	O
glutamate	O
receptor	O
NMDA	O
subunit	O
1	O
)	O
,	O
regulation	O
of	O
transmitter	O
release	O
(	O
member	O
of	O
RAB	O
family	O
of	O
small	O
GTPase	O
;	O
RAB3	O
GTPase	O
activating	O
protein	O
subunit	O
1	O
)	O
and	O
neuronal	O
excitability	O
(	O
potassium	O
channel	O
subfamily	O
K	O
member	O
15	O
)	O
.	O

Acoustic	O
trauma	O
resulted	O
in	O
unilateral	O
hearing	O
loss	O
and	O
hyperactivity	O
bilaterally	O
in	O
inferior	O
colliculus	O
.	O

Changes	O
in	O
expression	O
of	O
different	O
mRNAs	O
were	O
observed	O
in	O
ipsilateral	O
cochlear	O
nucleus	O
and	O
in	O
ipsi	O
-	O
and	O
contralateral	O
inferior	O
colliculus	O
,	O
immediately	O
after	O
acoustic	O
trauma	O
,	O
and	O
after	O
2	O
and	O
4	O
weeks	O
'	O
recovery	O
.	O

Gene	O
expression	O
was	O
generally	O
reduced	O
immediately	O
after	O
trauma	O
,	O
followed	O
by	O
a	O
return	O
to	O
near	O
normal	O
levels	O
or	O
over	O
-	O
expression	O
as	O
recovery	O
time	O
increased	O
.	O

Different	O
mechanisms	O
appear	O
to	O
underlie	O
the	O
spontaneous	O
hyperactivity	O
observed	O
.	O

There	O
is	O
evidence	O
of	O
down	O
-	O
regulation	O
of	O
genes	O
associated	O
with	O
neuronal	O
inhibition	O
in	O
the	O
contralateral	O
inferior	O
colliculus	O
,	O
whereas	O
in	O
ipsilateral	O
cochlear	O
nucleus	O
,	O
competing	O
actions	O
of	O
inhibitory	O
and	O
excitatory	O
systems	O
seem	O
to	O
play	O
a	O
major	O
role	O
in	O
determining	O
overall	O
excitability	O
.	O

Telomere	O
/	O
telomerase	O
interplay	O
in	O
virus	O
-	O
driven	O
and	O
virus	O
-	O
independent	O
lymphomagenesis	O
:	O
pathogenic	O
and	O
clinical	O
implications	O
.	O

Telomerase	O
is	O
a	O
ribonucleoprotein	O
complex	O
critically	O
involved	O
in	O
extending	O
and	O
maintaining	O
telomeres	O
.	O

Unlike	O
the	O
majority	O
of	O
somatic	O
cells	O
,	O
in	O
which	O
hTERT	O
and	O
telomerase	O
activity	O
are	O
generally	O
silent	O
,	O
normal	O
lymphocytes	O
show	O
transient	O
physiological	O
hTERT	O
expression	O
and	O
telomerase	O
activity	O
according	O
to	O
their	O
differentiation	O
/	O
activation	O
status	O
.	O

During	O
lymphomagenesis	O
,	O
induction	O
of	O
persistent	O
telomerase	O
expression	O
and	O
activity	O
may	O
occur	O
before	O
or	O
after	O
telomere	O
shortening	O
,	O
as	O
a	O
consequence	O
of	O
the	O
different	O
mechanisms	O
through	O
which	O
transforming	O
factors	O
/	O
agents	O
may	O
activate	O
telomerase	O
.	O

Available	O
data	O
indicate	O
that	O
the	O
timing	O
of	O
telomerase	O
activation	O
may	O
allow	O
the	O
distinction	O
of	O
two	O
different	O
lymphomagenetic	O
models	O
:	O
(	O
i	O
)	O
an	O
early	O
activation	O
of	O
telomerase	O
via	O
exogenous	O
regulators	O
of	O
hTERT	O
,	O
along	O
with	O
an	O
increased	O
lymphocyte	O
growth	O
and	O
a	O
subsequent	O
selection	O
of	O
cells	O
with	O
increased	O
transforming	O
potential	O
may	O
characterize	O
several	O
virus	O
-	O
related	O
lymphoid	O
malignancies	O
;	O
(	O
ii	O
)	O
a	O
progressive	O
shortening	O
of	O
telomeres	O
,	O
leading	O
to	O
genetic	O
instability	O
which	O
favors	O
a	O
subsequent	O
activation	O
of	O
telomerase	O
via	O
endogenous	O
regulators	O
may	O
occur	O
in	O
most	O
virus	O
-	O
unrelated	O
lymphoid	O
tumors	O
.	O

These	O
models	O
may	O
have	O
clinically	O
relevant	O
implications	O
,	O
particularly	O
for	O
the	O
tailoring	O
of	O
therapeutic	O
strategies	O
targeting	O
telomerase	O
.	O

Angiogenesis	O
inhibitors	O
:	O
current	O
strategies	O
and	O
future	O
prospects	O
.	O

Angiogenesis	O
has	O
become	O
an	O
attractive	O
target	O
for	O
drug	O
therapy	O
because	O
of	O
its	O
key	O
role	O
in	O
tumor	O
growth	O
.	O

An	O
extensive	O
array	O
of	O
compounds	O
is	O
currently	O
in	O
preclinical	O
development	O
,	O
with	O
many	O
now	O
entering	O
the	O
clinic	O
and	O
/	O
or	O
achieving	O
approval	O
from	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
.	O

Several	O
regulatory	O
and	O
signaling	O
molecules	O
governing	O
angiogenesis	O
are	O
of	O
interest	O
,	O
including	O
growth	O
factors	O
(	O
eg	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
platelet	O
-	O
derived	O
growth	O
factor	O
,	O
fibroblast	O
growth	O
factor	O
,	O
and	O
epidermal	O
growth	O
factor	O
)	O
,	O
receptor	O
tyrosine	O
kinases	O
,	O
and	O
transcription	O
factors	O
such	O
as	O
hypoxia	O
inducible	O
factor	O
,	O
as	O
well	O
as	O
molecules	O
involved	O
in	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
and	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3	O
K	O
)	O
signaling	O
.	O

Pharmacologic	O
agents	O
have	O
been	O
identified	O
that	O
target	O
these	O
pathways	O
,	O
yet	O
for	O
some	O
agents	O
(	O
notably	O
thalidomide	O
)	O
,	O
an	O
understanding	O
of	O
the	O
specific	O
mechanisms	O
of	O
antitumor	O
action	O
has	O
proved	O
elusive	O
.	O

The	O
following	O
review	O
describes	O
key	O
molecular	O
mechanisms	O
and	O
novel	O
therapies	O
that	O
are	O
on	O
the	O
horizon	O
for	O
antiangiogenic	O
tumor	O
therapy	O
.	O

A	O
generative	O
model	O
for	O
image	O
segmentation	O
based	O
on	O
label	O
fusion	O
.	O

We	O
propose	O
a	O
nonparametric	O
,	O
probabilistic	O
model	O
for	O
the	O
automatic	O
segmentation	O
of	O
medical	O
images	O
,	O
given	O
a	O
training	O
set	O
of	O
images	O
and	O
corresponding	O
label	O
maps	O
.	O

The	O
resulting	O
inference	O
algorithms	O
rely	O
on	O
pairwise	O
registrations	O
between	O
the	O
test	O
image	O
and	O
individual	O
training	O
images	O
.	O

The	O
training	O
labels	O
are	O
then	O
transferred	O
to	O
the	O
test	O
image	O
and	O
fused	O
to	O
compute	O
the	O
final	O
segmentation	O
of	O
the	O
test	O
subject	O
.	O

Such	O
label	O
fusion	O
methods	O
have	O
been	O
shown	O
to	O
yield	O
accurate	O
segmentation	O
,	O
since	O
the	O
use	O
of	O
multiple	O
registrations	O
captures	O
greater	O
inter	O
-	O
subject	O
anatomical	O
variability	O
and	O
improves	O
robustness	O
against	O
occasional	O
registration	O
failures	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
manuscript	O
presents	O
the	O
first	O
comprehensive	O
probabilistic	O
framework	O
that	O
rigorously	O
motivates	O
label	O
fusion	O
as	O
a	O
segmentation	O
approach	O
.	O

The	O
proposed	O
framework	O
allows	O
us	O
to	O
compare	O
different	O
label	O
fusion	O
algorithms	O
theoretically	O
and	O
practically	O
.	O

In	O
particular	O
,	O
recent	O
label	O
fusion	O
or	O
multiatlas	O
segmentation	O
algorithms	O
are	O
interpreted	O
as	O
special	O
cases	O
of	O
our	O
framework	O
.	O

We	O
conduct	O
two	O
sets	O
of	O
experiments	O
to	O
validate	O
the	O
proposed	O
methods	O
.	O

In	O
the	O
first	O
set	O
of	O
experiments	O
,	O
we	O
use	O
39	O
brain	O
MRI	O
scans	O
-	O
with	O
manually	O
segmented	O
white	O
matter	O
,	O
cerebral	O
cortex	O
,	O
ventricles	O
and	O
subcortical	O
structures	O
-	O
to	O
compare	O
different	O
label	O
fusion	O
algorithms	O
and	O
the	O
widely	O
-	O
used	O
FreeSurfer	O
whole	O
-	O
brain	O
segmentation	O
tool	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
proposed	O
framework	O
yields	O
more	O
accurate	O
segmentation	O
than	O
FreeSurfer	O
and	O
previous	O
label	O
fusion	O
algorithms	O
.	O

In	O
a	O
second	O
experiment	O
,	O
we	O
use	O
brain	O
MRI	O
scans	O
of	O
282	O
subjects	O
to	O
demonstrate	O
that	O
the	O
proposed	O
segmentation	O
tool	O
is	O
sufficiently	O
sensitive	O
to	O
robustly	O
detect	O
hippocampal	O
volume	O
changes	O
in	O
a	O
study	O
of	O
aging	O
and	O
Alzheimer	O
'	O
s	O
Disease	O
.	O

Yellow	O
-	O
green	O
52	O
.	O
3W	O
laser	O
at	O
556	O
nm	O
based	O
on	O
frequency	O
doubling	O
of	O
a	O
diode	O
side	O
-	O
pumped	O
Q	O
-	O
switched	O
Nd	O
:	O
YAG	O
laser	O
.	O

We	O
demonstrate	O
a	O
high	O
-	O
power	O
556	O
nm	O
yellow	O
-	O
green	O
laser	O
generated	O
by	O
intracavity	O
frequency	O
doubling	O
of	O
a	O
diode	O
side	O
-	O
pumped	O
Nd	O
:	O
YAG	O
laser	O
at	O
1112	O
nm	O
.	O

A	O
symmetrical	O
L	O
-	O
shaped	O
flat	O
-	O
flat	O
cavity	O
was	O
employed	O
to	O
implement	O
efficient	O
operation	O
of	O
the	O
low	O
-	O
gain	O
1112	O
nm	O
transition	O
and	O
to	O
achieve	O
good	O
power	O
scalability	O
.	O

The	O
coatings	O
of	O
the	O
cavity	O
mirrors	O
were	O
carefully	O
designed	O
to	O
optimize	O
the	O
performance	O
of	O
the	O
laser	O
,	O
and	O
a	O
92W	O
continuous	O
wave	O
laser	O
output	O
at	O
1112	O
nm	O
was	O
achieved	O
when	O
the	O
pumping	O
power	O
of	O
the	O
laser	O
diodes	O
reached	O
960W	O
.	O

By	O
intracavity	O
frequency	O
doubling	O
of	O
the	O
fundamental	O
laser	O
in	O
a	O
lithium	O
triborate	O
crystal	O
,	O
the	O
maximum	O
power	O
of	O
the	O
frequency	O
-	O
doubled	O
output	O
at	O
556	O
nm	O
was	O
found	O
to	O
be	O
as	O
high	O
as	O
52	O
.	O
3W	O
with	O
a	O
pulse	O
repetition	O
frequency	O
of	O
10kHz	O
.	O

This	O
corresponds	O
to	O
an	O
optical	O
-	O
to	O
-	O
optical	O
conversion	O
efficiency	O
of	O
about	O
5	O
.	O
4	O
%	O
.	O

Betulin	O
induces	O
mitochondrial	O
cytochrome	O
c	O
release	O
associated	O
apoptosis	O
in	O
human	O
cancer	O
cells	O
.	O

We	O
examined	O
whether	O
betulin	O
,	O
a	O
naturally	O
abundant	O
compound	O
,	O
has	O
anticancer	O
functions	O
in	O
human	O
cancer	O
cells	O
.	O

The	O
results	O
showed	O
that	O
betulin	O
significantly	O
inhibited	O
cell	O
viability	O
in	O
cervix	O
carcinoma	O
HeLa	B
cells	O
,	O
hepatoma	O
HepG2	B
cells	O
,	O
lung	O
adenocarcinoma	O
A549	B
cells	O
,	O
and	O
breast	O
cancer	O
MCF	B
-	I
7	I
cells	O
with	O
IC	O
(	O
50	O
)	O
values	O
ranging	O
from	O
10	O
to	O
15	O
microg	O
/	O
mL	O
.	O

While	O
betulin	O
exhibited	O
only	O
moderate	O
anticancer	O
activity	O
in	O
other	O
human	O
cancer	O
cells	O
such	O
as	O
hepatoma	O
SK	B
-	I
HEP	I
-	I
1	I
cells	O
,	O
prostate	O
carcinoma	O
PC	B
-	I
3	I
,	O
and	O
lung	O
carcinoma	O
NCI	B
-	I
H460	I
,	O
with	O
IC	O
(	O
50	O
)	O
values	O
ranging	O
from	O
20	O
to	O
60	O
microg	O
/	O
mL	O
,	O
it	O
showed	O
minor	O
growth	O
inhibition	O
in	O
human	O
erythroleukemia	O
K562	B
cells	O
(	O
IC	O
(	O
50	O
)	O
>	O
100	O
microg	O
/	O
mL	O
)	O
.	O

We	O
further	O
investigated	O
the	O
mechanism	O
of	O
anticancer	O
activity	O
by	O
betulin	O
,	O
using	O
HeLa	B
cells	O
as	O
an	O
experimental	O
model	O
.	O

Betulin	O
(	O
10	O
microg	O
/	O
mL	O
)	O
induces	O
apoptotic	O
cell	O
death	O
,	O
as	O
evidenced	O
by	O
morphological	O
characteristics	O
such	O
as	O
membrane	O
phosphatidylserine	O
translocation	O
,	O
nuclear	O
condensation	O
/	O
fragmentation	O
,	O
and	O
apoptotic	O
body	O
formation	O
.	O

A	O
kinetics	O
analysis	O
showed	O
that	O
the	O
depolarization	O
of	O
mitochondrial	O
membrane	O
potential	O
and	O
the	O
release	O
of	O
mitochondrial	O
cytochrome	O
c	O
occurred	O
as	O
early	O
as	O
30	O
min	O
after	O
treatment	O
with	O
betulin	O
.	O

Betulin	O
,	O
unlike	O
its	O
chemical	O
derivative	O
betulinic	O
acid	O
,	O
did	O
not	O
directly	O
trigger	O
mitochondrial	O
cytochrome	O
c	O
release	O
in	O
isolated	O
mitochondria	O
.	O

Importantly	O
,	O
Bax	O
and	O
Bak	O
were	O
rapidly	O
translocated	O
to	O
the	O
mitochondria	O
30	O
min	O
after	O
betulin	O
treatment	O
.	O

The	O
sequential	O
activation	O
of	O
caspase	O
-	O
9	O
and	O
caspase	O
-	O
3	O
/	O
-	O
7	O
and	O
the	O
cleavage	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
were	O
observed	O
behind	O
those	O
mitochondrial	O
events	O
.	O

Furthermore	O
,	O
specific	O
downregulation	O
of	O
either	O
caspase	O
-	O
9	O
,	O
Bax	O
,	O
or	O
Bak	O
by	O
siRNA	O
effectively	O
reduced	O
PARP	O
cleavage	O
and	O
caspase	O
-	O
3	O
activation	O
.	O

Taken	O
together	O
,	O
the	O
lines	O
of	O
evidence	O
demonstrate	O
that	O
betulin	O
triggers	O
apoptosis	O
of	O
human	O
cancer	O
cells	O
through	O
the	O
intrinsic	O
apoptotic	O
pathway	O
.	O

Relationship	O
and	O
prognostic	O
significance	O
of	O
SPARC	O
and	O
VEGF	O
protein	O
expression	O
in	O
colon	O
cancer	O
.	O

BACKGROUND	O
:	O
SPARC	O
(	O
secreted	O
protein	O
,	O
acidic	O
and	O
rich	O
in	O
cysteine	O
)	O
is	O
closely	O
related	O
with	O
the	O
progress	O
,	O
invasion	O
and	O
metastasis	O
of	O
malignant	O
tumor	O
and	O
angiogenesis	O
.	O

METHODS	O
:	O
Using	O
human	O
colon	O
adenocarcinoma	O
tissues	O
(	O
hereinafter	O
referred	O
to	O
as	O
colon	O
cancer	O
)	O
and	O
their	O
corresponding	O
non	O
-	O
diseased	O
colon	O
from	O
114	O
patients	O
'	O
biopsies	O
,	O
the	O
expression	O
of	O
SPARC	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
were	O
investigated	O
by	O
immunohistochemistry	O
staining	O
to	O
assessment	O
the	O
relationship	O
between	O
SPARC	O
and	O
VEGF	O
,	O
as	O
well	O
as	O
their	O
prognostic	O
significance	O
in	O
patients	O
.	O

Evaluation	O
of	O
VEGF	O
expression	O
level	O
with	O
the	O
same	O
tissues	O
was	O
used	O
to	O
establish	O
the	O
antigenic	O
profiles	O
,	O
and	O
the	O
marker	O
of	O
CD34	O
staining	O
was	O
used	O
as	O
an	O
indicator	O
of	O
microvessel	O
density	O
(	O
MVD	O
)	O
.	O

RESULTS	O
:	O
SPARC	O
expression	O
was	O
mainly	O
in	O
the	O
stromal	O
cells	O
surrounding	O
the	O
colon	O
cancer	O
,	O
and	O
was	O
significant	O
difference	O
in	O
those	O
tissues	O
with	O
the	O
lymph	O
node	O
metastasis	O
and	O
differentiation	O
degree	O
of	O
tumor	O
.	O

Expression	O
of	O
SPARC	O
was	O
significantly	O
correlated	O
with	O
the	O
expression	O
of	O
VEGF	O
and	O
MVD	O
in	O
colon	O
cancer	O
tissues	O
.	O

Patients	O
with	O
low	O
or	O
absence	O
expressing	O
SPARC	O
had	O
significantly	O
worse	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
in	O
a	O
Single	O
Factor	O
Analysis	O
;	O
Cox	O
Regression	O
Analysis	O
,	O
SPARC	O
emerged	O
as	O
an	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
independent	O
prognostic	O
factor	O
for	O
colon	O
cancer	O
.	O

CONCLUSION	O
:	O
The	O
low	O
expression	O
or	O
absence	O
of	O
stromal	O
SPARC	O
was	O
an	O
independent	O
prognostic	O
factor	O
for	O
poor	O
prognosis	O
of	O
colon	O
cancer	O
.	O

SPARC	O
maybe	O
involved	O
in	O
the	O
regulation	O
of	O
anti	O
-	O
angiogenesis	O
by	O
which	O
it	O
may	O
serve	O
as	O
a	O
novel	O
target	O
for	O
colon	O
cancer	O
treatment	O
as	O
well	O
as	O
a	O
novel	O
distinctive	O
marker	O
.	O

Prognostic	O
significance	O
of	O
TRAIL	O
signaling	O
molecules	O
in	O
stage	O
II	O
and	O
III	O
colorectal	O
cancer	O
.	O

PURPOSE	O
:	O

We	O
previously	O
found	O
that	O
cellular	O
FLICE	O
-	O
inhibitory	O
protein	O
(	O
c	O
-	O
FLIP	O
)	O
,	O
caspase	O
8	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
receptor	O
2	O
(	O
DR5	O
)	O
are	O
major	O
regulators	O
of	O
cell	O
viability	O
and	O
chemotherapy	O
-	O
induced	O
apoptosis	O
in	O
colorectal	O
cancer	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
prognostic	O
significance	O
of	O
c	O
-	O
FLIP	O
,	O
caspase	O
8	O
,	O
TRAIL	O
and	O
DR5	O
expression	O
in	O
tissues	O
from	O
patients	O
with	O
stage	O
II	O
and	O
III	O
colorectal	O
cancer	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O

Tissue	O
microarrays	O
were	O
constructed	O
from	O
matched	O
normal	O
and	O
tumor	O
tissue	O
derived	O
from	O
patients	O
(	O
n	O
=	O
253	O
)	O
enrolled	O
in	O
a	O
phase	O
III	O
trial	O
of	O
adjuvant	O
5	O
-	O
fluorouracil	O
-	O
based	O
chemotherapy	O
versus	O
postoperative	O
observation	O
alone	O
.	O

TRAIL	O
,	O
DR5	O
,	O
caspase	O
8	O
,	O
and	O
c	O
-	O
FLIP	O
expression	O
levels	O
were	O
determined	O
by	O
immunohistochemistry	O
.	O

RESULTS	O
:	O

Colorectal	O
tumors	O
displayed	O
significantly	O
higher	O
expression	O
levels	O
of	O
c	O
-	O
FLIP	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
caspase	O
8	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
and	O
DR5	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
lower	O
levels	O
of	O
TRAIL	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
compared	O
with	O
matched	O
normal	O
tissue	O
.	O

In	O
univariate	O
analysis	O
,	O
higher	O
TRAIL	O
expression	O
in	O
the	O
tumor	O
was	O
associated	O
with	O
worse	O
overall	O
survival	O
(	O
P	O
=	O
0	O
.	O
026	O
)	O
,	O
with	O
a	O
trend	O
to	O
decreased	O
relapse	O
-	O
free	O
survival	O
(	O
RFS	O
;	O
P	O
=	O
0	O
.	O
06	O
)	O
,	O
and	O
higher	O
tumor	O
c	O
-	O
FLIP	O
expression	O
was	O
associated	O
with	O
a	O
significantly	O
decreased	O
RFS	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

Using	O
multivariate	O
predictive	O
modeling	O
for	O
RFS	O
in	O
all	O
patients	O
and	O
including	O
all	O
biomarkers	O
,	O
age	O
,	O
treatment	O
,	O
and	O
stage	O
,	O
we	O
found	O
that	O
the	O
model	O
was	O
significant	O
when	O
the	O
mean	O
tumor	O
c	O
-	O
FLIP	O
expression	O
score	O
and	O
disease	O
stage	O
were	O
included	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

As	O
regards	O
overall	O
survival	O
,	O
the	O
overall	O
model	O
was	O
predictive	O
when	O
both	O
TRAIL	O
expression	O
and	O
disease	O
stage	O
were	O
included	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O

High	O
c	O
-	O
FLIP	O
and	O
TRAIL	O
expression	O
may	O
be	O
independent	O
adverse	O
prognostic	O
markers	O
in	O
stage	O
II	O
and	O
III	O
colorectal	O
cancer	O
and	O
might	O
identify	O
patients	O
most	O
at	O
risk	O
of	O
relapse	O
.	O

Overexpression	O
of	O
Bax	O
inhibitor	O
-	O
1	O
(	O
BI	O
-	O
1	O
)	O
induces	O
cell	O
transformation	O
in	O
NIH3T3	B
cells	O
.	O

BI	O
-	O
1	O
(	O
Bax	O
inhibitor	O
-	O
1	O
)	O
,	O
an	O
apoptosis	O
-	O
inhibiting	O
gene	O
belonging	O
to	O
the	O
Bcl	O
-	O
2	O
protein	O
family	O
,	O
plays	O
an	O
important	O
role	O
in	O
mitochondrial	O
apoptosis	O
pathway	O
to	O
suppress	O
Bax	O
-	O
induced	O
apoptosis	O
.	O

To	O
investigate	O
the	O
potential	O
role	O
of	O
BI	O
-	O
1	O
in	O
promoting	O
cell	O
growth	O
and	O
tumorigenesis	O
,	O
in	O
the	O
present	O
study	O
we	O
overexpressed	O
the	O
BI	O
-	O
1	O
gene	O
in	O
NIH3T3	B
cells	O
using	O
the	O
lentivirus	O
-	O
mediated	O
gene	O
expression	O
system	O
.	O

Our	O
in	O
vitro	O
studies	O
showed	O
that	O
NIH3T3	B
cells	O
overexpressing	O
BI	O
-	O
1	O
displayed	O
a	O
significantly	O
higher	O
growth	O
rate	O
and	O
formed	O
more	O
and	O
larger	O
colonies	O
than	O
the	O
control	O
cells	O
.	O

In	O
addition	O
,	O
our	O
in	O
vivo	O
studies	O
indicated	O
that	O
the	O
lenti	O
-	O
BI	O
-	O
1	O
-	O
infected	O
cells	O
formed	O
obvious	O
tumours	O
,	O
while	O
no	O
tumours	O
were	O
formed	O
by	O
the	O
control	O
cells	O
after	O
subcutaneously	O
injected	O
into	O
nude	O
mice	O
.	O

These	O
results	O
strongly	O
suggested	O
that	O
the	O
BI	O
-	O
1	O
gene	O
might	O
play	O
a	O
crucial	O
role	O
in	O
neoplastic	O
genesis	O
and	O
development	O
.	O

Structure	O
of	O
human	O
hemoglobin	O
messenger	O
RNA	O
and	O
its	O
relation	O
to	O
hemoglobinopathies	O
.	O

1	O
.	O

One	O
-	O
fifth	O
to	O
1	O
/	O
4	O
of	O
globin	O
mRNA	O
is	O
untranslated	O
sequence	O
other	O
than	O
polyadenylic	O
acid	O
.	O

2	O
.	O

The	O
untranslated	O
sequences	O
of	O
mRNA	O
vary	O
markedly	O
in	O
their	O
sequence	O
and	O
in	O
their	O
length	O
.	O

3	O
.	O

Globin	O
mRNAs	O
demonstrate	O
a	O
marked	O
bias	O
in	O
codon	O
selection	O
.	O

4	O
.	O

Viral	O
mRNA	O
shows	O
a	O
quite	O
different	O
pattern	O
of	O
codon	O
selection	O
;	O
therefore	O
,	O
the	O
selection	O
of	O
codons	O
is	O
not	O
uniform	O
for	O
all	O
mRNAs	O
functioning	O
in	O
animal	O
cells	O
.	O

5	O
.	O

Elongated	O
hemoglobin	O
chains	O
can	O
be	O
accounted	O
for	O
by	O
frame	O
-	O
shift	O
mutations	O
,	O
or	O
point	O
mutations	O
within	O
the	O
normal	O
termination	O
codon	O
.	O

The	O
additional	O
amino	O
acids	O
are	O
then	O
coded	O
for	O
by	O
sequences	O
that	O
are	O
normally	O
untranslated	O
.	O

6	O
.	O

Certain	O
hemoglobin	O
deletion	O
mutants	O
occur	O
at	O
sites	O
where	O
there	O
are	O
partially	O
reiterated	O
sequences	O
within	O
the	O
heomoglobin	O
messenger	O
RNA	O
.	O

Anti	O
-	O
metastasis	O
effects	O
of	O
gallic	O
acid	O
on	O
gastric	O
cancer	O
cells	O
involves	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
and	O
downregulation	O
of	O
PI3	O
K	O
/	O
AKT	O
/	O
small	O
GTPase	O
signals	O
.	O

Polyphenols	O
are	O
natural	O
antioxidants	O
that	O
are	O
thought	O
to	O
contribute	O
to	O
prevention	O
of	O
cardiovascular	O
disease	O
and	O
malignancy	O
.	O

Although	O
many	O
studies	O
have	O
been	O
carried	O
out	O
to	O
investigate	O
the	O
chemopreventive	O
role	O
of	O
flavonoids	O
,	O
less	O
attention	O
has	O
been	O
focused	O
on	O
phenolic	O
acids	O
.	O

In	O
this	O
study	O
,	O
the	O
aim	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
phenolic	O
acids	O
found	O
abundantly	O
in	O
vegetables	O
,	O
i	O
.	O
e	O
.	O
gallic	O
acid	O
(	O
GA	O
)	O
,	O
caffeic	O
acid	O
(	O
CA	O
)	O
and	O
protocatechuic	O
acid	O
(	O
PCA	O
)	O
,	O
on	O
the	O
inhibition	O
of	O
gastric	O
adenocarcinoma	O
(	O
AGS	O
)	O
cell	O
metastasis	O
.	O

The	O
results	O
showed	O
0	O
.	O
01	O
mM	O
GA	O
induced	O
the	O
same	O
level	O
of	O
cell	O
toxicity	O
as	O
4	O
.	O
0mM	O
PCA	O
.	O

Using	O
wound	O
-	O
healing	O
assay	O
and	O
Boyden	O
chamber	O
assay	O
,	O
GA	O
had	O
potent	O
inhibitory	O
effects	O
on	O
AGS	O
cell	O
migration	O
.	O

The	O
expression	O
of	O
MMP	O
-	O
2	O
/	O
9	O
of	O
AGS	O
cells	O
was	O
inhibited	O
by	O
2	O
.	O
0	O
microM	O
of	O
GA	O
.	O

It	O
is	O
possible	O
that	O
the	O
suppressive	O
effect	O
of	O
GA	O
on	O
MMP	O
-	O
2	O
/	O
9	O
might	O
involve	O
the	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
.	O

Multiple	O
proteins	O
involved	O
in	O
metastasis	O
and	O
the	O
cytoskeletal	O
reorganization	O
signal	O
pathway	O
,	O
including	O
Ras	O
,	O
Cdc42	O
,	O
Rac1	O
,	O
RhoA	O
,	O
RhoB	O
,	O
PI3	O
K	O
and	O
p38MAPK	O
,	O
were	O
also	O
inhibited	O
by	O
GA	O
.	O

Furthermore	O
,	O
immunoreactivity	O
assay	O
of	O
cytoskeletal	O
F	O
-	O
actin	O
demonstrated	O
a	O
significant	O
inhibitory	O
effect	O
of	O
GA	O
treatment	O
.	O

In	O
conclusion	O
,	O
GA	O
may	O
have	O
the	O
potential	O
to	O
be	O
an	O
effective	O
agent	O
for	O
prevention	O
and	O
treatment	O
of	O
gastric	O
cancer	O
metastasis	O
.	O

1	O
,	O
4	O
-	O
phenylenebis	O
(	O
methylene	O
)	O
selenocyanate	O
,	O
but	O
not	O
selenomethionine	O
,	O
inhibits	O
androgen	O
receptor	O
and	O
Akt	O
signaling	O
in	O
human	O
prostate	O
cancer	O
cells	O
.	O

The	O
lack	O
of	O
treatment	O
for	O
worried	O
-	O
well	O
patients	O
with	O
high	O
-	O
grade	O
prostatic	O
intraepithelial	O
neoplasia	O
combined	O
with	O
issues	O
of	O
recurrence	O
and	O
hormone	O
resistance	O
in	O
prostate	O
cancer	O
survivors	O
remains	O
a	O
major	O
public	O
health	O
obstacle	O
.	O

The	O
long	O
latency	O
of	O
prostate	O
cancer	O
development	O
provides	O
an	O
opportunity	O
to	O
intervene	O
with	O
agents	O
of	O
known	O
mechanisms	O
at	O
various	O
stages	O
of	O
disease	O
progression	O
.	O

A	O
number	O
of	O
signaling	O
cascades	O
have	O
been	O
shown	O
to	O
play	O
important	O
roles	O
in	O
prostate	O
cancer	O
development	O
and	O
progression	O
,	O
including	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
and	O
phosphatidylinositol	O
3	O
-	O
kinase	O
/	O
Akt	O
signaling	O
pathways	O
.	O

Crosstalk	O
between	O
these	O
two	O
pathways	O
is	O
also	O
thought	O
to	O
contribute	O
to	O
progression	O
and	O
hormone	O
-	O
refractory	O
prostate	O
disease	O
.	O

Our	O
initial	O
investigations	O
show	O
that	O
the	O
naturally	O
occurring	O
organoselenium	O
compound	O
selenomethionine	O
(	O
SM	O
)	O
and	O
the	O
synthetic	O
1	O
,	O
4	O
-	O
phenylenebis	O
(	O
methylene	O
)	O
selenocyanate	O
(	O
p	O
-	O
XSC	O
)	O
can	O
inhibit	O
human	O
prostate	O
cancer	O
cell	O
viability	O
;	O
however	O
,	O
in	O
contrast	O
to	O
SM	O
,	O
p	O
-	O
XSC	O
is	O
active	O
at	O
physiologically	O
relevant	O
doses	O
.	O

In	O
the	O
current	O
investigation	O
,	O
we	O
show	O
that	O
p	O
-	O
XSC	O
,	O
but	O
not	O
an	O
equivalent	O
dose	O
of	O
SM	O
,	O
alters	O
molecular	O
targets	O
and	O
induces	O
apoptosis	O
in	O
androgen	O
-	O
responsive	O
LNCaP	B
and	O
androgen	O
-	O
independent	O
LNCaP	B
C4	I
-	I
2	I
human	O
prostate	O
cancer	O
cells	O
.	O

p	O
-	O
XSC	O
effectively	O
inhibits	O
AR	O
expression	O
and	O
transcriptional	O
activity	O
in	O
both	O
cell	O
lines	O
.	O

p	O
-	O
XSC	O
also	O
decreases	O
Akt	O
phosphorylation	O
as	O
well	O
as	O
Akt	O
-	O
specific	O
phosphorylation	O
of	O
the	O
AR	O
.	O

Inhibition	O
of	O
Akt	O
,	O
however	O
,	O
does	O
not	O
fully	O
attenuate	O
p	O
-	O
XSC	O
-	O
mediated	O
downregulation	O
of	O
AR	O
activity	O
,	O
suggesting	O
that	O
inhibition	O
of	O
AR	O
signaling	O
by	O
p	O
-	O
XSC	O
does	O
not	O
occur	O
solely	O
through	O
alterations	O
in	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
/	O
Akt	O
survival	O
pathway	O
.	O

Our	O
data	O
suggest	O
that	O
p	O
-	O
XSC	O
inhibits	O
multiple	O
signaling	O
pathways	O
in	O
prostate	O
cancer	O
,	O
likely	O
accounting	O
for	O
the	O
downstream	O
effects	O
on	O
proliferation	O
and	O
apoptosis	O
.	O

Listerine	O
:	O
past	O
,	O
present	O
and	O
future	O
-	O
-	O
a	O
test	O
of	O
thyme	O
.	O

Listerine	O
,	O
a	O
mouthrinse	O
composed	O
of	O
a	O
mixture	O
of	O
essential	O
oils	O
,	O
was	O
created	O
in	O
1879	O
and	O
was	O
originally	O
formulated	O
as	O
a	O
surgical	O
antiseptic	O
.	O

In	O
spite	O
of	O
its	O
known	O
antimicrobial	O
properties	O
it	O
was	O
thought	O
of	O
as	O
a	O
product	O
in	O
search	O
of	O
a	O
use	O
and	O
promoted	O
as	O
a	O
deterrent	O
for	O
halitosis	O
and	O
as	O
a	O
floor	O
cleaner	O
.	O

In	O
the	O
last	O
several	O
years	O
Listerine	O
has	O
emerged	O
as	O
a	O
bona	O
fide	O
therapeutic	O
agent	O
for	O
reduction	O
of	O
plaque	O
induced	O
oral	O
diseases	O
.	O

In	O
contrast	O
to	O
the	O
inconsistent	O
history	O
of	O
Listerine	O
,	O
systemic	O
antibiotics	O
discovered	O
in	O
the	O
1940	O
'	O
s	O
were	O
heralded	O
as	O
miracle	O
drugs	O
.	O

However	O
,	O
the	O
value	O
of	O
prophylactic	O
usage	O
of	O
antibiotics	O
has	O
come	O
under	O
scrutiny	O
as	O
a	O
result	O
of	O
increasing	O
resistance	O
and	O
adverse	O
reactions	O
.	O

Moreover	O
,	O
reports	O
by	O
both	O
American	O
and	O
British	O
professional	O
societies	O
have	O
led	O
to	O
a	O
re	O
-	O
evaluation	O
of	O
the	O
relative	O
risks	O
associated	O
with	O
plaque	O
induced	O
bacteremia	O
when	O
twice	O
-	O
yearly	O
visits	O
to	O
dental	O
professionals	O
are	O
compared	O
to	O
daily	O
activities	O
.	O

These	O
new	O
recommendations	O
and	O
revelations	O
open	O
the	O
door	O
for	O
local	O
antimicrobial	O
approaches	O
to	O
reduce	O
the	O
challenge	O
of	O
plaque	O
-	O
induced	O
bacteremias	O
.	O

These	O
issues	O
will	O
be	O
discussed	O
in	O
the	O
context	O
of	O
Listerine	O
,	O
its	O
intricate	O
and	O
complicated	O
past	O
,	O
and	O
its	O
connection	O
to	O
current	O
uses	O
in	O
oral	O
health	O
and	O
beyond	O
.	O

Ventral	O
and	O
dorsal	O
striatal	O
dopamine	O
efflux	O
and	O
behavior	O
in	O
rats	O
with	O
simple	O
vs	O
.	O
co	O
-	O
morbid	O
histories	O
of	O
cocaine	O
sensitization	O
and	O
neonatal	O
ventral	O
hippocampal	O
lesions	O
.	O

UNLABELLED	O
:	O

RATIONAL	O
:	O
Exposing	O
animal	O
models	O
of	O
mental	O
illness	O
to	O
addictive	O
drugs	O
provides	O
an	O
approach	O
to	O
understanding	O
the	O
neural	O
etiology	O
of	O
dual	O
diagnosis	O
disorders	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
neonatal	O
ventral	O
hippocampal	O
lesions	O
(	O
NVHL	O
)	O
in	O
rats	O
produce	O
features	O
of	O
both	O
schizophrenia	O
and	O
addiction	O
vulnerability	O
.	O

OBJECTIVE	O
:	O

This	O
study	O
investigated	O
ventral	O
and	O
dorsal	O
striatal	O
dopamine	O
(	O
DA	O
)	O
efflux	O
in	O
NVHL	O
rats	O
combined	O
with	O
behavioral	O
sensitization	O
to	O
cocaine	O
.	O

METHODS	O
:	O

Adult	O
NVHL	O
vs	O
.	O
SHAM	O
-	O
operated	O
rats	O
underwent	O
a	O
5	O
-	O
day	O
injection	O
series	O
of	O
cocaine	O
(	O
15	O
mg	O
/	O
kg	O
/	O
day	O
)	O
vs	O
.	O
saline	O
.	O

One	O
week	O
later	O
,	O
rats	O
were	O
cannulated	O
in	O
nucleus	O
accumbens	O
SHELL	O
,	O
CORE	O
,	O
or	O
caudate	O
-	O
putamen	O
.	O

Another	O
week	O
later	O
,	O
in	O
vivo	O
microdialysis	O
sampled	O
DA	O
during	O
locomotor	O
testing	O
in	O
which	O
a	O
single	O
cocaine	O
injection	O
(	O
15	O
mg	O
/	O
kg	O
)	O
was	O
delivered	O
.	O

RESULTS	O
:	O

NVHLs	O
and	O
cocaine	O
history	O
significantly	O
increased	O
behavioral	O
activation	O
approximately	O
2	O
-	O
fold	O
over	O
SHAM	O
-	O
saline	O
history	O
rats	O
.	O

DA	O
efflux	O
curves	O
corresponded	O
time	O
dependently	O
with	O
the	O
cocaine	O
injection	O
and	O
locomotor	O
curves	O
and	O
varied	O
significantly	O
by	O
striatal	O
region	O
:	O
Baseline	O
DA	O
levels	O
increased	O
5	O
-	O
fold	O
while	O
cocaine	O
-	O
stimulated	O
DA	O
efflux	O
decreased	O
by	O
half	O
across	O
a	O
ventral	O
to	O
dorsal	O
striatal	O
gradient	O
.	O

However	O
,	O
NVHLs	O
,	O
prior	O
cocaine	O
history	O
,	O
and	O
individual	O
differences	O
in	O
behavior	O
were	O
not	O
underpinned	O
by	O
differential	O
DA	O
efflux	O
overall	O
or	O
within	O
any	O
striatal	O
region	O
.	O

CONCLUSION	O
:	O

Differences	O
in	O
ventral	O
/	O
dorsal	O
striatal	O
DA	O
efflux	O
are	O
not	O
present	O
in	O
and	O
are	O
not	O
required	O
for	O
producing	O
differential	O
levels	O
of	O
acute	O
cocaine	O
-	O
induced	O
behavioral	O
activation	O
in	O
NVHLs	O
with	O
and	O
without	O
a	O
behaviorally	O
sensitizing	O
cocaine	O
history	O
.	O

These	O
findings	O
suggest	O
other	O
neurotransmitter	O
systems	O
,	O
and	O
alterations	O
in	O
striatal	O
network	O
function	O
post	O
-	O
synaptic	O
to	O
DA	O
transmission	O
are	O
more	O
important	O
to	O
understanding	O
the	O
interactive	O
effects	O
of	O
addictive	O
drugs	O
and	O
mental	O
illness	O
.	O

Adenovirus	O
5	O
E1A	O
enhances	O
histone	O
deacetylase	O
inhibitors	O
-	O
induced	O
apoptosis	O
through	O
Egr	O
-	O
1	O
-	O
mediated	O
Bim	O
upregulation	O
.	O

Histone	O
deacetylase	O
inhibitors	O
(	O
HDACi	O
)	O
are	O
potent	O
anti	O
-	O
cancer	O
agents	O
for	O
variety	O
of	O
cancer	O
types	O
.	O

Suberoylanilide	O
hydroxamic	O
acid	O
(	O
SAHA	O
)	O
has	O
been	O
approved	O
as	O
a	O
drug	O
to	O
treat	O
cutaneous	O
T	O
cell	O
lymphoma	O
,	O
and	O
the	O
combination	O
of	O
HDACi	O
and	O
other	O
agents	O
have	O
been	O
actively	O
tested	O
in	O
many	O
clinical	O
trials	O
.	O

Adenovirus	O
5	O
early	O
region	O
1A	O
(	O
E1A	O
)	O
has	O
been	O
shown	O
to	O
exhibit	O
high	O
tumor	O
suppressor	O
activity	O
,	O
and	O
gene	O
therapy	O
using	O
E1A	O
has	O
been	O
tested	O
in	O
clinical	O
trials	O
.	O

Here	O
,	O
we	O
showed	O
that	O
proapoptotic	O
activity	O
of	O
HDACi	O
was	O
robustly	O
enhanced	O
by	O
E1A	O
in	O
multiple	O
cancer	O
cells	O
,	O
but	O
not	O
in	O
normal	O
cells	O
.	O

Moreover	O
,	O
we	O
showed	O
that	O
combination	O
of	O
E1A	O
gene	O
therapy	O
and	O
SAHA	O
showed	O
high	O
therapeutic	O
efficacy	O
with	O
low	O
toxicity	O
in	O
vivo	O
ovarian	O
and	O
breast	O
xenograft	O
models	O
.	O

SAHA	O
downregulated	O
Bcl	O
-	O
XL	O
and	O
upregulated	O
proapoptotic	O
BH3	O
-	O
only	O
protein	O
Bim	O
,	O
whose	O
expression	O
was	O
further	O
enhanced	O
by	O
E1A	O
in	O
cancer	O
cells	O
.	O

These	O
alterations	O
of	O
Bcl	O
-	O
2	O
family	O
proteins	O
were	O
critical	O
for	O
apoptosis	O
induced	O
by	O
the	O
combination	O
in	O
cancer	O
cells	O
.	O

SAHA	O
enhanced	O
acetylation	O
of	O
histone	O
H3	O
in	O
Bim	O
promoter	O
region	O
,	O
while	O
E1A	O
upregulated	O
Egr	O
-	O
1	O
,	O
which	O
was	O
directly	O
involved	O
in	O
Bim	O
transactivation	O
.	O

Together	O
,	O
our	O
results	O
provide	O
not	O
only	O
a	O
novel	O
insight	O
into	O
the	O
mechanisms	O
underlying	O
anti	O
-	O
tumor	O
activity	O
of	O
E1A	O
,	O
but	O
also	O
a	O
rationale	O
for	O
the	O
combined	O
HDACi	O
and	O
E1A	O
gene	O
therapy	O
in	O
future	O
clinical	O
trials	O
.	O

Sanguinarine	O
induces	O
apoptosis	O
of	O
human	O
osteosarcoma	O
cells	O
through	O
the	O
extrinsic	O
and	O
intrinsic	O
pathways	O
.	O

The	O
quaternary	O
benzo	O
[	O
c	O
]	O
phenanthridine	O
alkaloid	O
sanguinarine	O
inhibits	O
the	O
proliferation	O
of	O
cancerous	O
cells	O
from	O
different	O
origins	O
,	O
including	O
lung	O
,	O
breast	O
,	O
pancreatic	O
and	O
colon	O
,	O
but	O
nothing	O
is	O
known	O
of	O
its	O
effects	O
on	O
osteosarcoma	O
,	O
a	O
primary	O
malignant	O
bone	O
tumour	O
.	O

We	O
have	O
found	O
that	O
sanguinarine	O
alters	O
the	O
morphology	O
and	O
reduces	O
the	O
viability	O
of	O
MG	B
-	I
63	I
and	O
SaOS	B
-	I
2	I
human	O
osteosarcoma	O
cell	O
lines	O
in	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Incubation	O
with	O
1	O
micromol	O
/	O
L	O
sanguinarine	O
for	O
4	O
and	O
24h	O
killed	O
more	O
efficiently	O
MG	B
-	I
63	I
cells	O
than	O
SaOS	B
-	I
2	I
cells	O
,	O
while	O
incubation	O
with	O
5	O
micromol	O
/	O
L	O
sanguinarine	O
killed	O
almost	O
100	O
%	O
of	O
both	O
cell	O
populations	O
within	O
24h	O
.	O

This	O
treatment	O
also	O
changed	O
the	O
mitochondrial	O
membrane	O
potential	O
in	O
both	O
MG	B
-	I
63	I
and	O
SaOS	B
-	I
2	I
cells	O
within	O
1h	O
,	O
caused	O
chromatin	O
condensation	O
and	O
the	O
formation	O
of	O
apoptotic	O
bodies	O
.	O

It	O
activated	O
multicaspases	O
,	O
and	O
increased	O
the	O
activities	O
of	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
9	O
in	O
both	O
MG	B
-	I
63	I
and	O
SaOS	B
-	I
2	I
cells	O
.	O

These	O
data	O
highlight	O
sanguinarine	O
as	O
a	O
novel	O
potential	O
agent	O
for	O
bone	O
cancer	O
therapy	O
.	O

Using	O
a	O
web	O
-	O
based	O
orthopaedic	O
clinic	O
in	O
the	O
curricular	O
teaching	O
of	O
a	O
German	O
university	O
hospital	O
:	O
analysis	O
of	O
learning	O
effect	O
,	O
student	O
usage	O
and	O
reception	O
.	O

PURPOSE	O
:	O

Modern	O
teaching	O
concepts	O
for	O
undergraduate	O
medical	O
students	O
in	O
Germany	O
include	O
problem	O
based	O
learning	O
as	O
a	O
major	O
component	O
of	O
the	O
new	O
licensing	O
regulations	O
for	O
physicians	O
.	O

Here	O
we	O
describe	O
the	O
usage	O
of	O
a	O
web	O
-	O
based	O
virtual	O
outpatient	O
clinic	O
in	O
the	O
teaching	O
curriculum	O
of	O
undergraduate	O
medical	O
students	O
,	O
its	O
effect	O
on	O
learning	O
success	O
,	O
and	O
student	O
reception	O
.	O

METHODS	O
:	O

Fifth	O
year	O
medial	O
students	O
were	O
requested	O
to	O
examine	O
7	O
virtual	O
orthopaedic	O
patients	O
which	O
had	O
been	O
created	O
by	O
the	O
authors	O
using	O
the	O
Inmedea	O
-	O
Simulator	O
.	O

They	O
also	O
had	O
to	O
take	O
a	O
multiple	O
-	O
choice	O
examination	O
on	O
two	O
different	O
occasions	O
and	O
their	O
utilisation	O
of	O
the	O
simulator	O
was	O
analysed	O
subjectively	O
and	O
objectively	O
.	O

RESULTS	O
:	O

One	O
hundred	O
and	O
sixty	O
students	O
took	O
part	O
in	O
the	O
study	O
.	O

The	O
average	O
age	O
was	O
24	O
.	O
9	O
years	O
,	O
60	O
%	O
were	O
female	O
.	O

Most	O
of	O
the	O
participants	O
studied	O
on	O
their	O
own	O
using	O
their	O
private	O
computer	O
with	O
a	O
fast	O
internet	O
-	O
connection	O
at	O
home	O
.	O

The	O
average	O
usage	O
time	O
was	O
263	O
min	O
,	O
most	O
of	O
the	O
students	O
worked	O
with	O
the	O
system	O
in	O
the	O
afternoon	O
,	O
although	O
a	O
considerable	O
number	O
used	O
it	O
late	O
in	O
the	O
night	O
.	O

Regarding	O
learning	O
success	O
,	O
we	O
found	O
that	O
the	O
examination	O
results	O
were	O
significantly	O
better	O
after	O
using	O
the	O
system	O
(	O
7	O
.	O
66	O
versus	O
8	O
.	O
37	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Eighty	O
percent	O
of	O
the	O
students	O
enjoyed	O
dealing	O
with	O
the	O
virtual	O
patients	O
emphasizing	O
the	O
completeness	O
of	O
patient	O
cases	O
,	O
the	O
artistic	O
graphic	O
design	O
and	O
the	O
expert	O
comments	O
available	O
,	O
as	O
well	O
as	O
the	O
good	O
applicability	O
to	O
real	O
cases	O
.	O

Eighty	O
-	O
seven	O
percent	O
of	O
the	O
students	O
graded	O
the	O
virtual	O
orthopaedic	O
clinic	O
as	O
appropriate	O
to	O
teach	O
orthopaedic	O
content	O
.	O

CONCLUSION	O
:	O

Using	O
the	O
Inmedea	O
-	O
Simulator	O
is	O
an	O
effective	O
method	O
to	O
enhance	O
students	O
'	O
learning	O
efficacy	O
.	O

The	O
way	O
the	O
system	O
was	O
used	O
by	O
the	O
students	O
emphasises	O
the	O
advantages	O
of	O
the	O
internet	O
-	O
like	O
free	O
time	O
management	O
and	O
the	O
implementation	O
of	O
multimedia	O
-	O
based	O
content	O
.	O

Constitutively	O
nuclear	O
FOXO3a	O
localization	O
predicts	O
poor	O
survival	O
and	O
promotes	O
Akt	O
phosphorylation	O
in	O
breast	O
cancer	O
.	O

BACKGROUND	O
:	O
The	O
PI3	O
K	O
-	O
Akt	O
signal	O
pathway	O
plays	O
a	O
key	O
role	O
in	O
tumorigenesis	O
and	O
the	O
development	O
of	O
drug	O
-	O
resistance	O
.	O

Cytotoxic	O
chemotherapy	O
resistance	O
is	O
linked	O
to	O
limited	O
therapeutic	O
options	O
and	O
poor	O
prognosis	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Examination	O
of	O
FOXO3a	O
and	O
phosphorylated	O
-	O
Akt	O
(	O
P	O
-	O
Akt	O
)	O
expression	O
in	O
breast	O
cancer	O
tissue	O
microarrays	O
showed	O
nuclear	O
FOXO3a	O
was	O
associated	O
with	O
lymph	O
node	O
positivity	O
(	O
p	O
=	O
0	O
.	O
052	O
)	O
,	O
poor	O
prognosis	O
(	O
p	O
=	O
0	O
.	O
014	O
)	O
,	O
and	O
P	O
-	O
Akt	O
expression	O
in	O
invasive	O
ductal	O
carcinoma	O
.	O

Using	O
tamoxifen	O
and	O
doxorubicin	O
-	O
sensitive	O
and	O
-	O
resistant	O
breast	O
cancer	O
cell	O
lines	O
as	O
models	O
,	O
we	O
found	O
that	O
doxorubicin	O
-	O
but	O
not	O
tamoxifen	O
-	O
resistance	O
is	O
associated	O
with	O
nuclear	O
accumulation	O
of	O
FOXO3a	O
,	O
consistent	O
with	O
the	O
finding	O
that	O
sustained	O
nuclear	O
FOXO3a	O
is	O
associated	O
with	O
poor	O
prognosis	O
.	O

We	O
also	O
established	O
that	O
doxorubicin	O
treatment	O
induces	O
proliferation	O
arrest	O
and	O
FOXO3a	O
nuclear	O
relocation	O
in	O
sensitive	O
breast	O
cancer	O
cells	O
.	O

Induction	O
of	O
FOXO3a	O
activity	O
in	O
doxorubicin	O
-	O
sensitive	O
MCF	B
-	I
7	I
cells	O
was	O
sufficient	O
to	O
promote	O
Akt	O
phosphorylation	O
and	O
arrest	O
cell	O
proliferation	O
.	O

Conversely	O
,	O
knockdown	O
of	O
endogenous	O
FOXO3a	O
expression	O
reduced	O
PI3	O
K	O
/	O
Akt	O
activity	O
.	O

Using	O
MDA	B
-	I
MB	I
-	I
231	I
cells	O
,	O
in	O
which	O
FOXO3a	O
activity	O
can	O
be	O
induced	O
by	O
4	O
-	O
hydroxytamoxifen	O
,	O
we	O
showed	O
that	O
FOXO3a	O
induction	O
up	O
-	O
regulates	O
PI3	O
K	O
-	O
Akt	O
activity	O
and	O
enhanced	O
doxorubicin	O
resistance	O
.	O

However	O
FOXO3a	O
induction	O
has	O
little	O
effect	O
on	O
cell	O
proliferation	O
,	O
indicating	O
that	O
FOXO3a	O
or	O
its	O
downstream	O
activity	O
is	O
deregulated	O
in	O
the	O
cytotoxic	O
drug	O
resistant	O
breast	O
cancer	O
cells	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
sustained	O
FOXO3a	O
activation	O
can	O
enhance	O
hyperactivation	O
of	O
the	O
PI3	O
K	O
/	O
Akt	O
pathway	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
Together	O
these	O
data	O
suggest	O
that	O
lymph	O
node	O
metastasis	O
and	O
poor	O
survival	O
in	O
invasive	O
ductal	O
breast	O
carcinoma	O
are	O
linked	O
to	O
an	O
uncoupling	O
of	O
the	O
Akt	O
-	O
FOXO3a	O
signaling	O
axis	O
.	O

In	O
these	O
breast	O
cancers	O
activated	O
Akt	O
fails	O
to	O
inactivate	O
and	O
re	O
-	O
localize	O
FOXO3a	O
to	O
the	O
cytoplasm	O
,	O
and	O
nuclear	O
-	O
targeted	O
FOXO3a	O
does	O
not	O
induce	O
cell	O
death	O
or	O
cell	O
cycle	O
arrest	O
.	O

As	O
such	O
,	O
sustained	O
nuclear	O
FOXO3a	O
expression	O
in	O
breast	O
cancer	O
may	O
culminate	O
in	O
cancer	O
progression	O
and	O
the	O
development	O
of	O
an	O
aggressive	O
phenotype	O
similar	O
to	O
that	O
observed	O
in	O
cytotoxic	O
chemotherapy	O
resistant	O
breast	O
cancer	O
cell	O
models	O
.	O

The	O
neural	O
stem	O
cell	O
fate	O
determinant	O
TLX	O
promotes	O
tumorigenesis	O
and	O
genesis	O
of	O
cells	O
resembling	O
glioma	O
stem	O
cells	O
.	O

A	O
growing	O
body	O
of	O
evidence	O
indicates	O
that	O
deregulation	O
of	O
stem	O
cell	O
fate	O
determinants	O
is	O
a	O
hallmark	O
of	O
many	O
types	O
of	O
malignancies	O
.	O

The	O
neural	O
stem	O
cell	O
fate	O
determinant	O
TLX	O
plays	O
a	O
pivotal	O
role	O
in	O
neurogenesis	O
in	O
the	O
adult	O
brain	O
by	O
maintaining	O
neural	O
stem	O
cells	O
.	O

Here	O
,	O
we	O
report	O
a	O
tumorigenic	O
role	O
of	O
TLX	O
in	O
brain	O
tumor	O
initiation	O
and	O
progression	O
.	O

Increased	O
TLX	O
expression	O
was	O
observed	O
in	O
a	O
number	O
of	O
glioma	O
cells	O
and	O
glioma	O
stem	O
cells	O
,	O
and	O
correlated	O
with	O
poor	O
survival	O
of	O
patients	O
with	O
gliomas	O
.	O

Ectopic	O
expression	O
of	O
TLX	O
in	O
the	O
U87MG	B
glioma	O
cell	O
line	O
and	O
Ink4a	O
/	O
Arf	O
-	O
deficient	O
mouse	O
astrocytes	O
(	O
Ink4a	O
/	O
Arf	O
(	O
-	O
/	O
-	O
)	O
astrocytes	O
)	O
induced	O
cell	O
proliferation	O
with	O
a	O
concomitant	O
increase	O
in	O
cyclin	O
D	O
expression	O
,	O
and	O
accelerated	O
foci	O
formation	O
in	O
soft	O
agar	O
and	O
tumor	O
formation	O
in	O
in	O
vivo	O
transplantation	O
assays	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
TLX	O
in	O
Ink4a	O
/	O
Arf	O
(	O
-	O
/	O
-	O
)	O
astrocytes	O
inhibited	O
cell	O
migration	O
and	O
invasion	O
and	O
promoted	O
neurosphere	O
formation	O
and	O
Nestin	O
expression	O
,	O
which	O
are	O
hallmark	O
characteristics	O
of	O
glioma	O
stem	O
cells	O
,	O
under	O
stem	O
cell	O
culture	O
conditions	O
.	O

Our	O
results	O
indicate	O
that	O
TLX	O
is	O
involved	O
in	O
glioma	O
stem	O
cell	O
genesis	O
and	O
represents	O
a	O
potential	O
therapeutic	O
target	O
for	O
this	O
type	O
of	O
malignancy	O
.	O

Actin	O
-	O
sequestering	O
protein	O
,	O
thymosin	O
beta	O
-	O
4	O
,	O
is	O
a	O
novel	O
hypoxia	O
responsive	O
regulator	O
.	O

Angiogenesis	O
is	O
induced	O
by	O
soluble	O
factors	O
such	O
as	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
released	O
from	O
tumor	O
cells	O
in	O
hypoxia	O
.	O

It	O
enhances	O
solid	O
tumor	O
growth	O
and	O
provides	O
an	O
ability	O
to	O
establish	O
metastasis	O
at	O
peripheral	O
sites	O
by	O
tumor	O
cell	O
migration	O
.	O

Thymosin	O
beta	O
-	O
4	O
(	O
TB4	O
)	O
is	O
an	O
actin	O
-	O
sequestering	O
protein	O
to	O
control	O
cytoskeletal	O
reorganization	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
angiogenesis	O
and	O
tumor	O
metastasis	O
are	O
dependent	O
on	O
hypoxia	O
conditioning	O
-	O
induced	O
TB4	O
expression	O
in	O
B16F10	B
melanoma	O
cells	O
.	O

TB4	O
expression	O
in	O
B16F10	B
cells	O
was	O
increased	O
by	O
hypoxia	O
conditioning	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

In	O
addition	O
,	O
we	O
found	O
an	O
increase	O
of	O
angiogenesis	O
and	O
HIF	O
-	O
1alpha	O
expression	O
in	O
TB4	O
-	O
transgenic	O
(	O
Tg	O
)	O
mice	O
as	O
compared	O
to	O
wildtype	O
mice	O
.	O

When	O
wound	O
healing	O
assay	O
was	O
used	O
to	O
assess	O
in	O
vitro	O
tumor	O
cell	O
migration	O
,	O
hypoxia	O
conditioning	O
for	O
1	O
h	O
enhanced	O
B16F10	B
cell	O
migration	O
.	O

When	O
TB4	O
expression	O
in	O
B16F10	B
cells	O
was	O
inhibited	O
by	O
the	O
infection	O
with	O
small	O
hairpin	O
(	O
sh	O
)	O
RNA	O
of	O
TB4	O
cloned	O
in	O
lentiviral	O
vector	O
,	O
tumor	O
cell	O
migration	O
was	O
retarded	O
.	O

In	O
addition	O
,	O
hypoxia	O
conditioning	O
-	O
induced	O
tumor	O
cell	O
migration	O
was	O
reduced	O
by	O
the	O
infection	O
of	O
lentiviral	O
shRNA	O
of	O
TB4	O
.	O

HIF	O
-	O
1alpha	O
stabilization	O
and	O
the	O
expression	O
of	O
VEGF	O
isoform	O
165	O
and	O
121	O
in	O
hypoxia	O
were	O
also	O
reduced	O
by	O
the	O
infection	O
of	O
lentiviral	O
shRNA	O
of	O
TB4	O
in	O
B16F10	B
cells	O
.	O

We	O
also	O
found	O
an	O
increase	O
of	O
tumor	O
growth	O
and	O
lung	O
metastasis	O
count	O
in	O
TB4	O
-	O
Tg	O
mice	O
as	O
compared	O
to	O
wildtype	O
mice	O
.	O

Collectively	O
,	O
hypoxia	O
conditioning	O
induced	O
tumor	O
cell	O
migration	O
by	O
TB4	O
expression	O
-	O
dependent	O
HIF	O
-	O
1alpha	O
stabilization	O
.	O

It	O
suggests	O
that	O
TB4	O
could	O
be	O
a	O
hypoxia	O
responsive	O
regulator	O
to	O
control	O
tumor	O
cell	O
migration	O
in	O
angiogenesis	O
and	O
tumor	O
metastasis	O
.	O

Acute	O
ablation	O
of	O
Langerhans	O
cells	O
enhances	O
skin	O
immune	O
responses	O
.	O

Understanding	O
the	O
function	O
of	O
Langerhans	O
cells	O
(	O
LCs	O
)	O
in	O
vivo	O
has	O
been	O
complicated	O
by	O
conflicting	O
results	O
from	O
LC	O
-	O
deficient	O
mice	O
.	O

Human	O
Langerin	O
-	O
DTA	O
mice	O
constitutively	O
lack	O
LCs	O
and	O
develop	O
exaggerated	O
contact	O
hypersensitivity	O
(	O
CHS	O
)	O
responses	O
.	O

Murine	O
Langerin	O
-	O
diphtheria	O
toxin	O
receptor	O
(	O
DTR	O
)	O
mice	O
allow	O
for	O
the	O
inducible	O
elimination	O
of	O
LCs	O
and	O
Langerin	O
(	O
+	O
)	O
dermal	O
dendritic	O
cells	O
(	O
dDCs	O
)	O
after	O
administration	O
of	O
diphtheria	O
toxin	O
,	O
which	O
results	O
in	O
reduced	O
CHS	O
.	O

When	O
Langerin	O
(	O
+	O
)	O
dDCs	O
have	O
partially	O
repopulated	O
the	O
skin	O
but	O
LCs	O
are	O
still	O
absent	O
,	O
CHS	O
returns	O
to	O
normal	O
.	O

Thus	O
,	O
LCs	O
appear	O
to	O
be	O
suppressive	O
in	O
human	O
Langerin	O
-	O
DTA	O
mice	O
and	O
redundant	O
in	O
murine	O
Langerin	O
-	O
DTR	O
mice	O
.	O

To	O
determine	O
whether	O
inducible	O
versus	O
constitutive	O
LC	O
ablation	O
explains	O
these	O
results	O
,	O
we	O
engineered	O
human	O
Langerin	O
-	O
DTR	O
mice	O
in	O
which	O
diphtheria	O
toxin	O
ablates	O
LCs	O
without	O
affecting	O
Langerin	O
(	O
+	O
)	O
dDCs	O
.	O

The	O
inducible	O
ablation	O
of	O
LCs	O
in	O
human	O
Langerin	O
-	O
DTR	O
mice	O
resulted	O
in	O
increased	O
CHS	O
.	O

Thus	O
,	O
LC	O
-	O
mediated	O
suppression	O
does	O
not	O
require	O
their	O
absence	O
during	O
ontogeny	O
or	O
during	O
the	O
steady	O
-	O
state	O
and	O
is	O
consistent	O
with	O
a	O
model	O
in	O
which	O
LCs	O
actively	O
suppress	O
Ag	O
-	O
specific	O
CHS	O
responses	O
.	O

Skin	O
deep	O
and	O
deeper	O
:	O
multiple	O
pathways	O
in	O
basal	O
cell	O
carcinogenesis	O
.	O

This	O
perspective	O
places	O
the	O
report	O
by	O
Villani	O
et	O
al	O
.	O
that	O
appears	O
in	O
this	O
issue	O
of	O
the	O
journal	O
(	O
beginning	O
on	O
page	O
1222	O
)	O
in	O
the	O
context	O
of	O
recent	O
work	O
showing	O
an	O
intersection	O
between	O
two	O
important	O
developmental	O
pathways	O
implicated	O
in	O
oncogenesis	O
:	O
the	O
hedgehog	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
(	O
IGF	O
)	O
pathways	O
.	O

Villani	O
et	O
al	O
.	O
define	O
a	O
key	O
role	O
for	O
the	O
IGF	O
regulatory	O
protein	O
Igfbp2	O
in	O
a	O
genetic	O
model	O
of	O
basal	O
cell	O
carcinogenesis	O
driven	O
by	O
targeted	O
constitutive	O
activation	O
of	O
hedgehog	O
signaling	O
.	O

Placed	O
in	O
the	O
framework	O
of	O
other	O
recently	O
published	O
work	O
,	O
the	O
observations	O
of	O
Villani	O
et	O
al	O
.	O
both	O
raise	O
questions	O
about	O
the	O
cell	O
of	O
origin	O
for	O
basal	O
cell	O
cancers	O
and	O
define	O
additional	O
putative	O
therapeutic	O
and	O
preventive	O
targets	O
for	O
this	O
disease	O
.	O

Brick1	O
is	O
an	O
essential	O
regulator	O
of	O
actin	O
cytoskeleton	O
required	O
for	O
embryonic	O
development	O
and	O
cell	O
transformation	O
.	O

Brick1	O
(	O
Brk1	O
)	O
is	O
the	O
less	O
-	O
studied	O
component	O
of	O
the	O
Wave	O
/	O
Scar	O
pathway	O
involved	O
in	O
the	O
branched	O
nucleation	O
of	O
actin	O
fibers	O
.	O

The	O
clinical	O
relevance	O
of	O
Brk1	O
is	O
emphasized	O
by	O
correlative	O
data	O
showing	O
that	O
Von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
patients	O
that	O
also	O
lose	O
the	O
BRK1	O
gene	O
are	O
protected	O
against	O
the	O
development	O
of	O
tumors	O
.	O

This	O
contrasts	O
with	O
recent	O
evidence	O
suggesting	O
that	O
the	O
Wave	O
complex	O
may	O
function	O
as	O
an	O
invasion	O
suppressor	O
in	O
epithelial	O
cancers	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
downregulation	O
of	O
Brk1	O
results	O
in	O
abnormal	O
actin	O
stress	O
fiber	O
formation	O
and	O
vinculin	O
distribution	O
and	O
loss	O
of	O
Arp2	O
/	O
3	O
and	O
Wave	O
proteins	O
at	O
the	O
cellular	O
protrusions	O
.	O

Brk1	O
is	O
required	O
for	O
cell	O
proliferation	O
and	O
cell	O
transformation	O
by	O
oncogenes	O
.	O

In	O
addition	O
,	O
Brk1	O
downregulation	O
results	O
in	O
defective	O
directional	O
migration	O
and	O
invasive	O
growth	O
in	O
renal	O
cell	O
carcinoma	O
cells	O
as	O
well	O
as	O
in	O
other	O
tumor	O
cell	O
types	O
.	O

Finally	O
,	O
genetic	O
ablation	O
of	O
Brk1	O
results	O
in	O
dramatic	O
defects	O
in	O
embryo	O
compaction	O
and	O
development	O
,	O
suggesting	O
an	O
essential	O
role	O
for	O
this	O
protein	O
in	O
actin	O
dynamics	O
.	O

Thus	O
,	O
genetic	O
loss	O
or	O
inhibition	O
of	O
BRK1	O
is	O
likely	O
to	O
be	O
protective	O
against	O
tumor	O
development	O
due	O
to	O
proliferation	O
and	O
motility	O
defects	O
in	O
affected	O
cells	O
.	O

The	O
proenkephalin	O
-	O
A	O
-	O
derivative	O
Met	O
-	O
enkephalin	O
-	O
Arg	O
-	O
Gly	O
-	O
Leu	O
is	O
not	O
present	O
in	O
the	O
feline	O
species	O
.	O

No	O
opioid	O
octapeptide	O
Met	O
-	O
enkephalin	O
-	O
Arg	O
-	O
Gly	O
-	O
Leu	O
was	O
detected	O
either	O
in	O
the	O
brain	O
or	O
in	O
the	O
adrenal	O
gland	O
of	O
the	O
cat	O
using	O
a	O
specific	O
radioimmunoassay	O
.	O

Whereas	O
it	O
was	O
possible	O
to	O
determine	O
the	O
Met	O
-	O
enkephalin	O
and	O
Leu	O
-	O
enkephalin	O
contents	O
.	O

The	O
Met	O
-	O
enkephalin	O
versus	O
Leu	O
-	O
enkephalin	O
concentration	O
ratio	O
was	O
around	O
five	O
in	O
each	O
area	O
of	O
the	O
brain	O
assayed	O
.	O

The	O
presence	O
of	O
authentic	O
Met	O
-	O
enkephalin	O
and	O
Leu	O
-	O
enkephalin	O
was	O
confirmed	O
by	O
high	O
performance	O
liquid	O
chromatography	O
analysis	O
.	O

All	O
in	O
all	O
,	O
these	O
data	O
seem	O
to	O
indicate	O
that	O
the	O
cat	O
proenkephalin	O
is	O
partly	O
different	O
from	O
that	O
previously	O
analysed	O
in	O
mammalian	O
species	O
including	O
humans	O
,	O
rats	O
and	O
cows	O
.	O

Ras	O
-	O
association	O
domain	O
family	O
1C	O
protein	O
promotes	O
breast	O
cancer	O
cell	O
migration	O
and	O
attenuates	O
apoptosis	O
.	O

BACKGROUND	O
:	O
The	O
Ras	O
association	O
domain	O
family	O
1	O
(	O
RASSF1	O
)	O
gene	O
is	O
a	O
Ras	O
effector	O
encoding	O
two	O
major	O
mRNA	O
forms	O
,	O
RASSF1A	O
and	O
RASSF1C	O
,	O
derived	O
by	O
alternative	O
promoter	O
selection	O
and	O
alternative	O
mRNA	O
splicing	O
.	O

RASSF1A	O
is	O
a	O
tumor	O
suppressor	O
gene	O
.	O

However	O
,	O
very	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
RASSF1C	O
both	O
in	O
normal	O
and	O
transformed	O
cells	O
.	O

METHODS	O
:	O
Gene	O
silencing	O
and	O
over	O
-	O
expression	O
techniques	O
were	O
used	O
to	O
modulate	O
RASSF1C	O
expression	O
in	O
human	O
breast	O
cancer	O
cells	O
.	O

Affymetrix	O
-	O
microarray	O
analysis	O
was	O
performed	O
using	O
T47D	B
cells	O
over	O
-	O
expressing	O
RASSF1C	O
to	O
identify	O
RASSF1C	O
target	O
genes	O
.	O

RT	O
-	O
PCR	O
and	O
western	O
blot	O
techniques	O
were	O
used	O
to	O
validate	O
target	O
gene	O
expression	O
.	O

Cell	O
invasion	O
and	O
apoptosis	O
assays	O
were	O
also	O
performed	O
.	O

RESULTS	O
:	O
In	O
this	O
article	O
,	O
we	O
report	O
the	O
effects	O
of	O
altering	O
RASSF1C	O
expression	O
in	O
human	O
breast	O
cancer	O
cells	O
.	O

We	O
found	O
that	O
silencing	O
RASSF1C	O
mRNA	O
in	O
breast	O
cancer	O
cell	O
lines	O
(	O
MDA	B
-	I
MB231	I
and	O
T47D	B
)	O
caused	O
a	O
small	O
but	O
significant	O
decrease	O
in	O
cell	O
proliferation	O
.	O

Conversely	O
,	O
inducible	O
over	O
-	O
expression	O
of	O
RASSF1C	O
in	O
breast	O
cancer	O
cells	O
(	O
MDA	B
-	I
MB231	I
and	O
T47D	B
)	O
resulted	O
in	O
a	O
small	O
increase	O
in	O
cell	O
proliferation	O
.	O

We	O
also	O
report	O
on	O
the	O
identification	O
of	O
novel	O
RASSF1C	O
target	O
genes	O
.	O

RASSF1C	O
down	O
-	O
regulates	O
several	O
pro	O
-	O
apoptotic	O
and	O
tumor	O
suppressor	O
genes	O
and	O
up	O
-	O
regulates	O
several	O
growth	O
promoting	O
genes	O
in	O
breast	O
cancer	O
cells	O
.	O

We	O
further	O
show	O
that	O
down	O
-	O
regulation	O
of	O
caspase	O
3	O
via	O
overexpression	O
of	O
RASSF1C	O
reduces	O
breast	O
cancer	O
cells	O
'	O
sensitivity	O
to	O
the	O
apoptosis	O
inducing	O
agent	O
,	O
etoposide	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
RASSF1C	O
over	O
-	O
expression	O
enhances	O
T47D	B
cell	O
invasion	O
/	O
migration	O
in	O
vitro	O
.	O

CONCLUSION	O
:	O
Together	O
,	O
our	O
findings	O
suggest	O
that	O
RASSF1C	O
,	O
unlike	O
RASSF1A	O
,	O
is	O
not	O
a	O
tumor	O
suppressor	O
,	O
but	O
instead	O
may	O
play	O
a	O
role	O
in	O
stimulating	O
metastasis	O
and	O
survival	O
in	O
breast	O
cancer	O
cells	O
.	O

Androgen	O
stimulates	O
glycolysis	O
for	O
de	O
novo	O
lipid	O
synthesis	O
by	O
increasing	O
the	O
activities	O
of	O
hexokinase	O
2	O
and	O
6	O
-	O
phosphofructo	O
-	O
2	O
-	O
kinase	O
/	O
fructose	O
-	O
2	O
,	O
6	O
-	O
bisphosphatase	O
2	O
in	O
prostate	O
cancer	O
cells	O
.	O

Up	O
-	O
regulation	O
of	O
lipogenesis	O
by	O
androgen	O
is	O
one	O
of	O
the	O
most	O
characteristic	O
metabolic	O
features	O
of	O
LNCaP	B
prostate	O
cancer	O
cells	O
.	O

The	O
present	O
study	O
revealed	O
that	O
androgen	O
increases	O
glucose	O
utilization	O
for	O
de	O
novo	O
lipogenesis	O
in	O
LNCaP	B
cells	O
through	O
the	O
activation	O
of	O
HK2	O
(	O
hexokinase	O
2	O
)	O
and	O
activation	O
of	O
the	O
cardiac	O
isoform	O
of	O
PFKFB2	O
(	O
6	O
-	O
phosphofructo	O
-	O
2	O
-	O
kinase	O
/	O
fructose	O
-	O
2	O
,	O
6	O
-	O
bisphosphatase	O
)	O
.	O

Activation	O
of	O
PKA	O
(	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
)	O
by	O
androgen	O
increased	O
phosphorylation	O
of	O
CREB	O
[	O
CRE	O
(	O
cAMP	O
-	O
response	O
element	O
)	O
-	O
binding	O
protein	O
]	O
,	O
which	O
in	O
turn	O
bound	O
to	O
CRE	O
on	O
the	O
promoter	O
of	O
the	O
HK2	O
gene	O
resulting	O
in	O
transcriptional	O
activation	O
of	O
the	O
HK2	O
gene	O
.	O

Up	O
-	O
regulation	O
of	O
PFKFB2	O
expression	O
was	O
mediated	O
by	O
the	O
direct	O
binding	O
of	O
ligand	O
-	O
activated	O
androgen	O
receptor	O
to	O
the	O
PFKFB2	O
promoter	O
.	O

The	O
activated	O
PI3	O
K	O
(	O
phosphoinositide	O
3	O
-	O
kinase	O
)	O
/	O
Akt	O
signalling	O
pathway	O
in	O
LNCaP	B
cells	O
contributes	O
to	O
the	O
phosphorylation	O
of	O
PFKFB2	O
at	O
Ser466	O
and	O
Ser483	O
,	O
resulting	O
in	O
the	O
constitutive	O
activation	O
of	O
PFK	O
-	O
2	O
(	O
6	O
-	O
phosphofructo	O
-	O
2	O
-	O
kinase	O
)	O
activity	O
.	O

Glucose	O
uptake	O
and	O
lipogenesis	O
were	O
severely	O
blocked	O
by	O
knocking	O
-	O
down	O
of	O
PFKFB2	O
using	O
siRNA	O
(	O
small	O
interfering	O
RNA	O
)	O
or	O
by	O
inhibition	O
of	O
PFK	O
-	O
2	O
activity	O
with	O
LY294002	O
treatment	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
de	O
novo	O
lipid	O
synthesis	O
by	O
androgen	O
requires	O
the	O
transcriptional	O
up	O
-	O
regulation	O
of	O
HK2	O
and	O
PFKFB2	O
,	O
and	O
phosphorylation	O
of	O
PFKFB2	O
generated	O
by	O
the	O
PI3	O
K	O
/	O
Akt	O
signalling	O
pathway	O
to	O
supply	O
the	O
source	O
for	O
lipogenesis	O
from	O
glucose	O
in	O
prostate	O
cancer	O
cells	O
.	O

Expression	O
profiling	O
in	O
progressive	O
stages	O
of	O
fumarate	O
-	O
hydratase	O
deficiency	O
:	O
the	O
contribution	O
of	O
metabolic	O
changes	O
to	O
tumorigenesis	O
.	O

Hereditary	O
leiomyomatosis	O
and	O
renal	O
cell	O
carcinoma	O
(	O
HLRCC	O
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
Krebs	O
cycle	O
enzyme	O
fumarate	O
hydratase	O
(	O
FH	O
)	O
.	O

It	O
has	O
been	O
proposed	O
that	O
""""	O
pseudohypoxic	O
""""	O
stabilization	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
alpha	O
(	O
HIF	O
-	O
alpha	O
)	O
by	O
fumarate	O
accumulation	O
contributes	O
to	O
tumorigenesis	O
in	O
HLRCC	O
.	O

We	O
hypothesized	O
that	O
an	O
additional	O
direct	O
consequence	O
of	O
FH	O
deficiency	O
is	O
the	O
establishment	O
of	O
a	O
biosynthetic	O
milieu	O
.	O

To	O
investigate	O
this	O
hypothesis	O
,	O
we	O
isolated	O
primary	O
mouse	O
embryonic	O
fibroblast	O
(	O
MEF	O
)	O
lines	O
from	O
Fh1	O
-	O
deficient	O
mice	O
.	O

As	O
predicted	O
,	O
these	O
MEFs	O
upregulated	O
Hif	O
-	O
1alpha	O
and	O
HIF	O
target	O
genes	O
directly	O
as	O
a	O
result	O
of	O
FH	O
deficiency	O
.	O

In	O
addition	O
,	O
detailed	O
metabolic	O
assessment	O
of	O
these	O
MEFs	O
confirmed	O
their	O
dependence	O
on	O
glycolysis	O
,	O
and	O
an	O
elevated	O
rate	O
of	O
lactate	O
efflux	O
,	O
associated	O
with	O
the	O
upregulation	O
of	O
glycolytic	O
enzymes	O
known	O
to	O
be	O
associated	O
with	O
tumorigenesis	O
.	O

Correspondingly	O
,	O
Fh1	O
-	O
deficient	O
benign	O
murine	O
renal	O
cysts	O
and	O
an	O
advanced	O
human	O
HLRCC	O
-	O
related	O
renal	O
cell	O
carcinoma	O
manifested	O
a	O
prominent	O
and	O
progressive	O
increase	O
in	O
the	O
expression	O
of	O
HIF	O
-	O
alpha	O
target	O
genes	O
and	O
in	O
genes	O
known	O
to	O
be	O
relevant	O
to	O
tumorigenesis	O
and	O
metastasis	O
.	O

In	O
accord	O
with	O
our	O
hypothesis	O
,	O
in	O
a	O
variety	O
of	O
different	O
FH	O
-	O
deficient	O
tissues	O
,	O
including	O
a	O
novel	O
murine	O
model	O
of	O
Fh1	O
-	O
deficient	O
smooth	O
muscle	O
,	O
we	O
show	O
a	O
striking	O
and	O
progressive	O
upregulation	O
of	O
a	O
tumorigenic	O
metabolic	O
profile	O
,	O
as	O
manifested	O
by	O
increased	O
PKM2	O
and	O
LDHA	O
protein	O
.	O

Based	O
on	O
the	O
models	O
assessed	O
herein	O
,	O
we	O
infer	O
that	O
that	O
FH	O
deficiency	O
compels	O
cells	O
to	O
adopt	O
an	O
early	O
,	O
reversible	O
,	O
and	O
progressive	O
protumorigenic	O
metabolic	O
milieu	O
that	O
is	O
reminiscent	O
of	O
that	O
driving	O
the	O
Warburg	O
effect	O
.	O

Targets	O
identified	O
in	O
these	O
novel	O
and	O
diverse	O
FH	O
-	O
deficient	O
models	O
represent	O
excellent	O
potential	O
candidates	O
for	O
further	O
mechanistic	O
investigation	O
and	O
therapeutic	O
metabolic	O
manipulation	O
in	O
tumors	O
.	O

Role	O
of	O
stromal	O
myofibroblasts	O
in	O
invasive	O
breast	O
cancer	O
:	O
stromal	O
expression	O
of	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
correlates	O
with	O
worse	O
clinical	O
outcome	O
.	O

BACKGROUND	O
:	O
Recently	O
,	O
the	O
desmoplastic	O
reaction	O
has	O
been	O
implicated	O
as	O
having	O
an	O
important	O
function	O
in	O
epithelial	O
solid	O
tumor	O
biology	O
.	O

There	O
have	O
been	O
no	O
reports	O
showing	O
the	O
relativity	O
of	O
invasive	O
breast	O
cancer	O
and	O
the	O
desmoplastic	O
reaction	O
by	O
a	O
quantitative	O
analysis	O
of	O
the	O
myofibroblasts	O
that	O
were	O
an	O
important	O
player	O
in	O
the	O
desmoplastic	O
reaction	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
immunohistochemically	O
investigate	O
the	O
correlation	O
between	O
the	O
desmoplastic	O
reaction	O
and	O
the	O
clinicopathology	O
of	O
invasive	O
breast	O
cancer	O
.	O

METHODS	O
:	O
The	O
study	O
included	O
60	O
patients	O
with	O
a	O
known	O
prognosis	O
of	O
invasive	O
breast	O
cancer	O
.	O

We	O
quantified	O
the	O
expression	O
of	O
alpha	O
-	O
SMA	O
as	O
a	O
marker	O
of	O
myofibroblasts	O
in	O
the	O
invasive	O
breast	O
cancer	O
.	O

After	O
staining	O
samples	O
for	O
alpha	O
-	O
SMA	O
,	O
their	O
expression	O
was	O
extracted	O
and	O
quantified	O
as	O
a	O
relative	O
percentage	O
by	O
computer	O
-	O
assisted	O
image	O
analysis	O
.	O

RESULTS	O
:	O
There	O
was	O
relatively	O
wide	O
variation	O
in	O
the	O
expression	O
of	O
alpha	O
-	O
SMA	O
with	O
the	O
percentage	O
of	O
the	O
area	O
from	O
0	O
.	O
68	O
to	O
28	O
.	O
15	O
%	O
(	O
mean	O
8	O
.	O
48	O
+	O
/	O
-	O
5	O
.	O
40	O
%	O
)	O
.	O

The	O
metastasis	O
group	O
showed	O
significantly	O
higher	O
alpha	O
-	O
SMA	O
expression	O
compared	O
with	O
the	O
no	O
metastasis	O
group	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

When	O
the	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
according	O
to	O
their	O
alpha	O
-	O
SMA	O
expression	O
using	O
a	O
cutoff	O
point	O
at	O
the	O
mean	O
value	O
of	O
8	O
.	O
48	O
%	O
,	O
the	O
high	O
alpha	O
-	O
SMA	O
group	O
had	O
a	O
significantly	O
poorer	O
overall	O
survival	O
rate	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Multivariate	O
analysis	O
demonstrated	O
that	O
alpha	O
-	O
SMA	O
and	O
lymph	O
node	O
metastasis	O
were	O
identified	O
as	O
independent	O
predictive	O
factors	O
of	O
metastasis	O
.	O

CONCLUSION	O
:	O
Myofibroblasts	O
represent	O
an	O
important	O
prognostic	O
factor	O
for	O
invasive	O
growth	O
that	O
is	O
translated	O
into	O
a	O
poor	O
clinical	O
prognosis	O
for	O
patients	O
with	O
invasive	O
breast	O
cancer	O
.	O

A	O
STAT3	O
-	O
mediated	O
metabolic	O
switch	O
is	O
involved	O
in	O
tumour	O
transformation	O
and	O
STAT3	O
addiction	O
.	O

The	O
pro	O
-	O
oncogenic	O
transcription	O
factor	O
STAT3	O
is	O
constitutively	O
activated	O
in	O
a	O
wide	O
variety	O
of	O
tumours	O
that	O
often	O
become	O
addicted	O
to	O
its	O
activity	O
,	O
but	O
no	O
unifying	O
view	O
of	O
a	O
core	O
function	O
determining	O
this	O
widespread	O
STAT3	O
-	O
dependence	O
has	O
yet	O
emerged	O
.	O

We	O
show	O
here	O
that	O
constitutively	O
active	O
STAT3	O
acts	O
as	O
a	O
master	O
regulator	O
of	O
cell	O
metabolism	O
,	O
inducing	O
aerobic	O
glycolysis	O
and	O
down	O
-	O
regulating	O
mitochondrial	O
activity	O
both	O
in	O
primary	O
fibroblasts	O
and	O
in	O
STAT3	O
-	O
dependent	O
tumour	O
cell	O
lines	O
.	O

As	O
a	O
result	O
,	O
cells	O
are	O
protected	O
from	O
apoptosis	O
and	O
senescence	O
while	O
becoming	O
highly	O
sensitive	O
to	O
glucose	O
deprivation	O
.	O

We	O
show	O
that	O
enhanced	O
glycolysis	O
is	O
dependent	O
on	O
HIF	O
-	O
1alpha	O
up	O
-	O
regulation	O
,	O
while	O
reduced	O
mitochondrial	O
activity	O
is	O
HIF	O
-	O
1alpha	O
-	O
independent	O
and	O
likely	O
caused	O
by	O
STAT3	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
mitochondrial	O
proteins	O
.	O

The	O
induction	O
of	O
aerobic	O
glycolysis	O
is	O
an	O
important	O
component	O
of	O
STAT3	O
pro	O
-	O
oncogenic	O
activities	O
,	O
since	O
inhibition	O
of	O
STAT3	O
tyrosine	O
phosphorylation	O
in	O
the	O
tumour	O
cell	O
lines	O
down	O
-	O
regulates	O
glycolysis	O
prior	O
to	O
leading	O
to	O
growth	O
arrest	O
and	O
cell	O
death	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
propose	O
that	O
this	O
novel	O
,	O
central	O
metabolic	O
role	O
is	O
at	O
the	O
core	O
of	O
the	O
addiction	O
for	O
STAT3	O
shown	O
by	O
so	O
many	O
biologically	O
different	O
tumours	O
.	O

The	O
disintegrin	O
-	O
like	O
and	O
cysteine	O
-	O
rich	O
domains	O
of	O
ADAM	O
-	O
9	O
mediate	O
interactions	O
between	O
melanoma	O
cells	O
and	O
fibroblasts	O
.	O

A	O
characteristic	O
of	O
malignant	O
cells	O
is	O
their	O
capacity	O
to	O
invade	O
their	O
surrounding	O
and	O
to	O
metastasize	O
to	O
distant	O
organs	O
.	O

During	O
these	O
processes	O
,	O
proteolytic	O
activities	O
of	O
tumor	O
and	O
stromal	O
cells	O
modify	O
the	O
extracellular	O
matrix	O
to	O
produce	O
a	O
microenvironment	O
suitable	O
for	O
their	O
growth	O
and	O
migration	O
.	O

In	O
recent	O
years	O
the	O
family	O
of	O
ADAM	O
proteases	O
has	O
been	O
ascribed	O
important	O
roles	O
in	O
these	O
processes	O
.	O

ADAM	O
-	O
9	O
is	O
expressed	O
in	O
human	O
melanoma	O
at	O
the	O
tumor	O
-	O
stroma	O
border	O
where	O
direct	O
or	O
indirect	O
interactions	O
between	O
tumor	O
cells	O
and	O
fibroblasts	O
occur	O
.	O

To	O
analyze	O
the	O
role	O
of	O
ADAM	O
-	O
9	O
for	O
the	O
interaction	O
between	O
melanoma	O
cells	O
and	O
stromal	O
fibroblasts	O
,	O
we	O
produced	O
the	O
recombinant	O
disintegrin	O
-	O
like	O
and	O
cysteine	O
-	O
rich	O
domain	O
of	O
ADAM	O
-	O
9	O
(	O
DC	O
-	O
9	O
)	O
.	O

Melanoma	O
cells	O
and	O
human	O
fibroblasts	O
adhered	O
to	O
immobilized	O
DC	O
-	O
9	O
in	O
a	O
Mn	O
(	O
2	O
+	O
)	O
-	O
dependent	O
fashion	O
suggesting	O
an	O
integrin	O
-	O
mediated	O
process	O
.	O

Inhibition	O
studies	O
showed	O
that	O
adhesion	O
of	O
fibroblasts	O
was	O
mediated	O
by	O
several	O
beta1	O
integrin	O
receptors	O
independent	O
of	O
the	O
RGD	O
and	O
ECD	O
recognition	O
motif	O
.	O

Furthermore	O
,	O
interaction	O
of	O
fibroblasts	O
and	O
high	O
invasive	O
melanoma	O
cells	O
with	O
soluble	O
recombinant	O
DC	O
-	O
9	O
resulted	O
in	O
enhanced	O
expression	O
of	O
MMP	O
-	O
1	O
and	O
MMP	O
-	O
2	O
.	O

Silencing	O
of	O
ADAM	O
-	O
9	O
in	O
melanoma	O
cells	O
significantly	O
reduced	O
cell	O
adhesion	O
to	O
fibroblasts	O
.	O

Ablation	O
of	O
ADAM	O
-	O
9	O
in	O
fibroblasts	O
almost	O
completely	O
abolished	O
these	O
cellular	O
interactions	O
and	O
melanoma	O
cell	O
invasion	O
in	O
vitro	O
.	O

In	O
summary	O
,	O
these	O
results	O
suggest	O
that	O
ADAM	O
-	O
9	O
expression	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
cell	O
-	O
cell	O
contacts	O
between	O
fibroblasts	O
and	O
melanoma	O
cells	O
and	O
that	O
these	O
interactions	O
contribute	O
to	O
proteolytic	O
activities	O
required	O
during	O
invasion	O
of	O
melanoma	O
cells	O
.	O

Influences	O
on	O
the	O
pharmacokinetics	O
of	O
oxycodone	O
:	O
a	O
multicentre	O
cross	O
-	O
sectional	O
study	O
in	O
439	O
adult	O
cancer	O
patients	O
.	O

OBJECTIVE	O
:	O

Oxycodone	O
is	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
cancer	O
pain	O
,	O
but	O
little	O
is	O
known	O
of	O
its	O
pharmacokinetics	O
in	O
cancer	O
pain	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
relationships	O
between	O
ordinary	O
patient	O
characteristics	O
and	O
serum	O
concentrations	O
of	O
oxycodone	O
and	O
the	O
ratios	O
noroxycodone	O
or	O
oxymorphone	O
/	O
oxycodone	O
in	O
cancer	O
patients	O
.	O

METHODS	O
:	O

Four	O
hundred	O
and	O
thirty	O
-	O
nine	O
patients	O
using	O
oral	O
oxycodone	O
for	O
cancer	O
pain	O
were	O
included	O
.	O

The	O
patients	O
'	O
characteristics	O
(	O
sex	O
,	O
age	O
,	O
body	O
mass	O
index	O
[	O
BMI	O
]	O
,	O
Karnofsky	O
performance	O
status	O
,	O
""""	O
time	O
since	O
starting	O
opioids	O
""""	O
,	O
""""	O
oxycodone	O
total	O
daily	O
dose	O
""""	O
,	O
""""	O
time	O
from	O
last	O
oxycodone	O
dose	O
""""	O
,	O
use	O
of	O
CYP3A4	O
inducer	O
/	O
inhibitor	O
,	O
""""	O
use	O
of	O
systemic	O
steroids	O
""""	O
,	O
""""	O
number	O
of	O
medications	O
taken	O
in	O
the	O
last	O
24	O
h	O
""""	O
,	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
and	O
albumin	O
serum	O
concentrations	O
)	O
influence	O
on	O
oxycodone	O
serum	O
concentrations	O
or	O
metabolite	O
/	O
oxycodone	O
ratios	O
were	O
explored	O
by	O
multiple	O
regression	O
analyses	O
.	O

RESULTS	O
:	O

Sex	O
,	O
CYP3A4	O
inducers	O
/	O
inhibitors	O
,	O
total	O
daily	O
dose	O
,	O
and	O
""""	O
time	O
from	O
last	O
oxycodone	O
dose	O
""""	O
predicted	O
oxycodone	O
concentrations	O
.	O

CYP3A4	O
inducers	O
,	O
total	O
daily	O
dose	O
,	O
and	O
""""	O
number	O
of	O
medications	O
taken	O
in	O
the	O
last	O
24	O
h	O
""""	O
predicted	O
the	O
oxymorphone	O
/	O
oxycodone	O
ratio	O
.	O

Total	O
daily	O
dose	O
,	O
""""	O
time	O
from	O
last	O
dose	O
to	O
blood	O
sample	O
""""	O
,	O
albumin	O
,	O
sex	O
,	O
CYP3A4	O
inducers	O
/	O
inhibitors	O
,	O
steroids	O
,	O
BMI	O
and	O
GFR	O
predicted	O
the	O
noroxycodone	O
/	O
oxycodone	O
ratio	O
.	O

CONCLUSION	O
:	O

Women	O
had	O
lower	O
oxycodone	O
serum	O
concentrations	O
than	O
men	O
.	O

CYP3A4	O
inducers	O
/	O
inhibitors	O
should	O
be	O
used	O
with	O
caution	O
as	O
these	O
are	O
predicted	O
to	O
have	O
a	O
significant	O
impact	O
on	O
oxycodone	O
pharmacokinetics	O
.	O

Other	O
characteristics	O
explained	O
only	O
minor	O
parts	O
of	O
the	O
variability	O
of	O
the	O
outcomes	O
.	O

Emerging	O
metabolic	O
targets	O
in	O
cancer	O
therapy	O
.	O

Cancer	O
cells	O
are	O
different	O
from	O
normal	O
cells	O
in	O
their	O
metabolic	O
properties	O
.	O

Normal	O
cells	O
mostly	O
rely	O
on	O
mitochondrial	O
oxidative	O
phosphorylation	O
to	O
produce	O
energy	O
.	O

In	O
contrast	O
,	O
cancer	O
cells	O
depend	O
mostly	O
on	O
glycolysis	O
,	O
the	O
aerobic	O
breakdown	O
of	O
glucose	O
into	O
ATP	O
.	O

This	O
altered	O
energy	O
dependency	O
is	O
known	O
as	O
the	O
""""	O
Warburg	O
effect	O
""""	O
and	O
is	O
a	O
hallmark	O
of	O
cancer	O
cells	O
.	O

In	O
recent	O
years	O
,	O
investigating	O
the	O
metabolic	O
changes	O
within	O
cancer	O
cells	O
has	O
been	O
a	O
rapidly	O
growing	O
area	O
.	O

Emerging	O
evidence	O
shows	O
that	O
oncogenes	O
that	O
drive	O
the	O
cancer	O
-	O
promoting	O
signals	O
also	O
drive	O
the	O
altered	O
metabolism	O
.	O

Although	O
the	O
exact	O
mechanisms	O
underlying	O
the	O
Warburg	O
effect	O
are	O
unclear	O
,	O
the	O
existing	O
evidence	O
suggests	O
that	O
increased	O
glycolysis	O
plays	O
an	O
important	O
role	O
in	O
support	O
malignant	O
behavior	O
of	O
cancer	O
cells	O
.	O

A	O
thorough	O
understanding	O
of	O
the	O
unique	O
metabolism	O
of	O
cancer	O
cells	O
will	O
help	O
to	O
design	O
of	O
more	O
effective	O
drugs	O
targeting	O
metabolic	O
pathways	O
,	O
which	O
will	O
greatly	O
impact	O
the	O
capacity	O
to	O
effectively	O
treat	O
cancer	O
patients	O
.	O

Here	O
we	O
provide	O
an	O
overview	O
of	O
the	O
current	O
understanding	O
of	O
the	O
Warburg	O
effect	O
upon	O
tumor	O
cell	O
growth	O
and	O
survival	O
,	O
and	O
discussion	O
on	O
the	O
potential	O
metabolic	O
targets	O
for	O
cancer	O
therapy	O
.	O

MTSS1	O
:	O
a	O
multifunctional	O
protein	O
and	O
its	O
role	O
in	O
cancer	O
invasion	O
and	O
metastasis	O
.	O

MTSS1	O
(	O
metastasis	O
suppressor	O
-	O
1	O
)	O
was	O
first	O
identified	O
as	O
a	O
metastasis	O
suppressor	O
missing	O
in	O
metastatic	O
bladder	O
carcinoma	O
cell	O
lines	O
.	O

The	O
down	O
-	O
regulation	O
of	O
MTSS1	O
that	O
may	O
be	O
caused	O
by	O
DNA	O
methylation	O
was	O
also	O
observed	O
in	O
many	O
other	O
types	O
of	O
cancer	O
.	O

While	O
accumlating	O
evidence	O
for	O
the	O
function	O
of	O
MTSS1	O
support	O
the	O
concept	O
that	O
it	O
is	O
unlikely	O
to	O
be	O
a	O
metastasis	O
suppressor	O
,	O
but	O
actually	O
acts	O
as	O
a	O
scaffold	O
protein	O
that	O
interacts	O
with	O
multiple	O
partners	O
to	O
regulate	O
actin	O
dynamics	O
.	O

It	O
has	O
also	O
been	O
demonstrated	O
that	O
MTSS1	O
is	O
involved	O
in	O
the	O
Shh	O
signaling	O
pathway	O
in	O
the	O
developing	O
hair	O
follicle	O
and	O
in	O
basal	O
cell	O
carcinomas	O
of	O
the	O
skin	O
.	O

Such	O
evidence	O
indicates	O
that	O
MTSS1	O
as	O
a	O
multiple	O
functional	O
molecular	O
player	O
and	O
has	O
an	O
important	O
role	O
in	O
development	O
,	O
carcinogenesis	O
and	O
metastasis	O
.	O

However	O
,	O
the	O
biochemical	O
mechanisms	O
by	O
which	O
MTSS1	O
functions	O
in	O
cells	O
and	O
the	O
physiological	O
role	O
of	O
this	O
protein	O
in	O
animals	O
remain	O
largely	O
unknown	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
the	O
current	O
knowledge	O
of	O
MTSS1	O
'	O
s	O
role	O
in	O
cancer	O
metastasis	O
,	O
carcinogenesis	O
,	O
and	O
development	O
.	O

The	O
clinical	O
significance	O
of	O
MTSS1	O
will	O
also	O
be	O
discussed	O
.	O

Geometric	O
correlations	O
and	O
breakdown	O
of	O
mesoscopic	O
universality	O
in	O
spin	O
transport	O
.	O

We	O
construct	O
a	O
unified	O
semiclassical	O
theory	O
of	O
charge	O
and	O
spin	O
transport	O
in	O
chaotic	O
ballistic	O
and	O
disordered	O
diffusive	O
mesoscopic	O
systems	O
with	O
spin	O
-	O
orbit	O
interaction	O
.	O

Neglecting	O
dynamic	O
effects	O
of	O
spin	O
-	O
orbit	O
interaction	O
,	O
we	O
reproduce	O
the	O
random	O
matrix	O
theory	O
results	O
that	O
the	O
spin	O
conductance	O
fluctuates	O
universally	O
around	O
zero	O
average	O
.	O

Incorporating	O
these	O
effects	O
into	O
the	O
theory	O
,	O
we	O
show	O
that	O
geometric	O
correlations	O
generate	O
finite	O
average	O
spin	O
conductances	O
,	O
but	O
that	O
they	O
do	O
not	O
affect	O
the	O
charge	O
conductance	O
to	O
leading	O
order	O
.	O

The	O
theory	O
,	O
which	O
is	O
confirmed	O
by	O
numerical	O
transport	O
calculations	O
,	O
allows	O
us	O
to	O
investigate	O
the	O
entire	O
range	O
from	O
the	O
weak	O
to	O
the	O
previously	O
unexplored	O
strong	O
spin	O
-	O
orbit	O
regime	O
,	O
where	O
the	O
spin	O
rotation	O
time	O
is	O
shorter	O
than	O
the	O
momentum	O
relaxation	O
time	O
.	O

Development	O
and	O
validation	O
of	O
an	O
approach	O
to	O
produce	O
large	O
-	O
scale	O
quantities	O
of	O
CpG	O
-	O
methylated	O
plasmid	O
DNA	O
.	O

The	O
prokaryotic	O
CpG	O
-	O
specific	O
DNA	O
methylase	O
from	O
Spiroplasma	O
,	O
SssI	O
methylase	O
,	O
has	O
been	O
extensively	O
used	O
to	O
methylate	O
plasmid	O
DNA	O
in	O
vitro	O
to	O
investigate	O
the	O
effects	O
of	O
methylation	O
in	O
vertebrate	O
systems	O
.	O

Currently	O
available	O
methods	O
to	O
produce	O
CpG	O
-	O
methylated	O
plasmid	O
DNA	O
have	O
certain	O
limitations	O
and	O
can	O
not	O
generate	O
large	O
quantities	O
of	O
methylated	O
DNA	O
without	O
cost	O
or	O
problems	O
of	O
purity	O
.	O

Here	O
we	O
describe	O
an	O
approach	O
in	O
which	O
the	O
SssI	O
methylase	O
gene	O
has	O
been	O
introduced	O
into	O
the	O
Escherichia	O
coli	O
bacterial	O
genome	O
under	O
the	O
control	O
of	O
an	O
inducible	O
promoter	O
.	O

Plasmid	O
DNA	O
propagated	O
in	O
this	O
bacterium	O
under	O
conditions	O
which	O
induce	O
the	O
methylase	O
gene	O
result	O
in	O
significant	O
(	O
>	O
90	O
%	O
)	O
CpG	O
methylation	O
.	O

Methylated	O
DNA	O
produced	O
by	O
this	O
approach	O
behaves	O
similarly	O
to	O
methylated	O
DNA	O
produced	O
in	O
vitro	O
using	O
the	O
purified	O
methylase	O
.	O

The	O
approach	O
is	O
scalable	O
allowing	O
for	O
the	O
production	O
of	O
milligram	O
quantities	O
of	O
methylated	O
plasmid	O
DNA	O
.	O

Dissecting	O
genetic	O
networks	O
underlying	O
complex	O
phenotypes	O
:	O
the	O
theoretical	O
framework	O
.	O

Great	O
progress	O
has	O
been	O
made	O
in	O
genetic	O
dissection	O
of	O
quantitative	O
trait	O
variation	O
during	O
the	O
past	O
two	O
decades	O
,	O
but	O
many	O
studies	O
still	O
reveal	O
only	O
a	O
small	O
fraction	O
of	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
,	O
and	O
epistasis	O
remains	O
elusive	O
.	O

We	O
integrate	O
contemporary	O
knowledge	O
of	O
signal	O
transduction	O
pathways	O
with	O
principles	O
of	O
quantitative	O
and	O
population	O
genetics	O
to	O
characterize	O
genetic	O
networks	O
underlying	O
complex	O
traits	O
,	O
using	O
a	O
model	O
founded	O
upon	O
one	O
-	O
way	O
functional	O
dependency	O
of	O
downstream	O
genes	O
on	O
upstream	O
regulators	O
(	O
the	O
principle	O
of	O
hierarchy	O
)	O
and	O
mutual	O
functional	O
dependency	O
among	O
related	O
genes	O
(	O
functional	O
genetic	O
units	O
,	O
FGU	O
)	O
.	O

Both	O
simulated	O
and	O
real	O
data	O
suggest	O
that	O
complementary	O
epistasis	O
contributes	O
greatly	O
to	O
quantitative	O
trait	O
variation	O
,	O
and	O
obscures	O
the	O
phenotypic	O
effects	O
of	O
many	O
'	O
downstream	O
'	O
loci	O
in	O
pathways	O
.	O

The	O
mathematical	O
relationships	O
between	O
the	O
main	O
effects	O
and	O
epistatic	O
effects	O
of	O
genes	O
acting	O
at	O
different	O
levels	O
of	O
signaling	O
pathways	O
were	O
established	O
using	O
the	O
quantitative	O
and	O
population	O
genetic	O
parameters	O
.	O

Both	O
loss	O
of	O
function	O
and	O
""""	O
co	O
-	O
adapted	O
""""	O
gene	O
complexes	O
formed	O
by	O
multiple	O
alleles	O
with	O
differentiated	O
functions	O
(	O
effects	O
)	O
are	O
predicted	O
to	O
be	O
frequent	O
types	O
of	O
allelic	O
diversity	O
at	O
loci	O
that	O
contribute	O
to	O
the	O
genetic	O
variation	O
of	O
complex	O
traits	O
in	O
populations	O
.	O

Downstream	O
FGUs	O
appear	O
to	O
be	O
more	O
vulnerable	O
to	O
loss	O
of	O
function	O
than	O
their	O
upstream	O
regulators	O
,	O
but	O
this	O
vulnerability	O
is	O
apparently	O
compensated	O
by	O
different	O
FGUs	O
of	O
similar	O
functions	O
.	O

Other	O
predictions	O
from	O
the	O
model	O
may	O
account	O
for	O
puzzling	O
results	O
regarding	O
responses	O
to	O
selection	O
,	O
genotype	O
by	O
environment	O
interaction	O
,	O
and	O
the	O
genetic	O
basis	O
of	O
heterosis	O
.	O

Ras	O
p21	O
onco	O
-	O
protein	O
in	O
the	O
sera	O
of	O
mice	O
carrying	O
an	O
experimentally	O
induced	O
tumor	O
and	O
in	O
human	O
cancer	O
patients	O
.	O

We	O
have	O
established	O
a	O
model	O
system	O
to	O
detect	O
the	O
presence	O
of	O
ras	O
p21	O
in	O
the	O
sera	O
of	O
Balb	O
/	O
c	O
mice	O
carrying	O
tumors	O
induced	O
by	O
a	O
mouse	O
cell	O
line	O
transformed	O
with	O
the	O
Harvey	O
murine	O
sarcoma	O
virus	O
in	O
the	O
presence	O
of	O
a	O
helper	O
Friend	O
murine	O
leukemia	O
virus	O
.	O

As	O
determined	O
by	O
ELISA	O
and	O
immunoblot	O
assays	O
,	O
ras	O
p21	O
in	O
the	O
serum	O
increased	O
with	O
increased	O
tumor	O
growth	O
.	O

Since	O
ras	O
genes	O
have	O
been	O
found	O
to	O
be	O
frequently	O
activated	O
in	O
human	O
tumours	O
,	O
we	O
examined	O
the	O
levels	O
of	O
ras	O
p21	O
in	O
the	O
sera	O
of	O
a	O
variety	O
of	O
human	O
cancer	O
patients	O
.	O

In	O
only	O
3	O
out	O
of	O
13	O
cases	O
,	O
representing	O
patients	O
with	O
adenocarcinomas	O
of	O
the	O
stomach	O
receiving	O
chemotherapy	O
,	O
was	O
ras	O
p21	O
detected	O
at	O
elevated	O
levels	O
,	O
whereas	O
in	O
patients	O
with	O
the	O
following	O
types	O
of	O
cancer	O
no	O
substantial	O
change	O
in	O
serum	O
ras	O
p21	O
was	O
observed	O
;	O
nine	O
with	O
breast	O
,	O
5	O
colon	O
,	O
5	O
lung	O
,	O
5	O
ovarian	O
and	O
5	O
hepatocellular	O
carcinomas	O
.	O

Serum	O
soluble	O
vascular	O
adhesion	O
protein	O
-	O
1	O
is	O
a	O
valuable	O
prognostic	O
marker	O
in	O
gastric	O
cancer	O
.	O

BACKGROUND	O
:	O
Vascular	O
adhesion	O
protein	O
-	O
1	O
(	O
VAP	O
-	O
1	O
)	O
regulates	O
leukocyte	O
tissue	O
infiltration	O
.	O

Elevated	O
serum	O
soluble	O
VAP	O
-	O
1	O
(	O
sVAP	O
-	O
1	O
)	O
levels	O
occur	O
in	O
certain	O
diseases	O
having	O
an	O
inflammatory	O
component	O
.	O

We	O
previously	O
showed	O
in	O
colorectal	O
cancer	O
that	O
sVAP	O
-	O
1	O
expression	O
is	O
significantly	O
higher	O
relative	O
to	O
controls	O
,	O
and	O
this	O
decreased	O
expression	O
is	O
associated	O
with	O
poor	O
prognosis	O
and	O
lymph	O
node	O
and	O
liver	O
metastasis	O
.	O

However	O
,	O
sVAP	O
-	O
1	O
expression	O
has	O
not	O
been	O
described	O
for	O
gastric	O
cancer	O
.	O

This	O
study	O
determines	O
the	O
relationship	O
between	O
preoperative	O
serum	O
sVAP	O
-	O
1	O
levels	O
and	O
clinicopathological	O
features	O
and	O
prognosis	O
in	O
gastric	O
cancer	O
.	O

METHODS	O
:	O
Preoperative	O
serum	O
was	O
collected	O
from	O
107	O
gastric	O
cancer	O
patients	O
and	O
33	O
normal	O
controls	O
.	O

sVAP	O
-	O
1	O
levels	O
were	O
assayed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

RESULTS	O
:	O
The	O
mean	O
sVAP	O
-	O
1	O
level	O
for	O
cancer	O
patients	O
was	O
significantly	O
higher	O
relative	O
to	O
controls	O
,	O
and	O
decreased	O
with	O
disease	O
progression	O
.	O

Tumor	O
size	O
,	O
serosal	O
invasion	O
,	O
lymph	O
node	O
metastasis	O
,	O
peritoneal	O
dissemination	O
,	O
and	O
TNM	O
classification	O
was	O
significantly	O
correlated	O
with	O
sVAP	O
-	O
1	O
level	O
.	O

sVAP	O
-	O
1	O
is	O
also	O
an	O
independent	O
predictive	O
marker	O
for	O
lymph	O
node	O
metastasis	O
.	O

Patients	O
having	O
low	O
sVAP	O
-	O
1	O
levels	O
had	O
significantly	O
poorer	O
prognosis	O
relative	O
to	O
patients	O
having	O
elevated	O
sVAP	O
-	O
1	O
in	O
all	O
or	O
stages	O
I	O
-	O
III	O
gastric	O
cancer	O
patients	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
Low	O
sVAP	O
-	O
1	O
levels	O
are	O
associated	O
with	O
poor	O
prognosis	O
in	O
gastric	O
cancer	O
.	O

Determining	O
sVAP	O
-	O
1	O
levels	O
may	O
be	O
valuable	O
for	O
predicting	O
prognosis	O
and	O
lymph	O
node	O
metastasis	O
.	O

Diallyl	O
trisulfide	O
(	O
DATS	O
)	O
inhibits	O
mouse	O
colon	O
tumor	O
in	O
mouse	O
CT	B
-	I
26	I
cells	O
allograft	O
model	O
in	O
vivo	O
.	O

Our	O
earlier	O
studies	O
showed	O
that	O
DATS	O
induced	O
apoptosis	O
in	O
human	O
colon	O
cancer	O
HT29	B
and	O
colo	B
205	I
cell	O
lines	O
in	O
vitro	O
.	O

However	O
,	O
there	O
is	O
no	O
report	O
to	O
show	O
that	O
DATS	O
induced	O
apoptosis	O
in	O
vitro	O
and	O
inhibited	O
CT26	B
cancer	O
cells	O
in	O
vivo	O
on	O
a	O
murine	O
allograft	O
animal	O
model	O
.	O

In	O
vitro	O
studies	O
,	O
the	O
results	O
indicated	O
that	O
DATS	O
induced	O
morphological	O
changes	O
and	O
induction	O
of	O
apoptosis	O
in	O
CT26	B
cells	O
.	O

In	O
vivo	O
studies	O
,	O
CT26	B
cancer	O
cells	O
were	O
implanted	O
into	O
BALB	O
/	O
c	O
mice	O
and	O
groups	O
of	O
mice	O
were	O
treated	O
with	O
vehicle	O
,	O
DATS	O
(	O
10	O
and	O
50	O
mg	O
/	O
kg	O
of	O
body	O
weight	O
)	O
.	O

DATS	O
were	O
injected	O
once	O
per	O
four	O
days	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
,	O
with	O
treatment	O
starting	O
4	O
weeks	O
prior	O
to	O
cells	O
inoculation	O
.	O

Treatment	O
with	O
vehicle	O
or	O
with	O
10	O
and	O
50	O
mg	O
/	O
kg	O
of	O
DATS	O
resulted	O
in	O
a	O
reduction	O
in	O
tumor	O
volume	O
and	O
weight	O
.	O

Tumor	O
volume	O
and	O
total	O
hemoglobin	O
in	O
allograft	O
mice	O
treated	O
with	O
50	O
mg	O
/	O
kg	O
DATS	O
were	O
significantly	O
smaller	O
than	O
that	O
in	O
the	O
control	O
group	O
.	O

These	O
findings	O
indicated	O
that	O
DATS	O
inhibits	O
tumor	O
growth	O
in	O
an	O
allograft	O
animal	O
model	O
.	O

Thus	O
,	O
DATS	O
may	O
represent	O
a	O
colon	O
cancer	O
preventive	O
agent	O
and	O
can	O
be	O
used	O
in	O
the	O
future	O
.	O

Metabolic	O
regulation	O
by	O
p53	O
.	O

We	O
are	O
increasingly	O
aware	O
that	O
cellular	O
metabolism	O
plays	O
a	O
vital	O
role	O
in	O
diseases	O
such	O
as	O
cancer	O
,	O
and	O
that	O
p53	O
is	O
an	O
important	O
regulator	O
of	O
metabolic	O
pathways	O
.	O

By	O
transcriptional	O
activation	O
and	O
other	O
means	O
,	O
p53	O
is	O
able	O
to	O
contribute	O
to	O
the	O
regulation	O
of	O
glycolysis	O
,	O
oxidative	O
phosphorylation	O
,	O
glutaminolysis	O
,	O
insulin	O
sensitivity	O
,	O
nucleotide	O
biosynthesis	O
,	O
mitochondrial	O
integrity	O
,	O
fatty	O
acid	O
oxidation	O
,	O
antioxidant	O
response	O
,	O
autophagy	O
and	O
mTOR	O
signalling	O
.	O

The	O
ability	O
to	O
positively	O
and	O
negatively	O
regulate	O
many	O
of	O
these	O
pathways	O
,	O
combined	O
with	O
feedback	O
signalling	O
from	O
these	O
pathways	O
to	O
p53	O
,	O
demonstrates	O
the	O
reciprocal	O
and	O
flexible	O
nature	O
of	O
the	O
regulation	O
,	O
facilitating	O
a	O
diverse	O
range	O
of	O
responses	O
to	O
metabolic	O
stress	O
.	O

Intriguingly	O
,	O
metabolic	O
stress	O
triggers	O
primarily	O
an	O
adaptive	O
(	O
rather	O
than	O
pro	O
-	O
apoptotic	O
)	O
p53	O
response	O
,	O
and	O
p53	O
is	O
emerging	O
as	O
an	O
important	O
regulator	O
of	O
metabolic	O
homeostasis	O
.	O

A	O
better	O
understanding	O
of	O
how	O
p53	O
coordinates	O
metabolic	O
adaptation	O
will	O
facilitate	O
the	O
identification	O
of	O
novel	O
therapeutic	O
targets	O
and	O
will	O
also	O
illuminate	O
the	O
wider	O
role	O
of	O
p53	O
in	O
human	O
biology	O
.	O

Use	O
of	O
DNA	O
microarray	O
and	O
small	O
animal	O
positron	O
emission	O
tomography	O
in	O
preclinical	O
drug	O
evaluation	O
of	O
RAF265	O
,	O
a	O
novel	O
B	O
-	O
Raf	O
/	O
VEGFR	O
-	O
2	O
inhibitor	O
.	O

Positron	O
emission	O
tomography	O
(	O
PET	O
)	O
imaging	O
has	O
become	O
a	O
useful	O
tool	O
for	O
assessing	O
early	O
biologic	O
response	O
to	O
cancer	O
therapy	O
and	O
may	O
be	O
particularly	O
useful	O
in	O
the	O
development	O
of	O
new	O
cancer	O
therapeutics	O
.	O

RAF265	O
,	O
a	O
novel	O
B	O
-	O
Raf	O
/	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
2	O
inhibitor	O
,	O
was	O
evaluated	O
in	O
the	O
preclinical	O
setting	O
for	O
its	O
ability	O
to	O
inhibit	O
the	O
uptake	O
of	O
PET	O
tracers	O
in	O
the	O
A375	B
M	I
(	O
B	O
-	O
Raf	O
(	O
V600E	O
)	O
)	O
human	O
melanoma	O
cell	O
line	O
.	O

RAF265	O
inhibited	O
2	O
-	O
deoxy	O
-	O
2	O
-	O
[	O
(	O
18	O
)	O
F	O
]	O
fluoro	O
-	O
d	O
-	O
glucose	O
(	O
FDG	O
)	O
accumulation	O
in	O
cell	O
culture	O
at	O
28	O
hours	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

RAF265	O
also	O
inhibited	O
FDG	O
accumulation	O
in	O
tumor	O
xenografts	O
after	O
1	O
day	O
of	O
drug	O
treatment	O
.	O

This	O
decrease	O
persisted	O
for	O
the	O
remaining	O
2	O
weeks	O
of	O
treatment	O
.	O

DNA	O
microarray	O
analysis	O
of	O
treated	O
tumor	O
xenografts	O
revealed	O
significantly	O
decreased	O
expression	O
of	O
genes	O
regulating	O
glucose	O
and	O
thymidine	O
metabolism	O
and	O
revealed	O
changes	O
in	O
apoptotic	O
genes	O
,	O
suggesting	O
that	O
the	O
imaging	O
tracers	O
FDG	O
,	O
3	O
-	O
deoxy	O
-	O
3	O
-	O
[	O
(	O
18	O
)	O
F	O
]	O
fluorothymidine	O
,	O
and	O
annexin	O
V	O
could	O
serve	O
as	O
potential	O
imaging	O
biomarkers	O
for	O
RAF265	O
therapy	O
monitoring	O
.	O

We	O
concluded	O
that	O
RAF265	O
is	O
highly	O
efficacious	O
in	O
this	O
xenograft	O
model	O
of	O
human	O
melanoma	O
and	O
decreases	O
glucose	O
metabolism	O
as	O
measured	O
by	O
DNA	O
microarray	O
analysis	O
,	O
cell	O
culture	O
assays	O
,	O
and	O
small	O
animal	O
FDG	O
PET	O
scans	O
as	O
early	O
as	O
1	O
day	O
after	O
treatment	O
.	O

Our	O
results	O
support	O
the	O
use	O
of	O
FDG	O
PET	O
in	O
clinical	O
trials	O
with	O
RAF265	O
to	O
assess	O
early	O
tumor	O
response	O
.	O

DNA	O
microarray	O
analysis	O
and	O
small	O
animal	O
PET	O
studies	O
may	O
be	O
used	O
as	O
complementary	O
technologies	O
in	O
drug	O
development	O
.	O

DNA	O
microarray	O
analysis	O
allows	O
for	O
analysis	O
of	O
drug	O
effects	O
on	O
multiple	O
pathways	O
linked	O
to	O
cancer	O
and	O
can	O
suggest	O
corresponding	O
imaging	O
tracers	O
for	O
further	O
analysis	O
as	O
biomarkers	O
of	O
tumor	O
response	O
.	O

Predictive	O
value	O
of	O
serum	O
carbohydrate	O
antigen	O
19	O
-	O
9	O
in	O
malignant	O
intraductal	O
papillary	O
mucinous	O
neoplasms	O
.	O

BACKGROUND	O
:	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
predictive	O
value	O
of	O
serum	O
carbohydrate	O
antigen	O
19	O
-	O
9	O
(	O
CA	O
19	O
-	O
9	O
)	O
in	O
the	O
diagnosis	O
of	O
malignant	O
intraductal	O
papillary	O
mucinous	O
neoplasms	O
of	O
pancreas	O
(	O
IPMNs	O
)	O
.	O

METHODS	O
:	O

Eighty	O
-	O
six	O
patients	O
with	O
pathological	O
diagnosis	O
of	O
IPMNs	O
in	O
Zhongshan	O
Hospital	O
between	O
March	O
1999	O
and	O
November	O
2008	O
were	O
retrospectively	O
reviewed	O
.	O

Data	O
reflecting	O
clinical	O
characteristics	O
,	O
tumor	O
marker	O
level	O
,	O
and	O
prognosis	O
were	O
collected	O
.	O

The	O
potential	O
predictive	O
value	O
of	O
CA	O
19	O
-	O
9	O
was	O
analyzed	O
by	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
.	O

RESULTS	O
:	O

Eighty	O
-	O
six	O
consecutive	O
patients	O
with	O
IPMNs	O
all	O
underwent	O
surgical	O
intervention	O
.	O

A	O
high	O
level	O
of	O
CA	O
19	O
-	O
9	O
or	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
was	O
associated	O
with	O
more	O
advanced	O
stage	O
of	O
malignant	O
IPMNs	O
.	O

Carbohydrate	O
antigen	O
19	O
-	O
9	O
was	O
significant	O
for	O
judging	O
malignant	O
IPMNs	O
in	O
the	O
binary	O
logistic	O
regression	O
model	O
(	O
p	O
=	O
0	O
.	O
047	O
)	O
.	O

The	O
hazard	O
ratio	O
was	O
1	O
.	O
014	O
,	O
whose	O
95	O
.	O
0	O
%	O
confidence	O
interval	O
was	O
0	O
.	O
91	O
-	O
1	O
.	O
028	O
.	O

Receiver	O
operating	O
characteristic	O
analysis	O
showed	O
that	O
the	O
serum	O
CA	O
19	O
-	O
9	O
level	O
had	O
good	O
predictive	O
value	O
for	O
malignant	O
or	O
invasive	O
IPMNs	O
,	O
postoperative	O
survival	O
,	O
and	O
disease	O
-	O
specific	O
recurrence	O
.	O

The	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
was	O
0	O
.	O
856	O
,	O
0	O
.	O
893	O
,	O
0	O
.	O
815	O
,	O
and	O
0	O
.	O
857	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
respectively	O
.	O

According	O
to	O
the	O
follow	O
-	O
up	O
,	O
mean	O
survival	O
time	O
for	O
groups	O
with	O
CA	O
19	O
-	O
9	O
>	O
63	O
.	O
60	O
U	O
/	O
ml	O
was	O
dramatically	O
shorter	O
than	O
that	O
for	O
groups	O
with	O
CA	O
19	O
-	O
9	O
<	O
=	O
63	O
.	O
60	O
U	O
/	O
ml	O
(	O
57	O
.	O
38	O
+	O
/	O
-	O
2	O
.	O
85	O
versus	O
29	O
.	O
24	O
+	O
/	O
-	O
5	O
.	O
82	O
[	O
months	O
]	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O

Serum	O
CA	O
19	O
-	O
9	O
level	O
has	O
good	O
predictive	O
value	O
for	O
malignant	O
or	O
invasive	O
IPMNs	O
.	O

Patients	O
with	O
CA	O
19	O
-	O
9	O
>	O
63	O
.	O
60	O
U	O
/	O
ml	O
had	O
poor	O
postoperative	O
prognosis	O
in	O
IPMNs	O
.	O

Preoperative	O
abnormal	O
serum	O
CA	O
19	O
-	O
9	O
might	O
be	O
predictive	O
for	O
an	O
aggressive	O
surgical	O
intervention	O
in	O
IPMNs	O
.	O

Saliva	O
proteins	O
of	O
vector	O
Culicoides	O
modify	O
structure	O
and	O
infectivity	O
of	O
bluetongue	O
virus	O
particles	O
.	O

Bluetongue	O
virus	O
(	O
BTV	O
)	O
and	O
epizootic	O
haemorrhagic	O
disease	O
virus	O
(	O
EHDV	O
)	O
are	O
related	O
orbiviruses	O
,	O
transmitted	O
between	O
their	O
ruminant	O
hosts	O
primarily	O
by	O
certain	O
haematophagous	O
midge	O
vectors	O
(	O
Culicoides	O
spp	O
.	O
)	O
.	O

The	O
larger	O
of	O
the	O
BTV	O
outer	O
-	O
capsid	O
proteins	O
,	O
'	O
VP2	O
'	O
,	O
can	O
be	O
cleaved	O
by	O
proteases	O
(	O
including	O
trypsin	O
or	O
chymotrypsin	O
)	O
,	O
forming	O
infectious	O
subviral	O
particles	O
(	O
ISVP	O
)	O
which	O
have	O
enhanced	O
infectivity	O
for	O
adult	O
Culicoides	O
,	O
or	O
KC	O
cells	O
(	O
a	O
cell	O
-	O
line	O
derived	O
from	O
C	O
.	O
sonorensis	O
)	O
.	O

We	O
demonstrate	O
that	O
VP2	O
present	O
on	O
purified	O
virus	O
particles	O
from	O
3	O
different	O
BTV	O
strains	O
can	O
also	O
be	O
cleaved	O
by	O
treatment	O
with	O
saliva	O
from	O
adult	O
Culicoides	O
.	O

The	O
saliva	O
proteins	O
from	O
C	O
.	O
sonorensis	O
(	O
a	O
competent	O
BTV	O
vector	O
)	O
,	O
cleaved	O
BTV	O
-	O
VP2	O
more	O
efficiently	O
than	O
those	O
from	O
C	O
.	O
nubeculosus	O
(	O
a	O
less	O
competent	O
/	O
non	O
-	O
vector	O
species	O
)	O
.	O

Electrophoresis	O
and	O
mass	O
spectrometry	O
identified	O
a	O
trypsin	O
-	O
like	O
protease	O
in	O
C	O
.	O
sonorensis	O
saliva	O
,	O
which	O
was	O
significantly	O
reduced	O
or	O
absent	O
from	O
C	O
.	O
nubeculosus	O
saliva	O
.	O

Incubating	O
purified	O
BTV	O
-	O
1	O
with	O
C	O
.	O
sonorensis	O
saliva	O
proteins	O
also	O
increased	O
their	O
infectivity	O
for	O
KC	O
cells	O
~	O
10	O
fold	O
,	O
while	O
infectivity	O
for	O
BHK	B
cells	O
was	O
reduced	O
by	O
2	O
-	O
6	O
fold	O
.	O

Treatment	O
of	O
an	O
'	O
eastern	O
'	O
strain	O
of	O
EHDV	O
-	O
2	O
with	O
saliva	O
proteins	O
of	O
either	O
C	O
.	O
sonorensis	O
or	O
C	O
.	O
nubeculosus	O
cleaved	O
VP2	O
,	O
but	O
a	O
'	O
western	O
'	O
strain	O
of	O
EHDV	O
-	O
2	O
remained	O
unmodified	O
.	O

These	O
results	O
indicate	O
that	O
temperature	O
,	O
strain	O
of	O
virus	O
and	O
protein	O
composition	O
of	O
Culicoides	O
saliva	O
(	O
particularly	O
its	O
protease	O
content	O
which	O
is	O
dependent	O
upon	O
vector	O
species	O
)	O
,	O
can	O
all	O
play	O
a	O
significant	O
role	O
in	O
the	O
efficiency	O
of	O
VP2	O
cleavage	O
,	O
influencing	O
virus	O
infectivity	O
.	O

Saliva	O
of	O
several	O
other	O
arthropod	O
species	O
has	O
previously	O
been	O
shown	O
to	O
increase	O
transmission	O
,	O
infectivity	O
and	O
virulence	O
of	O
certain	O
arboviruses	O
,	O
by	O
modulating	O
and	O
/	O
or	O
suppressing	O
the	O
mammalian	O
immune	O
response	O
.	O

The	O
findings	O
presented	O
here	O
,	O
however	O
,	O
demonstrate	O
a	O
novel	O
mechanism	O
by	O
which	O
proteases	O
in	O
Culicoides	O
saliva	O
can	O
also	O
directly	O
modify	O
the	O
orbivirus	O
particle	O
structure	O
,	O
leading	O
to	O
increased	O
infectivity	O
specifically	O
for	O
Culicoides	O
cells	O
and	O
,	O
in	O
turn	O
,	O
efficiency	O
of	O
transmission	O
to	O
the	O
insect	O
vector	O
.	O

Systematic	O
proteomic	O
analysis	O
of	O
human	O
hepotacellular	O
carcinoma	O
cells	O
reveals	O
molecular	O
pathways	O
and	O
networks	O
involved	O
in	O
metastasis	O
.	O

Systematic	O
proteomic	O
studying	O
of	O
the	O
mechanism	O
of	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
metastasis	O
remains	O
challenging	O
.	O

We	O
performed	O
comparative	O
proteomic	O
and	O
pathway	O
analysis	O
of	O
four	O
human	O
metastatic	O
HCC	O
cell	O
lines	O
to	O
identify	O
metastasis	O
-	O
associated	O
proteins	O
.	O

These	O
HCC	O
cell	O
lines	O
had	O
a	O
similar	O
genetic	O
background	O
but	O
with	O
an	O
increasing	O
potential	O
of	O
metastasis	O
.	O

Using	O
a	O
combination	O
of	O
two	O
dimensional	O
electrophoresis	O
(	O
2	O
-	O
DE	O
)	O
and	O
MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
,	O
a	O
total	O
of	O
125	O
proteins	O
and	O
their	O
post	O
-	O
translational	O
modification	O
forms	O
or	O
isoforms	O
were	O
found	O
to	O
be	O
differentially	O
expressed	O
in	O
the	O
cell	O
lines	O
.	O

Among	O
them	O
,	O
29	O
were	O
gradually	O
up	O
-	O
regulated	O
whereas	O
17	O
were	O
down	O
-	O
regulated	O
with	O
increasing	O
metastatic	O
potential	O
.	O

Instead	O
of	O
a	O
traditional	O
single	O
-	O
gene	O
readout	O
,	O
global	O
bioinformatics	O
analysis	O
was	O
carried	O
out	O
,	O
which	O
revealed	O
that	O
the	O
glycolysis	O
pathway	O
was	O
the	O
most	O
significantly	O
enriched	O
pathway	O
.	O

The	O
heat	O
shock	O
proteins	O
(	O
HSPs	O
)	O
centered	O
and	O
NF	O
-	O
kappaB	O
centered	O
networks	O
were	O
also	O
enriched	O
in	O
the	O
result	O
,	O
which	O
may	O
imply	O
the	O
key	O
function	O
of	O
inflaming	O
on	O
metastasis	O
.	O

Meanwhile	O
,	O
knockdown	O
of	O
HDGF	O
,	O
an	O
up	O
-	O
regulated	O
protein	O
and	O
a	O
target	O
of	O
NF	O
-	O
kappaB	O
,	O
induced	O
cell	O
apoptosis	O
in	O
the	O
metastatic	O
HCC	O
cells	O
.	O

This	O
work	O
provides	O
a	O
demonstration	O
that	O
a	O
combination	O
of	O
bioinformatics	O
and	O
comparative	O
proteomics	O
can	O
help	O
in	O
finding	O
out	O
potential	O
biomarkers	O
associated	O
with	O
HCC	O
metastasis	O
on	O
the	O
level	O
of	O
pathways	O
.	O

Roles	O
of	O
brca2	O
(	O
fancd1	O
)	O
in	O
oocyte	O
nuclear	O
architecture	O
,	O
gametogenesis	O
,	O
gonad	O
tumors	O
,	O
and	O
genome	O
stability	O
in	O
zebrafish	O
.	O

Mild	O
mutations	O
in	O
BRCA2	O
(	O
FANCD1	O
)	O
cause	O
Fanconi	O
anemia	O
(	O
FA	O
)	O
when	O
homozygous	O
,	O
while	O
severe	O
mutations	O
cause	O
common	O
cancers	O
including	O
breast	O
,	O
ovarian	O
,	O
and	O
prostate	O
cancers	O
when	O
heterozygous	O
.	O

Here	O
we	O
report	O
a	O
zebrafish	O
brca2	O
insertional	O
mutant	O
that	O
shares	O
phenotypes	O
with	O
human	O
patients	O
and	O
identifies	O
a	O
novel	O
brca2	O
function	O
in	O
oogenesis	O
.	O

Experiments	O
showed	O
that	O
mutant	O
embryos	O
and	O
mutant	O
cells	O
in	O
culture	O
experienced	O
genome	O
instability	O
,	O
as	O
do	O
cells	O
in	O
FA	O
patients	O
.	O

In	O
wild	O
-	O
type	O
zebrafish	O
,	O
meiotic	O
cells	O
expressed	O
brca2	O
;	O
and	O
,	O
unexpectedly	O
,	O
transcripts	O
in	O
oocytes	O
localized	O
asymmetrically	O
to	O
the	O
animal	O
pole	O
.	O

In	O
juvenile	O
brca2	O
mutants	O
,	O
oocytes	O
failed	O
to	O
progress	O
through	O
meiosis	O
,	O
leading	O
to	O
female	O
-	O
to	O
-	O
male	O
sex	O
reversal	O
.	O

Adult	O
mutants	O
became	O
sterile	O
males	O
due	O
to	O
the	O
meiotic	O
arrest	O
of	O
spermatocytes	O
,	O
which	O
then	O
died	O
by	O
apoptosis	O
,	O
followed	O
by	O
neoplastic	O
proliferation	O
of	O
gonad	O
somatic	O
cells	O
that	O
was	O
similar	O
to	O
neoplasia	O
observed	O
in	O
ageing	O
dead	O
end	O
(	O
dnd	O
)	O
-	O
knockdown	O
males	O
,	O
which	O
lack	O
germ	O
cells	O
.	O

The	O
construction	O
of	O
animals	O
doubly	O
mutant	O
for	O
brca2	O
and	O
the	O
apoptotic	O
gene	O
tp53	O
(	O
p53	O
)	O
rescued	O
brca2	O
-	O
dependent	O
sex	O
reversal	O
.	O

Double	O
mutants	O
developed	O
oocytes	O
and	O
became	O
sterile	O
females	O
that	O
produced	O
only	O
aberrant	O
embryos	O
and	O
showed	O
elevated	O
risk	O
for	O
invasive	O
ovarian	O
tumors	O
.	O

Oocytes	O
in	O
double	O
-	O
mutant	O
females	O
showed	O
normal	O
localization	O
of	O
brca2	O
and	O
pou5f1	O
transcripts	O
to	O
the	O
animal	O
pole	O
and	O
vasa	O
transcripts	O
to	O
the	O
vegetal	O
pole	O
,	O
but	O
had	O
a	O
polarized	O
rather	O
than	O
symmetrical	O
nucleus	O
with	O
the	O
distribution	O
of	O
nucleoli	O
and	O
chromosomes	O
to	O
opposite	O
nuclear	O
poles	O
;	O
this	O
result	O
revealed	O
a	O
novel	O
role	O
for	O
Brca2	O
in	O
establishing	O
or	O
maintaining	O
oocyte	O
nuclear	O
architecture	O
.	O

Mutating	O
tp53	O
did	O
not	O
rescue	O
the	O
infertility	O
phenotype	O
in	O
brca2	O
mutant	O
males	O
,	O
suggesting	O
that	O
brca2	O
plays	O
an	O
essential	O
role	O
in	O
zebrafish	O
spermatogenesis	O
.	O

Overall	O
,	O
this	O
work	O
verified	O
zebrafish	O
as	O
a	O
model	O
for	O
the	O
role	O
of	O
Brca2	O
in	O
human	O
disease	O
and	O
uncovered	O
a	O
novel	O
function	O
of	O
Brca2	O
in	O
vertebrate	O
oocyte	O
nuclear	O
architecture	O
.	O

Induction	O
of	O
I	O
d	O
-	O
1	O
by	O
FGF	O
-	O
2	O
involves	O
activity	O
of	O
EGR	O
-	O
1	O
and	O
sensitizes	O
neuroblastoma	O
cells	O
to	O
cell	O
death	O
.	O

Inhibitor	O
of	O
differentiation	O
-	O
1	O
(	O
I	O
d	O
-	O
1	O
)	O
is	O
a	O
member	O
of	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
HLH	O
)	O
family	O
of	O
proteins	O
that	O
regulate	O
gene	O
transcription	O
through	O
their	O
inhibitory	O
binding	O
to	O
basic	O
-	O
HLH	O
transcription	O
factors	O
.	O

Similarly	O
to	O
other	O
members	O
of	O
this	O
family	O
,	O
I	O
d	O
-	O
1	O
is	O
involved	O
in	O
the	O
repression	O
of	O
cell	O
differentiation	O
and	O
activation	O
of	O
cell	O
growth	O
.	O

The	O
dual	O
function	O
of	O
I	O
d	O
-	O
1	O
,	O
inhibition	O
of	O
differentiation	O
,	O
and	O
stimulation	O
of	O
cell	O
proliferation	O
,	O
might	O
be	O
interdependent	O
,	O
as	O
cell	O
differentiation	O
is	O
generally	O
coupled	O
with	O
the	O
exit	O
from	O
the	O
cell	O
cycle	O
.	O

Fibroblast	O
growth	O
factor	O
-	O
2	O
(	O
FGF	O
-	O
2	O
)	O
has	O
been	O
reported	O
to	O
play	O
multiple	O
roles	O
in	O
different	O
biological	O
processes	O
during	O
development	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

In	O
addition	O
,	O
FGF	O
-	O
2	O
has	O
been	O
described	O
to	O
induce	O
""""	O
neuronal	O
-	O
like	O
""""	O
differentiation	O
and	O
trigger	O
apoptosis	O
in	O
neuroblastoma	O
SK	B
-	I
N	I
-	I
MC	I
cells	O
.	O

Although	O
regulation	O
of	O
I	O
d	O
-	O
1	O
protein	O
by	O
several	O
mitogenic	O
factors	O
is	O
well	O
-	O
established	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
FGF	O
-	O
2	O
in	O
the	O
regulation	O
of	O
I	O
d	O
-	O
1	O
.	O

Using	O
human	O
neuroblastoma	O
cell	O
line	O
,	O
SK	B
-	I
N	I
-	I
MC	I
,	O
we	O
found	O
that	O
treatment	O
of	O
these	O
cells	O
with	O
FGF	O
-	O
2	O
resulted	O
in	O
early	O
induction	O
of	O
both	O
I	O
d	O
-	O
1	O
mRNA	O
and	O
protein	O
.	O

The	O
induction	O
occurs	O
within	O
1	O
h	O
from	O
FGF	O
-	O
2	O
treatment	O
and	O
is	O
mediated	O
by	O
ERK1	O
/	O
2	O
pathway	O
,	O
which	O
in	O
turn	O
stimulates	O
expression	O
of	O
the	O
early	O
growth	O
response	O
-	O
1	O
(	O
Egr	O
-	O
1	O
)	O
transcription	O
factor	O
.	O

We	O
also	O
demonstrate	O
direct	O
interaction	O
of	O
Egr	O
-	O
1	O
with	O
I	O
d	O
-	O
1	O
promoter	O
in	O
vitro	O
and	O
in	O
cell	O
culture	O
.	O

Finally	O
,	O
inhibition	O
of	O
I	O
d	O
-	O
1	O
expression	O
results	O
in	O
G	O
(	O
2	O
)	O
/	O
M	O
accumulation	O
of	O
FGF	O
-	O
2	O
-	O
treated	O
cells	O
and	O
delayed	O
cell	O
death	O
.	O

Vimentin	O
is	O
preferentially	O
expressed	O
in	O
human	O
breast	O
carcinomas	O
with	O
low	O
estrogen	O
receptor	O
and	O
high	O
Ki	O
-	O
67	O
growth	O
fraction	O
.	O

Vimentin	O
expression	O
,	O
growth	O
fractions	O
(	O
GF	O
)	O
,	O
and	O
estrogen	O
receptor	O
(	O
ER	O
)	O
levels	O
were	O
determined	O
for	O
90	O
untreated	O
primary	O
breast	O
carcinomas	O
.	O

Coexpression	O
of	O
keratin	O
and	O
vimentin	O
was	O
found	O
in	O
approximately	O
20	O
%	O
of	O
the	O
tumors	O
regardless	O
of	O
menopausal	O
status	O
.	O

Vimentin	O
was	O
expressed	O
preferentially	O
in	O
tumor	O
cells	O
of	O
high	O
-	O
grade	O
ductal	O
breast	O
carcinomas	O
(	O
15	O
of	O
28	O
histologic	O
grade	O
3	O
vs	O
.	O
0	O
of	O
40	O
grades	O
1	O
and	O
2	O
)	O
.	O

Vimentin	O
expression	O
was	O
found	O
preferentially	O
in	O
tumors	O
with	O
high	O
GF	O
(	O
greater	O
than	O
15	O
%	O
Ki	O
-	O
67	O
positive	O
by	O
immunoperoxidase	O
staining	O
)	O
and	O
low	O
ER	O
levels	O
(	O
less	O
than	O
60	O
fmols	O
/	O
mg	O
protein	O
by	O
a	O
monoclonal	O
enzyme	O
immunoassay	O
)	O
.	O

Sixty	O
-	O
eight	O
percent	O
of	O
tumors	O
in	O
this	O
group	O
were	O
vimentin	O
positive	O
and	O
88	O
%	O
of	O
all	O
vimentin	O
-	O
positive	O
tumors	O
fell	O
into	O
this	O
category	O
.	O

More	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
coexpressed	O
vimentin	O
and	O
keratin	O
.	O

Thus	O
,	O
vimentin	O
expression	O
may	O
be	O
helpful	O
in	O
identifying	O
a	O
substantial	O
subset	O
of	O
ER	O
-	O
independent	O
breast	O
carcinomas	O
with	O
poor	O
prognostic	O
indicators	O
.	O

High	O
-	O
mobility	O
group	O
A2	O
protein	O
modulates	O
hTERT	O
transcription	O
to	O
promote	O
tumorigenesis	O
.	O

The	O
high	O
-	O
mobility	O
group	O
A2	O
gene	O
(	O
HMGA2	O
)	O
is	O
one	O
of	O
the	O
most	O
frequently	O
amplified	O
genes	O
in	O
human	O
cancers	O
.	O

However	O
,	O
functions	O
of	O
HMGA2	O
in	O
tumorigenesis	O
are	O
not	O
fully	O
understood	O
due	O
to	O
limited	O
knowledge	O
of	O
its	O
targets	O
in	O
tumor	O
cells	O
.	O

Our	O
study	O
reveals	O
a	O
novel	O
link	O
between	O
HMGA2	O
and	O
the	O
regulation	O
of	O
human	O
telomerase	O
reverse	O
transcriptase	O
(	O
hTERT	O
)	O
,	O
the	O
catalytic	O
subunit	O
of	O
telomerase	O
,	O
which	O
offers	O
critical	O
insight	O
into	O
how	O
HMGA2	O
contributes	O
to	O
tumorigenesis	O
.	O

The	O
expression	O
of	O
HMGA2	O
modulates	O
the	O
expression	O
of	O
hTERT	O
,	O
resulting	O
in	O
cells	O
with	O
enhanced	O
telomerase	O
activities	O
and	O
increased	O
telomere	O
length	O
.	O

Treatment	O
with	O
suberoylanilide	O
hydroxamide	O
(	O
SAHA	O
)	O
,	O
a	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitor	O
,	O
causes	O
dose	O
-	O
dependent	O
hTERT	O
reporter	O
activation	O
,	O
mimicking	O
HMGA2	O
overexpression	O
.	O

By	O
interacting	O
with	O
Sp1	O
,	O
HMGA2	O
interferes	O
with	O
the	O
recruitment	O
of	O
HDAC2	O
to	O
the	O
hTERT	O
proximal	O
promoter	O
,	O
enhancing	O
localized	O
histone	O
H3	O
-	O
K9	O
acetylation	O
and	O
thereby	O
stimulating	O
hTERT	O
expression	O
and	O
telomerase	O
activity	O
.	O

Moreover	O
,	O
HMGA2	O
knockdown	O
by	O
short	O
hairpin	O
HMGA2	O
in	O
HepG2	B
cells	O
leads	O
to	O
progressive	O
telomere	O
shortening	O
and	O
a	O
concurrent	O
decrease	O
of	O
steady	O
-	O
state	O
hTERT	O
mRNA	O
levels	O
,	O
attenuating	O
their	O
ability	O
to	O
form	O
colonies	O
in	O
soft	O
agar	O
.	O

Importantly	O
,	O
HMGA2	O
partially	O
replaces	O
the	O
function	O
of	O
hTERT	O
during	O
the	O
tumorigenic	O
transformation	O
of	O
normal	O
human	O
fibroblasts	O
.	O

These	O
findings	O
are	O
potentially	O
clinically	O
relevant	O
,	O
because	O
HMGA2	O
expression	O
is	O
reported	O
to	O
be	O
upregulated	O
in	O
a	O
number	O
of	O
human	O
cancers	O
as	O
telomere	O
maintenance	O
is	O
essential	O
for	O
tumorigenesis	O
.	O

3	O
-	O
[	O
(	O
Methyl	O
-	O
carbamo	O
-	O
yl	O
)	O
amino	O
]	O
-	O
1H	O
-	O
isoindolium	O
chloride	O
.	O

The	O
title	O
compound	O
,	O
C	O
(	O
10	O
)	O
H	O
(	O
12	O
)	O
N	O
(	O
3	O
)	O
O	O
(	O
+	O
)	O
.	O
Cl	O
(	O
-	O
)	O
,	O
is	O
a	O
derivative	O
of	O
o	O
-	O
phthaldehyde	O
and	O
methyl	O
-	O
thio	O
-	O
urea	O
.	O

The	O
mol	O
-	O
ecules	O
form	O
dimers	O
through	O
intra	O
-	O
and	O
inter	O
-	O
molecular	O
N	O
-	O
H	O
.	O
.	O
.	O
O	O
hydrogen	O
bonds	O
.	O

The	O
dimers	O
are	O
further	O
linked	O
into	O
chains	O
through	O
one	O
C	O
-	O
H	O
.	O
.	O
.	O
Cl	O
and	O
two	O
N	O
-	O
H	O
.	O
.	O
.	O
Cl	O
hydrogen	O
bonds	O
.	O

mirAct	O
:	O
a	O
web	O
tool	O
for	O
evaluating	O
microRNA	O
activity	O
based	O
on	O
gene	O
expression	O
data	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
critical	O
regulators	O
in	O
the	O
complex	O
cellular	O
networks	O
.	O

The	O
mirAct	O
web	O
server	O
(	O
http	O
:	O
/	O
/	O
sysbio	O
.	O
ustc	O
.	O
edu	O
.	O
cn	O
/	O
software	O
/	O
mirAct	O
)	O
is	O
a	O
tool	O
designed	O
to	O
investigate	O
miRNA	O
activity	O
based	O
on	O
gene	O
-	O
expression	O
data	O
by	O
using	O
the	O
negative	O
regulation	O
relationship	O
between	O
miRNAs	O
and	O
their	O
target	O
genes	O
.	O

mirAct	O
supports	O
multiple	O
-	O
class	O
data	O
and	O
enables	O
clustering	O
analysis	O
based	O
on	O
computationally	O
determined	O
miRNA	O
activity	O
.	O

Here	O
,	O
we	O
describe	O
the	O
framework	O
of	O
mirAct	O
,	O
demonstrate	O
its	O
performance	O
by	O
comparing	O
with	O
other	O
similar	O
programs	O
and	O
exemplify	O
its	O
applications	O
using	O
case	O
studies	O
.	O

Non	O
-	O
heart	O
-	O
beating	O
organ	O
donation	O
in	O
Italy	O
.	O

In	O
2007	O
the	O
non	O
-	O
heart	O
-	O
beating	O
organ	O
donation	O
(	O
NHBD	O
)	O
""""	O
Programma	O
Alba	O
""""	O
(	O
Sunrise	O
Programme	O
)	O
started	O
in	O
Pavia	O
,	O
Italy	O
.	O

The	O
initial	O
plan	O
was	O
to	O
cut	O
down	O
waiting	O
list	O
for	O
kidney	O
transplantation	O
,	O
while	O
its	O
final	O
aim	O
is	O
to	O
shorten	O
organ	O
transplantation	O
waiting	O
lists	O
.	O

When	O
compared	O
to	O
European	O
countries	O
and	O
the	O
USA	O
,	O
the	O
Italian	O
NHBD	O
program	O
has	O
taken	O
longer	O
to	O
get	O
established	O
.	O

Initially	O
Italian	O
physicians	O
were	O
not	O
entirely	O
aware	O
of	O
the	O
NHBD	O
organ	O
viability	O
for	O
transplantation	O
,	O
furthermore	O
ethical	O
issues	O
and	O
the	O
need	O
to	O
regulate	O
medical	O
requirements	O
to	O
Italian	O
law	O
slowed	O
down	O
the	O
NHBD	O
program	O
.	O

In	O
particular	O
,	O
Italian	O
legislation	O
provides	O
for	O
death	O
ascertainment	O
after	O
irreversible	O
cardiac	O
arrest	O
,	O
20	O
-	O
minute	O
flat	O
electrocardiogram	O
.	O

This	O
no	O
-	O
touch	O
period	O
is	O
longer	O
when	O
compared	O
to	O
worldwide	O
legislation	O
,	O
and	O
organ	O
viability	O
has	O
been	O
a	O
main	O
concern	O
for	O
Italian	O
transplant	O
doctors	O
over	O
the	O
years	O
.	O

However	O
,	O
recent	O
data	O
let	O
up	O
to	O
40	O
-	O
minute	O
warm	O
ischemia	O
time	O
to	O
preserve	O
organ	O
viability	O
;	O
this	O
has	O
encouraged	O
Pavia	O
'	O
s	O
group	O
to	O
establish	O
the	O
NHBD	O
""""	O
Programma	O
Alba	O
""""	O
.	O

It	O
was	O
designed	O
according	O
to	O
Italian	O
legislation	O
from	O
death	O
diagnosis	O
to	O
graft	O
placement	O
,	O
from	O
this	O
perspective	O
must	O
the	O
significant	O
role	O
of	O
the	O
Transplant	O
coordinator	O
be	O
recognized	O
.	O

Since	O
2007	O
seven	O
kidneys	O
have	O
been	O
gathered	O
from	O
seven	O
NHBD	O
.	O

Of	O
these	O
,	O
six	O
NHBD	O
kidneys	O
have	O
been	O
transplanted	O
.	O

Currently	O
,	O
four	O
patients	O
are	O
out	O
of	O
dialysis	O
.	O

This	O
report	O
is	O
a	O
detailed	O
description	O
of	O
NHBD	O
""""	O
Programma	O
Alba	O
""""	O
and	O
its	O
preliminary	O
results	O
.	O

KISS1	O
methylation	O
and	O
expression	O
as	O
tumor	O
stratification	O
biomarkers	O
and	O
clinical	O
outcome	O
prognosticators	O
for	O
bladder	O
cancer	O
patients	O
.	O

KISS1	O
is	O
a	O
metastasis	O
suppressor	O
gene	O
that	O
is	O
lost	O
in	O
several	O
malignancies	O
,	O
including	O
bladder	O
cancer	O
.	O

We	O
tested	O
the	O
epigenetic	O
silencing	O
hypothesis	O
and	O
evaluated	O
the	O
biological	O
influence	O
of	O
KISS1	O
methylation	O
on	O
its	O
expression	O
and	O
clinical	O
relevance	O
in	O
bladder	O
cancer	O
.	O

KISS1	O
hypermethylation	O
was	O
frequent	O
in	O
bladder	O
cancer	O
cells	O
analyzed	O
by	O
methylation	O
-	O
specific	O
PCR	O
and	O
bisulfite	O
sequencing	O
and	O
was	O
associated	O
with	O
low	O
gene	O
expression	O
,	O
being	O
restored	O
in	O
vitro	O
by	O
demethylating	O
azacytidine	O
.	O

Hypermethylation	O
was	O
also	O
frequently	O
observed	O
in	O
a	O
large	O
series	O
of	O
bladder	O
tumors	O
(	O
83	O
.	O
1	O
%	O
,	O
n	O
=	O
804	O
)	O
.	O

KISS1	O
methylation	O
was	O
associated	O
with	O
increasing	O
stage	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
tumor	O
grade	O
(	O
P	O
=	O
0	O
.	O
010	O
)	O
.	O

KISS1	O
methylation	O
was	O
associated	O
with	O
low	O
KISS1	O
transcript	O
expression	O
by	O
quantitative	O
RT	O
-	O
PCR	O
(	O
P	O
=	O
0	O
.	O
037	O
)	O
.	O

KISS1	O
transcript	O
expression	O
was	O
also	O
associated	O
with	O
histopathological	O
tumor	O
stage	O
(	O
P	O
<	O
0	O
.	O
0005	O
)	O
.	O

Low	O
transcript	O
expression	O
alone	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
or	O
combined	O
with	O
methylation	O
(	O
P	O
=	O
0	O
.	O
019	O
)	O
was	O
associated	O
with	O
poor	O
disease	O
-	O
specific	O
survival	O
(	O
n	O
=	O
205	O
)	O
.	O

KISS1	O
transcript	O
expression	O
remained	O
an	O
independent	O
prognosticator	O
in	O
multivariate	O
analyses	O
(	O
P	O
=	O
0	O
.	O
017	O
)	O
.	O

KISS1	O
hypermethylation	O
was	O
identified	O
in	O
bladder	O
cancer	O
,	O
providing	O
a	O
potential	O
mechanistic	O
explanation	O
(	O
epigenetic	O
silencing	O
)	O
for	O
the	O
observed	O
loss	O
of	O
KISS1	O
in	O
uroepithelial	O
malignancies	O
.	O

Associations	O
of	O
KISS1	O
methylation	O
and	O
its	O
expression	O
with	O
histopathological	O
variables	O
and	O
poor	O
survival	O
suggest	O
the	O
utility	O
of	O
incorporating	O
KISS1	O
measurement	O
using	O
paraffin	O
-	O
embedded	O
material	O
for	O
tumor	O
stratification	O
and	O
clinical	O
outcome	O
prognosis	O
of	O
patients	O
with	O
uroepithelial	O
neoplasias	O
.	O

Oscillatory	O
alpha	O
-	O
band	O
mechanisms	O
and	O
the	O
deployment	O
of	O
spatial	O
attention	O
to	O
anticipated	O
auditory	O
and	O
visual	O
target	O
locations	O
:	O
supramodal	O
or	O
sensory	O
-	O
specific	O
control	O
mechanisms	O
?	O

Oscillatory	O
alpha	O
-	O
band	O
activity	O
(	O
8	O
-	O
15	O
Hz	O
)	O
over	O
parieto	O
-	O
occipital	O
cortex	O
in	O
humans	O
plays	O
an	O
important	O
role	O
in	O
suppression	O
of	O
processing	O
for	O
inputs	O
at	O
to	O
-	O
be	O
-	O
ignored	O
regions	O
of	O
space	O
,	O
with	O
increased	O
alpha	O
-	O
band	O
power	O
observed	O
over	O
cortex	O
contralateral	O
to	O
locations	O
expected	O
to	O
contain	O
distractors	O
.	O

It	O
is	O
unclear	O
whether	O
similar	O
processes	O
operate	O
during	O
deployment	O
of	O
spatial	O
attention	O
in	O
other	O
sensory	O
modalities	O
.	O

Evidence	O
from	O
lesion	O
patients	O
suggests	O
that	O
parietal	O
regions	O
house	O
supramodal	O
representations	O
of	O
space	O
.	O

The	O
parietal	O
lobes	O
are	O
prominent	O
generators	O
of	O
alpha	O
oscillations	O
,	O
raising	O
the	O
possibility	O
that	O
alpha	O
is	O
a	O
neural	O
signature	O
of	O
supramodal	O
spatial	O
attention	O
.	O

Furthermore	O
,	O
when	O
spatial	O
attention	O
is	O
deployed	O
within	O
vision	O
,	O
processing	O
of	O
task	O
-	O
irrelevant	O
auditory	O
inputs	O
at	O
attended	O
locations	O
is	O
also	O
enhanced	O
,	O
pointing	O
to	O
automatic	O
links	O
between	O
spatial	O
deployments	O
across	O
senses	O
.	O

Here	O
,	O
we	O
asked	O
whether	O
lateralized	O
alpha	O
-	O
band	O
activity	O
is	O
also	O
evident	O
in	O
a	O
purely	O
auditory	O
spatial	O
-	O
cueing	O
task	O
and	O
whether	O
it	O
had	O
the	O
same	O
underlying	O
generator	O
configuration	O
as	O
in	O
a	O
purely	O
visuospatial	O
task	O
.	O

If	O
common	O
to	O
both	O
sensory	O
systems	O
,	O
this	O
would	O
provide	O
strong	O
support	O
for	O
""""	O
supramodal	O
""""	O
attention	O
theory	O
.	O

Alternately	O
,	O
alpha	O
-	O
band	O
differences	O
between	O
auditory	O
and	O
visual	O
tasks	O
would	O
support	O
a	O
sensory	O
-	O
specific	O
account	O
.	O

Lateralized	O
shifts	O
in	O
alpha	O
-	O
band	O
activity	O
were	O
indeed	O
observed	O
during	O
a	O
purely	O
auditory	O
spatial	O
task	O
.	O

Crucially	O
,	O
there	O
were	O
clear	O
differences	O
in	O
scalp	O
topographies	O
of	O
this	O
alpha	O
activity	O
depending	O
on	O
the	O
sensory	O
system	O
within	O
which	O
spatial	O
attention	O
was	O
deployed	O
.	O

Findings	O
suggest	O
that	O
parietally	O
generated	O
alpha	O
-	O
band	O
mechanisms	O
are	O
central	O
to	O
attentional	O
deployments	O
across	O
modalities	O
but	O
that	O
they	O
are	O
invoked	O
in	O
a	O
sensory	O
-	O
specific	O
manner	O
.	O

The	O
data	O
support	O
an	O
""""	O
interactivity	O
account	O
,	O
""""	O
whereby	O
a	O
supramodal	O
system	O
interacts	O
with	O
sensory	O
-	O
specific	O
control	O
systems	O
during	O
deployment	O
of	O
spatial	O
attention	O
.	O

[	O
Expression	O
of	O
Merlin	O
protein	O
in	O
non	O
-	O
small	O
cell	O
lung	O
carcinoma	O
and	O
the	O
clinical	O
significance	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
expression	O
and	O
clinical	O
significance	O
of	O
Merlin	O
protein	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

METHODS	O
:	O
The	O
expression	O
of	O
Merlin	O
protein	O
in	O
45	O
cases	O
of	O
NSCLC	O
and	O
adjacent	O
tissue	O
of	O
NSCLC	O
and	O
normal	O
lung	O
tissue	O
was	O
checked	O
by	O
immunohistochemistry	O
.	O

The	O
relation	O
between	O
the	O
expression	O
of	O
Merlin	O
protein	O
and	O
the	O
multiple	O
factors	O
of	O
pathological	O
type	O
,	O
gender	O
,	O
P	O
-	O
TNM	O
stage	O
,	O
differentiation	O
and	O
lymph	O
node	O
metastasis	O
was	O
analyzed	O
.	O

RESULTS	O
:	O
The	O
expression	O
rates	O
of	O
Merlin	O
protein	O
in	O
NSCLC	O
and	O
normal	O
lung	O
tissue	O
sections	O
were	O
73	O
.	O
33	O
%	O
and	O
15	O
.	O
56	O
%	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
expression	O
of	O
Merlin	O
protein	O
was	O
not	O
associated	O
with	O
the	O
pathological	O
type	O
,	O
gender	O
,	O
P	O
-	O
TNM	O
stage	O
,	O
differentiation	O
and	O
lymph	O
node	O
metastasis	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
Merlin	O
protein	O
might	O
contribute	O
to	O
the	O
initiation	O
of	O
metastasis	O
of	O
NSCLC	O
.	O

The	O
members	O
of	O
an	O
Epstein	O
-	O
Barr	O
virus	O
microRNA	O
cluster	O
cooperate	O
to	O
transform	O
B	O
lymphocytes	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
transforms	O
B	O
lymphocytes	O
through	O
the	O
expression	O
of	O
the	O
latent	O
viral	O
proteins	O
EBNA	O
and	O
latent	O
membrane	O
protein	O
(	O
LMP	O
)	O
.	O

Recently	O
,	O
it	O
has	O
become	O
apparent	O
that	O
microRNAs	O
(	O
miRNAs	O
)	O
also	O
contribute	O
to	O
EBV	O
'	O
s	O
oncogenic	O
properties	O
;	O
recombinant	O
EBVs	O
that	O
lack	O
the	O
BHRF1	O
miRNA	O
cluster	O
display	O
a	O
reduced	O
ability	O
to	O
transform	O
B	O
lymphocytes	O
in	O
vitro	O
.	O

Furthermore	O
,	O
infected	O
cells	O
evince	O
a	O
marked	O
upregulation	O
of	O
the	O
EBNA	O
genes	O
.	O

Using	O
recombinant	O
viruses	O
that	O
lack	O
only	O
one	O
member	O
of	O
the	O
cluster	O
,	O
we	O
now	O
show	O
that	O
all	O
three	O
BHRF1	O
miRNAs	O
contribute	O
to	O
B	O
-	O
cell	O
transformation	O
.	O

Recombinants	O
that	O
lacked	O
miR	O
-	O
BHRF1	O
-	O
2	O
or	O
miR	O
-	O
BHRF1	O
-	O
3	O
displayed	O
enhanced	O
EBNA	O
expression	O
initiated	O
at	O
the	O
Cp	O
and	O
Wp	O
promoters	O
.	O

Interestingly	O
,	O
we	O
find	O
that	O
the	O
deletion	O
of	O
miR	O
-	O
BHRF1	O
-	O
2	O
reduced	O
the	O
expression	O
level	O
of	O
miR	O
-	O
BHRF1	O
-	O
3	O
and	O
possibly	O
that	O
of	O
miR	O
-	O
BHRF1	O
-	O
1	O
,	O
demonstrating	O
that	O
the	O
expression	O
of	O
one	O
miRNA	O
can	O
potentiate	O
the	O
expression	O
of	O
other	O
miRNAs	O
located	O
in	O
the	O
same	O
cluster	O
.	O

Therefore	O
,	O
the	O
phenotypic	O
traits	O
of	O
the	O
miR	O
-	O
BHRF1	O
-	O
2	O
null	O
mutant	O
could	O
result	O
partly	O
from	O
reduced	O
miR	O
-	O
BHRF1	O
-	O
1	O
and	O
miR	O
-	O
BHRF1	O
-	O
3	O
expression	O
levels	O
.	O

Nevertheless	O
,	O
using	O
an	O
miR	O
-	O
BHRF1	O
-	O
1	O
and	O
miR	O
-	O
BHRF1	O
-	O
3	O
double	O
mutant	O
,	O
we	O
could	O
directly	O
assess	O
and	O
confirm	O
the	O
contribution	O
of	O
miR	O
-	O
BHRF1	O
-	O
2	O
to	O
B	O
-	O
cell	O
transformation	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
potentiating	O
effect	O
of	O
miR	O
-	O
BHRF1	O
-	O
2	O
on	O
miR	O
-	O
BHRF1	O
-	O
3	O
synthesis	O
can	O
be	O
reproduced	O
with	O
simple	O
expression	O
plasmids	O
,	O
provided	O
that	O
both	O
miRNAs	O
are	O
processed	O
from	O
the	O
same	O
transcript	O
.	O

Therefore	O
,	O
this	O
enhancing	O
effect	O
does	O
not	O
result	O
from	O
an	O
idiosyncrasy	O
of	O
the	O
EBV	O
genome	O
but	O
rather	O
reflects	O
a	O
general	O
property	O
of	O
these	O
miRNAs	O
.	O

This	O
study	O
highlights	O
the	O
advantages	O
of	O
arranging	O
the	O
BHRF1	O
miRNAs	O
in	O
clusters	O
:	O
it	O
allows	O
the	O
synchronous	O
and	O
synergistic	O
expression	O
of	O
genetic	O
elements	O
that	O
cooperate	O
to	O
transform	O
their	O
target	O
cells	O
.	O

Hedgehog	O
signaling	O
:	O
networking	O
to	O
nurture	O
a	O
promalignant	O
tumor	O
microenvironment	O
.	O

In	O
addition	O
to	O
its	O
role	O
in	O
embryonic	O
development	O
,	O
the	O
Hedgehog	O
pathway	O
has	O
been	O
shown	O
to	O
be	O
an	O
active	O
participant	O
in	O
cancer	O
development	O
,	O
progression	O
,	O
and	O
metastasis	O
.	O

Although	O
this	O
pathway	O
is	O
activated	O
by	O
autocrine	O
signaling	O
by	O
Hedgehog	O
ligands	O
,	O
it	O
can	O
also	O
initiate	O
paracrine	O
signaling	O
with	O
cells	O
in	O
the	O
microenvironment	O
.	O

This	O
creates	O
a	O
network	O
of	O
Hedgehog	O
signaling	O
that	O
determines	O
the	O
malignant	O
behavior	O
of	O
the	O
tumor	O
cells	O
.	O

As	O
a	O
result	O
of	O
paracrine	O
signal	O
transmission	O
,	O
the	O
effects	O
of	O
Hedgehog	O
signaling	O
most	O
profoundly	O
influence	O
the	O
stromal	O
cells	O
that	O
constitute	O
the	O
tumor	O
microenvironment	O
.	O

The	O
stromal	O
cells	O
in	O
turn	O
produce	O
factors	O
that	O
nurture	O
the	O
tumor	O
.	O

Thus	O
,	O
such	O
a	O
resonating	O
cross	O
-	O
talk	O
can	O
amplify	O
Hedgehog	O
signaling	O
,	O
resulting	O
in	O
molecular	O
chatter	O
that	O
overall	O
promotes	O
tumor	O
progression	O
.	O

Inhibitors	O
of	O
Hedgehog	O
signaling	O
have	O
been	O
the	O
subject	O
of	O
intense	O
research	O
.	O

Several	O
of	O
these	O
inhibitors	O
are	O
currently	O
being	O
evaluated	O
in	O
clinical	O
trials	O
.	O

Here	O
,	O
we	O
review	O
the	O
role	O
of	O
the	O
Hedgehog	O
pathway	O
in	O
the	O
signature	O
characteristics	O
of	O
cancer	O
cells	O
that	O
determine	O
tumor	O
development	O
,	O
progression	O
,	O
and	O
metastasis	O
.	O

This	O
review	O
condenses	O
the	O
latest	O
findings	O
on	O
the	O
signaling	O
pathways	O
that	O
are	O
activated	O
and	O
/	O
or	O
regulated	O
by	O
molecules	O
generated	O
from	O
Hedgehog	O
signaling	O
in	O
cancer	O
and	O
cites	O
promising	O
clinical	O
interventions	O
.	O

Finally	O
,	O
we	O
discuss	O
future	O
directions	O
for	O
identifying	O
the	O
appropriate	O
patients	O
for	O
therapy	O
,	O
developing	O
reliable	O
markers	O
of	O
efficacy	O
of	O
treatment	O
,	O
and	O
combating	O
resistance	O
to	O
Hedgehog	O
pathway	O
inhibitors	O
.	O

Analysis	O
of	O
molecular	O
aberrations	O
of	O
Wnt	O
pathway	O
gladiators	O
in	O
colorectal	O
cancer	O
in	O
the	O
Kashmiri	O
population	O
.	O

The	O
development	O
and	O
progression	O
of	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
is	O
a	O
multi	O
-	O
step	O
process	O
,	O
and	O
the	O
Wnt	O
pathways	O
with	O
its	O
two	O
molecular	O
gladiators	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
and	O
beta	O
-	O
catenin	O
plays	O
an	O
important	O
role	O
in	O
transforming	O
a	O
normal	O
tissue	O
into	O
a	O
malignant	O
one	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
role	O
of	O
aberrations	O
in	O
the	O
APC	O
and	O
beta	O
-	O
catenin	O
genes	O
in	O
the	O
pathogenesis	O
of	O
CRC	O
in	O
the	O
Kashmir	O
valley	O
,	O
and	O
to	O
correlate	O
it	O
with	O
various	O
clinicopathological	O
variables	O
.	O

We	O
examined	O
the	O
paired	O
tumour	O
and	O
normal	O
-	O
tissue	O
specimens	O
of	O
86	O
CRC	O
patients	O
for	O
the	O
occurrence	O
of	O
aberrations	O
in	O
the	O
mutation	O
cluster	O
region	O
(	O
MCR	O
)	O
of	O
the	O
APC	O
gene	O
and	O
exon	O
3	O
of	O
the	O
beta	O
-	O
catenin	O
gene	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
and	O
/	O
or	O
PCR	O
-	O
direct	O
sequencing	O
.	O

Analysis	O
of	O
promoter	O
hypermethylation	O
of	O
the	O
APC	O
gene	O
was	O
also	O
carried	O
out	O
using	O
methylation	O
-	O
specific	O
PCR	O
(	O
MS	O
-	O
PCR	O
)	O
.	O

The	O
overall	O
mutation	O
rate	O
of	O
the	O
MCR	O
of	O
the	O
APC	O
gene	O
among	O
86	O
CRC	O
cases	O
was	O
12	O
.	O
8	O
per	O
cent	O
(	O
11	O
of	O
86	O
)	O
.	O

Promoter	O
hypermethylation	O
of	O
APC	O
was	O
observed	O
in	O
54	O
.	O
65	O
per	O
cent	O
(	O
47	O
of	O
86	O
)	O
of	O
cases	O
.	O

Furthermore	O
,	O
we	O
found	O
a	O
significant	O
association	O
between	O
tumour	O
location	O
,	O
tumour	O
grade	O
and	O
node	O
status	O
and	O
the	O
methylation	O
status	O
of	O
the	O
APC	O
gene	O
(	O
p	O
<	O
=	O
0	O
.	O
05	O
)	O
.	O

Although	O
the	O
number	O
of	O
mutations	O
in	O
the	O
APC	O
and	O
beta	O
-	O
catenin	O
genes	O
in	O
our	O
CRC	O
cases	O
was	O
very	O
low	O
,	O
the	O
study	O
confirms	O
the	O
role	O
of	O
epigenetic	O
gene	O
silencing	O
of	O
the	O
pivotal	O
molecular	O
gladiator	O
,	O
APC	O
,	O
of	O
the	O
Wnt	O
pathway	O
in	O
the	O
development	O
of	O
CRC	O
in	O
the	O
Kashmiri	O
population	O
.	O

Massive	O
osteolysis	O
in	O
a	O
dog	O
resembling	O
Gorham	O
'	O
s	O
disease	O
in	O
humans	O
.	O

An	O
eight	O
-	O
month	O
-	O
old	O
mixed	O
-	O
breed	O
dog	O
was	O
presented	O
with	O
a	O
history	O
of	O
sudden	O
onset	O
pelvic	O
limb	O
lameness	O
.	O

Radiographic	O
and	O
computed	O
tomographic	O
examinations	O
demonstrated	O
an	O
osteolytic	O
process	O
involving	O
the	O
lumbar	O
spine	O
and	O
pelvis	O
.	O

A	O
comprehensive	O
work	O
-	O
up	O
including	O
serial	O
radiographic	O
skeletal	O
survey	O
,	O
biopsy	O
,	O
routine	O
laboratory	O
investigation	O
and	O
evaluation	O
of	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
and	O
25	O
-	O
hydroxy	O
-	O
vitamin	O
D	O
levels	O
failed	O
to	O
reveal	O
any	O
underlying	O
cause	O
for	O
the	O
osteolysis	O
.	O

Conservative	O
treatment	O
using	O
the	O
bisphosphonate	O
drug	O
alendronate	O
and	O
oral	O
analgesic	O
medications	O
resulted	O
in	O
a	O
return	O
to	O
nearly	O
normal	O
long	O
-	O
term	O
function	O
,	O
despite	O
massive	O
lumbar	O
and	O
pelvic	O
osteolysis	O
.	O

The	O
clinical	O
,	O
radiological	O
and	O
histopathological	O
features	O
in	O
this	O
dog	O
are	O
reported	O
,	O
and	O
similarities	O
with	O
the	O
human	O
condition	O
known	O
as	O
Gorham	O
'	O
s	O
disease	O
are	O
discussed	O
.	O

Correlation	O
of	O
lymphatic	O
vessel	O
density	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
with	O
nodal	O
metastasis	O
in	O
papillary	O
thyroid	O
microcarcinoma	O
.	O

BACKGROUND	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
not	O
only	O
the	O
intratumoral	O
and	O
peritumoral	O
lymphatic	O
vessel	O
density	O
(	O
ILD	O
and	O
PLD	O
)	O
but	O
also	O
the	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factors	O
(	O
VEGFs	O
)	O
and	O
to	O
test	O
their	O
correlation	O
with	O
regional	O
lymph	O
nodal	O
metastases	O
in	O
papillary	O
thyroid	O
microcarcinoma	O
(	O
PTMC	O
)	O
.	O

METHODS	O
:	O
A	O
clinicopathologic	O
data	O
review	O
was	O
performed	O
in	O
60	O
patients	O
with	O
PTMC	O
treated	O
with	O
total	O
thyroidectomies	O
involving	O
neck	O
dissections	O
.	O

The	O
patterns	O
of	O
lymphatic	O
vessels	O
,	O
the	O
expression	O
of	O
VEGFs	O
,	O
and	O
their	O
correlation	O
with	O
neck	O
metastases	O
were	O
assessed	O
.	O

RESULTS	O
:	O
PLD	O
was	O
significantly	O
higher	O
than	O
ILD	O
(	O
p	O
<	O
.	O
001	O
)	O
.	O

Patients	O
with	O
high	O
PLD	O
(	O
>	O
8	O
.	O
0	O
)	O
showed	O
higher	O
rates	O
of	O
neck	O
metastases	O
than	O
low	O
PLD	O
(	O
<	O
=	O
8	O
.	O
0	O
)	O
(	O
74	O
.	O
0	O
%	O
vs	O
46	O
.	O
8	O
%	O
,	O
p	O
=	O
.	O
03	O
)	O
.	O

Univariate	O
and	O
multivariate	O
analyses	O
revealed	O
high	O
PLD	O
as	O
the	O
only	O
independent	O
variable	O
predictive	O
of	O
neck	O
metastasis	O
.	O

The	O
expression	O
of	O
VEGFs	O
did	O
not	O
correlate	O
with	O
either	O
lymphatic	O
density	O
or	O
neck	O
metastasis	O
.	O

CONCLUSIONS	O
:	O
PLD	O
may	O
be	O
of	O
potential	O
benefit	O
in	O
the	O
prediction	O
of	O
neck	O
metastasis	O
in	O
PTMC	O
.	O

Inhibition	O
of	O
autophagy	O
potentiates	O
the	O
antitumor	O
effect	O
of	O
the	O
multikinase	O
inhibitor	O
sorafenib	O
in	O
hepatocellular	O
carcinoma	O
.	O

Multikinase	O
inhibitor	O
sorafenib	O
inhibits	O
proliferation	O
and	O
angiogenesis	O
of	O
tumors	O
by	O
suppressing	O
the	O
Raf	O
/	O
MEK	O
/	O
ERK	O
signaling	O
pathway	O
and	O
VEGF	O
receptor	O
tyrosine	O
kinase	O
.	O

It	O
significantly	O
prolongs	O
median	O
survival	O
of	O
patients	O
with	O
advanced	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
but	O
the	O
response	O
is	O
disease	O
-	O
stabilizing	O
and	O
cytostatic	O
rather	O
than	O
one	O
of	O
tumor	O
regression	O
.	O

To	O
examine	O
the	O
mechanisms	O
underlying	O
the	O
relative	O
resistance	O
in	O
HCC	O
,	O
we	O
investigated	O
the	O
role	O
of	O
autophagy	O
,	O
an	O
evolutionarily	O
conserved	O
self	O
-	O
digestion	O
pathway	O
,	O
in	O
hepatoma	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Sorafenib	O
treatment	O
led	O
to	O
accumulation	O
of	O
autophagosomes	O
as	O
evidenced	O
by	O
conversion	O
from	O
LC3	O
-	O
I	O
to	O
LC3	O
-	O
II	O
observed	O
by	O
immunoblot	O
in	O
Huh7	B
,	O
HLF	B
and	O
PLC	B
/	I
PRF	I
/	I
5	I
cells	O
.	O

This	O
induction	O
was	O
due	O
to	O
activation	O
of	O
autophagic	O
flux	O
,	O
as	O
there	O
was	O
further	O
increase	O
in	O
LC3	O
-	O
II	O
expression	O
upon	O
treatment	O
with	O
lysosomal	O
inhibitors	O
,	O
clear	O
decline	O
of	O
the	O
autophagy	O
substrate	O
p62	O
,	O
and	O
an	O
mRFP	O
-	O
GFP	O
-	O
LC3	O
fluorescence	O
change	O
in	O
sorafenib	O
-	O
treated	O
hepatoma	O
cells	O
.	O

Sorafenib	O
inhibited	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
complex	O
1	O
and	O
its	O
inhibition	O
led	O
to	O
accumulation	O
of	O
LC3	O
-	O
II	O
.	O

Pharmacological	O
inhibition	O
of	O
autophagic	O
flux	O
by	O
chloroquine	O
increased	O
apoptosis	O
and	O
decreased	O
cell	O
viability	O
in	O
hepatoma	O
cells	O
.	O

siRNA	O
-	O
mediated	O
knockdown	O
of	O
the	O
ATG7	O
gene	O
also	O
sensitized	O
hepatoma	O
cells	O
to	O
sorafenib	O
.	O

Finally	O
,	O
sorafenib	O
induced	O
autophagy	O
in	O
Huh7	B
xenograft	O
tumors	O
in	O
nude	O
mice	O
and	O
coadministration	O
with	O
chloroquine	O
significantly	O
suppressed	O
tumor	O
growth	O
compared	O
with	O
sorafenib	O
alone	O
.	O

In	O
conclusion	O
,	O
sorafenib	O
administration	O
induced	O
autophagosome	O
formation	O
and	O
enhanced	O
autophagic	O
activity	O
,	O
which	O
conferred	O
a	O
survival	O
advantage	O
to	O
hepatoma	O
cells	O
.	O

Concomitant	O
inhibition	O
of	O
autophagy	O
may	O
be	O
an	O
attractive	O
strategy	O
for	O
unlocking	O
the	O
antitumor	O
potential	O
of	O
sorafenib	O
in	O
HCC	O
.	O

Desensitization	O
of	O
prostaglandin	O
F2	O
alpha	O
-	O
stimulated	O
inositol	O
phosphate	O
generation	O
in	O
NIH	B
-	I
3T3	I
fibroblasts	O
transformed	O
by	O
overexpression	O
of	O
normal	O
c	O
-	O
Ha	O
-	O
ras	O
-	O
1	O
,	O
c	O
-	O
Ki	O
-	O
ras	O
-	O
2	O
and	O
c	O
-	O
N	O
-	O
ras	O
genes	O
.	O

The	O
stimulation	O
of	O
inositol	O
phosphate	O
generation	O
in	O
control	O
and	O
ras	O
-	O
gene	O
-	O
transformed	O
NIH	B
-	I
3T3	I
cells	O
by	O
prostaglandin	O
F2	O
alpha	O
(	O
PGF2	O
alpha	O
)	O
was	O
investigated	O
.	O

Compared	O
with	O
the	O
control	O
cells	O
,	O
a	O
desensitization	O
of	O
the	O
response	O
was	O
observed	O
in	O
cells	O
transformed	O
by	O
the	O
overexpression	O
of	O
N	O
-	O
,	O
Ha	O
-	O
,	O
or	O
Ki	O
-	O
ras	O
genes	O
.	O

This	O
desensitization	O
was	O
without	O
effect	O
upon	O
the	O
concentration	O
causing	O
half	O
-	O
maximal	O
effect	O
(	O
EC50	O
)	O
,	O
dissociation	O
constant	O
(	O
Kd	O
)	O
or	O
number	O
of	O
PGF2	O
alpha	O
receptors	O
.	O

Inhibition	O
of	O
PG	O
synthesis	O
was	O
without	O
effect	O
upon	O
desensitization	O
,	O
demonstrating	O
that	O
the	O
effect	O
was	O
not	O
agonist	O
-	O
induced	O
.	O

Desensitization	O
could	O
be	O
induced	O
in	O
NIH	B
-	I
3T3	I
cells	O
by	O
culturing	O
under	O
conditions	O
where	O
the	O
cells	O
were	O
all	O
in	O
the	O
exponential	O
growth	O
phase	O
,	O
or	O
by	O
a	O
12	O
h	O
exposure	O
to	O
a	O
C	O
-	O
kinase	O
-	O
activating	O
phorbol	O
ester	O
.	O

These	O
results	O
suggest	O
that	O
desensitization	O
of	O
certain	O
agonist	O
-	O
induced	O
inositol	O
phospholipid	O
responses	O
in	O
ras	O
-	O
transformed	O
cells	O
is	O
a	O
consequence	O
of	O
increased	O
cell	O
proliferation	O
and	O
associated	O
amplification	O
in	O
C	O
-	O
kinase	O
activity	O
and	O
is	O
an	O
indirect	O
consequence	O
of	O
transformation	O
by	O
ras	O
.	O

Sunitinib	O
induces	O
apoptosis	O
in	O
pheochromocytoma	O
tumor	O
cells	O
by	O
inhibiting	O
VEGFR2	O
/	O
Akt	O
/	O
mTOR	O
/	O
S6K1	O
pathways	O
through	O
modulation	O
of	O
Bcl	O
-	O
2	O
and	O
BAD	O
.	O

Sunitinib	O
is	O
an	O
oral	O
multitargeted	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
with	O
antiangiogenic	O
and	O
antitumor	O
activity	O
that	O
mainly	O
targets	O
vascular	O
endothelial	O
growth	O
factor	O
receptors	O
(	O
VEGFRs	O
)	O
.	O

Very	O
recently	O
,	O
sunitinib	O
has	O
been	O
shown	O
to	O
be	O
an	O
active	O
agent	O
for	O
the	O
treatment	O
of	O
malignant	O
pheochromocytomas	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
sunitinib	O
acts	O
only	O
through	O
an	O
antiangiogenic	O
mechanism	O
or	O
whether	O
it	O
may	O
also	O
directly	O
target	O
tumor	O
cells	O
.	O

Sunitinib	O
markedly	O
induced	O
apoptosis	O
of	O
PC12	B
cells	O
in	O
a	O
dose	O
-	O
dependent	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Furthermore	O
,	O
in	O
support	O
of	O
these	O
findings	O
,	O
we	O
found	O
that	O
sunitinib	O
induced	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
the	O
antiapoptotic	O
molecule	O
Bcl	O
-	O
2	O
as	O
well	O
as	O
dephosphorylation	O
of	O
the	O
proapoptotic	O
molecule	O
BAD	O
,	O
which	O
results	O
in	O
the	O
activation	O
of	O
BAD	O
in	O
these	O
cells	O
.	O

Consistent	O
with	O
these	O
apoptotic	O
effects	O
,	O
our	O
results	O
showed	O
that	O
sunitinib	O
inhibited	O
phosphorylation	O
of	O
Akt	O
and	O
mTOR	O
and	O
was	O
followed	O
by	O
a	O
reduction	O
of	O
S6K1	O
,	O
which	O
is	O
a	O
well	O
-	O
known	O
target	O
of	O
mTOR	O
.	O

Knockdown	O
of	O
VEGFR	O
-	O
2	O
attenuated	O
the	O
sunitinib	O
-	O
induced	O
effects	O
,	O
including	O
apoptosis	O
and	O
inhibition	O
of	O
signaling	O
pathways	O
such	O
as	O
the	O
phosphorylation	O
of	O
Akt	O
as	O
well	O
as	O
mTOR	O
,	O
and	O
Bcl	O
-	O
2	O
,	O
which	O
confirmed	O
that	O
these	O
effects	O
could	O
be	O
mediated	O
by	O
VEGFR	O
-	O
2	O
.	O

In	O
addition	O
,	O
silencing	O
of	O
S6K1	O
induced	O
apoptosis	O
accompanied	O
by	O
a	O
decrease	O
in	O
the	O
phosphorylation	O
of	O
BAD	O
and	O
Bcl	O
-	O
2	O
,	O
similar	O
to	O
that	O
observed	O
with	O
sunitinib	O
treatment	O
.	O

Thus	O
,	O
these	O
results	O
together	O
suggest	O
that	O
sunitinib	O
initially	O
exerts	O
its	O
apoptotic	O
effect	O
through	O
the	O
inhibition	O
of	O
VEGFR	O
-	O
2	O
,	O
which	O
,	O
when	O
followed	O
by	O
reduction	O
of	O
its	O
downstream	O
effectors	O
,	O
including	O
Akt	O
/	O
mTOR	O
/	O
S6K1	O
,	O
may	O
lead	O
to	O
inhibition	O
of	O
the	O
antiapoptotic	O
molecule	O
Bcl	O
-	O
2	O
and	O
activation	O
of	O
the	O
proapoptotic	O
molecule	O
BAD	O
in	O
PC12	B
cells	O
.	O

However	O
,	O
PC12	B
cells	O
do	O
not	O
precisely	O
reflect	O
the	O
pathogenesis	O
of	O
malignant	O
cells	O
.	O

Therefore	O
,	O
we	O
confirmed	O
the	O
key	O
findings	O
by	O
replicating	O
these	O
experiments	O
in	O
human	O
neuroblastoma	O
SK	B
-	I
N	I
-	I
SH	I
cells	O
.	O

Development	O
of	O
a	O
mouse	O
model	O
for	O
lymph	O
node	O
metastasis	O
with	O
endometrial	O
cancer	O
.	O

Controlling	O
lymph	O
node	O
metastasis	O
is	O
currently	O
a	O
key	O
issue	O
in	O
cancer	O
therapy	O
.	O

Lymph	O
node	O
metastasis	O
is	O
one	O
of	O
the	O
most	O
important	O
prognostic	O
factors	O
in	O
various	O
types	O
of	O
cancers	O
,	O
including	O
endometrial	O
cancer	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
-	O
C	O
(	O
VEGF	O
-	O
C	O
)	O
plays	O
a	O
crucial	O
role	O
in	O
lymphangiogenesis	O
,	O
and	O
is	O
implicated	O
to	O
play	O
an	O
important	O
role	O
in	O
lymph	O
node	O
metastasis	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
VEGF	O
-	O
C	O
in	O
lymph	O
node	O
metastasis	O
,	O
we	O
developed	O
an	O
animal	O
model	O
by	O
using	O
an	O
endometrial	O
cancer	O
cell	O
line	O
,	O
HEC1A	B
.	O

This	O
cell	O
line	O
is	O
not	O
invasive	O
by	O
nature	O
and	O
secretes	O
moderate	O
amounts	O
of	O
VEGF	O
-	O
C	O
;	O
intrauterine	O
injection	O
of	O
HEC1A	B
cells	O
into	O
Balb	O
/	O
c	O
nude	O
mice	O
resulted	O
in	O
uterine	O
cancer	O
with	O
lymph	O
node	O
metastasis	O
after	O
8	O
weeks	O
.	O

To	O
analyze	O
the	O
contribution	O
of	O
VEGF	O
-	O
C	O
to	O
lymph	O
node	O
metastasis	O
,	O
its	O
corresponding	O
gene	O
was	O
stably	O
introduced	O
into	O
HEC1A	B
cells	O
(	O
HEC1A	B
/	O
VEGF	O
-	O
C	O
)	O
,	O
which	O
then	O
produced	O
more	O
than	O
10	O
times	O
the	O
amount	O
of	O
VEGF	O
-	O
C	O
.	O

The	O
number	O
of	O
lymph	O
node	O
metastases	O
was	O
significantly	O
higher	O
in	O
HEC1A	B
/	I
VEGF	I
-	I
C	I
cells	O
than	O
in	O
HEC1A	B
cells	O
(	O
3	O
.	O
2	O
vs	O
1	O
.	O
1	O
nodes	O
/	O
animal	O
,	O
respectively	O
)	O
.	O

Augmented	O
lymphangiogenesis	O
was	O
observed	O
within	O
tumors	O
when	O
HEC1A	B
/	I
VEGF	I
-	I
C	I
cells	O
were	O
inoculated	O
.	O

These	O
results	O
indicate	O
that	O
VEGF	O
-	O
C	O
plays	O
a	O
critical	O
role	O
in	O
lymph	O
node	O
metastasis	O
,	O
in	O
addition	O
to	O
serving	O
as	O
a	O
platform	O
to	O
test	O
the	O
efficacy	O
of	O
various	O
therapeutic	O
modalities	O
against	O
lymph	O
node	O
metastasis	O
.	O

[	O
Rubella	O
in	O
Poland	O
in	O
2009	O
]	O
.	O

In	O
Poland	O
,	O
7	O
,	O
587	O
cases	O
of	O
rubella	O
were	O
registered	O
in	O
2009	O
(	O
incidence	O
19	O
.	O
9	O
per	O
100	O
,	O
000	O
population	O
)	O
.	O

According	O
to	O
a	O
new	O
rubella	O
case	O
definition	O
,	O
introduced	O
in	O
2009	O
,	O
7	O
(	O
0	O
.	O
1	O
%	O
)	O
cases	O
were	O
classified	O
as	O
confirmed	O
cases	O
,	O
30	O
(	O
0	O
.	O
4	O
%	O
)	O
as	O
probable	O
.	O

One	O
case	O
of	O
congenital	O
rubella	O
syndrome	O
was	O
reported	O
.	O

The	O
incidence	O
in	O
men	O
(	O
26	O
.	O
6	O
)	O
was	O
1	O
.	O
9	O
-	O
times	O
higher	O
than	O
in	O
women	O
(	O
13	O
.	O
6	O
)	O
.	O

The	O
highest	O
incidence	O
was	O
observed	O
in	O
children	O
aged	O
7	O
and	O
8	O
years	O
(	O
180	O
.	O
3	O
and	O
175	O
.	O
6	O
,	O
respectively	O
)	O
.	O

No	O
rubella	O
deaths	O
were	O
registered	O
.	O

An	O
improvement	O
of	O
laboratory	O
diagnosis	O
of	O
reported	O
cases	O
is	O
necessary	O
to	O
assess	O
the	O
impact	O
of	O
2	O
-	O
dose	O
immunization	O
implemented	O
in	O
2003	O
on	O
rubella	O
epidemiology	O
in	O
Poland	O
.	O

Burns	O
from	O
hot	O
wheat	O
bags	O
:	O
a	O
public	O
safety	O
issue	O
.	O

Introduction	O
:	O
Wheat	O
bags	O
are	O
therapeutic	O
devices	O
that	O
are	O
heated	O
in	O
microwaves	O
and	O
commonly	O
used	O
to	O
provide	O
relief	O
from	O
muscle	O
and	O
joint	O
pain	O
.	O

The	O
Royal	O
Adelaide	O
Hospital	O
Burns	O
Unit	O
has	O
observed	O
a	O
number	O
of	O
patients	O
with	O
significant	O
burn	O
injuries	O
resulting	O
from	O
their	O
use	O
.	O

Despite	O
their	O
dangers	O
,	O
the	O
products	O
come	O
with	O
limited	O
safety	O
information	O
.	O

Methods	O
:	O
Data	O
were	O
collected	O
from	O
the	O
Burns	O
Unit	O
database	O
for	O
all	O
patients	O
admitted	O
with	O
burns	O
due	O
to	O
hot	O
wheat	O
bags	O
from	O
2004	O
to	O
2009	O
.	O

This	O
was	O
analyzed	O
to	O
determine	O
the	O
severity	O
of	O
the	O
burn	O
injury	O
and	O
identify	O
any	O
predisposing	O
factors	O
.	O

An	O
experimental	O
study	O
was	O
performed	O
to	O
measure	O
the	O
temperature	O
of	O
wheat	O
bags	O
when	O
heated	O
to	O
determine	O
their	O
potential	O
for	O
causing	O
thermal	O
injury	O
.	O

Results	O
:	O
11	O
patients	O
were	O
admitted	O
with	O
burns	O
due	O
to	O
hot	O
wheat	O
bags	O
.	O

The	O
median	O
age	O
was	O
52	O
years	O
and	O
the	O
mean	O
total	O
body	O
surface	O
area	O
was	O
1	O
.	O
1	O
%	O
.	O

All	O
burns	O
were	O
either	O
deep	O
dermal	O
(	O
45	O
.	O
5	O
%	O
)	O
or	O
full	O
thickness	O
(	O
54	O
.	O
5	O
%	O
)	O
.	O

Ten	O
patients	O
required	O
operative	O
management	O
.	O

Predisposing	O
factors	O
(	O
eg	O
,	O
neuropathy	O
)	O
to	O
thermal	O
injury	O
were	O
identified	O
in	O
7	O
patients	O
.	O

The	O
experimental	O
study	O
showed	O
that	O
hot	O
wheat	O
bags	O
reached	O
temperatures	O
of	O
57	O
.	O
3degreesC	O
(	O
135	O
.	O
1degreesF	O
)	O
when	O
heated	O
according	O
to	O
instructions	O
,	O
63	O
.	O
3degreesC	O
(	O
145	O
.	O
9degreesF	O
)	O
in	O
a	O
1000	O
W	O
microwave	O
and	O
69	O
.	O
6degreesC	O
(	O
157	O
.	O
3degreesF	O
)	O
on	O
reheating	O
.	O

Conclusions	O
:	O
Hot	O
wheat	O
bags	O
cause	O
serious	O
burn	O
injury	O
.	O

When	O
heated	O
improperly	O
,	O
they	O
can	O
reach	O
temperatures	O
high	O
enough	O
to	O
cause	O
epidermal	O
necrosis	O
in	O
a	O
short	O
period	O
of	O
time	O
.	O

Patients	O
with	O
impaired	O
temperature	O
sensation	O
are	O
particularly	O
at	O
risk	O
.	O

There	O
should	O
be	O
greater	O
public	O
awareness	O
of	O
the	O
dangers	O
of	O
wheat	O
bag	O
use	O
and	O
more	O
specific	O
safety	O
warnings	O
on	O
the	O
products	O
.	O

IL	O
-	O
17F	O
deficiency	O
inhibits	O
small	O
intestinal	O
tumorigenesis	O
in	O
ApcMin	O
/	O
+	O
mice	O
.	O

IL	O
-	O
17	O
plays	O
an	O
important	O
role	O
in	O
gut	O
homeostasis	O
.	O

However	O
,	O
the	O
role	O
of	O
IL	O
-	O
17F	O
in	O
intestinal	O
tumorigenesis	O
has	O
not	O
been	O
addressed	O
.	O

Here	O
we	O
demonstrate	O
that	O
ablation	O
of	O
IL	O
-	O
17F	O
significantly	O
inhibits	O
spontaneous	O
intestinal	O
tumorigenesis	O
in	O
the	O
small	O
intestine	O
of	O
Apc	O
(	O
Min	O
/	O
+	O
)	O
mice	O
.	O

IL	O
-	O
17F	O
ablation	O
decreased	O
IL	O
-	O
1beta	O
and	O
Cox	O
-	O
2	O
expression	O
as	O
well	O
as	O
IL	O
-	O
17	O
receptor	O
C	O
(	O
IL	O
-	O
17RC	O
)	O
expression	O
,	O
which	O
were	O
increased	O
in	O
tumors	O
from	O
Apc	O
(	O
Min	O
/	O
+	O
)	O
mice	O
.	O

Lack	O
of	O
IL	O
-	O
17F	O
did	O
not	O
reverse	O
the	O
splenomegaly	O
but	O
partially	O
restored	O
thymic	O
atrophy	O
,	O
suggesting	O
a	O
local	O
effect	O
of	O
IL	O
-	O
17F	O
in	O
the	O
intestine	O
.	O

IL	O
-	O
17F	O
deficient	O
Apc	O
(	O
Min	O
/	O
+	O
)	O
mice	O
showed	O
a	O
significant	O
decrease	O
in	O
immune	O
cell	O
infiltration	O
in	O
the	O
lamina	O
propria	O
.	O

Interestingly	O
,	O
the	O
expression	O
of	O
IL	O
-	O
17A	O
from	O
CD4	O
T	O
cells	O
in	O
the	O
lamina	O
propria	O
remains	O
unchanged	O
in	O
the	O
absence	O
of	O
IL	O
-	O
17F	O
.	O

Collectively	O
,	O
our	O
results	O
suggest	O
the	O
proinflammatory	O
and	O
essential	O
role	O
of	O
IL	O
-	O
17F	O
to	O
develop	O
spontaneous	O
intestinal	O
tumorigenesis	O
in	O
Apc	O
(	O
Min	O
/	O
+	O
)	O
mice	O
in	O
the	O
presence	O
of	O
IL	O
-	O
17A	O
.	O

Curcumin	O
inhibits	O
metastatic	O
progression	O
of	O
breast	O
cancer	O
cell	O
through	O
suppression	O
of	O
urokinase	O
-	O
type	O
plasminogen	O
activator	O
by	O
NF	O
-	O
kappa	O
B	O
signaling	O
pathways	O
.	O

Curcumin	O
(	O
1	O
,	O
7	O
-	O
bis	O
(	O
4	O
-	O
hydroxy	O
-	O
3	O
-	O
methoxyphenyl	O
)	O
-	O
1	O
,	O
6	O
-	O
heptadiene	O
-	O
3	O
,	O
5	O
-	O
dione	O
)	O
,	O
is	O
extracted	O
from	O
the	O
plant	O
Curcuma	O
longa	O
.	O

It	O
was	O
recently	O
reported	O
for	O
its	O
anticancer	O
effect	O
on	O
several	O
types	O
of	O
cancer	O
cells	O
in	O
vitro	O
however	O
,	O
the	O
molecular	O
mechanisms	O
of	O
this	O
anticancer	O
effect	O
are	O
not	O
fully	O
understood	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
curcumin	O
on	O
human	O
mammary	O
epithelial	O
carcinoma	O
MCF	B
-	I
7	I
cells	O
.	O

Cells	O
were	O
treated	O
with	O
curcumin	O
and	O
examined	O
for	O
cell	O
viability	O
by	O
MTT	O
assay	O
.	O

The	O
cells	O
invasion	O
was	O
demonstrated	O
by	O
transwell	O
assay	O
.	O

The	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
to	O
DNA	O
was	O
examined	O
in	O
nuclear	O
extracts	O
using	O
Trans	O
-	O
AM	O
NF	O
-	O
kappaB	O
ELISA	O
kit	O
.	O

Western	O
blot	O
was	O
performed	O
to	O
detect	O
the	O
effect	O
of	O
curcumin	O
on	O
the	O
expression	O
of	O
uPA	O
.	O

Our	O
results	O
showed	O
that	O
curcumin	O
dose	O
-	O
dependently	O
inhibited	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
the	O
proliferation	O
of	O
MCF	B
-	I
7	I
cells	O
.	O

Meanwhile	O
,	O
the	O
adhesion	O
and	O
invasion	O
ability	O
of	O
MCF	B
-	I
7	I
cells	O
were	O
sharply	O
inhibited	O
when	O
treated	O
with	O
different	O
concentrations	O
of	O
curcumin	O
.	O

Curcumin	O
also	O
significantly	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
the	O
expression	O
of	O
uPA	O
and	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
,	O
respectively	O
.	O

It	O
is	O
concluded	O
that	O
curcumin	O
inhibits	O
the	O
adhesion	O
and	O
invasion	O
of	O
MCF	B
-	I
7	I
cells	O
through	O
down	O
-	O
regulating	O
the	O
protein	O
expression	O
of	O
uPA	O
via	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

Accordingly	O
,	O
the	O
therapeutic	O
potential	O
of	O
curcumin	O
for	O
breast	O
cancer	O
deserves	O
further	O
study	O
.	O

Aglycon	O
of	O
rhizochalin	O
from	O
the	O
Rhizochalina	O
incrustata	O
induces	O
apoptosis	O
via	O
activation	O
of	O
AMP	O
-	O
activated	O
protein	O
kinase	O
in	O
HT	B
-	I
29	I
colon	O
cancer	O
cells	O
.	O

Rhizochalin	O
is	O
a	O
two	O
-	O
headed	O
sphingolipid	O
-	O
like	O
compound	O
isolated	O
from	O
the	O
sponge	O
Rhizochalina	O
incrustata	O
.	O

It	O
has	O
been	O
reported	O
that	O
rhizocalin	O
and	O
its	O
derivates	O
have	O
a	O
chemopreventive	O
and	O
chemotherapeutic	O
effect	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
of	O
these	O
effects	O
is	O
not	O
understood	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
aglycon	O
of	O
rhizochalin	O
(	O
AglRhz	O
)	O
from	O
the	O
Rhizochalina	O
incrustata	O
induces	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
phosphorylation	O
,	O
and	O
thereby	O
inhibits	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
-	O
p70S6	O
kinase	O
-	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
signaling	O
and	O
activator	O
protein	O
1	O
(	O
AP	O
-	O
1	O
)	O
activity	O
via	O
phosphorylation	O
of	O
Raptor	O
in	O
HT	B
-	I
29	I
cells	O
.	O

In	O
addition	O
,	O
AglRhz	O
induced	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
,	O
and	O
DNA	O
fragmentation	O
in	O
HT	B
-	I
29	I
cells	O
,	O
leads	O
to	O
induction	O
of	O
apoptosis	O
as	O
well	O
as	O
suppression	O
of	O
tumorigenicity	O
of	O
HT	B
-	I
29	I
cells	O
.	O

Notably	O
,	O
AglRhz	O
inhibits	O
insulin	O
-	O
like	O
growth	O
factor	O
(	O
IGF	O
)	O
-	O
1	O
-	O
induced	O
AP	O
-	O
1	O
activity	O
and	O
cell	O
transformation	O
in	O
JB6	B
Cl41	I
cells	O
.	O

Overall	O
,	O
our	O
findings	O
identify	O
AMPK	O
as	O
an	O
important	O
target	O
protein	O
for	O
mediating	O
the	O
anti	O
-	O
tumor	O
properties	O
of	O
AglRhz	O
in	O
HT	B
-	I
29	I
colon	O
cancer	O
cells	O
and	O
have	O
important	O
implication	O
for	O
sponges	O
,	O
the	O
most	O
important	O
marine	O
source	O
,	O
in	O
colon	O
cancer	O
.	O

Expression	O
of	O
thymidylate	O
synthase	O
and	O
dihydropyrimidine	O
dehydrogenase	O
in	O
primary	O
oral	O
squamous	O
cell	O
carcinoma	O
and	O
corresponding	O
metastases	O
in	O
cervical	O
lymph	O
nodes	O
:	O
association	O
with	O
the	O
metastasis	O
suppressor	O
CD82	O
.	O

Thymidylate	O
synthase	O
(	O
TS	O
)	O
and	O
dihydropyrimidine	O
dehydrogenase	O
(	O
DPD	O
)	O
are	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
metabolizing	O
enzymes	O
and	O
are	O
involved	O
in	O
the	O
sensitivity	O
of	O
carcinoma	O
patients	O
to	O
5	O
-	O
FU	O
.	O

Although	O
5	O
-	O
FU	O
is	O
often	O
used	O
for	O
the	O
treatment	O
of	O
oral	O
carcinoma	O
,	O
there	O
has	O
not	O
been	O
any	O
investigation	O
into	O
the	O
expression	O
of	O
these	O
enzymes	O
in	O
metastatic	O
lymph	O
nodes	O
or	O
of	O
their	O
roles	O
in	O
the	O
effectiveness	O
of	O
5	O
-	O
FU	O
in	O
treating	O
lymph	O
node	O
-	O
metastatic	O
cancer	O
.	O

Oral	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
often	O
metastasizes	O
to	O
the	O
lymph	O
nodes	O
,	O
and	O
these	O
enzymes	O
may	O
be	O
significant	O
in	O
the	O
survival	O
of	O
patients	O
with	O
this	O
disease	O
.	O

This	O
study	O
investigated	O
the	O
expression	O
of	O
TS	O
and	O
DPD	O
in	O
cervical	O
lymph	O
node	O
metastases	O
and	O
its	O
relationship	O
with	O
primary	O
OSCC	O
,	O
as	O
well	O
as	O
the	O
interaction	O
between	O
these	O
enzymes	O
and	O
Kangai	O
1	O
(	O
KAI1	O
/	O
CD82	O
)	O
which	O
is	O
a	O
metastasis	O
suppressor	O
protein	O
.	O

Surgical	O
specimens	O
from	O
20	O
cases	O
of	O
OSCC	O
with	O
lymph	O
node	O
metastasis	O
,	O
20	O
cases	O
of	O
OSCC	O
without	O
lymph	O
node	O
metastasis	O
,	O
and	O
10	O
cases	O
of	O
normal	O
mucosa	O
were	O
examined	O
by	O
immunohistochemistry	O
.	O

The	O
relationship	O
between	O
TS	O
and	O
DPD	O
expression	O
and	O
clinicopathological	O
data	O
was	O
analyzed	O
.	O

TS	O
and	O
DPD	O
proteins	O
were	O
overexpressed	O
in	O
primary	O
OSCC	O
compared	O
to	O
that	O
in	O
normal	O
mucosa	O
.	O

TS	O
expression	O
of	O
the	O
primary	O
oral	O
cancer	O
cells	O
in	O
the	O
group	O
with	O
lymph	O
node	O
metastasis	O
was	O
higher	O
than	O
that	O
of	O
those	O
without	O
.	O

DPD	O
expression	O
did	O
not	O
significantly	O
correlate	O
with	O
the	O
occurrence	O
of	O
lymph	O
node	O
metastasis	O
,	O
nor	O
was	O
it	O
different	O
between	O
primary	O
oral	O
cancer	O
cells	O
and	O
cervical	O
metastases	O
.	O

CD82	O
expression	O
was	O
significantly	O
reduced	O
in	O
lymph	O
node	O
metastases	O
.	O

These	O
findings	O
indicate	O
that	O
TS	O
and	O
CD82	O
may	O
be	O
of	O
great	O
value	O
in	O
assessing	O
lymph	O
node	O
metastasis	O
of	O
OSCC	O
,	O
and	O
could	O
be	O
taken	O
as	O
new	O
targets	O
for	O
therapy	O
of	O
metastatic	O
OSCC	O
.	O

c	O
-	O
MYC	O
functions	O
as	O
a	O
molecular	O
switch	O
to	O
alter	O
the	O
response	O
of	O
human	O
mammary	O
epithelial	O
cells	O
to	O
oncostatin	O
M	O
.	O

Cytokines	O
play	O
an	O
important	O
role	O
in	O
creating	O
an	O
inflammatory	O
microenvironment	O
,	O
which	O
is	O
now	O
considered	O
a	O
hallmark	O
of	O
cancer	O
.	O

Although	O
tumor	O
cells	O
can	O
exploit	O
cytokine	O
signaling	O
to	O
promote	O
growth	O
,	O
invasion	O
,	O
and	O
metastasis	O
,	O
the	O
response	O
of	O
normal	O
and	O
premalignant	O
epithelial	O
cells	O
to	O
cytokines	O
present	O
in	O
a	O
developing	O
tumor	O
microenvironment	O
remains	O
unclear	O
.	O

Oncostatin	O
M	O
(	O
OSM	O
)	O
,	O
an	O
IL	O
-	O
6	O
family	O
cytokine	O
responsible	O
for	O
STAT3	O
activation	O
,	O
has	O
been	O
implicated	O
in	O
cancer	O
development	O
,	O
progression	O
,	O
invasion	O
,	O
and	O
metastasis	O
.	O

Paradoxically	O
,	O
OSM	O
can	O
also	O
suppress	O
the	O
growth	O
of	O
normal	O
cells	O
and	O
certain	O
tumor	O
-	O
derived	O
cell	O
lines	O
.	O

Using	O
isogenic	O
human	O
mammary	O
epithelial	O
cells	O
(	O
HMEC	O
)	O
at	O
different	O
stages	O
of	O
neoplastic	O
transformation	O
,	O
we	O
found	O
that	O
OSM	O
signaling	O
suppressed	O
c	O
-	O
MYC	O
expression	O
and	O
engaged	O
a	O
p16	O
-	O
and	O
p53	O
-	O
independent	O
growth	O
arrest	O
that	O
required	O
STAT3	O
activity	O
.	O

Inhibition	O
of	O
STAT3	O
activation	O
by	O
expressing	O
a	O
dominant	O
-	O
negative	O
STAT3	O
protein	O
or	O
a	O
STAT3	O
-	O
shRNA	O
prevented	O
the	O
OSM	O
-	O
mediated	O
arrest	O
.	O

In	O
addition	O
,	O
expression	O
of	O
c	O
-	O
MYC	O
from	O
a	O
constitutive	O
promoter	O
also	O
abrogated	O
the	O
STAT3	O
-	O
mediated	O
arrest	O
,	O
and	O
strikingly	O
,	O
cooperated	O
with	O
OSM	O
to	O
promote	O
anchorage	O
-	O
independent	O
growth	O
(	O
AIG	O
)	O
,	O
a	O
property	O
associated	O
with	O
malignant	O
transformation	O
.	O

Cooperative	O
transformation	O
by	O
c	O
-	O
MYC	O
and	O
OSM	O
required	O
PI3	O
K	O
and	O
AKT	O
signaling	O
,	O
showing	O
the	O
importance	O
of	O
multiple	O
signaling	O
pathways	O
downstream	O
of	O
the	O
OSM	O
receptor	O
in	O
defining	O
the	O
cellular	O
response	O
to	O
cytokines	O
.	O

These	O
findings	O
identify	O
c	O
-	O
MYC	O
as	O
an	O
important	O
molecular	O
switch	O
that	O
alters	O
the	O
cellular	O
response	O
to	O
OSM	O
-	O
mediated	O
signaling	O
from	O
tumor	O
suppressive	O
to	O
tumor	O
promoting	O
.	O

PTHrP	O
drives	O
breast	O
tumor	O
initiation	O
,	O
progression	O
,	O
and	O
metastasis	O
in	O
mice	O
and	O
is	O
a	O
potential	O
therapy	O
target	O
.	O

Parathyroid	O
hormone	O
-	O
related	O
protein	O
(	O
PTHrP	O
)	O
is	O
a	O
secreted	O
factor	O
expressed	O
in	O
almost	O
all	O
normal	O
fetal	O
and	O
adult	O
tissues	O
.	O

It	O
is	O
involved	O
in	O
a	O
wide	O
range	O
of	O
developmental	O
and	O
physiological	O
processes	O
,	O
including	O
serum	O
calcium	O
regulation	O
.	O

PTHrP	O
is	O
also	O
associated	O
with	O
the	O
progression	O
of	O
skeletal	O
metastases	O
,	O
and	O
its	O
dysregulated	O
expression	O
in	O
advanced	O
cancers	O
causes	O
malignancy	O
-	O
associated	O
hypercalcemia	O
.	O

Although	O
PTHrP	O
is	O
frequently	O
expressed	O
by	O
breast	O
tumors	O
and	O
other	O
solid	O
cancers	O
,	O
its	O
effects	O
on	O
tumor	O
progression	O
are	O
unclear	O
.	O

Here	O
,	O
we	O
demonstrate	O
in	O
mice	O
pleiotropic	O
involvement	O
of	O
PTHrP	O
in	O
key	O
steps	O
of	O
breast	O
cancer	O
-	O
it	O
influences	O
the	O
initiation	O
and	O
progression	O
of	O
primary	O
tumors	O
and	O
metastases	O
.	O

Pthrp	O
ablation	O
in	O
the	O
mammary	O
epithelium	O
of	O
the	O
PyMT	O
-	O
MMTV	O
breast	O
cancer	O
mouse	O
model	O
caused	O
a	O
delay	O
in	O
primary	O
tumor	O
initiation	O
,	O
inhibited	O
tumor	O
progression	O
,	O
and	O
reduced	O
metastasis	O
to	O
distal	O
sites	O
.	O

Mechanistically	O
,	O
it	O
reduced	O
expression	O
of	O
molecular	O
markers	O
of	O
cell	O
proliferation	O
(	O
Ki67	O
)	O
and	O
angiogenesis	O
(	O
factor	O
VIII	O
)	O
,	O
antiapoptotic	O
factor	O
Bcl	O
-	O
2	O
,	O
cell	O
-	O
cycle	O
progression	O
regulator	O
cyclin	O
D1	O
,	O
and	O
survival	O
factor	O
AKT1	O
.	O

PTHrP	O
also	O
influenced	O
expression	O
of	O
the	O
adhesion	O
factor	O
CXCR4	O
,	O
and	O
coexpression	O
of	O
PTHrP	O
and	O
CXCR4	O
was	O
crucial	O
for	O
metastatic	O
spread	O
.	O

Importantly	O
,	O
PTHrP	O
-	O
specific	O
neutralizing	O
antibodies	O
slowed	O
the	O
progression	O
and	O
metastasis	O
of	O
human	O
breast	O
cancer	O
xenografts	O
.	O

Our	O
data	O
identify	O
what	O
we	O
believe	O
to	O
be	O
new	O
functions	O
for	O
PTHrP	O
in	O
several	O
key	O
steps	O
of	O
breast	O
cancer	O
and	O
suggest	O
that	O
PTHrP	O
may	O
constitute	O
a	O
novel	O
target	O
for	O
therapeutic	O
intervention	O
.	O

Aquaporins	O
in	O
human	O
breast	O
cancer	O
:	O
identification	O
and	O
involvement	O
in	O
carcinogenesis	O
of	O
breast	O
cancer	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Aquaporins	O
(	O
AQPs	O
)	O
play	O
important	O
roles	O
in	O
water	O
and	O
glycerol	O
transport	O
.	O

Recently	O
,	O
the	O
role	O
of	O
AQPs	O
in	O
human	O
carcinogenesis	O
has	O
become	O
an	O
area	O
of	O
great	O
interest	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
AQPs	O
in	O
human	O
breast	O
cancer	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
expression	O
profile	O
of	O
AQPs	O
in	O
human	O
breast	O
cancer	O
and	O
its	O
significance	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
screened	O
the	O
expression	O
profile	O
of	O
AQP0	O
-	O
12	O
in	O
breast	O
cancer	O
tissues	O
and	O
corresponding	O
normal	O
tissues	O
by	O
RT	O
-	O
PCR	O
,	O
Western	O
blotting	O
and	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
AQP1	O
,	O
3	O
-	O
5	O
,	O
and	O
10	O
-	O
12	O
were	O
expressed	O
in	O
human	O
breast	O
cancer	O
and	O
/	O
or	O
normal	O
breast	O
tissues	O
,	O
and	O
AQP1	O
and	O
3	O
-	O
5	O
exhibited	O
differential	O
expression	O
.	O

AQP1	O
was	O
expressed	O
in	O
cell	O
membranes	O
and	O
its	O
expression	O
was	O
higher	O
in	O
cancer	O
than	O
that	O
in	O
normal	O
tissues	O
.	O

AQP4	O
was	O
expressed	O
in	O
the	O
cell	O
membrane	O
and	O
cytoplasm	O
and	O
was	O
detected	O
markedly	O
stronger	O
in	O
normal	O
than	O
in	O
cancer	O
tissues	O
.	O

AQP5	O
was	O
expressed	O
mainly	O
in	O
cell	O
membranes	O
in	O
carcinoma	O
tissues	O
,	O
but	O
was	O
almost	O
absent	O
in	O
normal	O
breast	O
tissues	O
.	O

Expression	O
of	O
AQP5	O
was	O
associated	O
with	O
cellular	O
differentiation	O
,	O
lymph	O
node	O
invasion	O
,	O
and	O
clinicopathological	O
staging	O
.	O

CONCLUSIONS	O
:	O
These	O
observations	O
suggested	O
that	O
several	O
subtypes	O
of	O
the	O
AQP	O
family	O
play	O
a	O
role	O
in	O
human	O
breast	O
carcinogenesis	O
.	O

Absence	O
of	O
antisperm	O
antibodies	O
in	O
anejaculatory	O
men	O
.	O

Antisperm	O
antibodies	O
were	O
assessed	O
in	O
the	O
serum	O
samples	O
of	O
73	O
men	O
unable	O
to	O
ejaculate	O
naturally	O
and	O
on	O
the	O
sperm	O
cells	O
of	O
13	O
of	O
these	O
men	O
.	O

None	O
of	O
the	O
serum	O
samples	O
were	O
found	O
to	O
be	O
positive	O
by	O
sperm	O
agglutination	O
or	O
sperm	O
immobilization	O
methods	O
and	O
antibodies	O
were	O
detected	O
by	O
an	O
immunobead	O
assay	O
on	O
the	O
sperm	O
cells	O
of	O
one	O
of	O
the	O
13	O
men	O
examined	O
.	O

Research	O
and	O
discovery	O
of	O
the	O
first	O
human	O
cancer	O
virus	O
,	O
HTLV	O
-	O
1	O
.	O

Human	O
T	O
-	O
cell	O
lymphoma	O
virus	O
(	O
HTLV	O
)	O
-	O
1	O
was	O
the	O
first	O
human	O
retrovirus	O
to	O
be	O
discovered	O
.	O

It	O
has	O
been	O
recognized	O
as	O
the	O
cause	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

In	O
addition	O
to	O
giving	O
a	O
historical	O
perspective	O
on	O
HTLV	O
-	O
1	O
and	O
other	O
retrovirus	O
research	O
,	O
this	O
paper	O
discusses	O
the	O
origin	O
of	O
HTLV	O
-	O
1	O
;	O
the	O
modes	O
of	O
transmission	O
and	O
global	O
epidemiology	O
of	O
HTLV	O
-	O
1	O
infection	O
;	O
the	O
genome	O
of	O
HTLV	O
-	O
1	O
and	O
the	O
mechanism	O
of	O
HTLV	O
-	O
1	O
-	O
induced	O
leukemogenesis	O
;	O
the	O
role	O
of	O
HTLV	O
-	O
1	O
in	O
other	O
diseases	O
,	O
and	O
recent	O
breakthroughs	O
in	O
ATL	O
therapy	O
.	O

Relationship	O
between	O
of	O
blood	O
flow	O
,	O
glucose	O
metabolism	O
,	O
protein	O
synthesis	O
,	O
glucose	O
and	O
ATP	O
content	O
in	O
experimentally	O
-	O
induced	O
glioma	O
(	O
RG1	O
2	O
.	O
2	O
)	O
of	O
rat	O
brain	O
.	O

In	O
experimental	O
RG1	O
2	O
.	O
2	O
glioma	O
of	O
rat	O
brain	O
,	O
local	O
blood	O
flow	O
,	O
glucose	O
utilization	O
,	O
protein	O
synthesis	O
,	O
glucose	O
and	O
ATP	O
content	O
were	O
measured	O
by	O
means	O
of	O
triple	O
tracer	O
autoradiography	O
and	O
bioluminescence	O
technique	O
,	O
respectively	O
,	O
to	O
determine	O
hemodynamic	O
and	O
metabolic	O
thresholds	O
for	O
local	O
tumor	O
energy	O
failure	O
.	O

Perfusion	O
thresholds	O
were	O
estimated	O
at	O
tumor	O
blood	O
flow	O
values	O
of	O
69	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
estimate	O
+	O
/	O
-	O
standard	O
error	O
)	O
and	O
of	O
69	O
+	O
/	O
-	O
7	O
.	O
1	O
ml	O
/	O
100	O
g	O
/	O
min	O
for	O
the	O
beginning	O
of	O
the	O
decline	O
in	O
regional	O
ATP	O
and	O
glucose	O
content	O
,	O
respectively	O
.	O

Metabolic	O
thresholds	O
were	O
derived	O
at	O
tumor	O
glucose	O
utilization	O
values	O
of	O
70	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
3	O
mumol	O
/	O
100	O
g	O
/	O
min	O
for	O
reduced	O
protein	O
synthesis	O
,	O
of	O
55	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
2	O
mumol	O
/	O
100	O
g	O
/	O
min	O
for	O
the	O
decrease	O
in	O
glucose	O
content	O
,	O
and	O
34	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
7	O
mumol	O
/	O
100	O
g	O
/	O
min	O
for	O
decline	O
in	O
ATP	O
content	O
.	O

Our	O
results	O
suggest	O
that	O
blood	O
flow	O
limits	O
glucose	O
supply	O
to	O
tumor	O
tissue	O
at	O
much	O
higher	O
flow	O
rates	O
than	O
in	O
normal	O
brain	O
which	O
,	O
in	O
turn	O
,	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
tumor	O
glucose	O
utilization	O
.	O

A	O
reduction	O
and	O
not	O
an	O
increase	O
in	O
tumor	O
glucose	O
availability	O
could	O
be	O
a	O
more	O
appropriate	O
strategy	O
for	O
the	O
induction	O
of	O
energy	O
failure	O
in	O
tumors	O
.	O

Selective	O
inhibition	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
by	O
nuclear	O
factor	O
-	O
kappaB	O
essential	O
modulator	O
-	O
binding	O
domain	O
peptide	O
suppresses	O
the	O
metastasis	O
of	O
highly	O
metastatic	O
oral	O
squamous	O
cell	O
carcinoma	O
.	O

Nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
activation	O
contributes	O
to	O
the	O
development	O
of	O
metastasis	O
,	O
thus	O
leading	O
to	O
a	O
poor	O
prognosis	O
in	O
many	O
cancers	O
,	O
including	O
OSCC	O
.	O

However	O
,	O
little	O
in	O
vivo	O
experimental	O
data	O
are	O
available	O
about	O
the	O
effects	O
of	O
NF	O
-	O
kappaB	O
inhibition	O
on	O
OSCC	O
metastasis	O
.	O

OSCC	B
sublines	O
were	O
established	O
from	O
a	O
GFP	O
-	O
expressing	O
parental	O
cell	O
line	O
,	O
GSAS	B
,	O
and	O
designated	O
GSAS	B
/	O
N3	O
and	O
N5	O
according	O
to	O
the	O
in	O
vivo	O
passage	O
number	O
after	O
cervical	O
lymph	O
node	O
metastasis	O
by	O
a	O
serial	O
orthotopic	O
transplantation	O
model	O
.	O

In	O
vitro	O
migration	O
and	O
invasion	O
were	O
assessed	O
in	O
these	O
cells	O
,	O
and	O
the	O
NF	O
-	O
kappaB	O
activities	O
and	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
regulated	O
metastasis	O
-	O
related	O
molecules	O
were	O
also	O
examined	O
.	O

In	O
in	O
vivo	O
experiments	O
,	O
the	O
metastasis	O
and	O
survival	O
of	O
tumor	O
-	O
engrafted	O
mice	O
were	O
monitored	O
.	O

Furthermore	O
,	O
the	O
effects	O
of	O
a	O
selective	O
NF	O
-	O
kappaB	O
inhibitor	O
,	O
NEMO	O
-	O
binding	O
domain	O
(	O
NBD	O
)	O
peptide	O
,	O
on	O
metastasis	O
in	O
GSAS	B
/	O
N5	O
-	O
engrafted	O
mice	O
were	O
assessed	O
,	O
and	O
engrafted	O
tongue	O
tumors	O
were	O
immunohistochemically	O
examined	O
.	O

Highly	O
metastatic	O
GSAS	B
/	O
N3	O
and	O
N5	O
cells	O
showed	O
an	O
enhanced	O
NF	O
-	O
kappaB	O
activity	O
,	O
thus	O
contributing	O
to	O
increased	O
migration	O
,	O
invasion	O
,	O
and	O
a	O
poor	O
prognosis	O
compared	O
with	O
the	O
parent	O
cells	O
.	O

Furthermore	O
,	O
the	O
expression	O
levels	O
of	O
NF	O
-	O
kappaB	O
-	O
regulated	O
metastasis	O
-	O
related	O
molecules	O
,	O
such	O
as	O
fibronectin	O
,	O
beta1	O
integrin	O
,	O
MMP	O
-	O
1	O
,	O
-	O
2	O
,	O
-	O
9	O
,	O
and	O
-	O
14	O
,	O
and	O
VEGF	O
-	O
C	O
,	O
were	O
upregulated	O
in	O
the	O
highly	O
metastatic	O
cells	O
.	O

The	O
NBD	O
peptide	O
suppressed	O
metastasis	O
and	O
tongue	O
tumor	O
growth	O
in	O
GSAS	B
/	O
N5	O
-	O
inoculated	O
mice	O
,	O
and	O
was	O
accompanied	O
by	O
the	O
downregulation	O
of	O
the	O
NF	O
-	O
kappaB	O
-	O
regulated	O
metastasis	O
-	O
related	O
molecules	O
in	O
engrafted	O
tongue	O
tumors	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
selective	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
NBD	O
peptide	O
may	O
provide	O
an	O
effective	O
approach	O
for	O
the	O
treatment	O
of	O
highly	O
metastatic	O
OSCC	O
.	O

beta	O
-	O
catenin	O
signaling	O
controls	O
metastasis	O
in	O
Braf	O
-	O
activated	O
Pten	O
-	O
deficient	O
melanomas	O
.	O

Malignant	O
melanoma	O
is	O
characterized	O
by	O
frequent	O
metastasis	O
,	O
however	O
,	O
specific	O
changes	O
that	O
regulate	O
this	O
process	O
have	O
not	O
been	O
clearly	O
delineated	O
.	O

Although	O
it	O
is	O
well	O
known	O
that	O
Wnt	O
signaling	O
is	O
frequently	O
dysregulated	O
in	O
melanoma	O
,	O
the	O
functional	O
implications	O
of	O
this	O
observation	O
are	O
unclear	O
.	O

By	O
modulating	O
beta	O
-	O
catenin	O
levels	O
in	O
a	O
mouse	O
model	O
of	O
melanoma	O
that	O
is	O
based	O
on	O
melanocyte	O
-	O
specific	O
Pten	O
loss	O
and	O
Braf	O
(	O
V600E	O
)	O
mutation	O
,	O
we	O
demonstrate	O
that	O
beta	O
-	O
catenin	O
is	O
a	O
central	O
mediator	O
of	O
melanoma	O
metastasis	O
to	O
the	O
lymph	O
nodes	O
and	O
lungs	O
.	O

In	O
addition	O
to	O
altering	O
metastasis	O
,	O
beta	O
-	O
catenin	O
levels	O
control	O
tumor	O
differentiation	O
and	O
regulate	O
both	O
MAPK	O
/	O
Erk	O
and	O
PI3	O
K	O
/	O
Akt	O
signaling	O
.	O

Highly	O
metastatic	O
tumors	O
with	O
beta	O
-	O
catenin	O
stabilization	O
are	O
very	O
similar	O
to	O
a	O
subset	O
of	O
human	O
melanomas	O
.	O

Together	O
these	O
findings	O
establish	O
Wnt	O
signaling	O
as	O
a	O
metastasis	O
regulator	O
in	O
melanoma	O
.	O

Impaired	O
CK1	O
delta	O
activity	O
attenuates	O
SV40	O
-	O
induced	O
cellular	O
transformation	O
in	O
vitro	O
and	O
mouse	O
mammary	O
carcinogenesis	O
in	O
vivo	O
.	O

Simian	O
virus	O
40	O
(	O
SV40	O
)	O
is	O
a	O
powerful	O
tool	O
to	O
study	O
cellular	O
transformation	O
in	O
vitro	O
,	O
as	O
well	O
as	O
tumor	O
development	O
and	O
progression	O
in	O
vivo	O
.	O

Various	O
cellular	O
kinases	O
,	O
among	O
them	O
members	O
of	O
the	O
CK1	O
family	O
,	O
play	O
an	O
important	O
role	O
in	O
modulating	O
the	O
transforming	O
activity	O
of	O
SV40	O
,	O
including	O
the	O
transforming	O
activity	O
of	O
T	O
-	O
Ag	O
,	O
the	O
major	O
transforming	O
protein	O
of	O
SV40	O
,	O
itself	O
.	O

Here	O
we	O
characterized	O
the	O
effects	O
of	O
mutant	O
CK1delta	O
variants	O
with	O
impaired	O
kinase	O
activity	O
on	O
SV40	O
-	O
induced	O
cell	O
transformation	O
in	O
vitro	O
,	O
and	O
on	O
SV40	O
-	O
induced	O
mammary	O
carcinogenesis	O
in	O
vivo	O
in	O
a	O
transgenic	O
/	O
bi	O
-	O
transgenic	O
mouse	O
model	O
.	O

CK1delta	O
mutants	O
exhibited	O
a	O
reduced	O
kinase	O
activity	O
compared	O
to	O
wtCK1delta	O
in	O
in	O
vitro	O
kinase	O
assays	O
.	O

Molecular	O
modeling	O
studies	O
suggested	O
that	O
mutation	O
N172D	O
,	O
located	O
within	O
the	O
substrate	O
binding	O
region	O
,	O
is	O
mainly	O
responsible	O
for	O
impaired	O
mutCK1delta	O
activity	O
.	O

When	O
stably	O
over	O
-	O
expressed	O
in	O
maximal	O
transformed	O
SV	B
-	I
52	I
cells	O
,	O
CK1delta	O
mutants	O
induced	O
reversion	O
to	O
a	O
minimal	O
transformed	O
phenotype	O
by	O
dominant	O
-	O
negative	O
interference	O
with	O
endogenous	O
wtCK1delta	O
.	O

To	O
characterize	O
the	O
effects	O
of	O
CK1delta	O
on	O
SV40	O
-	O
induced	O
mammary	O
carcinogenesis	O
,	O
we	O
generated	O
transgenic	O
mice	O
expressing	O
mutant	O
CK1delta	O
under	O
the	O
control	O
of	O
the	O
whey	O
acidic	O
protein	O
(	O
WAP	O
)	O
gene	O
promoter	O
,	O
and	O
crossed	O
them	O
with	O
SV40	O
transgenic	O
WAP	O
-	O
T	O
-	O
antigen	O
(	O
WAP	O
-	O
T	O
)	O
mice	O
.	O

Both	O
WAP	O
-	O
T	O
mice	O
as	O
well	O
as	O
WAP	O
-	O
mutCK1delta	O
/	O
WAP	O
-	O
T	O
bi	O
-	O
transgenic	O
mice	O
developed	O
breast	O
cancer	O
.	O

However	O
,	O
tumor	O
incidence	O
was	O
lower	O
and	O
life	O
span	O
was	O
significantly	O
longer	O
in	O
WAP	O
-	O
mutCK1delta	O
/	O
WAP	O
-	O
T	O
bi	O
-	O
transgenic	O
animals	O
.	O

The	O
reduced	O
CK1delta	O
activity	O
did	O
not	O
affect	O
early	O
lesion	O
formation	O
during	O
tumorigenesis	O
,	O
suggesting	O
that	O
impaired	O
CK1delta	O
activity	O
reduces	O
the	O
probability	O
for	O
outgrowth	O
of	O
in	O
situ	O
carcinomas	O
to	O
invasive	O
carcinomas	O
.	O

The	O
different	O
tumorigenic	O
potential	O
of	O
SV40	O
in	O
WAP	O
-	O
T	O
and	O
WAP	O
-	O
mutCK1delta	O
/	O
WAP	O
-	O
T	O
tumors	O
was	O
also	O
reflected	O
by	O
a	O
significantly	O
different	O
expression	O
of	O
various	O
genes	O
known	O
to	O
be	O
involved	O
in	O
tumor	O
progression	O
,	O
specifically	O
of	O
those	O
involved	O
in	O
wnt	O
-	O
signaling	O
and	O
DNA	O
repair	O
.	O

Our	O
data	O
show	O
that	O
inactivating	O
mutations	O
in	O
CK1delta	O
impair	O
SV40	O
-	O
induced	O
cellular	O
transformation	O
in	O
vitro	O
and	O
mouse	O
mammary	O
carcinogenesis	O
in	O
vivo	O
.	O

Mitochondrial	O
apoptosis	O
and	O
FAK	O
signaling	O
disruption	O
by	O
a	O
novel	O
histone	O
deacetylase	O
inhibitor	O
,	O
HTPB	O
,	O
in	O
antitumor	O
and	O
antimetastatic	O
mouse	O
models	O
.	O

BACKGROUND	O
:	O
Compound	O
targeting	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
represents	O
a	O
new	O
era	O
in	O
molecular	O
cancer	O
therapeutics	O
.	O

However	O
,	O
effective	O
HDAC	O
inhibitors	O
for	O
the	O
treatment	O
of	O
solid	O
tumors	O
remain	O
to	O
be	O
developed	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Here	O
,	O
we	O
propose	O
a	O
novel	O
HDAC	O
inhibitor	O
,	O
N	O
-	O
Hydroxy	O
-	O
4	O
-	O
(	O
4	O
-	O
phenylbutyryl	O
-	O
amino	O
)	O
benzamide	O
(	O
HTPB	O
)	O
,	O
as	O
a	O
potential	O
chemotherapeutic	O
drug	O
for	O
solid	O
tumors	O
.	O

The	O
HDAC	O
inhibition	O
of	O
HTPB	O
was	O
confirmed	O
using	O
HDAC	O
activity	O
assay	O
.	O

The	O
antiproliferative	O
and	O
anti	O
-	O
migratory	O
mechanisms	O
of	O
HTPB	O
were	O
investigated	O
by	O
cell	O
proliferation	O
,	O
flow	O
cytometry	O
,	O
DNA	O
ladder	O
,	O
caspase	O
activity	O
,	O
Rho	O
activity	O
,	O
F	O
-	O
actin	O
polymerization	O
,	O
and	O
gelatin	O
-	O
zymography	O
for	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
.	O

Mice	O
with	O
tumor	O
xenograft	O
and	O
experimental	O
metastasis	O
model	O
were	O
used	O
to	O
evaluate	O
effects	O
on	O
tumor	O
growth	O
and	O
metastasis	O
.	O

Our	O
results	O
indicated	O
that	O
HTPB	O
was	O
a	O
pan	O
-	O
HDAC	O
inhibitor	O
in	O
suppressing	O
cell	O
viability	O
specifically	O
of	O
lung	O
cancer	O
cells	O
but	O
not	O
of	O
the	O
normal	O
lung	O
cells	O
.	O

Upon	O
HTPB	O
treatment	O
,	O
cell	O
cycle	O
arrest	O
was	O
induced	O
and	O
subsequently	O
led	O
to	O
mitochondria	O
-	O
mediated	O
apoptosis	O
.	O

HTPB	O
disrupted	O
F	O
-	O
actin	O
dynamics	O
via	O
downregulating	O
RhoA	O
activity	O
.	O

Moreover	O
,	O
HTPB	O
inhibited	O
activity	O
of	O
MMP2	O
and	O
MMP9	O
,	O
reduced	O
integrin	O
-	O
beta1	O
/	O
focal	O
adhesion	O
complex	O
formation	O
and	O
decreased	O
pericellular	O
poly	O
-	O
fibronectin	O
assemblies	O
.	O

Finally	O
,	O
intraperitoneal	O
injection	O
or	O
oral	O
administration	O
of	O
HTPB	O
efficiently	O
inhibited	O
A549	B
xenograft	O
tumor	O
growth	O
in	O
vivo	O
without	O
side	O
effects	O
.	O

HTPB	O
delayed	O
lung	O
metastasis	O
of	O
4T1	B
mouse	O
breast	O
cancer	O
cells	O
.	O

Acetylation	O
of	O
histone	O
and	O
non	O
-	O
histone	O
proteins	O
,	O
induction	O
of	O
apoptotic	O
-	O
related	O
proteins	O
and	O
de	O
-	O
phosphorylation	O
of	O
focal	O
adhesion	O
kinase	O
were	O
confirmed	O
in	O
treated	O
mice	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
These	O
results	O
suggested	O
that	O
intrinsic	O
apoptotic	O
pathway	O
may	O
involve	O
in	O
anti	O
-	O
tumor	O
growth	O
effects	O
of	O
HTPB	O
in	O
lung	O
cancer	O
cells	O
.	O

HTPB	O
significantly	O
suppresses	O
tumor	O
metastasis	O
partly	O
through	O
inhibition	O
of	O
integrin	O
-	O
beta1	O
/	O
FAK	O
/	O
MMP	O
/	O
RhoA	O
/	O
F	O
-	O
actin	O
pathways	O
.	O

We	O
have	O
provided	O
convincing	O
preclinical	O
evidence	O
that	O
HTPB	O
is	O
a	O
potent	O
HDAC	O
targeted	O
inhibitor	O
and	O
is	O
thus	O
a	O
promising	O
candidate	O
for	O
lung	O
cancer	O
chemotherapy	O
.	O

Inactivation	O
of	O
androgen	O
-	O
induced	O
regulator	O
ARD1	O
inhibits	O
androgen	O
receptor	O
acetylation	O
and	O
prostate	O
tumorigenesis	O
.	O

Androgen	O
signaling	O
through	O
androgen	O
receptor	O
(	O
AR	O
)	O
is	O
critical	O
for	O
prostate	O
tumorigenesis	O
.	O

Given	O
that	O
AR	O
-	O
mediated	O
gene	O
regulation	O
is	O
enhanced	O
by	O
AR	O
coregulators	O
,	O
inactivation	O
of	O
those	O
coregulators	O
is	O
emerging	O
as	O
a	O
promising	O
therapy	O
for	O
prostate	O
cancer	O
(	O
PCa	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
N	O
-	O
acetyltransferase	O
arrest	O
-	O
defect	O
1	O
protein	O
(	O
ARD1	O
)	O
functions	O
as	O
a	O
unique	O
AR	O
regulator	O
in	O
PCa	O
cells	O
.	O

ARD1	O
is	O
up	O
-	O
regulated	O
in	O
human	O
PCa	O
cell	O
lines	O
and	O
primary	O
tumor	O
biopsies	O
.	O

The	O
expression	O
of	O
ARD1	O
was	O
augmented	O
by	O
treatment	O
with	O
synthetic	O
androgen	O
(	O
R1881	O
)	O
unless	O
AR	O
is	O
deficient	O
or	O
is	O
inhibited	O
by	O
AR	O
-	O
specific	O
siRNA	O
or	O
androgen	O
inhibitor	O
bicalutamide	O
(	O
Casodex	O
)	O
.	O

Depletion	O
of	O
ARD1	O
by	O
shRNA	O
suppressed	O
PCa	O
cell	O
proliferation	O
,	O
anchorage	O
-	O
independent	O
growth	O
,	O
and	O
xenograft	O
tumor	O
formation	O
in	O
SCID	O
mice	O
,	O
suggesting	O
that	O
AR	O
-	O
dependent	O
ARD1	O
expression	O
is	O
biologically	O
germane	O
.	O

Notably	O
,	O
ARD1	O
was	O
critical	O
for	O
transcriptionally	O
regulating	O
a	O
number	O
of	O
AR	O
target	O
genes	O
that	O
are	O
involved	O
in	O
prostate	O
tumorigenesis	O
.	O

Furthermore	O
,	O
ARD1	O
interacted	O
physically	O
with	O
and	O
acetylated	O
the	O
AR	O
protein	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Because	O
AR	O
-	O
ARD1	O
interaction	O
facilitated	O
the	O
AR	O
binding	O
to	O
its	O
targeted	O
promoters	O
for	O
gene	O
transcription	O
,	O
we	O
propose	O
that	O
ARD1	O
functions	O
as	O
a	O
unique	O
AR	O
regulator	O
and	O
forms	O
a	O
positive	O
feedback	O
loop	O
for	O
AR	O
-	O
dependent	O
prostate	O
tumorigenesis	O
.	O

Disruption	O
of	O
AR	O
-	O
ARD1	O
interactions	O
may	O
be	O
a	O
potent	O
intervention	O
for	O
androgen	O
-	O
dependent	O
PCa	O
therapy	O
.	O

The	O
role	O
of	O
He	O
s	O
genes	O
in	O
intestinal	O
development	O
,	O
homeostasis	O
and	O
tumor	O
formation	O
.	O

Notch	O
signaling	O
regulates	O
intestinal	O
development	O
,	O
homeostasis	O
and	O
tumorigenesis	O
,	O
but	O
its	O
precise	O
downstream	O
mechanism	O
remains	O
largely	O
unknown	O
.	O

Here	O
we	O
found	O
that	O
inactivation	O
of	O
the	O
Notch	O
effectors	O
Hes1	O
,	O
Hes3	O
and	O
Hes5	O
,	O
but	O
not	O
Hes1	O
alone	O
,	O
led	O
to	O
reduced	O
cell	O
proliferation	O
,	O
increased	O
secretory	O
cell	O
formation	O
and	O
altered	O
intestinal	O
structures	O
in	O
adult	O
mice	O
.	O

However	O
,	O
in	O
Apc	O
mutation	O
-	O
induced	O
intestinal	O
tumors	O
,	O
inactivation	O
of	O
Hes1	O
alone	O
was	O
sufficient	O
for	O
reducing	O
tumor	O
cell	O
proliferation	O
and	O
inducing	O
differentiation	O
of	O
tumor	O
cells	O
into	O
all	O
types	O
of	O
intestinal	O
epithelial	O
cells	O
,	O
but	O
without	O
affecting	O
the	O
homeostasis	O
of	O
normal	O
crypts	O
owing	O
to	O
genetic	O
redundancy	O
.	O

These	O
results	O
indicated	O
that	O
He	O
s	O
genes	O
cooperatively	O
regulate	O
intestinal	O
development	O
and	O
homeostasis	O
and	O
raised	O
the	O
possibility	O
that	O
Hes1	O
is	O
a	O
promising	O
target	O
to	O
induce	O
the	O
differentiation	O
of	O
tumor	O
cells	O
.	O

Activation	O
-	O
induced	O
cytidine	O
deaminase	O
in	O
antibody	O
diversification	O
and	O
chromosome	O
translocation	O
.	O

DNA	O
damage	O
,	O
rearrangement	O
,	O
and	O
mutation	O
of	O
the	O
human	O
genome	O
are	O
the	O
basis	O
of	O
carcinogenesis	O
and	O
thought	O
to	O
be	O
avoided	O
at	O
all	O
costs	O
.	O

An	O
exception	O
is	O
the	O
adaptive	O
immune	O
system	O
where	O
lymphocytes	O
utilize	O
programmed	O
DNA	O
damage	O
to	O
effect	O
antigen	O
receptor	O
diversification	O
.	O

Both	O
B	O
and	O
T	O
lymphocytes	O
diversify	O
their	O
antigen	O
receptors	O
through	O
RAG1	O
/	O
2	O
mediated	O
recombination	O
,	O
but	O
B	O
cells	O
undergo	O
two	O
additional	O
processes	O
-	O
-	O
somatic	O
hypermutation	O
(	O
SHM	O
)	O
and	O
class	O
-	O
switch	O
recombination	O
(	O
CSR	O
)	O
,	O
both	O
initiated	O
by	O
activation	O
-	O
induced	O
cytidine	O
deaminase	O
(	O
AID	O
)	O
.	O

AID	O
deaminates	O
cytidines	O
in	O
DNA	O
resulting	O
in	O
U	O
:	O
G	O
mismatches	O
that	O
are	O
processed	O
into	O
point	O
mutations	O
in	O
SHM	O
or	O
double	O
-	O
strand	O
breaks	O
in	O
CSR	O
.	O

Although	O
AID	O
activity	O
is	O
focused	O
at	O
Immunoglobulin	O
(	O
Ig	O
)	O
gene	O
loci	O
,	O
it	O
also	O
targets	O
a	O
wide	O
array	O
of	O
non	O
-	O
Ig	O
genes	O
including	O
oncogenes	O
associated	O
with	O
lymphomas	O
.	O

Here	O
,	O
we	O
review	O
the	O
molecular	O
basis	O
of	O
AID	O
regulation	O
,	O
targeting	O
,	O
and	O
initiation	O
of	O
CSR	O
and	O
SHM	O
,	O
as	O
well	O
as	O
AID	O
'	O
s	O
role	O
in	O
generating	O
chromosome	O
translocations	O
that	O
contribute	O
to	O
lymphomagenesis	O
.	O

Expression	O
of	O
HER2	O
and	O
bradykinin	O
B1	O
receptors	O
in	O
precursor	O
lesions	O
of	O
gallbladder	O
carcinoma	O
.	O

AIM	O
:	O
To	O
determine	O
the	O
expression	O
of	O
HER2	O
and	O
bradykinin	O
B	O
(	O
1	O
)	O
receptors	O
(	O
B	O
(	O
1	O
)	O
R	O
)	O
in	O
the	O
two	O
pathogenic	O
models	O
of	O
gallbladder	O
cancer	O
:	O
the	O
metaplasia	O
-	O
dysplasia	O
-	O
carcinoma	O
and	O
the	O
adenoma	O
-	O
carcinoma	O
pathways	O
.	O

METHODS	O
:	O
Receptor	O
proteins	O
were	O
visualized	O
by	O
immunohistochemistry	O
on	O
5	O
-	O
mum	O
sections	O
of	O
paraffin	O
-	O
embedded	O
tissue	O
.	O

Expression	O
of	O
both	O
receptors	O
was	O
studied	O
in	O
biopsy	O
samples	O
from	O
92	O
patients	O
(	O
6	O
males	O
and	O
86	O
females	O
;	O
age	O
ranging	O
from	O
28	O
to	O
86	O
years	O
,	O
mean	O
56	O
years	O
)	O
.	O

High	O
HER2	O
expression	O
in	O
specimens	O
was	O
additionally	O
investigated	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

Cell	O
proliferation	O
in	O
each	O
sample	O
was	O
assessed	O
by	O
using	O
the	O
Ki	O
-	O
67	O
proliferation	O
marker	O
.	O

RESULTS	O
:	O
HER2	O
receptor	O
protein	O
was	O
absent	O
in	O
adenomas	O
and	O
in	O
normal	O
gallbladder	O
epithelium	O
.	O

On	O
the	O
contrary	O
,	O
there	O
was	O
intense	O
staining	O
for	O
HER2	O
on	O
the	O
basolateral	O
membrane	O
of	O
epithelial	O
cells	O
of	O
intestinal	O
metaplasia	O
(	O
22	O
/	O
24	O
;	O
91	O
.	O
7	O
%	O
)	O
and	O
carcinoma	O
in	O
situ	O
(	O
9	O
/	O
10	O
;	O
90	O
%	O
)	O
,	O
the	O
lesions	O
that	O
displayed	O
a	O
significantly	O
high	O
proliferation	O
index	O
.	O

Protein	O
up	O
-	O
regulation	O
of	O
HER2	O
in	O
the	O
epithelium	O
with	O
metaplasia	O
or	O
carcinoma	O
in	O
situ	O
was	O
not	O
accompanied	O
by	O
HER2	O
gene	O
amplification	O
.	O

A	O
similar	O
result	O
was	O
observed	O
in	O
invasive	O
carcinomas	O
(	O
0	O
/	O
12	O
)	O
.	O

The	O
B	O
(	O
1	O
)	O
R	O
distribution	O
pattern	O
mirrored	O
that	O
of	O
HER2	O
except	O
that	O
B	O
(	O
1	O
)	O
R	O
was	O
additionally	O
observed	O
in	O
the	O
adenomas	O
.	O

The	O
B	O
(	O
1	O
)	O
R	O
appeared	O
either	O
as	O
cytoplasmic	O
dots	O
or	O
labeling	O
on	O
the	O
apical	O
cell	O
membrane	O
of	O
the	O
cells	O
composing	O
the	O
epithelia	O
with	O
intestinal	O
metaplasia	O
(	O
24	O
/	O
24	O
;	O
100	O
%	O
)	O
and	O
carcinoma	O
in	O
situ	O
(	O
10	O
/	O
10	O
;	O
100	O
%	O
)	O
and	O
in	O
the	O
epithelial	O
cells	O
of	O
adenomas	O
.	O

In	O
contrast	O
,	O
both	O
HER2	O
(	O
4	O
/	O
12	O
;	O
33	O
%	O
)	O
and	O
B	O
(	O
1	O
)	O
R	O
(	O
1	O
/	O
12	O
;	O
8	O
.	O
3	O
%	O
)	O
showed	O
a	O
low	O
expression	O
in	O
invasive	O
gallbladder	O
carcinomas	O
.	O

CONCLUSION	O
:	O
The	O
up	O
-	O
regulation	O
of	O
HER2	O
and	O
B	O
(	O
1	O
)	O
R	O
in	O
precursor	O
lesions	O
of	O
gallbladder	O
carcinoma	O
suggests	O
cross	O
-	O
talk	O
between	O
these	O
two	O
receptors	O
that	O
may	O
be	O
of	O
importance	O
in	O
the	O
modulation	O
of	O
cell	O
proliferation	O
in	O
gallbladder	O
carcinogenesis	O
.	O

Expression	O
of	O
basic	O
fibroblast	O
growth	O
factor	O
in	O
normal	O
human	O
tissues	O
.	O

The	O
distribution	O
of	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
was	O
studied	O
immunohistochemically	O
in	O
fresh	O
frozen	O
sections	O
of	O
normal	O
human	O
tissues	O
.	O

Immunodetection	O
was	O
performed	O
with	O
a	O
specific	O
anti	O
-	O
bFGF	O
mouse	O
monoclonal	O
antibody	O
that	O
was	O
found	O
to	O
react	O
with	O
recombinant	O
human	O
bFGF	O
in	O
Western	O
blot	O
analysis	O
,	O
and	O
to	O
specifically	O
neutralize	O
the	O
mitogenic	O
activity	O
of	O
bFGF	O
on	O
bovine	O
vascular	O
endothelial	O
cells	O
.	O

Expression	O
of	O
bFGF	O
on	O
normal	O
human	O
tissues	O
was	O
ubiquitously	O
detected	O
in	O
the	O
basement	O
membranes	O
of	O
all	O
size	O
blood	O
vessels	O
,	O
but	O
was	O
not	O
found	O
in	O
epidermal	O
or	O
epithelial	O
basement	O
membranes	O
of	O
a	O
variety	O
of	O
tissues	O
tested	O
.	O

Intensity	O
and	O
patterns	O
of	O
localization	O
in	O
blood	O
vessels	O
was	O
consistent	O
in	O
various	O
tissues	O
,	O
but	O
varied	O
among	O
different	O
regions	O
of	O
the	O
vascular	O
bed	O
.	O

Whereas	O
homogeneous	O
and	O
intense	O
immunoreactivity	O
were	O
observed	O
in	O
large	O
and	O
intermediate	O
size	O
blood	O
vessels	O
,	O
heterogeneity	O
of	O
expression	O
was	O
found	O
in	O
capillaries	O
.	O

The	O
most	O
intense	O
immunoreactivity	O
was	O
observed	O
in	O
branching	O
capillaries	O
.	O

Endothelial	O
cell	O
staining	O
was	O
heterogeneous	O
and	O
varied	O
in	O
different	O
regions	O
.	O

Strong	O
staining	O
for	O
bFGF	O
was	O
also	O
found	O
in	O
cardiac	O
muscle	O
fibers	O
,	O
smooth	O
muscle	O
cells	O
of	O
mid	O
-	O
size	O
blood	O
vessels	O
,	O
the	O
gut	O
and	O
the	O
myometrium	O
,	O
in	O
central	O
nervous	O
system	O
neurons	O
and	O
cerebellar	O
Purkinje	O
cells	O
,	O
and	O
on	O
epithelial	O
cells	O
of	O
the	O
bronchi	O
,	O
colon	O
,	O
endometrium	O
,	O
and	O
sweat	O
gland	O
ducts	O
of	O
the	O
skin	O
.	O

The	O
presence	O
of	O
bFGF	O
in	O
the	O
extracellular	O
compartment	O
of	O
a	O
diverse	O
variety	O
of	O
organs	O
may	O
play	O
a	O
role	O
in	O
angiogenesis	O
.	O

However	O
,	O
the	O
function	O
of	O
bFGF	O
in	O
parenchymal	O
cells	O
remains	O
to	O
be	O
determined	O
.	O

Incidence	O
of	O
BRAF	O
p	O
.	O
Val600Glu	O
and	O
p	O
.	O
Val600Lys	O
mutations	O
in	O
a	O
consecutive	O
series	O
of	O
183	O
metastatic	O
melanoma	O
patients	O
from	O
a	O
high	O
incidence	O
region	O
.	O

AIM	O
:	O
Approximately	O
40	O
-	O
60	O
%	O
of	O
melanomas	O
from	O
Caucasian	O
populations	O
carry	O
activating	O
mutations	O
in	O
the	O
BRAF	O
oncogene	O
,	O
with	O
the	O
most	O
common	O
being	O
the	O
p	O
.	O
Val600Glu	O
(	O
V600E	O
)	O
hotspot	O
mutation	O
in	O
exon	O
15	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
frequency	O
of	O
the	O
less	O
common	O
p	O
.	O
Val600Lys	O
(	O
V600	O
K	O
)	O
mutation	O
in	O
metastatic	O
melanoma	O
from	O
a	O
high	O
incidence	O
region	O
.	O

METHOD	O
:	O
Dideoxy	O
sequencing	O
and	O
fluorescent	O
single	O
strand	O
conformation	O
analysis	O
were	O
used	O
to	O
screen	O
for	O
mutations	O
in	O
exon	O
15	O
of	O
BRAF	O
in	O
183	O
cases	O
of	O
metastatic	O
melanoma	O
.	O

RESULTS	O
:	O
The	O
overall	O
incidence	O
of	O
BRAF	O
mutation	O
(	O
89	O
/	O
183	O
,	O
49	O
%	O
)	O
was	O
very	O
similar	O
to	O
other	O
large	O
studies	O
of	O
Caucasian	O
populations	O
.	O

However	O
,	O
the	O
frequency	O
of	O
the	O
p	O
.	O
Val600Lys	O
mutation	O
was	O
higher	O
than	O
in	O
most	O
other	O
studies	O
and	O
comprised	O
almost	O
one	O
-	O
third	O
of	O
all	O
BRAF	O
mutations	O
in	O
our	O
cohort	O
(	O
27	O
/	O
89	O
,	O
30	O
%	O
)	O
.	O

CONCLUSION	O
:	O
BRAF	O
p	O
.	O
Val600Lys	O
mutations	O
were	O
present	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
this	O
cohort	O
of	O
metastatic	O
melanoma	O
patients	O
(	O
27	O
/	O
183	O
,	O
15	O
%	O
)	O
.	O

Assays	O
used	O
to	O
screen	O
for	O
BRAF	O
mutations	O
in	O
the	O
clinic	O
should	O
be	O
robust	O
enough	O
to	O
detect	O
the	O
p	O
.	O
Val600Lys	O
mutation	O
,	O
as	O
this	O
may	O
have	O
therapeutic	O
implications	O
.	O

[	O
Biotechnological	O
and	O
biomedical	O
aspects	O
of	O
production	O
and	O
study	O
of	O
metal	O
cation	O
-	O
phospholipid	O
complexes	O
]	O
.	O

Problems	O
relating	O
to	O
the	O
technology	O
of	O
a	O
phospholipid	O
preparation	O
from	O
natural	O
materials	O
,	O
liposome	O
production	O
,	O
and	O
studies	O
into	O
the	O
mechanisms	O
of	O
interaction	O
between	O
metal	O
(	O
trace	O
elements	O
)	O
cations	O
and	O
model	O
bilayer	O
lipid	O
membranes	O
are	O
discussed	O
.	O

The	O
proposed	O
technology	O
of	O
extraction	O
allows	O
for	O
preparation	O
of	O
phospholipids	O
utilizable	O
for	O
liposome	O
formation	O
.	O

The	O
cation	O
specificity	O
of	O
lipid	O
bilayers	O
is	O
found	O
to	O
be	O
determined	O
by	O
the	O
presence	O
of	O
anionic	O
phosphate	O
adsorption	O
sites	O
on	O
their	O
surface	O
.	O

Overexpression	O
confers	O
an	O
oncogenic	O
potential	O
upon	O
the	O
eph	O
gene	O
.	O

The	O
eph	O
gene	O
encodes	O
a	O
putative	O
receptor	O
tyrosine	O
kinase	O
for	O
an	O
as	O
yet	O
unknown	O
ligand	O
.	O

Some	O
human	O
cancer	O
cells	O
have	O
been	O
found	O
to	O
overexpress	O
eph	O
mRNAs	O
without	O
gene	O
amplification	O
.	O

We	O
show	O
here	O
that	O
NIH3T3	B
cells	O
acquire	O
tumorigenic	O
ability	O
in	O
nude	O
mice	O
and	O
make	O
colonies	O
in	O
soft	O
agar	O
with	O
a	O
viral	O
LTR	O
(	O
Long	O
Terminal	O
Repeat	O
)	O
-	O
driven	O
artificial	O
expression	O
of	O
the	O
eph	O
gene	O
to	O
a	O
high	O
level	O
.	O

This	O
result	O
supports	O
the	O
alleged	O
contribution	O
of	O
overexpressed	O
receptor	O
tyrosine	O
kinases	O
to	O
cell	O
transformation	O
.	O

The	O
enlarging	O
clinical	O
spectrum	O
of	O
Lyme	O
disease	O
:	O
Lyme	O
cerebral	O
vasculitis	O
,	O
a	O
new	O
disease	O
entity	O
.	O

The	O
case	O
of	O
a	O
patient	O
with	O
cerebral	O
vasculitis	O
with	O
a	O
right	O
thalamic	O
infarct	O
associated	O
with	O
cerebral	O
spinal	O
fluid	O
Lyme	O
disease	O
is	O
presented	O
.	O

This	O
entity	O
has	O
not	O
been	O
described	O
in	O
the	O
United	O
States	O
,	O
and	O
only	O
one	O
similar	O
case	O
in	O
the	O
world	O
literature	O
could	O
be	O
found	O
.	O

The	O
patient	O
presented	O
with	O
a	O
progressive	O
headache	O
and	O
subsequent	O
development	O
of	O
grand	O
mal	O
seizure	O
activity	O
.	O

Lyme	O
disease	O
has	O
been	O
associated	O
with	O
cranial	O
nerve	O
palsies	O
,	O
peripheral	O
and	O
cranial	O
radiculopathies	O
,	O
aseptic	O
meningitis	O
,	O
encephalitic	O
symptoms	O
,	O
chorea	O
,	O
and	O
demyelinating	O
polyneuropathy	O
presenting	O
like	O
Guillain	O
-	O
Barre	O
syndrome	O
.	O

These	O
syndromes	O
can	O
occur	O
separately	O
or	O
in	O
combination	O
.	O

Stroke	O
and	O
strokelike	O
syndromes	O
have	O
been	O
attributed	O
to	O
Lyme	O
disease	O
.	O

The	O
literature	O
concerning	O
the	O
neurologic	O
manifestations	O
of	O
Lyme	O
disease	O
is	O
reviewed	O
.	O

Amplification	O
of	O
mineralocorticoid	O
activity	O
of	O
aldosterone	O
by	O
18	O
-	O
hydroxy	O
-	O
corticosterone	O
and	O
18	O
-	O
hydroxy	O
-	O
19	O
-	O
nor	O
-	O
corticosterone	O
in	O
adrenalectomized	O
rats	O
.	O

A	O
combination	O
of	O
aldosterone	O
(	O
1	O
micrograms	O
)	O
with	O
either	O
18	O
-	O
OH	O
-	O
corticosterone	O
(	O
1	O
micrograms	O
)	O
or	O
18	O
-	O
OH	O
-	O
19	O
-	O
norcorticosterone	O
(	O
1	O
micrograms	O
)	O
injected	O
to	O
adrenalectomized	O
rats	O
indicated	O
an	O
amplification	O
of	O
mineralocorticoid	O
activity	O
as	O
expressed	O
by	O
Na	O
/	O
K	O
ratio	O
in	O
urine	O
.	O

Without	O
aldosterone	O
their	O
mineralocorticoid	O
potency	O
was	O
negligible	O
.	O

Alterations	O
in	O
carbohydrate	O
metabolism	O
in	O
canine	O
lymphoma	O
.	O

Following	O
an	O
overnight	O
fast	O
,	O
blood	O
samples	O
were	O
obtained	O
from	O
14	O
dogs	O
with	O
previously	O
untreated	O
lymphoma	O
before	O
and	O
5	O
,	O
15	O
,	O
30	O
,	O
45	O
,	O
60	O
,	O
and	O
90	O
minutes	O
following	O
an	O
intravenous	O
challenge	O
with	O
500	O
mg	O
/	O
kg	O
dextrose	O
.	O

Samples	O
were	O
assayed	O
for	O
glucose	O
,	O
lactate	O
,	O
and	O
insulin	O
concentrations	O
and	O
compared	O
statistically	O
with	O
ten	O
control	O
dogs	O
of	O
similar	O
weight	O
and	O
age	O
undergoing	O
an	O
identical	O
dextrose	O
challenge	O
.	O

Dogs	O
with	O
lymphoma	O
had	O
similar	O
glucose	O
tolerance	O
curves	O
when	O
compared	O
with	O
controls	O
.	O

Lactate	O
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
at	O
baseline	O
and	O
all	O
time	O
periods	O
of	O
the	O
glucose	O
tolerance	O
test	O
in	O
dogs	O
with	O
lymphoma	O
when	O
compared	O
with	O
controls	O
.	O

Rise	O
in	O
lactate	O
concentrations	O
over	O
baseline	O
levels	O
in	O
the	O
first	O
30	O
minutes	O
of	O
the	O
glucose	O
tolerance	O
test	O
were	O
significantly	O
higher	O
in	O
dogs	O
with	O
lymphoma	O
(	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O

Insulin	O
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
at	O
baseline	O
and	O
at	O
the	O
5	O
-	O
,	O
45	O
-	O
,	O
60	O
-	O
,	O
and	O
90	O
-	O
minute	O
time	O
periods	O
of	O
the	O
glucose	O
tolerance	O
test	O
in	O
dogs	O
with	O
lymphoma	O
.	O

Rise	O
in	O
insulin	O
concentrations	O
over	O
baseline	O
in	O
the	O
first	O
5	O
minutes	O
of	O
the	O
glucose	O
tolerance	O
test	O
were	O
also	O
significantly	O
greater	O
in	O
dogs	O
with	O
lymphoma	O
(	O
P	O
=	O
0	O
.	O
021	O
)	O
.	O

These	O
results	O
indicate	O
carbohydrate	O
metabolism	O
is	O
altered	O
in	O
dogs	O
with	O
lymphoma	O
.	O

Many	O
of	O
these	O
alterations	O
parallel	O
those	O
observed	O
in	O
human	O
patients	O
suffering	O
from	O
cancer	O
cachexia	O
making	O
canine	O
lymphoma	O
a	O
potential	O
model	O
for	O
further	O
study	O
of	O
the	O
pathogenesis	O
and	O
therapy	O
of	O
cancer	O
cachexia	O
.	O

Retinal	O
revascularisation	O
in	O
diabetic	O
retinopathy	O
.	O

The	O
case	O
history	O
of	O
a	O
33	O
-	O
year	O
-	O
old	O
diabetic	O
patient	O
who	O
has	O
had	O
diabetes	O
for	O
24	O
years	O
is	O
presented	O
.	O

When	O
first	O
seen	O
in	O
1975	O
he	O
had	O
bilateral	O
proliferative	O
retinopathy	O
with	O
new	O
vessels	O
in	O
the	O
retinal	O
periphery	O
.	O

He	O
had	O
large	O
areas	O
of	O
capillary	O
non	O
-	O
perfusion	O
lateral	O
to	O
the	O
macula	O
in	O
the	O
right	O
eye	O
associated	O
with	O
the	O
new	O
vessels	O
.	O

Nine	O
years	O
later	O
,	O
after	O
extensive	O
repeated	O
photocoagulation	O
,	O
revascularisation	O
of	O
large	O
areas	O
previously	O
not	O
perfused	O
were	O
seen	O
.	O

The	O
vessels	O
are	O
in	O
the	O
plane	O
of	O
the	O
retina	O
and	O
do	O
not	O
have	O
the	O
appearance	O
of	O
new	O
vessels	O
.	O

Members	O
of	O
the	O
src	O
and	O
ras	O
oncogene	O
families	O
supplant	O
the	O
epidermal	O
growth	O
factor	O
requirement	O
of	O
BALB	O
/	O
MK	O
-	O
2	O
keratinocytes	O
and	O
induce	O
distinct	O
alterations	O
in	O
their	O
terminal	O
differentiation	O
program	O
.	O

BALB	O
-	O
/	O
MK	O
-	O
2	O
mouse	O
epidermal	O
keratinocytes	O
required	O
epidermal	O
growth	O
factor	O
for	O
proliferation	O
and	O
terminally	O
differentiated	O
in	O
response	O
to	O
high	O
Ca2	O
+	O
concentration	O
.	O

Infection	O
with	O
retroviruses	O
containing	O
transforming	O
genes	O
of	O
the	O
src	O
and	O
ras	O
oncogene	O
families	O
led	O
to	O
rapid	O
loss	O
of	O
epidermal	O
growth	O
factor	O
dependence	O
,	O
in	O
some	O
cases	O
,	O
accompanied	O
by	O
alterations	O
in	O
cellular	O
morphology	O
.	O

The	O
virus	O
-	O
altered	O
cells	O
continued	O
to	O
proliferate	O
in	O
the	O
presence	O
of	O
high	O
levels	O
of	O
extracellular	O
calcium	O
but	O
exhibited	O
alterations	O
in	O
normal	O
keratinocyte	O
terminal	O
differentiation	O
that	O
appear	O
to	O
be	O
specific	O
to	O
the	O
particular	O
oncogene	O
.	O

These	O
alterations	O
bore	O
similarities	O
to	O
abnormalities	O
in	O
differentiation	O
observed	O
in	O
naturally	O
occurring	O
squamous	O
epithelial	O
malignancies	O
.	O

Experimental	O
drug	O
therapy	O
of	O
peritumoral	O
brain	O
edema	O
.	O

Four	O
drugs	O
with	O
potential	O
anti	O
-	O
peritumoral	O
brain	O
edema	O
activity	O
were	O
studied	O
using	O
the	O
VX2	O
rabbit	O
brain	O
tumor	O
model	O
.	O

Meclofenamate	O
and	O
indomethacin	O
were	O
tested	O
in	O
an	O
attempt	O
to	O
confirm	O
recent	O
reports	O
of	O
anti	O
-	O
edema	O
activity	O
in	O
non	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAID	O
'	O
s	O
)	O
.	O

The	O
'	O
angiostatic	O
'	O
steroids	O
17	O
hydroxyprogesterone	O
and	O
epicortisol	O
were	O
tested	O
because	O
of	O
their	O
lack	O
of	O
glucocorticoid	O
and	O
mineralocorticoid	O
effects	O
and	O
their	O
structural	O
similarity	O
to	O
glucocorticoids	O
.	O

The	O
protein	O
and	O
water	O
component	O
of	O
brain	O
edema	O
were	O
indirectly	O
quantitated	O
.	O

None	O
of	O
the	O
test	O
drugs	O
demonstrated	O
significant	O
anti	O
-	O
edema	O
activity	O
.	O

This	O
work	O
does	O
not	O
confirm	O
reports	O
that	O
NSAID	O
'	O
s	O
have	O
anti	O
-	O
edema	O
activity	O
and	O
suggests	O
that	O
there	O
may	O
be	O
no	O
correlation	O
between	O
'	O
angiostatic	O
'	O
and	O
anti	O
-	O
edema	O
activity	O
in	O
certain	O
steroid	O
compounds	O
.	O

Gastric	O
microcirculatory	O
change	O
and	O
development	O
of	O
acute	O
gastric	O
mucosal	O
lesions	O
(	O
stress	O
ulcer	O
)	O
.	O

Concerning	O
the	O
pathogenesis	O
of	O
acute	O
gastric	O
mucosal	O
lesions	O
,	O
gastric	O
microcirculatory	O
change	O
has	O
drawn	O
attention	O
as	O
an	O
important	O
factor	O
.	O

In	O
view	O
of	O
this	O
fact	O
,	O
gastric	O
mucosal	O
blood	O
flow	O
and	O
microvascular	O
structure	O
were	O
investigated	O
in	O
normal	O
and	O
in	O
burn	O
stressed	O
rats	O
.	O

Moreover	O
,	O
alterations	O
in	O
acid	O
and	O
pepsin	O
activities	O
in	O
by	O
morphological	O
and	O
biochemical	O
procedures	O
in	O
order	O
to	O
evaluate	O
the	O
relationship	O
between	O
defensive	O
and	O
aggressive	O
factors	O
of	O
the	O
gastric	O
mucosa	O
.	O

Gastric	O
mucosal	O
blood	O
flow	O
decreased	O
significantly	O
in	O
early	O
period	O
after	O
induction	O
of	O
stress	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

The	O
incidence	O
of	O
ulceration	O
showed	O
a	O
correlative	O
relation	O
with	O
the	O
decrease	O
of	O
mucosal	O
blood	O
flow	O
.	O

Reduction	O
of	O
blood	O
flow	O
in	O
burn	O
was	O
due	O
to	O
opening	O
of	O
arteriovenular	O
shunt	O
and	O
it	O
appeared	O
that	O
this	O
was	O
responsible	O
for	O
mucosal	O
ischemia	O
and	O
congestion	O
.	O

Following	O
the	O
decrease	O
of	O
blood	O
flow	O
,	O
acid	O
output	O
was	O
lower	O
in	O
stress	O
than	O
that	O
in	O
control	O
.	O

Finally	O
,	O
the	O
results	O
of	O
these	O
studies	O
demonstrated	O
the	O
importance	O
of	O
defensive	O
factors	O
.	O

The	O
reduction	O
of	O
mucosal	O
blood	O
flow	O
resulted	O
in	O
the	O
sequence	O
of	O
events	O
that	O
led	O
to	O
formation	O
of	O
acute	O
gastric	O
mucosal	O
lesion	O
.	O

Identification	O
of	O
a	O
small	O
region	O
of	O
the	O
v	O
-	O
fos	O
gene	O
product	O
that	O
is	O
sufficient	O
for	O
transforming	O
potential	O
and	O
growth	O
-	O
stimulating	O
activity	O
.	O

To	O
analyze	O
the	O
structure	O
-	O
function	O
relationship	O
for	O
the	O
v	O
-	O
fos	O
protein	O
,	O
we	O
constructed	O
in	O
-	O
frame	O
insertion	O
and	O
deletion	O
mutants	O
of	O
the	O
v	O
-	O
fos	O
gene	O
carried	O
by	O
FBJ	O
-	O
MuSV	O
,	O
and	O
expressed	O
them	O
in	O
chicken	O
primary	O
cells	O
using	O
retrovirus	O
vectors	O
.	O

We	O
assessed	O
the	O
effects	O
of	O
these	O
mutations	O
on	O
the	O
ability	O
of	O
the	O
v	O
-	O
fos	O
protein	O
to	O
transform	O
chicken	O
embryo	O
fibroblasts	O
and	O
to	O
stimulate	O
cellular	O
proliferation	O
of	O
chicken	O
neuroretinal	O
cells	O
.	O

The	O
mutant	O
which	O
retains	O
only	O
the	O
central	O
region	O
of	O
the	O
v	O
-	O
fos	O
protein	O
(	O
Met111	O
-	O
Ile206	O
)	O
have	O
both	O
activities	O
,	O
but	O
the	O
mutants	O
which	O
have	O
deletions	O
in	O
this	O
region	O
,	O
and	O
one	O
of	O
the	O
mutants	O
that	O
has	O
a	O
four	O
amino	O
acid	O
insertion	O
in	O
it	O
,	O
lost	O
both	O
activities	O
.	O

The	O
central	O
region	O
that	O
is	O
sufficient	O
for	O
these	O
activities	O
includes	O
the	O
evolutionarily	O
highly	O
conserved	O
region	O
among	O
human	O
,	O
mouse	O
and	O
chicken	O
c	O
-	O
fos	O
proteins	O
.	O

Additionally	O
,	O
this	O
sequence	O
shares	O
some	O
homology	O
with	O
the	O
DNA	O
binding	O
domain	O
of	O
GCN4	O
and	O
c	O
-	O
jun	O
protein	O
.	O

The	O
truncated	O
fos	O
protein	O
that	O
contains	O
only	O
part	O
of	O
the	O
central	O
region	O
is	O
not	O
phosphorylated	O
in	O
chicken	O
embryo	O
fibroblasts	O
,	O
indicating	O
that	O
phosphorylation	O
of	O
the	O
fos	O
protein	O
is	O
not	O
necessary	O
for	O
the	O
transforming	O
activity	O
.	O

Inhibition	O
by	O
retinoic	O
acid	O
of	O
type	O
IV	O
collagenolysis	O
and	O
invasion	O
through	O
reconstituted	O
basement	O
membrane	O
by	O
metastatic	O
rat	O
mammary	O
adenocarcinoma	O
cells	O
.	O

The	O
activity	O
of	O
type	O
IV	O
collagenase	O
,	O
which	O
enables	O
tumor	O
cells	O
to	O
degrade	O
collagen	O
type	O
IV	O
found	O
in	O
the	O
subendothelial	O
basement	O
membrane	O
,	O
has	O
been	O
correlated	O
with	O
the	O
metastatic	O
potential	O
in	O
several	O
tumor	O
types	O
,	O
including	O
the	O
rat	O
13762NF	B
mammary	O
adenocarcinoma	O
cell	O
line	O
and	O
its	O
clones	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
all	O
-	O
trans	O
-	O
RA	O
)	O
and	O
other	O
retinoids	O
,	O
which	O
exhibit	O
antitumor	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
affect	O
the	O
collagenolytic	O
activity	O
of	O
metastatic	O
rat	O
13762NF	B
mammary	O
adenocarcinoma	O
cells	O
.	O

Cells	O
of	O
the	O
highly	O
metastatic	O
lung	O
-	O
colonizing	O
clone	O
MTF7	B
.	I
T35	I
.	I
3	I
,	O
derived	O
from	O
the	O
13762NF	B
cell	O
line	O
,	O
were	O
treated	O
for	O
3	O
days	O
with	O
0	O
.	O
1	O
,	O
1	O
,	O
or	O
10	O
microM	O
all	O
-	O
trans	O
-	O
RA	O
,	O
harvested	O
,	O
and	O
seeded	O
on	O
[	O
3H	O
]	O
proline	O
-	O
labeled	O
extracellular	O
matrix	O
deposited	O
by	O
cultured	O
rat	O
lung	O
endothelial	O
cells	O
or	O
on	O
a	O
film	O
of	O
purified	O
[	O
3H	O
]	O
proline	O
-	O
labeled	O
type	O
IV	O
collagen	O
.	O

The	O
amount	O
of	O
radioactivity	O
released	O
into	O
the	O
medium	O
during	O
the	O
subsequent	O
24	O
to	O
72	O
h	O
was	O
measured	O
,	O
and	O
it	O
was	O
found	O
that	O
all	O
-	O
trans	O
-	O
RA	O
treatment	O
inhibited	O
degradation	O
of	O
extracellular	O
matrix	O
and	O
type	O
IV	O
collagen	O
by	O
50	O
to	O
60	O
%	O
.	O

This	O
effect	O
was	O
observed	O
whether	O
the	O
cells	O
had	O
been	O
treated	O
with	O
all	O
-	O
trans	O
-	O
RA	O
in	O
serum	O
-	O
free	O
medium	O
or	O
in	O
medium	O
supplemented	O
with	O
heat	O
-	O
inactivated	O
or	O
acid	O
-	O
treated	O
fetal	O
bovine	O
serum	O
.	O

The	O
growth	O
of	O
the	O
cells	O
was	O
not	O
inhibited	O
under	O
these	O
conditions	O
,	O
except	O
after	O
treatment	O
with	O
10	O
microM	O
all	O
-	O
trans	O
-	O
RA	O
in	O
serum	O
-	O
free	O
medium	O
.	O

The	O
reduction	O
in	O
collagenolytic	O
activity	O
was	O
observed	O
in	O
viable	O
cells	O
as	O
well	O
as	O
in	O
conditioned	O
medium	O
.	O

A	O
24	O
-	O
h	O
exposure	O
of	O
cells	O
to	O
all	O
-	O
trans	O
-	O
RA	O
was	O
sufficient	O
to	O
cause	O
a	O
30	O
%	O
decrease	O
in	O
the	O
collagenolytic	O
activity	O
,	O
and	O
this	O
inhibitory	O
effect	O
was	O
reversible	O
.	O

The	O
direct	O
addition	O
of	O
all	O
-	O
trans	O
-	O
RA	O
to	O
conditioned	O
medium	O
had	O
no	O
effect	O
on	O
secreted	O
collagenase	O
activity	O
.	O

The	O
apparent	O
molecular	O
weights	O
of	O
the	O
collagenolytic	O
enzymes	O
were	O
determined	O
by	O
electrophoresis	O
of	O
cell	O
extracts	O
and	O
concentrated	O
conditioned	O
medium	O
in	O
type	O
IV	O
collagen	O
-	O
embedded	O
polyacrylamide	O
gels	O
followed	O
by	O
renaturation	O
and	O
activation	O
of	O
the	O
enzymes	O
within	O
the	O
gels	O
.	O

Two	O
major	O
type	O
IV	O
collagenolytic	O
metalloproteinases	O
exhibiting	O
molecular	O
weights	O
of	O
64	O
,	O
000	O
and	O
88	O
,	O
000	O
,	O
respectively	O
,	O
were	O
detected	O
by	O
this	O
method	O
.	O

These	O
two	O
enzymes	O
were	O
also	O
found	O
to	O
have	O
specificity	O
for	O
gelatin	O
.	O

The	O
Mr	O
64	O
,	O
000	O
enzyme	O
could	O
be	O
extracted	O
from	O
viable	O
cells	O
(	O
presumably	O
from	O
the	O
cell	O
membrane	O
)	O
by	O
2	O
%	O
1	O
-	O
butanol	O
.	O

Treatment	O
with	O
all	O
-	O
trans	O
-	O
RA	O
decreased	O
the	O
level	O
of	O
these	O
enzymes	O
in	O
the	O
cellular	O
,	O
cell	O
membrane	O
,	O
and	O
conditioned	O
medium	O
compartments	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Type	O
-	O
A	O
cholecystokinin	O
receptors	O
in	O
CHP212	B
neuroblastoma	O
cells	O
:	O
evidence	O
for	O
association	O
with	O
G	O
protein	O
and	O
activation	O
of	O
phosphoinositide	O
hydrolysis	O
.	O

125I	O
-	O
Bolton	O
Hunter	O
-	O
cholecystokinin	O
octapeptide	O
(	O
BH	O
-	O
CCK8	O
)	O
and	O
(	O
-	O
)	O
-	O
[	O
3H	O
]	O
L	O
-	O
364718	O
membrane	O
binding	O
assays	O
were	O
used	O
to	O
identify	O
and	O
characterize	O
cholecystokinin	O
(	O
CCK	O
)	O
receptors	O
in	O
CHP212	B
human	O
neuroblastoma	O
cells	O
.	O

The	O
ligand	O
binding	O
properties	O
of	O
CCK	O
receptors	O
in	O
these	O
cells	O
are	O
similar	O
to	O
those	O
found	O
in	O
pancreas	O
(	O
CCK	O
-	O
A	O
sites	O
)	O
and	O
differ	O
from	O
the	O
predominant	O
type	O
of	O
CCK	O
binding	O
site	O
found	O
in	O
brain	O
(	O
CCK	O
-	O
B	O
sites	O
)	O
.	O

The	O
specific	O
binding	O
of	O
125I	O
-	O
BH	O
-	O
CCK8	O
but	O
not	O
(	O
-	O
)	O
-	O
[	O
3H	O
]	O
L	O
-	O
364718	O
was	O
reduced	O
by	O
the	O
metabolically	O
stable	O
GTP	O
analog	O
guanosine	O
5	O
'	O
-	O
(	O
beta	O
-	O
delta	O
-	O
imido	O
)	O
trisphosphate	O
.	O

A	O
substantial	O
difference	O
in	O
the	O
Bmax	O
for	O
the	O
radiolabeled	O
agonist	O
(	O
125I	O
-	O
BH	O
-	O
CCK8	O
)	O
and	O
antagonist	O
[	O
(	O
-	O
)	O
-	O
[	O
3H	O
]	O
L	O
-	O
364718	O
]	O
was	O
noted	O
.	O

These	O
observations	O
are	O
consistent	O
with	O
CCK	O
receptors	O
existing	O
in	O
guanine	O
nucleotide	O
-	O
binding	O
protein	O
-	O
coupled	O
and	O
-	O
uncoupled	O
states	O
.	O

Similar	O
to	O
its	O
action	O
in	O
pancreatic	O
acinar	O
cells	O
,	O
CCK8	O
(	O
S	O
)	O
stimulated	O
the	O
accumulation	O
of	O
[	O
3H	O
]	O
inositol	O
phosphates	O
in	O
cells	O
prelabeled	O
with	O
[	O
3H	O
]	O
myo	O
-	O
inositol	O
(	O
EC50	O
=	O
3	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
4	O
nM	O
;	O
maximum	O
response	O
=	O
4	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
4	O
x	O
basal	O
)	O
.	O

The	O
intrinsic	O
activity	O
of	O
CCK	O
analogues	O
in	O
stimulating	O
phosphoinositide	O
hydrolysis	O
was	O
substantially	O
less	O
than	O
their	O
reported	O
intrinsic	O
activity	O
in	O
stimulating	O
phosphoinositide	O
hydrolysis	O
in	O
pancreatic	O
acinar	O
cells	O
.	O

The	O
CHP212	B
neuroblastoma	O
cell	O
may	O
serve	O
as	O
a	O
useful	O
model	O
for	O
the	O
recently	O
reported	O
CCK	O
-	O
A	O
binding	O
site	O
found	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Energy	O
supply	O
of	O
the	O
mitotic	O
cell	O
cycle	O
and	O
the	O
Na	O
+	O
/	O
H	O
+	O
-	O
antiport	O
in	O
ascites	O
tumors	O
.	O

The	O
activation	O
of	O
Na	O
+	O
transport	O
is	O
due	O
to	O
the	O
exchange	O
of	O
protons	O
formed	O
via	O
glucose	O
conversion	O
into	O
lactate	O
for	O
Na	O
+	O
,	O
i	O
.	O
e	O
.	O
,	O
to	O
the	O
stimulation	O
of	O
the	O
Na	O
+	O
/	O
H	O
+	O
-	O
antiport	O
.	O

Experimental	O
results	O
and	O
theoretical	O
calculations	O
suggest	O
that	O
in	O
glucose	O
-	O
containing	O
medium	O
the	O
Na	O
+	O
transport	O
increases	O
from	O
0	O
.	O
75	O
to	O
1	O
.	O
78	O
pmol	O
/	O
hour	O
per	O
cell	O
.	O

The	O
permeability	O
of	O
plasma	O
membranes	O
for	O
K	O
+	O
increases	O
2	O
.	O
75	O
fold	O
,	O
while	O
the	O
passive	O
flux	O
of	O
Na	O
+	O
diminishes	O
.	O

The	O
intensity	O
of	O
O2	O
adsorption	O
by	O
ascites	O
tumor	O
cells	O
does	O
not	O
practically	O
depend	O
on	O
the	O
monovalent	O
cation	O
concentration	O
gradient	O
between	O
the	O
cells	O
and	O
the	O
culture	O
medium	O
,	O
whereas	O
the	O
rate	O
of	O
glycolysis	O
decreases	O
simultaneously	O
with	O
the	O
diminution	O
of	O
the	O
concentration	O
gradient	O
.	O

In	O
synchronized	O
cultures	O
at	O
the	O
beginning	O
of	O
the	O
mitotic	O
cycle	O
,	O
the	O
bulk	O
of	O
ATP	O
resynthesized	O
via	O
glycolysis	O
is	O
utilized	O
for	O
the	O
synthesis	O
of	O
biopolymers	O
,	O
whereas	O
that	O
at	O
the	O
end	O
of	O
the	O
S	O
-	O
phase	O
and	O
in	O
the	O
G2	O
-	O
phase	O
is	O
utilized	O
for	O
cation	O
transport	O
across	O
plasma	O
membranes	O
.	O

From	O
35	O
to	O
100	O
%	O
of	O
the	O
whole	O
amount	O
of	O
ATP	O
resynthesized	O
via	O
glycolysis	O
is	O
utilized	O
for	O
transport	O
purposes	O
.	O

It	O
is	O
concluded	O
that	O
the	O
observed	O
increase	O
in	O
the	O
Na	O
+	O
/	O
K	O
+	O
ratio	O
in	O
ascites	O
tumor	O
cells	O
is	O
connected	O
with	O
their	O
enhanced	O
ability	O
to	O
synthesize	O
lactic	O
acid	O
.	O

Presumably	O
,	O
glycolysis	O
is	O
one	O
of	O
the	O
regulatory	O
mechanisms	O
of	O
intracellular	O
ratios	O
of	O
monovalent	O
cations	O
.	O

Endoscopic	O
injection	O
therapy	O
for	O
acute	O
upper	O
GI	O
bleeding	O
.	O

In	O
summary	O
,	O
we	O
have	O
found	O
this	O
technique	O
to	O
be	O
useful	O
in	O
patients	O
in	O
whom	O
coagulation	O
therapy	O
is	O
not	O
possible	O
or	O
effective	O
.	O

It	O
must	O
still	O
be	O
considered	O
a	O
technique	O
which	O
is	O
undergoing	O
evaluation	O
.	O

Prospective	O
randomized	O
trials	O
comparing	O
this	O
therapy	O
with	O
other	O
currently	O
available	O
therapies	O
such	O
a	O
electrocoagulation	O
,	O
laser	O
and	O
conservative	O
management	O
must	O
be	O
completed	O
to	O
firmly	O
define	O
its	O
place	O
in	O
treatment	O
strategy	O
for	O
acute	O
upper	O
GI	O
bleeding	O
.	O

Screening	O
method	O
for	O
insecticidal	O
activity	O
using	O
first	O
instars	O
of	O
black	O
blow	O
fly	O
(	O
Diptera	O
:	O
Calliphoridae	O
)	O
.	O

A	O
bioassay	O
method	O
suitable	O
for	O
rapid	O
mass	O
screening	O
of	O
fermentation	O
and	O
synthetic	O
organic	O
compounds	O
for	O
insecticidal	O
activity	O
is	O
described	O
.	O

The	O
test	O
,	O
which	O
uses	O
first	O
instars	O
of	O
susceptible	O
black	O
blow	O
fly	O
,	O
Phormia	O
regina	O
(	O
Meigen	O
)	O
,	O
in	O
a	O
bovine	O
serum	O
medium	O
,	O
detects	O
insecticidal	O
activity	O
with	O
reproducible	O
results	O
.	O

It	O
is	O
capable	O
of	O
selecting	O
the	O
most	O
active	O
compound	O
in	O
structure	O
-	O
activity	O
relationships	O
by	O
minimum	O
effective	O
dose	O
concentration	O
studies	O
.	O

The	O
bioassay	O
system	O
is	O
easy	O
to	O
operate	O
and	O
requires	O
only	O
a	O
minute	O
quantity	O
of	O
chemical	O
compound	O
.	O

Osteonectin	O
transcript	O
and	O
metastatic	O
behavior	O
in	O
v	O
-	O
Ki	O
-	O
ras	O
transformed	O
fibroblasts	O
.	O

Osteonectin	O
is	O
one	O
of	O
the	O
major	O
non	O
-	O
collagenous	O
proteins	O
of	O
bone	O
.	O

However	O
,	O
its	O
transcript	O
has	O
been	O
found	O
in	O
many	O
soft	O
,	O
extracellular	O
matrix	O
-	O
producing	O
tissues	O
;	O
an	O
osteonectin	O
-	O
related	O
protein	O
was	O
detected	O
in	O
tumor	O
basement	O
membrane	O
.	O

We	O
have	O
investigated	O
the	O
expression	O
of	O
osteonectin	O
gene	O
in	O
fresh	O
BALB	B
/	I
c	I
fibroblasts	O
transformed	O
by	O
v	O
-	O
Ki	O
-	O
ras	O
.	O

Transformed	O
cells	O
exhibited	O
lower	O
levels	O
of	O
RNA	O
as	O
compared	O
with	O
normal	O
fibroblasts	O
.	O

The	O
transformed	O
cells	O
were	O
cloned	O
after	O
in	O
vivo	O
tumorigenic	O
assay	O
,	O
and	O
4	O
clones	O
were	O
analyzed	O
for	O
osteonectin	O
expression	O
by	O
Northern	O
blots	O
.	O

Two	O
of	O
them	O
were	O
selected	O
for	O
high	O
or	O
low	O
osteonectin	O
expression	O
and	O
tested	O
in	O
vivo	O
in	O
spontaneous	O
and	O
artificial	O
metastasis	O
assays	O
.	O

High	O
osteonectin	O
expression	O
was	O
correlated	O
with	O
high	O
lung	O
colonization	O
.	O

When	O
10	O
(	O
5	O
)	O
cells	O
were	O
injected	O
i	O
.	O
v	O
.	O
,	O
median	O
colony	O
value	O
was	O
55	O
and	O
20	O
in	O
higher	O
expressor	O
vs	O
.	O
lower	O
expressor	O
respectively	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

Spontaneous	O
metastasis	O
indicates	O
a	O
possible	O
reverse	O
correlation	O
.	O

Our	O
data	O
align	O
osteonectin	O
with	O
other	O
matrix	O
-	O
components	O
and	O
adhesion	O
molecules	O
in	O
affecting	O
potential	O
metastatic	O
spreading	O
of	O
transformed	O
cells	O
.	O

Early	O
post	O
-	O
mortem	O
metabolism	O
and	O
muscle	O
shortening	O
in	O
the	O
Pectoralis	O
major	O
muscle	O
of	O
broiler	O
chickens	O
.	O

Three	O
experiments	O
were	O
conducted	O
to	O
examine	O
the	O
effects	O
of	O
sodium	O
pentobarbital	O
(	O
SP	O
)	O
,	O
iodoacetate	O
(	O
IO	O
)	O
,	O
tubocurarine	O
(	O
TC	O
)	O
,	O
and	O
surgical	O
denervation	O
(	O
DN	O
)	O
on	O
early	O
rigor	O
development	O
in	O
broiler	O
breast	O
muscle	O
.	O

In	O
Experiment	O
1	O
,	O
birds	O
were	O
either	O
anesthetized	O
or	O
not	O
with	O
SP	O
before	O
receiving	O
an	O
injection	O
of	O
IO	O
or	O
TC	O
or	O
maintained	O
as	O
noninjected	O
controls	O
.	O

Experiment	O
2	O
was	O
identical	O
except	O
that	O
a	O
treatment	O
of	O
denervation	O
of	O
the	O
breast	O
muscle	O
was	O
added	O
.	O

Experiment	O
3	O
was	O
conducted	O
to	O
contrast	O
birds	O
at	O
1	O
day	O
(	O
DN1	O
)	O
and	O
3	O
days	O
(	O
DN3	O
)	O
denervation	O
prior	O
to	O
slaughter	O
to	O
nonoperated	O
controls	O
.	O

Measurements	O
of	O
muscle	O
lactate	O
,	O
ATP	O
,	O
R	O
value	O
(	O
ratio	O
of	O
inosine	O
to	O
adenine	O
nucleotides	O
)	O
,	O
pH	O
,	O
sarcomere	O
lengths	O
,	O
and	O
shear	O
were	O
used	O
to	O
evaluate	O
treatment	O
effects	O
.	O

Results	O
for	O
Experiment	O
1	O
showed	O
no	O
significant	O
differences	O
among	O
treatment	O
and	O
control	O
groups	O
for	O
ATP	O
and	O
lactate	O
contents	O
,	O
R	O
values	O
,	O
or	O
sarcomere	O
lengths	O
;	O
however	O
,	O
significantly	O
lower	O
pH	O
and	O
higher	O
shear	O
values	O
were	O
observed	O
for	O
control	O
birds	O
.	O

In	O
Experiment	O
2	O
,	O
no	O
significant	O
differences	O
were	O
observed	O
among	O
the	O
treatment	O
groups	O
for	O
ATP	O
,	O
R	O
values	O
,	O
or	O
sarcomere	O
lengths	O
.	O

However	O
,	O
lactate	O
and	O
shear	O
values	O
were	O
significantly	O
lower	O
,	O
and	O
pH	O
higher	O
,	O
for	O
the	O
DN	O
and	O
SP	O
treated	O
birds	O
.	O

Experiment	O
3	O
resulted	O
in	O
lower	O
lactate	O
and	O
higher	O
pH	O
values	O
for	O
the	O
DN3	O
treatment	O
in	O
comparison	O
with	O
both	O
DN1	O
and	O
control	O
groups	O
.	O

Results	O
of	O
these	O
studies	O
indicate	O
that	O
the	O
use	O
of	O
SP	O
and	O
DN	O
can	O
be	O
used	O
to	O
alter	O
the	O
early	O
profiles	O
of	O
rigor	O
development	O
.	O

Effects	O
of	O
hypertension	O
and	O
sympathetic	O
denervation	O
on	O
cerebral	O
blood	O
flow	O
in	O
newborn	O
pigs	O
.	O

To	O
investigate	O
the	O
potential	O
role	O
of	O
sympathetic	O
nerves	O
in	O
preventing	O
pronounced	O
increases	O
in	O
cerebral	O
blood	O
flow	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
abrupt	O
hypertension	O
on	O
the	O
cerebral	O
circulation	O
of	O
newborn	O
pigs	O
with	O
intact	O
cerebral	O
sympathetic	O
innervation	O
and	O
after	O
cerebral	O
sympathetic	O
denervation	O
.	O

Epinephrine	O
infusion	O
was	O
used	O
to	O
induce	O
abrupt	O
increases	O
in	O
mean	O
(	O
+	O
/	O
-	O
SEM	O
)	O
arterial	O
pressure	O
(	O
innervated	O
pigs	O
,	O
62	O
+	O
/	O
-	O
3	O
mm	O
of	O
Hg	O
to	O
115	O
+	O
/	O
-	O
3	O
mm	O
of	O
Hg	O
;	O
denervated	O
pigs	O
,	O
71	O
+	O
/	O
-	O
4	O
mm	O
of	O
Hg	O
to	O
132	O
+	O
/	O
-	O
4	O
mm	O
of	O
Hg	O
)	O
that	O
remained	O
increased	O
for	O
the	O
3	O
minutes	O
of	O
the	O
study	O
.	O

Abrupt	O
hypertension	O
increased	O
blood	O
flow	O
to	O
all	O
brain	O
regions	O
.	O

In	O
denervated	O
pigs	O
,	O
the	O
increased	O
flow	O
to	O
the	O
cerebrum	O
was	O
prolonged	O
,	O
compared	O
with	O
that	O
in	O
pigs	O
with	O
intact	O
sympathetic	O
innervation	O
.	O

Differences	O
between	O
pigs	O
of	O
the	O
innervated	O
and	O
denervated	O
groups	O
were	O
not	O
apparent	O
,	O
with	O
respect	O
to	O
blood	O
flow	O
to	O
any	O
other	O
region	O
(	O
caudate	O
region	O
,	O
brain	O
stem	O
,	O
cerebellum	O
)	O
.	O

In	O
newborn	O
pigs	O
,	O
sympathetic	O
nerves	O
may	O
attenuate	O
hypertension	O
-	O
induced	O
increases	O
in	O
blood	O
flow	O
to	O
the	O
cerebrum	O
,	O
but	O
do	O
not	O
appear	O
to	O
affect	O
flow	O
to	O
the	O
rest	O
of	O
the	O
brain	O
.	O

[	O
Tumor	O
metastasis	O
and	O
the	O
fibrinolytic	O
system	O
]	O
.	O

Metastatic	O
spread	O
of	O
malignant	O
tumor	O
appears	O
to	O
correlate	O
with	O
activation	O
of	O
the	O
fibrolytic	O
system	O
.	O

The	O
role	O
of	O
fibrinolysis	O
in	O
growth	O
and	O
metastasis	O
was	O
examined	O
in	O
Lewis	O
lung	O
carcinoma	O
of	O
mice	O
.	O

The	O
inhibition	O
of	O
fibrinolysis	O
or	O
proteases	O
decreased	O
the	O
primary	O
tumor	O
growth	O
and	O
pulmonary	O
metastasis	O
,	O
whereas	O
the	O
activation	O
of	O
fibrinolysis	O
or	O
proteases	O
increased	O
the	O
number	O
of	O
metastatic	O
foci	O
in	O
the	O
lung	O
.	O

Electronmicroscopically	O
,	O
thrombus	O
formation	O
in	O
the	O
primary	O
site	O
prevented	O
tumor	O
invasion	O
and	O
metastasis	O
formation	O
.	O

Plasminogen	O
activator	O
(	O
PA	O
)	O
content	O
of	O
excised	O
tumors	O
was	O
determined	O
by	O
SDS	O
-	O
PAGE	O
,	O
and	O
major	O
PA	O
was	O
found	O
to	O
be	O
urokinase	O
(	O
UK	O
)	O
type	O
.	O

Immunohistochemical	O
study	O
with	O
specific	O
antisera	O
was	O
done	O
.	O

When	O
tumor	O
cells	O
possessed	O
a	O
high	O
level	O
of	O
UK	O
,	O
laminin	O
and	O
type	O
IV	O
collagen	O
,	O
components	O
of	O
the	O
basement	O
membrane	O
,	O
disappeared	O
from	O
tumor	O
tissues	O
.	O

These	O
findings	O
suggest	O
that	O
PA	O
through	O
protease	O
cascade	O
plays	O
a	O
role	O
in	O
tumor	O
invasion	O
and	O
metastasis	O
.	O

Clinically	O
,	O
patients	O
with	O
advanced	O
cancer	O
are	O
usually	O
in	O
a	O
hypercoagulable	O
state	O
with	O
elevated	O
fibrinogen	O
,	O
and	O
fibrin	O
deposition	O
around	O
tumor	O
mass	O
is	O
a	O
serious	O
problem	O
in	O
cancer	O
chemotherapy	O
.	O

UK	O
infusion	O
prior	O
to	O
5	O
-	O
fluorouracil	O
increased	O
tissue	O
concentration	O
of	O
antitumor	O
agent	O
.	O

However	O
,	O
development	O
of	O
consumption	O
coagulopathy	O
characterized	O
by	O
progression	O
from	O
hypercoagulable	O
state	O
to	O
disseminated	O
intravascular	O
coagulation	O
has	O
also	O
been	O
found	O
in	O
several	O
cases	O
.	O

[	O
Intraepithelial	O
neoplasm	O
of	O
the	O
uterine	O
cervix	O
and	O
angiogenesis	O
:	O
morphologic	O
study	O
]	O

Thirty	O
uterine	O
cervix	O
specimens	O
sampled	O
following	O
conization	O
or	O
total	O
hysterectomy	O
were	O
studied	O
using	O
histology	O
,	O
histoenzymology	O
(	O
vessel	O
phosphatase	O
alkaline	O
activity	O
)	O
,	O
and	O
immunohistochemistry	O
(	O
demonstration	O
of	O
laminin	O
and	O
type	O
IV	O
collagen	O
in	O
epithelium	O
and	O
vessel	O
basement	O
membranes	O
)	O
.	O

Pathologic	O
conditions	O
included	O
dystrophia	O
,	O
moderate	O
dysplasia	O
,	O
severe	O
dysplasia	O
,	O
and	O
intraepithelial	O
carcinoma	O
.	O

Results	O
were	O
compared	O
to	O
findings	O
in	O
a	O
control	O
group	O
.	O

We	O
found	O
that	O
the	O
severity	O
of	O
vascular	O
abnormalities	O
correlated	O
positively	O
with	O
the	O
severity	O
of	O
histologic	O
epithelial	O
lesions	O
;	O
this	O
finding	O
is	O
consistent	O
with	O
colposcopic	O
results	O
.	O

Anarchic	O
angiogenesis	O
with	O
large	O
,	O
moniliform	O
,	O
tortuous	O
vessels	O
was	O
seen	O
in	O
severe	O
dysplasias	O
and	O
carcinomas	O
.	O

The	O
vascular	O
anomalies	O
seem	O
to	O
precede	O
the	O
development	O
of	O
histologic	O
lesions	O
in	O
some	O
instances	O
.	O

Histogenesis	O
of	O
the	O
abnormal	O
vessels	O
may	O
involve	O
production	O
of	O
an	O
angiogenic	O
factor	O
by	O
the	O
cancerized	O
epithelia	O
.	O

Glycolysis	O
and	O
glutaminolysis	O
in	O
perifused	O
Ehrlich	O
ascites	O
tumour	O
cells	O
.	O

A	O
perifusion	O
system	O
was	O
designed	O
in	O
order	O
to	O
study	O
glucose	O
and	O
glutamine	O
metabolism	O
by	O
freshly	O
harvested	O
Ehrlich	O
ascites	O
tumour	O
cells	O
in	O
steady	O
state	O
conditions	O
.	O

Cells	O
were	O
perifused	O
in	O
the	O
presence	O
of	O
5	O
mM	O
glucose	O
,	O
0	O
.	O
5	O
mM	O
glutamine	O
or	O
5	O
mM	O
glucose	O
and	O
0	O
.	O
5	O
mM	O
glutamine	O
.	O

The	O
results	O
in	O
steady	O
state	O
reveal	O
that	O
both	O
substrates	O
glucose	O
and	O
glutamine	O
are	O
continuously	O
wasted	O
by	O
tumour	O
cells	O
,	O
excreting	O
two	O
moles	O
of	O
lactate	O
per	O
mol	O
of	O
glucose	O
and	O
one	O
mol	O
of	O
glutamate	O
and	O
ammonia	O
per	O
mol	O
of	O
glutamine	O
consumed	O
into	O
the	O
medium	O
.	O

Glutamine	O
consumption	O
in	O
the	O
presence	O
of	O
glucose	O
was	O
higher	O
than	O
with	O
glutamine	O
alone	O
.	O

Invagination	O
of	O
the	O
otic	O
placode	O
:	O
normal	O
development	O
and	O
experimental	O
manipulation	O
.	O

The	O
inner	O
ear	O
forms	O
from	O
paired	O
ectodermal	O
primordia	O
that	O
lie	O
to	O
either	O
side	O
of	O
the	O
developing	O
hindbrain	O
.	O

Initially	O
each	O
primordium	O
forms	O
a	O
shallow	O
depression	O
in	O
the	O
ectodermal	O
surface	O
.	O

Invagination	O
to	O
form	O
an	O
otic	O
pit	O
coincides	O
with	O
the	O
formation	O
of	O
several	O
deep	O
folds	O
in	O
the	O
epithelial	O
surface	O
.	O

An	O
initial	O
fold	O
appears	O
parallel	O
to	O
the	O
embryonic	O
axis	O
and	O
at	O
the	O
junction	O
of	O
the	O
rhombencephalon	O
with	O
somitomeric	O
mesoderm	O
.	O

This	O
is	O
followed	O
by	O
formation	O
of	O
cranial	O
and	O
caudal	O
folds	O
perpendicular	O
to	O
the	O
axis	O
and	O
minor	O
folds	O
that	O
are	O
within	O
the	O
pit	O
formed	O
by	O
earlier	O
folding	O
.	O

The	O
central	O
region	O
of	O
the	O
otic	O
primordium	O
remains	O
in	O
close	O
apposition	O
to	O
the	O
lateral	O
surface	O
of	O
the	O
neural	O
tube	O
during	O
the	O
process	O
of	O
fold	O
formation	O
,	O
until	O
the	O
otic	O
pit	O
becomes	O
quite	O
deep	O
.	O

At	O
that	O
time	O
,	O
mesenchymal	O
cells	O
penetrate	O
between	O
the	O
two	O
layers	O
.	O

Experimental	O
analysis	O
of	O
invagination	O
supports	O
the	O
conclusion	O
that	O
otic	O
invagination	O
is	O
controlled	O
differently	O
from	O
that	O
of	O
similar	O
organ	O
primordia	O
,	O
such	O
as	O
the	O
eye	O
and	O
thyroid	O
.	O

Whereas	O
these	O
other	O
primordia	O
can	O
be	O
stimulated	O
to	O
undergo	O
normal	O
morphogenetic	O
shape	O
changes	O
precociously	O
by	O
treatments	O
that	O
presumably	O
activate	O
motile	O
processes	O
in	O
the	O
cytoskeleton	O
,	O
the	O
same	O
conditions	O
have	O
little	O
effect	O
on	O
the	O
otic	O
placode	O
.	O

Similarly	O
,	O
neither	O
inhibitors	O
of	O
calcium	O
transport	O
nor	O
inactivators	O
of	O
calmodulin	O
activity	O
prevent	O
otic	O
pit	O
formation	O
,	O
while	O
these	O
drugs	O
block	O
invagination	O
of	O
other	O
primordia	O
.	O

These	O
results	O
suggest	O
that	O
otic	O
invagination	O
may	O
be	O
caused	O
by	O
changes	O
in	O
the	O
surrounding	O
tissues	O
rather	O
than	O
by	O
an	O
activation	O
of	O
motility	O
within	O
the	O
primordium	O
.	O

Anaplastic	O
and	O
sarcomatoid	O
carcinoma	O
of	O
the	O
small	O
intestine	O
:	O
a	O
clinicopathologic	O
study	O
.	O

Carcinomas	O
involving	O
the	O
jejunum	O
and	O
ileum	O
are	O
rare	O
tumors	O
.	O

During	O
a	O
review	O
of	O
small	O
intestinal	O
neoplasms	O
,	O
six	O
primary	O
carcinomas	O
of	O
jejunum	O
or	O
ileum	O
with	O
an	O
anaplastic	O
and	O
sarcomatoid	O
histology	O
were	O
identified	O
.	O

At	O
presentation	O
,	O
three	O
of	O
the	O
patients	O
had	O
symptoms	O
related	O
to	O
metastatic	O
disease	O
and	O
three	O
had	O
symptoms	O
referable	O
to	O
the	O
local	O
tumor	O
.	O

The	O
tumors	O
were	O
large	O
(	O
greater	O
than	O
4	O
.	O
5	O
cm	O
in	O
diameter	O
)	O
,	O
usually	O
endophytic	O
masses	O
composed	O
of	O
large	O
cells	O
with	O
eosinophilic	O
cytoplasm	O
,	O
anaplastic	O
nuclei	O
,	O
and	O
prominent	O
nucleoli	O
.	O

In	O
many	O
areas	O
,	O
the	O
cells	O
had	O
a	O
spindled	O
configuration	O
.	O

Mucin	O
positivity	O
was	O
identified	O
in	O
all	O
six	O
cases	O
.	O

Electron	O
microscopic	O
findings	O
in	O
two	O
cases	O
were	O
indicative	O
of	O
epithelial	O
differentiation	O
.	O

The	O
tumors	O
behaved	O
aggressively	O
;	O
all	O
five	O
patients	O
for	O
whom	O
there	O
was	O
clinical	O
follow	O
-	O
up	O
died	O
of	O
metastases	O
within	O
40	O
months	O
.	O

The	O
six	O
anaplastic	O
and	O
sarcomatoid	O
carcinomas	O
were	O
compared	O
with	O
29	O
typical	O
adenocarcinomas	O
arising	O
in	O
the	O
jejunum	O
or	O
ileum	O
.	O

Only	O
two	O
of	O
the	O
latter	O
group	O
had	O
symptoms	O
referable	O
to	O
distant	O
metastases	O
at	O
presentation	O
.	O

These	O
tumors	O
also	O
tended	O
to	O
be	O
smaller	O
at	O
presentation	O
(	O
11	O
tumors	O
were	O
less	O
than	O
4	O
cm	O
in	O
greatest	O
dimension	O
)	O
.	O

Of	O
25	O
patients	O
with	O
typical	O
adenocarcinomas	O
who	O
had	O
acceptable	O
follow	O
-	O
up	O
,	O
18	O
(	O
72	O
%	O
)	O
died	O
of	O
disease	O
and	O
five	O
(	O
20	O
%	O
)	O
were	O
alive	O
with	O
no	O
evidence	O
of	O
disease	O
after	O
5	O
years	O
.	O

We	O
conclude	O
that	O
anaplastic	O
and	O
sarcomatoid	O
carcinoma	O
is	O
a	O
rare	O
variant	O
of	O
small	O
intestinal	O
carcinoma	O
with	O
an	O
aggressive	O
clinical	O
course	O
.	O

Time	O
course	O
of	O
transmitter	O
action	O
at	O
the	O
sympathetic	O
neuroeffector	O
junction	O
in	O
rodent	O
vascular	O
and	O
non	O
-	O
vascular	O
smooth	O
muscle	O
.	O

1	O
.	O

Transmitter	O
release	O
from	O
sympathetic	O
postganglionic	O
nerve	O
terminals	O
innervating	O
the	O
guinea	O
-	O
pig	O
and	O
mouse	O
vas	O
deferens	O
and	O
the	O
rat	O
tail	O
artery	O
has	O
been	O
studied	O
in	O
vitro	O
by	O
focal	O
extracellular	O
recording	O
with	O
particular	O
emphasis	O
on	O
the	O
time	O
course	O
of	O
transmitter	O
action	O
underlying	O
the	O
intracellular	O
potential	O
changes	O
.	O

2	O
.	O

In	O
the	O
absence	O
of	O
stimulation	O
,	O
spontaneous	O
excitatory	O
junction	O
currents	O
(	O
SEJCs	O
)	O
were	O
recorded	O
with	O
amplitudes	O
up	O
to	O
500	O
microV	O
and	O
durations	O
between	O
40	O
and	O
100	O
ms	O
.	O

SEJCs	O
were	O
unaffected	O
by	O
the	O
competitive	O
alpha	O
-	O
adrenoceptor	O
antagonist	O
prazosin	O
but	O
blocked	O
by	O
alpha	O
,	O
beta	O
-	O
methylene	O
ATP	O
which	O
desensitizes	O
P2	O
-	O
purinoceptors	O
.	O

3	O
.	O

During	O
trains	O
of	O
supramaximal	O
stimuli	O
at	O
0	O
.	O
1	O
-	O
4	O
Hz	O
stimulus	O
locked	O
excitatory	O
junction	O
currents	O
(	O
EJCs	O
)	O
were	O
evoked	O
intermittently	O
from	O
the	O
population	O
of	O
varicosities	O
located	O
under	O
the	O
suction	O
electrode	O
.	O

4	O
.	O

SEJCs	O
were	O
similar	O
in	O
amplitude	O
and	O
time	O
course	O
to	O
EJCs	O
evoked	O
by	O
low	O
-	O
frequency	O
stimulation	O
in	O
the	O
same	O
attachment	O
in	O
all	O
three	O
tissues	O
.	O

5	O
.	O

SEJCs	O
recorded	O
using	O
either	O
a	O
conventional	O
AC	O
amplifier	O
or	O
a	O
patch	O
clamp	O
amplifier	O
had	O
the	O
same	O
time	O
course	O
.	O

6	O
.	O

These	O
studies	O
show	O
that	O
the	O
time	O
course	O
of	O
the	O
current	O
underlying	O
the	O
excitatory	O
junction	O
potential	O
is	O
brief	O
and	O
essentially	O
the	O
same	O
in	O
three	O
different	O
tissues	O
.	O

The	O
prolonged	O
time	O
course	O
of	O
the	O
excitatory	O
junction	O
potential	O
in	O
different	O
tissues	O
can	O
be	O
accounted	O
for	O
by	O
the	O
passive	O
membrane	O
properties	O
.	O

Phase	O
II	O
trial	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
in	O
prostatic	O
carcinoma	O
:	O
comparison	O
with	O
other	O
hormonal	O
agents	O
.	O

Various	O
approaches	O
to	O
hormonal	O
treatment	O
of	O
prostate	O
carcinoma	O
are	O
discussed	O
.	O

Eighty	O
-	O
one	O
patients	O
with	O
prostatic	O
carcinoma	O
,	O
eight	O
with	O
stage	O
B	O
,	O
nine	O
with	O
stage	O
C	O
,	O
and	O
64	O
with	O
stage	O
D	O
disease	O
,	O
were	O
treated	O
subcutaneously	O
daily	O
for	O
3	O
months	O
with	O
the	O
LH	O
-	O
RH	O
agonist	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
(	O
Decapeptyl	O
)	O
in	O
order	O
to	O
evaluate	O
the	O
incidence	O
of	O
remissions	O
according	O
to	O
WHO	O
recommendations	O
for	O
oncologic	O
trials	O
.	O

The	O
findings	O
were	O
compared	O
to	O
those	O
obtained	O
with	O
other	O
hormonal	O
therapies	O
of	O
prostatic	O
carcinoma	O
according	O
to	O
the	O
statistical	O
method	O
of	O
""""	O
expected	O
response	O
rate	O
""""	O
as	O
adapted	O
by	O
Lee	O
and	O
Wesley	O
for	O
phase	O
II	O
trials	O
.	O

Treatment	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
greatly	O
reduced	O
serum	O
LH	O
and	O
testosterone	O
levels	O
without	O
raising	O
serum	O
prolactin	O
.	O

After	O
1	O
-	O
2	O
weeks	O
of	O
therapy	O
,	O
there	O
was	O
relief	O
of	O
subjective	O
symptoms	O
and	O
a	O
reversal	O
of	O
the	O
signs	O
of	O
prostatism	O
as	O
well	O
as	O
a	O
marked	O
decrease	O
in	O
bone	O
pain	O
.	O

At	O
90	O
days	O
52	O
patients	O
had	O
complete	O
relief	O
of	O
prostatism	O
and	O
21	O
had	O
only	O
mild	O
signs	O
and	O
symptoms	O
.	O

Seventy	O
patients	O
were	O
experiencing	O
no	O
bone	O
pain	O
and	O
an	O
additional	O
six	O
had	O
only	O
mild	O
pain	O
.	O

Prostatic	O
size	O
,	O
evaluated	O
by	O
rectal	O
examination	O
and	O
transabdominal	O
ultrasonography	O
,	O
reverted	O
to	O
normal	O
in	O
26	O
.	O
4	O
%	O
of	O
patients	O
(	O
complete	O
remission	O
)	O
and	O
was	O
reduced	O
by	O
more	O
than	O
50	O
%	O
in	O
an	O
additional	O
17	O
.	O
6	O
%	O
(	O
partial	O
remission	O
)	O
,	O
the	O
overall	O
rate	O
of	O
complete	O
plus	O
partial	O
regression	O
of	O
prostatic	O
enlargement	O
being	O
44	O
%	O
.	O

Scans	O
showed	O
a	O
major	O
improvement	O
of	O
bone	O
lesions	O
in	O
14	O
.	O
8	O
%	O
of	O
cases	O
.	O

This	O
response	O
increased	O
to	O
37	O
%	O
after	O
more	O
than	O
6	O
months	O
of	O
follow	O
-	O
up	O
.	O

Prostatic	O
acid	O
phosphatase	O
levels	O
were	O
decreased	O
by	O
more	O
than	O
50	O
%	O
in	O
61	O
%	O
of	O
the	O
patients	O
,	O
but	O
this	O
test	O
appears	O
to	O
be	O
a	O
less	O
valid	O
marker	O
than	O
the	O
lipid	O
-	O
associated	O
sialic	O
acid	O
(	O
LASA	O
)	O
.	O

The	O
increase	O
in	O
LASA	O
before	O
treatment	O
and	O
a	O
reduction	O
after	O
treatment	O
can	O
frequently	O
be	O
correlated	O
with	O
the	O
objective	O
volume	O
of	O
the	O
neoplasms	O
.	O

No	O
flare	O
-	O
up	O
of	O
the	O
disease	O
was	O
encountered	O
,	O
and	O
there	O
were	O
no	O
side	O
effects	O
except	O
for	O
impotence	O
.	O

Statistical	O
analyses	O
of	O
results	O
by	O
the	O
method	O
of	O
Lee	O
and	O
Wesley	O
indicated	O
that	O
the	O
incidence	O
of	O
complete	O
and	O
partial	O
regression	O
(	O
CR	O
and	O
PR	O
)	O
observed	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
was	O
not	O
significantly	O
different	O
from	O
that	O
recorded	O
in	O
previous	O
studies	O
for	O
another	O
LH	O
-	O
RH	O
analog	O
,	O
Buserelin	O
.	O

However	O
,	O
CR	O
and	O
PR	O
obtained	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
(	O
44	O
%	O
)	O
were	O
significantly	O
higher	O
than	O
with	O
subcapsular	O
orchiectomy	O
(	O
22	O
%	O
)	O
.	O

Hormonal	O
effects	O
and	O
some	O
other	O
actions	O
of	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
were	O
compared	O
and	O
contrasted	O
with	O
those	O
produced	O
by	O
castration	O
,	O
estrogens	O
,	O
antiandrogens	O
,	O
and	O
progestogens	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

On	O
the	O
mechanism	O
of	O
glycolysis	O
stimulation	O
by	O
neutral	O
detergents	O
in	O
3T3	B
and	O
Ehrlich	O
ascites	O
tumor	O
cells	O
.	O

Glycolysis	O
of	O
3T3	B
and	O
Ehrlich	O
ascites	O
tumor	O
cells	O
was	O
greatly	O
enhanced	O
by	O
Nonidet	O
P	O
-	O
40	O
or	O
Triton	O
X	O
-	O
100	O
at	O
about	O
100	O
micrograms	O
/	O
mg	O
cell	O
protein	O
.	O

This	O
enhanced	O
glycolysis	O
was	O
partly	O
sensitive	O
to	O
rutamycin	O
and	O
partly	O
sensitive	O
to	O
ouabain	O
,	O
suggesting	O
that	O
the	O
detergent	O
released	O
the	O
control	O
of	O
the	O
ATPase	O
of	O
the	O
mitochondria	O
and	O
of	O
the	O
plasma	O
membrane	O
Na	O
+	O
K	O
+	O
-	O
ATPase	O
.	O

Nonidet	O
P	O
-	O
40	O
had	O
no	O
effect	O
on	O
glycolysis	O
in	O
cell	O
-	O
free	O
extracts	O
from	O
Ehrlich	O
ascites	O
tumor	O
cells	O
to	O
which	O
soluble	O
mitochondrial	O
ATPase	O
was	O
added	O
.	O

Measuring	O
ouabain	O
-	O
sensitive	O
22Na	O
efflux	O
and	O
using	O
ouabain	O
-	O
sensitive	O
lactate	O
production	O
as	O
a	O
measure	O
of	O
ATP	O
hydrolysis	O
by	O
the	O
Na	O
+	O
K	O
+	O
pump	O
,	O
it	O
was	O
shown	O
that	O
Nonidet	O
P	O
-	O
40	O
greatly	O
decreased	O
the	O
efficiency	O
of	O
the	O
Na	O
+	O
K	O
+	O
pump	O
.	O

Quercetin	O
increased	O
the	O
efficiency	O
of	O
pumping	O
in	O
EAT	O
cells	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
the	O
detergent	O
.	O

Elevated	O
levels	O
of	O
diacylglycerol	O
and	O
decreased	O
phorbol	O
ester	O
sensitivity	O
in	O
ras	O
-	O
transformed	O
fibroblasts	O
.	O

Diacylglycerol	O
(	O
DG	O
)	O
plays	O
a	O
central	O
role	O
in	O
phospholipid	O
metabolism	O
and	O
is	O
an	O
endogenous	O
activator	O
of	O
protein	O
kinase	O
C	O
.	O

We	O
have	O
suggested	O
that	O
constitutive	O
activation	O
of	O
this	O
kinase	O
is	O
one	O
mechanism	O
by	O
which	O
oncogenes	O
transform	O
cells	O
.	O

The	O
ras	O
-	O
encoded	O
proteins	O
are	O
similar	O
to	O
regulatory	O
G	O
-	O
proteins	O
and	O
are	O
candidates	O
for	O
the	O
unknown	O
G	O
-	O
protein	O
that	O
modulates	O
phosphatidylinositol	O
(	O
PI	O
)	O
turnover	O
.	O

Differences	O
in	O
polyphosphoinositide	O
metabolism	O
have	O
been	O
reported	O
for	O
ras	O
-	O
transformed	O
cells	O
.	O

But	O
because	O
these	O
experiments	O
were	O
performed	O
on	O
confluent	O
cultures	O
of	O
established	O
cell	O
lines	O
,	O
the	O
differences	O
are	O
difficult	O
to	O
attribute	O
to	O
ras	O
transformation	O
.	O

Here	O
we	O
show	O
that	O
exponentially	O
growing	O
NIH	B
3T3	I
fibroblasts	O
recently	O
transformed	O
by	O
Ha	O
-	O
ras	O
or	O
Ki	O
-	O
ras	O
possess	O
elevated	O
DG	O
concentrations	O
without	O
significant	O
alterations	O
in	O
the	O
levels	O
of	O
other	O
polyphosphoinositide	O
metabolites	O
.	O

The	O
basal	O
phosphorylation	O
of	O
protein	O
kinase	O
C	O
substrate	O
of	O
relative	O
molecular	O
mass	O
(	O
Mr	O
)	O
80	O
,	O
000	O
(	O
80	O
K	O
)	O
is	O
significantly	O
increased	O
in	O
all	O
the	O
ras	O
-	O
transformed	O
cell	O
lines	O
.	O

Surprisingly	O
,	O
however	O
,	O
further	O
phosphorylation	O
of	O
this	O
protein	O
on	O
addition	O
of	O
phorbol	O
ester	O
was	O
greatly	O
reduced	O
.	O

Ha	O
-	O
ras	O
cells	O
also	O
show	O
less	O
binding	O
of	O
phorbol	O
ester	O
than	O
control	O
cells	O
,	O
suggesting	O
that	O
elevation	O
of	O
DG	O
causes	O
partial	O
down	O
-	O
regulation	O
in	O
addition	O
to	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

Epidermal	O
growth	O
factor	O
and	O
its	O
receptor	O
.	O

Epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
binds	O
with	O
high	O
affinity	O
and	O
specificity	O
to	O
a	O
single	O
site	O
on	O
the	O
external	O
domain	O
of	O
its	O
transmembrane	O
receptor	O
to	O
activate	O
the	O
tyrosine	O
protein	O
kinase	O
activity	O
of	O
its	O
cytoplasmic	O
portion	O
.	O

The	O
EGF	O
receptor	O
gene	O
is	O
amplified	O
and	O
over	O
-	O
expressed	O
in	O
several	O
human	O
tumors	O
,	O
suggesting	O
that	O
increased	O
concentrations	O
of	O
the	O
proto	O
-	O
oncogene	O
leads	O
to	O
constitutive	O
activity	O
similar	O
to	O
that	O
seen	O
with	O
oncogene	O
erb	O
B	O
.	O

Synthesis	O
and	O
degradation	O
of	O
the	O
EGF	O
receptor	O
are	O
regulated	O
,	O
in	O
addition	O
,	O
covalent	O
modification	O
by	O
phosphorylation	O
regulates	O
activity	O
of	O
the	O
receptor	O
protein	O
.	O

Intramolecular	O
self	O
-	O
phosphorylation	O
of	O
Tyr1173	O
removes	O
a	O
competitive	O
inhibitory	O
constraint	O
to	O
enhance	O
phosphorylation	O
of	O
substrates	O
.	O

Phosphorylation	O
of	O
Thr654	O
by	O
protein	O
kinase	O
C	O
decreases	O
high	O
affinity	O
EGF	O
binding	O
and	O
EGF	O
-	O
stimulated	O
tyrosine	O
protein	O
kinase	O
activity	O
,	O
providing	O
a	O
mechanism	O
for	O
heterologous	O
regulation	O
of	O
the	O
EGF	O
receptor	O
by	O
tumor	O
promoters	O
and	O
other	O
ligand	O
X	O
receptor	O
complexes	O
.	O

Extensive	O
regulation	O
contributes	O
to	O
normal	O
growth	O
control	O
,	O
abrogation	O
of	O
regulatory	O
controls	O
contributes	O
to	O
uncontrolled	O
growth	O
as	O
seen	O
with	O
erb	O
B	O
transformation	O
and	O
EGF	O
receptor	O
gene	O
amplification	O
in	O
human	O
tumors	O
.	O

Malate	O
-	O
citrate	O
cycle	O
during	O
glycolysis	O
and	O
glutaminolysis	O
in	O
Ehrlich	O
ascites	O
tumor	O
cells	O
.	O

The	O
malate	O
-	O
citrate	O
cycle	O
was	O
studied	O
during	O
aerobic	O
glycolysis	O
and	O
glutaminolysis	O
in	O
a	O
strain	O
of	O
Ehrlich	O
ascites	O
tumor	O
cells	O
which	O
showed	O
a	O
very	O
low	O
malate	O
-	O
aspartate	O
shuttle	O
system	O
activity	O
.	O

The	O
experimental	O
approach	O
includes	O
:	O
estimation	O
of	O
mitochondrial	O
NAD	O
[	O
P	O
]	O
+	O
-	O
dependent	O
malic	O
enzyme	O
activity	O
;	O
respiratory	O
activity	O
of	O
freshly	O
harvested	O
or	O
fasted	O
cells	O
,	O
and	O
of	O
isolated	O
mitochondria	O
;	O
and	O
determination	O
of	O
the	O
metabolites	O
involved	O
in	O
the	O
glycolytic	O
and	O
glutaminolytic	O
pathways	O
.	O

The	O
results	O
suggest	O
that	O
in	O
this	O
strain	O
,	O
the	O
malate	O
-	O
citrate	O
shuttle	O
is	O
not	O
an	O
effective	O
pathway	O
for	O
transferring	O
glycolytic	O
reducing	O
equivalents	O
from	O
cytosol	O
to	O
mitochondria	O
.	O

Less	O
than	O
15	O
%	O
of	O
the	O
glucose	O
uptake	O
was	O
affected	O
by	O
the	O
1	O
,	O
2	O
,	O
3	O
-	O
benzenetricarboxylate	O
inhibition	O
of	O
the	O
malate	O
-	O
citrate	O
shuttle	O
.	O

Moreover	O
,	O
in	O
the	O
presence	O
of	O
glucose	O
,	O
the	O
malate	O
-	O
citrate	O
cycle	O
did	O
not	O
appear	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
glutaminolytic	O
process	O
.	O

The	O
present	O
work	O
supports	O
and	O
extends	O
the	O
finding	O
of	O
previous	O
studies	O
,	O
since	O
the	O
results	O
showed	O
that	O
the	O
glucose	O
metabolism	O
depressed	O
the	O
oxidative	O
processes	O
in	O
Ehrlich	O
ascites	O
tumor	O
mitochondria	O
,	O
not	O
only	O
alone	O
,	O
but	O
also	O
in	O
the	O
presence	O
of	O
glutamine	O
.	O

Interestingly	O
,	O
the	O
high	O
glutamine	O
uptake	O
was	O
maintained	O
in	O
the	O
presence	O
of	O
glucose	O
.	O

Differential	O
secretion	O
of	O
proteins	O
and	O
glycoproteins	O
by	O
livers	O
of	O
immature	O
and	O
adult	O
rats	O
.	O

Effect	O
of	O
antimicrotubule	O
drugs	O
.	O

This	O
study	O
was	O
initiated	O
to	O
re	O
-	O
examine	O
reported	O
differences	O
in	O
the	O
action	O
of	O
antimicrotubule	O
agents	O
on	O
plasma	O
protein	O
secretion	O
from	O
livers	O
of	O
immature	O
versus	O
adult	O
rats	O
.	O

The	O
aim	O
was	O
(	O
1	O
)	O
to	O
determine	O
the	O
composition	O
and	O
to	O
monitor	O
the	O
secretion	O
of	O
various	O
plasma	O
proteins	O
and	O
glycoproteins	O
from	O
liver	O
slices	O
labeled	O
in	O
vitro	O
with	O
specific	O
amino	O
acids	O
and	O
sugar	O
residues	O
,	O
and	O
(	O
2	O
)	O
to	O
correlate	O
observed	O
differences	O
in	O
secretion	O
of	O
these	O
proteins	O
with	O
structural	O
changes	O
in	O
the	O
hepatocytes	O
of	O
the	O
different	O
aged	O
animals	O
.	O

For	O
the	O
most	O
part	O
,	O
slices	O
of	O
liver	O
from	O
fetal	O
(	O
term	O
)	O
,	O
neonatal	O
(	O
4	O
-	O
to	O
5	O
days	O
old	O
)	O
,	O
and	O
adult	O
rats	O
(	O
70	O
days	O
old	O
)	O
were	O
incubated	O
with	O
radioactive	O
amino	O
acids	O
or	O
various	O
tritiated	O
sugars	O
specific	O
for	O
N	O
-	O
linked	O
core	O
oligosaccharide	O
and	O
/	O
or	O
N	O
-	O
linked	O
terminal	O
oligosaccharide	O
chains	O
.	O

Our	O
findings	O
indicate	O
that	O
liver	O
slices	O
of	O
fetal	O
and	O
neonatal	O
rats	O
are	O
efficient	O
in	O
synthesizing	O
plasma	O
proteins	O
including	O
fully	O
glycosylated	O
glycoproteins	O
.	O

The	O
secretion	O
of	O
glycosylated	O
and	O
nonglycosylated	O
proteins	O
believed	O
to	O
be	O
processed	O
through	O
Golgi	O
complexes	O
was	O
inhibited	O
to	O
the	O
same	O
extent	O
(	O
approximately	O
70	O
-	O
80	O
%	O
)	O
by	O
antimicrotubule	O
agents	O
,	O
regardless	O
of	O
the	O
age	O
of	O
the	O
host	O
animal	O
.	O

However	O
,	O
other	O
proteins	O
and	O
glycoproteins	O
secreted	O
by	O
livers	O
of	O
immature	O
rats	O
were	O
found	O
to	O
be	O
relatively	O
insensitive	O
(	O
i	O
.	O
e	O
.	O
inhibited	O
to	O
only	O
30	O
-	O
40	O
%	O
)	O
to	O
the	O
action	O
of	O
various	O
antimicrotubule	O
drugs	O
.	O

The	O
glycoproteins	O
were	O
found	O
to	O
lack	O
N	O
-	O
linked	O
terminal	O
sugars	O
(	O
although	O
the	O
glycoproteins	O
did	O
contain	O
N	O
-	O
linked	O
core	O
sugars	O
)	O
,	O
and	O
it	O
is	O
likely	O
that	O
the	O
drug	O
-	O
insensitive	O
proteins	O
bypassed	O
critical	O
glycosylating	O
sites	O
in	O
the	O
Golgi	O
compartment	O
prior	O
to	O
release	O
.	O

Overall	O
,	O
these	O
findings	O
support	O
earlier	O
data	O
showing	O
that	O
antimicrotubule	O
drugs	O
have	O
a	O
special	O
impact	O
on	O
Golgi	O
-	O
associated	O
events	O
in	O
liver	O
cells	O
.	O

To	O
what	O
extent	O
these	O
findings	O
are	O
related	O
to	O
the	O
action	O
of	O
microtubules	O
remains	O
to	O
be	O
seen	O
.	O

Multi	O
-	O
step	O
neoplastic	O
transformation	O
of	O
normal	O
human	O
fibroblasts	O
by	O
Co	O
-	O
60	O
gamma	O
rays	O
and	O
Ha	O
-	O
ras	O
oncogenes	O
.	O

As	O
reported	O
previously	O
(	O
Namba	O
et	O
al	O
.	O
,	O
1985	O
;	O
Namba	O
,	O
1985	O
)	O
,	O
normal	O
human	O
fibroblasts	O
were	O
transformed	O
into	O
immortal	O
cells	O
with	O
abnormal	O
karyotypes	O
by	O
Co	O
-	O
60	O
gamma	O
-	O
ray	O
irradiation	O
.	O

These	O
immortally	O
transformed	O
cells	O
(	O
KMST	B
-	I
6	I
)	O
showed	O
no	O
clonability	O
in	O
soft	O
agar	O
and	O
were	O
not	O
tumorigenic	O
.	O

However	O
,	O
by	O
treatment	O
with	O
Ha	O
-	O
ras	O
oncogenes	O
derived	O
from	O
a	O
human	O
lung	O
carcinoma	O
or	O
Harvey	O
murine	O
sarcoma	O
virus	O
,	O
the	O
KMST	B
-	I
6	I
cells	O
acquired	O
elevated	O
clonability	O
in	O
soft	O
agar	O
and	O
transplantability	O
in	O
nude	O
mice	O
.	O

All	O
the	O
tumors	O
produced	O
grew	O
progressively	O
without	O
showing	O
regression	O
and	O
killed	O
the	O
mice	O
.	O

The	O
tumors	O
were	O
also	O
serially	O
transplantable	O
into	O
other	O
mice	O
.	O

The	O
Ha	O
-	O
ras	O
oncogene	O
alone	O
did	O
not	O
convert	O
normal	O
human	O
fibroblasts	O
into	O
either	O
immortal	O
or	O
tumorigenic	O
cells	O
.	O

Our	O
current	O
data	O
suggest	O
that	O
gamma	O
rays	O
worked	O
as	O
an	O
initiator	O
of	O
carcinogenesis	O
in	O
normal	O
human	O
cells	O
,	O
giving	O
rise	O
to	O
chromosome	O
aberrations	O
and	O
immortality	O
,	O
and	O
the	O
Ha	O
-	O
ras	O
oncogene	O
played	O
a	O
role	O
in	O
the	O
progression	O
of	O
the	O
immortally	O
transformed	O
cell	O
population	O
to	O
a	O
neoplastic	O
one	O
showing	O
enhanced	O
colony	O
formation	O
in	O
soft	O
agar	O
and	O
tumorigenicity	O
in	O
nude	O
mice	O
.	O

N	O
-	O
methyl	O
-	O
N	O
-	O
nitrosourea	O
-	O
induced	O
transformation	O
of	O
rat	O
urothelial	O
cells	O
in	O
vitro	O
is	O
not	O
mediated	O
by	O
activation	O
of	O
ras	O
oncogenes	O
.	O

Adult	O
rat	O
urothelial	O
cells	O
were	O
transformed	O
in	O
vitro	O
following	O
treatment	O
with	O
a	O
single	O
dose	O
of	O
N	O
-	O
methyl	O
-	O
N	O
-	O
nitrosourea	O
(	O
MNU	O
)	O
or	O
MNU	O
treatment	O
followed	O
by	O
promotion	O
with	O
sodium	O
saccharin	O
.	O

This	O
in	O
vitro	O
transformation	O
process	O
involves	O
multiple	O
steps	O
:	O
slow	O
-	O
growing	O
'	O
pre	O
-	O
neoplastic	O
'	O
epithelial	O
foci	O
are	O
induced	O
70	O
-	O
100	O
days	O
after	O
MNU	O
treatment	O
and	O
from	O
such	O
foci	O
rapidly	O
proliferating	O
immortal	O
cell	O
lines	O
were	O
established	O
,	O
some	O
of	O
which	O
became	O
tumorigenic	O
after	O
a	O
further	O
latent	O
period	O
.	O

A	O
series	O
of	O
epithelial	O
cell	O
lines	O
and	O
a	O
single	O
fibroblast	O
cell	O
line	O
established	O
in	O
this	O
way	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
transforming	O
genes	O
by	O
DNA	O
transfection	O
into	O
NIH3T3	B
cells	O
.	O

None	O
of	O
the	O
epithelial	O
cell	O
lines	O
induced	O
foci	O
in	O
a	O
focus	O
formation	O
assay	O
.	O

The	O
single	O
non	O
-	O
epithelial	O
line	O
induced	O
foci	O
and	O
was	O
found	O
to	O
contain	O
an	O
activated	O
c	O
-	O
Ki	O
-	O
ras	O
gene	O
with	O
a	O
G	O
-	O
-	O
-	O
-	O
A	O
transition	O
in	O
codon	O
12	O
.	O

To	O
assay	O
for	O
the	O
possible	O
presence	O
of	O
transforming	O
genes	O
which	O
were	O
not	O
active	O
in	O
a	O
focus	O
formation	O
assay	O
,	O
two	O
of	O
the	O
epithelial	O
lines	O
were	O
analysed	O
further	O
by	O
co	O
-	O
transfection	O
with	O
a	O
dominant	O
selectable	O
marker	O
,	O
followed	O
by	O
selection	O
and	O
inoculation	O
into	O
nude	O
mice	O
.	O

No	O
tumours	O
were	O
induced	O
within	O
the	O
latent	O
period	O
for	O
tumour	O
production	O
by	O
control	O
cells	O
transfected	O
with	O
NIH3T3	B
cell	O
DNA	O
(	O
40	O
-	O
60	O
days	O
)	O
.	O

These	O
results	O
suggest	O
that	O
there	O
is	O
cell	O
type	O
specificity	O
for	O
oncogene	O
activation	O
during	O
in	O
vitro	O
rat	O
bladder	O
transformation	O
initiated	O
by	O
a	O
single	O
carcinogen	O
and	O
that	O
ras	O
gene	O
activation	O
is	O
not	O
a	O
necessary	O
step	O
in	O
urothelial	O
transformation	O
in	O
vitro	O
.	O

The	O
posterior	O
tether	O
in	O
scoliosis	O
.	O

The	O
hypothesis	O
that	O
a	O
localized	O
lordosis	O
,	O
or	O
tethering	O
of	O
the	O
posterior	O
elements	O
of	O
the	O
spine	O
,	O
is	O
the	O
primary	O
cause	O
of	O
the	O
vertebral	O
rotation	O
in	O
idiopathic	O
scoliosis	O
was	O
investigated	O
in	O
anatomic	O
specimens	O
of	O
human	O
and	O
calf	O
spinal	O
columns	O
.	O

The	O
specimens	O
were	O
axially	O
loaded	O
with	O
and	O
without	O
a	O
posterior	O
tether	O
created	O
using	O
Zielke	O
instrumentation	O
.	O

Lateral	O
deflection	O
and	O
axial	O
rotation	O
were	O
monitored	O
roentgenographically	O
.	O

The	O
vertebrae	O
of	O
tethered	O
spines	O
showed	O
increased	O
rotation	O
in	O
the	O
direction	O
associated	O
with	O
idiopathic	O
scoliosis	O
.	O

The	O
spinous	O
processes	O
moved	O
toward	O
the	O
concavity	O
at	O
the	O
apex	O
of	O
the	O
induced	O
lateral	O
curve	O
.	O

Conversely	O
,	O
untethered	O
spines	O
either	O
exhibited	O
little	O
rotation	O
or	O
rotated	O
in	O
the	O
opposite	O
direction	O
;	O
the	O
spinous	O
processes	O
moved	O
toward	O
the	O
convexity	O
of	O
the	O
curve	O
.	O

Rotations	O
toward	O
the	O
convexity	O
occur	O
in	O
rotational	O
kyphosis	O
.	O

Thus	O
the	O
hypothesis	O
that	O
idiopathic	O
scoliosis	O
is	O
a	O
rotational	O
lordosis	O
is	O
substantiated	O
;	O
the	O
characteristic	O
rotation	O
can	O
be	O
explained	O
with	O
the	O
aid	O
of	O
a	O
geometric	O
model	O
.	O

Glutamine	O
and	O
glucose	O
as	O
energy	O
substrates	O
for	O
Ehrlich	O
ascites	O
tumour	O
cells	O
.	O

Energy	O
metabolism	O
of	O
freshly	O
harvested	O
Ehrlich	O
ascites	O
tumour	O
cells	O
in	O
the	O
presence	O
of	O
5	O
mM	O
glucose	O
and	O
/	O
or	O
0	O
.	O
5	O
mM	O
glutamine	O
was	O
studied	O
.	O

The	O
rate	O
of	O
oxygen	O
utilization	O
was	O
not	O
altered	O
by	O
the	O
addition	O
of	O
0	O
.	O
5	O
mM	O
glutamine	O
;	O
5	O
mM	O
glucose	O
induced	O
an	O
inhibition	O
of	O
respiration	O
.	O

In	O
the	O
presence	O
of	O
both	O
glucose	O
and	O
glutamine	O
,	O
the	O
Crabtree	O
effect	O
decreased	O
.	O

In	O
these	O
conditions	O
,	O
the	O
rates	O
of	O
oxygen	O
uptake	O
,	O
the	O
CO2	O
evolution	O
and	O
the	O
changes	O
in	O
the	O
redox	O
states	O
of	O
cytochromes	O
indicate	O
that	O
glucose	O
is	O
preferred	O
by	O
Ehrlich	O
ascites	O
tumour	O
cells	O
as	O
energy	O
substrate	O
.	O

Glucose	O
decreased	O
the	O
rate	O
of	O
glutamine	O
utilization	O
by	O
34	O
%	O
.	O

On	O
the	O
other	O
hand	O
,	O
glutaminolysis	O
did	O
not	O
inhibit	O
glycolysis	O
.	O

Sensitivity	O
analysis	O
of	O
the	O
influence	O
of	O
source	O
-	O
term	O
and	O
environmental	O
parameters	O
on	O
the	O
radiological	O
risk	O
of	O
coal	O
-	O
fired	O
plants	O
.	O

A	O
sensitivity	O
analysis	O
was	O
undertaken	O
to	O
determine	O
the	O
influence	O
of	O
different	O
source	O
-	O
term	O
and	O
environmental	O
parameters	O
on	O
the	O
radiological	O
risks	O
from	O
a	O
coal	O
-	O
fired	O
plant	O
(	O
CFP	O
)	O
.	O

It	O
was	O
found	O
that	O
the	O
release	O
rate	O
of	O
radionuclides	O
and	O
the	O
effective	O
release	O
height	O
most	O
significantly	O
influence	O
radiological	O
risk	O
.	O

Site	O
characteristics	O
,	O
such	O
as	O
rain	O
scavenging	O
coefficients	O
and	O
food	O
acquirement	O
habits	O
,	O
have	O
a	O
lesser	O
influence	O
,	O
and	O
some	O
parameters	O
,	O
such	O
as	O
time	O
delay	O
before	O
ingestion	O
of	O
contaminated	O
food	O
,	O
have	O
practically	O
no	O
influence	O
on	O
the	O
radiological	O
impact	O
of	O
a	O
CFP	O
.	O

The	O
contribution	O
to	O
radiation	O
risks	O
of	O
different	O
exposure	O
modes	O
(	O
i	O
.	O
e	O
.	O
inhalation	O
,	O
ingestion	O
and	O
contact	O
with	O
ground	O
surface	O
)	O
were	O
also	O
analyzed	O
,	O
as	O
well	O
as	O
of	O
specific	O
radionuclides	O
and	O
human	O
body	O
organs	O
.	O

Results	O
of	O
the	O
sensitivity	O
analysis	O
were	O
interpreted	O
in	O
terms	O
of	O
the	O
characteristics	O
of	O
the	O
fuel	O
,	O
facilities	O
and	O
site	O
of	O
a	O
CFP	O
.	O

It	O
is	O
concluded	O
that	O
by	O
proper	O
choice	O
of	O
coal	O
,	O
furnace	O
,	O
ash	O
filtration	O
and	O
stack	O
height	O
,	O
as	O
well	O
as	O
by	O
proper	O
siting	O
,	O
the	O
radiological	O
impact	O
of	O
a	O
CFP	O
can	O
be	O
drastically	O
reduced	O
.	O

Cigarette	O
smoking	O
and	O
alveolar	O
bone	O
height	O
in	O
subjects	O
with	O
a	O
high	O
standard	O
of	O
oral	O
hygiene	O
.	O

Smokers	O
and	O
non	O
-	O
smokers	O
were	O
compared	O
with	O
respect	O
to	O
alveolar	O
bone	O
height	O
.	O

The	O
study	O
covered	O
235	O
subjects	O
aged	O
21	O
-	O
60	O
years	O
,	O
72	O
of	O
whom	O
were	O
smokers	O
.	O

Oral	O
hygiene	O
status	O
and	O
dental	O
care	O
habits	O
were	O
above	O
average	O
and	O
of	O
equal	O
standard	O
in	O
both	O
groups	O
(	O
PlI	O
=	O
0	O
.	O
9	O
)	O
.	O

Alveolar	O
bone	O
height	O
was	O
assessed	O
on	O
radiographs	O
and	O
expressed	O
as	O
%	O
of	O
the	O
root	O
length	O
.	O

Alveolar	O
bone	O
height	O
was	O
significantly	O
reduced	O
in	O
smokers	O
as	O
compared	O
to	O
non	O
-	O
smokers	O
,	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
being	O
77	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
3	O
%	O
and	O
82	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
6	O
%	O
,	O
respectively	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Regression	O
analysis	O
suggested	O
that	O
periodontal	O
breakdown	O
judged	O
from	O
loss	O
of	O
alveolar	O
bone	O
over	O
time	O
was	O
more	O
accelerated	O
in	O
smokers	O
than	O
non	O
-	O
smokers	O
.	O

The	O
lower	O
bone	O
height	O
in	O
smokers	O
remained	O
when	O
age	O
and	O
oral	O
hygiene	O
were	O
allowed	O
for	O
.	O

It	O
is	O
concluded	O
that	O
smoking	O
is	O
a	O
risk	O
factor	O
for	O
periodontal	O
health	O
.	O

Growth	O
state	O
-	O
dependent	O
regulation	O
of	O
protein	O
kinase	O
C	O
in	O
normal	O
and	O
transformed	O
murine	O
cells	O
.	O

We	O
determined	O
whether	O
growth	O
state	O
can	O
influence	O
the	O
action	O
of	O
protein	O
kinase	O
C	O
by	O
measuring	O
protein	O
kinase	O
C	O
activity	O
in	O
growing	O
and	O
stationary	O
cultures	O
of	O
normal	O
and	O
transformed	O
cells	O
.	O

Two	O
approaches	O
were	O
used	O
to	O
measure	O
protein	O
kinase	O
C	O
:	O
assay	O
of	O
intact	O
cells	O
for	O
inhibition	O
of	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
binding	O
in	O
response	O
to	O
phorbol	O
dibutyrate	O
(	O
PDBu	O
)	O
;	O
and	O
assay	O
of	O
detergent	O
extracts	O
for	O
total	O
calcium	O
,	O
phospholipid	O
-	O
dependent	O
kinase	O
activity	O
.	O

In	O
extracts	O
of	O
growing	O
and	O
stationary	O
Swiss	B
3T3	I
cells	O
,	O
the	O
total	O
amount	O
of	O
protein	O
kinase	O
C	O
activity	O
was	O
similar	O
,	O
indicating	O
that	O
growth	O
state	O
does	O
not	O
alter	O
the	O
level	O
of	O
enzyme	O
in	O
the	O
cell	O
.	O

The	O
short	O
-	O
term	O
response	O
of	O
Swiss	B
3T3	I
cells	O
to	O
an	O
activator	O
of	O
protein	O
kinase	O
C	O
also	O
appeared	O
to	O
be	O
independent	O
of	O
growth	O
state	O
,	O
since	O
the	O
50	O
%	O
effective	O
dose	O
for	O
PDBu	O
inhibition	O
of	O
EGF	O
binding	O
to	O
its	O
receptor	O
was	O
approximately	O
7	O
nM	O
for	O
both	O
growth	O
conditions	O
.	O

In	O
contrast	O
,	O
the	O
response	O
of	O
cells	O
to	O
long	O
-	O
term	O
treatment	O
with	O
PDBu	O
was	O
significantly	O
different	O
depending	O
upon	O
the	O
initial	O
growth	O
state	O
of	O
the	O
cells	O
.	O

In	O
both	O
growth	O
states	O
,	O
PDBu	O
caused	O
loss	O
of	O
protein	O
kinase	O
C	O
activity	O
,	O
which	O
reflected	O
a	O
loss	O
in	O
protein	O
mass	O
as	O
determined	O
by	O
immunoblotting	O
with	O
antiserum	O
to	O
protein	O
kinase	O
C	O
.	O

However	O
,	O
the	O
maximum	O
decrease	O
approached	O
100	O
%	O
in	O
stationary	O
cultures	O
versus	O
approximately	O
75	O
%	O
in	O
growing	O
cells	O
.	O

Protein	O
kinase	O
C	O
levels	O
in	O
several	O
transformed	O
cell	O
lines	O
were	O
subject	O
to	O
down	O
modulation	O
in	O
a	O
similar	O
growth	O
state	O
-	O
dependent	O
manner	O
.	O

Further	O
,	O
the	O
inhibition	O
of	O
EGF	O
binding	O
by	O
tumor	O
promoters	O
following	O
long	O
-	O
term	O
treatment	O
of	O
Swiss	B
3T3	I
cells	O
with	O
PDBu	O
also	O
varied	O
with	O
growth	O
state	O
.	O

In	O
down	O
modulated	O
growing	O
cells	O
,	O
PDBu	O
caused	O
almost	O
complete	O
inhibition	O
of	O
EGF	O
binding	O
,	O
whereas	O
in	O
down	O
modulated	O
stationary	O
cells	O
,	O
minimal	O
inhibition	O
of	O
EGF	O
binding	O
by	O
PDBu	O
was	O
observed	O
.	O

These	O
results	O
suggest	O
that	O
prolonged	O
treatment	O
with	O
tumor	O
promoters	O
alters	O
the	O
sensitivity	O
of	O
cells	O
to	O
activators	O
of	O
protein	O
kinase	O
C	O
in	O
a	O
growth	O
state	O
-	O
dependent	O
manner	O
.	O

Suppression	O
and	O
re	O
-	O
expression	O
of	O
transformed	O
phenotype	O
in	O
hybrids	O
of	O
HA	O
-	O
ras	O
-	O
1	O
-	O
transformed	O
rat	B
-	I
1	I
cells	O
and	O
early	O
-	O
passage	O
rat	O
embryonic	O
fibroblasts	O
.	O

Rat	B
-	I
1	I
cells	O
which	O
had	O
been	O
transformed	O
with	O
the	O
activated	O
Ha	O
-	O
ras	O
-	O
1	O
gene	O
from	O
human	O
EJ	B
bladder	O
carcinoma	O
cells	O
were	O
fused	O
with	O
diploid	O
embryonic	O
rat	O
fibroblasts	O
.	O

Four	O
selected	O
cell	O
hybrids	O
expressed	O
the	O
human	O
transforming	O
gene	O
product	O
p21	O
at	O
levels	O
of	O
10	O
to	O
30	O
%	O
compared	O
to	O
100	O
%	O
in	O
the	O
transformed	O
parental	O
cells	O
.	O

The	O
hybrid	O
cells	O
,	O
however	O
,	O
exhibited	O
normal	O
morphology	O
,	O
anchorage	O
requirement	O
for	O
proliferation	O
,	O
and	O
largely	O
extended	O
latency	O
periods	O
of	O
tumorigenicity	O
in	O
newborn	O
rats	O
.	O

Tumorigenic	O
hybrid	O
derivatives	O
contained	O
lower	O
numbers	O
of	O
chromosomes	O
than	O
the	O
tetraploid	O
parental	O
hybrids	O
.	O

DNA	O
of	O
the	O
non	O
-	O
tumorigenic	O
cell	O
hybrids	O
transformed	O
Rat	B
-	I
1	I
cells	O
to	O
anchorage	O
-	O
independent	O
proliferation	O
as	O
expected	O
for	O
the	O
transforming	O
human	O
Ha	O
-	O
ras	O
gene	O
present	O
in	O
the	O
donor	O
DNA	O
.	O

We	O
conclude	O
that	O
the	O
transforming	O
properties	O
of	O
the	O
activated	O
Ha	O
-	O
ras	O
gene	O
in	O
Rat	B
-	I
1	I
cells	O
can	O
be	O
suppressed	O
at	O
the	O
post	O
-	O
translational	O
level	O
by	O
the	O
presence	O
of	O
the	O
genome	O
from	O
diploid	O
embryonic	O
rat	O
fibroblasts	O
but	O
additional	O
controls	O
of	O
expression	O
of	O
the	O
transforming	O
gene	O
are	O
likely	O
to	O
exist	O
.	O

Normal	O
cells	O
contain	O
suppressor	O
gene	O
(	O
s	O
)	O
which	O
safeguard	O
these	O
cells	O
against	O
transformation	O
by	O
the	O
product	O
of	O
the	O
transforming	O
Ha	O
-	O
ras	O
-	O
1	O
oncogene	O
.	O

Antishock	O
trousers	O
:	O
a	O
collective	O
review	O
.	O

Antishock	O
trousers	O
have	O
become	O
an	O
integral	O
part	O
of	O
emergency	O
medical	O
care	O
for	O
many	O
traumatic	O
and	O
life	O
-	O
threatening	O
emergencies	O
.	O

This	O
article	O
represents	O
a	O
summary	O
of	O
the	O
current	O
state	O
of	O
knowledge	O
concerning	O
the	O
use	O
of	O
this	O
device	O
.	O

A	O
brief	O
history	O
of	O
the	O
development	O
of	O
antishock	O
garments	O
is	O
discussed	O
.	O

This	O
is	O
followed	O
by	O
a	O
discussion	O
of	O
human	O
clinical	O
studies	O
and	O
results	O
of	O
clinical	O
research	O
on	O
hemodynamics	O
,	O
respiration	O
,	O
use	O
in	O
head	O
injury	O
,	O
and	O
effects	O
on	O
vascular	O
hemostasis	O
.	O

Indications	O
,	O
contraindications	O
,	O
complications	O
,	O
and	O
recommended	O
procedure	O
for	O
use	O
are	O
discussed	O
.	O

Based	O
on	O
randomized	O
prospective	O
studies	O
,	O
antishock	O
garments	O
have	O
not	O
,	O
as	O
yet	O
,	O
been	O
shown	O
to	O
improve	O
patient	O
morbidity	O
or	O
mortality	O
.	O

Proper	O
use	O
of	O
antishock	O
garments	O
requires	O
an	O
understanding	O
of	O
both	O
their	O
function	O
and	O
their	O
limitations	O
.	O

Measurement	O
of	O
serum	O
glycosylated	O
proteins	O
and	O
glycosylated	O
low	O
density	O
lipoprotein	O
fraction	O
in	O
diabetes	O
mellitus	O
.	O

A	O
simple	O
method	O
was	O
developed	O
for	O
estimating	O
serum	O
glycosylated	O
protein	O
levels	O
using	O
gel	O
filtration	O
with	O
Bio	O
-	O
Gel	O
P6	O
by	O
determining	O
the	O
protein	O
and	O
sugar	O
content	O
in	O
the	O
void	O
volume	O
fraction	O
.	O

The	O
glycosylated	O
protein	O
levels	O
(	O
GSP	O
)	O
correlated	O
well	O
with	O
fasting	O
blood	O
sugar	O
levels	O
and	O
glycosylated	O
albumin	O
level	O
(	O
G	O
-	O
ALB	O
)	O
determined	O
by	O
affinity	O
chromatography	O
with	O
Blue	O
Sepharose	O
CL6B	O
.	O

The	O
glycosylation	O
level	O
of	O
heparin	O
-	O
citrate	O
precipitable	O
fraction	O
of	O
serum	O
which	O
predominantly	O
contained	O
low	O
density	O
lipoprotein	O
(	O
G	O
-	O
LDL	O
)	O
also	O
correlated	O
well	O
with	O
GSP	O
and	O
LDL	O
-	O
cholesterol	O
levels	O
.	O

Significantly	O
different	O
values	O
were	O
obtained	O
for	O
GSP	O
,	O
G	O
-	O
ALB	O
,	O
and	O
G	O
-	O
LDL	O
between	O
normals	O
and	O
diabetics	O
.	O

Combined	O
aortic	O
,	O
mitral	O
and	O
tricuspid	O
surgery	O
:	O
results	O
in	O
78	O
patients	O
.	O

Between	O
1968	O
and	O
1984	O
,	O
78	O
patients	O
(	O
mean	O
age	O
43	O
,	O
range	O
14	O
to	O
65	O
years	O
)	O
underwent	O
combined	O
aortic	O
,	O
mitral	O
and	O
tricuspid	O
surgery	O
(	O
22	O
triple	O
valve	O
replacements	O
,	O
56	O
aortic	O
valve	O
replacements	O
with	O
tricuspid	O
conservative	O
surgery	O
and	O
mitral	O
valve	O
replacement	O
(	O
N	O
=	O
48	O
)	O
,	O
or	O
commissuroplasty	O
(	O
N	O
=	O
8	O
)	O
.	O

Pre	O
-	O
operative	O
consequences	O
of	O
valvular	O
disease	O
(	O
mainly	O
mixed	O
valve	O
disease	O
)	O
were	O
severe	O
as	O
assessed	O
by	O
functional	O
class	O
(	O
72	O
pts	O
in	O
III	O
or	O
IV	O
NYHA	O
)	O
,	O
cardiomegaly	O
(	O
CTR	O
:	O
62	O
+	O
/	O
-	O
6	O
%	O
)	O
,	O
increase	O
of	O
mean	O
pulmonary	O
arterial	O
and	O
wedge	O
pressures	O
(	O
respectively	O
30	O
+	O
/	O
-	O
12	O
and	O
19	O
+	O
/	O
-	O
6	O
mmHg	O
)	O
decrease	O
in	O
cardiac	O
index	O
(	O
2	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
5	O
l	O
min	O
-	O
1	O
m	O
-	O
2	O
)	O
,	O
LV	O
dilatation	O
(	O
LV	O
end	O
diastolic	O
volume	O
:	O
184	O
+	O
/	O
-	O
86	O
ml	O
m	O
-	O
2	O
)	O
and	O
impairment	O
of	O
LV	O
systolic	O
function	O
(	O
LV	O
ejection	O
fraction	O
:	O
50	O
+	O
/	O
-	O
12	O
%	O
)	O
.	O

Operative	O
mortality	O
rate	O
was	O
11	O
.	O
5	O
%	O
.	O

The	O
69	O
survivors	O
were	O
all	O
followed	O
up	O
,	O
for	O
a	O
mean	O
of	O
56	O
months	O
(	O
2	O
to	O
207	O
)	O
.	O

16	O
late	O
deaths	O
occurred	O
.	O

Actuarial	O
survival	O
rate	O
at	O
10	O
years	O
was	O
58	O
.	O
4	O
%	O
,	O
and	O
greatly	O
influenced	O
by	O
pre	O
-	O
operative	O
NYHA	O
class	O
.	O

Linearized	O
rates	O
of	O
thromboembolic	O
events	O
,	O
valve	O
thrombosis	O
and	O
haemorrhage	O
were	O
respectively	O
6	O
.	O
4	O
,	O
1	O
.	O
5	O
and	O
1	O
.	O
2	O
%	O
pt	O
-	O
1	O
yr	O
-	O
1	O
.	O

Those	O
of	O
infective	O
endocarditis	O
,	O
periprosthetic	O
leak	O
,	O
reoperation	O
and	O
valve	O
failure	O
were	O
0	O
.	O
6	O
,	O
3	O
.	O
3	O
and	O
4	O
.	O
9	O
%	O
pt	O
-	O
1	O
yr	O
-	O
1	O
respectively	O
.	O

At	O
9	O
years	O
,	O
42	O
%	O
of	O
the	O
patients	O
were	O
in	O
NYHA	O
class	O
I	O
or	O
II	O
and	O
free	O
from	O
complications	O
.	O

Torsade	O
de	O
pointes	O
during	O
loading	O
with	O
amiodarone	O
.	O

Torsade	O
de	O
pointes	O
represents	O
a	O
potential	O
complication	O
of	O
chronic	O
amiodarone	O
therapy	O
.	O

Several	O
reports	O
have	O
emphasized	O
the	O
need	O
for	O
a	O
loading	O
dose	O
in	O
order	O
to	O
achieve	O
therapeutic	O
blood	O
levels	O
rapidly	O
.	O

We	O
report	O
a	O
case	O
of	O
torsade	O
de	O
pointes	O
following	O
a	O
single	O
oral	O
dose	O
of	O
amiodarone	O
(	O
1400	O
mg	O
or	O
30	O
mg	O
kg	O
-	O
1	O
)	O
administered	O
after	O
short	O
intravenous	O
loading	O
for	O
prevention	O
of	O
paroxysmal	O
atrial	O
flutter	O
.	O

Torsades	O
de	O
pointes	O
were	O
preceded	O
and	O
associated	O
with	O
marked	O
QT	O
prolongation	O
and	O
bradycardia	O
.	O

This	O
report	O
suggests	O
that	O
careful	O
monitoring	O
of	O
patients	O
undergoing	O
oral	O
amiodarone	O
loading	O
is	O
necessary	O
.	O

Conjunctival	O
hypoxia	O
in	O
diabetes	O
mellitus	O
.	O

A	O
frequently	O
cited	O
theory	O
for	O
the	O
pathogenesis	O
of	O
neovascularization	O
in	O
diabetic	O
retinopathy	O
is	O
that	O
retinal	O
hypoxia	O
and	O
/	O
or	O
ischemia	O
release	O
a	O
factor	O
which	O
stimulates	O
neovascularization	O
.	O

To	O
the	O
authors	O
'	O
knowledge	O
,	O
there	O
is	O
no	O
direct	O
in	O
vivo	O
evidence	O
in	O
the	O
human	O
proving	O
this	O
theory	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
two	O
diabetic	O
subjects	O
were	O
studied	O
to	O
see	O
whether	O
worsening	O
retinopathy	O
was	O
associated	O
with	O
changes	O
in	O
conjunctival	O
oxygen	O
tension	O
(	O
pO2	O
)	O
.	O

Diabetics	O
without	O
retinopathy	O
had	O
a	O
conjunctival	O
pO2	O
which	O
was	O
similar	O
to	O
an	O
age	O
-	O
matched	O
normal	O
population	O
.	O

Diabetics	O
with	O
only	O
background	O
retinopathy	O
had	O
a	O
significantly	O
lower	O
conjunctival	O
pO2	O
than	O
those	O
without	O
retinopathy	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Diabetics	O
with	O
proliferative	O
retinopathy	O
showed	O
a	O
conjunctival	O
pO2	O
that	O
was	O
significantly	O
lower	O
than	O
either	O
of	O
the	O
first	O
two	O
groups	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
lowest	O
value	O
of	O
all	O
was	O
found	O
in	O
patients	O
with	O
rubeosis	O
iridis	O
.	O

Duration	O
of	O
diabetes	O
alone	O
did	O
not	O
correlate	O
significantly	O
to	O
conjunctival	O
pO2	O
.	O

These	O
findings	O
support	O
the	O
hypoxic	O
theory	O
of	O
diabetic	O
neovascular	O
retinopathy	O
.	O

Unsatisfactory	O
forehead	O
scar	O
following	O
face	O
lift	O
.	O

The	O
W	O
-	O
plasty	O
scar	O
revision	O
technique	O
has	O
been	O
found	O
to	O
be	O
effective	O
in	O
the	O
repair	O
of	O
the	O
difficult	O
and	O
cosmetically	O
unsatisfactory	O
hairline	O
scar	O
following	O
the	O
ill	O
-	O
advised	O
face	O
lift	O
technique	O
that	O
excises	O
forehead	O
skin	O
.	O

Clinical	O
evaluation	O
of	O
radiotherapy	O
for	O
Graves	O
'	O
ophthalmopathy	O
.	O

Seventeen	O
patients	O
with	O
moderately	O
severe	O
ophthalmopathy	O
due	O
to	O
Graves	O
'	O
disease	O
were	O
treated	O
by	O
cobalt	O
or	O
supervoltage	O
radiotherapy	O
.	O

All	O
patients	O
complained	O
of	O
diplopia	O
.	O

The	O
mean	O
proptosis	O
value	O
was	O
21	O
.	O
4	O
mm	O
.	O

Three	O
patients	O
(	O
18	O
%	O
)	O
showed	O
good	O
response	O
,	O
7	O
(	O
41	O
%	O
)	O
moderate	O
and	O
7	O
minimal	O
or	O
no	O
response	O
.	O

Improvement	O
was	O
noted	O
mainly	O
in	O
soft	O
tissue	O
changes	O
and	O
diplopia	O
,	O
while	O
proptosis	O
decreased	O
in	O
only	O
5	O
patients	O
.	O

All	O
except	O
one	O
patient	O
who	O
had	O
marked	O
extraocular	O
muscle	O
involvement	O
revealed	O
by	O
computed	O
tomography	O
responded	O
to	O
treatment	O
.	O

These	O
data	O
indicate	O
that	O
radiotherapy	O
may	O
be	O
indicated	O
in	O
patients	O
with	O
progressive	O
ophthalmopathy	O
,	O
especially	O
in	O
those	O
who	O
are	O
associated	O
with	O
extraocular	O
muscle	O
enlargement	O
.	O

The	O
origin	O
of	O
yolk	O
-	O
DNA	O
in	O
Xenopus	O
laevis	O
.	O

Xenopus	O
laevis	O
serum	O
and	O
plasma	O
was	O
found	O
to	O
contain	O
an	O
average	O
of	O
25	O
microgram	O
DNA	O
/	O
ml	O
.	O

Isolated	O
X	O
.	O
laevis	O
oocytes	O
incubated	O
in	O
medium	O
containing	O
25	O
microgram	O
DNA	O
/	O
ml	O
labeled	O
with	O
either	O
125I	O
,	O
32P	O
or	O
14C	O
and	O
from	O
three	O
different	O
sources	O
(	O
bovine	O
,	O
E	O
.	O
coli	O
and	O
X	O
.	O
laevis	O
)	O
,	O
incorporated	O
the	O
label	O
at	O
an	O
average	O
rate	O
of	O
0	O
.	O
11	O
ng	O
.	O
mm	O
-	O
2	O
.	O
hr	O
-	O
1	O
.	O

Sucrose	O
gradient	O
fractionation	O
of	O
oocytes	O
revealed	O
that	O
40	O
-	O
75	O
%	O
of	O
the	O
acid	O
-	O
precipitable	O
label	O
incorporated	O
was	O
associated	O
with	O
the	O
yolk	O
platelets	O
.	O

Additional	O
incubations	O
of	O
oocytes	O
in	O
unlabeled	O
medium	O
demonstrated	O
that	O
the	O
DNA	O
incorporated	O
into	O
the	O
yolk	O
platelets	O
was	O
undergoing	O
turnover	O
;	O
only	O
20	O
%	O
of	O
the	O
yolk	O
-	O
associated	O
DNA	O
was	O
still	O
present	O
after	O
a	O
one	O
-	O
week	O
incubation	O
.	O

Our	O
data	O
suggest	O
that	O
yolk	O
-	O
DNA	O
arises	O
by	O
the	O
adventitious	O
uptake	O
of	O
DNA	O
present	O
in	O
the	O
maternal	O
serum	O
by	O
vitellogenic	O
oocytes	O
.	O

New	O
functions	O
of	O
epidermal	O
growth	O
factor	O
:	O
stimulation	O
of	O
capillary	O
endothelial	O
cell	O
migration	O
and	O
matrix	O
dependent	O
proliferation	O
.	O

The	O
proliferative	O
response	O
of	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
to	O
EGF	O
is	O
dependent	O
upon	O
attaching	O
the	O
cells	O
to	O
a	O
matrix	O
of	O
fibronectin	O
.	O

Bovine	O
capillary	O
endothelial	O
cells	O
are	O
also	O
stimulated	O
to	O
actively	O
migrate	O
when	O
exposed	O
to	O
EGF	O
in	O
vitro	O
.	O

These	O
activities	O
provide	O
an	O
explanation	O
for	O
the	O
angiogenic	O
properties	O
of	O
EGF	O
in	O
vivo	O
.	O

Capillary	O
cell	O
migration	O
and	O
proliferation	O
are	O
proposed	O
as	O
sensitive	O
quantifiable	O
bioassays	O
to	O
explore	O
the	O
functional	O
domains	O
of	O
the	O
EGF	O
molecule	O
.	O

Studies	O
on	O
the	O
inactivation	O
of	O
these	O
properties	O
of	O
EGF	O
by	O
specific	O
cleavage	O
of	O
the	O
molecule	O
with	O
CNBr	O
or	O
proteases	O
suggest	O
that	O
an	O
intact	O
loop	O
composed	O
in	O
part	O
by	O
amino	O
acid	O
residues	O
20	O
to	O
31	O
is	O
essential	O
for	O
at	O
least	O
some	O
functions	O
.	O

The	O
effect	O
of	O
aflatoxin	O
B1	O
on	O
the	O
utilization	O
of	O
serum	O
calcium	O
.	O

The	O
mathematical	O
analysis	O
for	O
plasma	O
disappearance	O
curve	O
of	O
aflatoxicosed	O
animals	O
,	O
subsequently	O
injected	O
with	O
45Ca	O
was	O
determined	O
.	O

The	O
analysis	O
showed	O
that	O
the	O
three	O
main	O
compartments	O
of	O
the	O
calcium	O
pool	O
(	O
plasma	O
,	O
bone	O
and	O
the	O
labile	O
calcium	O
pool	O
on	O
the	O
surface	O
of	O
bone	O
and	O
soft	O
tissues	O
)	O
had	O
been	O
affected	O
.	O

Specifically	O
,	O
the	O
fractional	O
rate	O
constant	O
for	O
migration	O
of	O
45Ca	O
from	O
plasma	O
pool	O
to	O
the	O
labile	O
pool	O
had	O
been	O
diminished	O
to	O
its	O
third	O
value	O
.	O

This	O
led	O
to	O
a	O
corresponding	O
reduction	O
in	O
the	O
calcium	O
content	O
of	O
the	O
bone	O
ash	O
.	O

The	O
probable	O
mechanism	O
by	O
which	O
aflatoxin	O
B1	O
affects	O
calcium	O
dynamics	O
may	O
be	O
interpreted	O
by	O
the	O
inhibitory	O
effect	O
of	O
aflatoxin	O
in	O
the	O
hydroxylation	O
mechanism	O
of	O
vitamin	O
D3	O
into	O
an	O
active	O
intermediate	O
.	O

During	O
aflatoxicosis	O
(	O
induction	O
of	O
15	O
days	O
)	O
the	O
animals	O
entered	O
a	O
state	O
of	O
calcium	O
deficiency	O
,	O
secondary	O
to	O
intestinal	O
absorption	O
inhibition	O
.	O

This	O
was	O
followed	O
by	O
bone	O
resorption	O
and	O
disturbance	O
of	O
the	O
fractional	O
removal	O
rate	O
constant	O
among	O
different	O
calcium	O
compartments	O
.	O

Low	O
-	O
level	O
X	O
-	O
radiation	O
effects	O
on	O
functional	O
vascular	O
changes	O
in	O
Syrian	O
hamster	O
cheek	O
pouch	O
epithelium	O
during	O
hydrocarbon	O
carcinogenesis	O
.	O

Effects	O
of	O
repeated	O
low	O
-	O
level	O
X	O
radiation	O
on	O
functional	O
microvascular	O
changes	O
in	O
hamster	O
cheek	O
pouch	O
epithelium	O
during	O
and	O
following	O
carcinogenesis	O
by	O
7	O
,	O
12	O
-	O
dimethylbenz	O
[	O
a	O
]	O
anthracene	O
(	O
DMBA	O
)	O
were	O
studied	O
.	O

Prior	O
studies	O
showed	O
enhancement	O
of	O
such	O
carcinogenesis	O
by	O
repeated	O
20	O
rad	O
head	O
and	O
neck	O
X	O
-	O
radiation	O
exposures	O
,	O
and	O
it	O
was	O
proposed	O
that	O
one	O
possible	O
mechanism	O
was	O
radiogenic	O
alteration	O
of	O
the	O
functional	O
microvasculature	O
in	O
a	O
manner	O
which	O
favored	O
subsequent	O
tumor	O
development	O
.	O

Hamsters	O
were	O
treated	O
with	O
either	O
radiation	O
,	O
DMBA	O
,	O
radiation	O
+	O
DMBA	O
,	O
or	O
no	O
treatment	O
.	O

Animals	O
were	O
sacrificed	O
at	O
3	O
-	O
week	O
intervals	O
from	O
0	O
to	O
39	O
weeks	O
after	O
treatments	O
began	O
.	O

Pouch	O
vascular	O
volume	O
and	O
permeability	O
changes	O
were	O
studied	O
by	O
fractional	O
distributions	O
of	O
radiotracers	O
and	O
were	O
analyzed	O
by	O
a	O
variety	O
of	O
statistical	O
methods	O
which	O
explored	O
the	O
vascular	O
parameters	O
,	O
treatment	O
types	O
,	O
elapsed	O
time	O
,	O
presence	O
of	O
the	O
carcinogen	O
,	O
and	O
histopathologic	O
changes	O
.	O

All	O
treatments	O
resulted	O
in	O
significant	O
changes	O
in	O
vascular	O
volume	O
with	O
time	O
,	O
while	O
only	O
DMBA	O
treatments	O
alone	O
resulted	O
in	O
significant	O
changes	O
in	O
vascular	O
permeability	O
with	O
time	O
.	O

Prior	O
to	O
the	O
appearances	O
of	O
frank	O
neoplasms	O
,	O
volumetric	O
changes	O
in	O
DMBA	O
only	O
and	O
radiation	O
only	O
groups	O
were	O
similar	O
,	O
while	O
volume	O
changes	O
in	O
DMBA	O
+	O
radiation	O
groups	O
increased	O
slowly	O
to	O
a	O
peak	O
later	O
than	O
in	O
other	O
groups	O
and	O
then	O
declined	O
steadily	O
to	O
levels	O
similar	O
to	O
the	O
radiation	O
only	O
group	O
.	O

As	O
in	O
prior	O
studies	O
,	O
there	O
were	O
significant	O
vascular	O
volume	O
differences	O
between	O
DMBA	O
and	O
DMBA	O
+	O
radiation	O
groups	O
of	O
tumor	O
-	O
bearing	O
cheek	O
pouches	O
.	O

DMBA	O
maxima	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
DMBA	O
+	O
radiation	O
.	O

Radiation	O
significantly	O
affected	O
DMBA	O
-	O
associated	O
vascular	O
volume	O
and	O
permeability	O
changes	O
during	O
carcinogenesis	O
.	O

Several	O
possible	O
explanations	O
for	O
the	O
relationship	O
of	O
these	O
changes	O
to	O
the	O
enhancement	O
of	O
DMBA	O
carcinogenesis	O
include	O
:	O
radiation	O
blocking	O
normal	O
capillary	O
proliferative	O
and	O
/	O
or	O
dilatory	O
responses	O
to	O
inflammation	O
secondary	O
to	O
neoplastic	O
changes	O
;	O
radiation	O
-	O
induced	O
focal	O
increases	O
in	O
the	O
pericapillary	O
connective	O
tissue	O
histohematic	O
barrier	O
,	O
stimulating	O
angiogenesis	O
but	O
reducing	O
nutrient	O
diffusion	O
;	O
radiation	O
exposures	O
sensitizing	O
vascular	O
endothelium	O
to	O
subsequent	O
angiogenic	O
stimulation	O
from	O
premalignant	O
tissues	O
;	O
DMBA	O
vascular	O
and	O
epithelial	O
effects	O
partially	O
or	O
completely	O
blocking	O
radiation	O
effects	O
on	O
epithelial	O
and	O
/	O
or	O
endothelial	O
cells	O
;	O
and	O
radiation	O
damage	O
to	O
vessel	O
walls	O
partially	O
or	O
fully	O
inhibiting	O
normal	O
physiologic	O
mechanisms	O
of	O
repairing	O
DMBA	O
damage	O
to	O
the	O
vessels	O
.	O

Immunoglobulins	O
associated	O
with	O
elevated	O
riboflavin	O
binding	O
by	O
plasma	O
from	O
cancer	O
patients	O
.	O

Plasma	O
from	O
182	O
patients	O
with	O
different	O
malignant	O
diseases	O
was	O
tested	O
for	O
riboflavin	O
binding	O
by	O
immunoglobulins	O
,	O
which	O
have	O
been	O
recently	O
identified	O
as	O
major	O
carriers	O
of	O
this	O
micronutrient	O
.	O

A	O
wide	O
range	O
of	O
binding	O
(	O
5	O
.	O
9	O
to	O
130	O
pmole	O
/	O
ml	O
plasma	O
)	O
was	O
observed	O
,	O
and	O
significant	O
elevations	O
were	O
found	O
for	O
patients	O
having	O
breast	O
cancer	O
(	O
21	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
9	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
melanoma	O
(	O
25	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
9	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
compared	O
to	O
controls	O
(	O
15	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
9	O
)	O
.	O

The	O
proteins	O
responsible	O
for	O
a	O
majority	O
of	O
the	O
higher	O
binding	O
were	O
identified	O
as	O
immunoglobulins	O
,	O
based	O
on	O
their	O
elution	O
from	O
gel	O
filtration	O
columns	O
and	O
the	O
removal	O
of	O
57	O
-	O
88	O
%	O
of	O
the	O
non	O
-	O
albumin	O
binding	O
by	O
treating	O
of	O
plasma	O
with	O
Protein	O
A	O
-	O
agarose	O
.	O

The	O
binding	O
was	O
only	O
weakly	O
related	O
to	O
the	O
total	O
concentration	O
of	O
immunoglobulins	O
(	O
r	O
=	O
0	O
.	O
11	O
by	O
linear	O
regression	O
analysis	O
)	O
,	O
however	O
,	O
and	O
is	O
apparently	O
due	O
to	O
a	O
subclass	O
that	O
is	O
elevated	O
in	O
some	O
types	O
of	O
cancer	O
.	O

Elevated	O
levels	O
of	O
these	O
immunoglobulins	O
may	O
contribute	O
to	O
the	O
lower	O
urinary	O
levels	O
and	O
clearance	O
of	O
riboflavin	O
in	O
cancer	O
.	O

Mast	O
cells	O
and	O
tumors	O
.	O

The	O
specific	O
enhancement	O
of	O
tumor	O
proliferation	O
in	O
vitro	O
.	O

Mast	O
cells	O
were	O
found	O
to	O
be	O
unique	O
among	O
the	O
peritoneal	O
leukocytes	O
by	O
virtue	O
of	O
their	O
capacity	O
to	O
enhance	O
profoundly	O
the	O
proliferation	O
of	O
a	O
variety	O
of	O
tumors	O
in	O
vitro	O
.	O

This	O
phenomenon	O
occurs	O
at	O
mast	O
cell	O
/	O
tumor	O
ratios	O
which	O
reflect	O
the	O
stoichiometry	O
of	O
host	O
cell	O
/	O
tumor	O
relationships	O
in	O
vivo	O
.	O

The	O
growth	O
factor	O
was	O
found	O
to	O
reside	O
in	O
mast	O
cell	O
granules	O
and	O
was	O
identified	O
as	O
heparin	O
by	O
sequential	O
purification	O
and	O
enzymatic	O
degradation	O
.	O

This	O
cellular	O
interaction	O
was	O
tumor	O
-	O
specific	O
,	O
although	O
isolated	O
granules	O
could	O
enhance	O
fibroblast	O
proliferation	O
.	O

The	O
findings	O
are	O
discussed	O
in	O
relation	O
to	O
previous	O
morphologic	O
studies	O
,	O
reports	O
of	O
in	O
vitro	O
mast	O
-	O
cell	O
-	O
mediated	O
tumor	O
cytotoxicity	O
,	O
and	O
the	O
role	O
of	O
mast	O
cells	O
in	O
angiogenesis	O
and	O
connective	O
tissue	O
proliferation	O
.	O

Management	O
of	O
the	O
tortuous	O
internal	O
carotid	O
artery	O
.	O

The	O
tortuous	O
internal	O
carotid	O
artery	O
as	O
the	O
basis	O
of	O
cerebral	O
vascular	O
insufficiency	O
is	O
a	O
controversial	O
entity	O
,	O
as	O
such	O
lesions	O
frequently	O
occur	O
without	O
neurologic	O
symptoms	O
.	O

However	O
,	O
some	O
tortuous	O
vessels	O
are	O
associated	O
with	O
significant	O
carotid	O
atherosclerotic	O
disease	O
requiring	O
a	O
specific	O
surgical	O
approach	O
.	O

This	O
formed	O
the	O
basis	O
of	O
our	O
report	O
.	O

Symptoms	O
of	O
cerebrovascular	O
insufficiency	O
in	O
association	O
with	O
a	O
tortuous	O
internal	O
carotid	O
artery	O
was	O
encountered	O
in	O
27	O
of	O
853	O
carotid	O
endarterectomies	O
over	O
a	O
22	O
year	O
period	O
.	O

Stenosis	O
of	O
hemodynamic	O
significance	O
was	O
noted	O
in	O
nine	O
patients	O
and	O
irregularities	O
or	O
ulceration	O
were	O
noted	O
in	O
the	O
rest	O
.	O

With	O
the	O
standard	O
technique	O
of	O
carotid	O
endarterectomy	O
,	O
removal	O
of	O
plaque	O
from	O
a	O
tortuous	O
vessel	O
leads	O
to	O
loss	O
of	O
the	O
stenting	O
effect	O
provided	O
by	O
the	O
plaque	O
such	O
that	O
angulation	O
occlusion	O
is	O
likely	O
to	O
occur	O
.	O

The	O
optimal	O
reconstruction	O
in	O
our	O
experience	O
is	O
eversion	O
endarterectomy	O
by	O
transection	O
and	O
lower	O
reimplantation	O
of	O
the	O
internal	O
carotid	O
artery	O
on	O
the	O
common	O
carotid	O
artery	O
.	O

Our	O
experience	O
with	O
17	O
such	O
procedures	O
in	O
15	O
patients	O
has	O
been	O
presented	O
.	O

Postpartum	O
rubella	O
immunization	O
:	O
association	O
with	O
development	O
of	O
prolonged	O
arthritis	O
,	O
neurological	O
sequelae	O
,	O
and	O
chronic	O
rubella	O
viremia	O
.	O

Six	O
women	O
developed	O
chronic	O
long	O
-	O
term	O
arthropathy	O
after	O
postpartum	O
immunization	O
against	O
rubella	O
.	O

All	O
individuals	O
developed	O
acute	O
polyarticular	O
arthritis	O
within	O
12	O
days	O
to	O
three	O
weeks	O
postimmunization	O
and	O
have	O
had	O
continuing	O
chronic	O
or	O
recurrent	O
arthralgia	O
or	O
arthritis	O
for	O
two	O
to	O
seven	O
years	O
after	O
vaccination	O
.	O

Acute	O
neurological	O
manifestations	O
,	O
consisting	O
of	O
carpal	O
tunnel	O
syndrome	O
or	O
multiple	O
paresthesiae	O
,	O
developed	O
postvaccination	O
in	O
three	O
women	O
.	O

Two	O
have	O
developed	O
continuing	O
active	O
or	O
chronic	O
recurrent	O
episodes	O
of	O
blurred	O
vision	O
,	O
paresthesiae	O
,	O
and	O
painful	O
limb	O
syndromes	O
together	O
with	O
recurrent	O
joint	O
symptoms	O
.	O

Chronic	O
rubella	O
viremia	O
has	O
been	O
detected	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
(	O
MNC	O
)	O
populations	O
in	O
five	O
of	O
the	O
six	O
women	O
up	O
to	O
six	O
years	O
after	O
vaccination	O
.	O

In	O
addition	O
rubella	O
virus	O
was	O
isolated	O
from	O
breast	O
milk	O
MNCs	O
in	O
one	O
individual	O
at	O
nine	O
months	O
postvaccination	O
and	O
from	O
peripheral	O
blood	O
MNCs	O
in	O
two	O
of	O
four	O
breast	O
-	O
fed	O
infants	O
studied	O
at	O
12	O
-	O
18	O
months	O
of	O
age	O
.	O

Immune	O
responses	O
to	O
rubella	O
virus	O
studied	O
at	O
sequential	O
intervals	O
after	O
vaccination	O
correlated	O
with	O
development	O
of	O
rheumatologic	O
and	O
neurological	O
manifestations	O
.	O

Rapid	O
enzyme	O
analysis	O
of	O
amniotic	O
fluid	O
phospholipids	O
containing	O
choline	O
:	O
a	O
comparison	O
with	O
the	O
lecithin	O
to	O
sphingomyelin	O
ratio	O
in	O
prenatal	O
assessment	O
of	O
fetal	O
lung	O
maturity	O
.	O

The	O
relation	O
between	O
the	O
choline	O
containing	O
surfactant	O
phospholipids	O
lecithin	O
and	O
sphingomyelin	O
in	O
amniotic	O
fluid	O
and	O
fetal	O
lung	O
maturity	O
is	O
well	O
established	O
.	O

An	O
enzymatic	O
method	O
that	O
had	O
been	O
automated	O
and	O
optimised	O
for	O
use	O
on	O
a	O
centrifugal	O
analyser	O
was	O
used	O
to	O
measure	O
the	O
total	O
choline	O
containing	O
phospholipids	O
in	O
amniotic	O
fluid	O
.	O

The	O
total	O
time	O
taken	O
for	O
this	O
assay	O
was	O
10	O
minutes	O
.	O

The	O
results	O
obtained	O
from	O
100	O
patient	O
samples	O
,	O
using	O
this	O
procedure	O
,	O
compared	O
favourably	O
with	O
the	O
results	O
obtained	O
by	O
the	O
thin	O
layer	O
chromatography	O
procedure	O
used	O
to	O
determine	O
the	O
lecithin	O
to	O
sphingomyelin	O
ratio	O
(	O
r	O
=	O
0	O
.	O
93	O
)	O
.	O

A	O
clinical	O
study	O
of	O
60	O
patients	O
showed	O
that	O
this	O
assay	O
predicted	O
prenatal	O
respiratory	O
distress	O
syndrome	O
as	O
well	O
as	O
the	O
lecithin	O
to	O
sphingomyelin	O
ratios	O
.	O

The	O
advantage	O
of	O
this	O
assay	O
over	O
existing	O
procedures	O
is	O
that	O
it	O
requires	O
minimum	O
preparation	O
of	O
the	O
specimen	O
and	O
no	O
extraction	O
,	O
is	O
quick	O
,	O
and	O
shows	O
a	O
high	O
degree	O
of	O
precision	O
.	O

[	O
Histophysiology	O
and	O
histopathology	O
of	O
the	O
adrenals	O
in	O
experimental	O
hypokinesia	O
]	O
.	O

In	O
experiments	O
on	O
male	O
rats	O
in	O
the	O
course	O
of	O
3	O
-	O
month	O
hypokinesia	O
phasic	O
changes	O
were	O
observed	O
in	O
the	O
relative	O
adrenal	O
gland	O
weight	O
,	O
in	O
the	O
volume	O
of	O
the	O
cell	O
nuclei	O
of	O
the	O
glomerular	O
,	O
fasicular	O
zones	O
and	O
the	O
medulla	O
,	O
in	O
the	O
activity	O
of	O
the	O
succinic	O
dehydrogenase	O
,	O
alkaline	O
and	O
acid	O
phosphatases	O
,	O
in	O
the	O
RNA	O
and	O
catecholamine	O
content	O
.	O

These	O
changes	O
are	O
associated	O
with	O
variations	O
in	O
the	O
secretion	O
and	O
biosynthesis	O
of	O
the	O
hormones	O
of	O
the	O
cortical	O
and	O
the	O
medullary	O
layer	O
of	O
the	O
adrenal	O
glands	O
during	O
the	O
hypokinetic	O
stress	O
development	O
.	O

Cardiac	O
gap	O
junction	O
configuration	O
after	O
an	O
uncoupling	O
treatment	O
as	O
a	O
function	O
of	O
time	O
.	O

Rabbit	O
ventricle	O
either	O
was	O
fixed	O
in	O
glutaraldehyde	O
without	O
injury	O
(	O
control	O
)	O
or	O
was	O
injured	O
before	O
fixation	O
,	O
presumably	O
causing	O
electrical	O
uncoupling	O
of	O
the	O
gap	O
junctions	O
.	O

All	O
tissue	O
was	O
then	O
processed	O
for	O
freeze	O
-	O
fracture	O
.	O

Replicas	O
of	O
control	O
gap	O
junctions	O
exhibited	O
irregular	O
packing	O
of	O
the	O
P	O
-	O
face	O
particles	O
and	O
E	O
-	O
face	O
pits	O
.	O

Average	O
center	O
-	O
to	O
-	O
center	O
spacing	O
of	O
the	O
particles	O
was	O
10	O
.	O
5	O
nm	O
.	O

Tissue	O
fixed	O
1	O
-	O
5	O
min	O
after	O
injury	O
showed	O
clumping	O
of	O
gap	O
junctional	O
particles	O
and	O
pits	O
.	O

Within	O
the	O
clumps	O
,	O
the	O
particles	O
and	O
pits	O
were	O
hexagonally	O
packed	O
and	O
the	O
center	O
-	O
to	O
-	O
center	O
spacing	O
of	O
the	O
particles	O
averaged	O
9	O
.	O
5	O
nm	O
.	O

In	O
tissue	O
fixed	O
15	O
-	O
30	O
min	O
after	O
injury	O
,	O
the	O
clumps	O
of	O
gap	O
junctional	O
particles	O
had	O
coalesced	O
into	O
a	O
homogeneous	O
structure	O
in	O
most	O
junctions	O
.	O

The	O
packing	O
of	O
the	O
particles	O
and	O
pits	O
was	O
hexagonal	O
and	O
the	O
spacing	O
of	O
the	O
particles	O
averaged	O
9	O
.	O
5	O
nm	O
.	O

A	O
few	O
pieces	O
of	O
rabbit	O
atrium	O
were	O
frozen	O
without	O
prior	O
fixation	O
or	O
cryoprotection	O
to	O
try	O
to	O
assess	O
the	O
effect	O
of	O
glutarldehyde	O
fixation	O
on	O
gap	O
junction	O
structure	O
.	O

In	O
this	O
tissue	O
the	O
gap	O
junctional	O
particles	O
were	O
irregularly	O
packed	O
and	O
their	O
spacing	O
averaged	O
10	O
.	O
0	O
nm	O
.	O

Absence	O
of	O
effect	O
of	O
prenatal	O
ethanol	O
on	O
adult	O
emotionality	O
and	O
ethanol	O
consumption	O
in	O
rats	O
.	O

Lower	O
peak	O
blood	O
ethanol	O
concentrations	O
after	O
1	O
and	O
2	O
g	O
of	O
ethanol	O
per	O
kg	O
were	O
found	O
in	O
pregnant	O
rats	O
than	O
in	O
virgin	O
females	O
.	O

No	O
significant	O
differences	O
in	O
adult	O
""""	O
emotionality	O
""""	O
or	O
ethanol	O
consumption	O
were	O
found	O
in	O
rats	O
exposed	O
to	O
prenatal	O
alcohol	O
and	O
in	O
pair	O
-	O
fed	O
and	O
untreated	O
controls	O
.	O

Tropical	O
splenomegaly	O
syndrome	O
in	O
Zambia	O
:	O
further	O
observations	O
and	O
effects	O
of	O
cycloguanil	O
and	O
proguanil	O
.	O

Nineteen	O
Zambian	O
patients	O
with	O
the	O
tropical	O
splenomegaly	O
syndrome	O
and	O
sinusoidal	O
lymphocytosis	O
on	O
liver	O
biopsy	O
were	O
studied	O
.	O

The	O
association	O
of	O
macrobulinaemia	O
with	O
the	O
tropical	O
splenomegaly	O
syndrome	O
has	O
again	O
been	O
confirmed	O
.	O

Sixteen	O
patients	O
were	O
treated	O
with	O
antimalarials	O
-	O
12	O
with	O
cycloguanil	O
pamoate	O
alone	O
,	O
3	O
with	O
cycloguanil	O
and	O
proguanil	O
,	O
and	O
1	O
with	O
proguanil	O
alone	O
.	O

Twelve	O
patients	O
were	O
observed	O
for	O
periods	O
of	O
sufficient	O
length	O
for	O
the	O
drug	O
effect	O
to	O
be	O
assessed	O
,	O
and	O
in	O
11	O
there	O
was	O
a	O
good	O
response	O
in	O
terms	O
of	O
decrease	O
in	O
spleen	O
size	O
.	O
Cycloguanil	O
pamoate	O
may	O
be	O
of	O
value	O
both	O
for	O
prophylaxis	O
and	O
treatment	O
in	O
areas	O
where	O
tropical	O
splenomegaly	O
syndrome	O
is	O
endemic	O
.	O

Regulation	O
of	O
glucosyl	O
-	O
and	O
fructosyltransferase	O
synthesis	O
by	O
continuous	O
cultures	O
of	O
Streptococcus	O
mutans	O
.	O

Streptococcus	O
mutans	O
strains	O
Ingbritt	O
,	O
and	O
its	O
derivative	O
B7	O
which	O
had	O
been	O
passaged	O
through	O
monkeys	O
,	O
have	O
been	O
used	O
to	O
investigate	O
how	O
the	O
synthesis	O
of	O
extracellular	O
glucosyl	O
-	O
and	O
fructosyltransferases	O
is	O
regulated	O
.	O

The	O
most	O
active	O
enzyme	O
from	O
carbon	O
-	O
limited	O
continuous	O
cultures	O
was	O
a	O
fructosyltransferase	O
;	O
enzymes	O
catalysing	O
the	O
formation	O
of	O
water	O
-	O
insoluble	O
glucans	O
from	O
sucrose	O
were	O
relatively	O
inactive	O
.	O

Dextransucrase	O
(	O
EC	O
2	O
.	O
4	O
.	O
1	O
.	O
5	O
)	O
,	O
which	O
catalyses	O
soluble	O
glucan	O
synthesis	O
,	O
was	O
most	O
active	O
in	O
the	O
supernatant	O
fluid	O
from	O
cultures	O
grown	O
with	O
excess	O
glucose	O
,	O
fructose	O
or	O
sucrose	O
,	O
but	O
full	O
activity	O
was	O
detected	O
only	O
when	O
the	O
enzyme	O
was	O
incubated	O
with	O
both	O
sucrose	O
and	O
dextran	O
.	O

Little	O
dextransucrase	O
activity	O
was	O
detected	O
in	O
carbon	O
-	O
limited	O
cultures	O
.	O

It	O
is	O
concluded	O
that	O
glucosyl	O
-	O
and	O
fructosyltransferases	O
are	O
constitutive	O
enzymes	O
in	O
that	O
they	O
are	O
synthesized	O
at	O
similar	O
rates	O
during	O
growth	O
with	O
an	O
excess	O
of	O
the	O
substrate	O
or	O
of	O
the	O
products	O
of	O
the	O
reactions	O
which	O
they	O
catalyse	O
.	O

Although	O
the	O
Ingbritt	O
strain	O
was	O
originally	O
isolated	O
from	O
a	O
carious	O
lesion	O
,	O
it	O
is	O
now	O
a	O
poor	O
source	O
of	O
glucosyltransferase	O
activity	O
.	O

Glucosyltransferases	O
were	O
extremely	O
active	O
in	O
cultures	O
of	O
a	O
recent	O
clinical	O
isolate	O
,	O
strain	O
3209	O
,	O
and	O
were	O
apparently	O
induced	O
during	O
growth	O
with	O
excess	O
glucose	O
.	O

Differences	O
between	O
the	O
arterial	O
and	O
the	O
venous	O
pathomorphology	O
in	O
Buerger	O
'	O
s	O
disease	O
.	O

Morphological	O
lesions	O
were	O
found	O
to	O
be	O
different	O
in	O
arteries	O
and	O
in	O
veins	O
,	O
in	O
9	O
cases	O
of	O
Buerger	O
'	O
s	O
disease	O
.	O

The	O
arterial	O
lesions	O
were	O
not	O
characteristic	O
and	O
consisted	O
of	O
non	O
-	O
specific	O
inflammation	O
,	O
thrombosis	O
and	O
obliteration	O
which	O
also	O
occur	O
in	O
many	O
other	O
disease	O
.	O

In	O
contrast	O
,	O
in	O
addition	O
to	O
wall	O
infiltration	O
and	O
thrombosis	O
,	O
the	O
veins	O
showed	O
microabscesses	O
and	O
giant	O
cell	O
granulomas	O
,	O
which	O
we	O
believe	O
to	O
be	O
absent	O
in	O
all	O
other	O
known	O
diseases	O
.	O

The	O
affected	O
venous	O
segment	O
exhibited	O
a	O
variety	O
of	O
lesions	O
.	O

In	O
the	O
earliest	O
period	O
,	O
the	O
morphological	O
aspect	O
of	O
inflammation	O
in	O
arteries	O
and	O
veins	O
was	O
fairly	O
similar	O
.	O

In	O
a	O
late	O
periods	O
,	O
that	O
is	O
those	O
of	O
vascular	O
obliteration	O
,	O
the	O
arteries	O
and	O
veins	O
did	O
not	O
show	O
any	O
distinguishing	O
morphological	O
differences	O
.	O

Scanning	O
electron	O
microscopy	O
of	O
vascular	O
casts	O
in	O
experimental	O
ocular	O
vasoproliferation	O
.	O

Scanning	O
electron	O
microscopy	O
of	O
vascular	O
casts	O
was	O
used	O
to	O
investigate	O
three	O
experimental	O
models	O
of	O
neovascularization	O
.	O

In	O
each	O
experimental	O
situation	O
,	O
the	O
casts	O
provided	O
a	O
valuable	O
three	O
dimensional	O
representation	O
of	O
the	O
newly	O
formed	O
blood	O
vessels	O
and	O
permitted	O
subclassification	O
of	O
the	O
vessels	O
within	O
normal	O
and	O
proliferating	O
vascular	O
networks	O
.	O

They	O
defined	O
also	O
the	O
predominant	O
origin	O
of	O
new	O
vessels	O
from	O
venules	O
and	O
capillaries	O
,	O
and	O
enabled	O
the	O
evolution	O
of	O
proliferating	O
vessels	O
into	O
arterioles	O
and	O
venules	O
to	O
be	O
documented	O
.	O

Although	O
vascular	O
casts	O
must	O
be	O
interpreted	O
with	O
caution	O
in	O
light	O
of	O
the	O
possibility	O
of	O
incomplete	O
filling	O
and	O
other	O
artifacts	O
,	O
they	O
are	O
a	O
valuable	O
tool	O
in	O
the	O
study	O
of	O
ocular	O
vasoproliferation	O
.	O

Identification	O
of	O
the	O
putative	O
transforming	O
protein	O
of	O
the	O
human	O
T	O
-	O
cell	O
leukemia	O
viruses	O
HTLV	O
-	O
I	O
and	O
HTLV	O
-	O
II	O
.	O

The	O
human	O
T	O
-	O
cell	O
leukemia	O
viruses	O
HTLV	O
-	O
I	O
and	O
HTLV	O
-	O
II	O
are	O
unique	O
among	O
the	O
transforming	O
retroviruses	O
of	O
vertebrates	O
in	O
their	O
ability	O
to	O
transform	O
human	O
T	O
cells	O
in	O
vitro	O
and	O
in	O
their	O
close	O
association	O
with	O
human	O
malignancies	O
(	O
T	O
-	O
cell	O
lymphomas	O
and	O
leukemia	O
)	O
.	O

Their	O
genomes	O
are	O
relatively	O
simple	O
,	O
containing	O
the	O
genes	O
gag	O
,	O
pol	O
,	O
env	O
,	O
and	O
a	O
3	O
'	O
region	O
termed	O
""""	O
X	O
.	O
""""	O
This	O
3	O
'	O
region	O
may	O
be	O
responsible	O
for	O
the	O
transforming	O
potential	O
of	O
the	O
viruses	O
.	O

The	O
existence	O
of	O
proteins	O
encoded	O
by	O
the	O
3	O
'	O
region	O
has	O
been	O
postulated	O
on	O
the	O
basis	O
of	O
multiple	O
open	O
reading	O
frames	O
.	O

In	O
the	O
present	O
study	O
this	O
region	O
is	O
shown	O
to	O
contain	O
a	O
gene	O
encoding	O
a	O
protein	O
of	O
40	O
kilodaltons	O
in	O
HTLV	O
-	O
I	O
and	O
37	O
kilodaltons	O
in	O
HTLV	O
-	O
II	O
.	O

It	O
is	O
proposed	O
that	O
these	O
proteins	O
be	O
called	O
,	O
respectively	O
,	O
p40xI	O
and	O
p37xII	O
.	O

Participation	O
of	O
p53	O
cellular	O
tumour	O
antigen	O
in	O
transformation	O
of	O
normal	O
embryonic	O
cells	O
.	O

The	O
cellular	O
tumour	O
antigen	O
p53	O
is	O
found	O
at	O
elevated	O
levels	O
in	O
a	O
wide	O
variety	O
of	O
transformed	O
cells	O
(	O
for	O
reviews	O
see	O
refs	O
1	O
,	O
2	O
)	O
.	O

Very	O
little	O
is	O
yet	O
known	O
about	O
the	O
precise	O
relationship	O
of	O
p53	O
to	O
malignant	O
transformation	O
.	O

Although	O
the	O
increase	O
in	O
p53	O
levels	O
could	O
be	O
a	O
secondary	O
by	O
-	O
product	O
of	O
the	O
transformed	O
state	O
,	O
it	O
is	O
equally	O
possible	O
that	O
p53	O
is	O
actively	O
involved	O
in	O
altering	O
cellular	O
growth	O
properties	O
,	O
especially	O
as	O
it	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
normal	O
cell	O
proliferation	O
.	O

We	O
sought	O
to	O
test	O
whether	O
p53	O
could	O
behave	O
in	O
a	O
manner	O
similar	O
to	O
known	O
genes	O
in	O
a	O
biological	O
test	O
system	O
,	O
and	O
we	O
demonstrate	O
here	O
that	O
p53	O
can	O
cooperate	O
with	O
the	O
activated	O
Ha	O
-	O
ras	O
oncogene	O
to	O
transform	O
normal	O
embryonic	O
cells	O
.	O

The	O
resultant	O
foci	O
contain	O
cells	O
of	O
a	O
markedly	O
altered	O
morphology	O
which	O
produce	O
high	O
levels	O
of	O
p53	O
.	O

Cell	O
lines	O
established	O
from	O
such	O
foci	O
elicit	O
tumours	O
in	O
syngeneic	O
animals	O
.	O

Dynorphin	O
is	O
contained	O
within	O
hippocampal	O
mossy	O
fibers	O
:	O
immunochemical	O
alterations	O
after	O
kainic	O
acid	O
administration	O
and	O
colchicine	O
-	O
induced	O
neurotoxicity	O
.	O

Antisera	O
raised	O
against	O
synthetic	O
dynorphin	O
or	O
[	O
Leu5	O
]	O
enkephalin	O
demonstrate	O
immunostaining	O
in	O
hippocampal	O
mossy	O
fibers	O
and	O
in	O
dentate	O
granule	O
cells	O
.	O

However	O
,	O
dynorphin	O
immunoreactivity	O
(	O
ir	O
)	O
appears	O
to	O
be	O
denser	O
in	O
immunocytochemical	O
preparations	O
and	O
is	O
quantitatively	O
greater	O
by	O
radioimmunoassay	O
than	O
enkephalin	O
-	O
ir	O
.	O

Immunostaining	O
with	O
dynorphin	O
antisera	O
is	O
eliminated	O
by	O
adsorption	O
with	O
1	O
-	O
100	O
microM	O
dynorphin	O
-	O
17	O
whereas	O
immunostaining	O
with	O
enkephalin	O
antisera	O
is	O
eliminated	O
by	O
adsorption	O
with	O
1	O
-	O
100	O
microM	O
[	O
Leu5	O
]	O
enkephalin	O
,	O
dynorphin	O
-	O
17	O
,	O
dynorphin	O
-	O
(	O
1	O
-	O
13	O
)	O
,	O
or	O
alpha	O
-	O
neo	O
-	O
endorphin	O
.	O

Intrahippocampal	O
colchicine	O
injections	O
,	O
which	O
selectively	O
destroy	O
dentate	O
granule	O
cells	O
,	O
significantly	O
decrease	O
the	O
dynorphin	O
-	O
ir	O
and	O
enkephalin	O
-	O
ir	O
levels	O
in	O
rat	O
hippocampus	O
.	O

Intraventricularly	O
administered	O
kainic	O
acid	O
,	O
which	O
selectively	O
destroys	O
CA3	O
-	O
4	O
pyramidal	O
cells	O
,	O
results	O
in	O
an	O
increase	O
of	O
enkephalin	O
immunostaining	O
in	O
mossy	O
fibers	O
and	O
a	O
significant	O
increase	O
in	O
enkephalin	O
-	O
ir	O
by	O
radioimmunoassay	O
in	O
whole	O
hippocampus	O
.	O

The	O
enkephalin	O
-	O
ir	O
cells	O
and	O
fibers	O
in	O
entorhinal	O
/	O
perirhinal	O
cortex	O
,	O
which	O
innervate	O
rat	O
hippocampus	O
and	O
dentate	O
gyrus	O
,	O
do	O
not	O
contain	O
dynorphin	O
-	O
ir	O
.	O

Interaction	O
between	O
cellular	O
and	O
viral	O
genes	O
in	O
the	O
expression	O
of	O
the	O
RSV	O
-	O
induced	O
transformation	O
-	O
specific	O
cell	O
-	O
surface	O
antigen	O
VCSA	O
.	O

Transformation	O
of	O
BHK	B
hamster	O
fibroblasts	O
by	O
an	O
env	O
-	O
strain	O
of	O
Rous	O
sarcoma	O
virus	O
(	O
RSV	O
)	O
leads	O
to	O
the	O
appearance	O
at	O
the	O
cell	O
surface	O
of	O
a	O
virus	O
-	O
induced	O
nonvirion	O
antigen	O
(	O
VCSA	O
)	O
,	O
specific	O
for	O
transformation	O
,	O
whose	O
expression	O
is	O
controlled	O
by	O
the	O
transforming	O
src	O
gene	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
a	O
rabbit	O
anti	O
-	O
VCSA	O
serum	O
lyses	O
specifically	O
,	O
in	O
the	O
presence	O
of	O
complement	O
,	O
51Cr	O
-	O
labelled	O
RSV	O
-	O
transformed	O
cells	O
from	O
different	O
animal	O
species	O
.	O

Now	O
,	O
by	O
competition	O
experiments	O
with	O
a	O
panel	O
of	O
different	O
unlabelled	O
cells	O
we	O
show	O
that	O
the	O
VCSA	O
expressed	O
on	O
RSV	O
-	O
transformed	O
hamster	O
fibroblasts	O
is	O
a	O
complex	O
of	O
at	O
least	O
three	O
distinct	O
antigenic	O
specificities	O
:	O
(	O
1	O
)	O
one	O
expressed	O
on	O
all	O
RSV	O
-	O
transformed	O
fibroblasts	O
,	O
regardless	O
their	O
species	O
and	O
the	O
subgroup	O
or	O
strain	O
of	O
the	O
transforming	O
virus	O
;	O
(	O
2	O
)	O
one	O
cross	O
-	O
reacting	O
with	O
a	O
cell	O
-	O
surface	O
antigen	O
(	O
CSA	O
)	O
expressed	O
at	O
various	O
degrees	O
on	O
untransformed	O
avian	O
fibroblasts	O
,	O
but	O
not	O
on	O
mammalian	O
fibroblasts	O
;	O
(	O
3	O
)	O
one	O
species	O
-	O
specific	O
,	O
present	O
only	O
on	O
RSV	O
-	O
transformed	O
hamster	O
fibroblasts	O
.	O

It	O
is	O
concluded	O
that	O
VCSA	O
is	O
a	O
complex	O
of	O
several	O
antigenic	O
determinants	O
,	O
and	O
that	O
some	O
of	O
these	O
differ	O
in	O
different	O
cells	O
transformed	O
by	O
RSV	O
.	O

This	O
observation	O
indicates	O
that	O
VCSA	O
expression	O
at	O
the	O
cell	O
surface	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
the	O
interaction	O
between	O
the	O
viral	O
src	O
gene	O
product	O
pp60src	O
with	O
host	O
cell	O
gene	O
(	O
s	O
)	O
or	O
gene	O
product	O
(	O
s	O
)	O
,	O
rather	O
than	O
the	O
simple	O
expression	O
of	O
this	O
molecule	O
at	O
the	O
cell	O
surface	O
.	O

Angiogenesis	O
:	O
initiation	O
and	O
control	O
.	O

From	O
in	O
vivo	O
experiments	O
using	O
new	O
methods	O
such	O
as	O
the	O
rabbit	O
cornea	O
,	O
it	O
is	O
now	O
becoming	O
clear	O
that	O
the	O
growth	O
of	O
a	O
capillary	O
involves	O
an	O
ordered	O
sequence	O
of	O
events	O
that	O
includes	O
lysis	O
of	O
the	O
basement	O
membrane	O
of	O
a	O
parent	O
venule	O
,	O
directional	O
migration	O
of	O
capillary	O
endothelial	O
cells	O
toward	O
the	O
angiogenic	O
stimulus	O
,	O
lumen	O
formation	O
,	O
development	O
of	O
branches	O
,	O
and	O
anastomosis	O
of	O
the	O
tip	O
of	O
one	O
tube	O
with	O
another	O
to	O
form	O
a	O
loop	O
.	O

It	O
is	O
also	O
clear	O
that	O
diffusible	O
angiogenic	O
stimuli	O
can	O
be	O
released	O
not	O
only	O
from	O
most	O
solid	O
tumors	O
,	O
but	O
also	O
from	O
at	O
least	O
three	O
non	O
-	O
neoplastic	O
cells	O
.	O

These	O
include	O
activated	O
macrophages	O
,	O
sensitized	O
lymphocytes	O
,	O
and	O
adipocytes	O
.	O

Other	O
normal	O
tissues	O
can	O
also	O
stimulate	O
angiogenesis	O
,	O
but	O
the	O
type	O
of	O
cell	O
giving	O
rise	O
to	O
the	O
angiogenic	O
stimulus	O
is	O
unknown	O
,	O
and	O
the	O
period	O
of	O
angiogenic	O
stimulation	O
is	O
brief	O
.	O

With	O
the	O
recent	O
ability	O
to	O
clone	O
capillary	O
endothelial	O
cells	O
and	O
to	O
carry	O
them	O
in	O
long	O
-	O
term	O
culture	O
,	O
it	O
has	O
been	O
possible	O
to	O
further	O
delineate	O
the	O
mechanism	O
of	O
capillary	O
growth	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
the	O
mast	O
cell	O
seems	O
to	O
behave	O
as	O
a	O
helper	O
cell	O
for	O
capillary	O
endothelial	O
cells	O
,	O
in	O
some	O
way	O
speeding	O
up	O
their	O
rate	O
of	O
directional	O
migration	O
.	O

At	O
this	O
writing	O
,	O
heparin	O
appears	O
to	O
be	O
the	O
principal	O
mast	O
cell	O
factor	O
responsible	O
for	O
this	O
effect	O
on	O
capillary	O
endothelial	O
cells	O
.	O

One	O
theoretical	O
possibility	O
is	O
that	O
mast	O
cells	O
may	O
prepare	O
the	O
matrix	O
,	O
perhaps	O
by	O
slow	O
release	O
of	O
heparin	O
,	O
so	O
that	O
capillary	O
sprouts	O
can	O
more	O
easily	O
move	O
through	O
it	O
toward	O
their	O
angiogenic	O
target	O
.	O

While	O
the	O
study	O
of	O
angiogenesis	O
as	O
a	O
phenomenon	O
is	O
still	O
in	O
an	O
early	O
phase	O
,	O
it	O
has	O
become	O
possible	O
,	O
by	O
using	O
a	O
combination	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
techniques	O
,	O
to	O
more	O
thoroughly	O
understand	O
the	O
initiation	O
and	O
control	O
of	O
capillary	O
growth	O
.	O

Role	O
of	O
interleukin	O
1	O
in	O
antigen	O
-	O
specific	O
T	O
cell	O
proliferation	O
.	O

The	O
role	O
of	O
interleukin	O
1	O
(	O
IL	O
1	O
)	O
in	O
human	O
antigen	O
-	O
specific	O
T	O
cell	O
proliferation	O
was	O
examined	O
.	O

Nylon	O
wool	O
-	O
purified	O
T	O
cells	O
proliferated	O
in	O
the	O
presence	O
of	O
autologous	O
monocytes	O
(	O
Mo	O
.	O
)	O
pulsed	O
for	O
18	O
h	O
with	O
tetanus	O
toxoid	O
(	O
TT	O
)	O
antigen	O
(	O
Mo	O
.	O
TT	O
)	O
.	O

Irradiation	O
of	O
Mo	O
.	O
TT	O
with	O
ultraviolet	O
(	O
UV	O
)	O
light	O
(	O
72	O
J	O
/	O
m2	O
)	O
abolished	O
their	O
capacity	O
to	O
support	O
T	O
cell	O
proliferation	O
and	O
drastically	O
reduced	O
their	O
capacity	O
to	O
secrete	O
IL	O
1	O
after	O
stimulation	O
with	O
Staphylococcus	O
albus	O
.	O

The	O
defect	O
in	O
antigen	O
presentation	O
induced	O
by	O
UV	O
irradiation	O
of	O
Mo	O
.	O
TT	O
was	O
reversed	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
the	O
addition	O
of	O
two	O
different	O
preparations	O
containing	O
human	O
interleukin	O
1	O
(	O
IL	O
1	O
)	O
.	O

The	O
first	O
preparation	O
consisted	O
of	O
supernatants	O
of	O
Mo	O
.	O
stimulated	O
with	O
Con	O
A	O
for	O
18	O
hr	O
and	O
in	O
which	O
Con	O
A	O
activity	O
was	O
blocked	O
by	O
alpha	O
-	O
D	O
-	O
methyl	O
-	O
mannoside	O
(	O
Mo	O
.	O
-	O
Con	O
A	O
-	O
Sup	O
)	O
.	O

The	O
second	O
preparation	O
consisted	O
of	O
human	O
IL	O
1	O
partially	O
purified	O
from	O
supernatants	O
of	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
stimulated	O
with	O
S	O
.	O
albus	O
.	O

This	O
IL	O
1	O
copurified	O
with	O
human	O
leukocyte	O
pyrogen	O
(	O
LP	O
)	O
and	O
was	O
termed	O
IL	O
1	O
/	O
LP	O
.	O

Both	O
IL	O
1	O
-	O
containing	O
preparations	O
enhanced	O
the	O
response	O
of	O
C57BL	O
/	O
6	O
mouse	O
thymocytes	O
to	O
phytohemagglutinin	O
.	O

A	O
rabbit	O
antibody	O
to	O
human	O
IL	O
1	O
/	O
LP	O
inhibited	O
the	O
capacity	O
of	O
T	O
cells	O
to	O
proliferate	O
in	O
response	O
to	O
Mo	O
.	O
TT	O
and	O
inhibited	O
the	O
capacity	O
of	O
Mo	O
.	O
-	O
Con	O
A	O
-	O
Sup	O
to	O
reconstitute	O
the	O
T	O
cell	O
response	O
to	O
UV	O
-	O
irradiated	O
Mo	O
.	O
TT	O
.	O

IL	O
1	O
/	O
LP	O
was	O
not	O
necessary	O
for	O
T	O
cells	O
to	O
recognize	O
the	O
immunogenic	O
moiety	O
presented	O
by	O
Mo	O
.	O
,	O
because	O
monolayers	O
of	O
UV	O
-	O
irradiated	O
Mo	O
.	O
TT	O
were	O
equivalent	O
to	O
monolayers	O
of	O
unirradiated	O
MO	O
.	O
TT	O
in	O
their	O
capacity	O
to	O
adsorb	O
TT	O
-	O
reactive	O
T	O
cells	O
specifically	O
.	O

Furthermore	O
,	O
the	O
addition	O
of	O
rabbit	O
antibody	O
to	O
IL	O
1	O
/	O
LP	O
did	O
not	O
interfere	O
with	O
the	O
capacity	O
of	O
UV	O
-	O
irradiated	O
Mo	O
.	O
TT	O
to	O
adsorb	O
TT	O
-	O
reactive	O
T	O
cells	O
.	O

The	O
results	O
obtained	O
in	O
this	O
study	O
indicate	O
that	O
IL	O
1	O
is	O
involved	O
in	O
optimal	O
antigen	O
-	O
driven	O
proliferation	O
of	O
human	O
T	O
lymphocytes	O
.	O

Ca	O
+	O
+	O
distribution	O
after	O
Na	O
+	O
pump	O
inhibition	O
in	O
cultured	O
neonatal	O
rat	O
myocardial	O
cells	O
.	O

The	O
influence	O
of	O
inhibition	O
of	O
the	O
Na	O
+	O
pump	O
,	O
with	O
secondary	O
stimulation	O
of	O
Na	O
+	O
-	O
Ca	O
+	O
+	O
exchange	O
,	O
on	O
cellular	O
Ca	O
+	O
+	O
distribution	O
is	O
examined	O
using	O
the	O
on	O
-	O
line	O
scintillation	O
disk	O
technique	O
and	O
cultured	O
neonatal	O
rat	O
myocardial	O
cells	O
.	O

Under	O
control	O
conditions	O
,	O
La	O
+	O
+	O
+	O
displaced	O
78	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
13	O
%	O
(	O
SEM	O
)	O
of	O
the	O
total	O
cell	O
associated	O
45Ca	O
.	O

Application	O
of	O
1	O
mm	O
ouabain	O
or	O
reduction	O
of	O
[	O
K	O
+	O
]	O
o	O
to	O
0	O
.	O
5	O
mM	O
resulted	O
in	O
a	O
net	O
increase	O
of	O
10	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
%	O
and	O
13	O
.	O
8	O
+	O
/	O
-	O
2	O
%	O
,	O
respectively	O
,	O
in	O
total	O
cell	O
-	O
associated	O
Ca	O
+	O
+	O
.	O

Of	O
this	O
added	O
45Ca	O
,	O
75	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
7	O
%	O
and	O
78	O
.	O
4	O
+	O
/	O
-	O
2	O
.	O
1	O
%	O
,	O
respectively	O
remained	O
La	O
+	O
+	O
+	O
-	O
displaceable	O
.	O

The	O
45Ca	O
-	O
binding	O
characteristics	O
of	O
isolated	O
sarcolemma	O
,	O
prepared	O
from	O
the	O
cultured	O
neonatal	O
rat	O
myocardial	O
cells	O
using	O
the	O
gas	O
dissection	O
technique	O
,	O
were	O
examined	O
.	O

When	O
treated	O
with	O
either	O
ouabain	O
or	O
low	O
[	O
K	O
+	O
]	O
o	O
solutions	O
,	O
sarcolemmal	O
45Ca	O
binding	O
did	O
not	O
change	O
.	O

This	O
result	O
indicates	O
that	O
functional	O
,	O
intact	O
tissue	O
is	O
necessary	O
to	O
observe	O
the	O
Ca	O
+	O
+	O
increase	O
.	O

Treatment	O
of	O
the	O
cells	O
with	O
verapamil	O
before	O
and	O
during	O
ouabain	O
exposure	O
failed	O
to	O
inhibit	O
the	O
ouabain	O
-	O
induced	O
increase	O
in	O
cell	O
-	O
associated	O
45Ca	O
.	O

The	O
evidence	O
indicates	O
that	O
inhibition	O
of	O
the	O
Na	O
+	O
-	O
pump	O
,	O
and	O
secondary	O
stimulation	O
of	O
Na	O
+	O
-	O
Ca	O
+	O
+	O
exchange	O
,	O
result	O
in	O
a	O
net	O
increase	O
of	O
11	O
-	O
15	O
%	O
in	O
cell	O
-	O
associated	O
Ca	O
+	O
+	O
,	O
78	O
%	O
of	O
which	O
remains	O
La	O
+	O
+	O
+	O
-	O
displaceable	O
and	O
is	O
,	O
therefore	O
,	O
localized	O
to	O
the	O
sarcolemma	O
-	O
glycocalyx	O
complex	O
.	O

Phosphorylation	O
-	O
induced	O
mobility	O
shift	O
in	O
phospholamban	O
in	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gels	O
.	O

Evidence	O
for	O
a	O
protein	O
structure	O
consisting	O
of	O
multiple	O
identical	O
phosphorylatable	O
subunits	O
.	O

Phosphorylation	O
of	O
purified	O
phospholamban	O
isolated	O
from	O
canine	O
cardiac	O
sarcoplasmic	O
reticulum	O
vesicles	O
decreased	O
the	O
electrophoretic	O
mobility	O
of	O
the	O
protein	O
in	O
sodium	O
dodecyl	O
sulfate	O
(	O
SDS	O
)	O
-	O
polyacrylamide	O
gels	O
.	O

Different	O
mobility	O
forms	O
of	O
phospholamban	O
in	O
SDS	O
gels	O
were	O
visualized	O
both	O
by	O
direct	O
protein	O
staining	O
and	O
by	O
autoradiography	O
.	O

Unphosphorylated	O
phospholamban	O
migrated	O
with	O
an	O
apparent	O
Mr	O
=	O
25	O
,	O
000	O
in	O
SDS	O
gels	O
;	O
maximal	O
phosphorylation	O
of	O
phospholamban	O
by	O
cAMP	O
-	O
or	O
Ca2	O
+	O
-	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
increased	O
the	O
apparent	O
Mr	O
to	O
27	O
,	O
000	O
.	O

Partial	O
phosphorylation	O
of	O
phospholamban	O
by	O
either	O
protein	O
kinase	O
gave	O
intermediate	O
mobility	O
forms	O
of	O
molecular	O
weights	O
between	O
25	O
,	O
000	O
and	O
27	O
,	O
000	O
,	O
suggesting	O
that	O
more	O
than	O
one	O
phosphorylation	O
site	O
was	O
present	O
on	O
the	O
holoprotein	O
for	O
each	O
activity	O
.	O

Boiling	O
of	O
phospholamban	O
in	O
SDS	O
dissociated	O
the	O
holoprotein	O
into	O
an	O
apparently	O
homogeneous	O
class	O
of	O
low	O
molecular	O
weight	O
""""	O
monomers	O
.	O
""""	O
Only	O
two	O
mobility	O
forms	O
of	O
monomeric	O
phospholamban	O
were	O
observed	O
in	O
SDS	O
gels	O
after	O
phosphorylation	O
by	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
,	O
corresponding	O
to	O
9	O
-	O
kDa	O
dephospho	O
-	O
and	O
11	O
-	O
kDa	O
phosphoproteins	O
.	O

All	O
of	O
the	O
9	O
-	O
kDa	O
protein	O
could	O
be	O
phosphorylated	O
and	O
converted	O
into	O
the	O
11	O
-	O
kDa	O
mobility	O
form	O
,	O
suggesting	O
the	O
presence	O
of	O
only	O
one	O
site	O
of	O
phosphorylation	O
on	O
a	O
single	O
type	O
of	O
monomer	O
for	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
.	O

Simultaneous	O
phosphorylation	O
of	O
monomeric	O
phospholamban	O
by	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
and	O
Ca2	O
+	O
-	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
gave	O
an	O
additional	O
mobility	O
form	O
of	O
the	O
protein	O
,	O
suggesting	O
that	O
different	O
sites	O
of	O
phosphorylation	O
were	O
present	O
for	O
each	O
activity	O
on	O
each	O
monomer	O
.	O

Incomplete	O
dissociation	O
of	O
the	O
holoprotein	O
by	O
boiling	O
it	O
in	O
a	O
relatively	O
low	O
concentration	O
of	O
SDS	O
facilitated	O
the	O
detection	O
of	O
five	O
major	O
mobility	O
forms	O
of	O
the	O
protein	O
in	O
SDS	O
gels	O
,	O
and	O
the	O
mobilities	O
of	O
all	O
of	O
these	O
forms	O
were	O
decreased	O
by	O
phosphorylation	O
.	O

We	O
propose	O
that	O
the	O
high	O
molecular	O
weight	O
form	O
of	O
phospholamban	O
is	O
a	O
multimer	O
of	O
electrophoretically	O
indistinguishable	O
monomers	O
,	O
each	O
of	O
which	O
contains	O
a	O
different	O
phosphorylation	O
site	O
for	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
activity	O
and	O
Ca2	O
+	O
-	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
activity	O
.	O

Phosphorylation	O
of	O
phospholamban	O
at	O
multiple	O
sites	O
is	O
responsible	O
for	O
the	O
various	O
mobility	O
forms	O
of	O
the	O
holoprotein	O
detected	O
in	O
SDS	O
-	O
polyacrylamide	O
gels	O
.	O

Protection	O
from	O
experimental	O
ocular	O
herpetic	O
keratitis	O
by	O
a	O
heat	O
-	O
killed	O
virus	O
vaccine	O
.	O

New	O
Zealand	O
white	O
rabbits	O
were	O
given	O
limbal	O
inoculations	O
of	O
a	O
heat	O
-	O
killed	O
suspension	O
of	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
in	O
a	O
lysate	O
of	O
human	O
embryonic	O
kidney	O
cells	O
.	O

At	O
intervals	O
of	O
four	O
to	O
14	O
days	O
,	O
the	O
animals	O
were	O
challenged	O
by	O
intrastromal	O
inoculation	O
with	O
10	O
,	O
000	O
plaque	O
-	O
forming	O
units	O
of	O
viable	O
HSV	O
.	O

Epithelial	O
keratitis	O
,	O
disciform	O
edema	O
,	O
and	O
necrotizing	O
keratitis	O
with	O
neovascularization	O
of	O
the	O
cornea	O
developed	O
in	O
control	O
animals	O
.	O

Epithelial	O
keratitis	O
and	O
corneal	O
edema	O
also	O
developed	O
in	O
the	O
immunized	O
animals	O
during	O
the	O
first	O
week	O
after	O
virus	O
challenge	O
,	O
but	O
these	O
symptoms	O
rapidly	O
resolved	O
during	O
the	O
following	O
weeks	O
.	O

The	O
absence	O
of	O
iritis	O
,	O
neovascularization	O
,	O
and	O
necrotizing	O
keratitis	O
in	O
the	O
corneas	O
of	O
the	O
immunized	O
animals	O
was	O
particularly	O
striking	O
.	O

Cells	O
transformed	O
by	O
Rous	O
sarcoma	O
virus	O
release	O
transforming	O
growth	O
factors	O
.	O

Chicken	O
embryo	O
fibroblasts	O
and	O
hamster	O
BHK	B
cells	O
transformed	O
by	O
Rous	O
sarcoma	O
virus	O
(	O
RSV	O
)	O
release	O
in	O
their	O
culture	O
media	O
growth	O
factors	O
which	O
enhance	O
markedly	O
anchorage	O
-	O
independent	O
colony	O
formation	O
in	O
gelified	O
medium	O
,	O
at	O
the	O
restrictive	O
temperature	O
(	O
41	O
degrees	O
5	O
C	O
)	O
,	O
of	O
chicken	O
embryo	O
fibroblasts	O
(	O
CEF	O
)	O
infected	O
by	O
RSV	O
mutants	O
with	O
a	O
ts	O
mutation	O
of	O
the	O
src	O
gene	O
.	O

This	O
action	O
is	O
not	O
observed	O
with	O
uninfected	O
CEF	O
,	O
and	O
,	O
therefore	O
,	O
appears	O
to	O
require	O
some	O
expression	O
of	O
the	O
viral	O
src	O
gene	O
in	O
the	O
target	O
cells	O
.	O

The	O
enhancing	O
factors	O
are	O
proteins	O
related	O
to	O
the	O
family	O
of	O
the	O
transforming	O
growth	O
factors	O
(	O
TGFs	O
)	O
by	O
their	O
molecular	O
weight	O
(	O
about	O
20	O
kd	O
)	O
,	O
their	O
heat	O
and	O
acid	O
resistance	O
,	O
and	O
their	O
sensitivity	O
to	O
dithiothreitol	O
.	O

They	O
do	O
not	O
compete	O
with	O
125I	O
EGF	O
for	O
binding	O
on	O
the	O
EGF	O
receptors	O
of	O
the	O
membrane	O
of	O
A431	B
cells	O
.	O

As	O
chicken	O
embryo	O
fibroblasts	O
are	O
devoid	O
of	O
EGF	O
receptors	O
,	O
their	O
activity	O
is	O
not	O
potentiated	O
by	O
EGF	O
.	O

The	O
genetics	O
of	O
transformation	O
by	O
SV	O
40	O
.	O

Experiments	O
using	O
the	O
tsA	O
58	O
allele	O
of	O
the	O
SV	O
40	O
-	O
A	O
gene	O
have	O
demonstrated	O
that	O
the	O
SV	O
40	O
large	O
T	O
-	O
antigen	O
is	O
strictly	O
required	O
both	O
for	O
immortalization	O
and	O
induction	O
anchorage	O
independence	O
of	O
cells	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
immortalized	O
phenotype	O
is	O
mediated	O
by	O
an	O
extra	O
cellular	O
factor	O
.	O

The	O
synthesis	O
and	O
/	O
or	O
the	O
excretion	O
of	O
this	O
factor	O
in	O
a	O
medium	O
is	O
controlled	O
by	O
the	O
A	O
gene	O
.	O

Effects	O
of	O
growth	O
temperature	O
,	O
47	O
-	O
megadalton	O
plasmid	O
,	O
and	O
calcium	O
deficiency	O
on	O
the	O
outer	O
membrane	O
protein	O
porin	O
and	O
lipopolysaccharide	O
composition	O
of	O
Yersinia	O
pestis	O
EV76	O
.	O

The	O
expression	O
of	O
several	O
virulence	O
determinants	O
of	O
Yersinia	O
pestis	O
is	O
known	O
to	O
be	O
dependent	O
on	O
the	O
in	O
vitro	O
growth	O
temperature	O
.	O

One	O
of	O
these	O
,	O
calcium	O
dependence	O
,	O
is	O
associated	O
with	O
the	O
presence	O
of	O
a	O
47	O
-	O
megadalton	O
plasmid	O
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
incubation	O
temperature	O
,	O
calcium	O
in	O
the	O
growth	O
medium	O
,	O
the	O
presence	O
of	O
the	O
47	O
-	O
megadalton	O
plasmid	O
on	O
the	O
outer	O
membrane	O
protein	O
,	O
and	O
the	O
lipopolysaccharide	O
composition	O
of	O
Y	O
.	O
pestis	O
EV76	O
.	O

When	O
cells	O
were	O
grown	O
at	O
37	O
degrees	O
C	O
as	O
opposed	O
to	O
26	O
degrees	O
C	O
,	O
a	O
change	O
in	O
lipopolysaccharide	O
composition	O
and	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
an	O
outer	O
membrane	O
protein	O
(	O
protein	O
E	O
)	O
were	O
observed	O
.	O

The	O
lipopolysaccharide	O
obtained	O
from	O
cells	O
incubated	O
at	O
37	O
degrees	O
C	O
had	O
a	O
lower	O
proportion	O
of	O
2	O
keto	O
-	O
3	O
-	O
deoxyoctanate	O
,	O
a	O
lower	O
phosphate	O
to	O
2	O
-	O
keto	O
-	O
3	O
-	O
deoxyoctanate	O
ratio	O
,	O
and	O
an	O
increased	O
gel	O
mobility	O
upon	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
when	O
compared	O
with	O
lipopolysaccharide	O
obtained	O
from	O
cells	O
grown	O
at	O
26	O
degrees	O
C	O
.	O

Because	O
of	O
its	O
growth	O
temperature	O
-	O
related	O
abundance	O
,	O
we	O
investigated	O
the	O
nature	O
of	O
protein	O
E	O
.	O

This	O
protein	O
had	O
physical	O
properties	O
similar	O
to	O
those	O
of	O
other	O
enterobacterial	O
porins	O
,	O
including	O
apparent	O
formation	O
of	O
an	O
oligomer	O
on	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gels	O
when	O
solubilized	O
at	O
low	O
temperature	O
,	O
acidic	O
isoelectric	O
point	O
,	O
and	O
strong	O
noncovalent	O
association	O
with	O
the	O
peptidoglycan	O
.	O

Protein	O
E	O
was	O
purified	O
and	O
shown	O
to	O
form	O
an	O
aqueous	O
channel	O
in	O
planar	O
lipid	O
membranes	O
with	O
a	O
conductance	O
of	O
1	O
.	O
1	O
nS	O
in	O
1	O
M	O
KCl	O
.	O

In	O
addition	O
to	O
growth	O
temperature	O
-	O
related	O
alterations	O
in	O
the	O
lipopolysaccharide	O
and	O
porin	O
components	O
of	O
the	O
outer	O
membrane	O
,	O
the	O
amount	O
of	O
three	O
spots	O
in	O
two	O
-	O
dimensional	O
polyacrylamide	O
gels	O
was	O
shown	O
to	O
be	O
related	O
to	O
the	O
temperature	O
or	O
the	O
presence	O
of	O
calcium	O
during	O
growth	O
.	O

One	O
of	O
these	O
spots	O
was	O
shown	O
to	O
contain	O
residual	O
unmodified	O
portions	O
of	O
two	O
major	O
heat	O
-	O
modifiable	O
proteins	O
which	O
failed	O
to	O
shift	O
to	O
their	O
heat	O
-	O
modified	O
positions	O
on	O
gels	O
,	O
despite	O
solubilization	O
at	O
100	O
degrees	O
C	O
for	O
10	O
min	O
before	O
electrophoresis	O
.	O

The	O
other	O
two	O
spots	O
were	O
the	O
heat	O
-	O
modified	O
and	O
unmodified	O
forms	O
of	O
another	O
outer	O
membrane	O
protein	O
(	O
J	O
)	O
which	O
did	O
not	O
appear	O
in	O
the	O
isoelectric	O
focusing	O
gel	O
of	O
cells	O
grown	O
at	O
37	O
degrees	O
C	O
.	O

It	O
is	O
proposed	O
that	O
the	O
appearance	O
of	O
these	O
spots	O
in	O
two	O
-	O
dimensional	O
analyses	O
is	O
related	O
to	O
the	O
lipopolysaccharide	O
composition	O
of	O
the	O
cells	O
from	O
which	O
the	O
outer	O
membrane	O
is	O
derived	O
and	O
reflects	O
lipopolysaccharide	O
-	O
protein	O
interactions	O
or	O
calcium	O
-	O
protein	O
interactions	O
.	O

Protein	O
kinase	O
activities	O
in	O
immune	O
complexes	O
of	O
simian	O
virus	O
40	O
large	O
T	O
-	O
antigen	O
and	O
transformation	O
-	O
associated	O
cellular	O
p53	O
protein	O
.	O

Immune	O
complex	O
kinase	O
assays	O
in	O
the	O
simian	O
virus	O
40	O
system	O
were	O
performed	O
by	O
incubation	O
of	O
immunoprecipitates	O
containing	O
tumor	O
antigens	O
with	O
[	O
gamma	O
-	O
32P	O
]	O
ATP	O
,	O
followed	O
by	O
analysis	O
of	O
any	O
phosphoacceptor	O
proteins	O
.	O

These	O
assays	O
yielded	O
mainly	O
the	O
viral	O
large	O
T	O
-	O
antigen	O
and	O
,	O
in	O
particular	O
,	O
the	O
associated	O
cellular	O
p53	O
as	O
endogenous	O
substrates	O
.	O

The	O
nature	O
of	O
these	O
substrates	O
was	O
confirmed	O
by	O
proteolysis	O
techniques	O
.	O

Under	O
specific	O
conditions	O
,	O
casein	O
could	O
be	O
used	O
as	O
an	O
exogenous	O
substrate	O
as	O
well	O
.	O

The	O
kinase	O
reactions	O
showed	O
preference	O
for	O
ATP	O
and	O
MgCl2	O
instead	O
of	O
GTP	O
or	O
MnCl2	O
.	O

Both	O
phosphoserine	O
and	O
phosphothreonine	O
,	O
but	O
in	O
no	O
case	O
phosphotyrosine	O
,	O
were	O
detected	O
after	O
an	O
immune	O
complex	O
kinase	O
reaction	O
.	O

Apparently	O
,	O
several	O
in	O
vivo	O
phosphorylation	O
sites	O
were	O
recognized	O
in	O
vitro	O
in	O
both	O
large	O
T	O
-	O
antigen	O
and	O
p53	O
,	O
but	O
the	O
presence	O
of	O
some	O
artifactual	O
sites	O
could	O
not	O
be	O
completely	O
excluded	O
.	O

Although	O
contaminating	O
kinases	O
were	O
detectable	O
in	O
the	O
immune	O
complexes	O
,	O
at	O
least	O
the	O
p53	O
molecules	O
were	O
phosphorylated	O
in	O
vitro	O
in	O
a	O
more	O
specific	O
way	O
.	O

This	O
followed	O
from	O
several	O
characteristics	O
of	O
the	O
immune	O
complex	O
kinase	O
reactions	O
and	O
especially	O
from	O
the	O
strong	O
inhibition	O
of	O
p53	O
phosphorylation	O
by	O
two	O
anti	O
-	O
large	O
-	O
T	O
monoclonal	O
antibodies	O
.	O

It	O
was	O
shown	O
that	O
large	O
T	O
-	O
antigen	O
showed	O
associated	O
kinase	O
activity	O
,	O
although	O
none	O
of	O
our	O
results	O
could	O
unambiguously	O
demonstrate	O
an	O
intrinsic	O
kinase	O
activity	O
of	O
this	O
protein	O
.	O

Finally	O
,	O
anti	O
-	O
p53	O
monoclonal	O
antibodies	O
only	O
slightly	O
affected	O
in	O
vitro	O
phosphorylation	O
reactions	O
,	O
whereas	O
a	O
p53	O
molecule	O
from	O
a	O
simian	O
virus	O
40	O
-	O
free	O
,	O
chemically	O
transformed	O
human	O
cell	O
line	O
was	O
not	O
phosphorylated	O
in	O
vitro	O
under	O
any	O
condition	O
tested	O
.	O

Thus	O
,	O
it	O
is	O
highly	O
unlikely	O
that	O
the	O
p53	O
molecule	O
per	O
se	O
carries	O
intrinsic	O
or	O
even	O
associated	O
kinase	O
activities	O
.	O

Molecular	O
events	O
leading	O
to	O
enhanced	O
glucose	O
transport	O
in	O
Rous	O
sarcoma	O
virus	O
-	O
transformed	O
cells	O
.	O

Transformation	O
by	O
Rous	O
sarcoma	O
virus	O
results	O
in	O
a	O
dramatic	O
increase	O
in	O
the	O
rate	O
at	O
which	O
the	O
transformed	O
cells	O
transport	O
glucose	O
across	O
the	O
cell	O
membrane	O
.	O

The	O
increased	O
transport	O
rate	O
is	O
a	O
consequence	O
of	O
an	O
increased	O
number	O
of	O
transporters	O
in	O
the	O
transformed	O
cells	O
.	O

Utilizing	O
antibody	O
raised	O
against	O
the	O
purified	O
human	O
erythrocyte	O
glucose	O
transporter	O
,	O
we	O
have	O
identified	O
the	O
glucose	O
transporter	O
as	O
a	O
membrane	O
glycoprotein	O
with	O
a	O
monomer	O
Mr	O
of	O
approximately	O
41	O
,	O
000	O
.	O

The	O
increased	O
rate	O
of	O
glucose	O
transport	O
is	O
dependent	O
on	O
the	O
activity	O
of	O
pp60src	O
,	O
the	O
transforming	O
protein	O
of	O
Rous	O
sarcoma	O
virus	O
.	O

This	O
protein	O
has	O
been	O
shown	O
to	O
be	O
a	O
protein	O
kinase	O
that	O
phosphorylates	O
on	O
tyrosine	O
residues	O
.	O

We	O
have	O
examined	O
the	O
tyrosine	O
phosphorylation	O
of	O
a	O
major	O
cellular	O
protein	O
of	O
Mr	O
36	O
,	O
000	O
in	O
cells	O
infected	O
with	O
a	O
panel	O
of	O
partially	O
transforming	O
mutants	O
of	O
Rous	O
sarcoma	O
virus	O
.	O

One	O
of	O
these	O
mutants	O
(	O
CU2	O
)	O
increases	O
the	O
rate	O
of	O
glucose	O
transport	O
only	O
slightly	O
and	O
does	O
not	O
render	O
the	O
infected	O
cells	O
fully	O
anchorage	O
independent	O
or	O
tumorigenic	O
(	O
although	O
other	O
transformation	O
parameters	O
are	O
fully	O
induced	O
)	O
.	O

Cells	O
infected	O
with	O
this	O
mutant	O
display	O
a	O
36	O
,	O
000	O
-	O
dalton	O
protein	O
that	O
is	O
phosphorylated	O
to	O
a	O
considerably	O
lesser	O
extent	O
than	O
cells	O
infected	O
with	O
wild	O
-	O
type	O
virus	O
.	O

Analyses	O
of	O
this	O
sort	O
may	O
help	O
to	O
identify	O
the	O
cellular	O
targets	O
of	O
pp60src	O
whose	O
phosphorylation	O
is	O
necessary	O
for	O
the	O
increased	O
glucose	O
transport	O
rate	O
.	O

Preliminary	O
evidence	O
for	O
a	O
pyridine	O
nucleotide	O
cycle	O
in	O
Bordetella	O
pertussis	O
.	O

Preliminary	O
evidence	O
that	O
Bordetella	O
pertussis	O
has	O
a	O
functional	O
pyridine	O
nucleotide	O
cycle	O
was	O
the	O
observation	O
that	O
[	O
14C	O
]	O
-	O
nicotinic	O
acid	O
was	O
rapidly	O
metabolized	O
during	O
its	O
uptake	O
by	O
the	O
bacteria	O
to	O
pyridine	O
nucleotides	O
and	O
nicotinamide	O
.	O

Nicotinamide	O
deamidase	O
activity	O
,	O
necessary	O
for	O
the	O
completion	O
of	O
the	O
cycle	O
by	O
conversion	O
of	O
nicotinamide	O
to	O
nicotinic	O
acid	O
,	O
was	O
found	O
in	O
a	O
soluble	O
extract	O
(	O
20	O
000	O
X	O
g	O
supernatant	O
)	O
of	O
B	O
.	O
pertussis	O
cell	O
lysates	O
.	O

Use	O
of	O
monoclonal	O
antibodies	O
to	O
investigate	O
a	O
possible	O
role	O
of	O
thyroglobulin	O
in	O
the	O
pathogenesis	O
of	O
Graves	O
'	O
ophthalmopathy	O
.	O

One	O
possible	O
mechanism	O
for	O
Graves	O
'	O
ophthalmopathy	O
is	O
that	O
the	O
progressive	O
orbital	O
inflammation	O
is	O
initiated	O
by	O
formation	O
of	O
thyroglobulin	O
(	O
Tg	O
)	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
at	O
sites	O
of	O
Tg	O
binding	O
to	O
extraocular	O
muscle	O
membranes	O
.	O

In	O
this	O
study	O
monoclonal	O
antibodies	O
(	O
MCAB	O
)	O
against	O
human	O
Tg	O
were	O
used	O
as	O
probes	O
(	O
1	O
)	O
to	O
identify	O
Tg	O
in	O
eye	O
muscle	O
membranes	O
prepared	O
from	O
normal	O
subjects	O
and	O
(	O
2	O
)	O
to	O
measure	O
binding	O
of	O
human	O
Tg	O
and	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
to	O
eye	O
muscle	O
membranes	O
.	O

Reactivity	O
of	O
anti	O
-	O
Tg	O
MCAB	O
with	O
Tg	O
,	O
thyroid	O
,	O
and	O
eye	O
muscle	O
membranes	O
was	O
determined	O
by	O
binding	O
of	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
monoclonal	O
antibody	O
,	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
and	O
the	O
indirect	O
immunofluorescence	O
technique	O
.	O

Seven	O
membrane	O
fractions	O
,	O
prepared	O
by	O
differential	O
sucrose	O
gradient	O
centrifugation	O
,	O
were	O
used	O
.	O

Whereas	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
MCAB	O
bound	O
to	O
all	O
thyroid	O
membrane	O
fractions	O
tested	O
,	O
no	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
bound	O
to	O
eye	O
muscle	O
membranes	O
.	O

Similarly	O
,	O
reactivity	O
of	O
anti	O
-	O
Tg	O
MCAB	O
with	O
eye	O
muscle	O
membranes	O
was	O
not	O
demonstrated	O
in	O
ELISA	O
or	O
immunofluorescence	O
tests	O
.	O

Although	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
bound	O
to	O
thyroid	O
membranes	O
,	O
such	O
complexes	O
did	O
not	O
bind	O
to	O
eye	O
muscle	O
membranes	O
.	O

Significant	O
binding	O
of	O
[	O
125I	O
]	O
human	O
Tg	O
to	O
eye	O
muscle	O
or	O
thyroid	O
membranes	O
was	O
not	O
demonstrated	O
for	O
any	O
membrane	O
preparation	O
.	O

On	O
the	O
other	O
hand	O
moderate	O
,	O
but	O
significant	O
,	O
binding	O
to	O
skeletal	O
muscle	O
was	O
shown	O
.	O

Similar	O
results	O
were	O
found	O
using	O
an	O
ELISA	O
.	O

Binding	O
of	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
-	O
Tg	O
complexes	O
of	O
[	O
125I	O
]	O
Tg	O
to	O
thyroid	O
and	O
eye	O
muscle	O
membranes	O
was	O
not	O
affected	O
by	O
the	O
presence	O
of	O
normal	O
human	O
serum	O
,	O
phosphate	O
ions	O
,	O
pH	O
,	O
or	O
incubation	O
temperature	O
,	O
conditions	O
claimed	O
by	O
others	O
to	O
be	O
critical	O
for	O
Tg	O
and	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complex	O
binding	O
.	O

Since	O
Tg	O
is	O
not	O
present	O
in	O
normal	O
human	O
eye	O
muscle	O
a	O
major	O
role	O
of	O
Tg	O
,	O
or	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
,	O
in	O
the	O
pathogenesis	O
of	O
Graves	O
'	O
ophthalmopathy	O
appears	O
to	O
have	O
been	O
excluded	O
by	O
these	O
findings	O
.	O

DNA	O
methylation	O
and	O
expression	O
of	O
HLA	O
-	O
DR	O
alpha	O
.	O

B	O
-	O
cell	O
lines	O
established	O
from	O
two	O
individuals	O
with	O
T	O
-	O
cell	O
acute	O
lymphocytic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
express	O
HLA	O
-	O
DR	O
antigens	O
,	O
whereas	O
the	O
isogenic	O
T	O
-	O
cells	O
do	O
not	O
.	O

The	O
lack	O
of	O
expression	O
correlates	O
with	O
a	O
lack	O
of	O
detectable	O
HLA	O
-	O
DR	O
mRNA	O
.	O

All	O
of	O
the	O
DR	O
alpha	O
DNA	O
sequences	O
detected	O
by	O
a	O
cloned	O
DR	O
alpha	O
cDNA	O
probe	O
are	O
contained	O
in	O
a	O
BglII	O
fragment	O
which	O
varies	O
slightly	O
in	O
size	O
(	O
4	O
.	O
0	O
to	O
4	O
.	O
8	O
kilobases	O
)	O
from	O
one	O
individual	O
to	O
another	O
.	O

In	O
DNA	O
from	O
the	O
T	O
-	O
cells	O
not	O
expressing	O
DR	O
alpha	O
mRNA	O
,	O
all	O
of	O
the	O
potential	O
HpaII	O
sites	O
within	O
the	O
BglII	O
fragment	O
appeared	O
to	O
be	O
methylated	O
.	O

In	O
contrast	O
,	O
at	O
least	O
some	O
of	O
these	O
sites	O
were	O
not	O
methylated	O
in	O
DNA	O
from	O
the	O
B	O
-	O
cells	O
expressing	O
high	O
levels	O
of	O
DR	O
alpha	O
mRNA	O
.	O

Treatment	O
of	O
these	O
T	O
-	O
cells	O
with	O
5	O
-	O
azacytidine	O
resulted	O
in	O
the	O
induction	O
of	O
DR	O
surface	O
antigen	O
expression	O
,	O
the	O
appearance	O
of	O
DR	O
alpha	O
mRNA	O
,	O
and	O
the	O
partial	O
demethylation	O
of	O
the	O
DR	O
alpha	O
DNA	O
sequences	O
.	O

T	O
-	O
cell	O
lines	O
established	O
from	O
human	O
T	O
-	O
cell	O
leukemia	O
-	O
lymphoma	O
virus	O
associated	O
T	O
-	O
cell	O
neoplasias	O
,	O
in	O
contrast	O
to	O
the	O
T	O
-	O
cell	O
acute	O
lymphocytic	O
leukemia	O
cell	O
lines	O
,	O
expressed	O
both	O
DR	O
antigens	O
and	O
DR	O
alpha	O
mRNA	O
;	O
the	O
HpaII	O
sites	O
within	O
the	O
BglII	O
fragment	O
of	O
DR	O
alpha	O
DNA	O
of	O
these	O
human	O
T	O
-	O
cell	O
leukemia	O
-	O
lymphoma	O
virus	O
-	O
positive	O
T	O
-	O
cell	O
lines	O
were	O
in	O
all	O
cases	O
at	O
least	O
partially	O
unmethylated	O
.	O

Uncultured	O
peripheral	O
blood	O
T	O
-	O
cells	O
from	O
human	O
T	O
-	O
cell	O
leukemia	O
-	O
lymphoma	O
virus	O
-	O
infected	O
individuals	O
expressed	O
DR	O
antigens	O
at	O
a	O
low	O
level	O
,	O
and	O
the	O
DR	O
alpha	O
locus	O
was	O
partially	O
unmethylated	O
.	O

After	O
48	O
h	O
in	O
culture	O
,	O
DR	O
antigen	O
expression	O
was	O
substantially	O
increased	O
,	O
but	O
no	O
significant	O
changes	O
were	O
observed	O
in	O
methylation	O
of	O
the	O
DR	O
alpha	O
locus	O
or	O
in	O
the	O
amount	O
of	O
DR	O
mRNA	O
which	O
was	O
present	O
.	O

This	O
suggests	O
that	O
expression	O
of	O
DR	O
antigens	O
also	O
can	O
be	O
modulated	O
post	O
-	O
transcriptionally	O
.	O

Oesophageal	O
candidiasis	O
and	O
croup	O
in	O
a	O
child	O
with	O
defective	O
neutrophil	O
motility	O
.	O

Severe	O
oesophageal	O
candidiasis	O
and	O
croup	O
due	O
to	O
involvement	O
of	O
the	O
larynx	O
developed	O
insidiously	O
in	O
a	O
girl	O
aged	O
20	O
months	O
.	O

There	O
had	O
been	O
delayed	O
separation	O
of	O
the	O
umbilical	O
cord	O
and	O
repeated	O
infections	O
associated	O
with	O
a	O
defect	O
of	O
neutrophil	O
motility	O
.	O

The	O
significance	O
of	O
the	O
early	O
clinical	O
features	O
was	O
not	O
fully	O
appreciated	O
and	O
the	O
diagnosis	O
considered	O
only	O
when	O
stricture	O
of	O
the	O
oesophagus	O
became	O
evident	O
.	O

She	O
was	O
treated	O
with	O
oral	O
ketoconazole	O
100	O
mg	O
daily	O
.	O

After	O
one	O
month	O
'	O
s	O
treatment	O
there	O
was	O
striking	O
radiological	O
improvement	O
apart	O
from	O
the	O
persistence	O
of	O
the	O
oesophageal	O
stricture	O
.	O

The	O
croup	O
resolved	O
completely	O
but	O
there	O
was	O
only	O
partial	O
relief	O
of	O
dysphagia	O
because	O
of	O
the	O
residual	O
stricture	O
.	O

We	O
would	O
emphasis	O
that	O
candidiasis	O
should	O
be	O
anticipated	O
and	O
treated	O
vigorously	O
in	O
children	O
with	O
such	O
a	O
defect	O
of	O
neutrophil	O
motility	O
.	O

Rapid	O
micromeasurement	O
of	O
lactate	O
in	O
whole	O
blood	O
.	O

A	O
new	O
lactate	O
sensor	O
makes	O
it	O
possible	O
to	O
measure	O
the	O
lactate	O
content	O
of	O
whole	O
blood	O
directly	O
in	O
less	O
than	O
1	O
min	O
,	O
using	O
only	O
a	O
10	O
-	O
microL	O
blood	O
sample	O
.	O

The	O
procedure	O
works	O
equally	O
well	O
with	O
plasma	O
,	O
serum	O
,	O
spinal	O
fluid	O
,	O
other	O
body	O
fluids	O
,	O
or	O
tissue	O
homogenates	O
.	O

The	O
instrument	O
is	O
calibrated	O
with	O
lactate	O
standards	O
between	O
0	O
and	O
15	O
mMol	O
/	O
L	O
.	O

The	O
sensor	O
,	O
a	O
polarographic	O
enzyme	O
electrode	O
,	O
gives	O
a	O
current	O
which	O
is	O
a	O
linear	O
function	O
of	O
the	O
lactate	O
concentration	O
.	O

There	O
is	O
no	O
interference	O
from	O
glucose	O
,	O
pyruvate	O
,	O
alcohol	O
,	O
ascorbate	O
,	O
anticoagulants	O
,	O
lidocaine	O
,	O
acetaminophen	O
,	O
or	O
other	O
drugs	O
and	O
metabolites	O
commonly	O
encountered	O
in	O
critically	O
ill	O
patients	O
.	O

The	O
lactate	O
sensor	O
is	O
composed	O
of	O
a	O
peroxide	O
sensor	O
and	O
an	O
enzyme	O
transducer	O
membrane	O
.	O

The	O
lactate	O
is	O
stoichiometrically	O
converted	O
to	O
pyruvate	O
and	O
hydrogen	O
peroxide	O
by	O
lactate	O
oxygen	O
oxidoreductase	O
derived	O
from	O
Pediococcus	O
species	O
.	O

The	O
oxygen	O
required	O
for	O
the	O
enzymatic	O
oxidation	O
is	O
supplied	O
via	O
an	O
air	O
-	O
permeable	O
silicone	O
elastomeric	O
membrane	O
used	O
for	O
stirring	O
.	O

Comparison	O
of	O
our	O
new	O
electroenzymatic	O
method	O
with	O
the	O
Boehringer	O
-	O
Mannheim	O
photoenzymatic	O
method	O
gives	O
correlations	O
of	O
0	O
.	O
997	O
for	O
both	O
whole	O
blood	O
and	O
plasma	O
.	O

The	O
effect	O
of	O
translocations	O
on	O
the	O
cellular	O
myc	O
gene	O
in	O
Burkitt	O
lymphomas	O
.	O

Chromosomal	O
translocations	O
are	O
found	O
to	O
be	O
a	O
characteristic	O
feature	O
of	O
Burkitt	O
lymphomas	O
.	O

Similar	O
translocations	O
are	O
found	O
in	O
mouse	O
plasmacytomas	O
and	O
both	O
diseases	O
involve	O
interchanges	O
between	O
one	O
of	O
the	O
immunoglobulin	O
loci	O
and	O
DNA	O
in	O
the	O
vicinity	O
of	O
the	O
myc	O
gene	O
.	O

The	O
structure	O
of	O
the	O
myc	O
gene	O
has	O
been	O
elucidated	O
from	O
studies	O
on	O
translocated	O
versions	O
of	O
the	O
gene	O
.	O

Activation	O
of	O
the	O
myc	O
gene	O
may	O
play	O
a	O
role	O
in	O
transformation	O
by	O
promoting	O
growth	O
of	O
the	O
cells	O
bearing	O
the	O
rearranged	O
chromosomes	O
.	O

Preparation	O
and	O
physicochemical	O
and	O
immunological	O
characterization	O
of	O
polysaccharide	O
-	O
outer	O
membrane	O
protein	O
complexes	O
of	O
Neisseria	O
meningitidis	O
.	O

A	O
crude	O
complex	O
containing	O
group	O
C	O
polysaccharide	O
,	O
outer	O
membrane	O
proteins	O
,	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
was	O
isolated	O
from	O
the	O
cell	O
-	O
free	O
culture	O
liquid	O
of	O
Neisseria	O
meningitidis	O
serogroup	O
C	O
,	O
serotype	O
2a	O
.	O

Group	O
C	O
polysaccharide	O
and	O
LPS	O
were	O
removed	O
from	O
this	O
complex	O
,	O
resulting	O
in	O
an	O
outer	O
membrane	O
complex	O
and	O
a	O
purified	O
complex	O
,	O
respectively	O
.	O

Analysis	O
by	O
electron	O
microscopy	O
showed	O
the	O
outer	O
membrane	O
origin	O
of	O
the	O
crude	O
complex	O
and	O
the	O
outer	O
membrane	O
complex	O
,	O
whereas	O
such	O
a	O
structure	O
was	O
absent	O
in	O
the	O
purified	O
complex	O
.	O

Sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
patterns	O
of	O
the	O
three	O
complexes	O
were	O
identical	O
.	O

Pyrolysis	O
-	O
mass	O
spectrometry	O
data	O
correlated	O
well	O
with	O
those	O
obtained	O
by	O
the	O
biochemical	O
assays	O
and	O
suggested	O
a	O
low	O
LPS	O
content	O
in	O
the	O
purified	O
complex	O
and	O
a	O
low	O
polysaccharide	O
content	O
in	O
the	O
outer	O
membrane	O
complex	O
.	O

The	O
purified	O
complex	O
was	O
shown	O
to	O
be	O
nonpyrogenic	O
and	O
could	O
be	O
prepared	O
with	O
the	O
same	O
yield	O
as	O
that	O
of	O
purified	O
polysaccharide	O
.	O

The	O
immunogenic	O
activities	O
of	O
the	O
complexes	O
were	O
studied	O
in	O
mice	O
.	O

The	O
antibodies	O
were	O
measured	O
by	O
the	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
;	O
and	O
the	O
bactericidal	O
antibody	O
assay	O
.	O

All	O
complexes	O
induced	O
immunoglobulin	O
G	O
antibodies	O
to	O
group	O
C	O
polysaccharide	O
as	O
well	O
as	O
to	O
the	O
serotype	O
antigen	O
,	O
although	O
the	O
removal	O
of	O
polysaccharide	O
and	O
LPS	O
resulted	O
in	O
a	O
reduction	O
of	O
the	O
immunogenic	O
activities	O
of	O
outer	O
membrane	O
complex	O
and	O
purified	O
complex	O
,	O
respectively	O
.	O

A	O
second	O
dose	O
of	O
all	O
complexes	O
produced	O
a	O
clear	O
booster	O
effect	O
of	O
both	O
antibody	O
responses	O
.	O

The	O
antibodies	O
were	O
bactericidal	O
.	O

[	O
Suppurated	O
acute	O
obstructive	O
cholangitis	O
.	O
Anatomoclinical	O
and	O
therapeutic	O
aspects	O
]	O
.	O

A	O
total	O
of	O
134	O
cases	O
are	O
discussed	O
,	O
with	O
suppurated	O
acute	O
obstructive	O
angiocholitis	O
,	O
that	O
underwent	O
surgical	O
treatment	O
over	O
a	O
period	O
of	O
10	O
years	O
,	O
representing	O
12	O
,	O
8	O
%	O
of	O
the	O
total	O
number	O
of	O
organic	O
obstructions	O
of	O
the	O
hepato	O
-	O
choledocus	O
.	O

From	O
the	O
standpoint	O
of	O
the	O
etiopathogenic	O
mechanisms	O
the	O
angiocholitis	O
was	O
determined	O
by	O
biliary	O
lithiasis	O
in	O
59	O
cases	O
,	O
by	O
sclerosis	O
of	O
the	O
Oddi	O
sphincter	O
in	O
5	O
cases	O
,	O
by	O
postoperative	O
cicatriceal	O
stenosis	O
of	O
the	O
main	O
biliary	O
pathway	O
in	O
2	O
cases	O
,	O
by	O
hepatic	O
hydatitosis	O
in	O
16	O
cases	O
,	O
by	O
Vater	O
ampuloma	O
in	O
10	O
cases	O
by	O
cancers	O
of	O
the	O
main	O
biliary	O
pathway	O
in	O
40	O
cases	O
and	O
by	O
the	O
congenital	O
cyst	O
of	O
the	O
choledocus	O
in	O
one	O
case	O
.	O

The	O
high	O
frequency	O
was	O
noted	O
,	O
of	O
the	O
severe	O
forms	O
of	O
ictero	O
-	O
uremigenic	O
angiocholitis	O
(	O
representing	O
68	O
cases	O
,	O
or	O
50	O
,	O
7	O
%	O
of	O
the	O
total	O
,	O
with	O
a	O
death	O
rate	O
of	O
34	O
%	O
)	O
.	O

Medico	O
-	O
surgical	O
treatment	O
should	O
be	O
performed	O
as	O
early	O
as	O
possible	O
,	O
and	O
it	O
must	O
be	O
intensive	O
,	O
complex	O
,	O
and	O
adapted	O
to	O
the	O
anatomo	O
-	O
clinical	O
forms	O
.	O

The	O
authors	O
performed	O
evacuation	O
choledocotomy	O
with	O
external	O
draining	O
in	O
22	O
cases	O
(	O
3	O
deaths	O
)	O
,	O
and	O
choledoco	O
-	O
duodenal	O
anastomosis	O
in	O
46	O
cases	O
(	O
10	O
deaths	O
)	O
,	O
choledoco	O
-	O
jejunostomia	O
in	O
3	O
cases	O
,	O
Oddi	O
sphincterotomia	O
in	O
12	O
cases	O
(	O
2	O
deaths	O
)	O
ampulectomia	O
in	O
5	O
cases	O
(	O
2	O
deaths	O
)	O
.	O

Peripheral	O
bilio	O
-	O
hepatodigestive	O
anastomoses	O
were	O
performed	O
in	O
40	O
cases	O
with	O
5	O
deaths	O
.	O

[	O
Reactive	O
states	O
among	O
psychopathic	O
personalities	O
of	O
different	O
clinical	O
groups	O
]	O
.	O

On	O
the	O
basis	O
of	O
a	O
clinical	O
follow	O
-	O
up	O
of	O
71	O
psychopaths	O
with	O
manifestations	O
of	O
reactive	O
psychosis	O
,	O
the	O
authors	O
established	O
the	O
clinico	O
-	O
typological	O
characteristics	O
of	O
both	O
groups	O
of	O
pathology	O
and	O
the	O
system	O
of	O
correlations	O
between	O
them	O
.	O

They	O
also	O
described	O
the	O
structure	O
of	O
the	O
psychopathic	O
and	O
psychogenic	O
syndromes	O
,	O
the	O
type	O
of	O
psychopathic	O
personality	O
reaction	O
and	O
the	O
form	O
of	O
psychogenic	O
responses	O
and	O
proved	O
statistically	O
their	O
close	O
interrelationship	O
.	O

Data	O
were	O
obtained	O
on	O
some	O
general	O
regularities	O
of	O
interrelations	O
of	O
reactive	O
psychoses	O
with	O
a	O
psychopathic	O
background	O
which	O
are	O
important	O
for	O
the	O
prognosis	O
,	O
prophylaxis	O
and	O
therapy	O
of	O
reactive	O
states	O
.	O

Hemostasis	O
and	O
mechanism	O
of	O
action	O
of	O
selective	O
antimetastatic	O
drugs	O
in	O
mice	O
bearing	O
Lewis	O
lung	O
carcinoma	O
.	O

The	O
selective	O
antimetastatic	O
agents	O
p	O
-	O
(	O
3	O
,	O
3	O
-	O
dimethyl	O
-	O
1	O
-	O
triazeno	O
)	O
benzoic	O
acid	O
potassium	O
salt	O
(	O
DM	O
-	O
COOK	O
)	O
,	O
5	O
-	O
(	O
3	O
,	O
3	O
-	O
dimethyl	O
-	O
1	O
-	O
triazeno	O
)	O
imidazole	O
-	O
4	O
-	O
carboxamide	O
(	O
DTIC	O
)	O
and	O
(	O
+	O
/	O
-	O
)	O
1	O
,	O
2	O
-	O
di	O
(	O
3	O
,	O
5	O
-	O
dioxopiperazin	O
-	O
1	O
-	O
yl	O
)	O
propane	O
(	O
ICRF	O
-	O
159	O
)	O
have	O
been	O
shown	O
to	O
markedly	O
depress	O
the	O
formation	O
of	O
spontaneous	O
hematogenous	O
metastases	O
in	O
mice	O
bearing	O
s	O
.	O
c	O
.	O

Lewis	O
lung	O
carcinoma	O
,	O
with	O
a	O
mechanism	O
unrelated	O
to	O
cytotoxicity	O
for	O
tumor	O
cells	O
.	O

The	O
effects	O
on	O
hemostasis	O
of	O
DM	O
-	O
COOK	O
,	O
DTIC	O
and	O
ICRF	O
-	O
159	O
have	O
thus	O
been	O
examined	O
in	O
comparison	O
with	O
those	O
of	O
a	O
purely	O
cytotoxic	O
agent	O
,	O
cyclophosphamide	O
,	O
in	O
mice	O
bearing	O
i	O
.	O
m	O
.	O

Lewis	O
lung	O
carcinoma	O
.	O

The	O
parameters	O
considered	O
are	O
the	O
number	O
of	O
platelets	O
and	O
their	O
aggregability	O
,	O
prothrombin	O
and	O
partial	O
thromboplastin	O
times	O
,	O
plasma	O
fibrinogen	O
concentration	O
and	O
tumor	O
cell	O
procoagulant	O
activity	O
.	O

Slight	O
variations	O
are	O
caused	O
by	O
drug	O
treatment	O
in	O
tumor	O
-	O
bearing	O
mice	O
as	O
compared	O
with	O
untreated	O
tumor	O
-	O
bearing	O
controls	O
;	O
the	O
pattern	O
of	O
effects	O
of	O
the	O
selective	O
antimetastatic	O
agents	O
does	O
not	O
differ	O
from	O
that	O
of	O
the	O
reference	O
cytotoxic	O
compound	O
used	O
,	O
cyclophosphamide	O
.	O

These	O
data	O
thus	O
indicate	O
that	O
the	O
effects	O
on	O
hemostasis	O
of	O
the	O
drugs	O
examined	O
can	O
contribute	O
only	O
marginally	O
to	O
their	O
antimetastatic	O
action	O
,	O
since	O
more	O
pronounced	O
effects	O
on	O
hemostasis	O
have	O
been	O
shown	O
to	O
be	O
required	O
to	O
significantly	O
affect	O
metastasis	O
formation	O
.	O

Purification	O
and	O
characterization	O
of	O
various	O
esterases	O
from	O
rat	O
liver	O
.	O

The	O
major	O
rat	O
liver	O
microsomal	O
esterases	O
acting	O
on	O
o	O
-	O
nitrophenylacetate	O
with	O
isoelectric	O
points	O
5	O
.	O
0	O
,	O
5	O
.	O
5	O
,	O
6	O
.	O
1	O
and	O
6	O
.	O
4	O
were	O
resolved	O
by	O
isoelectric	O
focusing	O
.	O

Molecular	O
weights	O
were	O
determined	O
by	O
sedimentation	O
analysis	O
in	O
isokinetic	O
gradients	O
of	O
sucrose	O
and	O
,	O
after	O
purification	O
,	O
in	O
sodium	O
dodecyl	O
sulphate	O
/	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

Their	O
subunit	O
molecular	O
weights	O
were	O
between	O
57	O
000	O
and	O
60	O
000	O
.	O

They	O
behaved	O
as	O
monomers	O
except	O
the	O
pI	O
-	O
6	O
.	O
1	O
enzyme	O
which	O
behaved	O
as	O
a	O
trimer	O
.	O

Esterases	O
of	O
pI	O
5	O
.	O
0	O
,	O
pI	O
6	O
.	O
1	O
and	O
pI	O
6	O
.	O
4	O
behaved	O
like	O
glycoproteins	O
of	O
the	O
polymannose	O
type	O
in	O
the	O
presence	O
of	O
125I	O
-	O
labelled	O
concanavalin	O
A	O
.	O

Preparations	O
of	O
the	O
pI	O
-	O
5	O
.	O
0	O
enzyme	O
contained	O
two	O
esterases	O
of	O
highly	O
homologous	O
structure	O
.	O

Antibodies	O
directed	O
against	O
this	O
preparation	O
did	O
not	O
inhibit	O
but	O
precipitated	O
pI	O
-	O
5	O
.	O
0	O
esterase	O
activity	O
quantitatively	O
.	O

They	O
did	O
not	O
react	O
with	O
the	O
pI	O
-	O
6	O
.	O
1	O
and	O
pI	O
-	O
6	O
.	O
4	O
esterases	O
but	O
precipitated	O
several	O
nonimmunologically	O
related	O
esterases	O
.	O

Two	O
of	O
these	O
enzymes	O
were	O
inducible	O
by	O
phenobarbital	O
.	O

Total	O
activity	O
was	O
very	O
low	O
in	O
3	O
-	O
day	O
-	O
old	O
animals	O
.	O

Individual	O
esterase	O
activities	O
rose	O
at	O
different	O
rates	O
during	O
development	O
;	O
the	O
enzyme	O
focusing	O
near	O
pI	O
5	O
.	O
0	O
was	O
about	O
three	O
times	O
more	O
active	O
in	O
adult	O
females	O
than	O
in	O
males	O
.	O

All	O
microsomal	O
esterases	O
are	O
located	O
on	O
the	O
luminal	O
side	O
of	O
the	O
endoplasmic	O
reticulum	O
.	O

Hippocampal	O
afterdischarge	O
interferes	O
with	O
storage	O
of	O
spatial	O
information	O
in	O
a	O
working	O
memory	O
test	O
.	O

In	O
an	O
attempt	O
to	O
impair	O
spatial	O
working	O
memory	O
by	O
reversible	O
functional	O
blockade	O
rather	O
than	O
by	O
irreversible	O
lesion	O
of	O
the	O
hippocampus	O
,	O
eight	O
male	O
hooded	O
rats	O
were	O
trained	O
to	O
asymptotic	O
performance	O
of	O
1	O
.	O
2	O
to	O
1	O
.	O
4	O
errors	O
per	O
trial	O
in	O
the	O
spatial	O
12	O
-	O
choice	O
apparatus	O
(	O
Bure	O
s	O
et	O
al	O
.	O
1982	O
)	O
,	O
formally	O
similar	O
to	O
the	O
radial	O
maze	O
.	O

The	O
rats	O
were	O
implanted	O
with	O
hippocampal	O
stimulating	O
and	O
recording	O
electrodes	O
,	O
which	O
were	O
used	O
for	O
eliciting	O
and	O
monitoring	O
hippocampal	O
afterdischarge	O
(	O
HAD	O
)	O
lasting	O
for	O
at	O
least	O
20	O
s	O
.	O

In	O
Experiment	O
1	O
,	O
HAD	O
elicited	O
1	O
or	O
10	O
min	O
before	O
testing	O
increased	O
the	O
incidence	O
of	O
errors	O
to	O
2	O
.	O
75	O
or	O
2	O
.	O
50	O
per	O
trial	O
,	O
respectively	O
,	O
but	O
the	O
performance	O
still	O
remained	O
above	O
chance	O
level	O
(	O
4	O
.	O
18	O
)	O
.	O

In	O
Experiment	O
2	O
,	O
interruption	O
of	O
the	O
trial	O
by	O
1	O
,	O
10	O
,	O
20	O
and	O
30	O
min	O
intervals	O
inserted	O
between	O
choices	O
6	O
and	O
7	O
increased	O
the	O
incidence	O
of	O
errors	O
in	O
choices	O
7	O
to	O
12	O
to	O
1	O
.	O
0	O
,	O
1	O
.	O
5	O
,	O
2	O
.	O
1	O
and	O
2	O
.	O
5	O
,	O
respectively	O
.	O

HAD	O
elicited	O
immediately	O
after	O
choice	O
6	O
increased	O
error	O
incidence	O
in	O
the	O
subsequent	O
6	O
choices	O
performed	O
after	O
1	O
-	O
min	O
or	O
10	O
-	O
min	O
intervals	O
to	O
3	O
.	O
1	O
or	O
2	O
.	O
75	O
,	O
respectively	O
,	O
i	O
.	O
e	O
.	O
to	O
the	O
chance	O
level	O
of	O
3	O
errors	O
in	O
6	O
choices	O
.	O

It	O
is	O
concluded	O
that	O
HAD	O
elicits	O
transient	O
shortening	O
of	O
the	O
memory	O
span	O
for	O
newly	O
acquired	O
spatial	O
information	O
(	O
anterograde	O
effect	O
)	O
and	O
erases	O
the	O
current	O
spatial	O
working	O
memory	O
record	O
(	O
retrograde	O
effect	O
)	O
.	O

Inhibition	O
by	O
N	O
-	O
(	O
phosphonacetyl	O
)	O
-	O
L	O
-	O
aspartate	O
of	O
Ehrlich	O
ascites	O
tumour	O
growth	O
and	O
glucose	O
transport	O
.	O

N	O
-	O
(	O
Phosphonacetyl	O
)	O
-	O
L	O
-	O
aspartate	O
(	O
PALA	O
)	O
suppressed	O
the	O
growth	O
of	O
Ehrlich	O
ascites	O
tumour	O
cells	O
in	O
vivo	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Simultaneously	O
as	O
the	O
growth	O
rate	O
decreased	O
,	O
the	O
cellular	O
uptake	O
of	O
glucose	O
and	O
the	O
density	O
of	O
a	O
class	O
of	O
glucose	O
-	O
reversible	O
binding	O
sites	O
for	O
cytochalasin	O
B	O
on	O
the	O
cell	O
surface	O
were	O
also	O
found	O
to	O
be	O
reduced	O
.	O

There	O
is	O
a	O
highly	O
significant	O
correlation	O
between	O
the	O
magnitude	O
of	O
changes	O
in	O
the	O
number	O
of	O
cytochalasin	O
B	O
binding	O
sites	O
and	O
the	O
magnitude	O
of	O
changes	O
in	O
glucose	O
uptake	O
.	O

The	O
physiological	O
significance	O
of	O
these	O
observations	O
are	O
discussed	O
.	O

[	O
In	O
vitro	O
studies	O
of	O
the	O
thyroid	O
gland	O
regulation	O
principles	O
and	O
their	O
evaluation	O
]	O
.	O

The	O
free	O
fractions	O
of	O
the	O
thyroid	O
hormone	O
further	O
the	O
metabolism	O
of	O
the	O
body	O
cells	O
and	O
regulate	O
the	O
synthesis	O
of	O
the	O
thyroid	O
hormone	O
.	O

Once	O
the	O
level	O
of	O
FT3	O
and	O
FT4	O
decreases	O
.	O

With	O
the	O
help	O
of	O
a	O
liberation	O
of	O
the	O
hormone	O
stimulating	O
the	O
thyroid	O
gland	O
from	O
the	O
anterior	O
lobe	O
of	O
the	O
pituitary	O
gland	O
the	O
lack	O
of	O
thyroid	O
hormone	O
is	O
corrected	O
.	O

The	O
synthesis	O
and	O
secretion	O
of	O
the	O
thyroid	O
gland	O
stimulating	O
hormone	O
is	O
induced	O
by	O
the	O
thyreotropin	O
releasing	O
hormone	O
which	O
is	O
given	O
by	O
the	O
hypothalamus	O
.	O

Moreover	O
,	O
the	O
organism	O
is	O
able	O
as	O
needed	O
to	O
carry	O
out	O
the	O
monodiodation	O
of	O
LT4	O
to	O
biologically	O
active	O
LT3	O
or	O
biologically	O
inactive	O
so	O
-	O
called	O
revers	O
T3	O
(	O
RT3	O
)	O
.	O

The	O
estimation	O
of	O
thyroid	O
gland	O
stimulating	O
hormone	O
before	O
and	O
30	O
minutes	O
after	O
intravenous	O
application	O
of	O
thyreotropin	O
releasing	O
hormone	O
has	O
its	O
main	O
importance	O
for	O
the	O
early	O
recognition	O
of	O
a	O
disturbance	O
of	O
the	O
regulating	O
circle	O
hypophysis	O
-	O
thyroid	O
gland	O
,	O
above	O
all	O
in	O
the	O
diagnosis	O
of	O
clinically	O
not	O
yet	O
manifest	O
clinical	O
pictures	O
,	O
such	O
as	O
the	O
latent	O
hypothyreosis	O
and	O
the	O
latent	O
hyperthyreosis	O
,	O
respectively	O
(	O
Basedow	O
hyperthyreosis	O
and	O
thyroidal	O
autonomy	O
)	O
.	O

According	O
to	O
the	O
questioning	O
the	O
estimations	O
of	O
the	O
levels	O
of	O
the	O
thyroid	O
hormones	O
and	O
of	O
the	O
thyroid	O
gland	O
stimulating	O
hormone	O
should	O
be	O
used	O
stepwise	O
.	O

Relationship	O
of	O
self	O
-	O
concept	O
during	O
late	O
pregnancy	O
to	O
neonatal	O
perception	O
and	O
parenting	O
profile	O
.	O

Thirty	O
-	O
one	O
gravidas	O
were	O
studied	O
to	O
examine	O
the	O
relationship	O
between	O
a	O
woman	O
'	O
s	O
feelings	O
about	O
herself	O
during	O
late	O
pregnancy	O
,	O
her	O
perception	O
of	O
her	O
newborn	O
,	O
and	O
her	O
profile	O
of	O
parenting	O
.	O

The	O
Tennessee	O
Self	O
-	O
Concept	O
Scale	O
was	O
completed	O
during	O
the	O
third	O
trimester	O
of	O
pregnancy	O
,	O
the	O
Neonatal	O
Perception	O
Inventory	O
I	O
at	O
one	O
-	O
to	O
-	O
two	O
days	O
postpartum	O
,	O
and	O
the	O
Neonatal	O
Perception	O
Inventory	O
II	O
and	O
the	O
Michigan	O
Screening	O
Profile	O
of	O
Parenting	O
at	O
four	O
-	O
to	O
-	O
six	O
weeks	O
postpartum	O
.	O

When	O
considered	O
separately	O
,	O
no	O
positive	O
significant	O
relationships	O
were	O
found	O
between	O
scores	O
on	O
these	O
variables	O
.	O

However	O
,	O
all	O
subjects	O
with	O
negative	O
scores	O
on	O
both	O
self	O
-	O
concept	O
and	O
neonatal	O
perception	O
had	O
negative	O
scores	O
on	O
at	O
least	O
two	O
subscales	O
of	O
the	O
parenting	O
profile	O
.	O

Differential	O
reactivity	O
of	O
the	O
functional	O
sulfhydryl	O
groups	O
of	O
cysteine	O
-	O
32	O
and	O
cysteine	O
-	O
35	O
present	O
in	O
the	O
reduced	O
form	O
of	O
thioredoxin	O
from	O
Escherichia	O
coli	O
.	O

Only	O
one	O
of	O
the	O
sulfhydryl	O
groups	O
from	O
Cys	O
-	O
32	O
and	O
Cys	O
-	O
35	O
in	O
the	O
active	O
center	O
of	O
native	O
Escherichia	O
coli	O
thioredoxin	O
-	O
(	O
SH	O
)	O
2	O
was	O
alkylated	O
by	O
excess	O
iodoacetic	O
acid	O
at	O
pH	O
values	O
below	O
8	O
.	O
0	O
.	O

Both	O
groups	O
reacted	O
in	O
the	O
protein	O
denatured	O
with	O
4	O
.	O
5	O
M	O
guanidine	O
hydrochloride	O
.	O

The	O
second	O
order	O
rate	O
of	O
alkylation	O
of	O
thioredoxin	O
-	O
(	O
SH	O
)	O
2	O
with	O
1	O
eq	O
of	O
iodoacetic	O
acid	O
was	O
pH	O
-	O
dependent	O
and	O
showed	O
independent	O
initial	O
reactions	O
of	O
one	O
thiolate	O
ion	O
with	O
a	O
pK	O
value	O
of	O
6	O
.	O
7	O
and	O
a	O
second	O
with	O
a	O
pK	O
value	O
close	O
to	O
9	O
.	O
0	O
.	O

The	O
same	O
pH	O
dependence	O
was	O
observed	O
for	O
alkylation	O
with	O
iodoacetamide	O
but	O
the	O
apparent	O
rate	O
constant	O
,	O
107	O
M	O
-	O
1	O
S	O
-	O
1	O
at	O
pH	O
7	O
.	O
2	O
,	O
was	O
about	O
20	O
-	O
fold	O
higher	O
than	O
the	O
corresponding	O
rate	O
with	O
iodoacetate	O
.	O

The	O
sulfhydryl	O
group	O
with	O
a	O
pK	O
value	O
of	O
6	O
.	O
7	O
was	O
shown	O
to	O
belong	O
to	O
Cys	O
-	O
32	O
by	O
labeling	O
thioredoxin	O
with	O
[	O
14C	O
]	O
iodoacetic	O
acid	O
followed	O
by	O
complete	O
alkylation	O
with	O
[	O
3H	O
]	O
iodoacetate	O
and	O
amino	O
acid	O
sequence	O
analysis	O
of	O
peptides	O
from	O
the	O
active	O
center	O
.	O

The	O
abnormally	O
low	O
pK	O
value	O
of	O
Cys	O
-	O
32	O
is	O
suggested	O
to	O
arise	O
by	O
electrostatic	O
influence	O
from	O
a	O
positive	O
charge	O
on	O
the	O
amino	O
group	O
of	O
Lys	O
-	O
36	O
.	O

A	O
mechanism	O
of	O
action	O
for	O
thioredoxin	O
-	O
(	O
SH	O
)	O
2	O
as	O
a	O
protein	O
disulfide	O
reductase	O
has	O
been	O
formulated	O
.	O

This	O
is	O
based	O
on	O
an	O
initial	O
nucleophilic	O
attack	O
by	O
the	O
thiolate	O
of	O
Cys	O
-	O
32	O
with	O
the	O
formation	O
of	O
an	O
unstable	O
transient	O
mixed	O
disulfide	O
involving	O
Cys	O
-	O
32	O
and	O
one	O
of	O
the	O
sulfurs	O
in	O
the	O
substrate	O
.	O

This	O
is	O
followed	O
by	O
a	O
conformational	O
change	O
and	O
a	O
nucleophilic	O
attack	O
of	O
Cys	O
-	O
35	O
to	O
give	O
the	O
14	O
-	O
membered	O
disulfide	O
ring	O
in	O
thioredoxin	O
-	O
S2	O
and	O
the	O
dithiol	O
of	O
the	O
substrate	O
.	O

Subretinal	O
neovascularization	O
following	O
rubella	O
retinopathy	O
.	O

A	O
17	O
-	O
year	O
-	O
old	O
girl	O
and	O
an	O
11	O
-	O
year	O
-	O
old	O
girl	O
with	O
rubella	O
retinopathy	O
had	O
decreased	O
vision	O
in	O
one	O
eye	O
secondary	O
to	O
subretinal	O
neovascularization	O
and	O
hemorrhage	O
.	O

In	O
both	O
cases	O
a	O
disciform	O
scar	O
with	O
permanent	O
decrease	O
in	O
central	O
vision	O
resulted	O
.	O

Verrucous	O
carcinoma	O
of	O
the	O
endometrium	O
-	O
-	O
a	O
unique	O
neoplasm	O
with	O
long	O
survival	O
.	O

A	O
case	O
of	O
verrucous	O
carcinoma	O
of	O
the	O
endometrium	O
with	O
long	O
survival	O
is	O
described	O
.	O

It	O
represents	O
the	O
first	O
of	O
its	O
type	O
to	O
be	O
recorded	O
in	O
this	O
site	O
.	O

The	O
literature	O
on	O
verrucous	O
carcinoma	O
and	O
on	O
other	O
cases	O
of	O
squamous	O
carcinoma	O
of	O
the	O
endometrium	O
is	O
briefly	O
reviewed	O
.	O

Effects	O
of	O
3	O
-	O
chloromethylthiochromone	O
-	O
1	O
,	O
1	O
-	O
dioxide	O
on	O
nucleic	O
acid	O
,	O
protein	O
,	O
and	O
aerobic	O
and	O
anaerobic	O
metabolism	O
of	O
Ehrlich	O
ascites	O
tumor	O
cells	O
.	O

3	O
-	O
Chloromethylthiochromone	O
-	O
1	O
,	O
1	O
-	O
dioxide	O
was	O
observed	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
Ehrlich	O
ascites	O
carcinoma	O
growth	O
and	O
a	O
moderate	O
inhibitor	O
of	O
P	B
-	I
388	I
lymphocytic	O
leukemia	O
growth	O
at	O
10	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Preliminary	O
in	O
vitro	O
studies	O
showed	O
that	O
the	O
agents	O
significantly	O
inhibited	O
RNA	O
and	O
DNA	O
synthesis	O
in	O
Ehrlich	O
ascites	O
cells	O
.	O

In	O
vivo	O
studies	O
after	O
dosing	O
on	O
Days	O
6	O
,	O
7	O
,	O
and	O
8	O
demonstrated	O
the	O
same	O
reductions	O
in	O
nucleic	O
acid	O
synthesis	O
and	O
a	O
moderate	O
reduction	O
in	O
protein	O
synthesis	O
.	O

The	O
primary	O
site	O
of	O
nucleic	O
acid	O
synthesis	O
,	O
which	O
was	O
blocked	O
by	O
3	O
-	O
chloromethylthiochromone	O
,	O
was	O
at	O
orotidine	O
monophosphate	O
decarboxylase	O
in	O
the	O
primidine	O
pathway	O
.	O

Other	O
enzymes	O
,	O
in	O
anaerobic	O
and	O
aerobic	O
glycolysis	O
,	O
which	O
were	O
blocked	O
include	O
hexokinase	O
,	O
phosphofructokinase	O
,	O
succinic	O
and	O
alpha	O
-	O
ketoglutarate	O
dehydrogenases	O
,	O
as	O
well	O
as	O
States	O
3	O
and	O
4	O
of	O
oxidative	O
phosphorylation	O
.	O

Metabolic	O
alterations	O
in	O
a	O
noncachectic	O
animal	O
tumor	O
system	O
.	O

The	O
increased	O
energy	O
expended	O
by	O
the	O
host	O
to	O
synthesize	O
substrate	O
,	O
which	O
is	O
utilized	O
by	O
the	O
tumor	O
,	O
is	O
a	O
potential	O
cause	O
of	O
cancer	O
cachexia	O
.	O

In	O
vivo	O
glucose	O
and	O
alanine	O
kinetics	O
were	O
examined	O
by	O
tracer	O
methodology	O
in	O
a	O
sarcoma	O
-	O
bearing	O
rat	O
model	O
.	O

The	O
effects	O
of	O
3	O
-	O
mercaptopicolinic	O
acid	O
,	O
a	O
potent	O
inhibitor	O
of	O
gluconeogenesis	O
,	O
was	O
also	O
examined	O
on	O
this	O
model	O
.	O

Both	O
tumor	O
-	O
bearing	O
(	O
TB	O
)	O
and	O
nontumor	O
bearing	O
(	O
NTB	O
)	O
animals	O
were	O
gaining	O
weight	O
prior	O
to	O
study	O
and	O
the	O
tumors	O
were	O
relatively	O
small	O
.	O

The	O
TB	O
animals	O
had	O
significantly	O
lower	O
plasma	O
glucose	O
and	O
higher	O
blood	O
lactic	O
acid	O
levels	O
compared	O
with	O
NTB	O
animals	O
.	O

After	O
inhibition	O
of	O
gluconeogenesis	O
,	O
the	O
plasma	O
glucose	O
decreased	O
and	O
the	O
blood	O
lactate	O
increased	O
significantly	O
more	O
in	O
TB	O
than	O
NTB	O
animals	O
.	O

The	O
glucose	O
turnover	O
rate	O
was	O
significantly	O
greater	O
in	O
TB	O
compared	O
with	O
NTB	O
animals	O
,	O
as	O
was	O
the	O
rate	O
of	O
glucose	O
recycling	O
and	O
the	O
rate	O
of	O
gluconeogenesis	O
(	O
alanine	O
leads	O
to	O
glucose	O
)	O
,	O
both	O
energy	O
demanding	O
processes	O
.	O

These	O
results	O
suggest	O
that	O
the	O
tumor	O
-	O
bearing	O
animal	O
,	O
even	O
prior	O
to	O
significant	O
cachexia	O
,	O
has	O
an	O
excess	O
demand	O
for	O
energy	O
,	O
the	O
provision	O
of	O
which	O
may	O
be	O
a	O
significant	O
factor	O
in	O
malignant	O
cachexia	O
.	O

[	O
Organization	O
of	O
pectoral	O
muscle	O
motor	O
neurons	O
in	O
the	O
rat	O
.	O
Contribution	O
to	O
the	O
study	O
of	O
the	O
axillary	O
arch	O
(	O
Achselbogen	O
)	O
]	O
.	O

In	O
spite	O
of	O
their	O
role	O
of	O
the	O
forelimb	O
activity	O
,	O
the	O
organization	O
of	O
the	O
mammalian	O
pectoral	O
muscles	O
remains	O
unclear	O
.	O

In	O
order	O
to	O
get	O
more	O
information	O
,	O
we	O
have	O
studied	O
,	O
qualitatively	O
and	O
quantitatively	O
,	O
the	O
motor	O
pools	O
of	O
the	O
various	O
pectoral	O
muscles	O
in	O
the	O
rat	O
(	O
musculus	O
pectoralis	O
major	O
,	O
musculus	O
pectoralis	O
minor	O
and	O
musculus	O
panniculus	O
carnosus	O
)	O
.	O

The	O
method	O
applied	O
was	O
the	O
retrograde	O
transport	O
of	O
horseradish	O
peroxidase	O
by	O
the	O
peripheral	O
nerves	O
supplying	O
the	O
various	O
muscles	O
.	O

The	O
results	O
provided	O
the	O
precise	O
localization	O
within	O
the	O
ventral	O
horn	O
of	O
the	O
motor	O
neurons	O
from	O
the	O
pectoral	O
muscles	O
which	O
were	O
all	O
in	O
the	O
most	O
ventral	O
part	O
of	O
the	O
gray	O
matter	O
.	O

Three	O
distinct	O
motor	O
pools	O
were	O
observed	O
,	O
which	O
confirms	O
the	O
functional	O
identity	O
of	O
each	O
muscle	O
.	O

The	O
motor	O
neurons	O
of	O
m	O
.	O
panniculus	O
carnosus	O
exhibited	O
some	O
particularities	O
.	O

They	O
were	O
4	O
times	O
more	O
numerous	O
than	O
those	O
from	O
m	O
.	O
pectoralis	O
major	O
,	O
they	O
occupied	O
the	O
whole	O
ventral	O
edge	O
of	O
the	O
ventral	O
horn	O
,	O
from	O
its	O
medial	O
part	O
to	O
its	O
lateral	O
tip	O
.	O

The	O
cell	O
size	O
was	O
different	O
from	O
that	O
of	O
the	O
other	O
muscles	O
.	O

These	O
results	O
were	O
discussed	O
,	O
according	O
to	O
the	O
role	O
of	O
this	O
muscle	O
,	O
which	O
links	O
the	O
forelimb	O
to	O
the	O
whole	O
trunk	O
.	O

In	O
mammals	O
,	O
m	O
.	O
panniculus	O
carnosus	O
constitutes	O
,	O
with	O
musculus	O
latissimus	O
dorsi	O
,	O
the	O
axillary	O
arch	O
(	O
Achselbogen	O
)	O
.	O

A	O
small	O
area	O
of	O
overlapping	O
between	O
the	O
motor	O
pools	O
of	O
these	O
two	O
muscles	O
was	O
observed	O
.	O

It	O
was	O
suggested	O
that	O
the	O
muscular	O
fibers	O
from	O
the	O
axillary	O
arch	O
were	O
innervated	O
by	O
the	O
same	O
,	O
well	O
-	O
defined	O
spinal	O
area	O
,	O
independent	O
of	O
the	O
muscle	O
from	O
which	O
they	O
originate	O
.	O

An	O
unusual	O
case	O
of	O
benign	O
mucous	O
membrane	O
pemphigoid	O
.	O

This	O
case	O
of	O
benign	O
mucous	O
membrane	O
pemphigoid	O
(	O
BMMP	O
)	O
is	O
unusual	O
in	O
that	O
blistering	O
,	O
scarring	O
lesions	O
were	O
confined	O
to	O
the	O
skin	O
for	O
15	O
years	O
before	O
mucous	O
membranes	O
were	O
involved	O
.	O

The	O
onset	O
of	O
this	O
disorder	O
at	O
the	O
age	O
of	O
38	O
is	O
also	O
unusual	O
.	O

Detailed	O
immunological	O
investigation	O
was	O
performed	O
on	O
this	O
patient	O
but	O
the	O
results	O
in	O
no	O
way	O
clarify	O
the	O
present	O
confusion	O
regarding	O
the	O
immunopathological	O
processes	O
in	O
BMMP	O
related	O
to	O
those	O
operative	O
in	O
bullous	O
pemphigoid	O
.	O

Mast	O
cell	O
heparin	O
stimulates	O
migration	O
of	O
capillary	O
endothelial	O
cells	O
in	O
vitro	O
.	O

Migration	O
of	O
capillary	O
endothelial	O
cells	O
is	O
an	O
important	O
component	O
of	O
angiogenesis	O
in	O
vivo	O
.	O

Increased	O
numbers	O
of	O
mast	O
cells	O
have	O
been	O
associated	O
with	O
several	O
types	O
of	O
angiogenesis	O
.	O

We	O
have	O
used	O
a	O
quantitative	O
assay	O
in	O
vitro	O
to	O
demonstrate	O
that	O
mast	O
cells	O
release	O
a	O
factor	O
that	O
significantly	O
increases	O
bovine	O
capillary	O
endothelial	O
cell	O
migration	O
.	O

The	O
factor	O
is	O
present	O
in	O
medium	O
conditioned	O
by	O
mast	O
cells	O
as	O
well	O
as	O
lysates	O
of	O
mast	O
cells	O
.	O

The	O
stimulatory	O
effect	O
of	O
mast	O
cells	O
on	O
migration	O
is	O
specific	O
for	O
capillary	O
endothelial	O
cells	O
.	O

Furthermore	O
,	O
mast	O
cells	O
have	O
no	O
mitogenic	O
activity	O
for	O
capillary	O
endothelial	O
cells	O
.	O

Of	O
all	O
the	O
secretory	O
products	O
of	O
mast	O
cells	O
tested	O
,	O
only	O
heparin	O
stimulated	O
capillary	O
endothelial	O
cell	O
migration	O
in	O
vitro	O
.	O

Heparin	O
preparations	O
from	O
a	O
variety	O
of	O
sources	O
stimulated	O
capillary	O
endothelial	O
cell	O
migration	O
to	O
the	O
same	O
degree	O
but	O
did	O
not	O
stimulate	O
migration	O
of	O
several	O
other	O
cell	O
types	O
.	O

The	O
migration	O
activity	O
of	O
heparin	O
and	O
mast	O
cell	O
conditioned	O
medium	O
was	O
blocked	O
by	O
specific	O
antagonists	O
of	O
heparin	O
(	O
protamine	O
and	O
heparinase	O
)	O
,	O
but	O
not	O
by	O
chondroitinase	O
ABC	O
.	O

The	O
migration	O
activity	O
of	O
mast	O
cell	O
conditioned	O
medium	O
was	O
resistant	O
to	O
heat	O
(	O
100	O
degrees	O
C	O
)	O
and	O
incubation	O
with	O
proteolytic	O
enzymes	O
.	O

These	O
results	O
suggest	O
that	O
the	O
role	O
of	O
mast	O
cells	O
in	O
angiogenesis	O
may	O
be	O
to	O
enhance	O
migration	O
of	O
the	O
endothelial	O
cells	O
of	O
growing	O
capillaries	O
.	O

The	O
inhibition	O
of	O
cultured	O
myoblast	O
differentiation	O
by	O
the	O
simian	O
virus	O
40	O
large	O
T	O
antigen	O
occurs	O
after	O
myogenin	O
expression	O
and	O
Rb	O
up	O
-	O
regulation	O
and	O
is	O
not	O
exerted	O
by	O
transformation	O
-	O
competent	O
cytoplasmic	O
mutants	O
.	O

We	O
have	O
investigated	O
the	O
mechanism	O
by	O
which	O
the	O
simian	O
virus	O
40	O
large	O
T	O
antigen	O
(	O
SVLT	O
)	O
interferes	O
with	O
the	O
differentiation	O
of	O
C2	B
myoblasts	O
.	O

SVLT	O
mutants	O
,	O
defective	O
either	O
in	O
the	O
Rb	O
binding	O
site	O
,	O
near	O
the	O
N	O
-	O
terminal	O
end	O
,	O
in	O
a	O
region	O
that	O
affects	O
binding	O
to	O
p53	O
,	O
or	O
in	O
the	O
nuclear	O
transport	O
signal	O
,	O
were	O
also	O
employed	O
to	O
determine	O
whether	O
the	O
interference	O
was	O
especially	O
dependent	O
on	O
these	O
functional	O
domains	O
.	O

It	O
was	O
found	O
that	O
wild	O
-	O
type	O
(	O
wt	O
)	O
SVLT	O
strongly	O
inhibited	O
the	O
terminal	O
differentiation	O
of	O
mouse	O
C2	B
myoblasts	O
,	O
but	O
this	O
arrest	O
occurred	O
only	O
after	O
the	O
synthesis	O
of	O
myogenin	O
,	O
an	O
initial	O
step	O
in	O
biochemical	O
differentiation	O
.	O

Neither	O
the	O
synthesis	O
nor	O
some	O
basic	O
activities	O
of	O
MyoD	O
appeared	O
to	O
be	O
affected	O
by	O
wt	O
SVLT	O
.	O

In	O
these	O
transformants	O
,	O
mitogen	O
depletion	O
elicited	O
an	O
increase	O
in	O
the	O
Rb	O
level	O
comparable	O
to	O
that	O
in	O
normal	O
C2	B
cells	O
;	O
wt	O
SVLT	O
,	O
however	O
,	O
promoted	O
the	O
phosphorylation	O
of	O
a	O
large	O
part	O
of	O
the	O
induced	O
Rb	O
.	O

Mutations	O
affecting	O
nuclear	O
transport	O
were	O
far	O
more	O
critical	O
for	O
the	O
ability	O
to	O
interfere	O
with	O
myogenic	O
differentiation	O
than	O
were	O
those	O
affecting	O
the	O
transforming	O
potential	O
;	O
cytoplasmic	O
SVLT	O
expression	O
was	O
fully	O
compatible	O
with	O
the	O
terminal	O
differentiation	O
of	O
C2	B
cells	O
,	O
despite	O
enabling	O
them	O
to	O
grow	O
in	O
semisolid	O
medium	O
,	O
thus	O
showing	O
that	O
the	O
myogenesis	O
-	O
inhibiting	O
property	O
can	O
be	O
dissociated	O
from	O
transforming	O
competence	O
.	O

The	O
remaining	O
SVLT	O
mutants	O
presented	O
different	O
degrees	O
of	O
ability	O
to	O
inhibit	O
differentiation	O
(	O
as	O
shown	O
by	O
the	O
expression	O
of	O
tissue	O
-	O
specific	O
markers	O
in	O
transformants	O
)	O
.	O

The	O
inhibiting	O
mutants	O
,	O
including	O
the	O
Rb	O
binding	O
site	O
mutant	O
,	O
were	O
able	O
to	O
promote	O
a	O
higher	O
state	O
of	O
Rb	O
phosphorylation	O
than	O
that	O
observed	O
in	O
either	O
normal	O
cells	O
or	O
cytoplasmic	O
-	O
SVLT	O
transformants	O
.	O

A	O
transcript	O
from	O
the	O
long	O
terminal	O
repeats	O
of	O
a	O
murine	O
retrovirus	O
associated	O
with	O
trans	O
activation	O
of	O
cellular	O
genes	O
.	O

Infection	O
of	O
human	O
or	O
murine	O
cells	O
with	O
murine	O
leukemia	O
viruses	O
rapidly	O
increases	O
the	O
expression	O
of	O
a	O
number	O
of	O
genes	O
that	O
belong	O
to	O
the	O
immunoglobulin	O
superfamily	O
and	O
are	O
involved	O
in	O
T	O
-	O
lymphocyte	O
activation	O
,	O
including	O
the	O
class	O
I	O
major	O
histocompatibility	O
complex	O
antigens	O
.	O

We	O
have	O
reported	O
recently	O
that	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
Moloney	O
murine	O
leukemia	O
virus	O
encodes	O
a	O
trans	O
activator	O
which	O
induces	O
transcription	O
and	O
expression	O
of	O
class	O
I	O
major	O
histocompatibility	O
complex	O
genes	O
and	O
certain	O
cytokine	O
genes	O
.	O

The	O
portion	O
of	O
the	O
LTR	O
responsible	O
for	O
trans	O
activation	O
was	O
mapped	O
by	O
deletions	O
to	O
lie	O
within	O
the	O
U3	O
region	O
.	O

We	O
demonstrate	O
here	O
that	O
a	O
transcript	O
is	O
initiated	O
within	O
the	O
U3	O
region	O
and	O
that	O
its	O
presence	O
correlates	O
with	O
the	O
trans	O
-	O
activating	O
activity	O
.	O

Analysis	O
of	O
the	O
LTR	O
region	O
reveals	O
a	O
potential	O
internal	O
promoter	O
element	O
for	O
RNA	O
polymerase	O
III	O
transcription	O
within	O
the	O
U3	O
region	O
.	O

Studies	O
with	O
polymerase	O
inhibitors	O
suggest	O
that	O
this	O
LTR	O
transcript	O
,	O
designated	O
let	O
(	O
LTR	O
-	O
encoded	O
trans	O
activator	O
)	O
,	O
is	O
a	O
product	O
of	O
RNA	O
polymerase	O
III	O
.	O

The	O
mechanisms	O
whereby	O
RNA	O
leukemia	O
viruses	O
cause	O
lymphoid	O
neoplasia	O
after	O
a	O
long	O
latent	O
period	O
have	O
been	O
extensively	O
studied	O
but	O
are	O
only	O
partially	O
understood	O
.	O

The	O
region	O
of	O
the	O
LTR	O
identified	O
here	O
as	O
being	O
important	O
in	O
trans	O
activation	O
has	O
recently	O
been	O
shown	O
to	O
be	O
a	O
critical	O
determinant	O
of	O
the	O
leukemogenicity	O
and	O
latency	O
of	O
Moloney	O
murine	O
leukemia	O
virus	O
.	O

These	O
findings	O
suggest	O
a	O
novel	O
mechanism	O
of	O
retrovirus	O
-	O
induced	O
activation	O
of	O
cellular	O
gene	O
expression	O
,	O
potentially	O
contributing	O
to	O
leukemogenesis	O
.	O

Cancer	O
progression	O
and	O
p53	O
.	O

In	O
a	O
complex	O
organism	O
,	O
somatic	O
cells	O
are	O
under	O
intermittent	O
selection	O
pressure	O
for	O
the	O
emergence	O
of	O
mutants	O
that	O
can	O
survive	O
environmental	O
insults	O
and	O
that	O
can	O
grow	O
autonomously	O
despite	O
adverse	O
conditions	O
.	O

Repeated	O
rounds	O
of	O
mutation	O
,	O
selection	O
,	O
and	O
proliferation	O
may	O
lead	O
to	O
cancer	O
.	O

The	O
organism	O
prevents	O
malignant	O
transformation	O
by	O
assuring	O
accurate	O
DNA	O
repair	O
before	O
cell	O
division	O
,	O
by	O
forcing	O
the	O
death	O
of	O
cells	O
with	O
excessive	O
DNA	O
damage	O
,	O
and	O
by	O
placing	O
limits	O
on	O
the	O
replicative	O
lifespans	O
of	O
most	O
somatic	O
cells	O
.	O

The	O
p53	O
gene	O
is	O
a	O
""""	O
guardian	O
of	O
the	O
genome	O
""""	O
-	O
-	O
it	O
regulates	O
multiple	O
components	O
of	O
the	O
DNA	O
damage	O
control	O
response	O
and	O
promotes	O
cellular	O
senescence	O
.	O

Disabling	O
mutations	O
and	O
deletions	O
of	O
p53	O
occur	O
in	O
50	O
%	O
of	O
human	O
tumours	O
.	O

p53	O
-	O
deficient	O
cancers	O
are	O
often	O
unstable	O
,	O
aggressive	O
,	O
and	O
resistant	O
to	O
therapy	O
.	O

Anti	O
-	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
antibodies	O
inhibit	O
breast	O
cancer	O
cell	O
tumorigenicity	O
and	O
increase	O
mouse	O
spleen	O
natural	O
killer	O
cell	O
activity	O
.	O

Implications	O
for	O
a	O
possible	O
role	O
of	O
tumor	O
cell	O
/	O
host	O
TGF	O
-	O
beta	O
interactions	O
in	O
human	O
breast	O
cancer	O
progression	O
.	O

TGF	O
-	O
beta	O
effects	O
on	O
angiogenesis	O
,	O
stroma	O
formation	O
,	O
and	O
immune	O
function	O
suggest	O
its	O
possible	O
involvement	O
in	O
tumor	O
progression	O
.	O

This	O
hypothesis	O
was	O
tested	O
using	O
the	O
2G7	O
IgG2b	O
,	O
which	O
neutralizes	O
TGF	O
-	O
beta	O
1	O
,	O
-	O
beta	O
2	O
,	O
and	O
-	O
beta	O
3	O
,	O
and	O
the	O
MDA	B
-	I
231	I
human	O
breast	O
cancer	O
cell	O
line	O
.	O

Inoculation	O
of	O
these	O
cells	O
in	O
athymic	O
mice	O
decreases	O
mouse	O
spleen	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
.	O

Intraperitoneal	O
injections	O
of	O
2G7	O
starting	O
1	O
d	O
after	O
intraperitoneal	O
inoculation	O
of	O
tumor	O
cells	O
suppressed	O
intraabdominal	O
tumor	O
and	O
lung	O
metastases	O
,	O
whereas	O
the	O
nonneutralizing	O
anti	O
-	O
TGF	O
-	O
beta	O
12H5	O
IgG2a	O
had	O
no	O
effect	O
.	O

2G7	O
transiently	O
inhibited	O
growth	O
of	O
established	O
MDA	B
-	I
231	I
subcutaneous	O
tumors	O
.	O

Histologically	O
,	O
both	O
2G7	O
-	O
treated	O
and	O
control	O
tumors	O
were	O
identical	O
.	O

Intraperitoneal	O
administration	O
of	O
2G7	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
mouse	O
spleen	O
NK	O
cell	O
activity	O
.	O

2G7	O
did	O
not	O
inhibit	O
MDA	B
-	I
231	I
primary	O
tumor	O
or	O
metastases	O
formation	O
,	O
nor	O
did	O
it	O
stimulate	O
NK	O
cell	O
-	O
mediated	O
cytotoxicity	O
in	O
beige	O
NK	O
-	O
deficient	O
nude	O
mice	O
.	O

Finally	O
,	O
serum	O
-	O
free	O
conditioned	O
medium	O
from	O
MDA	B
-	I
231	I
cells	O
inhibited	O
the	O
NK	O
cell	O
activity	O
of	O
human	O
blood	O
lymphocytes	O
.	O

This	O
inhibition	O
was	O
blocked	O
by	O
the	O
neutralizing	O
anti	O
-	O
TGF	O
-	O
beta	O
2G7	O
antibody	O
but	O
not	O
by	O
a	O
nonspecific	O
IgG2	O
.	O

These	O
data	O
support	O
a	O
possible	O
role	O
for	O
tumor	O
cell	O
TGF	O
-	O
beta	O
in	O
the	O
progression	O
of	O
mammary	O
carcinomas	O
by	O
suppressing	O
host	O
immune	O
surveillance	O
.	O

The	O
Met	O
proto	O
-	O
oncogene	O
mesenchymal	O
to	O
epithelial	O
cell	O
conversion	O
.	O

Coexpression	O
of	O
the	O
human	O
Met	O
receptor	O
and	O
its	O
ligand	O
,	O
hepatocyte	O
growth	O
factor	O
/	O
scatter	O
factor	O
(	O
HGF	O
/	O
SF	O
)	O
,	O
in	O
NIH	B
3T3	I
fibroblasts	O
causes	O
the	O
cells	O
to	O
become	O
tumorigenic	O
in	O
nude	O
mice	O
.	O

The	O
resultant	O
tumors	O
display	O
lumen	O
-	O
like	O
morphology	O
,	O
contain	O
carcinoma	O
-	O
like	O
focal	O
areas	O
with	O
intercellular	O
junctions	O
resembling	O
desmosomes	O
,	O
and	O
coexpress	O
epithelial	O
(	O
cytokeratin	O
)	O
and	O
mesenchymal	O
(	O
vimentin	O
)	O
cytoskeletal	O
markers	O
.	O

The	O
tumor	O
cells	O
also	O
display	O
enhanced	O
expression	O
of	O
desmosomal	O
and	O
tight	O
-	O
junction	O
proteins	O
.	O

The	O
apparent	O
mesenchymal	O
to	O
epithelial	O
conversion	O
of	O
the	O
tumor	O
cells	O
mimics	O
the	O
conversion	O
that	O
occurs	O
during	O
embryonic	O
kidney	O
development	O
,	O
suggesting	O
that	O
Met	O
-	O
HGF	O
/	O
SF	O
signaling	O
plays	O
a	O
role	O
in	O
this	O
process	O
as	O
well	O
as	O
in	O
tumors	O
that	O
express	O
both	O
epithelial	O
and	O
mesenchymal	O
markers	O
.	O

Additional	O
tests	O
of	O
interest	O
to	O
the	O
dermatologist	O
.	O

The	O
carcinoid	O
syndrome	O
and	O
its	O
clinical	O
manifestations	O
have	O
been	O
discussed	O
.	O

The	O
standard	O
laboratory	O
test	O
for	O
making	O
that	O
diagnosis	O
is	O
urinary	O
5	O
-	O
HIAA	O
levels	O
but	O
newer	O
,	O
more	O
sensitive	O
tests	O
may	O
also	O
be	O
available	O
.	O

Molecular	O
mediators	O
of	O
interactions	O
with	O
extracellular	O
matrix	O
components	O
in	O
metastasis	O
and	O
angiogenesis	O
.	O

Metastasis	O
and	O
tumor	O
angiogenesis	O
are	O
invasive	O
phenomena	O
and	O
share	O
many	O
common	O
properties	O
at	O
the	O
physiological	O
level	O
and	O
some	O
similarities	O
at	O
the	O
molecular	O
level	O
.	O

Each	O
consists	O
of	O
repetitive	O
cycles	O
of	O
interaction	O
with	O
adjacent	O
extracellular	O
matrix	O
components	O
by	O
mediating	O
cellular	O
adhesion	O
,	O
matrix	O
dissolution	O
,	O
and	O
cellular	O
motility	O
to	O
achieve	O
metastasis	O
of	O
cancer	O
cells	O
or	O
neovascularization	O
of	O
tumors	O
.	O

Molecular	O
factors	O
which	O
implement	O
this	O
triad	O
of	O
events	O
are	O
reviewed	O
,	O
as	O
are	O
several	O
signal	O
transduction	O
components	O
which	O
may	O
regulate	O
them	O
.	O

Some	O
potentially	O
promising	O
prognostic	O
,	O
diagnostic	O
,	O
and	O
therapeutic	O
modalities	O
for	O
tumor	O
angiogenesis	O
and	O
metastatic	O
disease	O
are	O
also	O
discussed	O
.	O

Enhanced	O
DNA	O
-	O
binding	O
activity	O
of	O
a	O
Stat3	O
-	O
related	O
protein	O
in	O
cells	O
transformed	O
by	O
the	O
Src	O
oncoprotein	O
.	O

Cytokines	O
and	O
growth	O
factors	O
induce	O
tyrosine	O
phosphorylation	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STATs	O
)	O
that	O
directly	O
activate	O
gene	O
expression	O
.	O

Cells	O
stably	O
transformed	O
by	O
the	O
Src	O
oncogene	O
tyrosine	O
kinase	O
were	O
examined	O
for	O
STAT	O
protein	O
activation	O
.	O

Assays	O
of	O
electrophoretic	O
mobility	O
,	O
DNA	O
-	O
binding	O
specificity	O
,	O
and	O
antigenicity	O
indicated	O
that	O
Stat3	O
or	O
a	O
closely	O
related	O
STAT	O
family	O
member	O
was	O
constitutively	O
activated	O
by	O
the	O
Src	O
oncoprotein	O
.	O

Induction	O
of	O
this	O
DNA	O
-	O
binding	O
activity	O
was	O
accompanied	O
by	O
tyrosine	O
phosphorylation	O
of	O
Stat3	O
and	O
correlated	O
with	O
Src	O
transformation	O
.	O

These	O
findings	O
demonstrate	O
that	O
Src	O
can	O
activate	O
STAT	O
signaling	O
pathways	O
and	O
raise	O
the	O
possibility	O
that	O
Stat3	O
contributes	O
to	O
oncogenesis	O
by	O
Src	O
.	O

Ultraviolet	O
B	O
irradiation	O
promotes	O
tumorigenic	O
and	O
metastatic	O
properties	O
in	O
primary	O
cutaneous	O
melanoma	O
via	O
induction	O
of	O
interleukin	O
8	O
.	O

UV	O
radiation	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
the	O
initiation	O
of	O
human	O
cutaneous	O
melanoma	O
,	O
but	O
its	O
role	O
in	O
the	O
development	O
of	O
malignant	O
melanoma	O
to	O
the	O
metastatic	O
state	O
is	O
not	O
very	O
well	O
defined	O
.	O

Although	O
previous	O
studies	O
have	O
concentrated	O
on	O
the	O
effect	O
of	O
UV	O
-	O
B	O
on	O
the	O
host	O
immune	O
response	O
,	O
the	O
effect	O
of	O
UV	O
-	O
B	O
on	O
the	O
tumor	O
cells	O
was	O
not	O
elucidated	O
.	O

Here	O
we	O
show	O
that	O
UV	O
-	O
B	O
can	O
induce	O
interleukin	O
8	O
(	O
IL	O
-	O
8	O
)	O
mRNA	O
and	O
protein	O
secretion	O
in	O
human	O
cutaneous	O
melanoma	O
with	O
negligible	O
expression	O
of	O
IL	O
-	O
8	O
.	O

UV	O
-	O
B	O
-	O
induced	O
IL	O
-	O
8	O
was	O
constitutively	O
expressed	O
60	O
days	O
after	O
irradiation	O
in	O
tumors	O
implanted	O
in	O
mice	O
.	O

Induction	O
of	O
IL	O
-	O
8	O
was	O
UV	O
-	O
B	O
dose	O
dependent	O
and	O
blocked	O
by	O
cyclohexamide	O
,	O
indicating	O
that	O
de	O
novo	O
protein	O
synthesis	O
is	O
required	O
for	O
its	O
expression	O
.	O

The	O
UV	O
-	O
irradiated	O
cells	O
demonstrated	O
enhanced	O
tumorigenicity	O
and	O
metastatic	O
potential	O
in	O
nude	O
mice	O
.	O

The	O
increase	O
in	O
tumorigenicity	O
and	O
metastatic	O
ability	O
could	O
be	O
explained	O
by	O
the	O
increase	O
in	O
Mr	O
72	O
,	O
000	O
type	O
IV	O
collagenase	O
activity	O
and	O
angiogenesis	O
attributed	O
to	O
the	O
induction	O
of	O
IL	O
-	O
8	O
after	O
irradiation	O
.	O

The	O
acquisition	O
of	O
the	O
metastatic	O
phenotype	O
induced	O
by	O
UV	O
-	O
B	O
could	O
not	O
be	O
attributed	O
to	O
abnormalities	O
in	O
the	O
p53	O
or	O
MTS	O
-	O
1	O
(	O
p16INK4	O
)	O
genes	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
to	O
show	O
that	O
UV	O
-	O
B	O
can	O
increase	O
the	O
aggressiveness	O
of	O
human	O
cutaneous	O
melanoma	O
for	O
growth	O
and	O
metastasis	O
.	O

Suppressed	O
transformation	O
and	O
induced	O
differentiation	O
of	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
breast	O
cancer	O
cells	O
by	O
emodin	O
.	O

The	O
amplification	O
and	O
overexpression	O
of	O
the	O
HER	O
-	O
2	O
/	O
neu	O
proto	O
-	O
oncogene	O
,	O
which	O
encodes	O
the	O
tyrosine	O
kinase	O
receptor	O
p185neu	O
,	O
have	O
been	O
observed	O
frequently	O
in	O
tumors	O
from	O
human	O
breast	O
cancer	O
patients	O
and	O
are	O
correlated	O
with	O
poor	O
prognosis	O
.	O

To	O
explore	O
the	O
potential	O
of	O
chemotherapy	O
directed	O
at	O
the	O
tyrosine	O
kinase	O
of	O
p185neu	O
,	O
we	O
have	O
found	O
that	O
emodin	O
(	O
3	O
-	O
methyl	O
-	O
1	O
,	O
6	O
,	O
8	O
-	O
trihydroxyanthraquinone	O
)	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
suppresses	O
autophosphorylation	O
and	O
transphosphorylation	O
activities	O
of	O
HER	O
-	O
2	O
/	O
neu	O
tyrosine	O
kinase	O
,	O
resulting	O
in	O
tyrosine	O
hypophosphorylation	O
of	O
p185neu	O
in	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
breast	O
cancer	O
cells	O
.	O

Emodin	O
,	O
at	O
a	O
40	O
-	O
microM	O
concentration	O
,	O
which	O
repressed	O
tyrosine	O
kinase	O
of	O
p185neu	O
,	O
efficiently	O
inhibited	O
both	O
anchorage	O
-	O
dependent	O
and	O
anchorage	O
-	O
independent	O
growth	O
of	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
breast	O
cancer	O
cells	O
.	O

However	O
,	O
the	O
inhibition	O
was	O
much	O
less	O
effective	O
for	O
those	O
cells	O
expressing	O
basal	O
levels	O
of	O
p185neu	O
under	O
the	O
same	O
conditions	O
.	O

Emodin	O
also	O
induced	O
differentiation	O
of	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
breast	O
cancer	O
cells	O
by	O
exhibiting	O
a	O
morphological	O
maturation	O
property	O
of	O
large	O
lacy	O
nuclei	O
surrounded	O
by	O
sizable	O
flat	O
cytoplasm	O
and	O
by	O
showing	O
a	O
measurable	O
production	O
of	O
large	O
lipid	O
droplets	O
,	O
which	O
is	O
a	O
marker	O
of	O
mature	O
breast	O
cells	O
.	O

Therefore	O
,	O
our	O
results	O
indicate	O
that	O
emodin	O
inhibits	O
HER	O
-	O
2	O
/	O
neu	O
tyrosine	O
kinase	O
activity	O
and	O
preferentially	O
suppresses	O
growth	O
and	O
induces	O
differentiation	O
of	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
cancer	O
cells	O
.	O

These	O
results	O
may	O
have	O
chemotherapeutic	O
implications	O
for	O
using	O
emodin	O
to	O
target	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
cancer	O
cells	O
.	O

The	O
LHRH	O
pulse	O
generator	O
:	O
a	O
mediobasal	O
hypothalamic	O
location	O
.	O

The	O
location	O
and	O
mechanism	O
of	O
LHRH	O
pulse	O
generator	O
are	O
discussed	O
based	O
on	O
our	O
series	O
of	O
experiments	O
.	O

Suckling	O
stimulus	O
is	O
a	O
novel	O
stimulus	O
that	O
inhibits	O
LH	O
pulses	O
without	O
any	O
cooperation	O
from	O
ovarian	O
steroids	O
,	O
unlike	O
other	O
stimuli	O
such	O
as	O
stress	O
,	O
photoperiod	O
etc	O
.	O

It	O
is	O
directly	O
involved	O
in	O
suppressing	O
the	O
activity	O
of	O
the	O
LHRH	O
pulse	O
generator	O
.	O

The	O
information	O
from	O
teats	O
suckled	O
by	O
pups	O
or	O
babies	O
is	O
conveyed	O
dorsally	O
to	O
the	O
mediobasal	O
hypothalamus	O
(	O
MBH	O
)	O
,	O
where	O
the	O
LHRH	O
pulse	O
generator	O
may	O
be	O
located	O
.	O

Experiments	O
using	O
various	O
types	O
of	O
deafferentation	O
and	O
fetal	O
brain	O
tissue	O
transplantation	O
confirmed	O
that	O
the	O
LHRH	O
pulse	O
generator	O
is	O
located	O
in	O
the	O
MBH	O
and	O
suggested	O
that	O
LHRH	O
pulse	O
generator	O
consists	O
of	O
nonLHRH	O
neurons	O
.	O

Endogenous	O
excitatory	O
amino	O
acid	O
is	O
one	O
of	O
the	O
possible	O
neurotransmitters	O
that	O
regulate	O
LHRH	O
release	O
at	O
the	O
nerve	O
terminal	O
in	O
ME	O
.	O

Bicistronic	O
retroviral	O
vector	O
reveals	O
capacity	O
of	O
v	O
-	O
erbA	O
to	O
induce	O
erythroleukemia	O
and	O
to	O
co	O
-	O
operate	O
with	O
v	O
-	O
myb	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
v	O
-	O
erbA	O
and	O
v	O
-	O
myb	O
can	O
induce	O
the	O
proliferation	O
of	O
avian	O
erythroid	O
cells	O
in	O
culture	O
.	O

To	O
study	O
the	O
combined	O
effects	O
of	O
v	O
-	O
erbA	O
and	O
v	O
-	O
myb	O
,	O
the	O
two	O
oncogenes	O
were	O
engineered	O
into	O
a	O
retrovirus	O
bicistronic	O
vector	O
with	O
an	O
internal	O
ribosomal	O
entry	O
site	O
(	O
IRES	O
)	O
or	O
into	O
a	O
vector	O
with	O
a	O
splice	O
acceptor	O
(	O
SPL	O
)	O
.	O

This	O
allowed	O
coexpression	O
of	O
the	O
two	O
proteins	O
and	O
a	O
comparison	O
with	O
the	O
same	O
vector	O
containing	O
either	O
v	O
-	O
erbA	O
or	O
v	O
-	O
myb	O
only	O
.	O

Both	O
the	O
erbA	O
IRES	O
and	O
the	O
erbA	O
/	O
myb	O
IRES	O
virus	O
constructs	O
transformed	O
erythroid	O
cells	O
after	O
infection	O
of	O
bone	O
marrow	O
or	O
blastoderm	O
cultures	O
.	O

The	O
erbA	O
/	O
myb	O
IRES	O
virus	O
exhibited	O
a	O
5	O
-	O
10	O
-	O
fold	O
higher	O
transformed	O
colony	O
forming	O
efficiency	O
than	O
the	O
erbA	O
IRES	O
virus	O
in	O
the	O
blastoderm	O
assay	O
.	O

Surprisingly	O
,	O
when	O
injected	O
into	O
chicken	O
embryos	O
in	O
the	O
presence	O
of	O
helper	O
virus	O
,	O
both	O
viruses	O
induced	O
an	O
erythroleukemia	O
in	O
about	O
half	O
of	O
the	O
animals	O
.	O

In	O
contrast	O
,	O
no	O
leukemia	O
was	O
observed	O
with	O
a	O
myb	O
IRES	O
virus	O
,	O
with	O
spliced	O
vectors	O
containing	O
v	O
-	O
erbA	O
alone	O
or	O
v	O
-	O
erbA	O
in	O
combination	O
with	O
v	O
-	O
myb	O
,	O
nor	O
with	O
erbA	O
IRES	O
and	O
erbA	O
/	O
myb	O
IRES	O
viruses	O
produced	O
in	O
the	O
absence	O
of	O
helper	O
virus	O
.	O

The	O
average	O
latency	O
of	O
leukemia	O
induction	O
was	O
shorter	O
for	O
the	O
erbA	O
/	O
myb	O
IRES	O
virus	O
(	O
3	O
.	O
5	O
weeks	O
)	O
than	O
for	O
the	O
erbA	O
IRES	O
virus	O
(	O
5	O
weeks	O
)	O
.	O

Nevertheless	O
,	O
for	O
both	O
viruses	O
the	O
leukemic	O
blasts	O
retained	O
full	O
factor	O
dependence	O
for	O
growth	O
.	O

These	O
results	O
show	O
that	O
v	O
-	O
erbA	O
is	O
capable	O
of	O
inducing	O
an	O
erythroleukemia	O
when	O
expressed	O
by	O
a	O
high	O
titer	O
bicistronic	O
retrovirus	O
under	O
conditions	O
of	O
virus	O
spreading	O
and	O
that	O
its	O
in	O
vitro	O
and	O
in	O
vivo	O
transforming	O
potential	O
can	O
be	O
enhanced	O
by	O
v	O
-	O
myb	O
.	O

Cancer	O
metastasis	O
:	O
negative	O
regulation	O
by	O
an	O
invasion	O
-	O
suppressor	O
complex	O
.	O

Invasion	O
is	O
the	O
hallmark	O
of	O
tumor	O
malignancy	O
.	O

We	O
situate	O
invasion	O
within	O
microecosystems	O
comprising	O
neoplastic	O
cells	O
as	O
well	O
as	O
host	O
cells	O
.	O

Modulation	O
of	O
invasion	O
within	O
such	O
systems	O
is	O
ascribed	O
to	O
balances	O
between	O
promoter	O
and	O
suppressor	O
pathways	O
.	O

The	O
E	O
-	O
cadherin	O
/	O
alpha	O
-	O
,	O
beta	O
-	O
,	O
gamma	O
-	O
catenin	O
complex	O
has	O
an	O
invasion	O
-	O
suppressor	O
function	O
as	O
evidenced	O
by	O
transfections	O
either	O
with	O
sense	O
cDNA	O
encoding	O
these	O
molecules	O
or	O
with	O
antisense	O
cDNA	O
inhibiting	O
their	O
expression	O
.	O

Loss	O
of	O
heterozygosity	O
at	O
the	O
E	O
-	O
Cadherin	O
(	O
uvo	O
)	O
locus	O
has	O
been	O
reported	O
,	O
but	O
mutations	O
in	O
the	O
E	O
-	O
cadherin	O
gene	O
seem	O
to	O
be	O
rare	O
.	O

Downregulation	O
of	O
E	O
-	O
cadherin	O
occurred	O
at	O
the	O
level	O
of	O
transcription	O
or	O
of	O
mRNA	O
stability	O
.	O

Ex	O
vivo	O
cultures	O
from	O
invasive	O
tumors	O
or	O
metastases	O
produced	O
cells	O
that	O
were	O
homogeneously	O
E	O
-	O
cadherin	O
-	O
positive	O
and	O
noninvasive	O
in	O
vitro	O
.	O

These	O
observations	O
have	O
led	O
to	O
the	O
idea	O
that	O
factors	O
in	O
the	O
host	O
downmodulate	O
the	O
E	O
-	O
cadherin	O
complex	O
and	O
promote	O
invasion	O
most	O
probably	O
in	O
a	O
transient	O
way	O
.	O

VEGF165	O
expressed	O
by	O
a	O
replication	O
-	O
deficient	O
recombinant	O
adenovirus	O
vector	O
induces	O
angiogenesis	O
in	O
vivo	O
.	O

To	O
evaluate	O
the	O
concept	O
that	O
localized	O
delivery	O
of	O
angiogenic	O
factors	O
via	O
virus	O
-	O
mediated	O
gene	O
transfer	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
ischemic	O
disorders	O
,	O
the	O
replication	O
-	O
deficient	O
adenovirus	O
(	O
Ad	O
)	O
vector	O
AdCMV	O
.	O
VEGF165	O
(	O
where	O
CMV	O
is	O
cytomegalovirus	O
and	O
VEGF	O
is	O
vascular	O
endothelial	O
growth	O
factor	O
)	O
containing	O
the	O
cDNA	O
for	O
human	O
VEGF165	O
,	O
a	O
secreted	O
endothelial	O
cell	O
-	O
specific	O
angiogenic	O
growth	O
factor	O
,	O
was	O
constructed	O
.	O

Human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
and	O
rat	O
aorta	O
smooth	O
muscle	O
cells	O
(	O
RASMCs	O
)	O
infected	O
with	O
AdCMV	O
.	O
VEGF165	O
(	O
5	O
and	O
20	O
plaque	O
-	O
forming	O
units	O
[	O
pfu	O
]	O
per	O
cell	O
)	O
demonstrated	O
VEGF	O
mRNA	O
expression	O
and	O
protein	O
secretion	O
into	O
the	O
supernatant	O
.	O

Furthermore	O
,	O
the	O
conditioned	O
medium	O
from	O
these	O
cells	O
enhanced	O
vascular	O
permeability	O
in	O
vivo	O
.	O

In	O
contrast	O
,	O
neither	O
VEGF	O
mRNA	O
nor	O
secreted	O
protein	O
was	O
found	O
in	O
uninfected	O
HUVECs	O
or	O
RASMCs	O
or	O
in	O
cells	O
infected	O
with	O
the	O
control	O
vector	O
AdCMV	O
.	O
beta	O
gal	O
(	O
where	O
beta	O
gal	O
is	O
beta	O
-	O
galactosidase	O
)	O
.	O

Assessment	O
of	O
starved	O
HUVECs	O
at	O
14	O
days	O
demonstrated	O
sixfold	O
more	O
cells	O
for	O
AdCMV	O
.	O
VEGF165	O
-	O
infected	O
HUVECs	O
(	O
20	O
pfu	O
per	O
cell	O
)	O
than	O
for	O
either	O
infected	O
or	O
uninfected	O
control	O
cells	O
.	O

RASMC	O
proliferation	O
was	O
unaffected	O
by	O
infection	O
with	O
AdCMV	O
.	O
VEGF165	O
.	O

When	O
plated	O
in	O
2	O
%	O
serum	O
on	O
dishes	O
precoated	O
with	O
reconstituted	O
basement	O
membrane	O
(	O
Matrigel	O
)	O
,	O
HUVECs	O
infected	O
with	O
AdCMV	O
.	O
VEGF165	O
(	O
20	O
pfu	O
per	O
cell	O
)	O
differentiated	O
into	O
capillary	O
-	O
like	O
structures	O
.	O

Under	O
similar	O
conditions	O
,	O
both	O
uninfected	O
HUVECs	O
and	O
HUVECs	O
infected	O
with	O
AdCMV	O
.	O
beta	O
gal	O
did	O
not	O
differentiate	O
.	O

To	O
evaluate	O
the	O
ability	O
of	O
AdCMV	O
.	O
VEGF165	O
to	O
function	O
in	O
vivo	O
,	O
either	O
AdCMV	O
.	O

VEGF165	O
or	O
AdCMV	O
.	O
beta	O
gal	O
(	O
2	O
x	O
10	O
(	O
10	O
)	O
pfu	O
)	O
was	O
resuspended	O
in	O
0	O
.	O
5	O
mL	O
Matrigel	O
and	O
injected	O
subcutaneously	O
into	O
mice	O
.	O

Immunohistochemical	O
staining	O
demonstrated	O
VEGF	O
in	O
the	O
tissues	O
surrounding	O
the	O
Matrigel	O
plugs	O
containing	O
AdCMV	O
.	O
VEGF165	O
up	O
to	O
3	O
weeks	O
after	O
injection	O
,	O
whereas	O
no	O
VEGF	O
was	O
found	O
in	O
the	O
control	O
plugs	O
with	O
AdCMV	O
.	O
beta	O
gal	O
.	O

Two	O
weeks	O
after	O
injection	O
,	O
there	O
was	O
histological	O
evidence	O
of	O
neovascularization	O
in	O
the	O
tissues	O
surrounding	O
the	O
Matrigel	O
containing	O
AdCMV	O
.	O
VEGF165	O
,	O
whereas	O
no	O
significant	O
angiogenesis	O
was	O
observed	O
in	O
response	O
to	O
AdCMV	O
.	O
beta	O
gal	O
.	O

Furthermore	O
,	O
the	O
Matrigel	O
plugs	O
with	O
AdCMV	O
.	O
VEGF165	O
demonstrated	O
hemoglobin	O
content	O
fourfold	O
higher	O
than	O
the	O
plugs	O
with	O
AdCMV	O
.	O
beta	O
gal	O
.	O

Together	O
,	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
are	O
consistent	O
with	O
the	O
concept	O
that	O
Ad	O
vectors	O
may	O
provide	O
a	O
useful	O
strategy	O
for	O
efficient	O
local	O
delivery	O
of	O
VEGF165	O
in	O
the	O
treatment	O
of	O
ischemic	O
diseases	O
.	O

Identification	O
of	O
NAB1	O
,	O
a	O
repressor	O
of	O
NGFI	O
-	O
A	O
-	O
and	O
Krox20	O
-	O
mediated	O
transcription	O
.	O

NGFI	O
-	O
A	O
(	O
also	O
called	O
Egr1	O
,	O
Zif268	O
,	O
or	O
Krox24	O
)	O
and	O
the	O
closely	O
related	O
proteins	O
Krox20	O
,	O
NGFI	O
-	O
C	O
,	O
and	O
Egr3	O
are	O
zinc	O
-	O
finger	O
transcription	O
factors	O
encoded	O
by	O
immediate	O
-	O
early	O
genes	O
which	O
are	O
induced	O
by	O
a	O
wide	O
variety	O
of	O
extracellular	O
stimuli	O
.	O

NGFI	O
-	O
A	O
has	O
been	O
implicated	O
in	O
cell	O
proliferation	O
,	O
macrophage	O
differentiation	O
,	O
synaptic	O
activation	O
,	O
and	O
long	O
-	O
term	O
potentiation	O
,	O
whereas	O
Krox20	O
is	O
critical	O
for	O
proper	O
hindbrain	O
segmentation	O
and	O
peripheral	O
nerve	O
myelination	O
.	O

In	O
previous	O
work	O
,	O
a	O
structure	O
/	O
function	O
analysis	O
of	O
NGFI	O
-	O
A	O
revealed	O
a	O
34	O
-	O
aa	O
inhibitory	O
domain	O
that	O
was	O
hypothesized	O
to	O
be	O
the	O
target	O
of	O
a	O
cellular	O
factor	O
that	O
represses	O
NGFI	O
-	O
A	O
transcriptional	O
activity	O
.	O

Using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
we	O
have	O
isolated	O
a	O
cDNA	O
clone	O
which	O
encodes	O
a	O
protein	O
that	O
interacts	O
with	O
this	O
inhibitory	O
domain	O
and	O
inhibits	O
the	O
ability	O
of	O
NGFI	O
-	O
A	O
to	O
activate	O
transcription	O
.	O

This	O
NGFI	O
-	O
A	O
-	O
binding	O
protein	O
,	O
NAB1	O
,	O
is	O
a	O
570	O
-	O
aa	O
nuclear	O
protein	O
that	O
bears	O
no	O
obvious	O
sequence	O
homology	O
to	O
known	O
proteins	O
.	O

NAB1	O
also	O
represses	O
Krox20	O
activity	O
,	O
but	O
it	O
does	O
not	O
influence	O
Egr3	O
or	O
NGFI	O
-	O
G	O
,	O
thus	O
providing	O
a	O
mechanism	O
for	O
the	O
differential	O
regulation	O
of	O
this	O
family	O
of	O
immediate	O
-	O
early	O
transcription	O
factors	O
.	O

Metastatic	O
NIH	B
3T3	I
x	O
LTA	B
cell	O
hybrids	O
express	O
72	O
kDa	O
type	O
IV	O
collagenase	O
.	O

We	O
previously	O
reported	O
that	O
the	O
murine	O
fibroblast	O
cell	O
line	O
LTA	B
is	O
tumorigenic	O
but	O
non	O
-	O
metastatic	O
,	O
and	O
is	O
non	O
-	O
responsive	O
to	O
a	O
transfected	O
H	O
-	O
ras	O
oncogene	O
.	O

In	O
contrast	O
,	O
NIH	B
3T3	I
cells	O
are	O
non	O
-	O
tumorigenic	O
but	O
are	O
ras	O
-	O
responsive	O
and	O
become	O
metastatic	O
when	O
transfected	O
with	O
ras	O
.	O

Somatic	O
cell	O
hybrids	O
between	O
LTA	B
and	O
NIH	B
3T3	I
cells	O
are	O
tumorigenic	O
,	O
metastatic	O
and	O
ras	O
-	O
responsive	O
.	O

Here	O
we	O
examined	O
expression	O
of	O
type	O
IV	O
collagenases	O
in	O
parental	O
LTA	B
and	O
NIH	B
3T3	I
cells	O
(	O
with	O
and	O
without	O
ras	O
)	O
and	O
four	O
metastatic	O
LTA	B
x	O
NIH	B
3T3	I
hybrids	O
(	O
also	O
with	O
and	O
without	O
ras	O
)	O
.	O

Parental	O
NIH	B
3T3	I
-	O
derived	O
cells	O
had	O
both	O
72	O
kDa	O
and	O
92	O
kDa	O
gelatinase	O
activities	O
,	O
and	O
LTA	B
-	O
derived	O
cells	O
had	O
either	O
aberrantly	O
sized	O
approximately	O
90	O
kDa	O
activity	O
alone	O
or	O
neither	O
enzyme	O
activity	O
.	O

All	O
four	O
metastatic	O
hybrids	O
expressed	O
60	O
-	O
72	O
kDa	O
gelatinase	O
activity	O
,	O
while	O
three	O
of	O
them	O
also	O
had	O
92	O
kDa	O
activity	O
and	O
one	O
had	O
only	O
minimal	O
92	O
kDa	O
activity	O
.	O

Thus	O
the	O
metastatic	O
phenotype	O
of	O
the	O
hybrids	O
was	O
associated	O
with	O
expression	O
of	O
72	O
kDa	O
gelatinase	O
.	O

Levels	O
of	O
RNA	O
for	O
tissue	O
inhibitors	O
of	O
metalloproteinases	O
(	O
TIMP	O
-	O
1	O
,	O
TIMP	O
-	O
2	O
)	O
were	O
relatively	O
constant	O
,	O
suggesting	O
independent	O
regulation	O
of	O
type	O
IV	O
collagenases	O
and	O
their	O
inhibitors	O
.	O

Southern	O
blotting	O
and	O
probing	O
with	O
PCR	O
-	O
synthesized	O
cDNA	O
fragments	O
of	O
the	O
mouse	O
72	O
kDa	O
type	O
IV	O
collagenase	O
gene	O
showed	O
that	O
this	O
gene	O
was	O
present	O
in	O
all	O
cells	O
although	O
the	O
structure	O
of	O
this	O
gene	O
in	O
one	O
of	O
the	O
three	O
LTA	B
cell	O
lines	O
differed	O
from	O
that	O
of	O
the	O
other	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
a	O
key	O
change	O
in	O
the	O
metastatic	O
hybrids	O
,	O
relative	O
to	O
non	O
-	O
metastatic	O
parental	O
LTA	B
cells	O
,	O
is	O
induction	O
of	O
expression	O
of	O
72	O
kDa	O
type	O
IV	O
collagenase	O
.	O

Central	O
nervous	O
system	O
infection	O
with	O
Eikenella	O
corrodens	O
:	O
report	O
of	O
two	O
cases	O
.	O

Two	O
cases	O
of	O
central	O
nervous	O
system	O
infections	O
from	O
which	O
E	O
.	O
corrodens	O
has	O
been	O
isolated	O
are	O
reported	O
.	O

The	O
portals	O
of	O
entry	O
,	O
clinical	O
course	O
,	O
and	O
antimicrobial	O
responses	O
conform	O
to	O
other	O
reports	O
in	O
the	O
literature	O
.	O

The	O
importance	O
of	O
obtaining	O
careful	O
anaerobic	O
cultures	O
is	O
emphasized	O
.	O

Neoplastic	O
progression	O
of	O
human	O
colorectal	O
cancer	O
is	O
associated	O
with	O
overexpression	O
of	O
the	O
stromelysin	O
-	O
3	O
and	O
BM	O
-	O
40	O
/	O
SPARC	O
genes	O
.	O

The	O
interaction	O
of	O
neoplastic	O
cells	O
with	O
the	O
extracellular	O
matrix	O
is	O
a	O
critical	O
event	O
for	O
the	O
initiation	O
of	O
cancer	O
invasion	O
and	O
metastasis	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
potential	O
implication	O
of	O
stromelysin	O
-	O
3	O
(	O
ST3	O
)	O
,	O
a	O
newly	O
identified	O
member	O
of	O
the	O
matrix	O
-	O
degrading	O
metalloproteinase	O
family	O
,	O
and	O
of	O
BM	O
-	O
40	O
/	O
SPARC	O
,	O
a	O
glycoprotein	O
associated	O
with	O
the	O
extracellular	O
matrix	O
,	O
during	O
the	O
progression	O
of	O
human	O
colorectal	O
cancers	O
.	O

We	O
analyzed	O
the	O
relative	O
abundance	O
of	O
ST3	O
and	O
BM	O
-	O
40	O
/	O
SPARC	O
transcripts	O
by	O
Northern	O
blot	O
,	O
and	O
their	O
distribution	O
by	O
in	O
situ	O
hybridization	O
,	O
in	O
normal	O
mucosa	O
,	O
benign	O
adenomas	O
,	O
and	O
primary	O
colorectal	O
adenocarcinomas	O
and	O
their	O
liver	O
metastases	O
.	O

The	O
ST3	O
and	O
BM	O
-	O
40	O
/	O
SPARC	O
transcripts	O
were	O
overexpressed	O
in	O
primary	O
colorectal	O
cancers	O
and	O
their	O
liver	O
metastases	O
compared	O
to	O
non	O
-	O
neoplastic	O
mucosa	O
.	O

These	O
transcripts	O
were	O
localized	O
in	O
stromal	O
fibroblasts	O
adjacent	O
to	O
the	O
neoplastic	O
foci	O
.	O

Overexpression	O
of	O
ST3	O
correlated	O
with	O
the	O
progression	O
of	O
human	O
colorectal	O
tumors	O
toward	O
local	O
invasion	O
and	O
liver	O
metastasis	O
.	O

Induction	O
of	O
these	O
genes	O
also	O
occurred	O
in	O
diverticulitis	O
and	O
digestive	O
neoplasms	O
such	O
as	O
gastric	O
and	O
esophageal	O
carcinomas	O
.	O

Comparative	O
immunohistochemical	O
study	O
of	O
primary	O
and	O
metastatic	O
carcinomas	O
of	O
the	O
liver	O
.	O

Distinguishing	O
primary	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
from	O
metastatic	O
carcinomas	O
to	O
the	O
liver	O
is	O
often	O
difficult	O
,	O
if	O
not	O
impossible	O
,	O
particularly	O
in	O
needle	O
biopsy	O
and	O
fine	O
-	O
needle	O
aspiration	O
specimens	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
a	O
specific	O
immunohistochemical	O
profile	O
that	O
would	O
distinguish	O
HCC	O
from	O
metastatic	O
carcinomas	O
,	O
we	O
studied	O
56	O
HCCs	O
,	O
8	O
cholangiocarcinomas	O
,	O
and	O
24	O
metastatic	O
adenocarcinomas	O
with	O
monoclonal	O
antibodies	O
to	O
alpha	O
-	O
fetoprotein	O
(	O
AFP	O
)	O
,	O
keratin	O
(	O
AE1	O
,	O
AE3	O
,	O
and	O
CAM5	O
.	O
2	O
)	O
,	O
Leu	O
-	O
M1	O
,	O
human	O
milk	O
fat	O
globule	O
(	O
HMFG	O
-	O
2	O
)	O
,	O
tumor	O
-	O
associated	O
glycoprotein	O
-	O
72	O
(	O
B72	O
.	O
3	O
)	O
,	O
epithelial	O
specific	O
membrane	O
antigen	O
(	O
Ber	O
-	O
EP4	O
)	O
,	O
and	O
BCA	O
-	O
225	O
(	O
CU	O
-	O
18	O
)	O
.	O

Both	O
monoclonal	O
and	O
polyclonal	O
(	O
mCEA	O
and	O
pCEA	O
)	O
antibodies	O
to	O
carcinoembryonic	O
antigen	O
also	O
were	O
used	O
.	O

Metastatic	O
adenocarcinomas	O
were	O
often	O
positive	O
for	O
CU	O
-	O
18	O
(	O
71	O
%	O
)	O
,	O
Leu	O
-	O
M1	O
(	O
75	O
%	O
)	O
,	O
B72	O
.	O
3	O
(	O
50	O
%	O
)	O
,	O
HMFG	O
-	O
2	O
(	O
67	O
%	O
)	O
,	O
Ber	O
-	O
EP4	O
(	O
83	O
%	O
)	O
and	O
mCEA	O
(	O
71	O
%	O
)	O
.	O

Using	O
these	O
antibodies	O
,	O
the	O
frequency	O
of	O
positivity	O
for	O
HCC	O
was	O
9	O
%	O
,	O
16	O
%	O
,	O
11	O
%	O
,	O
20	O
%	O
,	O
36	O
%	O
,	O
and	O
11	O
%	O
,	O
respectively	O
.	O

CU	O
-	O
18	O
was	O
the	O
only	O
monoclonal	O
antibody	O
in	O
which	O
there	O
was	O
a	O
significant	O
difference	O
in	O
positive	O
rates	O
between	O
HCC	O
and	O
metastatic	O
adenocarcinomas	O
.	O

Most	O
HCCs	O
(	O
71	O
%	O
)	O
revealed	O
a	O
bile	O
canalicular	O
staining	O
pattern	O
with	O
pCEA	O
.	O

Because	O
this	O
staining	O
pattern	O
was	O
absent	O
in	O
metastatic	O
carcinomas	O
,	O
pCEA	O
appears	O
to	O
be	O
useful	O
in	O
confirming	O
a	O
diagnosis	O
of	O
HCC	O
.	O

AE1	O
,	O
AE3	O
and	O
CAM5	O
.	O
2	O
antibodies	O
were	O
not	O
useful	O
in	O
distinguishing	O
HCC	O
from	O
metastatic	O
carcinomas	O
.	O

Each	O
cholangiocarcinoma	O
shared	O
a	O
staining	O
profile	O
similar	O
to	O
that	O
of	O
metastatic	O
carcinomas	O
.	O

Heparin	O
-	O
steroid	O
conjugates	O
:	O
new	O
angiogenesis	O
inhibitors	O
with	O
antitumor	O
activity	O
in	O
mice	O
.	O

Inhibitors	O
of	O
angiogenesis	O
hold	O
potential	O
in	O
the	O
treatment	O
of	O
cancer	O
and	O
other	O
diseases	O
where	O
the	O
disease	O
is	O
caused	O
or	O
maintained	O
by	O
the	O
inappropriate	O
growth	O
of	O
blood	O
vessels	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
novel	O
inhibitor	O
of	O
angiogenesis	O
was	O
synthesized	O
by	O
covalently	O
linking	O
a	O
nonanticoagulating	O
derivative	O
of	O
heparin	O
,	O
heparin	O
adipic	O
hydrazide	O
(	O
HAH	O
)	O
,	O
by	O
an	O
acid	O
-	O
labile	O
bond	O
to	O
the	O
antiangiogenic	O
steroid	O
,	O
cortisol	O
.	O

The	O
rationale	O
was	O
that	O
the	O
heparin	O
derivative	O
,	O
which	O
binds	O
to	O
sulfated	O
polyanion	O
receptors	O
on	O
endothelial	O
cells	O
,	O
should	O
concentrate	O
the	O
steroid	O
on	O
the	O
surface	O
of	O
vascular	O
endothelial	O
cells	O
.	O

Endocytosis	O
of	O
the	O
conjugate	O
and	O
decomposition	O
of	O
the	O
acid	O
-	O
labile	O
linkage	O
inside	O
lysosomes	O
and	O
other	O
acidic	O
intracellular	O
compartments	O
should	O
then	O
lead	O
to	O
release	O
of	O
the	O
cortisol	O
and	O
expression	O
of	O
its	O
antiproliferative	O
activity	O
.	O

Analysis	O
of	O
the	O
stability	O
of	O
HAH	O
-	O
cortisol	O
showed	O
that	O
it	O
was	O
stable	O
at	O
pH	O
7	O
.	O
4	O
and	O
broke	O
down	O
rapidly	O
(	O
t1	O
/	O
2	O
15	O
min	O
)	O
at	O
pH	O
4	O
.	O
8	O
at	O
37	O
degrees	O
C	O
.	O

Treatment	O
of	O
murine	O
pulmonary	O
capillary	O
endothelial	O
cells	O
with	O
HAH	O
-	O
cortisol	O
at	O
10	O
(	O
-	O
5	O
)	O
M	O
(	O
with	O
respect	O
to	O
cortisol	O
)	O
suppressed	O
their	O
DNA	O
synthesis	O
by	O
50	O
%	O
and	O
inhibited	O
their	O
migration	O
into	O
wounded	O
areas	O
of	O
confluent	O
monolayers	O
.	O

HAH	O
-	O
cortisol	O
at	O
10	O
(	O
-	O
4	O
)	O
M	O
(	O
with	O
respect	O
to	O
cortisol	O
)	O
did	O
not	O
suppress	O
the	O
DNA	O
synthesis	O
of	O
Lewis	O
lung	O
carcinoma	O
cells	O
.	O

Daily	O
i	O
.	O
p	O
.	O
injections	O
of	O
HAH	O
-	O
cortisol	O
into	O
mice	O
bearing	O
s	O
.	O
c	O
.	O
sponge	O
implants	O
retarded	O
vascularization	O
of	O
the	O
sponge	O
,	O
and	O
injections	O
directly	O
into	O
the	O
sponge	O
abolished	O
vascularization	O
for	O
as	O
long	O
as	O
the	O
injections	O
were	O
continued	O
.	O

Daily	O
i	O
.	O
v	O
.	O
injections	O
of	O
HAH	O
-	O
cortisol	O
at	O
doses	O
causing	O
no	O
apparent	O
toxicity	O
retarded	O
the	O
growth	O
of	O
solid	O
s	O
.	O
c	O
.	O

Lewis	O
lung	O
carcinomas	O
in	O
mice	O
by	O
up	O
to	O
65	O
%	O
.	O

In	O
all	O
of	O
these	O
assays	O
,	O
equivalent	O
treatments	O
with	O
a	O
mixture	O
of	O
the	O
HAH	O
plus	O
cortisol	O
was	O
significantly	O
less	O
effective	O
.	O

The	O
antiproliferative	O
effect	O
of	O
HAH	O
-	O
cortisol	O
on	O
endothelial	O
cells	O
appeared	O
independent	O
of	O
the	O
glucocorticoid	O
activity	O
of	O
the	O
steroid	O
since	O
HAH	O
conjugated	O
to	O
5	O
beta	O
-	O
pregnane	O
-	O
3	O
alpha	O
,	O
17	O
alpha	O
,	O
21	O
-	O
triol	O
-	O
20	O
-	O
one	O
,	O
a	O
steroid	O
lacking	O
glucocorticoid	O
or	O
mineralocorticoid	O
activity	O
,	O
was	O
even	O
more	O
effective	O
at	O
inhibiting	O
DNA	O
synthesis	O
by	O
murine	O
pulmonary	O
capillary	O
endothelial	O
cells	O
than	O
was	O
HAH	O
-	O
cortisol	O
.	O

In	O
conclusion	O
,	O
HAH	O
-	O
cortisol	O
represents	O
the	O
prototype	O
of	O
a	O
new	O
class	O
of	O
angiogenesis	O
inhibitors	O
for	O
the	O
treatment	O
of	O
cancer	O
and	O
other	O
angiogenic	O
diseases	O
.	O

Colorimetrical	O
rate	O
assay	O
for	O
urinary	O
dipeptidyl	O
peptidase	O
IV	O
(	O
DPPIV	O
)	O
activity	O
using	O
a	O
new	O
substrate	O
.	O

We	O
synthesized	O
a	O
new	O
substrate	O
glycyl	O
-	O
L	O
-	O
proline	O
3	O
,	O
5	O
-	O
dibromo	O
-	O
4	O
-	O
hydroxyanilide	O
(	O
Gly	O
-	O
Pro	O
-	O
DBAP	O
)	O
,	O
for	O
dipeptidyl	O
peptidase	O
IV	O
(	O
DPPIV	O
)	O
.	O

Its	O
hydrolysis	O
by	O
DPPIV	O
resulted	O
in	O
the	O
formation	O
of	O
a	O
chromophore	O
,	O
2	O
,	O
6	O
-	O
dibromophenol	O
-	O
indo	O
-	O
p	O
-	O
xylenol	O
,	O
and	O
its	O
maximal	O
absorption	O
wavelength	O
(	O
600	O
nm	O
)	O
was	O
longer	O
than	O
that	O
of	O
p	O
-	O
nitroaniline	O
(	O
415	O
nm	O
)	O
released	O
from	O
conventional	O
substrate	O
,	O
glycyl	O
-	O
L	O
-	O
proline	O
p	O
-	O
nitroanilide	O
(	O
Gly	O
-	O
Pro	O
-	O
pNA	O
)	O
.	O

We	O
also	O
established	O
the	O
rate	O
assay	O
for	O
urinary	O
DPPIV	O
activity	O
using	O
Gly	O
-	O
Pro	O
-	O
DBAP	O
.	O

The	O
optimum	O
pH	O
was	O
between	O
8	O
.	O
5	O
and	O
9	O
.	O
0	O
.	O

The	O
apparent	O
Km	O
was	O
1	O
.	O
1	O
mmol	O
/	O
1	O
.	O

The	O
detectable	O
range	O
was	O
2	O
.	O
5	O
-	O
350	O
U	O
/	O
l	O
.	O

No	O
changes	O
in	O
blank	O
values	O
occurred	O
throughout	O
the	O
enzyme	O
reaction	O
in	O
the	O
optimum	O
pH	O
.	O

Its	O
value	O
was	O
also	O
much	O
lower	O
than	O
Gly	O
-	O
Pro	O
-	O
pNA	O
.	O

CVs	O
for	O
within	O
-	O
run	O
and	O
between	O
-	O
run	O
were	O
1	O
.	O
1	O
%	O
(	O
n	O
=	O
10	O
)	O
and	O
3	O
.	O
0	O
%	O
(	O
n	O
=	O
10	O
)	O
,	O
respectively	O
.	O

Among	O
tested	O
peptidases	O
,	O
only	O
DPPIV	O
could	O
hydrolyze	O
Gly	O
-	O
Pro	O
-	O
DBAP	O
.	O

Among	O
the	O
protease	O
inhibitors	O
,	O
only	O
two	O
,	O
diprotin	O
-	O
A	O
and	O
phenylmethylsulfonyl	O
fluoride	O
(	O
PMSA	O
)	O
,	O
could	O
inhibit	O
DPPIV	O
activity	O
.	O

The	O
present	O
method	O
did	O
not	O
interfere	O
with	O
urinary	O
ingredients	O
such	O
as	O
hemoglobin	O
.	O

The	O
correlation	O
between	O
the	O
present	O
(	O
y	O
)	O
and	O
conventional	O
(	O
x	O
)	O
methods	O
is	O
presented	O
by	O
the	O
equation	O
y	O
=	O
1	O
.	O
121x	O
+	O
0	O
.	O
096	O
(	O
r	O
=	O
0	O
.	O
993	O
)	O
.	O

Thus	O
the	O
present	O
method	O
provides	O
practical	O
advantages	O
over	O
the	O
conventional	O
method	O
for	O
routine	O
laboratory	O
use	O
.	O

Primary	O
hyperparathyroidism	O
and	O
the	O
heart	O
:	O
cardiac	O
abnormalities	O
correlated	O
to	O
clinical	O
and	O
biochemical	O
data	O
.	O

Comparing	O
patients	O
with	O
primary	O
hyperparathyroidism	O
(	O
PHP	O
)	O
to	O
a	O
normocalcemic	O
control	O
population	O
,	O
those	O
with	O
PHP	O
have	O
a	O
higher	O
incidence	O
of	O
cardiovascular	O
disease	O
and	O
cardiac	O
abnormalities	O
.	O

This	O
study	O
aimed	O
at	O
correlating	O
cardiac	O
findings	O
(	O
valvular	O
and	O
myocardial	O
calcification	O
,	O
myocardial	O
hypertrophy	O
)	O
with	O
clinical	O
data	O
(	O
age	O
,	O
sex	O
,	O
clinical	O
manifestation	O
,	O
nephrolithiasis	O
,	O
nephrocalcinosis	O
,	O
hypertension	O
,	O
skeletal	O
abnormalities	O
,	O
hypercalcemic	O
syndrome	O
)	O
and	O
biochemical	O
data	O
(	O
serum	O
calcium	O
,	O
serum	O
phosphate	O
,	O
serum	O
iPTH	O
level	O
,	O
serum	O
creatinine	O
)	O
.	O

A	O
group	O
of	O
132	O
consecutive	O
patients	O
with	O
surgically	O
verified	O
PHP	O
(	O
94	O
women	O
,	O
38	O
men	O
;	O
ages	O
15	O
-	O
86	O
,	O
mean	O
age	O
57	O
+	O
/	O
-	O
16	O
years	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O

Blood	O
chemistry	O
,	O
clinical	O
presentation	O
,	O
radiography	O
,	O
and	O
echocardiography	O
were	O
carried	O
out	O
in	O
all	O
patients	O
for	O
univariate	O
and	O
multivariate	O
analyses	O
of	O
all	O
parameters	O
.	O

There	O
was	O
no	O
statistical	O
correlation	O
between	O
clinical	O
symptoms	O
,	O
biochemical	O
data	O
,	O
and	O
cardiac	O
calcific	O
alterations	O
.	O

Typical	O
skeletal	O
manifestations	O
(	O
osteolysis	O
/	O
subperiostal	O
resorption	O
)	O
and	O
valvular	O
calcifications	O
were	O
significantly	O
correlated	O
to	O
left	O
ventricular	O
hypertrophy	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
.	O

Cardiac	O
abnormalities	O
such	O
as	O
calcific	O
myocardial	O
deposits	O
or	O
mitral	O
and	O
aortic	O
valvular	O
calcifications	O
do	O
not	O
correlate	O
with	O
laboratory	O
findings	O
and	O
clinical	O
presentation	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

There	O
was	O
no	O
biochemical	O
or	O
clinical	O
variable	O
that	O
could	O
predict	O
the	O
frequency	O
or	O
severity	O
of	O
valvular	O
sclerosis	O
or	O
calcific	O
deposits	O
in	O
the	O
myocardium	O
.	O

However	O
,	O
PHP	O
-	O
related	O
skeletal	O
abnormalities	O
and	O
valvular	O
calcification	O
were	O
predicting	O
factors	O
for	O
left	O
ventricular	O
hypertrophy	O
,	O
a	O
reversible	O
cardiac	O
manifestation	O
of	O
PHP	O
.	O

Myocardial	O
hypertrophy	O
is	O
more	O
often	O
found	O
with	O
classic	O
symptomatic	O
PHP	O
with	O
osseous	O
abnormalities	O
.	O

Childhood	O
conscientiousness	O
and	O
longevity	O
:	O
health	O
behaviors	O
and	O
cause	O
of	O
death	O
.	O

Previous	O
research	O
showed	O
that	O
conscientiousness	O
(	O
social	O
dependability	O
)	O
in	O
childhood	O
predicted	O
longevity	O
in	O
an	O
archival	O
prospective	O
cohort	O
study	O
of	O
bright	O
children	O
first	O
studied	O
by	O
Terman	O
in	O
the	O
1920s	O
(	O
H	O
.	O
S	O
.	O
Friedman	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O

Possible	O
behavioral	O
mechanisms	O
for	O
this	O
robust	O
association	O
are	O
now	O
examined	O
by	O
gathering	O
cause	O
of	O
death	O
information	O
and	O
by	O
considering	O
the	O
possible	O
mediating	O
influences	O
of	O
drinking	O
alcohol	O
,	O
smoking	O
,	O
and	O
overeating	O
.	O

Survival	O
analyses	O
(	O
N	O
=	O
1	O
,	O
215	O
)	O
suggest	O
that	O
the	O
protective	O
effect	O
of	O
conscientiousness	O
is	O
not	O
primarily	O
due	O
to	O
accident	O
avoidance	O
and	O
can	O
not	O
be	O
mostly	O
explained	O
by	O
abstinence	O
from	O
unhealthy	O
substance	O
intake	O
.	O

Conscientiousness	O
may	O
have	O
more	O
wide	O
-	O
ranging	O
effects	O
on	O
health	O
-	O
relevant	O
activities	O
.	O

Selenoperoxidase	O
-	O
dependent	O
glutathione	O
cycle	O
activity	O
in	O
peroxide	O
-	O
challenged	O
leukemia	O
cells	O
.	O

Murine	O
leukemia	O
L1210	B
cells	O
rendered	O
deficient	O
in	O
glutathione	O
peroxidase	O
(	O
GPX	O
)	O
and	O
phospholipid	O
hydroperoxide	O
glutathione	O
peroxidase	O
(	O
PHGPX	O
)	O
by	O
Se	O
deprivation	O
(	O
L	O
.	O
Se	O
(	O
-	O
)	O
cells	O
)	O
were	O
found	O
to	O
be	O
more	O
sensitive	O
to	O
tert	O
-	O
butyl	O
hydroperoxide	O
(	O
t	O
-	O
BuOOH	O
)	O
cytotoxicity	O
than	O
Se	O
-	O
replete	O
controls	O
(	O
L	O
.	O
Se	O
(	O
+	O
)	O
cells	O
)	O
.	O

Human	O
K562	B
cells	O
,	O
which	O
express	O
PHGPX	O
,	O
but	O
not	O
GPX	O
,	O
were	O
also	O
more	O
sensitive	O
to	O
t	O
-	O
BuOOH	O
in	O
the	O
Se	O
-	O
deficient	O
(	O
K	O
.	O
Se	O
(	O
-	O
)	O
)	O
than	O
Se	O
-	O
satisfied	O
(	O
K	O
.	O
Se	O
(	O
+	O
)	O
)	O
condition	O
.	O

In	O
examining	O
the	O
metabolic	O
basis	O
for	O
selenoperoxidase	O
-	O
dependent	O
resistance	O
,	O
we	O
found	O
that	O
glucose	O
-	O
replete	O
Se	O
(	O
-	O
)	O
cells	O
reduce	O
t	O
-	O
BuOOH	O
to	O
t	O
-	O
butanol	O
far	O
more	O
slowly	O
than	O
Se	O
(	O
+	O
)	O
cells	O
,	O
the	O
ratio	O
of	O
the	O
first	O
-	O
order	O
rate	O
constants	O
approximating	O
that	O
of	O
the	O
GPX	O
activities	O
(	O
L1210	B
cells	O
)	O
or	O
PHGPX	O
activities	O
(	O
K562	B
cells	O
)	O
.	O

Monitoring	O
peroxide	O
-	O
induced	O
changes	O
in	O
GSH	O
and	O
GSSG	O
gave	O
consistent	O
results	O
;	O
e	O
.	O
g	O
.	O
,	O
glucose	O
-	O
depleted	O
L	O
.	O
Se	O
(	O
+	O
)	O
cells	O
exhibited	O
a	O
first	O
order	O
loss	O
of	O
GSH	O
that	O
was	O
substantially	O
faster	O
than	O
that	O
of	O
glucose	O
-	O
depleted	O
L	O
.	O
Se	O
(	O
-	O
)	O
cells	O
.	O

Under	O
the	O
conditions	O
used	O
,	O
peroxide	O
-	O
induced	O
conversion	O
of	O
GSH	O
to	O
GSSG	O
could	O
be	O
stoichiometrically	O
reversed	O
by	O
resupplying	O
D	O
-	O
glucose	O
,	O
indicating	O
that	O
no	O
significant	O
lysis	O
or	O
GSSG	O
efflux	O
and	O
/	O
or	O
interchange	O
had	O
taken	O
place	O
.	O

The	O
apparent	O
first	O
-	O
order	O
rate	O
constant	O
for	O
GSH	O
decay	O
increased	O
progressively	O
for	O
L1210	B
cells	O
expressing	O
a	O
range	O
of	O
GPX	O
activities	O
from	O
approximately	O
5	O
%	O
to	O
100	O
%	O
,	O
demonstrating	O
that	O
peroxide	O
detoxification	O
is	O
strictly	O
dependent	O
on	O
enzyme	O
content	O
.	O

The	O
initial	O
rate	O
of	O
14CO2	O
release	O
from	O
D	O
-	O
[	O
1	O
-	O
14C	O
]	O
glucose	O
supplied	O
in	O
the	O
medium	O
was	O
much	O
greater	O
for	O
L	O
.	O
Se	O
(	O
+	O
)	O
or	O
K	O
.	O
Se	O
(	O
+	O
)	O
cells	O
than	O
for	O
their	O
respective	O
Se	O
(	O
-	O
)	O
counterparts	O
,	O
consistent	O
with	O
greater	O
hexose	O
monophosphate	O
shunt	O
activity	O
in	O
the	O
former	O
.	O

These	O
results	O
highlight	O
the	O
importance	O
of	O
selenoperoxidase	O
action	O
in	O
the	O
glutathione	O
cycle	O
as	O
a	O
means	O
by	O
which	O
tumor	O
cells	O
cope	O
with	O
hydroperoxide	O
stress	O
.	O

Differential	O
expression	O
and	O
mutation	O
of	O
NME	O
genes	O
in	O
autologous	O
cultured	O
human	O
melanoma	O
cells	O
with	O
different	O
metastatic	O
potentials	O
.	O

The	O
putative	O
metastasis	O
suppressor	O
genes	O
,	O
NME1	O
(	O
nm23	O
-	O
1	O
)	O
and	O
NME2	O
(	O
nm23	O
-	O
2	O
)	O
,	O
were	O
examined	O
in	O
a	O
model	O
system	O
we	O
developed	O
to	O
approximate	O
the	O
dissemination	O
of	O
melanoma	O
from	O
a	O
primary	O
skin	O
tumor	O
.	O

We	O
utilized	O
two	O
autologous	O
human	O
melanoma	O
cell	O
lines	O
,	O
IV	B
Cl	I
1	I
and	O
IV	B
Cl	I
3	I
,	O
which	O
displayed	O
qualitatively	O
different	O
metastatic	O
phenotypes	O
following	O
subdermal	O
inoculation	O
into	O
nude	O
mice	O
.	O

Highly	O
metastatic	O
IV	B
Cl	I
1	I
cells	O
expressed	O
approximately	O
5	O
fold	O
lower	O
levels	O
of	O
protein	O
encoded	O
by	O
NME	O
genes	O
than	O
non	O
-	O
metastatic	O
IV	B
Cl	I
3	I
cells	O
.	O

Similar	O
differences	O
in	O
NME	O
protein	O
levels	O
were	O
observed	O
in	O
tumors	O
induced	O
by	O
the	O
two	O
cell	O
lines	O
in	O
nude	O
mice	O
.	O

There	O
were	O
no	O
differences	O
in	O
NME	O
mRNA	O
levels	O
between	O
these	O
two	O
cell	O
lines	O
,	O
suggesting	O
that	O
expression	O
of	O
these	O
proteins	O
is	O
regulated	O
at	O
a	O
post	O
-	O
transcriptional	O
level	O
.	O

We	O
found	O
a	O
ser122	O
-	O
pro	O
mutation	O
in	O
the	O
NME2	O
gene	O
of	O
metastatic	O
IV	B
Cl	I
1	I
cells	O
.	O

A	O
similar	O
ser120	O
-	O
gly	O
mutation	O
in	O
NME1	O
has	O
been	O
found	O
in	O
human	O
neuroblastoma	O
,	O
suggesting	O
that	O
mutation	O
in	O
this	O
region	O
may	O
be	O
a	O
general	O
phenomenon	O
related	O
to	O
tumor	O
progression	O
.	O

These	O
mutations	O
may	O
have	O
functional	O
consequences	O
since	O
they	O
eliminate	O
potential	O
phosphorylation	O
sites	O
and	O
may	O
affect	O
the	O
tertiary	O
structure	O
of	O
mature	O
protein	O
complexes	O
.	O

Image	O
-	O
directed	O
and	O
color	O
Doppler	O
studies	O
of	O
gallbladder	O
tumors	O
.	O

Thirteen	O
cases	O
of	O
primary	O
adenocarcinoma	O
of	O
the	O
gallbladder	O
(	O
GB	O
)	O
,	O
1	O
of	O
malignant	O
fibrous	O
histocytoma	O
,	O
3	O
of	O
metastatic	O
adenocarcinoma	O
,	O
5	O
of	O
adenoma	O
,	O
5	O
of	O
polypus	O
,	O
2	O
of	O
xanthogranuloma	O
,	O
6	O
of	O
chronic	O
cholecystitis	O
,	O
4	O
of	O
acute	O
cholecystitis	O
,	O
and	O
8	O
of	O
subacute	O
cholecystitis	O
were	O
studied	O
by	O
image	O
-	O
directed	O
and	O
color	O
Doppler	O
ultrasonography	O
(	O
CDUS	O
)	O
.	O

All	O
of	O
the	O
14	O
cases	O
of	O
primary	O
GB	O
cancer	O
(	O
10	O
masses	O
,	O
4	O
thickening	O
wall	O
)	O
were	O
found	O
to	O
have	O
a	O
high	O
velocity	O
arterial	O
blood	O
flow	O
signal	O
in	O
the	O
wall	O
of	O
the	O
GB	O
.	O

In	O
contrast	O
,	O
the	O
3	O
cases	O
of	O
metastatic	O
cancer	O
of	O
the	O
GB	O
had	O
no	O
blood	O
flow	O
signal	O
in	O
the	O
wall	O
of	O
the	O
GB	O
.	O

For	O
the	O
30	O
cases	O
of	O
benign	O
lesions	O
of	O
the	O
GB	O
,	O
only	O
in	O
12	O
cases	O
was	O
a	O
low	O
velocity	O
blood	O
flow	O
signal	O
found	O
.	O

Nine	O
of	O
10	O
cases	O
of	O
primary	O
GB	O
malignancy	O
were	O
found	O
to	O
have	O
high	O
velocity	O
arterial	O
blood	O
flow	O
signals	O
in	O
the	O
tumor	O
masses	O
.	O

No	O
blood	O
flow	O
signal	O
was	O
observed	O
in	O
the	O
masses	O
of	O
13	O
cases	O
(	O
3	O
of	O
metastatic	O
adenocarcinoma	O
,	O
5	O
of	O
adenoma	O
,	O
5	O
of	O
polypus	O
)	O
.	O

An	O
abnormal	O
high	O
velocity	O
arterial	O
blood	O
flow	O
signal	O
observed	O
within	O
masses	O
in	O
the	O
GB	O
or	O
in	O
the	O
GB	O
wall	O
is	O
a	O
significant	O
feature	O
of	O
primary	O
GB	O
cancer	O
and	O
thus	O
helps	O
to	O
differentiate	O
primary	O
GB	O
cancer	O
from	O
metastatic	O
and	O
benign	O
lesions	O
of	O
the	O
GB	O
.	O

Differential	O
effects	O
of	O
carbachol	O
on	O
calcium	O
entry	O
and	O
release	O
in	O
CHO	B
cells	O
expressing	O
the	O
m3	O
muscarinic	O
receptor	O
.	O

Calcium	O
signalling	O
was	O
examined	O
in	O
CHO	B
-	I
k1	I
cells	O
that	O
stably	O
express	O
the	O
m3	O
subtype	O
of	O
the	O
muscarinic	O
receptor	O
.	O

The	O
calcium	O
indicator	O
Fura	O
-	O
2	O
was	O
retained	O
in	O
these	O
cells	O
only	O
in	O
the	O
presence	O
of	O
probenecid	O
(	O
1	O
mM	O
)	O
,	O
suggesting	O
that	O
Fura	O
-	O
2	O
efflux	O
was	O
mediated	O
by	O
an	O
organic	O
anion	O
transporter	O
.	O

The	O
addition	O
of	O
carbachol	O
(	O
CCh	O
)	O
to	O
Fura	O
-	O
2	O
loaded	O
cells	O
in	O
suspension	O
caused	O
a	O
rapid	O
transient	O
increase	O
in	O
intracellular	O
calcium	O
[	O
Ca	O
]	O
i	O
followed	O
by	O
a	O
smaller	O
sustained	O
plateau	O
phase	O
.	O

The	O
transient	O
rise	O
in	O
[	O
Ca	O
]	O
i	O
was	O
dose	O
-	O
dependent	O
with	O
a	O
threshold	O
response	O
of	O
89	O
+	O
/	O
-	O
18	O
nM	O
above	O
baseline	O
with	O
10	O
nM	O
CCh	O
and	O
a	O
maximum	O
stimulation	O
of	O
734	O
+	O
/	O
-	O
46	O
nM	O
with	O
10	O
microM	O
CCh	O
.	O

This	O
phase	O
was	O
accompanied	O
by	O
a	O
similar	O
dose	O
-	O
dependent	O
stimulation	O
of	O
total	O
inositol	O
phosphate	O
production	O
and	O
was	O
assumed	O
to	O
be	O
generated	O
by	O
release	O
from	O
intracellular	O
stores	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

The	O
sustained	O
increase	O
in	O
[	O
Ca	O
]	O
i	O
was	O
generated	O
by	O
entry	O
from	O
the	O
extracellular	O
bath	O
since	O
it	O
was	O
blocked	O
by	O
pretreatment	O
with	O
La3	O
+	O
(	O
1	O
microM	O
)	O
and	O
was	O
absent	O
when	O
bath	O
calcium	O
was	O
chelated	O
with	O
EGTA	O
.	O

This	O
phase	O
was	O
not	O
dependent	O
on	O
CCh	O
dose	O
,	O
and	O
a	O
stimulation	O
of	O
[	O
Ca	O
]	O
i	O
of	O
approximately	O
90	O
nM	O
above	O
baseline	O
was	O
observed	O
with	O
CCh	O
concentrations	O
between	O
50	O
nM	O
and	O
10	O
microM	O
.	O

With	O
this	O
dose	O
range	O
,	O
the	O
rate	O
of	O
Mn2	O
+	O
quenching	O
of	O
Fura	O
-	O
2	O
at	O
the	O
Ca	O
-	O
insensitive	O
excitation	O
wavelength	O
of	O
360	O
nm	O
was	O
likewise	O
maximally	O
stimulated	O
.	O

At	O
lower	O
CCh	O
concentrations	O
(	O
10	O
-	O
50	O
nM	O
)	O
,	O
it	O
was	O
clear	O
that	O
the	O
activation	O
of	O
Ca	O
entry	O
could	O
not	O
be	O
dissociated	O
from	O
a	O
threshold	O
release	O
of	O
Ca	O
from	O
intracellular	O
stores	O
.	O

The	O
phorbol	O
ester	O
PMA	O
,	O
which	O
uncouples	O
the	O
muscarinic	O
receptor	O
from	O
phospholipase	O
C	O
,	O
reduced	O
the	O
transient	O
rise	O
in	O
[	O
Ca	O
]	O
i	O
by	O
approximately	O
50	O
%	O
with	O
little	O
or	O
no	O
effect	O
on	O
Ca	O
entry	O
at	O
higher	O
CCh	O
levels	O
(	O
>	O
or	O
=	O
1	O
microM	O
)	O
.	O

At	O
lower	O
CCh	O
concentrations	O
(	O
<	O
or	O
=	O
100	O
nM	O
)	O
however	O
,	O
pretreatment	O
with	O
PMA	O
completely	O
blocked	O
all	O
Ca	O
mobilization	O
and	O
supports	O
the	O
contention	O
that	O
Ca	O
entry	O
is	O
coupled	O
to	O
Ca	O
release	O
from	O
stores	O
or	O
to	O
store	O
depletion	O
.	O

The	O
emptying	O
of	O
inositol	O
trisphosphate	O
-	O
sensitive	O
stores	O
with	O
thapsigargin	O
(	O
10	O
nM	O
)	O
stimulated	O
Ca	O
entry	O
and	O
also	O
the	O
rate	O
of	O
Mn2	O
+	O
quenching	O
.	O

Store	O
depletion	O
by	O
incubation	O
in	O
Ca	O
-	O
free	O
media	O
likewise	O
stimulated	O
Mn2	O
+	O
uptake	O
without	O
a	O
rise	O
in	O
[	O
Ca	O
]	O
i	O
.	O

Our	O
data	O
are	O
therefore	O
consistent	O
with	O
a	O
'	O
capacitative	O
'	O
coupling	O
model	O
,	O
whereby	O
the	O
activation	O
of	O
the	O
plasma	O
membrane	O
receptor	O
leads	O
to	O
an	O
InsP3	O
-	O
induced	O
change	O
in	O
the	O
degree	O
of	O
filling	O
of	O
the	O
ER	O
Ca	O
pool	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Down	O
-	O
regulation	O
of	O
collagen	O
XII	O
in	O
transformed	O
mesenchymal	O
cells	O
.	O

Collagen	O
XII	O
is	O
a	O
complex	O
multidomain	O
protein	O
associated	O
with	O
the	O
surface	O
of	O
interstitial	O
collagen	O
fibrils	O
.	O

This	O
protein	O
is	O
produced	O
in	O
large	O
amounts	O
by	O
fibroblasts	O
cultivated	O
in	O
vitro	O
.	O

However	O
,	O
it	O
is	O
completely	O
absent	O
from	O
cells	O
transformed	O
by	O
the	O
oncogene	O
v	O
-	O
myc	O
or	O
v	O
-	O
src	O
and	O
from	O
cells	O
derived	O
from	O
a	O
methylcholanthrene	O
-	O
induced	O
fibrosarcoma	O
.	O

Since	O
all	O
these	O
cells	O
lack	O
any	O
mRNA	O
for	O
collagen	O
,	O
XII	O
,	O
it	O
seems	O
likely	O
that	O
the	O
synthesis	O
is	O
blocked	O
at	O
the	O
transcriptional	O
level	O
.	O

Experiments	O
with	O
a	O
temperature	O
-	O
sensitive	O
mutant	O
of	O
Rous	O
sarcoma	O
virus	O
demonstrated	O
that	O
a	O
single	O
oncogene	O
product	O
is	O
sufficient	O
to	O
inhibit	O
the	O
synthesis	O
.	O

A	O
reduction	O
in	O
the	O
expression	O
of	O
collagen	O
XII	O
might	O
have	O
profound	O
effects	O
on	O
the	O
stability	O
of	O
the	O
extracellular	O
matrix	O
of	O
transformed	O
cells	O
.	O

Comparative	O
NMR	O
study	O
of	O
a	O
differentiated	O
rat	O
hepatoma	O
and	O
its	O
dedifferentiated	O
subclone	O
cultured	O
as	O
spheroids	O
and	O
as	O
implanted	O
tumors	O
.	O

H4IIEC3	B
(	O
H4	B
)	O
,	O
a	O
differentiated	O
rat	O
hepatoma	O
line	O
and	O
H5	B
,	O
its	O
dedifferentiated	O
subclone	O
,	O
were	O
investigated	O
as	O
proliferating	O
spheroids	O
and	O
as	O
implanted	O
subcutaneous	O
tumors	O
in	O
juvenile	O
rats	O
.	O

H4	B
cells	O
formed	O
tight	O
,	O
round	O
spheroids	O
whereas	O
H5	B
cells	O
formed	O
loose	O
,	O
grape	O
-	O
like	O
structures	O
.	O

31P	O
MR	O
spectra	O
showed	O
that	O
phosphocreatine	O
was	O
present	O
in	O
H5	B
spheroids	O
but	O
not	O
in	O
H4	B
spheroids	O
or	O
tumors	O
.	O

[	O
13C	O
]	O
Lactate	O
production	O
from	O
[	O
13C	O
]	O
glucose	O
,	O
with	O
no	O
detectable	O
uptake	O
of	O
[	O
13C	O
]	O
alanine	O
,	O
indicated	O
that	O
energy	O
production	O
in	O
H5	B
spheroids	O
was	O
primarily	O
via	O
glycolysis	O
.	O

No	O
[	O
13C	O
]	O
glucose	O
utilization	O
was	O
detected	O
in	O
H4	B
spheroids	O
,	O
but	O
uptake	O
of	O
alanine	O
and	O
accumulation	O
of	O
labeled	O
lactate	O
,	O
glutamate	O
and	O
glutamine	O
indicated	O
oxidation	O
via	O
the	O
tricarboxylic	O
acid	O
(	O
TCA	O
)	O
cycle	O
.	O

Tumors	O
of	O
H4	B
cells	O
were	O
well	O
perfused	O
,	O
unlike	O
tumors	O
of	O
H5	B
cells	O
which	O
were	O
highly	O
necrotic	O
.	O

Following	O
i	O
.	O
v	O
.	O
infusion	O
with	O
[	O
13C	O
]	O
alanine	O
,	O
[	O
13C	O
]	O
lactate	O
and	O
glutamate	O
,	O
evidence	O
of	O
oxidation	O
via	O
the	O
TCA	O
cycle	O
,	O
were	O
observed	O
in	O
H4	B
tumors	O
.	O

Thus	O
the	O
results	O
obtained	O
by	O
31P	O
and	O
13C	O
MRS	O
correlated	O
with	O
the	O
differentiation	O
state	O
of	O
H4	B
and	O
H5	B
spheroids	O
and	O
tumors	O
.	O

Modulation	O
of	O
apoptosis	O
in	O
human	O
myeloid	O
leukemic	O
cells	O
by	O
GM	O
-	O
CSF	O
.	O

Apoptosis	O
(	O
programmed	O
cell	O
death	O
)	O
regulates	O
cell	O
population	O
size	O
.	O

To	O
determine	O
the	O
mechanisms	O
whereby	O
hematopoietic	O
growth	O
factors	O
(	O
HGFs	O
)	O
modulate	O
apoptosis	O
in	O
human	O
myeloid	O
leukemic	O
cells	O
,	O
we	O
evaluated	O
the	O
roles	O
of	O
protein	O
and	O
mRNA	O
synthesis	O
for	O
altering	O
apoptosis	O
in	O
growth	O
factor	O
-	O
stimulated	O
vs	O
.	O
quiescent	O
leukemic	O
TF1	B
cells	O
.	O

Lysates	O
of	O
cells	O
from	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
-	O
dependent	O
myeloid	O
leukemic	O
cell	O
line	O
TF1	B
were	O
separated	O
into	O
high	O
molecular	O
weight	O
(	O
HMW	O
)	O
pellets	O
of	O
intact	O
DNA	O
and	O
supernatants	O
of	O
fragmented	O
low	O
MW	O
(	O
LMW	O
)	O
DNA	O
,	O
and	O
the	O
DNA	O
purified	O
from	O
these	O
fractions	O
was	O
quantified	O
.	O

In	O
the	O
absence	O
of	O
both	O
GM	O
-	O
CSF	O
and	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
,	O
70	O
%	O
of	O
the	O
DNA	O
was	O
fragmented	O
after	O
3	O
days	O
in	O
culture	O
,	O
with	O
a	O
characteristic	O
apoptotic	O
ladder	O
-	O
like	O
pattern	O
on	O
agarose	O
gel	O
electrophoresis	O
,	O
whereas	O
this	O
proportion	O
had	O
initially	O
been	O
<	O
5	O
%	O
.	O

In	O
contrast	O
,	O
less	O
than	O
5	O
%	O
of	O
the	O
DNA	O
was	O
fragmented	O
in	O
cells	O
incubated	O
with	O
GM	O
-	O
CSF	O
plus	O
FBS	O
or	O
GM	O
-	O
CSF	O
alone	O
.	O

Delayed	O
addition	O
of	O
GM	O
-	O
CSF	O
,	O
but	O
not	O
FBS	O
,	O
permitted	O
partial	O
rescue	O
of	O
the	O
cells	O
,	O
inhibiting	O
increasing	O
rates	O
of	O
accumulation	O
of	O
fragmented	O
DNA	O
.	O

When	O
the	O
macro	O
-	O
molecular	O
synthesis	O
inhibitor	O
cycloheximide	O
(	O
CHX	O
)	O
or	O
actinomycin	O
D	O
(	O
Act	O
D	O
)	O
was	O
present	O
for	O
26	O
hours	O
in	O
the	O
absence	O
of	O
GM	O
-	O
CSF	O
and	O
FBS	O
,	O
apoptosis	O
was	O
inhibited	O
.	O

In	O
contrast	O
,	O
in	O
the	O
presence	O
of	O
GM	O
-	O
CSF	O
or	O
FBS	O
,	O
apoptosis	O
was	O
enhanced	O
upon	O
addition	O
of	O
CHX	O
or	O
Act	O
D	O
.	O

The	O
latter	O
effect	O
persisted	O
even	O
with	O
the	O
late	O
addition	O
of	O
CHX	O
.	O

These	O
findings	O
indicate	O
that	O
disparate	O
mechanisms	O
of	O
enhancing	O
or	O
inhibiting	O
apoptosis	O
exist	O
in	O
myeloid	O
leukemic	O
cells	O
related	O
to	O
environmental	O
conditions	O
,	O
including	O
HGF	O
-	O
regulated	O
cellular	O
synthesis	O
of	O
distinct	O
proteins	O
and	O
mRNA	O
.	O

Effects	O
of	O
doxycycline	O
on	O
in	O
vitro	O
growth	O
,	O
migration	O
,	O
and	O
gelatinase	O
activity	O
of	O
breast	O
carcinoma	O
cells	O
.	O

Metastatic	O
disease	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
death	O
from	O
cancer	O
in	O
human	O
beings	O
.	O

Several	O
enzyme	O
systems	O
have	O
been	O
implicated	O
in	O
the	O
metastatic	O
process	O
,	O
but	O
the	O
metalloproteinases	O
(	O
MPs	O
)	O
appear	O
to	O
be	O
the	O
major	O
group	O
involved	O
in	O
most	O
instances	O
of	O
neoplastic	O
invasion	O
.	O

Increased	O
MP	O
activity	O
has	O
been	O
correlated	O
with	O
the	O
metastatic	O
potential	O
of	O
many	O
cancers	O
,	O
including	O
breast	O
cancer	O
.	O

MPs	O
also	O
play	O
a	O
role	O
in	O
tumor	O
angiogenesis	O
.	O

Tetracyclines	O
are	O
antimicrobial	O
agents	O
that	O
can	O
suppress	O
MP	O
activity	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
including	O
gingiva	O
,	O
bone	O
,	O
and	O
cartilage	O
.	O

Several	O
reports	O
have	O
indicated	O
that	O
tetracyclines	O
can	O
suppress	O
tumor	O
MPs	O
as	O
well	O
.	O

A	O
synthetic	O
tetracycline	O
,	O
doxycycline	O
,	O
inhibits	O
migration	O
of	O
human	O
MDA	B
-	I
MB	I
-	I
435	I
breast	O
adenocarcinoma	O
cells	O
through	O
a	O
reconstituted	O
basement	O
membrane	O
(	O
Matrigel	O
)	O
,	O
an	O
assay	O
used	O
as	O
an	O
in	O
vitro	O
surrogate	O
for	O
the	O
in	O
vivo	O
process	O
of	O
tumor	O
invasion	O
through	O
basement	O
membranes	O
.	O

Additionally	O
,	O
doxycycline	O
diminishes	O
the	O
proliferation	O
of	O
this	O
breast	O
cancer	O
cell	O
line	O
and	O
also	O
decreases	O
its	O
gelatinolytic	O
activity	O
,	O
as	O
determined	O
by	O
gel	O
zymography	O
.	O

[	O
The	O
erbB	O
gene	O
family	O
:	O
significance	O
for	O
tumor	O
development	O
,	O
prognosis	O
and	O
new	O
therapeutic	O
modalities	O
]	O
.	O

RNA	O
and	O
DNA	O
viruses	O
can	O
be	O
transforming	O
and	O
tumourigenic	O
agents	O
.	O

The	O
transformation	O
is	O
a	O
consequence	O
of	O
the	O
ability	O
of	O
viruses	O
to	O
integrate	O
into	O
the	O
host	O
cell	O
'	O
s	O
DNA	O
and	O
to	O
produce	O
transforming	O
proteins	O
.	O

These	O
proteins	O
are	O
mainly	O
produced	O
by	O
specific	O
integral	O
parts	O
of	O
the	O
viral	O
genome	O
,	O
the	O
oncogenes	O
.	O

Comparison	O
between	O
RNA	O
/	O
DNA	O
sequence	O
of	O
viral	O
oncogenes	O
and	O
normal	O
human	O
genome	O
of	O
non	O
-	O
transformed	O
cells	O
revealed	O
high	O
sequence	O
similarities	O
in	O
specific	O
genomic	O
areas	O
,	O
which	O
were	O
named	O
cellular	O
proto	O
-	O
oncogens	O
.	O

They	O
are	O
important	O
components	O
of	O
the	O
growth	O
regulatory	O
pathways	O
in	O
normal	O
cells	O
.	O

The	O
accumulation	O
of	O
genetic	O
alterations	O
of	O
some	O
proto	O
-	O
oncogens	O
,	O
like	O
the	O
erbB	O
-	O
family	O
,	O
may	O
be	O
part	O
of	O
the	O
mechanism	O
,	O
by	O
which	O
malignant	O
cells	O
can	O
acquire	O
a	O
selective	O
growth	O
advantage	O
.	O

The	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGF	O
-	O
R	O
,	O
c	O
-	O
erbB1	O
)	O
,	O
Her	O
-	O
2	O
/	O
neu	O
(	O
c	O
-	O
erbB2	O
)	O
,	O
and	O
c	O
-	O
erbB3	O
are	O
members	O
of	O
the	O
erbB	O
-	O
family	O
.	O

The	O
detection	O
of	O
increased	O
abundance	O
of	O
EGF	O
-	O
R	O
or	O
Her	O
-	O
2	O
/	O
neu	O
proteins	O
in	O
human	O
tumours	O
can	O
provide	O
additional	O
information	O
on	O
the	O
disease	O
-	O
free	O
survival	O
and	O
overall	O
survival	O
for	O
patients	O
with	O
breast	O
,	O
ovarian	O
,	O
endometrial	O
or	O
cervical	O
cancer	O
.	O

Molecular	O
and	O
cell	O
-	O
physiological	O
analyses	O
have	O
improved	O
the	O
understanding	O
of	O
tumour	O
biology	O
and	O
provide	O
the	O
opportunity	O
for	O
new	O
therapeutic	O
approaches	O
.	O

Monoclonal	O
antibody	O
targeted	O
therapy	O
directed	O
against	O
EGF	O
-	O
R	O
or	O
Her	O
-	O
2	O
/	O
neu	O
,	O
the	O
use	O
of	O
anti	O
-	O
sense	O
oligonucleotides	O
and	O
oligodeoxynucleotides	O
,	O
and	O
the	O
application	O
of	O
tyrosine	O
kinase	O
and	O
protein	O
C	O
-	O
kinase	O
inhibitors	O
are	O
currently	O
being	O
investigated	O
.	O

Transforming	O
growth	O
factor	O
beta	O
1	O
promotes	O
spontaneous	O
transformation	O
of	O
cultured	O
rat	O
liver	O
epithelial	O
cells	O
.	O

The	O
neoplastic	O
transformation	O
of	O
cultured	O
rat	O
liver	O
epithelial	O
cells	O
by	O
various	O
means	O
has	O
consistently	O
been	O
associated	O
with	O
the	O
development	O
of	O
resistance	O
to	O
the	O
mito	O
-	O
inhibitory	O
effect	O
of	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
,	O
suggesting	O
that	O
such	O
phenotype	O
plays	O
a	O
mechanistic	O
role	O
during	O
the	O
transformation	O
of	O
these	O
cells	O
.	O

We	O
have	O
studied	O
the	O
induction	O
of	O
the	O
""""	O
TGF	O
-	O
beta	O
-	O
resistant	O
""""	O
phenotype	O
in	O
a	O
clonal	O
strain	O
of	O
early	O
passage	O
WB	B
-	I
F344	I
normal	O
cultured	O
rat	O
liver	O
epithelial	O
cells	O
,	O
the	O
proliferation	O
of	O
which	O
was	O
markedly	O
inhibited	O
by	O
TGF	O
-	O
beta	O
.	O

The	O
control	O
WB	O
cells	O
in	O
continuous	O
culture	O
slowly	O
developed	O
TGF	O
-	O
beta	O
resistance	O
.	O

However	O
,	O
when	O
the	O
same	O
cells	O
were	O
exposed	O
to	O
step	O
-	O
wise	O
increases	O
of	O
TGF	O
-	O
beta	O
concentration	O
in	O
their	O
culture	O
medium	O
,	O
the	O
development	O
of	O
TGF	O
-	O
beta	O
resistance	O
was	O
accelerated	O
.	O

Cells	O
which	O
had	O
been	O
grown	O
in	O
medium	O
containing	O
1	O
ng	O
/	O
ml	O
TGF	O
-	O
beta	O
developed	O
colony	O
-	O
forming	O
capacity	O
in	O
soft	O
agar	O
containing	O
epidermal	O
growth	O
factor	O
.	O

Cells	O
which	O
were	O
grown	O
in	O
media	O
containing	O
5	O
and	O
10	O
ng	O
/	O
ml	O
TGF	O
-	O
beta	O
demonstrated	O
a	O
low	O
level	O
of	O
colony	O
-	O
forming	O
efficiency	O
in	O
soft	O
agar	O
medium	O
without	O
added	O
epidermal	O
growth	O
factor	O
and	O
tumorigenicity	O
in	O
isogeneic	O
rats	O
.	O

These	O
TGF	O
-	O
beta	O
-	O
resistant	O
cells	O
also	O
exhibited	O
progressively	O
increasing	O
levels	O
of	O
expression	O
of	O
the	O
c	O
-	O
fos	O
and	O
and	O
myc	O
mRNA	O
,	O
and	O
increased	O
resistance	O
to	O
the	O
cytotoxicity	O
of	O
Adriamycin	O
and	O
melphalan	O
.	O

The	O
latter	O
phenomenon	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
the	O
mdr	O
-	O
1	O
mRNA	O
expression	O
,	O
cellular	O
glutathione	O
level	O
,	O
and	O
glutathione	O
S	O
-	O
transferase	O
activity	O
.	O

The	O
results	O
suggest	O
that	O
chronic	O
exposure	O
to	O
high	O
concentration	O
of	O
TGF	O
-	O
beta	O
promotes	O
the	O
spontaneous	O
neoplastic	O
transformation	O
of	O
cultured	O
rat	O
liver	O
epithelial	O
cells	O
,	O
and	O
that	O
this	O
process	O
may	O
represent	O
one	O
of	O
the	O
mechanisms	O
of	O
cellular	O
adaptation	O
for	O
induction	O
of	O
the	O
multidrug	O
-	O
resistant	O
phenotype	O
during	O
the	O
carcinogenesis	O
of	O
epithelial	O
cells	O
.	O

Human	O
cytomegalovirus	O
elevates	O
levels	O
of	O
the	O
cellular	O
protein	O
p53	O
in	O
infected	O
fibroblasts	O
.	O

Human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
,	O
like	O
other	O
DNA	O
tumor	O
viruses	O
,	O
induces	O
morphological	O
transformation	O
of	O
cells	O
in	O
vitro	O
and	O
stimulates	O
host	O
cell	O
macromolecular	O
synthesis	O
in	O
infected	O
cells	O
.	O

Since	O
other	O
DNA	O
tumor	O
viruses	O
,	O
such	O
as	O
simian	O
virus	O
40	O
and	O
adenovirus	O
,	O
have	O
previously	O
been	O
shown	O
to	O
interact	O
with	O
cellular	O
protein	O
p53	O
,	O
we	O
investigated	O
whether	O
infection	O
of	O
cells	O
by	O
HCMV	O
would	O
modulate	O
cellular	O
p53	O
levels	O
.	O

Our	O
results	O
indicate	O
that	O
HCMV	O
elevates	O
cellular	O
p53	O
levels	O
on	O
the	O
order	O
of	O
10	O
-	O
to	O
20	O
-	O
fold	O
in	O
infected	O
fibroblasts	O
.	O

The	O
induction	O
of	O
elevated	O
p53	O
levels	O
was	O
dependent	O
upon	O
the	O
presence	O
of	O
active	O
virus	O
and	O
was	O
prevented	O
by	O
neutralizing	O
antibody	O
.	O

The	O
induction	O
of	O
elevated	O
p53	O
levels	O
was	O
determined	O
not	O
to	O
be	O
due	O
to	O
virus	O
-	O
receptor	O
interactions	O
or	O
HCMV	O
late	O
events	O
.	O

The	O
induction	O
of	O
elevated	O
p53	O
levels	O
commenced	O
at	O
immediate	O
-	O
early	O
times	O
of	O
the	O
HCMV	O
multiplication	O
cycle	O
(	O
6	O
h	O
postinfection	O
)	O
and	O
reached	O
maximal	O
levels	O
by	O
24	O
h	O
postinfection	O
,	O
before	O
most	O
of	O
the	O
HCMV	O
DNA	O
synthesis	O
was	O
initiated	O
.	O

HCMV	O
immediate	O
-	O
early	O
proteins	O
were	O
clearly	O
shown	O
to	O
be	O
responsible	O
for	O
elevating	O
p53	O
levels	O
in	O
infected	O
fibroblasts	O
;	O
expression	O
of	O
HCMV	O
immediate	O
-	O
early	O
region	O
1	O
and	O
2	O
proteins	O
resulted	O
in	O
elevation	O
of	O
p53	O
levels	O
in	O
transfected	O
human	O
fibroblasts	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
increased	O
p53	O
levels	O
caused	O
by	O
HCMV	O
in	O
infected	O
fibroblasts	O
.	O

Appetite	O
regulation	O
by	O
serotoninergic	O
mechanisms	O
and	O
effects	O
of	O
d	O
-	O
fenfluramine	O
.	O

In	O
this	O
literature	O
review	O
,	O
evidence	O
is	O
presented	O
for	O
the	O
theory	O
that	O
the	O
neurotransmitter	O
,	O
serotonin	O
(	O
5	O
-	O
hydroxytryptamine	O
,	O
5HT	O
)	O
,	O
in	O
medial	O
hypothalamic	O
centres	O
is	O
an	O
important	O
regulator	O
for	O
appetite	O
and	O
for	O
the	O
selection	O
of	O
major	O
food	O
constituents	O
.	O

High	O
local	O
levels	O
of	O
5HT	O
cause	O
a	O
reduction	O
of	O
appetite	O
and	O
a	O
preference	O
for	O
protein	O
,	O
low	O
levels	O
the	O
opposite	O
.	O

The	O
main	O
antagonistic	O
system	O
is	O
noradrenergic	O
.	O

The	O
drug	O
d	O
-	O
fenfluramine	O
mimics	O
the	O
effects	O
of	O
5HT	O
by	O
releasing	O
5HT	O
from	O
serotoninergic	O
nerve	O
endings	O
and	O
inhibiting	O
its	O
neuronal	O
re	O
-	O
uptake	O
.	O

Further	O
experimental	O
data	O
prove	O
that	O
a	O
high	O
-	O
carbohydrate	O
,	O
low	O
-	O
protein	O
diet	O
promotes	O
uptake	O
of	O
serum	O
tryptophan	O
in	O
the	O
brain	O
and	O
its	O
conversion	O
into	O
5HT	O
.	O

Hence	O
,	O
this	O
serotoninergic	O
system	O
may	O
function	O
as	O
a	O
self	O
-	O
regulatory	O
mechanism	O
.	O

In	O
patients	O
with	O
decreased	O
peripheral	O
insulin	O
sensitivity	O
,	O
the	O
system	O
may	O
be	O
disturbed	O
,	O
causing	O
overconsumption	O
of	O
carbohydrates	O
.	O

This	O
is	O
sometimes	O
compulsive	O
(	O
""""	O
carbohydrate	O
craving	O
""""	O
)	O
.	O

It	O
may	O
be	O
presumed	O
that	O
in	O
the	O
treatment	O
of	O
obesity	O
,	O
in	O
addition	O
to	O
the	O
use	O
of	O
serotoninergic	O
drugs	O
,	O
successes	O
with	O
reducing	O
diets	O
may	O
be	O
enhanced	O
by	O
including	O
periods	O
of	O
high	O
-	O
carbohydrate	O
,	O
low	O
-	O
protein	O
intake	O
.	O

It	O
would	O
be	O
worthwhile	O
to	O
explore	O
whether	O
similar	O
alimentary	O
self	O
-	O
regulatory	O
mechanisms	O
of	O
neurotransmitter	O
function	O
exist	O
in	O
other	O
regulatory	O
systems	O
.	O

Comparison	O
of	O
image	O
(	O
CAS	O
200	O
)	O
and	O
flow	O
cytometry	O
determined	O
DNA	O
content	O
of	O
paraffin	O
-	O
embedded	O
Hodgkin	O
'	O
s	O
disease	O
tissue	O
.	O

To	O
assess	O
the	O
reliability	O
of	O
DNA	O
estimation	O
using	O
image	O
cytometry	O
,	O
deparaffinized	O
lymph	O
nodes	O
from	O
70	O
patients	O
with	O
Hodgkin	O
'	O
s	O
disease	O
were	O
examined	O
and	O
the	O
results	O
obtained	O
were	O
compared	O
with	O
those	O
from	O
flow	O
cytometry	O
.	O

Image	O
analysis	O
without	O
discriminating	O
between	O
the	O
various	O
cell	O
types	O
,	O
as	O
found	O
in	O
Hodgkin	O
'	O
s	O
disease	O
,	O
revealed	O
no	O
separate	O
aneuploid	O
peak	O
.	O

Selecting	O
on	O
morphologically	O
defined	O
nuclear	O
types	O
DNA	O
aneuploidy	O
was	O
detected	O
in	O
20	O
%	O
of	O
the	O
cases	O
(	O
14	O
/	O
70	O
)	O
.	O

The	O
aneuploid	O
populations	O
were	O
limited	O
to	O
the	O
population	O
of	O
nuclei	O
defined	O
as	O
Reed	O
-	O
Sternberg	O
(	O
RS	O
)	O
-	O
like	O
or	O
medium	O
-	O
sized	O
lymphocytes	O
.	O

Benign	O
lymph	O
nodes	O
DNA	O
aneuploidy	O
was	O
not	O
found	O
in	O
any	O
of	O
the	O
controls	O
.	O

Comparison	O
of	O
DNA	O
histograms	O
obtained	O
by	O
image	O
and	O
flow	O
cytometry	O
showed	O
aneuploid	O
peaks	O
using	O
image	O
cytometry	O
in	O
4	O
of	O
30	O
diploid	O
and	O
10	O
of	O
40	O
aneuploid	O
flow	O
histograms	O
.	O

In	O
conclusion	O
,	O
image	O
analysis	O
using	O
the	O
CAS	O
200	O
system	O
as	O
compared	O
to	O
flow	O
cytometry	O
is	O
more	O
time	O
-	O
consuming	O
and	O
less	O
sensitive	O
to	O
assess	O
ploidy	O
status	O
,	O
although	O
it	O
may	O
provide	O
extra	O
information	O
in	O
some	O
selected	O
cases	O
.	O

Evidence	O
is	O
obtained	O
that	O
DNA	O
aneuploidy	O
in	O
Hodgkin	O
'	O
s	O
disease	O
is	O
preferentially	O
expressed	O
by	O
cells	O
with	O
the	O
RS	O
/	O
H	O
-	O
like	O
and	O
medium	O
-	O
sized	O
lymphocyte	O
morphology	O
.	O

Inhibition	O
of	O
calmodulin	O
-	O
dependent	O
myosin	O
light	O
-	O
chain	O
kinase	O
by	O
growth	O
-	O
hormone	O
-	O
releasing	O
factor	O
and	O
vasoactive	O
intestinal	O
peptide	O
.	O

In	O
view	O
of	O
the	O
ability	O
of	O
calmodulin	O
to	O
bind	O
vasoactive	O
intestinal	O
peptide	O
(	O
VIP	O
)	O
and	O
growth	O
-	O
hormone	O
-	O
releasing	O
factor	O
(	O
GRF	O
)	O
with	O
high	O
affinity	O
[	O
Stallwood	O
,	O
Brugger	O
,	O
Baggenstoss	O
,	O
Stemmer	O
,	O
Shiraga	O
,	O
Landers	O
and	O
Paul	O
(	O
1992	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
267	O
,	O
19617	O
-	O
19621	O
]	O
,	O
the	O
effects	O
of	O
these	O
neuropeptides	O
on	O
a	O
model	O
calmodulin	O
-	O
dependent	O
enzyme	O
,	O
myosin	O
light	O
-	O
chain	O
kinase	O
(	O
MLCK	O
)	O
,	O
were	O
studied	O
.	O

Both	O
peptides	O
were	O
potent	O
inhibitors	O
of	O
MLCK	O
activity	O
.	O

The	O
inhibition	O
of	O
enzyme	O
activity	O
by	O
VIP	O
and	O
GRF	O
was	O
progressively	O
overcome	O
with	O
increasing	O
calmodulin	O
concentrations	O
,	O
with	O
no	O
inhibition	O
observed	O
at	O
a	O
saturating	O
calmodulin	O
concentration	O
.	O

Nanomolar	O
concentrations	O
of	O
MLCK	O
blocked	O
the	O
formation	O
of	O
calmodulin	O
-	O
[	O
125I	O
-	O
Tyr10	O
]	O
VIP	O
complexes	O
.	O

These	O
data	O
provide	O
support	O
for	O
a	O
functional	O
role	O
of	O
VIP	O
and	O
GRF	O
binding	O
by	O
calmodulin	O
.	O

Cyclin	O
D1	O
/	O
bcl	O
-	O
1	O
cooperates	O
with	O
myc	O
genes	O
in	O
the	O
generation	O
of	O
B	O
-	O
cell	O
lymphoma	O
in	O
transgenic	O
mice	O
.	O

The	O
chromosomal	O
translocation	O
t	O
(	O
11	O
:	O
14	O
)	O
is	O
associated	O
with	O
human	O
lymphoid	O
neoplasia	O
affecting	O
centrocytic	O
B	O
-	O
cells	O
of	O
intermediate	O
differentiation	O
.	O

As	O
a	O
consequence	O
the	O
cyclin	O
D1	O
(	O
bcl	O
-	O
1	O
)	O
gene	O
is	O
juxtaposed	O
to	O
the	O
immunoglobulin	O
heavy	O
chain	O
enhancer	O
E	O
mu	O
.	O

To	O
show	O
that	O
transcriptional	O
activation	O
of	O
cyclin	O
D1	O
is	O
causally	O
involved	O
in	O
the	O
generation	O
of	O
B	O
-	O
cell	O
neoplasia	O
we	O
have	O
generated	O
transgenic	O
mice	O
that	O
carry	O
a	O
cyclin	O
D1	O
gene	O
under	O
the	O
transcriptional	O
control	O
of	O
the	O
E	O
mu	O
element	O
.	O

E	O
mu	O
cyclin	O
D1	O
transgenic	O
mice	O
show	O
only	O
very	O
subtle	O
alterations	O
in	O
the	O
cycling	O
behaviour	O
of	O
B	O
-	O
cell	O
populations	O
in	O
the	O
bone	O
marrow	O
compared	O
with	O
normal	O
mice	O
and	O
do	O
not	O
develop	O
lymphoid	O
tumours	O
.	O

However	O
,	O
E	O
mu	O
-	O
directed	O
coexpression	O
of	O
cyclin	O
D1	O
and	O
N	O
-	O
MYC	O
or	O
L	O
-	O
MYC	O
in	O
double	O
transgenic	O
mice	O
reveals	O
a	O
strong	O
cooperative	O
effect	O
between	O
MYC	O
and	O
cyclin	O
D1	O
provoking	O
the	O
rapid	O
development	O
of	O
clonal	O
pre	O
-	O
B	O
and	O
B	O
-	O
cell	O
lymphomas	O
.	O

Interestingly	O
,	O
crossing	O
of	O
cyclin	O
D1	O
transgenic	O
mice	O
with	O
E	O
mu	O
L	O
-	O
myc	O
transgenics	O
that	O
express	O
their	O
transgene	O
in	O
both	O
B	O
-	O
and	O
T	O
-	O
cells	O
but	O
predominantly	O
develop	O
T	O
-	O
cell	O
tumours	O
leads	O
in	O
double	O
transgenics	O
exclusively	O
to	O
B	O
-	O
cell	O
neoplasia	O
.	O

The	O
data	O
presented	O
here	O
demonstrate	O
that	O
transcriptional	O
activation	O
of	O
cyclin	O
D1	O
can	O
oncogenically	O
transform	O
B	O
-	O
cells	O
in	O
concert	O
with	O
a	O
myc	O
gene	O
.	O

They	O
establish	O
cyclin	O
D1	O
as	O
a	O
proto	O
-	O
oncogene	O
whose	O
activity	O
appears	O
to	O
depend	O
on	O
a	O
specific	O
cell	O
type	O
as	O
well	O
as	O
on	O
a	O
specific	O
cooperating	O
partner	O
and	O
link	O
disturbances	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
progression	O
to	O
the	O
development	O
of	O
human	O
malignancies	O
.	O

Imaging	O
techniques	O
for	O
the	O
assessment	O
of	O
body	O
composition	O
.	O

Three	O
imaging	O
methods	O
,	O
ultrasound	O
imaging	O
(	O
UI	O
)	O
,	O
computer	O
-	O
assisted	O
axial	O
tomography	O
(	O
CAT	O
)	O
and	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
,	O
are	O
widely	O
used	O
in	O
medicine	O
.	O

Their	O
application	O
to	O
the	O
assessment	O
of	O
body	O
composition	O
in	O
nutrition	O
research	O
is	O
still	O
being	O
explored	O
and	O
developed	O
.	O

Ultrasound	O
imaging	O
yields	O
poor	O
image	O
quality	O
but	O
,	O
because	O
it	O
is	O
cheap	O
and	O
safe	O
,	O
deserves	O
further	O
exploration	O
.	O

Both	O
CAT	O
and	O
MRI	O
can	O
produce	O
images	O
with	O
good	O
discrimination	O
among	O
bone	O
,	O
muscle	O
and	O
adipose	O
tissue	O
.	O

Movement	O
artifacts	O
tend	O
to	O
be	O
more	O
serious	O
in	O
MRI	O
than	O
in	O
CAT	O
due	O
to	O
the	O
longer	O
imaging	O
time	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
X	O
-	O
ray	O
exposure	O
in	O
CAT	O
is	O
likely	O
to	O
limit	O
its	O
use	O
in	O
human	O
nutrition	O
research	O
.	O

Repeated	O
measurements	O
of	O
tissue	O
volumes	O
by	O
CAT	O
and	O
MRI	O
give	O
similar	O
CV	O
.	O

In	O
both	O
CAT	O
and	O
MRI	O
,	O
intra	O
-	O
abdominal	O
adipose	O
tissue	O
presents	O
greater	O
problems	O
of	O
measurement	O
than	O
subcutaneous	O
adipose	O
tissue	O
.	O

Validation	O
studies	O
with	O
77	O
-	O
kg	O
pigs	O
of	O
MRI	O
,	O
using	O
13	O
slices	O
,	O
predicted	O
total	O
body	O
lipid	O
with	O
residual	O
standard	O
deviation	O
of	O
1	O
.	O
9	O
%	O
.	O

In	O
validating	O
any	O
of	O
these	O
methods	O
,	O
account	O
should	O
be	O
take	O
of	O
the	O
extent	O
to	O
which	O
the	O
information	O
they	O
give	O
can	O
augment	O
that	O
given	O
by	O
more	O
simple	O
measures	O
like	O
age	O
and	O
weight	O
.	O

[	O
Preliminary	O
results	O
of	O
observing	O
18	O
cases	O
of	O
retinoblastoma	O
carried	O
within	O
the	O
international	O
research	O
program	O
RICS	O
]	O
.	O

In	O
the	O
years	O
1988	O
-	O
1989	O
,	O
the	O
Ophthalmological	O
Clinic	O
in	O
Cracow	O
took	O
part	O
in	O
the	O
International	O
Research	O
Programme	O
on	O
Retinoblastoma	O
as	O
one	O
of	O
28	O
clinical	O
centres	O
in	O
14	O
countries	O
.	O

The	O
study	O
included	O
18	O
children	O
with	O
retinoblastoma	O
,	O
in	O
most	O
cases	O
in	O
the	O
advanced	O
stadium	O
of	O
the	O
disease	O
.	O

As	O
a	O
rule	O
,	O
the	O
eyes	O
filled	O
with	O
tumours	O
were	O
enucleated	O
,	O
and	O
the	O
less	O
advanced	O
cases	O
were	O
treated	O
with	O
combined	O
methods	O
applying	O
radiation	O
with	O
60Co	O
plaques	O
with	O
xenon	O
arc	O
photocoagulation	O
,	O
cryopexy	O
,	O
and	O
chemotherapy	O
.	O

In	O
18	O
treated	O
children	O
23	O
eyes	O
were	O
enucleated	O
(	O
in	O
5	O
children	O
both	O
eyes	O
,	O
in	O
6	O
children	O
with	O
bilateral	O
retinoblastoma	O
1	O
eye	O
,	O
and	O
7	O
eyes	O
in	O
all	O
unilateral	O
cases	O
)	O
.	O

Six	O
eyes	O
with	O
less	O
advanced	O
lesions	O
were	O
treated	O
with	O
combined	O
methods	O
.	O

One	O
child	O
died	O
because	O
of	O
metastases	O
to	O
the	O
brain	O
.	O

The	O
obtained	O
data	O
reveal	O
that	O
retinoblastoma	O
is	O
diagnosed	O
too	O
late	O
,	O
which	O
decreases	O
the	O
chance	O
of	O
cure	O
and	O
causes	O
great	O
danger	O
for	O
the	O
life	O
of	O
the	O
child	O
.	O

Identification	O
of	O
latency	O
-	O
associated	O
transcripts	O
that	O
map	O
antisense	O
to	O
the	O
ICP4	O
homolog	O
gene	O
of	O
Marek	O
'	O
s	O
disease	O
virus	O
.	O

Two	O
small	O
RNAs	O
(	O
0	O
.	O
9	O
and	O
0	O
.	O
75	O
kb	O
)	O
,	O
named	O
Marek	O
'	O
s	O
disease	O
virus	O
(	O
MDV	O
)	O
small	O
RNAs	O
(	O
MSRs	O
)	O
and	O
a	O
10	O
-	O
kb	O
RNA	O
,	O
all	O
of	O
which	O
map	O
antisense	O
to	O
the	O
MDV	O
ICP4	O
homolog	O
gene	O
,	O
have	O
been	O
readily	O
detected	O
in	O
MDCC	B
-	I
MSB1	I
MDV	O
-	O
transformed	O
T	O
-	O
lymphoblastoid	O
cells	O
.	O

These	O
RNAs	O
were	O
not	O
detectable	O
in	O
reticuloendotheliosis	O
virus	O
-	O
transformed	O
T	O
cells	O
.	O

When	O
MDV	O
was	O
reactivated	O
by	O
treatment	O
of	O
lymphoblastoid	O
cells	O
with	O
25	O
micrograms	O
of	O
iododeoxyuridine	O
per	O
ml	O
,	O
the	O
relative	O
levels	O
of	O
the	O
transcripts	O
decreased	O
.	O

These	O
RNAs	O
were	O
not	O
detected	O
by	O
Northern	O
(	O
RNA	O
)	O
hybridization	O
in	O
productively	O
infected	O
chicken	O
embryo	O
fibroblasts	O
48	O
h	O
postinfection	O
;	O
however	O
,	O
they	O
were	O
apparent	O
140	O
h	O
postinfection	O
.	O

By	O
using	O
Northern	O
hybridization	O
,	O
RNase	O
protection	O
assays	O
,	O
and	O
primer	O
extension	O
analysis	O
,	O
the	O
MSRs	O
were	O
determined	O
to	O
map	O
antisense	O
to	O
the	O
predicted	O
translational	O
start	O
site	O
of	O
the	O
ICP4	O
homolog	O
gene	O
.	O

The	O
conclusion	O
most	O
consistent	O
with	O
the	O
data	O
is	O
that	O
the	O
two	O
MSRs	O
are	O
overlapping	O
,	O
spliced	O
RNAs	O
.	O

Both	O
small	O
RNAs	O
contain	O
a	O
latency	O
promoter	O
binding	O
factor	O
consensus	O
recognition	O
sequence	O
located	O
toward	O
their	O
5	O
'	O
ends	O
as	O
well	O
as	O
two	O
potential	O
ICP4	O
recognition	O
consensus	O
sequences	O
,	O
one	O
in	O
each	O
orientation	O
.	O

The	O
region	O
contains	O
a	O
number	O
of	O
small	O
open	O
reading	O
frames	O
on	O
each	O
side	O
and	O
within	O
the	O
MSRs	O
.	O

Although	O
the	O
exact	O
endpoints	O
are	O
unknown	O
,	O
the	O
large	O
10	O
-	O
kb	O
species	O
spans	O
the	O
entire	O
ICP4	O
homolog	O
region	O
.	O

We	O
believe	O
that	O
this	O
group	O
of	O
RNAs	O
,	O
which	O
map	O
antisense	O
to	O
the	O
ICP4	O
homolog	O
gene	O
,	O
are	O
latency	O
-	O
associated	O
transcripts	O
of	O
MDV	O
.	O

Elevated	O
expression	O
of	O
the	O
junB	O
proto	O
-	O
oncogene	O
is	O
essential	O
for	O
v	O
-	O
fos	O
induced	O
transformation	O
of	O
Rat	B
-	I
1	I
cells	O
.	O

We	O
previously	O
described	O
the	O
isolation	O
of	O
non	O
-	O
tumorigenic	O
revertants	O
from	O
mutagenized	O
populations	O
of	O
v	O
-	O
fos	O
-	O
transformed	O
Rat	B
-	I
1	I
cells	O
(	O
Zarbl	O
et	O
al	O
.	O
,	O
1987	O
)	O
.	O

In	O
the	O
present	O
study	O
we	O
examined	O
the	O
possibility	O
that	O
the	O
revertant	O
phenotype	O
resulted	O
from	O
mutations	O
that	O
altered	O
the	O
expression	O
or	O
activities	O
of	O
the	O
c	O
-	O
jun	O
or	O
junB	O
proto	O
-	O
oncogenes	O
.	O

The	O
results	O
demonstrated	O
that	O
levels	O
of	O
the	O
c	O
-	O
jun	O
mRNA	O
and	O
protein	O
were	O
unchanged	O
in	O
the	O
revertants	O
when	O
compared	O
to	O
the	O
transformed	O
parental	O
cells	O
,	O
and	O
ectopic	O
overexpression	O
of	O
c	O
-	O
jun	O
failed	O
to	O
retransform	O
the	O
revertants	O
.	O

Although	O
one	O
mutant	O
allele	O
was	O
detected	O
in	O
revertant	O
EMS	B
-	I
1	I
-	I
19	I
,	O
overexpression	O
of	O
this	O
mutant	O
allele	O
failed	O
to	O
inhibit	O
v	O
-	O
fos	O
induced	O
cell	O
transformation	O
.	O

Together	O
these	O
results	O
indicated	O
that	O
the	O
revertant	O
phenotype	O
did	O
not	O
result	O
from	O
altered	O
expression	O
or	O
mutations	O
in	O
the	O
c	O
-	O
jun	O
gene	O
.	O

In	O
contrast	O
to	O
the	O
results	O
obtained	O
with	O
c	O
-	O
jun	O
,	O
the	O
levels	O
of	O
junB	O
mRNA	O
and	O
protein	O
were	O
found	O
to	O
be	O
reduced	O
two	O
-	O
or	O
threefold	O
in	O
revertant	O
EMS	B
-	I
1	I
-	I
19	I
.	O

Ectopic	O
overexpression	O
of	O
junB	O
induced	O
transformation	O
of	O
revertant	O
EMS	B
-	I
1	I
-	I
19	I
,	O
but	O
failed	O
to	O
transform	O
Rat	B
-	I
1	I
cells	O
.	O

Moreover	O
,	O
about	O
10	O
%	O
of	O
v	O
-	O
fos	O
transformed	O
cells	O
transfected	O
with	O
vectors	O
that	O
express	O
antisense	O
junB	O
mRNA	O
acquired	O
a	O
non	O
-	O
transformed	O
phenotype	O
.	O

Together	O
these	O
results	O
indicate	O
that	O
expression	O
of	O
junB	O
above	O
a	O
threshold	O
level	O
is	O
essential	O
for	O
v	O
-	O
fos	O
-	O
induced	O
transformation	O
of	O
Rat	B
-	I
1	I
fibroblasts	O
.	O

Increased	O
expression	O
of	O
specific	O
protein	O
tyrosine	O
phosphatases	O
in	O
human	O
breast	O
epithelial	O
cells	O
neoplastically	O
transformed	O
by	O
the	O
neu	O
oncogene	O
.	O

Protein	O
tyrosine	O
phosphorylation	O
/	O
dephosphorylation	O
is	O
a	O
fundamental	O
mechanism	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
and	O
neoplastic	O
transformation	O
;	O
this	O
metabolic	O
process	O
is	O
modulated	O
by	O
the	O
opposing	O
activities	O
of	O
protein	O
tyrosine	O
kinases	O
and	O
protein	O
tyrosine	O
phosphatases	O
(	O
PTPases	O
)	O
.	O

While	O
the	O
role	O
of	O
protein	O
tyrosine	O
kinases	O
has	O
been	O
examined	O
extensively	O
in	O
human	O
breast	O
tumorigenesis	O
,	O
the	O
role	O
of	O
PTPases	O
in	O
this	O
process	O
is	O
virtually	O
unknown	O
.	O

To	O
address	O
this	O
issue	O
,	O
an	O
activated	O
neu	O
oncogene	O
was	O
introduced	O
into	O
an	O
immortalized	O
nontumorigenic	O
human	O
breast	O
epithelial	O
cell	O
line	O
(	O
184B5	B
)	O
.	O

This	O
resulted	O
in	O
a	O
substantial	O
increase	O
in	O
P185neu	O
expression	O
,	O
which	O
led	O
to	O
the	O
formation	O
of	O
progressively	O
growing	O
carcinomas	O
after	O
such	O
cells	O
were	O
inoculated	O
into	O
athymic	O
nude	O
mice	O
.	O

Importantly	O
,	O
a	O
striking	O
increase	O
in	O
the	O
expression	O
of	O
specific	O
PTPases	O
,	O
LAR	O
and	O
PTP1B	O
,	O
was	O
observed	O
in	O
3	O
independently	O
neu	O
transformed	O
cell	O
lines	O
and	O
their	O
derived	O
tumors	O
.	O

This	O
elevation	O
was	O
verified	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
.	O

TC	O
-	O
PTP	O
PTPase	O
expression	O
was	O
only	O
slightly	O
increased	O
in	O
these	O
neu	O
transformed	O
cells	O
,	O
and	O
no	O
expression	O
of	O
CD45	O
PTPase	O
was	O
observed	O
.	O

The	O
level	O
of	O
neu	O
expression	O
,	O
as	O
well	O
as	O
the	O
differential	O
expression	O
between	O
P185neu	O
and	O
LAR	O
/	O
PTP1B	O
,	O
directly	O
correlated	O
with	O
tumorigenicity	O
.	O

Furthermore	O
,	O
rat	O
mammary	O
carcinomas	O
with	O
elevated	O
neu	O
expression	O
(	O
neu	O
-	O
induced	O
)	O
also	O
had	O
sharply	O
elevated	O
LAR	O
-	O
PTPase	O
expression	O
when	O
compared	O
to	O
rat	O
mammary	O
carcinomas	O
with	O
little	O
or	O
no	O
neu	O
expression	O
(	O
7	O
,	O
12	O
-	O
dimethylbenzanthracene	O
induced	O
)	O
;	O
the	O
level	O
of	O
expression	O
of	O
LAR	O
PTPase	O
was	O
directly	O
correlated	O
with	O
the	O
level	O
of	O
neu	O
expression	O
.	O

Thus	O
,	O
our	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
,	O
in	O
human	O
breast	O
carcinoma	O
cells	O
and	O
in	O
rat	O
mammary	O
carcinomas	O
that	O
have	O
an	O
induced	O
increase	O
in	O
neu	O
expression	O
,	O
a	O
consistent	O
and	O
substantial	O
increase	O
in	O
the	O
expression	O
of	O
specific	O
PTPases	O
occurs	O
.	O

The	O
relationship	O
between	O
P185neu	O
-	O
protein	O
tyrosine	O
kinase	O
expression	O
and	O
specific	O
PTPase	O
expression	O
may	O
play	O
a	O
critical	O
role	O
in	O
human	O
breast	O
tumorigenesis	O
.	O

Epilepsy	O
in	O
Down	O
syndrome	O
:	O
clinical	O
aspects	O
and	O
possible	O
mechanisms	O
.	O

Although	O
epilepsy	O
is	O
more	O
common	O
in	O
persons	O
with	O
trisomy	O
21	O
(	O
Down	O
syndrome	O
)	O
than	O
in	O
the	O
general	O
population	O
,	O
the	O
mechanisms	O
by	O
which	O
seizures	O
are	O
generated	O
in	O
this	O
population	O
have	O
received	O
little	O
attention	O
.	O

It	O
is	O
likely	O
that	O
this	O
increased	O
seizure	O
susceptibility	O
is	O
due	O
to	O
a	O
combination	O
of	O
medical	O
risk	O
factors	O
and	O
inherent	O
neurologic	O
abnormalities	O
characteristic	O
of	O
Down	O
syndrome	O
.	O

In	O
this	O
review	O
clinical	O
aspects	O
of	O
seizures	O
among	O
individuals	O
with	O
Down	O
syndrome	O
were	O
described	O
and	O
possible	O
mechanisms	O
by	O
which	O
the	O
trisomy	O
21	O
brain	O
may	O
generate	O
seizures	O
were	O
explored	O
.	O

In	O
vivo	O
effects	O
of	O
insulin	O
on	O
tumor	O
and	O
skeletal	O
muscle	O
glucose	O
metabolism	O
in	O
patients	O
with	O
lymphoma	O
.	O

BACKGROUND	O
:	O
The	O
anabolic	O
properties	O
of	O
insulin	O
have	O
been	O
suggested	O
for	O
use	O
to	O
reverse	O
malnutrition	O
associated	O
with	O
cancer	O
.	O

The	O
host	O
and	O
tumor	O
sensitivities	O
to	O
insulin	O
are	O
critical	O
for	O
such	O
treatments	O
,	O
which	O
aim	O
to	O
improve	O
patient	O
nutrition	O
.	O

The	O
authors	O
studied	O
insulin	O
effects	O
on	O
tumor	O
and	O
skeletal	O
muscle	O
metabolism	O
with	O
2	O
-	O
[	O
18F	O
]	O
-	O
fluoro	O
-	O
2	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
(	O
[	O
18F	O
]	O
FDG	O
)	O
and	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

METHODS	O
:	O
Six	O
patients	O
with	O
lymphoma	O
twice	O
underwent	O
[	O
18F	O
]	O
FDG	O
-	O
PET	O
imaging	O
:	O
once	O
after	O
fasting	O
overnight	O
and	O
once	O
during	O
euglycemic	O
hyperinsulinemic	O
clamp	O
.	O

The	O
dynamic	O
uptake	O
of	O
the	O
glucose	O
analogue	O
[	O
18F	O
]	O
FDG	O
was	O
measured	O
in	O
diseased	O
nodes	O
and	O
upper	O
arm	O
skeletal	O
muscle	O
in	O
both	O
metabolic	O
states	O
.	O

The	O
[	O
18F	O
]	O
FDG	O
uptake	O
in	O
muscle	O
and	O
the	O
whole	O
body	O
glucose	O
use	O
during	O
euglycemic	O
hyperinsulinemic	O
clamp	O
were	O
compared	O
with	O
those	O
of	O
weight	O
-	O
matched	O
healthy	O
subjects	O
studied	O
under	O
similar	O
circumstances	O
.	O

RESULTS	O
:	O
In	O
lymphomatous	O
tissue	O
,	O
[	O
18F	O
]	O
FDG	O
uptake	O
rates	O
were	O
similar	O
in	O
overnight	O
fasting	O
and	O
euglycemic	O
hyperinsulinemic	O
clamp	O
(	O
38	O
+	O
/	O
-	O
10	O
versus	O
41	O
+	O
/	O
-	O
9	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
not	O
significant	O
)	O
,	O
whereas	O
glucose	O
uptake	O
in	O
skeletal	O
muscle	O
was	O
increased	O
by	O
insulin	O
(	O
1	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
2	O
versus	O
3	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
012	O
)	O
.	O

Both	O
basal	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
2	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
061	O
)	O
and	O
insulin	O
-	O
stimulated	O
(	O
8	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
9	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
055	O
)	O
skeletal	O
arm	O
muscle	O
glucose	O
uptake	O
rates	O
were	O
higher	O
in	O
control	O
subjects	O
than	O
in	O
patients	O
.	O

Whole	O
body	O
glucose	O
use	O
was	O
55	O
%	O
lower	O
in	O
patients	O
than	O
in	O
control	O
subjects	O
(	O
17	O
+	O
/	O
-	O
3	O
mumol	O
/	O
kg	O
/	O
minute	O
versus	O
38	O
+	O
/	O
-	O
3	O
mumol	O
/	O
kg	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
,	O
consistent	O
with	O
insulin	O
resistance	O
in	O
cancer	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
that	O
insulin	O
does	O
not	O
induce	O
major	O
changes	O
in	O
glucose	O
uptake	O
of	O
lymphomatous	O
tissue	O
.	O

Although	O
insulin	O
sensitivity	O
of	O
skeletal	O
muscle	O
was	O
also	O
reduced	O
in	O
patients	O
with	O
lymphoma	O
,	O
the	O
net	O
insulin	O
effect	O
may	O
counteract	O
imbalance	O
between	O
glucose	O
uptake	O
of	O
tumor	O
and	O
muscle	O
,	O
offering	O
a	O
potential	O
means	O
to	O
circumvent	O
at	O
least	O
some	O
metabolic	O
abnormalities	O
found	O
in	O
cancer	O
.	O

Kinins	O
contribute	O
to	O
the	O
improvement	O
of	O
insulin	O
sensitivity	O
during	O
treatment	O
with	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
.	O

Although	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
and	O
alpha	O
1	O
-	O
blockers	O
have	O
been	O
reported	O
to	O
improve	O
insulin	O
sensitivity	O
,	O
their	O
mechanisms	O
of	O
action	O
have	O
not	O
been	O
elucidated	O
.	O

To	O
investigate	O
the	O
role	O
of	O
kinins	O
in	O
insulin	O
sensitivity	O
,	O
we	O
treated	O
4	O
-	O
week	O
-	O
old	O
spontaneously	O
hypertensive	O
rats	O
with	O
either	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
(	O
enalapril	O
)	O
,	O
an	O
alpha	O
1	O
-	O
blocker	O
(	O
doxazosin	O
)	O
,	O
or	O
an	O
angiotensin	O
II	O
antagonist	O
(	O
losartan	O
)	O
for	O
3	O
weeks	O
.	O

A	O
control	O
group	O
received	O
no	O
drugs	O
.	O

In	O
addition	O
,	O
18	O
rats	O
treated	O
with	O
enalapril	O
or	O
doxazosin	O
received	O
a	O
simultaneous	O
administration	O
of	O
a	O
kinin	O
antagonist	O
(	O
Hoe	O
140	O
)	O
.	O

Glucose	O
clamp	O
testing	O
was	O
performed	O
in	O
each	O
group	O
.	O

Enalapril	O
(	O
128	O
+	O
/	O
-	O
1	O
mmHg	O
)	O
and	O
doxazosin	O
(	O
132	O
+	O
/	O
-	O
2	O
mmHg	O
)	O
decreased	O
mean	O
blood	O
pressure	O
compared	O
with	O
control	O
levels	O
(	O
148	O
+	O
/	O
-	O
1	O
mmHg	O
)	O
(	O
P	O
<	O
.	O
01	O
)	O
.	O

The	O
glucose	O
requirement	O
for	O
the	O
clamp	O
test	O
during	O
the	O
administration	O
of	O
enalapril	O
(	O
25	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
or	O
doxazosin	O
(	O
28	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
was	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
(	O
19	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

Although	O
Hoe	O
140	O
did	O
not	O
alter	O
the	O
glucose	O
requirement	O
of	O
doxazosin	O
(	O
27	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
,	O
it	O
decreased	O
that	O
of	O
enalapril	O
(	O
22	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
9	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
(	O
P	O
<	O
.	O
05	O
)	O
without	O
affecting	O
the	O
changes	O
in	O
mean	O
blood	O
pressure	O
induced	O
by	O
enalapril	O
.	O

In	O
addition	O
,	O
losartan	O
decreased	O
mean	O
blood	O
pressure	O
but	O
did	O
not	O
affect	O
the	O
glucose	O
requirement	O
.	O

Thus	O
,	O
the	O
improvement	O
in	O
insulin	O
sensitivity	O
produced	O
by	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
is	O
mostly	O
dependent	O
on	O
kinins	O
but	O
not	O
on	O
angiotensin	O
II	O
antagonism	O
,	O
and	O
an	O
alpha	O
1	O
-	O
blocker	O
improves	O
insulin	O
sensitivity	O
irrespective	O
of	O
kinins	O
.	O

H	O
-	O
ras	O
mutations	O
in	O
human	O
pituitary	O
carcinoma	O
metastases	O
.	O

Molecular	O
mechanisms	O
of	O
pituitary	O
tumorigenesis	O
were	O
studied	O
using	O
Polymerase	O
chain	O
reaction	O
-	O
single	O
stranded	O
conformational	O
polymorphism	O
with	O
DNA	O
sequencing	O
to	O
identify	O
potential	O
mutations	O
in	O
the	O
ras	O
protooncogenes	O
and	O
the	O
tumor	O
suppressor	O
gene	O
p53	O
in	O
invasive	O
pituitary	O
adenomas	O
and	O
carcinomas	O
.	O

Sequencing	O
of	O
exons	O
5	O
through	O
8	O
of	O
the	O
p53	O
gene	O
revealed	O
no	O
mutations	O
,	O
nor	O
were	O
mutations	O
detected	O
in	O
the	O
N	O
-	O
or	O
K	O
-	O
ras	O
protooncogenes	O
in	O
four	O
of	O
the	O
carcinomas	O
and	O
their	O
respective	O
metastatic	O
deposits	O
.	O

Point	O
mutations	O
of	O
H	O
-	O
ras	O
however	O
,	O
were	O
identified	O
in	O
three	O
distant	O
metastatic	O
pituitary	O
tumor	O
secondaries	O
,	O
but	O
not	O
in	O
their	O
respective	O
primary	O
pituitary	O
carcinomas	O
,	O
or	O
in	O
six	O
invasive	O
adenomas	O
.	O

Two	O
of	O
the	O
mutations	O
included	O
a	O
G	O
to	O
C	O
substitution	O
at	O
codon	O
12	O
,	O
and	O
a	O
G	O
to	O
A	O
substitution	O
at	O
codon	O
18	O
,	O
resulting	O
in	O
a	O
glycine	O
to	O
arginine	O
,	O
and	O
an	O
alanine	O
to	O
threonine	O
change	O
at	O
these	O
amino	O
acids	O
,	O
respectively	O
.	O

A	O
third	O
mutation	O
involved	O
a	O
single	O
base	O
pair	O
(	O
adenine	O
)	O
deletion	O
in	O
codon	O
3	O
of	O
H	O
-	O
ras	O
which	O
causes	O
a	O
frame	O
shift	O
,	O
resulting	O
in	O
a	O
termination	O
signal	O
at	O
codon	O
19	O
.	O

These	O
results	O
suggest	O
that	O
point	O
mutations	O
in	O
p53	O
and	O
ras	O
are	O
not	O
associated	O
with	O
pituitary	O
tumorigenesis	O
,	O
however	O
,	O
point	O
mutations	O
of	O
the	O
H	O
-	O
ras	O
gene	O
may	O
be	O
important	O
in	O
the	O
formation	O
and	O
or	O
growth	O
of	O
pituitary	O
metastases	O
.	O

This	O
observed	O
genomic	O
instability	O
will	O
be	O
of	O
value	O
in	O
predicting	O
the	O
potential	O
metastatic	O
behavior	O
of	O
these	O
aggressive	O
pituitary	O
tumors	O
.	O

Distribution	O
and	O
predictors	O
of	O
depressive	O
symptoms	O
in	O
osteoarthritis	O
.	O

OBJECTIVE	O
:	O

To	O
determine	O
the	O
prevalence	O
and	O
correlates	O
of	O
depressive	O
symptoms	O
in	O
a	O
sample	O
of	O
elderly	O
persons	O
with	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

METHODS	O
:	O

Secondary	O
analysis	O
of	O
cross	O
sectional	O
interview	O
data	O
from	O
108	O
community	O
living	O
persons	O
age	O
50	O
or	O
over	O
who	O
met	O
American	O
College	O
of	O
Rheumatology	O
clinical	O
criteria	O
for	O
OA	O
of	O
the	O
hip	O
and	O
/	O
or	O
knee	O
.	O

RESULTS	O
:	O

The	O
prevalence	O
of	O
substantial	O
depressive	O
symptomatology	O
appeared	O
to	O
be	O
no	O
greater	O
than	O
would	O
be	O
expected	O
in	O
the	O
general	O
population	O
for	O
this	O
age	O
group	O
.	O

However	O
,	O
persons	O
currently	O
under	O
a	O
physician	O
'	O
s	O
care	O
for	O
OA	O
were	O
significantly	O
more	O
depressed	O
than	O
those	O
not	O
under	O
care	O
,	O
and	O
,	O
with	O
the	O
exception	O
of	O
those	O
who	O
had	O
post	O
-	O
high	O
school	O
education	O
,	O
depression	O
was	O
a	O
better	O
predictor	O
of	O
being	O
under	O
care	O
than	O
OA	O
symptoms	O
.	O

The	O
direct	O
and	O
interactive	O
effects	O
of	O
3	O
variables	O
-	O
-	O
education	O
,	O
age	O
and	O
self	O
-	O
perceived	O
impact	O
of	O
the	O
OA	O
problem	O
-	O
-	O
were	O
found	O
to	O
explain	O
40	O
%	O
of	O
variance	O
in	O
depression	O
scores	O
in	O
the	O
total	O
sample	O
and	O
50	O
%	O
among	O
those	O
currently	O
receiving	O
care	O
.	O

Younger	O
and	O
less	O
educated	O
subjects	O
had	O
relatively	O
more	O
depressive	O
symptoms	O
and	O
,	O
furthermore	O
,	O
in	O
this	O
subgroup	O
the	O
correlation	O
between	O
OA	O
impact	O
and	O
depression	O
was	O
high	O
.	O

CONCLUSIONS	O
:	O

The	O
importance	O
of	O
assessing	O
depression	O
in	O
persons	O
who	O
seek	O
care	O
for	O
OA	O
is	O
supported	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
the	O
observed	O
relationship	O
between	O
education	O
and	O
arthritis	O
outcomes	O
could	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
depression	O
.	O

Methotrexate	O
osteopathy	O
in	O
rheumatic	O
disease	O
.	O

OBJECTIVE	O
:	O

To	O
determine	O
whether	O
two	O
adults	O
with	O
stress	O
fractures	O
receiving	O
low	O
weekly	O
doses	O
of	O
methotrexate	O
had	O
methotrexate	O
osteopathy	O
.	O

CASE	O
REPORTS	O
:	O

Two	O
adult	O
patients	O
developed	O
features	O
consistent	O
with	O
methotrexate	O
osteopathy	O
while	O
receiving	O
low	O
weekly	O
doses	O
of	O
methotrexate	O
.	O

METHODS	O
:	O

Iliac	O
crest	O
biopsy	O
samples	O
were	O
taken	O
and	O
bone	O
histomorphometry	O
carried	O
out	O
.	O

RESULTS	O
:	O

Symptoms	O
resolved	O
when	O
the	O
methotrexate	O
was	O
discontinued	O
.	O

Bone	O
histology	O
showed	O
changes	O
consistent	O
with	O
osteoblast	O
inhibition	O
by	O
methotrexate	O
.	O

CONCLUSIONS	O
:	O

When	O
given	O
in	O
low	O
doses	O
for	O
prolonged	O
periods	O
,	O
methotrexate	O
may	O
have	O
adverse	O
effects	O
on	O
bone	O
,	O
particularly	O
in	O
post	O
-	O
menopausal	O
women	O
.	O

Overexpression	O
of	O
Glut	O
-	O
1	O
glucose	O
transporter	O
in	O
human	O
breast	O
cancer	O
.	O

An	O
immunohistochemical	O
study	O
.	O

BACKGROUND	O
:	O
Breast	O
cancers	O
have	O
higher	O
than	O
normal	O
glucose	O
metabolism	O
,	O
but	O
the	O
mechanism	O
of	O
glucose	O
entry	O
into	O
these	O
tumors	O
is	O
not	O
well	O
understood	O
.	O

METHODS	O
:	O
The	O
expression	O
of	O
five	O
facilitative	O
glucose	O
transporters	O
,	O
Glut	O
-	O
1	O
(	O
erythrocyte	O
type	O
)	O
,	O
Glut	O
-	O
2	O
(	O
liver	O
type	O
)	O
,	O
Glut	O
-	O
3	O
(	O
brain	O
type	O
)	O
,	O
Glut	O
-	O
4	O
(	O
muscle	O
/	O
fat	O
type	O
)	O
,	O
and	O
Glut	O
-	O
5	O
(	O
small	O
intestine	O
type	O
)	O
,	O
was	O
studied	O
by	O
immunohistochemistry	O
of	O
paraffin	O
sections	O
from	O
12	O
primary	O
human	O
breast	O
cancers	O
and	O
8	O
lymph	O
node	O
metastases	O
from	O
2	O
patients	O
.	O

Rat	O
tissues	O
known	O
to	O
express	O
these	O
glucose	O
transporters	O
were	O
used	O
as	O
controls	O
.	O

RESULTS	O
:	O
All	O
the	O
primary	O
breast	O
cancers	O
and	O
the	O
lymph	O
node	O
metastases	O
were	O
positive	O
for	O
Glut	O
-	O
1	O
.	O

This	O
transporter	O
was	O
expressed	O
on	O
the	O
cell	O
membrane	O
and	O
in	O
the	O
cytoplasm	O
of	O
the	O
tumor	O
cells	O
,	O
but	O
exhibited	O
marked	O
intratumoral	O
and	O
intertumoral	O
variability	O
in	O
the	O
proportions	O
of	O
positive	O
cells	O
and	O
the	O
intensity	O
of	O
staining	O
.	O

Staining	O
of	O
the	O
normal	O
mammary	O
epithelium	O
,	O
if	O
present	O
,	O
was	O
much	O
lower	O
than	O
observed	O
in	O
tumor	O
cells	O
from	O
the	O
same	O
patient	O
.	O

Glut	O
-	O
2	O
was	O
expressed	O
in	O
all	O
of	O
the	O
tumors	O
,	O
but	O
the	O
intensity	O
of	O
staining	O
was	O
not	O
consistently	O
stronger	O
than	O
that	O
seen	O
in	O
healthy	O
breast	O
.	O

Clusters	O
of	O
Glut	O
-	O
4	O
-	O
positive	O
granule	O
were	O
observed	O
in	O
cells	O
in	O
six	O
of	O
the	O
tumors	O
.	O

None	O
of	O
the	O
tumors	O
or	O
the	O
healthy	O
breast	O
in	O
the	O
tissues	O
studied	O
expressed	O
Glut	O
-	O
3	O
or	O
Glut	O
-	O
5	O
.	O

CONCLUSIONS	O
:	O
Higher	O
expression	O
of	O
the	O
glucose	O
transporter	O
Glut	O
-	O
1	O
by	O
breast	O
cancer	O
cells	O
compared	O
with	O
the	O
healthy	O
breast	O
tissue	O
is	O
common	O
.	O

Increased	O
glucose	O
transporter	O
protein	O
expression	O
may	O
contribute	O
to	O
the	O
increased	O
uptake	O
of	O
2	O
-	O
[	O
18F	O
]	O
-	O
fluoro	O
-	O
2	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
(	O
FDG	O
)	O
by	O
these	O
tumors	O
observed	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
imaging	O
.	O

Methodologies	O
for	O
measuring	O
carcinogen	O
adducts	O
in	O
humans	O
.	O

In	O
summary	O
,	O
although	O
some	O
of	O
the	O
more	O
optimistic	O
aspirations	O
for	O
human	O
biomonitoring	O
studies	O
envisaged	O
a	O
decade	O
ago	O
have	O
not	O
been	O
realized	O
thus	O
far	O
,	O
some	O
considerable	O
advances	O
have	O
been	O
made	O
.	O

The	O
examples	O
cited	O
above	O
indicate	O
that	O
the	O
feasibility	O
of	O
biomonitoring	O
has	O
been	O
clearly	O
established	O
.	O

In	O
addition	O
,	O
they	O
demonstrate	O
the	O
need	O
for	O
preliminary	O
biomarker	O
testing	O
and	O
validation	O
through	O
transitional	O
studies	O
prior	O
to	O
their	O
field	O
application	O
.	O

In	O
the	O
next	O
decade	O
of	O
research	O
into	O
carcinogen	O
adducts	O
in	O
humans	O
,	O
continued	O
improvements	O
in	O
the	O
reproducibility	O
and	O
specificity	O
of	O
assays	O
for	O
DNA	O
adducts	O
will	O
be	O
needed	O
.	O

Perhaps	O
the	O
increasing	O
use	O
of	O
hybrid	O
methodologies	O
to	O
concentrate	O
adducts	O
followed	O
by	O
specific	O
chemical	O
analyses	O
will	O
allow	O
such	O
adducts	O
to	O
be	O
monitored	O
more	O
precisely	O
.	O

Of	O
course	O
,	O
further	O
basic	O
research	O
into	O
the	O
mechanisms	O
of	O
carcinogenesis	O
will	O
allow	O
the	O
measurement	O
of	O
specific	O
novel	O
markers	O
which	O
are	O
more	O
closely	O
tied	O
to	O
the	O
disease	O
endpoint	O
than	O
adducts	O
.	O

The	O
development	O
of	O
new	O
assays	O
for	O
determining	O
metabolic	O
phenotypes	O
and	O
genotypes	O
relevant	O
to	O
carcinogenesis	O
should	O
improve	O
our	O
estimates	O
of	O
susceptibility	O
(	O
46	O
-	O
48	O
)	O
.	O

Such	O
new	O
approaches	O
along	O
with	O
the	O
sustained	O
improvement	O
of	O
current	O
assays	O
will	O
allow	O
molecular	O
approaches	O
to	O
continue	O
to	O
enrich	O
cancer	O
epidemiology	O
in	O
the	O
future	O
.	O

Effect	O
of	O
1	O
-	O
alkylpyrrolidine	O
N	O
-	O
oxides	O
on	O
energy	O
metabolism	O
of	O
cancer	O
cells	O
.	O

The	O
main	O
purpose	O
of	O
the	O
present	O
investigation	O
was	O
to	O
study	O
the	O
effect	O
of	O
a	O
homologous	O
series	O
of	O
1	O
-	O
alkylpyrrolidine	O
N	O
-	O
oxides	O
on	O
ATP	O
-	O
producing	O
processes	O
in	O
Ehrlich	O
ascites	O
and	O
L1210	B
murine	O
leukemia	O
cells	O
.	O

The	O
effect	O
on	O
aerobic	O
glucose	O
consumption	O
,	O
lactic	O
acid	O
formation	O
,	O
content	O
of	O
total	O
(	O
T	O
-	O
SH	O
)	O
and	O
non	O
-	O
protein	O
thiol	O
groups	O
(	O
NP	O
-	O
SH	O
)	O
,	O
endogenous	O
respiration	O
and	O
the	O
level	O
of	O
ATP	O
in	O
tumor	O
cells	O
incubated	O
in	O
vitro	O
was	O
investigated	O
.	O

1	O
-	O
Tetradecylpyrrolidine	O
N	O
-	O
oxide	O
(	O
TPNO	O
)	O
,	O
one	O
of	O
the	O
most	O
active	O
compounds	O
,	O
immediately	O
after	O
addition	O
to	O
the	O
suspension	O
of	O
Ehrlich	O
cells	O
in	O
an	O
ice	O
bath	O
,	O
decreased	O
the	O
level	O
of	O
ATP	O
to	O
the	O
same	O
extent	O
over	O
the	O
whole	O
concentration	O
range	O
.	O

After	O
2	O
h	O
incubation	O
at	O
37	O
degrees	O
C	O
the	O
drop	O
in	O
the	O
ATP	O
level	O
was	O
lower	O
.	O

The	O
decrease	O
in	O
ATP	O
level	O
might	O
be	O
explained	O
through	O
the	O
interaction	O
of	O
the	O
amine	O
oxide	O
with	O
the	O
cell	O
membrane	O
integrity	O
.	O

High	O
density	O
of	O
somatostatin	O
receptors	O
in	O
veins	O
surrounding	O
human	O
cancer	O
tissue	O
:	O
role	O
in	O
tumor	O
-	O
host	O
interaction	O
?	O

Somatostatin	O
receptors	O
were	O
detected	O
in	O
peritumoral	O
veins	O
of	O
various	O
human	O
cancer	O
tissue	O
specimens	O
.	O

Vascular	O
and	O
neoplastic	O
tissue	O
from	O
14	O
colonic	O
adenocarcinomas	O
,	O
13	O
carcinoids	O
,	O
6	O
renal	O
-	O
cell	O
carcinomas	O
and	O
7	O
malignant	O
lymphomas	O
were	O
analyzed	O
for	O
somatostatin	O
receptors	O
by	O
use	O
of	O
quantitative	O
receptor	O
autoradiography	O
.	O

In	O
colonic	O
carcinoma	O
specimens	O
,	O
the	O
peritumoral	O
vessels	O
expressed	O
a	O
high	O
density	O
of	O
somatostatin	O
receptors	O
,	O
whereas	O
the	O
neoplastic	O
tissue	O
itself	O
was	O
receptor	O
-	O
negative	O
in	O
many	O
cases	O
.	O

In	O
contrast	O
,	O
the	O
incidence	O
and	O
density	O
of	O
somatostatin	O
receptors	O
in	O
peritumoral	O
vessels	O
was	O
low	O
in	O
well	O
-	O
differentiated	O
gastrointestinal	O
and	O
bronchial	O
carcinoids	O
,	O
in	O
contrast	O
to	O
the	O
high	O
density	O
of	O
such	O
receptors	O
in	O
the	O
carcinoid	O
tumor	O
tissue	O
.	O

Autochthonous	O
vessels	O
surrounding	O
other	O
tumors	O
such	O
as	O
renal	O
-	O
cell	O
carcinomas	O
or	O
malignant	O
lymphomas	O
also	O
frequently	O
expressed	O
somatostatin	O
receptors	O
.	O

In	O
all	O
cases	O
,	O
the	O
somatostatin	O
receptors	O
were	O
localized	O
in	O
veins	O
,	O
particularly	O
in	O
the	O
smooth	O
-	O
muscle	O
cell	O
layer	O
.	O

They	O
exhibited	O
specific	O
and	O
high	O
-	O
affinity	O
binding	O
of	O
somatostatin	O
-	O
14	O
,	O
somatostatin	O
-	O
28	O
and	O
octreotide	O
,	O
suggesting	O
a	O
preferential	O
expression	O
of	O
the	O
SSTR2	O
receptor	O
subtype	O
.	O

Since	O
the	O
vessels	O
of	O
normal	O
non	O
-	O
neoplastic	O
human	O
tissues	O
,	O
e	O
.	O
g	O
.	O
of	O
intestine	O
or	O
lymphatic	O
organs	O
,	O
have	O
few	O
somatostatin	O
receptors	O
,	O
the	O
increased	O
somatostatin	O
receptor	O
expression	O
in	O
peritumoral	O
vessels	O
observed	O
in	O
this	O
study	O
may	O
be	O
linked	O
to	O
the	O
neoplastic	O
process	O
itself	O
.	O

The	O
results	O
suggest	O
that	O
somatostatin	O
and	O
somatostatin	O
receptors	O
may	O
play	O
a	O
regulatory	O
role	O
for	O
hemodynamic	O
tumor	O
-	O
host	O
interactions	O
,	O
possibly	O
involving	O
tumor	O
stroma	O
generation	O
,	O
tumor	O
environment	O
,	O
angiogenesis	O
and	O
,	O
particularly	O
,	O
vascular	O
drainage	O
of	O
poorly	O
differentiated	O
neoplasms	O
.	O

[	O
Treatment	O
of	O
the	O
diabetic	O
foot	O
by	O
hyperbaric	O
oxygen	O
]	O

Diabetic	O
foot	O
wounds	O
are	O
consequences	O
of	O
the	O
neuropathy	O
and	O
the	O
small	O
and	O
large	O
vessel	O
disease	O
that	O
complicate	O
diabetes	O
.	O

At	O
the	O
cellular	O
level	O
,	O
the	O
result	O
is	O
hypoxia	O
which	O
impairs	O
wound	O
healing	O
.	O

Hyperbaric	O
oxygenation	O
(	O
HBO	O
)	O
may	O
be	O
a	O
useful	O
adjuvant	O
to	O
wound	O
care	O
.	O

It	O
leads	O
to	O
enhanced	O
oxygenation	O
of	O
the	O
affected	O
tissues	O
,	O
has	O
an	O
antiseptic	O
effect	O
,	O
reduces	O
edema	O
,	O
and	O
accelerates	O
collagen	O
production	O
and	O
angiogenesis	O
,	O
thus	O
enhancing	O
tissue	O
repair	O
.	O

14	O
diabetics	O
with	O
chronic	O
nonhealing	O
wounds	O
which	O
did	O
not	O
respond	O
to	O
treatment	O
for	O
at	O
least	O
3	O
months	O
were	O
treated	O
by	O
HBO	O
.	O

All	O
had	O
palpable	O
pedal	O
pulses	O
.	O

Transcutaneous	O
measurements	O
of	O
tissue	O
pO2	O
showed	O
elevation	O
from	O
20	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
during	O
air	O
breathing	O
to	O
643	O
+	O
/	O
-	O
242	O
mm	O
Hg	O
while	O
breathing	O
pure	O
oxygen	O
at	O
2	O
.	O
5	O
ATA	O
.	O

They	O
were	O
treated	O
with	O
HBO	O
in	O
56	O
+	O
/	O
-	O
10	O
consecutive	O
HBO	O
sessions	O
.	O

In	O
11	O
there	O
was	O
complete	O
wound	O
healing	O
,	O
while	O
in	O
1	O
there	O
was	O
partial	O
response	O
,	O
in	O
1	O
minimal	O
response	O
,	O
and	O
in	O
1	O
a	O
transient	O
response	O
.	O

HBO	O
is	O
useful	O
in	O
chronic	O
nonhealing	O
wounds	O
of	O
the	O
diabetic	O
foot	O
and	O
of	O
the	O
diabetic	O
foot	O
with	O
impending	O
amputation	O
.	O

It	O
is	O
a	O
safe	O
mode	O
of	O
therapy	O
,	O
but	O
further	O
studies	O
are	O
required	O
to	O
establish	O
its	O
efficacy	O
and	O
to	O
ascertain	O
which	O
diabetic	O
patients	O
and	O
wounds	O
will	O
benefit	O
the	O
most	O
from	O
it	O
.	O

Chelation	O
treatment	O
of	O
neurological	O
Wilson	O
'	O
s	O
disease	O
.	O

The	O
results	O
of	O
chelation	O
treatment	O
of	O
137	O
patients	O
presenting	O
with	O
neurological	O
Wilson	O
'	O
s	O
disease	O
are	O
described	O
,	O
together	O
with	O
the	O
more	O
commonly	O
observed	O
toxic	O
reactions	O
to	O
the	O
various	O
drugs	O
employed	O
.	O

Fifty	O
-	O
seven	O
patients	O
made	O
an	O
excellent	O
response	O
to	O
treatment	O
and	O
became	O
symptom	O
free	O
.	O

Thirty	O
-	O
six	O
patients	O
made	O
a	O
good	O
recovery	O
,	O
but	O
were	O
left	O
with	O
some	O
minor	O
neurological	O
deficit	O
.	O

Twenty	O
-	O
four	O
patients	O
had	O
a	O
poor	O
response	O
:	O
although	O
the	O
disease	O
process	O
was	O
arrested	O
they	O
were	O
left	O
more	O
or	O
less	O
disabled	O
.	O

Twenty	O
patients	O
died	O
:	O
nine	O
had	O
little	O
or	O
no	O
treatment	O
,	O
but	O
11	O
died	O
despite	O
apparently	O
adequate	O
chelation	O
therapy	O
.	O

There	O
was	O
no	O
obvious	O
reason	O
for	O
this	O
failure	O
.	O

The	O
liver	O
copper	O
level	O
was	O
estimated	O
in	O
six	O
of	O
these	O
patients	O
:	O
it	O
was	O
still	O
significantly	O
elevated	O
in	O
only	O
one	O
,	O
but	O
in	O
all	O
four	O
in	O
whom	O
it	O
was	O
possible	O
to	O
make	O
the	O
determination	O
,	O
the	O
concentration	O
of	O
copper	O
in	O
the	O
basal	O
ganglia	O
was	O
in	O
excess	O
of	O
45	O
micrograms	O
/	O
g	O
wet	O
weight	O
.	O

It	O
was	O
not	O
apparent	O
why	O
adequate	O
therapy	O
failed	O
to	O
remove	O
copper	O
from	O
the	O
brains	O
of	O
these	O
patients	O
.	O

There	O
was	O
no	O
obvious	O
clinical	O
,	O
histological	O
or	O
biochemical	O
indicator	O
of	O
failure	O
to	O
respond	O
to	O
treatment	O
.	O

Initial	O
deterioration	O
before	O
improvement	O
was	O
seen	O
in	O
30	O
patients	O
:	O
the	O
prognosis	O
for	O
a	O
useful	O
recovery	O
was	O
not	O
necessarily	O
worse	O
than	O
that	O
in	O
patients	O
who	O
did	O
not	O
show	O
this	O
phenomenon	O
.	O

Transformation	O
-	O
associated	O
cytokine	O
9E3	O
/	O
CEF4	O
is	O
chemotactic	O
for	O
chicken	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

9E3	O
/	O
CEF4	O
,	O
which	O
is	O
released	O
from	O
transformed	O
chicken	O
embryo	O
fibroblasts	O
(	O
CEF	O
)	O
,	O
is	O
a	O
member	O
of	O
the	O
platelet	O
factor	O
4	O
family	O
of	O
inflammatory	O
proteins	O
and	O
may	O
be	O
the	O
avian	O
homolog	O
of	O
interleukin	O
-	O
8	O
.	O

Since	O
the	O
function	O
of	O
9E3	O
/	O
CEF4	O
is	O
unknown	O
,	O
we	O
examined	O
the	O
effect	O
of	O
the	O
protein	O
on	O
mitogenicity	O
and	O
chemotaxis	O
,	O
as	O
well	O
as	O
its	O
expression	O
,	O
in	O
fibroblasts	O
and	O
peripheral	O
blood	O
cells	O
.	O

9E3	O
/	O
CEF4	O
mRNA	O
was	O
expressed	O
in	O
chicken	O
peripheral	O
blood	O
monocytes	O
,	O
and	O
its	O
expression	O
was	O
stimulated	O
by	O
incubation	O
of	O
the	O
monocytes	O
with	O
lipopolysaccharide	O
or	O
phorbol	O
myristic	O
acetate	O
.	O

Boyden	O
double	O
-	O
membrane	O
analysis	O
of	O
chemotaxis	O
showed	O
that	O
9E3	O
/	O
CEF4	O
was	O
chemotactic	O
for	O
chicken	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
as	O
well	O
as	O
for	O
heterophils	O
.	O

Untransformed	O
CEF	O
and	O
CEF	O
transformed	O
with	O
Rous	O
sarcoma	O
virus	O
also	O
migrated	O
to	O
9E3	O
/	O
CEF4	O
protein	O
,	O
as	O
measured	O
by	O
Boyden	O
single	O
-	O
membrane	O
analysis	O
.	O

9E3	O
/	O
CEF4	O
was	O
slightly	O
mitogenic	O
for	O
CEF	O
,	O
causing	O
a	O
doubling	O
of	O
[	O
3H	O
]	O
thymidine	O
uptake	O
when	O
added	O
to	O
serum	O
-	O
starved	O
CEF	O
.	O
9E3	O
/	O
CEF4	O
was	O
found	O
associated	O
not	O
only	O
with	O
the	O
cell	O
and	O
in	O
the	O
culture	O
medium	O
of	O
Rous	O
sarcoma	O
virus	O
-	O
transformed	O
CEF	O
but	O
also	O
with	O
the	O
extracellular	O
matrix	O
.	O

The	O
in	O
vivo	O
role	O
of	O
9E3	O
/	O
CEF4	O
may	O
be	O
involved	O
with	O
chemotaxis	O
and	O
metastasis	O
,	O
rather	O
than	O
with	O
direct	O
stimulation	O
of	O
mitogenicity	O
.	O

Lactotransferrin	O
binding	O
to	O
its	O
platelet	O
receptor	O
inhibits	O
platelet	O
aggregation	O
.	O

A	O
fluorescent	O
lactotransferrin	O
probe	O
was	O
prepared	O
by	O
coupling	O
5	O
-	O
(	O
(	O
[	O
2	O
-	O
(	O
carbhydrazino	O
)	O
methyl	O
]	O
-	O
thio	O
)	O
acetyl	O
)	O
amino	O
fluorescein	O
to	O
aldehyde	O
groups	O
that	O
were	O
produced	O
by	O
a	O
mild	O
periodic	O
-	O
acid	O
oxidation	O
of	O
the	O
glycan	O
moieties	O
of	O
lactotransferrin	O
.	O

In	O
this	O
manner	O
,	O
the	O
receptor	O
-	O
binding	O
site	O
of	O
the	O
lactotransferrin	O
remains	O
active	O
in	O
contrast	O
to	O
the	O
binding	O
site	O
of	O
the	O
lactotransferrin	O
derivatized	O
with	O
fluorescein	O
isothiocyanate	O
.	O

The	O
fluorescent	O
probe	O
allowed	O
us	O
to	O
characterize	O
,	O
by	O
flow	O
cytometry	O
,	O
the	O
binding	O
of	O
lactotransferrin	O
to	O
non	O
-	O
activated	O
human	O
platelets	O
.	O

The	O
putative	O
lactotransferrin	O
platelet	O
receptor	O
was	O
purified	O
and	O
its	O
immunological	O
and	O
physico	O
-	O
chemical	O
properties	O
were	O
found	O
to	O
be	O
very	O
similar	O
to	O
those	O
of	O
the	O
receptor	O
previously	O
isolated	O
from	O
activated	O
human	O
lymphocytes	O
.	O

Lactotransferrin	O
inhibits	O
ADP	O
-	O
induced	O
platelet	O
aggregation	O
at	O
concentrations	O
down	O
to	O
5	O
nM	O
,	O
which	O
can	O
be	O
reached	O
in	O
the	O
plasma	O
after	O
leukocyte	O
degranulation	O
.	O

Inhibition	O
of	O
platelet	O
aggregation	O
was	O
also	O
observed	O
with	O
the	O
N	O
-	O
terminal	O
fragment	O
of	O
lactotransferrin	O
(	O
residues	O
3	O
-	O
281	O
;	O
50	O
%	O
inhibition	O
=	O
2	O
microM	O
)	O
and	O
with	O
CFQWQRNMRKVRGPPVSC	O
synthetic	O
octodecapeptide	O
(	O
residues	O
20	O
-	O
37	O
;	O
50	O
%	O
inhibition	O
=	O
20	O
microM	O
)	O
corresponding	O
to	O
one	O
of	O
the	O
two	O
external	O
loops	O
(	O
residues	O
28	O
-	O
34	O
and	O
39	O
-	O
42	O
)	O
where	O
we	O
recently	O
located	O
the	O
receptor	O
-	O
binding	O
site	O
.	O

The	O
activity	O
(	O
50	O
%	O
inhibition	O
=	O
500	O
microM	O
)	O
of	O
the	O
tetrapeptide	O
KRDS	O
(	O
residues	O
39	O
-	O
42	O
)	O
,	O
which	O
has	O
already	O
been	O
described	O
,	O
was	O
at	O
least	O
25	O
-	O
times	O
and	O
16000	O
-	O
times	O
lower	O
than	O
the	O
activity	O
of	O
the	O
octodecapeptide	O
and	O
of	O
the	O
lactotransferrin	O
molecules	O
,	O
respectively	O
.	O

Finally	O
,	O
the	O
inhibition	O
was	O
demonstrated	O
to	O
be	O
mediated	O
by	O
a	O
mechanism	O
which	O
requires	O
the	O
binding	O
of	O
lactotransferrin	O
to	O
its	O
putative	O
receptor	O
and	O
not	O
to	O
platelet	O
glycoprotein	O
IIb	O
-	O
IIIa	O
.	O

Vitamins	O
regulate	O
gene	O
expression	O
and	O
induce	O
differentiation	O
and	O
growth	O
inhibition	O
in	O
cancer	O
cells	O
.	O

Their	O
relevance	O
in	O
cancer	O
prevention	O
.	O

Although	O
several	O
hypotheses	O
for	O
human	O
carcinogenesis	O
have	O
been	O
proposed	O
,	O
the	O
specific	O
genetic	O
changes	O
that	O
cause	O
normal	O
cells	O
to	O
become	O
cancer	O
cells	O
have	O
not	O
been	O
identified	O
.	O

In	O
spite	O
of	O
uncertainties	O
regarding	O
the	O
mechanisms	O
of	O
carcinogenesis	O
,	O
several	O
vitamins	O
such	O
as	O
beta	O
-	O
carotene	O
and	O
vitamins	O
A	O
,	O
C	O
,	O
and	O
E	O
,	O
which	O
can	O
reduce	O
the	O
risk	O
of	O
cancer	O
,	O
have	O
been	O
identified	O
,	O
using	O
animal	O
and	O
in	O
vitro	O
models	O
of	O
carcinogenesis	O
.	O

These	O
studies	O
have	O
led	O
to	O
a	O
hypothesis	O
that	O
the	O
supplemental	O
intake	O
of	O
these	O
vitamins	O
may	O
reduce	O
the	O
risk	O
of	O
cancer	O
.	O

This	O
hypothesis	O
in	O
humans	O
can	O
be	O
tested	O
only	O
by	O
intervention	O
trials	O
that	O
are	O
in	O
progress	O
.	O

Prospective	O
and	O
retrospective	O
case	O
-	O
controlled	O
experimental	O
designs	O
are	O
not	O
suitable	O
for	O
testing	O
the	O
above	O
hypothesis	O
.	O

The	O
fact	O
that	O
some	O
vitamins	O
induce	O
cell	O
differentiation	O
and	O
/	O
or	O
growth	O
inhibition	O
in	O
tumor	O
cells	O
in	O
culture	O
suggests	O
that	O
the	O
use	O
of	O
these	O
vitamins	O
in	O
cancer	O
prevention	O
has	O
a	O
cellular	O
basis	O
.	O

In	O
addition	O
to	O
having	O
a	O
direct	O
effect	O
on	O
tumor	O
cells	O
,	O
vitamins	O
such	O
as	O
alpha	O
-	O
tocopheryl	O
succinate	O
and	O
beta	O
-	O
carotene	O
enhance	O
the	O
effect	O
of	O
other	O
agents	O
that	O
induce	O
differentiation	O
in	O
tumor	O
cells	O
.	O

Some	O
vitamins	O
like	O
beta	O
-	O
carotene	O
,	O
retinoic	O
acid	O
,	O
alpha	O
-	O
tocopheryl	O
succinate	O
,	O
and	O
vitamin	O
D	O
also	O
regulate	O
the	O
expressions	O
of	O
certain	O
oncogenes	O
and	O
cellular	O
genes	O
.	O

These	O
are	O
exciting	O
new	O
functions	O
of	O
vitamins	O
that	O
nobody	O
could	O
have	O
predicted	O
only	O
a	O
few	O
years	O
ago	O
.	O

Increased	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
messenger	O
RNA	O
expression	O
and	O
absence	O
of	O
mutations	O
in	O
colon	O
carcinomas	O
of	O
low	O
and	O
high	O
metastatic	O
potential	O
.	O

BACKGROUND	O
:	O
The	O
murine	O
nm23	O
gene	O
suppresses	O
the	O
metastatic	O
behavior	O
of	O
malignant	O
rodent	O
tumor	O
lines	O
,	O
and	O
reduced	O
nm23	O
expression	O
correlates	O
with	O
increased	O
likelihood	O
of	O
lymph	O
node	O
metastases	O
in	O
human	O
breast	O
cancers	O
.	O

More	O
recent	O
data	O
have	O
demonstrated	O
the	O
existence	O
of	O
two	O
human	O
nm23	O
gene	O
homologues	O
,	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
,	O
and	O
have	O
shown	O
that	O
deletion	O
of	O
nm23	O
-	O
H1	O
alleles	O
occurs	O
in	O
some	O
colon	O
carcinomas	O
associated	O
with	O
poor	O
prognosis	O
.	O

These	O
findings	O
suggest	O
that	O
nm23	O
-	O
H1	O
encodes	O
for	O
suppression	O
of	O
colon	O
carcinoma	O
metastasis	O
.	O

In	O
contrast	O
,	O
we	O
have	O
previously	O
reported	O
that	O
total	O
nm23	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O
is	O
increased	O
to	O
similar	O
levels	O
in	O
colon	O
tumors	O
of	O
both	O
high	O
and	O
low	O
metastatic	O
potential	O
.	O

PURPOSE	O
:	O
This	O
study	O
was	O
designed	O
to	O
reconcile	O
our	O
previous	O
findings	O
with	O
the	O
recent	O
report	O
of	O
nm23	O
-	O
H1	O
allelic	O
deletion	O
in	O
human	O
colon	O
cancers	O
associated	O
with	O
poor	O
prognosis	O
.	O

Our	O
purpose	O
was	O
to	O
examine	O
human	O
colon	O
cancers	O
for	O
inactivation	O
of	O
two	O
candidate	O
metastasis	O
suppressor	O
genes	O
,	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
,	O
either	O
by	O
mutation	O
or	O
by	O
loss	O
of	O
gene	O
transcription	O
.	O

METHODS	O
:	O
We	O
used	O
ribonuclease	O
protection	O
assays	O
to	O
analyze	O
human	O
colon	O
tumors	O
for	O
the	O
level	O
of	O
nm23	O
-	O
H1	O
(	O
43	O
samples	O
)	O
and	O
nm23	O
-	O
H2	O
(	O
41	O
samples	O
)	O
transcript	O
(	O
mRNA	O
)	O
expression	O
and	O
the	O
presence	O
of	O
mutations	O
that	O
could	O
inactivate	O
potential	O
suppressor	O
function	O
.	O

RESULTS	O
:	O
We	O
detected	O
only	O
wild	O
-	O
type	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
mRNA	O
.	O

Expression	O
of	O
nm23	O
-	O
H1	O
mRNA	O
increased	O
in	O
33	O
of	O
41	O
colon	O
tumors	O
,	O
and	O
expression	O
of	O
nm23	O
-	O
H2	O
mRNA	O
was	O
elevated	O
in	O
28	O
of	O
41	O
colon	O
tumors	O
relative	O
to	O
that	O
in	O
matched	O
normal	O
mucosa	O
.	O

Increases	O
in	O
these	O
mRNA	O
levels	O
were	O
similar	O
in	O
tumors	O
of	O
both	O
low	O
and	O
high	O
metastatic	O
potential	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
,	O
despite	O
correlation	O
of	O
nm23	O
-	O
H1	O
allelic	O
deletions	O
with	O
colon	O
cancers	O
associated	O
with	O
poor	O
prognosis	O
,	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
alleles	O
do	O
not	O
directly	O
mediate	O
metastasis	O
suppression	O
in	O
colon	O
carcinoma	O
.	O

Our	O
results	O
leave	O
unexplained	O
the	O
observation	O
that	O
nm23	O
-	O
H1	O
allelic	O
deletion	O
correlates	O
with	O
metastatic	O
potential	O
of	O
colon	O
carcinomas	O
.	O

IMPLICATIONS	O
:	O
These	O
findings	O
also	O
contrast	O
with	O
the	O
demonstration	O
of	O
nm23	O
metastasis	O
suppressor	O
activity	O
in	O
murine	O
melanoma	O
and	O
with	O
the	O
correlation	O
of	O
loss	O
of	O
nm23	O
expression	O
in	O
breast	O
cancer	O
with	O
poor	O
prognosis	O
.	O

It	O
may	O
be	O
that	O
metastasis	O
suppression	O
by	O
the	O
nm23	O
gene	O
is	O
a	O
tissue	O
-	O
specific	O
phenomenon	O
.	O

E	O
mu	O
-	O
bcl	O
-	O
2	O
transgene	O
facilitates	O
spontaneous	O
transformation	O
of	O
early	O
pre	O
-	O
B	O
and	O
immunoglobulin	O
-	O
secreting	O
cells	O
but	O
not	O
T	O
cells	O
.	O

To	O
assess	O
the	O
lymphoid	O
tumorigenic	O
potential	O
of	O
bcl	O
-	O
2	O
,	O
mice	O
of	O
five	O
independent	O
strains	O
expressing	O
a	O
bcl	O
-	O
2	O
transgene	O
in	O
B	O
and	O
/	O
or	O
T	O
cells	O
were	O
monitored	O
for	O
disease	O
up	O
to	O
12	O
months	O
of	O
age	O
.	O

Lymphoma	O
prevalence	O
was	O
minimal	O
in	O
the	O
T	O
lineage	O
but	O
significant	O
,	O
although	O
low	O
(	O
3	O
-	O
15	O
%	O
)	O
,	O
in	O
the	O
B	O
lineage	O
.	O

The	O
principal	O
types	O
of	O
tumors	O
were	O
plasmacytomas	O
secreting	O
immunoglobulin	O
and	O
novel	O
lymphomas	O
that	O
expressed	O
markers	O
such	O
as	O
Sca	O
-	O
1	O
,	O
CD4	O
,	O
Thy	O
-	O
1	O
,	O
CD34	O
and	O
CD45	O
(	O
B220	O
)	O
,	O
consistent	O
with	O
an	O
origin	O
very	O
early	O
in	O
B	O
-	O
lymphoid	O
development	O
.	O

Rearrangement	O
of	O
the	O
c	O
-	O
myc	O
gene	O
was	O
common	O
in	O
the	O
plasmacytomas	O
,	O
implying	O
a	O
synergistic	O
role	O
for	O
myc	O
and	O
bcl	O
-	O
2	O
in	O
their	O
etiology	O
,	O
but	O
was	O
not	O
detected	O
in	O
the	O
lymphomas	O
.	O

Appearance	O
of	O
tumorous	O
phenotypes	O
in	O
goldfish	O
erythrophores	O
transfected	O
with	O
ras	O
,	O
src	O
,	O
and	O
myc	O
oncogenes	O
and	O
spontaneous	O
differentiation	O
of	O
the	O
transformants	O
in	O
vitro	O
.	O

When	O
goldfish	O
erythrophores	O
isolated	O
from	O
the	O
skin	O
by	O
tissue	O
digestion	O
and	O
centrifugation	O
in	O
a	O
Percoll	O
density	O
gradient	O
were	O
transfected	O
in	O
a	O
monolayer	O
-	O
culture	O
with	O
v	O
-	O
Ha	O
-	O
ras	O
or	O
v	O
-	O
src	O
oncogene	O
either	O
singly	O
or	O
in	O
combination	O
with	O
v	O
-	O
myc	O
by	O
means	O
of	O
calcium	O
phosphate	O
-	O
DNA	O
co	O
-	O
precipitation	O
,	O
there	O
appeared	O
a	O
certain	O
number	O
of	O
transformants	O
manifesting	O
a	O
chromatoblast	O
-	O
like	O
profile	O
and	O
tumorous	O
phenotypes	O
as	O
seen	O
in	O
the	O
capability	O
for	O
unlimited	O
growth	O
,	O
and	O
piling	O
-	O
up	O
in	O
a	O
monolayer	O
-	O
culture	O
or	O
colony	O
formation	O
in	O
semi	O
-	O
solid	O
soft	O
agar	O
.	O

After	O
successive	O
growth	O
in	O
vitro	O
for	O
longer	O
than	O
one	O
month	O
which	O
was	O
scarcely	O
observed	O
with	O
the	O
erythrophores	O
,	O
the	O
vast	O
majority	O
of	O
such	O
transformants	O
began	O
to	O
differentiate	O
into	O
erythrophores	O
and	O
ceased	O
proliferation	O
spontaneously	O
.	O

The	O
onset	O
of	O
their	O
differentiation	O
was	O
ascertained	O
by	O
the	O
deposition	O
of	O
marker	O
pteridine	O
pigments	O
.	O

None	O
of	O
the	O
transformants	O
differentiated	O
into	O
melanophores	O
or	O
iridophores	O
or	O
other	O
neural	O
crest	O
derivatives	O
as	O
seen	O
in	O
goldfish	O
erythrophoroma	O
cells	O
.	O

Little	O
difference	O
was	O
observed	O
in	O
their	O
transforming	O
efficiency	O
(	O
0	O
.	O
2	O
-	O
0	O
.	O
3	O
transformants	O
/	O
micrograms	O
DNA	O
)	O
between	O
the	O
combinations	O
of	O
oncogenes	O
applied	O
but	O
a	O
tendency	O
was	O
noted	O
that	O
cells	O
transfected	O
with	O
ras	O
or	O
src	O
in	O
combination	O
with	O
myc	O
developed	O
the	O
capacity	O
to	O
grow	O
for	O
a	O
longer	O
period	O
and	O
differentiated	O
at	O
a	O
later	O
stage	O
than	O
those	O
transfected	O
solely	O
with	O
ras	O
or	O
src	O
.	O

One	O
cell	O
line	O
(	O
ESM	B
-	I
1	I
)	O
derived	O
from	O
the	O
erythrophores	O
transfected	O
with	O
src	O
/	O
myc	O
grew	O
successively	O
over	O
nine	O
months	O
,	O
indicating	O
its	O
acquisition	O
of	O
immortality	O
.	O

The	O
expression	O
of	O
the	O
transfected	O
oncogenes	O
in	O
this	O
cell	O
line	O
was	O
examined	O
in	O
comparison	O
with	O
the	O
erythrophoroma	O
cells	O
by	O
Western	O
and	O
Northern	O
blot	O
analyses	O
.	O

[	O
Prehospital	O
service	O
in	O
Denmark	O
]	O
.	O

In	O
Denmark	O
,	O
emergency	O
ambulances	O
are	O
dispatched	O
by	O
41	O
centres	O
manned	O
either	O
by	O
trained	O
firemen	O
(	O
in	O
Copenhagen	O
)	O
or	O
policemen	O
(	O
outside	O
Copenhagen	O
)	O
.	O

In	O
1990	O
,	O
emergency	O
ambulance	O
calls	O
totalled	O
284	O
,	O
000	O
.	O

Utilisation	O
of	O
emergency	O
ambulance	O
services	O
increases	O
with	O
urbanisation	O
.	O

A	O
doctor	O
-	O
manned	O
ambulance	O
is	O
in	O
operation	O
in	O
Copenhagen	O
,	O
and	O
in	O
some	O
other	O
large	O
towns	O
anaesthesiology	O
and	O
intensive	O
care	O
teams	O
can	O
be	O
dispatched	O
from	O
hospital	O
to	O
give	O
on	O
-	O
the	O
-	O
spot	O
care	O
.	O

In	O
less	O
populated	O
areas	O
,	O
some	O
general	O
practitioners	O
give	O
advanced	O
life	O
-	O
support	O
.	O

Although	O
many	O
areas	O
are	O
serviced	O
by	O
ambulances	O
equipped	O
with	O
defibrillators	O
,	O
the	O
majority	O
of	O
patients	O
receive	O
only	O
basic	O
life	O
-	O
support	O
from	O
ambulance	O
personnel	O
.	O

New	O
initiatives	O
resulting	O
from	O
a	O
recent	O
report	O
by	O
a	O
commission	O
appointed	O
by	O
central	O
authorities	O
,	O
and	O
focused	O
on	O
prehospital	O
treatment	O
,	O
are	O
expected	O
to	O
improve	O
the	O
service	O
by	O
raising	O
the	O
level	O
of	O
training	O
given	O
to	O
ambulance	O
personnel	O
.	O

Tumorigenic	O
activity	O
of	O
rho	O
genes	O
from	O
Aplysia	O
californica	O
.	O

rho	O
genes	O
have	O
been	O
found	O
in	O
both	O
lower	O
and	O
higher	O
eucaryotes	O
.	O

They	O
code	O
for	O
proteins	O
of	O
21	O
kDa	O
,	O
highly	O
conserved	O
in	O
evolution	O
,	O
which	O
belong	O
to	O
the	O
superfamily	O
of	O
ras	O
GTPases	O
.	O

Among	O
the	O
members	O
of	O
this	O
superfamily	O
there	O
are	O
proteins	O
with	O
a	O
regulatory	O
function	O
,	O
such	O
as	O
ras	O
,	O
and	O
proteins	O
involved	O
in	O
vesicular	O
trafficking	O
,	O
such	O
as	O
the	O
family	O
of	O
rab	O
proteins	O
.	O

We	O
have	O
investigated	O
the	O
putative	O
role	O
of	O
rho	O
proteins	O
from	O
Aplysia	O
californica	O
as	O
transforming	O
GTPases	O
utilizing	O
the	O
wild	O
-	O
type	O
and	O
a	O
Val	O
-	O
14	O
mutant	O
,	O
equivalent	O
to	O
the	O
oncogenic	O
Val	O
-	O
12	O
mutation	O
of	O
ras	O
genes	O
found	O
in	O
animal	O
and	O
human	O
tumors	O
.	O

Over	O
-	O
expression	O
of	O
either	O
rho	O
gene	O
was	O
sufficient	O
to	O
confer	O
anchorage	O
-	O
and	O
serum	O
-	O
independent	O
growth	O
.	O

Moreover	O
,	O
when	O
introduced	O
into	O
nude	O
mice	O
,	O
selected	O
clones	O
generated	O
from	O
either	O
gene	O
were	O
able	O
to	O
induce	O
tumors	O
,	O
although	O
those	O
carrying	O
the	O
mutated	O
version	O
were	O
more	O
efficient	O
.	O

Pathological	O
analysis	O
indicated	O
that	O
generated	O
tumors	O
corresponded	O
to	O
well	O
-	O
differentiated	O
fibrosarcomas	O
with	O
distinct	O
and	O
intersecting	O
bundles	O
and	O
spindle	O
cells	O
.	O

By	O
contrast	O
,	O
ras	O
-	O
induced	O
tumors	O
were	O
poorly	O
differentiated	O
fibrosarcomas	O
.	O

Thus	O
,	O
our	O
results	O
indicate	O
that	O
under	O
appropriate	O
conditions	O
rho	O
genes	O
function	O
as	O
oncogenes	O
and	O
may	O
have	O
a	O
role	O
in	O
the	O
regulation	O
of	O
proliferation	O
in	O
fibroblast	O
cells	O
.	O

Immune	O
consequences	O
of	O
burn	O
injury	O
.	O

The	O
purpose	O
of	O
the	O
immune	O
system	O
is	O
to	O
protect	O
cells	O
from	O
invasion	O
by	O
microorganisms	O
.	O

The	O
body	O
has	O
three	O
equally	O
important	O
interactive	O
immune	O
defense	O
systems	O
,	O
all	O
of	O
which	O
are	O
profoundly	O
disrupted	O
with	O
major	O
burn	O
injury	O
.	O

The	O
immune	O
response	O
to	O
burn	O
injury	O
is	O
immediate	O
,	O
prolonged	O
,	O
and	O
severe	O
.	O

The	O
end	O
result	O
in	O
individuals	O
surviving	O
burn	O
shock	O
is	O
immunosuppression	O
,	O
with	O
increased	O
susceptibility	O
to	O
potentially	O
fatal	O
systemic	O
burn	O
wound	O
or	O
pulmonary	O
sepsis	O
.	O

Nursing	O
actions	O
to	O
support	O
the	O
humoral	O
and	O
cell	O
-	O
mediated	O
immune	O
system	O
of	O
the	O
burned	O
patient	O
include	O
providing	O
nutritional	O
support	O
to	O
maintain	O
serum	O
protein	O
levels	O
at	O
optimal	O
levels	O
;	O
measures	O
to	O
decrease	O
edema	O
and	O
promote	O
angiogenesis	O
in	O
areas	O
of	O
partial	O
-	O
thickness	O
injury	O
;	O
meticulous	O
treatment	O
of	O
the	O
wound	O
to	O
prevent	O
infection	O
and	O
promote	O
healing	O
;	O
monitoring	O
of	O
antibiotic	O
use	O
;	O
conservative	O
use	O
of	O
invasive	O
techniques	O
,	O
including	O
intubation	O
and	O
vascular	O
access	O
devices	O
;	O
maintenance	O
of	O
fluid	O
and	O
electrolyte	O
balance	O
and	O
body	O
temperature	O
;	O
and	O
energy	O
conservation	O
measures	O
.	O

Autocrine	O
angiogenic	O
vascular	O
prosthesis	O
with	O
bone	O
marrow	O
transplantation	O
.	O

Synthetic	O
vascular	O
prostheses	O
are	O
foreign	O
bodies	O
,	O
so	O
that	O
blood	O
coagulation	O
can	O
occur	O
on	O
their	O
luminal	O
surfaces	O
,	O
causing	O
graft	O
occlusion	O
very	O
frequently	O
in	O
prostheses	O
of	O
small	O
diameter	O
.	O

A	O
vascular	O
prosthesis	O
needs	O
angiogenesis	O
for	O
endothelialization	O
of	O
the	O
luminal	O
surface	O
,	O
as	O
endothelial	O
cells	O
have	O
natural	O
and	O
permanent	O
antithrombogenic	O
properties	O
.	O

To	O
induce	O
capillary	O
growth	O
into	O
the	O
graft	O
,	O
we	O
developed	O
a	O
method	O
of	O
transplanting	O
bone	O
marrow	O
cells	O
,	O
which	O
are	O
primitive	O
,	O
strong	O
enough	O
to	O
survive	O
,	O
and	O
create	O
blood	O
cells	O
,	O
resulting	O
in	O
the	O
inducement	O
of	O
capillary	O
growth	O
.	O

In	O
an	O
animal	O
experiment	O
,	O
marrow	O
cells	O
were	O
infiltrated	O
into	O
the	O
walls	O
of	O
long	O
-	O
fibril	O
expanded	O
polytetrafluoroethylene	O
(	O
ePTFE	O
)	O
vascular	O
grafts	O
.	O

The	O
grafts	O
were	O
implanted	O
in	O
the	O
abdominal	O
aortic	O
position	O
of	O
24	O
dogs	O
autologously	O
.	O

Marrow	O
cells	O
survived	O
and	O
continued	O
exogenous	O
hemopoiesis	O
for	O
up	O
to	O
six	O
months	O
and	O
were	O
immunohistochemically	O
reactive	O
to	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
.	O

All	O
the	O
grafts	O
older	O
than	O
three	O
weeks	O
had	O
complete	O
endothelialization	O
and	O
maintained	O
their	O
patency	O
.	O

Twenty	O
grafts	O
without	O
bone	O
marrow	O
were	O
implanted	O
as	O
controls	O
.	O

Endothelialization	O
was	O
present	O
at	O
anastomotic	O
sites	O
,	O
but	O
other	O
areas	O
were	O
covered	O
with	O
fresh	O
thrombi	O
.	O

Four	O
out	O
of	O
seven	O
control	O
grafts	O
were	O
patent	O
with	O
endothelial	O
cell	O
lining	O
at	O
six	O
months	O
,	O
but	O
three	O
were	O
occluded	O
and	O
one	O
of	O
the	O
four	O
grafts	O
was	O
still	O
covered	O
with	O
a	O
thrombus	O
layer	O
.	O

Bone	O
marrow	O
with	O
its	O
unique	O
native	O
properties	O
produced	O
autocrine	O
angiogenicity	O
in	O
the	O
graft	O
.	O

Toward	O
a	O
theory	O
regarding	O
the	O
pathogenesis	O
of	O
the	O
systemic	O
inflammatory	O
response	O
syndrome	O
:	O
what	O
we	O
do	O
and	O
do	O
not	O
know	O
about	O
cytokine	O
regulation	O
.	O

OBJECTIVES	O
:	O

The	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
is	O
the	O
massive	O
inflammatory	O
reaction	O
resulting	O
from	O
systemic	O
mediator	O
release	O
that	O
may	O
lead	O
to	O
multiple	O
organ	O
dysfunction	O
.	O

The	O
objective	O
of	O
this	O
review	O
article	O
is	O
to	O
analyze	O
the	O
roles	O
of	O
cytokines	O
,	O
cytokine	O
production	O
,	O
and	O
the	O
relationship	O
of	O
cytokine	O
production	O
to	O
the	O
development	O
of	O
SIRS	O
.	O

DATA	O
SOURCES	O
:	O

Previous	O
research	O
and	O
clinical	O
studies	O
related	O
to	O
cytokines	O
and	O
their	O
relationship	O
to	O
SIRS	O
.	O

STUDY	O
SELECTION	O
:	O

From	O
the	O
studies	O
reviewed	O
,	O
three	O
critical	O
questions	O
are	O
addressed	O
.	O

First	O
,	O
what	O
is	O
the	O
definition	O
of	O
increased	O
cytokine	O
concentrations	O
?	O

Second	O
,	O
what	O
other	O
systemic	O
illnesses	O
besides	O
sepsis	O
can	O
alter	O
cytokine	O
concentrations	O
?	O

Third	O
,	O
what	O
are	O
the	O
right	O
cytokines	O
to	O
measure	O
?	O

DATA	O
SYNTHESIS	O
:	O

This	O
article	O
postulates	O
a	O
three	O
-	O
stage	O
development	O
of	O
SIRS	O
,	O
in	O
which	O
stage	O
1	O
is	O
a	O
local	O
production	O
of	O
cytokines	O
in	O
response	O
to	O
an	O
injury	O
or	O
infection	O
.	O

Stage	O
2	O
is	O
the	O
protective	O
release	O
of	O
a	O
small	O
amount	O
of	O
cytokines	O
into	O
the	O
body	O
'	O
s	O
circulation	O
.	O

Stage	O
3	O
is	O
the	O
massive	O
systemic	O
reaction	O
where	O
cytokines	O
turn	O
destructive	O
by	O
compromising	O
the	O
integrity	O
of	O
the	O
capillary	O
walls	O
and	O
flooding	O
end	O
organs	O
.	O

CONCLUSIONS	O
:	O

While	O
cytokines	O
are	O
generally	O
viewed	O
as	O
a	O
destructive	O
development	O
in	O
the	O
patient	O
that	O
generally	O
leads	O
to	O
multiple	O
organ	O
dysfunction	O
,	O
cytokines	O
also	O
protect	O
the	O
body	O
when	O
localized	O
.	O

It	O
will	O
be	O
necessary	O
to	O
study	O
the	O
positive	O
effects	O
of	O
cytokines	O
while	O
also	O
studying	O
their	O
role	O
in	O
causing	O
SIRS	O
.	O

It	O
will	O
also	O
be	O
important	O
to	O
investigate	O
the	O
relationship	O
between	O
cytokines	O
and	O
their	O
blockers	O
in	O
SIRS	O
.	O

Application	O
of	O
clonal	O
analysis	O
.	O

Differential	O
diagnosis	O
for	O
synchronous	O
primary	O
ovarian	O
and	O
endometrial	O
cancers	O
and	O
metastatic	O
cancer	O
.	O

Simultaneous	O
involvement	O
of	O
the	O
endometrium	O
and	O
the	O
ovary	O
by	O
carcinoma	O
is	O
a	O
familiar	O
problem	O
in	O
the	O
routine	O
practice	O
of	O
surgical	O
pathology	O
.	O

Such	O
cases	O
may	O
be	O
considered	O
either	O
examples	O
of	O
a	O
single	O
primary	O
carcinoma	O
with	O
metastasis	O
or	O
as	O
synchronous	O
primary	O
neoplasms	O
.	O

The	O
distinction	O
between	O
these	O
two	O
possibilities	O
is	O
made	O
based	O
on	O
clinicopathologic	O
observations	O
,	O
and	O
therefore	O
may	O
not	O
be	O
definitive	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
used	O
molecular	O
techniques	O
to	O
analyze	O
the	O
clonal	O
composition	O
of	O
five	O
cases	O
of	O
concurrent	O
adenocarcinomas	O
of	O
the	O
endometrium	O
and	O
ovary	O
that	O
were	O
clinicopathologically	O
diagnosed	O
as	O
synchronous	O
primary	O
tumors	O
.	O

Patterns	O
of	O
X	O
-	O
chromosome	O
inactivation	O
,	O
mutations	O
in	O
the	O
K	O
-	O
ras	O
gene	O
,	O
mutations	O
or	O
allelic	O
loss	O
of	O
the	O
p53	O
gene	O
,	O
or	O
human	O
papillomavirus	O
detection	O
were	O
identical	O
in	O
both	O
endometrial	O
and	O
ovarian	O
lesions	O
in	O
three	O
of	O
the	O
cases	O
suggesting	O
that	O
those	O
three	O
cases	O
represented	O
single	O
primary	O
tumors	O
with	O
metastases	O
.	O

In	O
both	O
of	O
the	O
other	O
two	O
cases	O
,	O
the	O
patterns	O
of	O
X	O
-	O
chromosome	O
inactivation	O
clearly	O
demonstrated	O
the	O
presence	O
of	O
independent	O
primary	O
tumors	O
.	O

The	O
application	O
of	O
molecular	O
technology	O
may	O
play	O
an	O
important	O
role	O
for	O
the	O
differential	O
diagnosis	O
between	O
synchronous	O
primary	O
carcinomas	O
and	O
a	O
single	O
carcinoma	O
with	O
metastasis	O
.	O

Pancreatic	O
somatostatin	O
-	O
secreting	O
gangliocytic	O
paraganglioma	O
with	O
lymph	O
node	O
metastases	O
.	O

Gangliocytic	O
paraganglioma	O
(	O
GPG	O
)	O
with	O
local	O
lymph	O
node	O
metastasis	O
was	O
found	O
in	O
the	O
pancreas	O
of	O
a	O
74	O
-	O
yr	O
-	O
old	O
female	O
who	O
presented	O
with	O
diarrhea	O
,	O
steatorrhea	O
,	O
vomiting	O
,	O
nausea	O
,	O
and	O
abdominal	O
pain	O
.	O

A	O
Whipple	O
procedure	O
led	O
to	O
a	O
complete	O
resolution	O
of	O
these	O
symptoms	O
and	O
a	O
return	O
of	O
an	O
elevated	O
stomatostatin	O
level	O
to	O
normal	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
GPG	O
in	O
this	O
location	O
and	O
the	O
first	O
endocrinologically	O
active	O
GPG	O
.	O

Molecular	O
biology	O
of	O
cervical	O
cancer	O
and	O
its	O
precursors	O
.	O

Cervical	O
cancer	O
develops	O
from	O
well	O
-	O
defined	O
precursor	O
lesions	O
referred	O
to	O
as	O
either	O
cervical	O
intraepithelial	O
neoplasia	O
or	O
squamous	O
intraepithelial	O
lesions	O
.	O

It	O
is	O
now	O
known	O
that	O
specific	O
types	O
of	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
are	O
the	O
principal	O
etiologic	O
agents	O
for	O
both	O
cervical	O
cancer	O
and	O
its	O
precursors	O
.	O

The	O
high	O
-	O
oncogenic	O
-	O
risk	O
HPV	O
types	O
associated	O
with	O
invasive	O
cervical	O
cancer	O
produce	O
two	O
oncoproteins	O
,	O
designated	O
E6	O
and	O
E7	O
,	O
which	O
interact	O
with	O
endogenous	O
cell	O
cycle	O
regulatory	O
proteins	O
,	O
including	O
p53	O
and	O
Rb	O
.	O

The	O
interaction	O
of	O
virally	O
derived	O
and	O
endogenous	O
cellular	O
proteins	O
converges	O
in	O
deregulation	O
of	O
cell	O
cycle	O
progression	O
and	O
appears	O
to	O
be	O
critical	O
for	O
the	O
development	O
of	O
cervical	O
cancers	O
.	O

However	O
,	O
the	O
development	O
of	O
cervical	O
cancer	O
is	O
a	O
multistep	O
process	O
that	O
can	O
not	O
be	O
explained	O
simply	O
by	O
infection	O
with	O
specific	O
types	O
of	O
HPV	O
.	O

One	O
additional	O
event	O
that	O
appears	O
to	O
play	O
a	O
role	O
in	O
tumor	O
progression	O
is	O
integration	O
of	O
HPV	O
DNA	O
into	O
the	O
host	O
genome	O
.	O

Integration	O
of	O
HPV	O
DNA	O
frequently	O
disrupts	O
the	O
E2	O
open	O
reading	O
frames	O
,	O
resulting	O
in	O
overexpression	O
of	O
the	O
E6	O
and	O
E7	O
oncoproteins	O
and	O
possibly	O
causing	O
genomic	O
instability	O
.	O

Additional	O
cofactors	O
and	O
mutational	O
events	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
invasive	O
cervical	O
cancers	O
and	O
may	O
include	O
chromosomal	O
rearrangements	O
,	O
loss	O
of	O
constitutional	O
heterozygosity	O
,	O
and	O
proto	O
-	O
oncogene	O
activation	O
.	O

Cell	O
surface	O
binding	O
characteristics	O
correlate	O
with	O
consensus	O
type	O
I	O
interferon	O
enhanced	O
activity	O
.	O

The	O
binding	O
characteristics	O
of	O
a	O
genetically	O
engineered	O
consensus	O
interferon	O
with	O
unusually	O
high	O
biologic	O
activity	O
were	O
compared	O
to	O
the	O
characteristics	O
of	O
recombinant	O
interferon	O
-	O
alpha	O
2	O
.	O

Both	O
interferon	O
-	O
alpha	O
2	O
and	O
the	O
consensus	O
interferon	O
produced	O
typical	O
biphasic	O
Scatchard	O
plots	O
,	O
indicating	O
multiple	O
independent	O
binding	O
sites	O
.	O

The	O
consensus	O
interferon	O
,	O
which	O
exhibited	O
a	O
biologic	O
potency	O
more	O
than	O
10	O
-	O
fold	O
greater	O
than	O
all	O
other	O
type	O
I	O
interferons	O
,	O
also	O
exhibited	O
binding	O
site	O
affinities	O
greater	O
than	O
those	O
for	O
IFN	O
-	O
alpha	O
2b	O
.	O

In	O
addition	O
,	O
a	O
larger	O
number	O
of	O
high	O
,	O
and	O
low	O
-	O
affinity	O
cell	O
surface	O
sites	O
were	O
recognized	O
by	O
the	O
consensus	O
interferon	O
,	O
resulting	O
in	O
equivalent	O
numbers	O
of	O
sites	O
at	O
reduced	O
molar	O
concentrations	O
compared	O
to	O
IFN	O
-	O
a2b	O
.	O

Thus	O
,	O
at	O
any	O
given	O
biologic	O
activity	O
,	O
similar	O
numbers	O
of	O
sites	O
were	O
bound	O
by	O
the	O
consensus	O
interferon	O
and	O
IFN	O
-	O
alpha	O
2	O
,	O
despite	O
differences	O
in	O
their	O
molar	O
concentrations	O
.	O

No	O
differences	O
in	O
internalization	O
kinetics	O
were	O
identified	O
between	O
the	O
two	O
interferons	O
,	O
indicating	O
that	O
the	O
differences	O
in	O
cell	O
surface	O
binding	O
may	O
be	O
sufficient	O
to	O
produce	O
the	O
differences	O
in	O
biologic	O
activity	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
viral	O
background	O
plays	O
a	O
major	O
role	O
in	O
development	O
of	O
resistance	O
to	O
protease	O
inhibitors	O
.	O

The	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
benefit	O
of	O
combination	O
treatment	O
with	O
anti	O
-	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
agents	O
prompted	O
us	O
to	O
examine	O
the	O
potential	O
of	O
resistance	O
development	O
when	O
two	O
protease	O
inhibitors	O
are	O
used	O
concurrently	O
.	O

Recombinant	O
HIV	O
-	O
1	O
(	O
NL4	O
-	O
3	O
)	O
proteases	O
containing	O
combined	O
resistance	O
mutations	O
associated	O
with	O
BMS	O
-	O
186318	O
and	O
A	O
-	O
77003	O
(	O
or	O
saquinavir	O
)	O
were	O
either	O
inactive	O
or	O
had	O
impaired	O
enzyme	O
activity	O
.	O

Subsequent	O
construction	O
of	O
HIV	O
-	O
1	O
(	O
NL4	O
-	O
3	O
)	O
proviral	O
clones	O
containing	O
the	O
same	O
mutations	O
yielded	O
viruses	O
that	O
were	O
severely	O
impaired	O
in	O
growth	O
or	O
nonviable	O
,	O
confirming	O
that	O
combination	O
therapy	O
may	O
be	O
advantageous	O
.	O

However	O
,	O
passage	O
of	O
BMS	O
-	O
186318	O
-	O
resistant	O
HIV	O
-	O
1	O
(	O
RF	O
)	O
in	O
the	O
presence	O
of	O
either	O
saquinavir	O
or	O
SC52151	O
,	O
which	O
represented	O
sequential	O
drug	O
treatment	O
,	O
produced	O
viable	O
viruses	O
resistant	O
to	O
both	O
BMS	O
-	O
186318	O
and	O
the	O
second	O
compound	O
.	O

The	O
predominant	O
breakthrough	O
virus	O
contained	O
the	O
G48V	O
/	O
A71	O
T	O
/	O
V82A	O
protease	O
mutations	O
.	O

The	O
clone	O
-	O
purified	O
RF	O
(	O
G48V	O
/	O
A71	O
T	O
/	O
V82A	O
)	O
virus	O
,	O
unlike	O
the	O
corresponding	O
defective	O
NL4	O
-	O
3	O
triple	O
mutant	O
,	O
grew	O
well	O
and	O
displayed	O
cross	O
-	O
resistance	O
to	O
four	O
distinct	O
protease	O
inhibitors	O
.	O

Chimeric	O
virus	O
and	O
in	O
vitro	O
mutagenesis	O
studies	O
indicated	O
that	O
the	O
RF	O
-	O
specific	O
protease	O
sequence	O
,	O
specifically	O
the	O
Ile	O
at	O
residue	O
10	O
,	O
enabled	O
the	O
NL4	O
-	O
3	O
strain	O
with	O
the	O
triple	O
mutant	O
to	O
grow	O
.	O

Our	O
results	O
clearly	O
indicate	O
that	O
viral	O
genetic	O
background	O
will	O
play	O
a	O
key	O
role	O
in	O
determining	O
whether	O
cross	O
-	O
resistance	O
variants	O
will	O
arise	O
.	O

The	O
effects	O
of	O
radiation	O
on	O
neovascularization	O
in	O
a	O
rat	O
model	O
.	O

It	O
is	O
thought	O
that	O
radiation	O
treatment	O
inhibits	O
neovascularization	O
of	O
recipient	O
and	O
/	O
or	O
graft	O
tissues	O
,	O
and	O
this	O
may	O
account	O
in	O
part	O
for	O
abnormalities	O
in	O
wound	O
healing	O
associated	O
with	O
radiation	O
therapy	O
.	O

We	O
have	O
examined	O
this	O
hypothesis	O
using	O
a	O
model	O
that	O
measures	O
the	O
neovascularization	O
of	O
an	O
implanted	O
foreign	O
material	O
.	O

Expanded	O
polytetrafluoroethylene	O
(	O
PTFE	O
)	O
sheets	O
were	O
implanted	O
adjacent	O
to	O
both	O
superficial	O
epigastric	O
vascular	O
pedicles	O
of	O
63	O
rats	O
distributed	O
into	O
7	O
groups	O
(	O
n	O
=	O
7	O
)	O
that	O
differed	O
with	O
respect	O
to	O
dose	O
and	O
timing	O
of	O
irradiation	O
.	O

Zero	O
to	O
10	O
daily	O
fractions	O
of	O
electron	O
-	O
beam	O
radiation	O
(	O
300	O
cGy	O
each	O
)	O
were	O
delivered	O
to	O
the	O
implant	O
in	O
the	O
right	O
groin	O
,	O
while	O
the	O
implant	O
in	O
the	O
left	O
groin	O
served	O
as	O
a	O
nonirradiated	O
internal	O
control	O
.	O

Unirradiated	O
animals	O
showed	O
equal	O
neovascularization	O
of	O
both	O
implants	O
.	O

Rats	O
that	O
were	O
irradiated	O
twice	O
(	O
single	O
fractions	O
at	O
0	O
and	O
24	O
hours	O
after	O
implantation	O
)	O
did	O
not	O
show	O
a	O
significant	O
decrease	O
in	O
the	O
neovascularization	O
of	O
the	O
irradiated	O
implant	O
compared	O
with	O
the	O
contralateral	O
control	O
implant	O
.	O

In	O
contrast	O
,	O
the	O
implants	O
that	O
were	O
irradiated	O
three	O
times	O
(	O
single	O
fractions	O
at	O
0	O
,	O
24	O
,	O
and	O
48	O
hours	O
after	O
implantation	O
)	O
demonstrated	O
significantly	O
diminished	O
(	O
greater	O
than	O
25	O
percent	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
neovascularization	O
beyond	O
day	O
7	O
,	O
whereas	O
implants	O
irradiated	O
only	O
at	O
48	O
hours	O
after	O
implantation	O
did	O
not	O
.	O

Interestingly	O
,	O
neovascularization	O
of	O
the	O
implants	O
irradiated	O
with	O
10	O
fractions	O
(	O
3000	O
cGy	O
)	O
was	O
not	O
significantly	O
decreased	O
compared	O
with	O
irradiation	O
with	O
three	O
fractions	O
(	O
900	O
cGy	O
)	O
.	O

Irradiation	O
delivered	O
before	O
implantation	O
(	O
900	O
cGy	O
)	O
inhibited	O
neovascularization	O
significantly	O
less	O
than	O
the	O
same	O
dose	O
administered	O
after	O
implantation	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
a	O
subclinical	O
cumulative	O
dose	O
of	O
900	O
cGy	O
is	O
the	O
threshold	O
for	O
impaired	O
tissue	O
revascularization	O
provided	O
that	O
treatment	O
is	O
delivered	O
immediately	O
after	O
implantation	O
over	O
a	O
48	O
-	O
hour	O
interval	O
.	O

Stimulation	O
of	O
endothelial	O
cell	O
migration	O
by	O
vascular	O
permeability	O
factor	O
/	O
vascular	O
endothelial	O
growth	O
factor	O
through	O
cooperative	O
mechanisms	O
involving	O
the	O
alphavbeta3	O
integrin	O
,	O
osteopontin	O
,	O
and	O
thrombin	O
.	O

We	O
have	O
identified	O
several	O
mechanisms	O
by	O
which	O
the	O
angiogenic	O
cytokine	O
vascular	O
permeability	O
factor	O
/	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VPF	O
/	O
VEGF	O
)	O
likely	O
regulates	O
endothelial	O
cells	O
(	O
EC	O
)	O
migration	O
.	O

VPF	O
/	O
VEGF	O
induced	O
dermal	O
microvascular	O
EC	O
expression	O
of	O
mRNAs	O
encoding	O
the	O
alphav	O
and	O
beta3	O
integrin	O
subunits	O
resulting	O
in	O
increased	O
levels	O
of	O
the	O
alphavbeta3	O
heterodimer	O
at	O
the	O
cell	O
surface	O
,	O
and	O
VPF	O
/	O
VEGF	O
also	O
induced	O
mRNA	O
encoding	O
osteopontin	O
(	O
OPN	O
)	O
,	O
an	O
alphavbeta3	O
ligand	O
.	O

OPN	O
promoted	O
EC	O
migration	O
in	O
vitro	O
;	O
and	O
VPF	O
/	O
VEGF	O
induction	O
of	O
alphavbeta3	O
was	O
accompanied	O
by	O
increased	O
EC	O
migration	O
toward	O
OPN	O
.	O

Because	O
thrombin	O
cleavage	O
of	O
OPN	O
results	O
in	O
substantial	O
enhancement	O
of	O
OPN	O
'	O
s	O
adhesive	O
properties	O
,	O
and	O
because	O
VPF	O
/	O
VEGF	O
promotes	O
increased	O
microvascular	O
permeability	O
leading	O
to	O
activation	O
of	O
the	O
extrinsic	O
coagulation	O
pathway	O
,	O
we	O
also	O
investigated	O
whether	O
VPF	O
/	O
VEGF	O
facilitates	O
thrombin	O
cleavage	O
of	O
OPN	O
in	O
vivo	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
co	O
-	O
injection	O
of	O
VPF	O
/	O
VEGF	O
together	O
with	O
OPN	O
resulted	O
in	O
rapid	O
cleavage	O
of	O
OPN	O
by	O
endogenous	O
thrombin	O
.	O

Furthermore	O
,	O
in	O
comparison	O
with	O
native	O
OPN	O
,	O
thrombin	O
-	O
cleaved	O
OPN	O
stimulated	O
a	O
greater	O
rate	O
of	O
EC	O
migration	O
in	O
vitro	O
,	O
which	O
was	O
additive	O
to	O
the	O
increased	O
migration	O
associated	O
with	O
induction	O
of	O
alpha	O
v	O
beta	O
3	O
.	O

Thus	O
,	O
these	O
data	O
demonstrate	O
cooperative	O
mechanisms	O
for	O
VPF	O
/	O
VEGF	O
regulation	O
of	O
EC	O
migration	O
involving	O
the	O
alphavbeta3	O
integrin	O
,	O
the	O
alphavbeta3	O
ligand	O
OPN	O
,	O
and	O
thrombin	O
cleavage	O
of	O
OPN	O
.	O

These	O
findings	O
also	O
illustrate	O
an	O
operational	O
link	O
between	O
VPF	O
/	O
VEGF	O
induction	O
of	O
EC	O
gene	O
expression	O
and	O
VPF	O
/	O
VEGF	O
enhancement	O
of	O
microvascular	O
permeability	O
,	O
suggesting	O
that	O
these	O
distinct	O
biological	O
activities	O
may	O
act	O
accordingly	O
to	O
stimulate	O
EC	O
migration	O
during	O
angiogenesis	O
.	O

Referral	O
bias	O
among	O
health	O
workers	O
in	O
studies	O
using	O
hospitalization	O
as	O
a	O
proxy	O
measure	O
of	O
the	O
underlying	O
incidence	O
rate	O
.	O

Contacts	O
with	O
health	O
services	O
like	O
hospitals	O
or	O
general	O
practitioners	O
are	O
usually	O
the	O
only	O
available	O
proxy	O
measure	O
of	O
incidence	O
of	O
disease	O
in	O
studies	O
based	O
on	O
secondary	O
data	O
and	O
differential	O
referrals	O
or	O
care	O
-	O
seeking	O
behavior	O
often	O
bias	O
such	O
proxy	O
measures	O
.	O

In	O
former	O
analyses	O
based	O
on	O
the	O
Occupational	O
Hospitalization	O
Register	O
in	O
Denmark	O
assisting	O
nurses	O
had	O
high	O
Standardized	O
Hospitalization	O
Ratios	O
for	O
many	O
diseases	O
.	O

It	O
was	O
,	O
however	O
,	O
suspected	O
that	O
it	O
fully	O
or	O
partly	O
was	O
due	O
to	O
a	O
referral	O
bias	O
or	O
self	O
-	O
selection	O
to	O
hospital	O
treatment	O
rather	O
than	O
exposures	O
to	O
occupational	O
hazards	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
evaluate	O
the	O
referral	O
bias	O
hypothesis	O
by	O
comparing	O
hospitalization	O
and	O
mortality	O
data	O
for	O
health	O
workers	O
for	O
a	O
disease	O
category	O
with	O
a	O
high	O
mortality	O
.	O

Cohorts	O
of	O
all	O
gainfully	O
employed	O
20	O
-	O
to	O
59	O
-	O
year	O
-	O
old	O
Danes	O
were	O
formed	O
in	O
order	O
to	O
compare	O
Standardized	O
Mortality	O
Ratios	O
and	O
Standardized	O
Hospitalization	O
Ratios	O
of	O
ischemic	O
heart	O
disease	O
(	O
IHD	O
)	O
in	O
occupational	O
groups	O
.	O

The	O
follow	O
-	O
up	O
period	O
was	O
10	O
years	O
.	O

For	O
most	O
of	O
the	O
investigated	O
occupational	O
groups	O
a	O
similar	O
disease	O
pattern	O
was	O
found	O
whether	O
hospitalization	O
or	O
death	O
was	O
used	O
as	O
the	O
outcome	O
measure	O
.	O

In	O
""""	O
nurse	O
assistants	O
""""	O
a	O
statistically	O
significant	O
higher	O
risk	O
was	O
,	O
however	O
,	O
found	O
using	O
hospitalization	O
due	O
to	O
IHD	O
as	O
the	O
end	O
point	O
rather	O
than	O
mortality	O
.	O

Additional	O
analysis	O
did	O
not	O
support	O
the	O
hypothesis	O
that	O
the	O
finding	O
could	O
be	O
explained	O
by	O
differentiated	O
hospitalization	O
due	O
to	O
social	O
factors	O
.	O

The	O
true	O
incidence	O
rates	O
of	O
the	O
disease	O
need	O
not	O
be	O
equally	O
well	O
described	O
by	O
proxy	O
measures	O
such	O
as	O
hospitalization	O
diagnosis	O
or	O
death	O
diagnosis	O
in	O
all	O
occupational	O
groups	O
.	O

Differential	O
access	O
to	O
medical	O
treatment	O
in	O
some	O
groups	O
may	O
lead	O
to	O
bias	O
when	O
hospital	O
data	O
are	O
used	O
as	O
proxy	O
measures	O
for	O
the	O
underlying	O
incidence	O
rates	O
.	O

Prognostic	O
value	O
of	O
angiogenesis	O
in	O
operable	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Tumour	O
angiogenesis	O
is	O
an	O
important	O
factor	O
for	O
tumour	O
growth	O
and	O
metastasis	O
.	O

Although	O
some	O
recent	O
reports	O
suggest	O
that	O
microvessel	O
counts	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
are	O
related	O
to	O
a	O
poor	O
disease	O
outcome	O
,	O
the	O
results	O
were	O
not	O
conclusive	O
and	O
were	O
not	O
compared	O
with	O
other	O
molecular	O
prognostic	O
markers	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
vascular	O
grade	O
was	O
assessed	O
in	O
107	O
(	O
T1	O
,	O
2	O
-	O
N0	O
,	O
1	O
)	O
operable	O
non	O
-	O
small	O
cell	O
lung	O
carcinomas	O
,	O
using	O
the	O
JC70	O
monoclonal	O
antibody	O
to	O
CD31	O
.	O

Three	O
vascular	O
grades	O
were	O
defined	O
with	O
appraisal	O
by	O
eye	O
and	O
by	O
Chalkley	O
counting	O
:	O
high	O
(	O
Chalkley	O
score	O
7	O
-	O
12	O
)	O
,	O
medium	O
(	O
5	O
-	O
6	O
)	O
,	O
and	O
low	O
(	O
2	O
-	O
4	O
)	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
eye	O
appraisal	O
and	O
Chalkley	O
counting	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

Vascular	O
grade	O
was	O
not	O
related	O
to	O
histology	O
,	O
grade	O
,	O
proliferation	O
index	O
(	O
Ki67	O
)	O
,	O
or	O
EGFR	O
or	O
p53	O
expression	O
.	O

Tumours	O
from	O
younger	O
patients	O
had	O
a	O
higher	O
grade	O
of	O
angiogenesis	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

Apart	O
from	O
the	O
vascular	O
grade	O
,	O
none	O
of	O
the	O
other	O
factors	O
examined	O
was	O
statistically	O
related	O
to	O
lymph	O
node	O
metastasis	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

A	O
univariate	O
analysis	O
of	O
survival	O
showed	O
that	O
vascular	O
grade	O
was	O
the	O
most	O
significant	O
prognostic	O
factor	O
(	O
P	O
=	O
0	O
.	O
0004	O
)	O
,	O
followed	O
by	O
N	O
-	O
stage	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

In	O
a	O
multivariate	O
analysis	O
,	O
N	O
-	O
stage	O
and	O
vascular	O
grade	O
were	O
not	O
found	O
to	O
be	O
independent	O
prognostic	O
factors	O
,	O
since	O
they	O
were	O
strongly	O
related	O
to	O
each	O
other	O
.	O

Excluding	O
N	O
-	O
stage	O
,	O
vascular	O
grade	O
was	O
the	O
only	O
independent	O
prognostic	O
factor	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O

Kaplan	O
-	O
Meier	O
survival	O
curves	O
showed	O
a	O
statistically	O
significant	O
worse	O
prognosis	O
for	O
patients	O
with	O
high	O
vascular	O
grade	O
,	O
but	O
no	O
difference	O
was	O
observed	O
between	O
low	O
and	O
medium	O
vascular	O
grade	O
.	O

These	O
data	O
suggest	O
that	O
angiogenesis	O
in	O
operable	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
is	O
a	O
major	O
prognostic	O
factor	O
for	O
survival	O
and	O
,	O
among	O
the	O
parameters	O
tested	O
,	O
is	O
the	O
only	O
factor	O
related	O
to	O
cancer	O
cell	O
migration	O
to	O
lymph	O
nodes	O
.	O

The	O
integration	O
of	O
vascular	O
grading	O
in	O
clinical	O
trials	O
on	O
adjuvant	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
could	O
substantially	O
contribute	O
in	O
defining	O
groups	O
of	O
operable	O
patients	O
who	O
might	O
benefit	O
from	O
cytotoxic	O
treatment	O
.	O

The	O
impact	O
of	O
multiskilling	O
on	O
quality	O
of	O
care	O
.	O

Hospital	O
finances	O
in	O
the	O
USA	O
are	O
in	O
a	O
crisis	O
.	O

While	O
profits	O
earned	O
from	O
the	O
healthcare	O
industry	O
appear	O
to	O
be	O
at	O
an	O
all	O
-	O
time	O
high	O
,	O
individual	O
hospitals	O
are	O
going	O
bankrupt	O
.	O

Hospitals	O
are	O
not	O
generating	O
sufficient	O
income	O
to	O
pay	O
their	O
expenses	O
given	O
how	O
they	O
have	O
traditionally	O
operated	O
.	O

Hence	O
,	O
we	O
are	O
witnessing	O
the	O
merger	O
and	O
consolidation	O
of	O
competitors	O
,	O
resulting	O
in	O
significantly	O
fewer	O
hospital	O
beds	O
in	O
certain	O
geographical	O
areas	O
.	O

In	O
addition	O
to	O
the	O
strategy	O
of	O
closing	O
hospital	O
beds	O
,	O
severe	O
budget	O
restrictions	O
are	O
impacting	O
upon	O
all	O
remaining	O
services	O
within	O
the	O
hospitals	O
.	O

Vitamin	O
E	O
inhibits	O
experimental	O
carcinogenesis	O
and	O
tumour	O
angiogenesis	O
.	O

In	O
an	O
experiment	O
in	O
which	O
vitamin	O
E	O
inhibited	O
carcinogenesis	O
,	O
it	O
was	O
found	O
that	O
tumour	O
angiogenesis	O
and	O
tumour	O
growth	O
-	O
factor	O
alpha	O
(	O
TGF	O
alpha	O
)	O
expression	O
were	O
also	O
inhibited	O
.	O

Forty	O
male	O
golden	O
hamsters	O
were	O
divided	O
into	O
four	O
equal	O
groups	O
.	O

Group	O
1	O
animals	O
had	O
the	O
left	O
buccal	O
pouches	O
painted	O
three	O
times	O
weekly	O
with	O
7	O
,	O
12	O
-	O
dimethylbenz	O
(	O
a	O
)	O
anthracene	O
(	O
DMBA	O
)	O
for	O
14	O
weeks	O
.	O

Group	O
2	O
animals	O
had	O
the	O
same	O
procedure	O
of	O
DMBA	O
applications	O
but	O
also	O
received	O
alpha	O
tocopherol	O
.	O

Groups	O
3	O
and	O
4	O
were	O
vitamin	O
E	O
and	O
untreated	O
controls	O
.	O

Angiogenesis	O
was	O
studied	O
with	O
factor	O
8	O
-	O
related	O
antigen	O
(	O
F8	O
-	O
RA	O
)	O
which	O
identifies	O
endothelial	O
cells	O
.	O

TGF	O
alpha	O
was	O
studied	O
with	O
the	O
appropriate	O
antibody	O
.	O

Staining	O
was	O
effected	O
by	O
the	O
standard	O
avidin	O
-	O
biotin	O
horseradish	O
peroxidase	O
system	O
.	O

Mean	O
tumour	O
volume	O
was	O
significantly	O
lower	O
in	O
the	O
DMBA	O
-	O
vitamin	O
E	O
group	O
compared	O
to	O
the	O
tumour	O
control	O
group	O
.	O

Angiogenesis	O
was	O
significantly	O
inhibited	O
in	O
the	O
DMBA	O
-	O
vitamin	O
E	O
group	O
and	O
TGF	O
alpha	O
expression	O
was	O
also	O
inhibited	O
.	O

It	O
is	O
suggested	O
that	O
inhibition	O
of	O
tumour	O
angiogenesis	O
by	O
vitamin	O
E	O
may	O
be	O
an	O
additional	O
mechanism	O
for	O
the	O
anticancer	O
action	O
of	O
vitamin	O
E	O
.	O

Acetaminophen	O
and	O
hepatic	O
dysfunction	O
in	O
infectious	O
mononucleosis	O
.	O

Two	O
family	O
members	O
developed	O
severe	O
hepatitic	O
dysfunction	O
in	O
association	O
with	O
infectious	O
mononucleosis	O
and	O
acetaminophen	O
administration	O
.	O

Since	O
severe	O
hepatitis	O
is	O
an	O
extremely	O
rare	O
complication	O
of	O
infectious	O
mononucleosis	O
,	O
we	O
postulate	O
that	O
the	O
hepatic	O
dysfunction	O
was	O
induced	O
by	O
acetaminophen	O
.	O

Syndecan	O
-	O
1	O
expression	O
in	O
mammary	O
epithelial	O
tumor	O
cells	O
is	O
E	O
-	O
cadherin	O
-	O
dependent	O
.	O

E	O
-	O
cadherin	O
is	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
cell	O
-	O
cell	O
adhesion	O
molecule	O
,	O
which	O
is	O
mainly	O
expressed	O
in	O
epithelial	O
cells	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
E	O
-	O
cadherin	O
has	O
an	O
important	O
role	O
as	O
an	O
invasion	O
suppressor	O
molecule	O
in	O
epithelial	O
tumor	O
cells	O
.	O

Syndecan	O
-	O
1	O
is	O
a	O
cell	O
surface	O
proteoglycan	O
that	O
has	O
been	O
implicated	O
in	O
a	O
number	O
of	O
cellular	O
functions	O
including	O
cell	O
-	O
cell	O
adhesion	O
,	O
cell	O
-	O
matrix	O
anchorage	O
and	O
growth	O
factor	O
presentation	O
for	O
signalling	O
receptors	O
.	O

Its	O
suppression	O
has	O
also	O
been	O
shown	O
to	O
be	O
associated	O
with	O
malignant	O
transformation	O
of	O
epithelial	O
cells	O
.	O

In	O
order	O
to	O
better	O
understand	O
the	O
coordinated	O
regulation	O
of	O
cell	O
-	O
cell	O
and	O
cell	O
-	O
matrix	O
interactions	O
during	O
malignant	O
transformation	O
,	O
we	O
have	O
studied	O
the	O
expression	O
of	O
syndecan	O
-	O
1	O
in	O
malignant	O
mammary	O
tumor	O
cells	O
genetically	O
manipulated	O
for	O
E	O
-	O
cadherin	O
expression	O
.	O

In	O
invasive	O
NM	B
-	I
e	I
-	O
ras	O
-	O
MAC1	O
cells	O
,	O
where	O
E	O
-	O
cadherin	O
was	O
partially	O
downregulated	O
by	O
specific	O
antisense	O
RNA	O
,	O
syndecan	O
-	O
1	O
expression	O
was	O
suppressed	O
.	O

Furthermore	O
,	O
transfection	O
of	O
E	O
-	O
cadherin	O
cDNA	O
into	O
invasive	O
NM	B
-	I
f	I
-	O
ras	O
-	O
TD	O
cells	O
resulted	O
in	O
the	O
upregulation	O
of	O
syndecan	O
-	O
1	O
expression	O
in	O
association	O
with	O
decreased	O
invasiveness	O
.	O

In	O
both	O
cases	O
,	O
regulation	O
of	O
syndecan	O
-	O
1	O
occurred	O
post	O
-	O
transcriptionally	O
,	O
since	O
syndecan	O
-	O
1	O
mRNA	O
levels	O
remained	O
unchanged	O
.	O

Instead	O
,	O
a	O
translational	O
regulation	O
is	O
suggested	O
,	O
since	O
syndecan	O
-	O
1	O
core	O
protein	O
synthesis	O
was	O
E	O
-	O
cadherin	O
dependent	O
.	O

Another	O
cell	O
adhesion	O
protein	O
,	O
beta	O
1	O
-	O
integrin	O
was	O
not	O
affected	O
by	O
E	O
-	O
cadherin	O
expression	O
.	O

The	O
data	O
provide	O
an	O
example	O
of	O
coordinated	O
changes	O
in	O
the	O
expression	O
of	O
two	O
cell	O
adhesion	O
molecules	O
,	O
syndecan	O
-	O
1	O
and	O
E	O
-	O
cadherin	O
during	O
epithelial	O
cell	O
transformation	O
.	O

Curcumin	O
induces	O
apoptosis	O
in	O
immortalized	O
NIH	B
3T3	I
and	O
malignant	O
cancer	O
cell	O
lines	O
.	O

Curcumin	O
,	O
which	O
is	O
a	O
widely	O
used	O
dietary	O
pigment	O
and	O
spice	O
,	O
has	O
been	O
demonstrated	O
to	O
be	O
an	O
effective	O
inhibitor	O
of	O
tumor	O
promotion	O
in	O
mouse	O
skin	O
carcinogenesis	O
.	O

We	O
report	O
that	O
curcumin	O
induces	O
cell	O
shrinkage	O
,	O
chromatin	O
condensation	O
,	O
and	O
DNA	O
fragmentation	O
,	O
characteristics	O
of	O
apoptosis	O
,	O
in	O
immortalized	O
mouse	O
embryo	O
fibroblast	O
NIH	B
3T3	I
erb	O
B2	O
oncogene	O
-	O
transformed	O
NIH	B
3T3	I
,	O
mouse	O
sarcoma	O
S180	B
,	O
human	O
colon	O
cancer	O
cell	O
HT	B
-	I
29	I
,	O
human	O
kidney	O
cancer	O
cell	O
293	B
,	O
and	O
human	O
hepatocellular	O
carcinoma	O
Hep	B
G2	I
cells	O
,	O
but	O
not	O
in	O
primary	O
culture	O
of	O
mouse	O
embryonic	O
fibroblast	O
C3H	B
10T1	I
/	I
2	I
,	O
rat	O
embryonic	O
fibroblast	O
,	O
and	O
human	O
foreskin	O
fibroblast	O
cells	O
in	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Many	O
cellular	O
and	O
biochemical	O
effects	O
of	O
curcumin	O
in	O
mouse	O
fibroblast	O
cells	O
have	O
been	O
reported	O
,	O
such	O
as	O
inhibition	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activity	O
induced	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
treatment	O
,	O
inhibition	O
of	O
tyrosine	O
protein	O
kinase	O
activity	O
,	O
and	O
inhibition	O
of	O
arachidonic	O
acid	O
(	O
AA	O
)	O
metabolism	O
.	O

Treatment	O
of	O
NIH	B
3T3	I
cells	O
with	O
the	O
PKC	O
inhibitor	O
staurosporine	O
,	O
the	O
tyrosine	O
kinase	O
inhibitor	O
herbimycin	O
A	O
,	O
and	O
the	O
AA	O
metabolism	O
inhibitor	O
quinacrine	O
induces	O
apoptotic	O
cell	O
death	O
.	O

These	O
results	O
suggest	O
that	O
,	O
in	O
some	O
immortalized	O
and	O
transformed	O
cells	O
,	O
blocking	O
the	O
cellular	O
signal	O
transduction	O
might	O
trigger	O
the	O
induction	O
of	O
apoptosis	O
.	O

c	O
-	O
erb	O
B2	O
overexpression	O
decreases	O
the	O
benefit	O
of	O
adjuvant	O
tamoxifen	O
in	O
early	O
-	O
stage	O
breast	O
cancer	O
without	O
axillary	O
lymph	O
node	O
metastases	O
.	O

PURPOSE	O
:	O
We	O
studied	O
retrospectively	O
the	O
interaction	O
between	O
c	O
-	O
erbB2	O
overexpression	O
and	O
adjuvant	O
tomoxifen	O
in	O
node	O
-	O
negative	O
breast	O
cancer	O
patients	O
enrolled	O
in	O
the	O
Gruppo	O
Universitario	O
Napoletano	O
1	O
(	O
GUN	O
-	O
1	O
)	O
trial	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
c	O
-	O
erbB2	O
,	O
evaluated	O
by	O
immunohistochemistry	O
in	O
145	O
of	O
173	O
patients	O
randomly	O
assigned	O
to	O
2	O
-	O
year	O
adjuvant	O
tamoxifen	O
or	O
no	O
further	O
therapy	O
,	O
was	O
considered	O
overexpressed	O
if	O
greater	O
than	O
10	O
%	O
of	O
the	O
cells	O
showed	O
specific	O
membrane	O
staining	O
.	O

The	O
role	O
of	O
each	O
prognostic	O
variable	O
and	O
their	O
independent	O
effect	O
were	O
studied	O
using	O
the	O
Cox	O
model	O
.	O

Disease	O
-	O
free	O
(	O
DFS	O
)	O
and	O
overall	O
(	O
OAS	O
)	O
survival	O
curves	O
were	O
estimated	O
by	O
the	O
Kaplan	O
-	O
Meier	O
method	O
.	O

RESULTS	O
:	O
As	O
of	O
November	O
30	O
,	O
1994	O
,	O
the	O
median	O
follow	O
-	O
up	O
period	O
was	O
12	O
years	O
.	O

c	O
-	O
erbB2	O
was	O
overexpressed	O
in	O
43	O
of	O
145	O
patients	O
(	O
29	O
.	O
7	O
%	O
)	O
,	O
which	O
directly	O
correlated	O
with	O
tumor	O
size	O
and	O
inversely	O
with	O
estrogen	O
receptor	O
(	O
ER	O
)	O
level	O
.	O

At	O
univariate	O
analysis	O
,	O
overexpression	O
of	O
c	O
-	O
erbB2	O
did	O
not	O
affect	O
either	O
DFS	O
or	O
OAS	O
;	O
tamoxifen	O
had	O
a	O
greater	O
effect	O
on	O
reducing	O
the	O
risk	O
of	O
recurrence	O
than	O
of	O
death	O
.	O

Addition	O
of	O
c	O
-	O
erbB2	O
to	O
a	O
multivariate	O
Cox	O
model	O
that	O
contained	O
menopausal	O
status	O
,	O
tumor	O
size	O
,	O
nuclear	O
grade	O
,	O
and	O
treatment	O
as	O
covariates	O
did	O
not	O
affect	O
the	O
significance	O
of	O
the	O
model	O
for	O
DSF	O
or	O
OAS	O
,	O
whereas	O
addition	O
of	O
the	O
first	O
-	O
order	O
interaction	O
between	O
c	O
-	O
erbB2	O
and	O
tamoxifen	O
was	O
statistically	O
significant	O
both	O
for	O
DFS	O
and	O
OAS	O
.	O

The	O
same	O
result	O
was	O
obtained	O
when	O
the	O
model	O
contained	O
ER	O
status	O
and	O
ER	O
-	O
tamoxifen	O
interaction	O
.	O

Indeed	O
,	O
adjuvant	O
tamoxifen	O
significantly	O
prolonged	O
DFS	O
and	O
OAS	O
in	O
c	O
-	O
erbB2	O
-	O
negative	O
cases	O
,	O
whereas	O
it	O
had	O
no	O
effect	O
on	O
DFS	O
and	O
OAS	O
in	O
c	O
-	O
erbB2	O
-	O
positive	O
patients	O
.	O

CONCLUSION	O
:	O
In	O
early	O
-	O
stage	O
breast	O
cancer	O
patients	O
,	O
overexpression	O
of	O
c	O
-	O
erbB2	O
is	O
a	O
marker	O
of	O
lack	O
of	O
efficacy	O
of	O
adjuvant	O
tamoxifen	O
.	O

Gene	O
transfer	O
of	O
naked	O
DNA	O
encoding	O
for	O
three	O
isoforms	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
stimulates	O
collateral	O
development	O
in	O
vivo	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
a	O
naturally	O
secreted	O
endothelial	O
cell	O
-	O
specific	O
mitogen	O
.	O

We	O
investigated	O
the	O
hypothesis	O
that	O
naked	O
DNA	O
encoding	O
for	O
VEGF	O
could	O
be	O
used	O
in	O
a	O
strategy	O
of	O
arterial	O
gene	O
therapy	O
to	O
stimulate	O
collateral	O
artery	O
development	O
.	O

Plasmid	O
DNA	O
encoding	O
each	O
of	O
the	O
three	O
principal	O
human	O
VEGF	O
isoforms	O
(	O
phVEGF121	O
,	O
phVEGF165	O
,	O
or	O
phVEGF189	O
)	O
was	O
applied	O
to	O
the	O
hydrogel	O
polymer	O
coating	O
of	O
an	O
angioplasty	O
balloon	O
and	O
delivered	O
percutaneously	O
to	O
one	O
iliac	O
artery	O
of	O
rabbits	O
with	O
operatively	O
induced	O
hindlimb	O
ischemia	O
.	O

Compared	O
with	O
control	O
animals	O
transfected	O
with	O
LacZ	O
,	O
site	O
-	O
specific	O
transfection	O
of	O
phVEGF	O
resulted	O
in	O
augmented	O
collateral	O
vessel	O
development	O
documented	O
by	O
serial	O
angiography	O
,	O
and	O
improvement	O
in	O
calf	O
blood	O
pressure	O
ratio	O
(	O
ischemic	O
to	O
normal	O
limb	O
)	O
,	O
resting	O
and	O
maximum	O
blood	O
flow	O
,	O
and	O
capillary	O
to	O
myocyte	O
ratio	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
phVEGF121	O
,	O
phVEGF165	O
,	O
and	O
phVEGF189	O
,	O
which	O
suggests	O
that	O
these	O
isoforms	O
are	O
biologically	O
equivalent	O
with	O
respect	O
to	O
in	O
vivo	O
angiogenesis	O
.	O

The	O
fact	O
that	O
viral	O
or	O
other	O
adjunctive	O
vectors	O
were	O
not	O
required	O
further	O
suggests	O
that	O
secreted	O
gene	O
products	O
may	O
have	O
potential	O
therapeutic	O
utility	O
even	O
when	O
the	O
number	O
of	O
successfully	O
transfected	O
cells	O
remains	O
low	O
.	O

Arterial	O
gene	O
transfer	O
of	O
naked	O
DNA	O
encoding	O
for	O
a	O
secreted	O
angiogenic	O
cytokine	O
,	O
thus	O
,	O
represents	O
a	O
potential	O
alternative	O
to	O
recombinant	O
protein	O
administration	O
for	O
stimulating	O
collateral	O
vessel	O
development	O
.	O

Metastasis	O
-	O
associated	O
5T4	O
antigen	O
disrupts	O
cell	O
-	O
cell	O
contacts	O
and	O
induces	O
cellular	O
motility	O
in	O
epithelial	O
cells	O
.	O

The	O
5T4	O
antigen	O
is	O
defined	O
by	O
a	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
specific	O
for	O
human	O
trophoblast	O
.	O

It	O
is	O
also	O
expressed	O
by	O
many	O
types	O
of	O
tumour	O
cell	O
and	O
has	O
been	O
associated	O
with	O
metastasis	O
and	O
poor	O
clinical	O
outcome	O
in	O
a	O
number	O
of	O
cancers	O
.	O

This	O
pattern	O
of	O
expression	O
is	O
consistent	O
with	O
a	O
mechanistic	O
involvement	O
of	O
5T4	O
molecules	O
in	O
the	O
spread	O
of	O
cancer	O
cells	O
.	O

The	O
5T4	O
antigen	O
is	O
a	O
transmembrane	O
glycoprotein	O
with	O
a	O
310	O
amino	O
acid	O
extracellular	O
domain	O
and	O
a	O
44	O
amino	O
acid	O
cytoplasmic	O
domain	O
.	O

Transfection	O
of	O
full	O
-	O
length	O
5T4	O
cDNA	O
into	O
epithelial	O
cells	O
alters	O
cell	O
-	O
cell	O
contacts	O
and	O
cellular	O
motility	O
.	O

Thus	O
,	O
in	O
5T4	O
-	O
transfected	O
CL	B
-	I
S1	I
murine	O
mammary	O
cells	O
,	O
5T4	O
expression	O
is	O
associated	O
with	O
dendritic	O
morphology	O
,	O
accompanied	O
by	O
abrogation	O
of	O
actin	O
/	O
cadherin	O
-	O
containing	O
contacts	O
and	O
increased	O
motility	O
.	O

In	O
transfected	O
MDCK	O
canine	O
kidney	O
epithelial	O
cells	O
,	O
5T4	O
over	O
-	O
expression	O
also	O
results	O
in	O
increased	O
motility	O
,	O
but	O
disruption	O
of	O
cell	O
-	O
cell	O
contacts	O
,	O
either	O
by	O
culturing	O
cells	O
in	O
low	O
calcium	O
medium	O
or	O
by	O
addition	O
of	O
HGF	O
/	O
SF	O
,	O
is	O
needed	O
.	O

The	O
effects	O
of	O
5T4	O
expression	O
on	O
morphology	O
and	O
motility	O
are	O
separable	O
since	O
cells	O
transfected	O
with	O
a	O
truncated	O
form	O
of	O
5T4	O
cDNA	O
in	O
which	O
the	O
cytoplasmic	O
domain	O
is	O
deleted	O
reveal	O
that	O
the	O
latter	O
is	O
necessary	O
to	O
abrogate	O
actin	O
/	O
cadherin	O
-	O
containing	O
contacts	O
but	O
does	O
not	O
influence	O
the	O
effects	O
on	O
motility	O
.	O

Thus	O
,	O
5T4	O
molecules	O
can	O
deliver	O
signals	O
through	O
both	O
the	O
extracellular	O
and	O
intracellular	O
domains	O
,	O
and	O
the	O
resultant	O
effects	O
are	O
consistent	O
with	O
a	O
role	O
for	O
5T4	O
molecules	O
in	O
invasion	O
processes	O
.	O

Induction	O
of	O
p18INK4c	O
and	O
its	O
predominant	O
association	O
with	O
CDK4	O
and	O
CDK6	O
during	O
myogenic	O
differentiation	O
.	O

Terminal	O
cell	O
differentiation	O
involves	O
permanent	O
withdrawal	O
from	O
the	O
cell	O
division	O
cycle	O
.	O

The	O
inhibitors	O
of	O
cyclin	O
-	O
dependent	O
kinases	O
(	O
CDKs	O
)	O
are	O
potential	O
molecules	O
functioning	O
to	O
couple	O
cell	O
cycle	O
arrest	O
and	O
cell	O
differentiation	O
.	O

In	O
murine	O
C2C12	B
myoblast	O
cells	O
,	O
G1	O
CDK	O
enzymes	O
(	O
CDK2	O
,	O
CDK4	O
,	O
and	O
CDK6	O
)	O
associate	O
with	O
four	O
CDK	O
inhibitors	O
:	O
p18INK4c	O
,	O
p19INK4d	O
,	O
p21	O
,	O
and	O
p27Kip1	O
.	O

During	O
induced	O
myogenesis	O
,	O
p21	O
and	O
its	O
associated	O
CDK	O
proteins	O
underwent	O
an	O
initial	O
increase	O
followed	O
by	O
a	O
decrease	O
as	O
cells	O
became	O
terminally	O
differentiated	O
.	O

The	O
level	O
of	O
p27	O
protein	O
gradually	O
increased	O
,	O
but	O
the	O
amount	O
of	O
total	O
associated	O
CDK	O
proteins	O
remained	O
unchanged	O
.	O

p19	O
protein	O
decreased	O
gradually	O
during	O
differentiation	O
,	O
as	O
did	O
its	O
associated	O
CDK4	O
protein	O
.	O

In	O
contrast	O
,	O
p18	O
protein	O
increased	O
50	O
-	O
fold	O
,	O
from	O
negligible	O
levels	O
in	O
proliferating	O
myoblasts	O
to	O
clearly	O
detectable	O
levels	O
within	O
8	O
-	O
12	O
h	O
of	O
myogenic	O
induction	O
.	O

This	O
initial	O
rise	O
was	O
followed	O
by	O
a	O
precipitous	O
increase	O
between	O
12	O
and	O
24	O
h	O
postinduction	O
,	O
with	O
p18	O
protein	O
finally	O
accumulating	O
to	O
its	O
highest	O
level	O
in	O
terminally	O
differentiated	O
cells	O
.	O

Induction	O
of	O
p18	O
correlated	O
with	O
increased	O
and	O
sequential	O
complex	O
formation	O
-	O
-	O
first	O
increasing	O
association	O
with	O
CDK6	O
and	O
then	O
with	O
CDK4	O
over	O
the	O
course	O
of	O
myogenic	O
differentiation	O
.	O

All	O
of	O
the	O
CDK6	O
and	O
half	O
of	O
the	O
CDK4	O
were	O
complexed	O
with	O
p18	O
in	O
terminally	O
differentiated	O
C2C12	B
cells	O
as	O
well	O
as	O
in	O
adult	O
mouse	O
muscle	O
tissue	O
.	O

Finally	O
,	O
kinase	O
activity	O
of	O
CDK2	O
and	O
CDK4	O
decreases	O
as	O
C2C12	B
cells	O
differentiate	O
,	O
whereas	O
the	O
CDK6	O
kinase	O
activity	O
is	O
low	O
in	O
both	O
proliferating	O
myoblasts	O
and	O
differentiated	O
myotubes	O
.	O

Our	O
results	O
indicate	O
that	O
p18	O
may	O
play	O
a	O
critical	O
role	O
in	O
causing	O
and	O
/	O
or	O
maintaining	O
permanent	O
cell	O
cycle	O
arrest	O
associated	O
with	O
mature	O
muscle	O
formation	O
.	O

Defective	O
biliary	O
copper	O
excretion	O
in	O
Wilson	O
'	O
s	O
disease	O
:	O
the	O
role	O
of	O
caeruloplasmin	O
.	O

Previous	O
studies	O
have	O
failed	O
to	O
explain	O
the	O
link	O
between	O
copper	O
accumulation	O
and	O
abnormal	O
caeruloplasmin	O
expression	O
in	O
Wilson	O
'	O
s	O
disease	O
.	O

Furthermore	O
,	O
despite	O
the	O
isolation	O
of	O
a	O
candidate	O
gene	O
for	O
Wilson	O
'	O
s	O
disease	O
,	O
which	O
predicts	O
a	O
defective	O
copper	O
transport	O
protein	O
,	O
the	O
localization	O
of	O
this	O
putative	O
protein	O
and	O
its	O
relationship	O
to	O
the	O
pathway	O
involved	O
in	O
copper	O
excretion	O
and	O
to	O
caeruloplasmin	O
remain	O
unknown	O
.	O

We	O
now	O
present	O
evidence	O
that	O
caeruloplasmin	O
,	O
the	O
major	O
plasma	O
copper	O
-	O
carrying	O
protein	O
,	O
is	O
present	O
in	O
the	O
liver	O
in	O
Wilson	O
'	O
s	O
disease	O
,	O
and	O
thus	O
that	O
reduced	O
circulating	O
levels	O
of	O
the	O
protein	O
result	O
from	O
a	O
post	O
-	O
translational	O
defect	O
in	O
the	O
secretory	O
pathway	O
.	O

We	O
have	O
also	O
identified	O
a	O
novel	O
form	O
of	O
caeruloplasmin	O
,	O
molecular	O
weight	O
125	O
kD	O
,	O
which	O
we	O
propose	O
may	O
act	O
as	O
the	O
carrier	O
for	O
excretory	O
copper	O
into	O
bile	O
,	O
since	O
it	O
is	O
normally	O
present	O
in	O
both	O
liver	O
and	O
bile	O
,	O
although	O
largely	O
absent	O
from	O
serum	O
,	O
and	O
undetectable	O
in	O
bile	O
from	O
Wilson	O
'	O
s	O
disease	O
patients	O
.	O

The	O
presence	O
of	O
this	O
form	O
of	O
caeruloplasmin	O
in	O
Wilson	O
'	O
s	O
disease	O
liver	O
suggests	O
that	O
a	O
related	O
post	O
-	O
translational	O
defect	O
may	O
also	O
be	O
responsible	O
for	O
its	O
absence	O
from	O
bile	O
in	O
Wilson	O
'	O
s	O
disease	O
.	O

This	O
study	O
thus	O
provides	O
the	O
first	O
plausible	O
explanation	O
of	O
a	O
link	O
between	O
the	O
defective	O
copper	O
excretion	O
and	O
the	O
reduced	O
plasma	O
caeruloplasmin	O
,	O
which	O
characterize	O
Wilson	O
'	O
s	O
disease	O
.	O

Functional	O
model	O
of	O
benign	O
paroxysmal	O
positional	O
vertigo	O
using	O
an	O
isolated	O
frog	O
semicircular	O
canal	O
.	O

Bull	O
frogs	O
posterior	O
semicircular	O
canals	O
(	O
psc	O
)	O
wee	O
used	O
to	O
simulate	O
the	O
condition	O
of	O
benign	O
paroxysmal	O
positional	O
vertigo	O
(	O
BPPV	O
)	O
.	O

The	O
psc	O
was	O
isolated	O
in	O
frog	O
Ringer	O
'	O
s	O
solution	O
,	O
and	O
the	O
saccular	O
otoconia	O
were	O
used	O
as	O
a	O
responsible	O
material	O
to	O
stimulate	O
the	O
cupula	O
.	O

When	O
the	O
otoconia	O
were	O
placed	O
on	O
the	O
cupular	O
surface	O
to	O
mimic	O
the	O
condition	O
of	O
cupulolithiasis	O
,	O
the	O
psc	O
ampullary	O
nerve	O
action	O
potentials	O
instantaneously	O
changed	O
according	O
to	O
the	O
direction	O
of	O
the	O
gravity	O
produced	O
by	O
otoconia	O
.	O

When	O
the	O
otoconia	O
were	O
dropped	O
into	O
the	O
canal	O
to	O
mimic	O
the	O
condition	O
of	O
moving	O
otoconia	O
in	O
the	O
canal	O
,	O
the	O
action	O
potentials	O
changed	O
together	O
with	O
the	O
otoconial	O
flow	O
after	O
a	O
latent	O
period	O
.	O

Both	O
cupulolithiasis	O
and	O
moving	O
otoconia	O
are	O
possibly	O
valid	O
mechanisms	O
of	O
BPPV	O
,	O
since	O
they	O
effectively	O
stimulate	O
the	O
cupula	O
.	O

However	O
,	O
moving	O
otoconia	O
with	O
a	O
latent	O
period	O
would	O
better	O
explain	O
clinical	O
features	O
of	O
BPPV	O
.	O

Do	O
we	O
know	O
how	O
much	O
people	O
like	O
one	O
another	O
?	O

Metaperception	O
is	O
a	O
person	O
'	O
s	O
perception	O
about	O
a	O
second	O
person	O
'	O
s	O
perception	O
of	O
a	O
third	O
person	O
.	O

The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
examine	O
the	O
accuracy	O
of	O
metaperceptions	O
of	O
liking	O
.	O

A	O
related	O
question	O
concerns	O
whether	O
the	O
heuristics	O
of	O
balance	O
,	O
reciprocity	O
,	O
and	O
agreement	O
are	O
used	O
by	O
perceivers	O
when	O
forming	O
such	O
judgments	O
.	O

The	O
authors	O
present	O
analyses	O
from	O
5	O
diverse	O
research	O
studies	O
that	O
used	O
an	O
adaptation	O
of	O
the	O
social	O
relations	O
model	O
for	O
triads	O
(	O
C	O
.	O
F	O
.	O
Bond	O
,	O
E	O
.	O
M	O
.	O
Horn	O
,	O
&	O
D	O
.	O
A	O
.	O
Kenny	O
,	O
in	O
press	O
)	O
.	O

The	O
results	O
indicate	O
that	O
people	O
know	O
how	O
much	O
people	O
like	O
one	O
another	O
,	O
even	O
with	O
small	O
amounts	O
of	O
information	O
.	O

Although	O
there	O
is	O
evidence	O
for	O
the	O
use	O
of	O
heuristics	O
,	O
particularly	O
reciprocity	O
and	O
agreement	O
,	O
accuracy	O
is	O
sometimes	O
enhanced	O
by	O
using	O
these	O
heuristics	O
.	O

Genetic	O
heterogeneity	O
evidenced	O
by	O
low	O
incidence	O
of	O
KAL	O
-	O
1	O
gene	O
mutations	O
in	O
sporadic	O
cases	O
of	O
gonadotropin	O
-	O
releasing	O
hormone	O
deficiency	O
.	O

Isolated	O
GnRH	O
deficiency	O
is	O
a	O
heritable	O
condition	O
characterized	O
by	O
a	O
functional	O
deficit	O
in	O
GnRH	O
secretion	O
.	O

Familial	O
cases	O
with	O
different	O
modes	O
of	O
inheritance	O
have	O
been	O
described	O
,	O
and	O
the	O
gene	O
responsible	O
for	O
the	O
X	O
-	O
linked	O
form	O
(	O
KAL	O
-	O
1	O
)	O
has	O
been	O
identified	O
.	O

However	O
,	O
sporadic	O
cases	O
with	O
no	O
documented	O
family	O
history	O
of	O
GnRH	O
deficiency	O
account	O
for	O
the	O
majority	O
of	O
the	O
affected	O
patients	O
.	O

For	O
this	O
reason	O
,	O
we	O
sought	O
to	O
determine	O
the	O
frequency	O
with	O
which	O
KAL	O
-	O
1	O
gene	O
mutations	O
occur	O
in	O
patients	O
with	O
sporadic	O
GnRH	O
deficiency	O
.	O

Only	O
1	O
of	O
21	O
patients	O
with	O
sporadic	O
GnRH	O
deficiency	O
was	O
found	O
to	O
bear	O
a	O
defect	O
in	O
the	O
KAL	O
-	O
1	O
gene	O
(	O
a	O
deletion	O
of	O
14	O
bases	O
starting	O
at	O
codon	O
464	O
)	O
.	O

Three	O
types	O
of	O
polymorphic	O
single	O
base	O
substitutions	O
with	O
no	O
apparent	O
correlation	O
with	O
GnRH	O
deficiency	O
were	O
also	O
detected	O
in	O
several	O
patients	O
.	O

In	O
each	O
of	O
3	O
different	O
patients	O
with	O
an	O
X	O
-	O
linked	O
mode	O
of	O
inheritance	O
,	O
3	O
genetic	O
defects	O
,	O
2	O
point	O
mutations	O
and	O
a	O
small	O
intragenic	O
deletion	O
,	O
were	O
detected	O
.	O

These	O
defects	O
consist	O
of	O
a	O
single	O
base	O
mutation	O
introducing	O
a	O
stop	O
codon	O
at	O
position	O
328	O
,	O
a	O
single	O
base	O
mutation	O
resulting	O
in	O
a	O
phenylalanine	O
to	O
leucine	O
substitution	O
at	O
position	O
517	O
,	O
and	O
a	O
9	O
-	O
base	O
deletion	O
at	O
the	O
3	O
'	O
-	O
exon	O
-	O
intron	O
splice	O
site	O
of	O
exon	O
8	O
,	O
respectively	O
.	O

All	O
identified	O
genetic	O
defects	O
occur	O
within	O
the	O
fibronectin	O
type	O
III	O
repeats	O
of	O
the	O
predicted	O
protein	O
encoded	O
by	O
the	O
KAL	O
-	O
1	O
gene	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
indicates	O
that	O
the	O
incidence	O
of	O
genetic	O
defects	O
within	O
the	O
coding	O
region	O
of	O
the	O
KAL	O
-	O
1	O
gene	O
in	O
patients	O
with	O
sporadic	O
GnRH	O
deficiency	O
is	O
low	O
(	O
5	O
-	O
8	O
%	O
)	O
,	O
thus	O
supporting	O
the	O
idea	O
that	O
the	O
X	O
-	O
linked	O
form	O
of	O
inheritance	O
represents	O
the	O
least	O
common	O
form	O
of	O
the	O
disease	O
.	O

[	O
Considerations	O
regarding	O
two	O
cases	O
of	O
macromastia	O
(	O
author	O
'	O
s	O
transl	O
)	O
]	O
.	O

Two	O
cases	O
of	O
macromastia	O
have	O
been	O
shown	O
;	O
one	O
which	O
appeared	O
during	O
puberty	O
,	O
the	O
other	O
during	O
menopause	O
.	O

Histopathological	O
examination	O
has	O
demonstrated	O
for	O
the	O
both	O
cases	O
a	O
cystic	O
degeneracy	O
of	O
the	O
glandular	O
tissue	O
with	O
a	O
hyperplazia	O
and	O
hypertrophy	O
of	O
the	O
conjunctive	O
tissue	O
.	O

The	O
pathogeny	O
of	O
macromastia	O
is	O
being	O
discussed	O
and	O
it	O
is	O
demonstrated	O
both	O
the	O
role	O
of	O
hypophysis	O
hormones	O
(	O
prolactine	O
and	O
growth	O
hormone	O
)	O
and	O
of	O
ovarian	O
hormones	O
(	O
estrogens	O
)	O
.	O

The	O
treatment	O
was	O
surgical	O
for	O
the	O
both	O
cases	O
.	O

The	O
effect	O
of	O
early	O
diagnosis	O
and	O
treatment	O
in	O
cystic	O
fibrosis	O
:	O
a	O
seven	O
-	O
year	O
study	O
of	O
16	O
sibling	O
pairs	O
.	O

Data	O
on	O
16	O
sibling	O
pairs	O
with	O
cystic	O
fibrosis	O
were	O
analyzed	O
to	O
test	O
the	O
hypothesis	O
that	O
early	O
treatment	O
of	O
this	O
condition	O
improves	O
prognosis	O
.	O

Younger	O
siblings	O
'	O
conditions	O
were	O
diagnosed	O
before	O
1	O
year	O
of	O
age	O
,	O
usually	O
before	O
the	O
onset	O
of	O
pulmonary	O
disease	O
.	O

Older	O
siblings	O
'	O
conditions	O
were	O
diagnosed	O
after	O
1	O
year	O
of	O
age	O
and	O
after	O
the	O
onset	O
of	O
pulmonary	O
disease	O
.	O

Although	O
the	O
sibling	O
pairs	O
received	O
similar	O
treatment	O
,	O
comparison	O
at	O
7	O
years	O
of	O
age	O
showed	O
that	O
the	O
younger	O
siblings	O
had	O
significantly	O
better	O
chest	O
roentgenogram	O
scores	O
,	O
total	O
clinical	O
scores	O
,	O
residual	O
lung	O
volumes	O
,	O
and	O
ratios	O
of	O
residual	O
volume	O
to	O
total	O
lung	O
volume	O
.	O

Younger	O
siblings	O
also	O
required	O
fewer	O
hospital	O
admissions	O
to	O
control	O
their	O
lung	O
disease	O
.	O

The	O
results	O
suggest	O
that	O
,	O
in	O
general	O
,	O
early	O
initiation	O
of	O
therapy	O
is	O
beneficial	O
for	O
patients	O
with	O
cystic	O
fibrosis	O
.	O

Comparison	O
of	O
transformation	O
by	O
manganese	O
sulfate	O
and	O
5	O
-	O
azacytidine	O
in	O
Rat	B
6	I
cells	O
overexpressing	O
the	O
c	O
-	O
myc	O
oncogene	O
.	O

Rat	B
6	I
cells	O
are	O
not	O
transformed	O
by	O
treatment	O
with	O
the	O
well	O
-	O
known	O
carcinogens	O
benzo	O
[	O
a	O
]	O
pyrene	O
(	O
BP	O
)	O
or	O
N	O
-	O
methyl	O
-	O
N	O
-	O
nitro	O
-	O
N	O
'	O
-	O
nitrosoguanidine	O
(	O
MNNG	O
)	O
.	O

Upon	O
retroviral	O
transduction	O
of	O
the	O
mouse	O
c	O
-	O
myc	O
gene	O
,	O
Rat	B
6	I
cells	O
showed	O
mildly	O
altered	O
morphology	O
and	O
formed	O
microcolonies	O
in	O
soft	O
agar	O
;	O
furthermore	O
,	O
they	O
could	O
be	O
transformed	O
by	O
BP	O
and	O
MNNG	O
to	O
form	O
large	O
colonies	O
in	O
agar	O
(	O
Hsiao	O
et	O
al	O
.	O
(	O
1992	O
)	O
Mol	O
.	O
Carcinogenesis	O
,	O
5	O
,	O
140	O
-	O
154	O
)	O
.	O

In	O
the	O
current	O
report	O
,	O
we	O
tested	O
the	O
sensitivity	O
of	O
the	O
c	O
-	O
myc	O
-	O
overexpressing	O
cells	O
(	O
Rat	B
6	I
/	O
c	O
-	O
myc	O
)	O
to	O
two	O
additional	O
chemicals	O
:	O
5	O
-	O
azacytidine	O
and	O
MnSO4	O
.	O

These	O
chemicals	O
differ	O
from	O
the	O
direct	O
-	O
acting	O
mutagens	O
tested	O
previously	O
.	O

5	O
-	O
Azacytidine	O
,	O
a	O
potent	O
DNA	O
methylation	O
inhibitor	O
,	O
induced	O
growth	O
of	O
large	O
colonies	O
in	O
soft	O
agar	O
cultures	O
of	O
Rat	B
6	I
or	O
Rat	B
6	I
/	O
c	O
-	O
myc	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
MnSO4	O
only	O
induced	O
transformation	O
in	O
Rat	B
6	I
/	O
c	O
-	O
myc	O
cells	O
,	O
but	O
not	O
the	O
parental	O
Rat	B
6	I
cells	O
.	O

Transformants	O
induced	O
by	O
5	O
-	O
azacytidine	O
lost	O
c	O
-	O
myc	O
-	O
induced	O
apoptotic	O
cell	O
death	O
,	O
whereas	O
MnSO4	O
-	O
induced	O
transformants	O
showed	O
a	O
higher	O
degree	O
of	O
apoptosis	O
than	O
the	O
parental	O
Rat	B
6	I
/	O
c	O
-	O
myc	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
MnSO4	O
co	O
-	O
operates	O
with	O
overexpressed	O
c	O
-	O
myc	O
in	O
inducing	O
transformation	O
,	O
while	O
5	O
-	O
azacytidine	O
transformation	O
is	O
independent	O
of	O
c	O
-	O
myc	O
overexpression	O
and	O
may	O
involve	O
alterations	O
in	O
the	O
regulation	O
of	O
apoptosis	O
.	O

Fas	O
-	O
signaling	O
and	O
effects	O
on	O
receptor	O
tyrosine	O
kinase	O
signal	O
transduction	O
in	O
human	O
breast	O
epithelial	O
cells	O
.	O

Fas	O
-	O
mediated	O
cell	O
death	O
was	O
examined	O
in	O
MCF	B
-	I
10AT	I
preneoplastic	O
human	O
breast	O
epithelial	O
cells	O
.	O

Treatment	O
with	O
anti	O
-	O
Fas	O
for	O
48	O
h	O
induced	O
apoptosis	O
with	O
cells	O
exhibiting	O
typical	O
apoptotic	O
features	O
including	O
loss	O
of	O
cell	O
contact	O
,	O
condensation	O
of	O
chromatin	O
,	O
and	O
increased	O
staining	O
of	O
the	O
nuclear	O
membrane	O
.	O

DNA	O
fragmentation	O
occurred	O
in	O
response	O
to	O
anti	O
-	O
Fas	O
treatment	O
.	O

Anti	O
-	O
Fas	O
treatment	O
resulted	O
in	O
decreased	O
p53	O
protein	O
levels	O
,	O
while	O
bcl	O
-	O
2	O
and	O
bax	O
protein	O
levels	O
remained	O
unaffected	O
.	O

Cells	O
treated	O
with	O
anti	O
-	O
Fas	O
also	O
exhibited	O
increased	O
tyrosine	O
phosphorylation	O
of	O
the	O
c	O
-	O
met	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
.	O

Immunoprecipitation	O
experiments	O
demonstrated	O
that	O
Fas	O
associated	O
with	O
c	O
-	O
erbB2	O
and	O
c	O
-	O
met	O
in	O
untreated	O
cells	O
.	O

Treatment	O
with	O
anti	O
-	O
Fas	O
,	O
however	O
,	O
significantly	O
decreased	O
Fas	O
-	O
c	O
-	O
erbB2	O
and	O
Fas	O
-	O
c	O
-	O
met	O
association	O
.	O

Anti	O
-	O
Fas	O
treatment	O
of	O
these	O
cells	O
caused	O
a	O
significant	O
decrease	O
in	O
p120	O
-	O
GAP	O
levels	O
,	O
ERK	O
-	O
1	O
levels	O
,	O
and	O
phosphorylation	O
,	O
as	O
well	O
as	O
Grb2	O
-	O
Sosl	O
and	O
MEK	O
-	O
1	O
-	O
ERK	O
-	O
1	O
association	O
.	O

These	O
results	O
show	O
that	O
Fas	O
-	O
signaling	O
exerted	O
a	O
suppressive	O
effect	O
on	O
p53	O
levels	O
and	O
on	O
downstream	O
effectors	O
of	O
receptor	O
tyrosine	O
kinase	O
signal	O
transduction	O
,	O
thereby	O
ensuring	O
cell	O
death	O
.	O

Prevention	O
of	O
hepatic	O
tumor	O
metastases	O
in	O
rats	O
with	O
herpes	O
viral	O
vaccines	O
and	O
gamma	O
-	O
interferon	O
.	O

Previous	O
studies	O
showed	O
that	O
gammaIFN	O
decreases	O
metastatic	O
hepatic	O
tumor	O
growth	O
by	O
stimulating	O
Kupffer	O
cells	O
(	O
KC	O
)	O
.	O

The	O
present	O
studies	O
examine	O
whether	O
lymphocyte	O
stimulation	O
via	O
cells	O
engineered	O
to	O
secrete	O
GM	O
-	O
CSF	O
or	O
IL	O
-	O
2	O
decreases	O
hepatic	O
tumor	O
growth	O
,	O
and	O
whether	O
stimulation	O
of	O
both	O
macrophages	O
and	O
lymphocytes	O
is	O
more	O
effective	O
than	O
either	O
individually	O
.	O

Rats	O
were	O
immunized	O
with	O
irradiated	O
hepatoma	O
cells	O
transduced	O
by	O
herpes	O
viral	O
amplicon	O
vectors	O
containing	O
the	O
genes	O
for	O
GM	O
-	O
CSF	O
,	O
IL	O
-	O
2	O
or	O
LacZ	O
.	O

On	O
day	O
18	O
,	O
half	O
of	O
each	O
group	O
was	O
treated	O
with	O
5	O
x	O
10	O
(	O
4	O
)	O
U	O
gammaIFN	O
,	O
or	O
saline	O
intraperitoneally	O
for	O
3	O
d	O
.	O

On	O
day	O
21	O
,	O
all	O
rats	O
received	O
5	O
x	O
10	O
(	O
5	O
)	O
hepatoma	O
cells	O
intrasplenically	O
.	O

On	O
day	O
41	O
,	O
rats	O
were	O
killed	O
and	O
tumor	O
nodules	O
were	O
counted	O
.	O

Separate	O
rats	O
underwent	O
splenocyte	O
and	O
KC	O
harvest	O
for	O
assessment	O
of	O
lymphocyte	O
-	O
and	O
macrophage	O
-	O
mediated	O
tumor	O
cell	O
kill	O
in	O
vitro	O
.	O

GM	O
-	O
CSF	O
or	O
IL	O
-	O
2	O
vaccines	O
or	O
gammaIFN	O
decreased	O
tumor	O
nodules	O
significantly	O
(	O
GM	O
-	O
CSF	O
13	O
+	O
/	O
-	O
4	O
,	O
IL	O
-	O
2	O
14	O
+	O
/	O
-	O
6	O
vs	O
.	O
control	O
75	O
+	O
/	O
-	O
24	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Combination	O
therapy	O
was	O
more	O
effective	O
,	O
and	O
completely	O
eliminated	O
tumor	O
in	O
4	O
of	O
12	O
IFN	O
-	O
GM	O
-	O
CSF	O
and	O
8	O
of	O
11	O
IFN	O
-	O
IL	O
-	O
2	O
animals	O
.	O

Additional	O
rats	O
underwent	O
partial	O
hepatectomy	O
,	O
an	O
immunosuppressive	O
procedure	O
known	O
to	O
accelerate	O
the	O
growth	O
of	O
hepatic	O
tumor	O
,	O
following	O
tumor	O
challenge	O
.	O

Therapy	O
was	O
equally	O
effective	O
in	O
this	O
immunosuppressive	O
setting	O
.	O

Vaccination	O
is	O
associated	O
with	O
enhancement	O
of	O
splenocyte	O
-	O
mediated	O
tumoricidal	O
activity	O
,	O
whereas	O
the	O
effect	O
of	O
gammaIFN	O
is	O
mediated	O
by	O
KC	O
.	O

GM	O
-	O
CSF	O
and	O
IL	O
-	O
2	O
vaccine	O
therapy	O
and	O
pretreatment	O
with	O
gammaIFN	O
represent	O
effective	O
strategies	O
in	O
reducing	O
hepatic	O
tumor	O
.	O

Combination	O
therapy	O
targets	O
both	O
lymphocytes	O
and	O
macrophages	O
,	O
and	O
is	O
more	O
effective	O
in	O
reducing	O
tumor	O
than	O
either	O
therapy	O
alone	O
.	O

[	O
Effects	O
of	O
carcinostatic	O
agents	O
in	O
the	O
hematogenous	O
metastasis	O
of	O
cancer	O
]	O
.	O

The	O
experimental	O
studies	O
in	O
vitro	O
and	O
in	O
vivo	O
were	O
performed	O
to	O
investigate	O
the	O
effects	O
of	O
carcinostatic	O
agents	O
in	O
the	O
adhesion	O
of	O
cancer	O
cells	O
to	O
endothelial	O
cells	O
.	O

Certain	O
carcinostatic	O
agents	O
induce	O
the	O
expression	O
of	O
E	O
-	O
selectin	O
on	O
endothelial	O
cells	O
and	O
enhance	O
the	O
expression	O
of	O
carbohydrate	O
ligands	O
on	O
cancer	O
cells	O
.	O

Consequently	O
,	O
increased	O
adhesion	O
of	O
cancer	O
cells	O
to	O
endothelial	O
cells	O
was	O
observed	O
by	O
the	O
treatment	O
of	O
carcinostatic	O
agents	O
.	O

In	O
the	O
trans	O
-	O
splenic	O
hepatic	O
metastasis	O
model	O
using	O
nude	O
mice	O
,	O
the	O
augmentation	O
of	O
cancer	O
metastasis	O
was	O
observed	O
by	O
the	O
treatment	O
of	O
carcinostatic	O
agents	O
.	O

From	O
the	O
above	O
,	O
we	O
concluded	O
that	O
carcinostatic	O
agents	O
may	O
increase	O
the	O
metastatic	O
ability	O
of	O
cancer	O
cells	O
in	O
patients	O
with	O
cancer	O
.	O

Procedural	O
memory	O
stimulation	O
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
impact	O
of	O
a	O
training	O
programme	O
.	O

The	O
study	O
evaluates	O
the	O
efficacy	O
of	O
a	O
procedural	O
memory	O
stimulation	O
programme	O
in	O
mild	O
and	O
mild	O
-	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O

Twenty	O
basic	O
and	O
instrumental	O
activities	O
of	O
daily	O
living	O
have	O
been	O
selected	O
,	O
and	O
divided	O
into	O
two	O
groups	O
,	O
comparable	O
for	O
difficulty	O
.	O

Ten	O
normal	O
elderly	O
subjects	O
(	O
age	O
68	O
.	O
0	O
+	O
/	O
-	O
4	O
.	O
8	O
years	O
;	O
MMSE	O
score	O
:	O
28	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
9	O
;	O
education	O
:	O
7	O
.	O
6	O
+	O
/	O
-	O
3	O
.	O
5	O
years	O
)	O
were	O
asked	O
to	O
perform	O
the	O
two	O
groups	O
of	O
daily	O
activities	O
and	O
the	O
time	O
required	O
to	O
perform	O
the	O
tasks	O
of	O
each	O
group	O
was	O
recorded	O
and	O
used	O
as	O
a	O
reference	O
.	O

Ten	O
mild	O
and	O
mild	O
-	O
moderate	O
AD	O
patients	O
(	O
age	O
77	O
.	O
2	O
+	O
/	O
-	O
5	O
.	O
3	O
years	O
;	O
MMSE	O
score	O
:	O
19	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
5	O
;	O
education	O
:	O
7	O
.	O
3	O
+	O
/	O
-	O
4	O
.	O
7	O
years	O
)	O
without	O
major	O
behavioural	O
disturbances	O
constituted	O
the	O
experimental	O
group	O
.	O

Patients	O
were	O
evaluated	O
in	O
all	O
20	O
daily	O
activities	O
and	O
the	O
time	O
employed	O
was	O
recorded	O
at	O
baseline	O
and	O
after	O
a	O
3	O
-	O
week	O
training	O
(	O
1	O
h	O
/	O
d	O
,	O
5	O
d	O
/	O
week	O
)	O
period	O
.	O

Five	O
patients	O
were	O
trained	O
during	O
the	O
3	O
weeks	O
on	O
half	O
of	O
the	O
20	O
daily	O
activities	O
and	O
the	O
other	O
five	O
patients	O
were	O
trained	O
on	O
the	O
remainder	O
.	O

This	O
procedure	O
was	O
adopted	O
in	O
order	O
to	O
detect	O
separately	O
the	O
improvement	O
in	O
""""	O
trained	O
""""	O
and	O
""""	O
not	O
trained	O
""""	O
activities	O
,	O
allowing	O
to	O
control	O
better	O
the	O
effects	O
of	O
the	O
intervention	O
.	O

The	O
assessment	O
of	O
the	O
functional	O
impact	O
of	O
the	O
training	O
was	O
directly	O
measured	O
,	O
through	O
the	O
variation	O
of	O
time	O
employed	O
to	O
perform	O
tasks	O
before	O
and	O
after	O
training	O
.	O

After	O
3	O
weeks	O
of	O
training	O
a	O
significant	O
improvement	O
was	O
observed	O
for	O
the	O
trained	O
activities	O
,	O
from	O
3	O
.	O
6	O
to	O
1	O
.	O
9	O
standard	O
deviations	O
below	O
the	O
performance	O
of	O
the	O
normal	O
elderly	O
controls	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

AD	O
patients	O
improved	O
also	O
in	O
not	O
-	O
trained	O
activities	O
from	O
3	O
.	O
5	O
to	O
2	O
.	O
7	O
standard	O
deviations	O
below	O
the	O
controls	O
'	O
performance	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
rehabilitation	O
of	O
activities	O
of	O
daily	O
living	O
through	O
developing	O
procedural	O
memory	O
strategies	O
may	O
be	O
effective	O
in	O
mild	O
and	O
mild	O
-	O
moderate	O
AD	O
patients	O
.	O

Regulation	O
of	O
p53	O
-	O
dependent	O
apoptosis	O
,	O
transcriptional	O
repression	O
,	O
and	O
cell	O
transformation	O
by	O
phosphorylation	O
of	O
the	O
55	O
-	O
kilodalton	O
E1B	O
protein	O
of	O
human	O
adenovirus	O
type	O
5	O
.	O

The	O
adenovirus	O
type	O
5	O
55	O
-	O
kDa	O
E1B	O
protein	O
(	O
E1B	O
-	O
55kDa	O
)	O
cooperates	O
with	O
E1A	O
gene	O
products	O
to	O
induce	O
cell	O
transformation	O
.	O

E1A	O
proteins	O
stimulate	O
DNA	O
synthesis	O
and	O
cell	O
proliferation	O
;	O
however	O
,	O
they	O
also	O
cause	O
rapid	O
cell	O
death	O
by	O
p53	O
-	O
dependent	O
and	O
p53	O
-	O
independent	O
apoptosis	O
.	O

It	O
is	O
believed	O
that	O
the	O
role	O
of	O
the	O
E1B	O
-	O
55kDa	O
protein	O
in	O
transformation	O
is	O
to	O
protect	O
against	O
p53	O
-	O
dependent	O
apoptosis	O
by	O
binding	O
to	O
and	O
inactivating	O
p53	O
.	O

It	O
has	O
been	O
shown	O
previously	O
that	O
the	O
55	O
-	O
kDa	O
polypeptide	O
abrogates	O
p53	O
-	O
mediated	O
transactivation	O
and	O
that	O
mutants	O
defective	O
in	O
p53	O
binding	O
are	O
unable	O
to	O
cooperate	O
with	O
E1A	O
in	O
transformation	O
.	O

We	O
have	O
previously	O
mapped	O
phosphorylation	O
sites	O
near	O
the	O
carboxy	O
terminus	O
of	O
the	O
E1B	O
-	O
55kDa	O
protein	O
at	O
Ser	O
-	O
490	O
and	O
Ser	O
-	O
491	O
,	O
which	O
lie	O
within	O
casein	O
kinase	O
II	O
consensus	O
sequences	O
.	O

Conversion	O
of	O
these	O
sites	O
to	O
alanine	O
residues	O
greatly	O
reduced	O
transforming	O
activity	O
,	O
and	O
although	O
the	O
mutant	O
55	O
-	O
kDa	O
protein	O
was	O
found	O
to	O
interact	O
with	O
p53	O
at	O
normal	O
levels	O
,	O
it	O
was	O
somewhat	O
defective	O
for	O
suppression	O
of	O
p53	O
transactivation	O
activity	O
.	O

We	O
now	O
report	O
that	O
a	O
nearby	O
residue	O
,	O
Thr	O
-	O
495	O
,	O
also	O
appears	O
to	O
be	O
phosphorylated	O
.	O

We	O
demonstrate	O
directly	O
that	O
the	O
wild	O
-	O
type	O
55	O
-	O
kDa	O
protein	O
is	O
able	O
to	O
block	O
E1A	O
-	O
induced	O
p53	O
-	O
dependent	O
apoptosis	O
,	O
whereas	O
cells	O
infected	O
by	O
mutant	O
pm490	O
/	O
1	O
/	O
5A	O
,	O
which	O
contains	O
alanine	O
residues	O
at	O
all	O
three	O
phosphorylation	O
sites	O
,	O
exhibited	O
extensive	O
DNA	O
fragmentation	O
and	O
classic	O
apoptotic	O
cell	O
death	O
.	O

The	O
E1B	O
-	O
55kDa	O
product	O
has	O
been	O
shown	O
to	O
exhibit	O
intrinsic	O
transcriptional	O
repression	O
activity	O
when	O
localized	O
to	O
promoters	O
,	O
such	O
as	O
by	O
fusion	O
with	O
the	O
GAL4	O
DNA	O
-	O
binding	O
domain	O
,	O
even	O
in	O
the	O
absence	O
of	O
p53	O
.	O

Such	O
repression	O
activity	O
was	O
totally	O
absent	O
with	O
mutant	O
pm490	O
/	O
1	O
/	O
5A	O
.	O

These	O
data	O
suggested	O
that	O
inhibition	O
of	O
p53	O
-	O
dependent	O
apoptosis	O
may	O
depend	O
on	O
the	O
transcriptional	O
repression	O
function	O
of	O
the	O
55	O
-	O
kDa	O
protein	O
,	O
which	O
appears	O
to	O
be	O
regulated	O
be	O
phosphorylation	O
at	O
the	O
carboxy	O
terminus	O
.	O

Non	O
-	O
invasive	O
grading	O
of	O
primary	O
brain	O
tumours	O
:	O
results	O
of	O
a	O
comparative	O
study	O
between	O
SPET	O
with	O
123I	O
-	O
alpha	O
-	O
methyl	O
tyrosine	O
and	O
PET	O
with	O
18F	O
-	O
deoxyglucose	O
.	O

Use	O
of	O
iodine	O
-	O
123	O
-	O
alpha	O
-	O
methyl	O
tyrosine	O
(	O
123I	O
-	O
IMT	O
)	O
allows	O
investigation	O
of	O
the	O
amino	O
acid	O
transport	O
rate	O
in	O
gliomas	O
.	O

It	O
was	O
the	O
aim	O
of	O
this	O
study	O
to	O
compare	O
the	O
value	O
of	O
measurement	O
of	O
glucose	O
metabolism	O
with	O
that	O
of	O
measurement	O
of	O
123I	O
-	O
IMT	O
uptake	O
for	O
the	O
non	O
-	O
invasive	O
grading	O
of	O
brain	O
tumours	O
.	O

The	O
study	O
population	O
comprised	O
23	O
patients	O
with	O
histopathologically	O
proven	O
primary	O
brain	O
tumours	O
;	O
14	O
had	O
high	O
-	O
grade	O
gliomas	O
,	O
and	O
nine	O
low	O
-	O
grade	O
brain	O
neoplasms	O
.	O

Glucose	O
metabolism	O
was	O
studied	O
using	O
an	O
ECAT	O
EXACT	O
47	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
camera	O
and	O
fluorine	O
-	O
18	O
fluorodeoxyglucose	O
(	O
18F	O
-	O
FDG	O
)	O
;	O
123I	O
-	O
IMT	O
uptake	O
was	O
measured	O
with	O
the	O
triple	O
-	O
headed	O
single	O
-	O
photon	O
emission	O
tomography	O
(	O
SPET	O
)	O
camera	O
,	O
MULTISPECT	O
3	O
.	O

18F	O
-	O
FDG	O
and	O
123I	O
-	O
IMT	O
uptake	O
was	O
quantified	O
as	O
ratios	O
between	O
the	O
uptake	O
by	O
the	O
tumour	O
and	O
contralateral	O
regions	O
of	O
reference	O
.	O

Glucose	O
metabolism	O
and	O
amino	O
acid	O
uptake	O
of	O
the	O
brain	O
tumours	O
correlated	O
significantly	O
(	O
r	O
=	O
0	O
.	O
71	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Assuming	O
discrimination	O
thresholds	O
between	O
high	O
-	O
grade	O
and	O
low	O
-	O
grade	O
tumours	O
of	O
0	O
.	O
8	O
for	O
18F	O
-	O
FDG	O
uptake	O
and	O
1	O
.	O
8	O
for	O
123I	O
-	O
IMT	O
uptake	O
,	O
the	O
accuracy	O
values	O
of	O
18F	O
-	O
FDG	O
PET	O
and	O
123I	O
-	O
IMT	O
SPET	O
for	O
differentiating	O
between	O
high	O
-	O
grade	O
and	O
low	O
-	O
grade	O
tumours	O
were	O
21	O
/	O
23	O
(	O
91	O
%	O
)	O
and	O
19	O
/	O
23	O
(	O
83	O
%	O
)	O
,	O
respectively	O
.	O

The	O
difference	O
in	O
diagnostic	O
performance	O
was	O
not	O
significant	O
on	O
receiver	O
operating	O
characteristic	O
analysis	O
(	O
P	O
>	O
0	O
.	O
4	O
)	O
.	O

It	O
is	O
concluded	O
that	O
there	O
is	O
no	O
major	O
difference	O
between	O
the	O
PET	O
investigation	O
of	O
glucose	O
metabolism	O
and	O
the	O
less	O
expensive	O
SPET	O
measurement	O
of	O
amino	O
acid	O
uptake	O
in	O
terms	O
of	O
their	O
accuracy	O
in	O
evaluating	O
the	O
malignancy	O
grade	O
of	O
primary	O
brain	O
tumours	O
.	O

This	O
encourages	O
the	O
performance	O
of	O
further	O
studies	O
to	O
analyse	O
the	O
potential	O
impact	O
of	O
123I	O
-	O
IMT	O
SPET	O
on	O
the	O
therapeutic	O
management	O
of	O
patients	O
with	O
brain	O
tumours	O
.	O

Some	O
findings	O
concerning	O
beliefs	O
about	O
alcoholism	O
.	O

The	O
beliefs	O
that	O
alcoholics	O
hold	O
about	O
alcoholism	O
and	O
themselves	O
,	O
and	O
the	O
beliefs	O
that	O
hospital	O
staff	O
and	O
other	O
personnel	O
hold	O
about	O
alcoholism	O
,	O
were	O
investigated	O
using	O
methods	O
derived	O
from	O
the	O
repertory	O
grid	O
,	O
with	O
anonymous	O
facial	O
photographs	O
as	O
elements	O
.	O

Data	O
are	O
presented	O
as	O
to	O
the	O
degree	O
of	O
association	O
of	O
various	O
characteristics	O
with	O
alcoholism	O
for	O
the	O
various	O
groups	O
.	O

Differences	O
between	O
groups	O
,	O
and	O
overall	O
changes	O
during	O
group	O
psychotherapy	O
for	O
patients	O
were	O
small	O
.	O

The	O
relative	O
contribution	O
of	O
personal	O
and	O
shared	O
aspects	O
of	O
belief	O
was	O
measured	O
.	O

It	O
was	O
found	O
that	O
the	O
agreement	O
between	O
groups	O
was	O
high	O
and	O
closely	O
similar	O
to	O
that	O
predictable	O
from	O
consistencies	O
within	O
groups	O
.	O

It	O
is	O
concluded	O
that	O
there	O
may	O
be	O
a	O
very	O
general	O
stereotype	O
of	O
alcoholism	O
,	O
consistent	O
with	O
a	O
personality	O
disorder	O
concept	O
which	O
is	O
implicitly	O
held	O
even	O
in	O
the	O
face	O
of	O
nominal	O
acceptance	O
of	O
other	O
concepts	O
.	O

The	O
self	O
constructs	O
of	O
alcoholics	O
were	O
found	O
to	O
be	O
complex	O
.	O

In	O
a	O
small	O
follow	O
-	O
up	O
study	O
of	O
patients	O
,	O
there	O
was	O
found	O
to	O
be	O
a	O
relationship	O
of	O
poor	O
outcome	O
with	O
tightness	O
of	O
construing	O
for	O
key	O
constructs	O
after	O
psychotherapy	O
.	O

The	O
implications	O
of	O
the	O
findings	O
are	O
discussed	O
briefly	O
.	O

The	O
effects	O
of	O
oxidative	O
stress	O
on	O
in	O
vivo	O
brain	O
GSH	O
turnover	O
in	O
young	O
and	O
mature	O
mice	O
.	O

Glutathione	O
(	O
GSH	O
)	O
synthetase	O
activities	O
and	O
GSH	O
turnover	O
rates	O
were	O
examined	O
during	O
severe	O
oxidative	O
stress	O
in	O
the	O
mouse	O
brain	O
as	O
induced	O
by	O
t	O
-	O
butylhydroperoxide	O
(	O
t	O
-	O
BuOOH	O
)	O
.	O

Brain	O
GSH	O
synthetase	O
activities	O
in	O
8	O
-	O
mo	O
-	O
old	O
mice	O
in	O
the	O
cortex	O
,	O
striatum	O
,	O
thalamus	O
,	O
hippocampus	O
,	O
midbrain	O
,	O
and	O
cerebellum	O
were	O
found	O
to	O
increase	O
following	O
t	O
-	O
BuOOH	O
treatment	O
.	O

The	O
effect	O
of	O
GSH	O
synthesis	O
on	O
brain	O
GSH	O
turnover	O
rates	O
for	O
2	O
-	O
and	O
8	O
-	O
mo	O
-	O
old	O
mice	O
were	O
determined	O
after	O
intracerebroventricular	O
(	O
icv	O
)	O
injection	O
of	O
[	O
35S	O
]	O
cysteine	O
.	O

Rate	O
constants	O
for	O
GSH	O
turnover	O
were	O
determined	O
by	O
least	O
-	O
squares	O
iterative	O
minimization	O
from	O
the	O
specific	O
activity	O
data	O
from	O
20	O
min	O
to	O
108	O
h	O
after	O
[	O
35S	O
]	O
cysteine	O
administration	O
.	O

GSH	O
and	O
glutathione	O
disulfide	O
(	O
GSSG	O
)	O
specific	O
activities	O
were	O
determined	O
after	O
separation	O
by	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
.	O

The	O
half	O
-	O
life	O
of	O
GSH	O
in	O
the	O
2	O
-	O
mo	O
-	O
old	O
mouse	O
was	O
59	O
.	O
5	O
h	O
and	O
in	O
the	O
8	O
-	O
mo	O
-	O
old	O
mouse	O
was	O
79	O
.	O
1	O
h	O
.	O

In	O
summary	O
,	O
defense	O
mechanisms	O
against	O
oxidative	O
stress	O
in	O
the	O
brain	O
differ	O
with	O
age	O
.	O

Young	O
mice	O
can	O
increase	O
the	O
cellular	O
availability	O
of	O
GSH	O
,	O
whereas	O
mature	O
mice	O
can	O
increase	O
GSH	O
synthetase	O
activity	O
during	O
oxidative	O
stress	O
.	O

These	O
differences	O
make	O
mature	O
mice	O
more	O
susceptible	O
to	O
brain	O
oxidative	O
damage	O
.	O

Changes	O
in	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
levels	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Increased	O
urokinase	O
plasminogen	O
activator	O
(	O
uPA	O
)	O
levels	O
are	O
increased	O
in	O
a	O
number	O
of	O
malignancies	O
and	O
have	O
been	O
correlated	O
with	O
decreased	O
disease	O
-	O
free	O
interval	O
and	O
decreased	O
overall	O
survival	O
.	O

We	O
have	O
,	O
therefore	O
,	O
examined	O
components	O
of	O
this	O
plasminogen	O
activating	O
system	O
in	O
patients	O
with	O
Non	O
-	O
Small	O
Cell	O
Lung	O
Cancer	O
(	O
NSCLC	O
)	O
.	O

Levels	O
of	O
uPA	O
,	O
urokinase	O
-	O
plasminogen	O
activator	O
receptor	O
(	O
uPAR	O
)	O
and	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
were	O
measured	O
semiquantitatively	O
in	O
paraffin	O
sections	O
of	O
tumours	O
from	O
147	O
patients	O
with	O
NSCLC	O
.	O

Immunohistochemically	O
stained	O
sections	O
of	O
tumour	O
were	O
allocated	O
a	O
score	O
for	O
stain	O
intensity	O
and	O
results	O
correlated	O
to	O
:	O
survival	O
;	O
tumour	O
stage	O
(	O
T	O
)	O
;	O
nodal	O
stage	O
(	O
N	O
)	O
;	O
stage	O
grouping	O
(	O
I	O
to	O
IIIb	O
)	O
,	O
survival	O
status	O
and	O
sex	O
.	O

Increased	O
levels	O
of	O
PAI	O
-	O
1	O
were	O
associated	O
with	O
a	O
decreased	O
survival	O
in	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
X2	O
=	O
5	O
.	O
72	O
,	O
p	O
=	O
0	O
.	O
017	O
(	O
n	O
=	O
74	O
)	O
.	O

There	O
was	O
a	O
significant	O
positive	O
relationship	O
between	O
PAI	O
-	O
1	O
levels	O
and	O
N	O
-	O
stage	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
,	O
presence	O
of	O
nodal	O
metastases	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
,	O
stage	O
grouping	O
(	O
p	O
=	O
<	O
0	O
.	O
01	O
)	O
and	O
extent	O
of	O
disease	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
total	O
group	O
and	O
the	O
SCC	O
subgroup	O
,	O
but	O
not	O
adenocarcinoma	O
.	O

There	O
was	O
a	O
significant	O
positive	O
relationship	O
between	O
PAI	O
-	O
1	O
levels	O
and	O
T	O
-	O
stage	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
total	O
group	O
,	O
and	O
survival	O
status	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
SCC	O
subgroup	O
alone	O
.	O

uPA	O
and	O
uPAR	O
levels	O
were	O
not	O
significantly	O
associated	O
with	O
tumour	O
staging	O
or	O
survival	O
.	O

We	O
conclude	O
that	O
increased	O
PAI	O
-	O
1	O
antigen	O
levels	O
may	O
be	O
associated	O
with	O
a	O
decreased	O
survival	O
in	O
patients	O
with	O
SCC	O
.	O

Insulin	O
-	O
like	O
growth	O
factor	O
I	O
induces	O
tumor	O
hexokinase	O
RNA	O
expression	O
in	O
cancer	O
cells	O
.	O

Increased	O
glycolysis	O
is	O
a	O
characteristic	O
of	O
cancer	O
cells	O
.	O

Though	O
less	O
efficient	O
in	O
energy	O
production	O
,	O
it	O
ensures	O
continuous	O
supply	O
of	O
energy	O
and	O
phosphometabolites	O
for	O
biosynthesis	O
enabling	O
metastatic	O
and	O
less	O
vascularized	O
cancer	O
cells	O
to	O
proliferate	O
even	O
under	O
hypoxic	O
conditions	O
.	O

Since	O
hexokinase	O
is	O
the	O
first	O
rate	O
limiting	O
enzyme	O
in	O
the	O
glycolytic	O
pathway	O
,	O
elevated	O
levels	O
of	O
Type	O
II	O
like	O
hexokinase	O
in	O
tumors	O
are	O
of	O
great	O
significance	O
in	O
this	O
context	O
.	O

Under	O
normal	O
conditions	O
insulin	O
regulates	O
expression	O
of	O
hexokinase	O
Type	O
II	O
isoenzyme	O
,	O
which	O
is	O
predominantly	O
expressed	O
in	O
muscle	O
.	O

On	O
the	O
other	O
hand	O
cancer	O
cells	O
overexpress	O
insulin	O
-	O
like	O
growth	O
factors	O
and	O
their	O
receptors	O
which	O
mimic	O
many	O
activities	O
of	O
insulin	O
.	O

This	O
prompted	O
us	O
to	O
examine	O
a	O
hypothesis	O
that	O
insulin	O
-	O
like	O
growth	O
factors	O
may	O
be	O
responsible	O
for	O
overexpression	O
of	O
tumor	O
hexokinase	O
.	O

Our	O
experiments	O
demonstrate	O
that	O
insulin	O
-	O
like	O
growth	O
factor	O
I	O
indeed	O
induces	O
hexokinase	O
gene	O
expression	O
in	O
a	O
concentration	O
and	O
time	O
dependent	O
manner	O
in	O
two	O
cancer	O
cell	O
lines	O
we	O
studied	O
.	O

The	O
Wilms	O
tumor	O
suppressor	O
gene	O
WT1	O
induces	O
G1	O
arrest	O
and	O
apoptosis	O
in	O
myeloblastic	O
leukemia	O
M1	B
cells	O
.	O

WT1	O
was	O
isolated	O
as	O
a	O
tumor	O
suppressor	O
gene	O
of	O
Wilms	O
tumor	O
.	O

However	O
,	O
high	O
expression	O
of	O
WT1	O
correlates	O
with	O
poor	O
prognosis	O
in	O
acute	O
leukemia	O
.	O

In	O
addition	O
suppression	O
of	O
WT1	O
expression	O
by	O
WT1	O
anti	O
-	O
sense	O
oligonucleotide	O
inhibits	O
proliferation	O
of	O
leukemia	O
cells	O
,	O
suggesting	O
that	O
WT1	O
is	O
important	O
for	O
their	O
proliferation	O
.	O

To	O
further	O
elucidate	O
the	O
biological	O
significance	O
of	O
WT1	O
in	O
leukemic	O
cell	O
growth	O
,	O
we	O
overexpressed	O
exogenous	O
WT1	O
in	O
murine	O
M1	B
myeloblastic	O
leukemia	O
cells	O
using	O
the	O
isopropyl	O
-	O
beta	O
-	O
D	O
-	O
thiogalactoside	O
(	O
IPTG	O
)	O
-	O
controlled	O
expression	O
system	O
.	O

We	O
found	O
that	O
induction	O
of	O
one	O
splicing	O
variant	O
of	O
WT1	O
[	O
WT1	O
-	O
17AA	O
(	O
+	O
)	O
-	O
KTS	O
(	O
-	O
)	O
]	O
in	O
M1	B
cells	O
induces	O
cell	O
cycle	O
arrest	O
and	O
apoptotic	O
cell	O
death	O
.	O

These	O
results	O
suggest	O
that	O
the	O
role	O
of	O
WT1	O
is	O
different	O
depending	O
on	O
the	O
type	O
of	O
leukemia	O
cell	O
in	O
which	O
it	O
is	O
expressed	O
.	O

[	O
Expression	O
of	O
metastasis	O
suppressor	O
gene	O
nm23	O
in	O
human	O
hepatocellular	O
carcinoma	O
]	O
.	O

For	O
the	O
purpose	O
of	O
investigating	O
the	O
relationship	O
between	O
the	O
metastatic	O
potential	O
of	O
the	O
tumor	O
as	O
well	O
as	O
the	O
expression	O
of	O
nm23	O
-	O
H1	O
mRNA	O
,	O
and	O
for	O
determing	O
the	O
location	O
of	O
the	O
positive	O
sites	O
in	O
the	O
cells	O
,	O
tumor	O
metastasis	O
suppressor	O
gene	O
nm23	O
-	O
H1	O
in	O
human	O
hepatocellular	O
carcinoma	O
(	O
and	O
the	O
nonneoplastic	O
area	O
surrounding	O
the	O
tumor	O
)	O
was	O
detected	O
by	O
in	O
situ	O
hybridization	O
using	O
digoxiginin	O
-	O
labeled	O
nm23	O
-	O
H1	O
antisense	O
complementary	O
RNA	O
probe	O
.	O

The	O
primary	O
results	O
indicated	O
(	O
i	O
)	O
positive	O
results	O
of	O
in	O
situ	O
hybridization	O
are	O
presence	O
of	O
granules	O
or	O
masses	O
in	O
the	O
cytoplasm	O
;	O
(	O
ii	O
)	O
the	O
less	O
expression	O
of	O
nm23	O
-	O
H1	O
mRNA	O
,	O
the	O
higher	O
metastatic	O
rate	O
of	O
the	O
human	O
hepatocellular	O
carcinoma	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
(	O
iii	O
)	O
expression	O
of	O
nm23	O
-	O
H1	O
mRNA	O
dose	O
not	O
correlate	O
with	O
some	O
other	O
factors	O
such	O
as	O
tumor	O
size	O
and	O
the	O
background	O
of	O
other	O
liver	O
diseases	O
.	O

Monitoring	O
the	O
efficiency	O
of	O
interferon	O
-	O
alpha	O
therapy	O
in	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
patients	O
by	O
competitive	O
polymerase	O
chain	O
reaction	O
.	O

Interferon	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
induces	O
cytogenetic	O
responses	O
of	O
variable	O
degree	O
in	O
patients	O
with	O
CML	O
.	O

We	O
sought	O
to	O
establish	O
the	O
relationship	O
between	O
BCR	O
-	O
ABL	O
transcript	O
numbers	O
measured	O
by	O
competitive	O
two	O
-	O
step	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
cytogenetic	O
status	O
in	O
CML	O
patients	O
treated	O
with	O
IFN	O
-	O
alpha	O
.	O

All	O
398	O
samples	O
from	O
163	O
patients	O
investigated	O
by	O
RT	O
-	O
PCR	O
were	O
positive	O
for	O
BCR	O
-	O
ABL	O
transcripts	O
.	O

In	O
order	O
to	O
standardize	O
results	O
for	O
variability	O
in	O
RNA	O
and	O
cDNA	O
quality	O
,	O
we	O
quantified	O
total	O
ABL	O
transcripts	O
in	O
each	O
sample	O
as	O
internal	O
control	O
.	O

The	O
BCR	O
-	O
ABL	O
/	O
ABL	O
ratios	O
correlated	O
with	O
the	O
cytogenetic	O
results	O
.	O

Quantitative	O
nested	O
PCR	O
allowed	O
the	O
detection	O
of	O
residual	O
BCR	O
-	O
ABL	O
transcripts	O
in	O
all	O
complete	O
cytogenetic	O
responders	O
on	O
IFN	O
-	O
alpha	O
.	O

We	O
conclude	O
that	O
competitive	O
PCR	O
with	O
internal	O
controls	O
is	O
a	O
reliable	O
method	O
for	O
monitoring	O
patients	O
on	O
IFN	O
-	O
alpha	O
and	O
reduces	O
the	O
need	O
for	O
repeated	O
marrow	O
investigations	O
.	O

Suppression	O
of	O
tumor	O
growth	O
by	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
mel	O
-	O
18	O
in	O
3Y1	B
cells	O
transformed	O
by	O
the	O
E6	O
and	O
E7	O
genes	O
of	O
human	O
papillomavirus	O
type	O
18	O
.	O

By	O
introducing	O
a	O
cDNA	O
library	O
derived	O
from	O
rat	O
embryonic	O
fibroblast	O
cells	O
,	O
we	O
isolated	O
several	O
morphologically	O
flat	O
revertants	O
of	O
rat	O
3Y1	B
cells	O
transformed	O
by	O
the	O
E6	O
and	O
E7	O
genes	O
of	O
human	O
papillomavirus	O
type	O
18	O
(	O
HPV18	O
)	O
.	O

From	O
one	O
of	O
the	O
revertants	O
,	O
we	O
recovered	O
a	O
0	O
.	O
2	O
-	O
kb	O
cDNA	O
,	O
N56	O
,	O
that	O
suppresses	O
the	O
tumor	O
growth	O
of	O
the	O
transformed	O
3Y1	B
cells	O
irrespective	O
of	O
the	O
expression	O
of	O
the	O
E6	O
and	O
E7	O
genes	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
cDNA	O
was	O
shown	O
to	O
be	O
identical	O
to	O
that	O
of	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
a	O
putative	O
mammalian	O
polycomb	O
group	O
gene	O
,	O
mel	O
-	O
18	O
.	O

[	O
Treatment	O
of	O
acute	O
liver	O
failure	O
in	O
children	O
]	O
.	O

Among	O
the	O
main	O
causes	O
of	O
acute	O
liver	O
failure	O
(	O
ALF	O
)	O
in	O
children	O
,	O
metabolic	O
diseases	O
(	O
especially	O
in	O
infants	O
)	O
,	O
viral	O
and	O
toxin	O
or	O
drug	O
induced	O
hepatitis	O
are	O
the	O
most	O
frequent	O
.	O

The	O
cause	O
remains	O
,	O
however	O
,	O
undetermined	O
in	O
about	O
30	O
%	O
of	O
the	O
cases	O
.	O

Management	O
must	O
be	O
conducted	O
in	O
a	O
pediatric	O
hepatology	O
unit	O
or	O
intensive	O
care	O
unit	O
in	O
relation	O
with	O
a	O
pediatric	O
transplant	O
team	O
in	O
order	O
:	O
1	O
)	O
to	O
perform	O
urgent	O
etiological	O
diagnosis	O
;	O
2	O
)	O
to	O
initiate	O
specific	O
therapy	O
and	O
symptomatic	O
treatment	O
;	O
3	O
)	O
to	O
evaluate	O
the	O
severity	O
and	O
prognosis	O
of	O
liver	O
disease	O
for	O
selection	O
of	O
children	O
for	O
emergency	O
liver	O
transplantation	O
;	O
4	O
)	O
to	O
evaluate	O
contraindications	O
to	O
liver	O
transplantation	O
.	O

The	O
overall	O
survival	O
of	O
post	O
-	O
emergency	O
liver	O
transplantation	O
for	O
ALF	O
in	O
children	O
averages	O
65	O
%	O
.	O

Blind	O
separation	O
of	O
auditory	O
event	O
-	O
related	O
brain	O
responses	O
into	O
independent	O
components	O
.	O

Averaged	O
event	O
-	O
related	O
potential	O
(	O
ERP	O
)	O
data	O
recorded	O
from	O
the	O
human	O
scalp	O
reveal	O
electroencephalographic	O
(	O
EEG	O
)	O
activity	O
that	O
is	O
reliably	O
time	O
-	O
locked	O
and	O
phase	O
-	O
locked	O
to	O
experimental	O
events	O
.	O

We	O
report	O
here	O
the	O
application	O
of	O
a	O
method	O
based	O
on	O
information	O
theory	O
that	O
decomposes	O
one	O
or	O
more	O
ERPs	O
recorded	O
at	O
multiple	O
scalp	O
sensors	O
into	O
a	O
sum	O
of	O
components	O
with	O
fixed	O
scalp	O
distributions	O
and	O
sparsely	O
activated	O
,	O
maximally	O
independent	O
time	O
courses	O
.	O

Independent	O
component	O
analysis	O
(	O
ICA	O
)	O
decomposes	O
ERP	O
data	O
into	O
a	O
number	O
of	O
components	O
equal	O
to	O
the	O
number	O
of	O
sensors	O
.	O

The	O
derived	O
components	O
have	O
distinct	O
but	O
not	O
necessarily	O
orthogonal	O
scalp	O
projections	O
.	O

Unlike	O
dipole	O
-	O
fitting	O
methods	O
,	O
the	O
algorithm	O
does	O
not	O
model	O
the	O
locations	O
of	O
their	O
generators	O
in	O
the	O
head	O
.	O

Unlike	O
methods	O
that	O
remove	O
second	O
-	O
order	O
correlations	O
,	O
such	O
as	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
,	O
ICA	O
also	O
minimizes	O
higher	O
-	O
order	O
dependencies	O
.	O

Applied	O
to	O
detected	O
-	O
and	O
undetected	O
-	O
target	O
ERPs	O
from	O
an	O
auditory	O
vigilance	O
experiment	O
,	O
the	O
algorithm	O
derived	O
ten	O
components	O
that	O
decomposed	O
each	O
of	O
the	O
major	O
response	O
peaks	O
into	O
one	O
or	O
more	O
ICA	O
components	O
with	O
relatively	O
simple	O
scalp	O
distributions	O
.	O

Three	O
of	O
these	O
components	O
were	O
active	O
only	O
when	O
the	O
subject	O
detected	O
the	O
targets	O
,	O
three	O
other	O
components	O
only	O
when	O
the	O
target	O
went	O
undetected	O
,	O
and	O
one	O
in	O
both	O
cases	O
.	O

Three	O
additional	O
components	O
accounted	O
for	O
the	O
steady	O
-	O
state	O
brain	O
response	O
to	O
a	O
39	O
-	O
Hz	O
background	O
click	O
train	O
.	O

Major	O
features	O
of	O
the	O
decomposition	O
proved	O
robust	O
across	O
sessions	O
and	O
changes	O
in	O
sensor	O
number	O
and	O
placement	O
.	O

This	O
method	O
of	O
ERP	O
analysis	O
can	O
be	O
used	O
to	O
compare	O
responses	O
from	O
multiple	O
stimuli	O
,	O
task	O
conditions	O
,	O
and	O
subject	O
states	O
.	O

CD56	O
+	O
putative	O
natural	O
killer	O
cell	O
lymphomas	O
:	O
production	O
of	O
cytolytic	O
effectors	O
and	O
related	O
proteins	O
mediating	O
tumor	O
cell	O
apoptosis	O
?	O

Apoptosis	O
is	O
a	O
regulated	O
form	O
of	O
cell	O
death	O
that	O
may	O
be	O
triggered	O
by	O
natural	O
killer	O
(	O
NK	O
)	O
or	O
cytotoxic	O
T	O
cells	O
,	O
which	O
effect	O
target	O
cell	O
lysis	O
by	O
cytolytic	O
effector	O
and	O
related	O
proteins	O
through	O
complex	O
intracellular	O
signals	O
.	O

This	O
study	O
was	O
aimed	O
to	O
investigate	O
whether	O
there	O
is	O
selective	O
expression	O
of	O
these	O
cytolytic	O
markers	O
in	O
the	O
putative	O
NK	O
-	O
cell	O
lymphomas	O
and	O
whether	O
there	O
is	O
correlation	O
with	O
zonal	O
tumor	O
cell	O
death	O
in	O
these	O
tumors	O
.	O

Expression	O
of	O
the	O
cytolytic	O
effectors	O
perforin	O
,	O
granzyme	O
B9	O
,	O
and	O
the	O
granule	O
membrane	O
protein	O
TIA1	O
were	O
examined	O
in	O
24	O
putative	O
NK	O
-	O
cell	O
lymphomas	O
,	O
18	O
postthymic	O
T	O
-	O
cell	O
lymphomas	O
(	O
one	O
case	O
CD8	O
+	O
CD56	O
+	O
and	O
three	O
anaplastic	O
large	O
cell	O
lymphomas	O
(	O
ALCL	O
)	O
,	O
three	O
T	O
-	O
lymphoblastic	O
lymphomas	O
,	O
and	O
20	O
B	O
-	O
cell	O
lymphomas	O
.	O

Nineteen	O
(	O
79	O
%	O
)	O
putative	O
NK	O
-	O
cell	O
lymphomas	O
expressed	O
perforin	O
,	O
and	O
all	O
24	O
cases	O
expressed	O
granzyme	O
B9	O
and	O
TIA1	O
.	O

The	O
only	O
CD8	O
+	O
CD56	O
+	O
postthymic	O
T	O
-	O
cell	O
lymphoma	O
also	O
expressed	O
all	O
three	O
cytolytic	O
markers	O
,	O
two	O
CD8	O
-	O
ALCL	O
expressed	O
TIA1	O
;	O
other	O
postthymic	O
T	O
-	O
cell	O
,	O
T	O
-	O
lymphoblastic	O
,	O
and	O
B	O
-	O
cell	O
lymphomas	O
were	O
consistently	O
negative	O
.	O

There	O
was	O
strong	O
correlation	O
between	O
percentage	O
perforin	O
-	O
positive	O
cells	O
and	O
zonal	O
tumor	O
cell	O
death	O
.	O

Angioinvasion	O
,	O
in	O
contrast	O
,	O
was	O
present	O
only	O
in	O
a	O
proportion	O
(	O
37	O
%	O
)	O
of	O
these	O
lymphomas	O
despite	O
the	O
frequent	O
presence	O
of	O
zonal	O
tumor	O
cell	O
death	O
(	O
71	O
%	O
)	O
.	O

We	O
propose	O
that	O
cytolytic	O
effector	O
and	O
related	O
proteins	O
produced	O
by	O
putative	O
NK	O
and	O
some	O
CD8	O
+	O
CD56	O
+	O
postthymic	O
T	O
-	O
cell	O
lymphomas	O
,	O
probably	O
in	O
conjunction	O
with	O
other	O
mechanisms	O
,	O
may	O
effect	O
massive	O
tumor	O
cell	O
apoptosis	O
.	O

The	O
frequent	O
expression	O
of	O
cytolytic	O
effector	O
markers	O
in	O
the	O
CD2	O
+	O
surface	O
CD3	O
-	O
CD56	O
+	O
putative	O
NK	O
-	O
cell	O
lymphomas	O
lends	O
further	O
support	O
to	O
their	O
probable	O
NK	O
cell	O
origin	O
.	O

Calretinin	O
.	O

A	O
selective	O
marker	O
of	O
normal	O
and	O
neoplastic	O
mesothelial	O
cells	O
in	O
serous	O
effusions	O
.	O

OBJECTIVE	O
:	O
To	O
document	O
that	O
a	O
polyclonal	O
antiserum	O
to	O
calretinin	O
,	O
a	O
29	O
-	O
kd	O
calcium	O
-	O
binding	O
protein	O
,	O
consistently	O
decorates	O
normal	O
and	O
tumor	O
mesothelial	O
cells	O
in	O
cytologic	O
preparations	O
.	O

STUDY	O
DESIGN	O
:	O
Thirty	O
-	O
three	O
archival	O
cytologic	O
specimens	O
from	O
eight	O
patients	O
with	O
histologically	O
confirmed	O
malignant	O
mesothelioma	O
and	O
13	O
from	O
patients	O
with	O
metastatic	O
serous	O
effusions	O
were	O
destained	O
and	O
then	O
immunostained	O
with	O
anticalretinin	O
antiserum	O
.	O

For	O
investigation	O
of	O
cell	O
suspensions	O
,	O
four	O
pleural	O
fluids	O
were	O
incubated	O
with	O
anticalretinin	O
antiserum	O
.	O

After	O
cytocentrifugation	O
the	O
specimens	O
were	O
stained	O
in	O
accordance	O
with	O
the	O
alkaline	O
phosphatase	O
anti	O
-	O
alkaline	O
phosphatase	O
(	O
APAAP	O
)	O
method	O
.	O

For	O
electron	O
microscopic	O
examination	O
the	O
cell	O
suspensions	O
were	O
then	O
incubated	O
with	O
gold	O
-	O
labeled	O
antirabbit	O
antibody	O
.	O

RESULTS	O
:	O
The	O
diagnostic	O
sensitivity	O
of	O
this	O
new	O
immunocytochemical	O
approach	O
reached	O
100	O
%	O
for	O
the	O
eight	O
malignant	O
mesotheliomas	O
investigated	O
.	O

Only	O
3	O
of	O
the	O
13	O
adenocarcinomas	O
metastatic	O
to	O
the	O
serous	O
membranes	O
included	O
in	O
this	O
study	O
were	O
weakly	O
reactive	O
,	O
accounting	O
for	O
81	O
%	O
specificity	O
.	O

Binding	O
of	O
anticalretinin	O
antiserum	O
to	O
living	O
mesothelial	O
cells	O
was	O
consistently	O
documented	O
in	O
all	O
four	O
cases	O
investigated	O
.	O

CONCLUSION	O
:	O
Calretinin	O
is	O
a	O
very	O
useful	O
marker	O
for	O
positive	O
identification	O
of	O
normal	O
and	O
tumor	O
mesothelial	O
cells	O
in	O
serous	O
effusions	O
.	O

[	O
Extra	O
-	O
anatomic	O
bypass	O
from	O
the	O
ascending	O
aorta	O
to	O
the	O
supraceliac	O
abdominal	O
aorta	O
-	O
-	O
surgical	O
option	O
applied	O
to	O
reoperation	O
for	O
aortic	O
coarctation	O
or	O
interruption	O
]	O
.	O

The	O
optimal	O
approach	O
for	O
reoperation	O
following	O
repair	O
of	O
aortic	O
coarctation	O
(	O
CoA	O
)	O
or	O
interruption	O
(	O
IAA	O
)	O
remains	O
controversial	O
.	O

Four	O
patients	O
underwent	O
extra	O
-	O
anatomic	O
bypass	O
for	O
restenosis	O
after	O
repair	O
of	O
CoA	O
or	O
IAA	O
.	O

The	O
age	O
ranged	O
from	O
4	O
to	O
12	O
years	O
.	O

The	O
initial	O
repairs	O
for	O
two	O
CoA	O
,	O
one	O
type	O
A	O
-	O
IAA	O
,	O
and	O
one	O
type	O
B	O
-	O
IAA	O
consisted	O
of	O
two	O
grafting	O
,	O
one	O
subclavian	O
arterial	O
turning	O
-	O
down	O
aortoplasty	O
,	O
and	O
one	O
subclavian	O
flap	O
aortoplasty	O
.	O

All	O
of	O
them	O
underwent	O
during	O
infancy	O
.	O

Preoperative	O
right	O
arm	O
systolic	O
pressure	O
ranged	O
from	O
140	O
to	O
190	O
mmHg	O
ar	O
rest	O
.	O

Through	O
a	O
midline	O
sternotomy	O
and	O
an	O
upper	O
laparotmy	O
incision	O
,	O
an	O
extra	O
-	O
anatomic	O
bypass	O
from	O
the	O
ascending	O
aorta	O
to	O
the	O
supraceliac	O
abdominal	O
aorta	O
was	O
employed	O
using	O
a	O
12	O
to	O
18	O
mm	O
tube	O
graft	O
.	O

All	O
patients	O
survived	O
surgeries	O
,	O
and	O
their	O
hypertension	O
markedly	O
improved	O
.	O

Our	O
experience	O
confirms	O
safety	O
and	O
effectiveness	O
of	O
this	O
option	O
in	O
selected	O
young	O
patients	O
with	O
re	O
-	O
stenosis	O
of	O
following	O
repair	O
of	O
CoA	O
or	O
IAA	O
.	O

Effect	O
of	O
a	O
mutation	O
in	O
the	O
anticodon	O
of	O
human	O
mitochondrial	O
tRNAPro	O
on	O
its	O
post	O
-	O
transcriptional	O
modification	O
pattern	O
.	O

Although	O
the	O
gene	O
sequences	O
of	O
all	O
22	O
tRNAs	O
encoded	O
in	O
the	O
human	O
mitochondrial	O
genome	O
are	O
known	O
,	O
little	O
information	O
exists	O
about	O
their	O
sequences	O
at	O
the	O
RNA	O
level	O
.	O

This	O
becomes	O
a	O
crucial	O
limitation	O
when	O
searching	O
for	O
a	O
molecular	O
understanding	O
of	O
the	O
growing	O
number	O
of	O
maternally	O
inherited	O
human	O
diseases	O
correlated	O
with	O
point	O
mutations	O
in	O
tRNA	O
genes	O
.	O

Here	O
we	O
describe	O
the	O
sequence	O
of	O
human	O
mt	O
-	O
tRNAPropurified	O
from	O
placenta	O
.	O

It	O
shows	O
absence	O
of	O
editing	O
events	O
in	O
this	O
tRNA	O
and	O
highlights	O
the	O
presence	O
of	O
eight	O
post	O
-	O
transcriptional	O
modifications	O
.	O

These	O
include	O
T54	O
,	O
never	O
found	O
so	O
far	O
in	O
an	O
animal	O
mt	O
-	O
tRNA	O
,	O
and	O
m1G37	O
,	O
a	O
modification	O
known	O
to	O
have	O
fundamental	O
functional	O
properties	O
in	O
a	O
number	O
of	O
canonical	O
tRNAs	O
.	O

Occurrence	O
of	O
m1G37	O
was	O
further	O
investigated	O
in	O
an	O
analysis	O
of	O
the	O
substrate	O
properties	O
of	O
in	O
vitro	O
transcripts	O
of	O
human	O
mt	O
-	O
tRNAProtowards	O
pure	O
Escherichia	O
coli	O
methylguanosine	O
transferase	O
.	O

This	O
enzyme	O
properly	O
methylates	O
G37	O
in	O
mt	O
-	O
tRNA	O
and	O
is	O
sensitive	O
to	O
the	O
presence	O
of	O
a	O
second	O
G	O
at	O
position	O
36	O
,	O
neighboring	O
the	O
target	O
nucleotide	O
for	O
methylation	O
.	O

Since	O
mutation	O
of	O
nt	O
36	O
was	O
shown	O
to	O
be	O
correlated	O
with	O
myopathy	O
,	O
the	O
potential	O
consequences	O
of	O
non	O
-	O
modification	O
or	O
under	O
-	O
modification	O
of	O
mt	O
-	O
tRNA	O
nucleotides	O
in	O
expression	O
of	O
the	O
particular	O
myopathy	O
and	O
of	O
mitochondrial	O
diseases	O
in	O
general	O
are	O
discussed	O
.	O

Prognostic	O
value	O
of	O
HLA	O
-	O
DR	O
expression	O
and	O
dendritic	O
cell	O
infiltration	O
in	O
gastric	O
cancer	O
.	O

We	O
attempted	O
to	O
correlate	O
the	O
expression	O
of	O
human	O
leukocyte	O
antigen	O
DR	O
(	O
HLA	O
-	O
DR	O
)	O
and	O
tumor	O
infiltration	O
by	O
S	O
-	O
100	O
-	O
protein	O
-	O
positive	O
dendritic	O
cells	O
with	O
clinicopathologic	O
features	O
in	O
165	O
patients	O
with	O
gastric	O
cancer	O
.	O

The	O
expression	O
of	O
HLA	O
-	O
DR	O
was	O
correlated	O
with	O
the	O
histologic	O
type	O
.	O

Infiltration	O
of	O
dendritic	O
cells	O
correlated	O
negatively	O
with	O
distant	O
lymph	O
node	O
metastases	O
,	O
clinical	O
stage	O
,	O
and	O
peritoneal	O
invasion	O
.	O

There	O
was	O
no	O
correlation	O
between	O
the	O
expression	O
of	O
HLA	O
-	O
DR	O
and	O
infiltration	O
by	O
dendritic	O
cells	O
.	O

In	O
patients	O
with	O
resectable	O
gastric	O
cancer	O
,	O
the	O
grade	O
of	O
infiltrating	O
dendritic	O
cells	O
may	O
be	O
a	O
suitable	O
predictor	O
of	O
prognosis	O
.	O

Integrin	O
alphavbeta3	O
requirement	O
for	O
sustained	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
activity	O
during	O
angiogenesis	O
.	O

Angiogenesis	O
depends	O
on	O
growth	O
factors	O
and	O
vascular	O
cell	O
adhesion	O
events	O
.	O

Integrins	O
and	O
growth	O
factors	O
are	O
capable	O
of	O
activating	O
the	O
ras	O
/	O
MAP	O
kinase	O
pathway	O
in	O
vitro	O
,	O
yet	O
how	O
these	O
signals	O
influence	O
endothelial	O
cells	O
during	O
angiogenesis	O
is	O
unknown	O
.	O

Upon	O
initiation	O
of	O
angiogenesis	O
with	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
on	O
the	O
chick	O
chorioallantoic	O
membrane	O
(	O
CAM	O
)	O
,	O
endothelial	O
cell	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
(	O
ERK	O
)	O
activity	O
was	O
detected	O
as	O
early	O
as	O
5	O
min	O
yet	O
was	O
sustained	O
for	O
at	O
least	O
20	O
h	O
.	O

The	O
initial	O
wave	O
of	O
ERK	O
activity	O
(	O
5	O
-	O
120	O
min	O
)	O
was	O
refractory	O
to	O
integrin	O
antagonists	O
,	O
whereas	O
the	O
sustained	O
activity	O
(	O
4	O
-	O
20	O
h	O
)	O
depended	O
on	O
integrin	O
alphavbeta3	O
,	O
but	O
not	O
beta1	O
integrins	O
.	O

Inhibition	O
of	O
MAP	O
kinase	O
kinase	O
(	O
MEK	O
)	O
during	O
this	O
sustained	O
alphavbeta3	O
-	O
dependent	O
ERK	O
signal	O
blocked	O
the	O
formation	O
of	O
new	O
blood	O
vessels	O
while	O
not	O
influencing	O
preexisting	O
blood	O
vessels	O
on	O
the	O
CAM	O
.	O

Inhibition	O
of	O
MEK	O
also	O
blocked	O
growth	O
factor	O
induced	O
migration	O
but	O
not	O
adhesion	O
of	O
endothelial	O
cells	O
in	O
vitro	O
.	O

Therefore	O
,	O
angiogenesis	O
depends	O
on	O
sustained	O
ERK	O
activity	O
regulated	O
by	O
the	O
ligation	O
state	O
of	O
both	O
a	O
growth	O
factor	O
receptor	O
and	O
integrin	O
alphavbeta3	O
.	O

Conservative	O
treatment	O
of	O
endometriosis	O
:	O
the	O
effects	O
of	O
limited	O
surgery	O
and	O
hormonal	O
pseudopregnancy	O
.	O

This	O
study	O
compares	O
the	O
effects	O
of	O
limited	O
surgery	O
or	O
hormonal	O
pseudopregnancy	O
,	O
or	O
a	O
combination	O
of	O
these	O
two	O
,	O
upon	O
fertility	O
and	O
the	O
need	O
for	O
subsequent	O
surgery	O
with	O
respect	O
to	O
the	O
extent	O
of	O
the	O
disease	O
at	O
the	O
time	O
of	O
initial	O
diagnosis	O
in	O
patients	O
with	O
endometriosis	O
externa	O
.	O

Of	O
the	O
61	O
patients	O
who	O
desired	O
to	O
enhance	O
or	O
preserve	O
reproductive	O
capacity	O
,	O
20	O
patients	O
became	O
pregnant	O
,	O
for	O
a	O
pregnancy	O
rate	O
of	O
33	O
%	O
.	O

The	O
pregnancy	O
rate	O
in	O
all	O
categories	O
,	O
that	O
is	O
,	O
those	O
patients	O
treated	O
with	O
pseudopregnancy	O
,	O
conservative	O
surgery	O
,	O
and	O
combined	O
pseudopregnancy	O
and	O
surgery	O
,	O
was	O
found	O
to	O
be	O
in	O
direct	O
relationship	O
to	O
the	O
initial	O
extent	O
of	O
disease	O
.	O

In	O
such	O
patients	O
,	O
conservative	O
surgery	O
alone	O
seemed	O
to	O
give	O
the	O
best	O
results	O
in	O
the	O
achievement	O
of	O
pregnancy	O
.	O

There	O
seemed	O
to	O
be	O
little	O
difference	O
between	O
pseudopregnancy	O
alone	O
and	O
conservative	O
surgery	O
in	O
regard	O
to	O
the	O
need	O
for	O
subsequent	O
surgery	O
after	O
initial	O
therapy	O
,	O
although	O
there	O
seemed	O
to	O
be	O
a	O
significantly	O
greater	O
chance	O
for	O
the	O
need	O
for	O
subsequent	O
surgery	O
in	O
patients	O
receiving	O
a	O
combination	O
of	O
the	O
two	O
forms	O
of	O
therapy	O
.	O

The	O
need	O
for	O
subsequent	O
surgery	O
after	O
initial	O
therapy	O
in	O
80	O
patients	O
increased	O
in	O
direct	O
relationship	O
to	O
the	O
initial	O
extent	O
of	O
disease	O
present	O
,	O
despite	O
the	O
form	O
of	O
therapy	O
used	O
.	O

Fifty	O
-	O
nine	O
other	O
patients	O
with	O
endometriosis	O
,	O
who	O
did	O
not	O
desire	O
to	O
preserve	O
fertility	O
and	O
presented	O
for	O
relief	O
of	O
other	O
symptoms	O
,	O
underwent	O
initial	O
""""	O
radical	O
""""	O
therapy	O
.	O

Forty	O
-	O
six	O
patients	O
underwent	O
complete	O
operation	O
,	O
including	O
removal	O
of	O
uterus	O
,	O
tubes	O
and	O
ovaries	O
,	O
and	O
none	O
required	O
subsequent	O
reoperation	O
.	O

Of	O
the	O
13	O
remaining	O
patients	O
,	O
who	O
underwent	O
incomplete	O
surgical	O
removal	O
,	O
leaving	O
one	O
or	O
both	O
ovaries	O
in	O
situ	O
,	O
11	O
required	O
subsequent	O
reoperation	O
for	O
recurrent	O
pelvic	O
endometriosis	O
.	O

Clozapine	O
-	O
induced	O
agranulocytosis	O
and	O
thrombopenia	O
in	O
a	O
patient	O
with	O
dopaminergic	O
psychosis	O
.	O

In	O
patients	O
with	O
Parkinson	O
'	O
disease	O
and	O
dopaminergic	O
psychosis	O
,	O
clozapine	O
treatment	O
is	O
recommended	O
as	O
the	O
drug	O
is	O
free	O
from	O
extrapyramidal	O
side	O
effects	O
and	O
does	O
not	O
worsen	O
motor	O
symptoms	O
of	O
the	O
underlying	O
disease	O
.	O

The	O
use	O
of	O
clozapine	O
,	O
however	O
,	O
is	O
limited	O
due	O
to	O
its	O
hematotoxic	O
side	O
effects	O
.	O

For	O
treatment	O
of	O
clozapine	O
-	O
induced	O
agranulocytosis	O
,	O
granulocyte	O
colony	O
-	O
stimulating	O
factors	O
(	O
G	O
-	O
CSF	O
)	O
are	O
recommended	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
72	O
-	O
years	O
-	O
old	O
male	O
patient	O
with	O
clozapine	O
-	O
induced	O
agranulocytosis	O
and	O
thrombopenia	O
.	O

Neutropenia	O
was	O
successfully	O
treated	O
with	O
G	O
-	O
CSF	O
,	O
but	O
thrombopenia	O
persisted	O
and	O
resolved	O
spontaneously	O
after	O
14	O
days	O
.	O

Bone	O
marrow	O
toxicity	O
of	O
clozapine	O
is	O
not	O
restricted	O
to	O
white	O
cell	O
maturation	O
,	O
but	O
may	O
also	O
impair	O
thrombocytopoesis	O
.	O

Basic	O
fibroblast	O
growth	O
factor	O
:	O
a	O
missing	O
link	O
between	O
collagen	O
VII	O
,	O
increased	O
collagenase	O
,	O
and	O
squamous	O
cell	O
carcinoma	O
in	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O

BACKGROUND	O
:	O
Patients	O
with	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
(	O
RDEB	O
)	O
have	O
deficiencies	O
of	O
collagen	O
type	O
VII	O
and	O
have	O
elevated	O
levels	O
of	O
fibroblast	O
collagenase	O
,	O
and	O
a	O
greatly	O
increased	O
risk	O
of	O
cutaneous	O
squamous	O
cell	O
carcinoma	O
.	O

Patients	O
with	O
other	O
genetic	O
blistering	O
disorders	O
do	O
not	O
have	O
elevated	O
collagenase	O
or	O
an	O
increased	O
risk	O
of	O
squamous	O
cell	O
carcinoma	O
,	O
despite	O
chronic	O
wounding	O
.	O

The	O
connection	O
between	O
collagen	O
type	O
VII	O
deficiency	O
,	O
increased	O
collagenase	O
,	O
and	O
squamous	O
cell	O
carcinoma	O
is	O
not	O
understood	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Urine	O
from	O
81	O
patients	O
with	O
RDEB	O
(	O
39	O
patients	O
)	O
,	O
junctional	O
epidermolysis	O
bullosa	O
(	O
JEB	O
;	O
12	O
patients	O
)	O
,	O
and	O
epidermolysis	O
bullosa	O
simplex	O
(	O
EBS	O
;	O
30	O
patients	O
)	O
,	O
as	O
well	O
as	O
unaffected	O
family	O
members	O
of	O
RDEB	O
patients	O
(	O
33	O
patients	O
)	O
,	O
was	O
tested	O
for	O
the	O
presence	O
of	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
using	O
a	O
sensitive	O
radioimmunoassay	O
.	O

These	O
patients	O
included	O
many	O
who	O
were	O
enrolled	O
in	O
the	O
Epidermolysis	O
Bullosa	O
Registry	O
and	O
others	O
who	O
were	O
referred	O
by	O
their	O
physicians	O
.	O

RESULTS	O
:	O
Fifty	O
-	O
one	O
percent	O
of	O
patients	O
with	O
RDEB	O
had	O
elevated	O
levels	O
(	O
greater	O
than	O
5000	O
pg	O
/	O
g	O
)	O
of	O
urinary	O
bFGF	O
.	O

In	O
contrast	O
,	O
none	O
of	O
the	O
patients	O
with	O
JEB	O
had	O
elevated	O
levels	O
of	O
bFGF	O
.	O

Twenty	O
-	O
one	O
percent	O
of	O
clinically	O
unaffected	O
family	O
members	O
had	O
elevated	O
levels	O
of	O
bFGF	O
,	O
and	O
13	O
%	O
of	O
patients	O
with	O
EBS	O
had	O
elevated	O
levels	O
of	O
bFGF	O
.	O

The	O
frequency	O
of	O
elevated	O
bFGF	O
values	O
among	O
all	O
groups	O
was	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
and	O
the	O
levels	O
of	O
bFGF	O
in	O
RDEB	O
patients	O
were	O
significantly	O
elevated	O
compared	O
with	O
those	O
of	O
other	O
groups	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
found	O
that	O
patients	O
with	O
RDEB	O
have	O
elevated	O
levels	O
of	O
bFGF	O
,	O
which	O
may	O
contribute	O
to	O
increased	O
fibroblast	O
collagenase	O
and	O
the	O
development	O
of	O
squamous	O
cell	O
carcinoma	O
.	O

These	O
results	O
suggest	O
a	O
novel	O
treatment	O
for	O
RDEB	O
,	O
namely	O
,	O
angiogenesis	O
inhibitors	O
,	O
which	O
may	O
antagonize	O
the	O
effects	O
of	O
bFGF	O
in	O
this	O
disorder	O
.	O

There	O
are	O
currently	O
no	O
other	O
means	O
of	O
treatment	O
for	O
this	O
disorder	O
,	O
which	O
has	O
a	O
high	O
morbidity	O
and	O
mortality	O
rate	O
.	O

Multiple	O
phosphotyrosine	O
phosphatase	O
mRNAs	O
are	O
expressed	O
in	O
the	O
human	O
lung	O
fibroblast	O
cell	O
line	O
WI	B
-	I
38	I
.	O

Protein	O
tyrosine	O
phosphatases	O
are	O
important	O
components	O
of	O
signal	O
transduction	O
pathways	O
.	O

The	O
authors	O
have	O
used	O
reverse	O
transcription	O
/	O
polymerase	O
chain	O
reactions	O
to	O
accomplish	O
a	O
comprehensive	O
examination	O
of	O
the	O
RNA	O
expression	O
for	O
58	O
distinct	O
mammalian	O
protein	O
tyrosine	O
and	O
dual	O
specificity	O
phosphatase	O
(	O
PTPase	O
)	O
and	O
PTPase	O
-	O
like	O
genes	O
in	O
the	O
normal	O
human	O
diploid	O
fibroblast	O
cell	O
line	O
WI	B
-	I
38	I
.	O

Thirty	O
-	O
seven	O
of	O
these	O
PTPase	O
genes	O
express	O
easily	O
measurable	O
RNA	O
,	O
and	O
four	O
simultaneously	O
express	O
the	O
RNA	O
for	O
two	O
or	O
more	O
isoforms	O
.	O

Messages	O
for	O
an	O
additional	O
eight	O
PTPase	O
genes	O
are	O
detectable	O
at	O
low	O
levels	O
.	O

Only	O
14	O
known	O
PTPase	O
genes	O
do	O
not	O
express	O
measurable	O
RNA	O
under	O
our	O
conditions	O
.	O

For	O
purposes	O
of	O
comparison	O
,	O
the	O
authors	O
also	O
assessed	O
the	O
PTPases	O
expressed	O
in	O
the	O
WI	B
-	I
38	I
cell	O
line	O
using	O
highly	O
degenerate	O
primers	O
to	O
conserved	O
motifs	O
found	O
in	O
the	O
classical	O
tyrosine	O
-	O
specific	O
PTPases	O
.	O

Only	O
eight	O
of	O
the	O
22	O
classic	O
tyrosine	O
-	O
specific	O
PTPases	O
detected	O
using	O
the	O
specific	O
primers	O
were	O
detected	O
using	O
these	O
degenerate	O
primers	O
.	O

Our	O
panel	O
of	O
specific	O
PTPase	O
primers	O
should	O
be	O
very	O
useful	O
for	O
semiquantitatively	O
assessing	O
the	O
repertoire	O
of	O
PTPases	O
expressed	O
by	O
cells	O
.	O

Epstein	O
-	O
Barr	O
virus	O
-	O
associated	O
nonsmall	O
cell	O
lung	O
carcinoma	O
:	O
undifferentiated	O
""""	O
lymphoepithelioma	O
-	O
like	O
""""	O
carcinoma	O
as	O
a	O
distinct	O
entity	O
with	O
better	O
prognosis	O
.	O

BACKGROUND	O
:	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
in	O
nonsmall	O
cell	O
lung	O
carcinoma	O
(	O
NSCLC	O
)	O
has	O
been	O
demonstrated	O
in	O
some	O
ethnic	O
groups	O
.	O

The	O
pathobiology	O
and	O
the	O
role	O
of	O
EBV	O
and	O
oncoprotein	O
expression	O
in	O
these	O
tumors	O
have	O
not	O
been	O
studied	O
extensively	O
.	O

In	O
this	O
study	O
,	O
the	O
authors	O
investigated	O
EBV	O
-	O
encoded	O
RNA	O
-	O
1	O
(	O
EBER1	O
)	O
transcripts	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
expression	O
of	O
latent	O
membrane	O
protein	O
-	O
1	O
(	O
LMP	O
-	O
1	O
)	O
and	O
bcl	O
-	O
2	O
protein	O
by	O
immunohistochemistry	O
in	O
NSCLC	O
patients	O
from	O
Taiwan	O
,	O
where	O
nasopharyngeal	O
carcinoma	O
is	O
endemic	O
.	O

METHODS	O
:	O

A	O
total	O
of	O
127	O
cases	O
of	O
NSCLC	O
(	O
43	O
cases	O
of	O
squamous	O
cell	O
carcinoma	O
[	O
SCC	O
]	O
,	O
67	O
cases	O
of	O
adenocarcinoma	O
[	O
AD	O
]	O
,	O
12	O
cases	O
of	O
large	O
cell	O
carcinoma	O
[	O
LCC	O
]	O
,	O
and	O
5	O
cases	O
of	O
lymphoepithelioma	O
-	O
like	O
carcinoma	O
[	O
LE	O
]	O
)	O
were	O
included	O
.	O

A	O
sensitive	O
polymerase	O
chain	O
reaction	O
-	O
derived	O
,	O
digoxigenin	O
-	O
labeled	O
DNA	O
probe	O
for	O
in	O
situ	O
detection	O
of	O
EBER1	O
transcripts	O
was	O
performed	O
for	O
the	O
detection	O
of	O
EBV	O
.	O

Immunohistochemistry	O
using	O
the	O
avidin	O
-	O
biotin	O
-	O
immunoperoxidase	O
method	O
was	O
also	O
performed	O
to	O
evaluate	O
the	O
expression	O
of	O
bcl	O
-	O
2	O
and	O
LMP	O
-	O
1	O
.	O

RESULTS	O
:	O

EBER1	O
was	O
detected	O
in	O
11	O
of	O
the	O
127	O
NSCLC	O
cases	O
(	O
8	O
.	O
7	O
%	O
;	O
6	O
SCC	O
cases	O
and	O
5	O
LE	O
cases	O
)	O
.	O

All	O
5	O
LE	O
cases	O
were	O
EBV	O
-	O
positive	O
,	O
whereas	O
only	O
6	O
of	O
the	O
43	O
SCC	O
cases	O
(	O
14	O
%	O
)	O
,	O
0	O
of	O
67	O
AD	O
cases	O
,	O
and	O
12	O
LCC	O
cases	O
were	O
EBV	O
-	O
positive	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

All	O
five	O
LE	O
cases	O
showed	O
diffuse	O
,	O
strong	O
,	O
positive	O
staining	O
of	O
tumor	O
cells	O
;	O
five	O
of	O
the	O
six	O
SCC	O
cases	O
showed	O
diffuse	O
but	O
weak	O
staining	O
.	O

Among	O
the	O
nontumor	O
epithelial	O
cells	O
,	O
there	O
was	O
no	O
EBER1	O
staining	O
of	O
any	O
of	O
the	O
11	O
EBER1	O
-	O
positive	O
cases	O
.	O

The	O
mean	O
age	O
of	O
the	O
LE	O
patients	O
was	O
10	O
years	O
younger	O
than	O
that	O
of	O
the	O
patients	O
with	O
other	O
histological	O
types	O
.	O

All	O
5	O
LE	O
patients	O
were	O
nonsmokers	O
,	O
whereas	O
3	O
of	O
the	O
6	O
patients	O
with	O
EBER1	O
-	O
positive	O
SCC	O
(	O
50	O
%	O
)	O
were	O
smokers	O
.	O

EBER1	O
expression	O
did	O
not	O
correlate	O
with	O
the	O
2	O
-	O
year	O
survival	O
rate	O
of	O
overall	O
cases	O
,	O
but	O
all	O
5	O
LE	O
patients	O
were	O
alive	O
without	O
clinical	O
evidence	O
of	O
disease	O
at	O
last	O
follow	O
-	O
up	O
.	O

Gender	O
,	O
lymph	O
node	O
or	O
distant	O
metastasis	O
,	O
and	O
clinical	O
stage	O
were	O
not	O
found	O
to	O
have	O
any	O
correlation	O
with	O
EBER1	O
expression	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

All	O
LE	O
cases	O
had	O
bcl	O
-	O
2	O
oncoprotein	O
expression	O
(	O
100	O
%	O
)	O
.	O

This	O
frequency	O
was	O
significantly	O
different	O
from	O
other	O
histologic	O
types	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
LMP	O
-	O
1	O
detection	O
rate	O
was	O
low	O
and	O
demonstrated	O
no	O
correlation	O
with	O
bcl	O
-	O
2	O
expression	O
.	O

CONCLUSIONS	O
:	O

In	O
this	O
study	O
,	O
the	O
authors	O
found	O
that	O
the	O
primary	O
LE	O
of	O
the	O
lung	O
is	O
associated	O
with	O
young	O
age	O
,	O
a	O
history	O
of	O
not	O
smoking	O
,	O
high	O
bcl	O
-	O
2	O
immunoreactivity	O
,	O
and	O
better	O
survival	O
rate	O
.	O

These	O
characteristics	O
demonstrate	O
that	O
EBV	O
-	O
associated	O
LE	O
of	O
the	O
lung	O
is	O
a	O
unique	O
entity	O
.	O

The	O
findings	O
of	O
the	O
current	O
study	O
suggest	O
that	O
EBV	O
infection	O
may	O
play	O
a	O
different	O
role	O
in	O
the	O
tumorigenesis	O
of	O
primary	O
LE	O
of	O
the	O
lung	O
than	O
it	O
does	O
in	O
other	O
EBER1	O
-	O
positive	O
NSCLCs	O
.	O

Prophylactic	O
thyroidectomy	O
in	O
MEN	O
IIA	O
:	O
does	O
the	O
calcitonin	O
level	O
correlate	O
with	O
tumor	O
spread	O
?	O

BACKGROUND	O
:	O
The	O
fate	O
of	O
patients	O
with	O
multiple	O
endocrine	O
neoplasia	O
of	O
type	O
II	O
A	O
(	O
MEN	O
II	O
A	O
)	O
is	O
determined	O
by	O
medullary	O
thyroid	O
carcinoma	O
,	O
which	O
occurs	O
in	O
all	O
cases	O
.	O

This	O
has	O
led	O
to	O
the	O
therapeutic	O
concept	O
of	O
prophylactic	O
thyroidectomy	O
in	O
affected	O
family	O
members	O
with	O
the	O
goal	O
of	O
removing	O
the	O
thyroid	O
before	O
the	O
manifestation	O
of	O
carcinoma	O
.	O

We	O
investigated	O
a	O
prophylactically	O
thyroidectomized	O
MEN	O
II	O
A	O
population	O
to	O
determine	O
whether	O
the	O
highly	O
specific	O
and	O
sensitive	O
tumor	O
marker	O
calcitonin	O
correlates	O
with	O
tumor	O
spread	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Fifteen	O
patients	O
with	O
MEN	O
II	O
A	O
(	O
aged	O
4	O
-	O
24	O
years	O
)	O
who	O
had	O
undergone	O
prophylactic	O
thyroidectomy	O
since	O
1990	O
were	O
included	O
in	O
the	O
study	O
.	O

Baseline	O
and	O
pentagastrin	O
-	O
stimulated	O
calcitonin	O
levels	O
were	O
preoperatively	O
determined	O
in	O
all	O
cases	O
.	O

The	O
indication	O
for	O
surgery	O
was	O
established	O
on	O
the	O
basis	O
of	O
pathologic	O
calcitonin	O
levels	O
in	O
the	O
first	O
seven	O
patients	O
and	O
on	O
the	O
basis	O
of	O
detected	O
RET	O
proto	O
-	O
oncogene	O
mutation	O
in	O
the	O
other	O
eight	O
patients	O
.	O

Bilateral	O
central	O
lymphadenectomy	O
was	O
performed	O
in	O
all	O
patients	O
in	O
addition	O
to	O
thyroidectomy	O
.	O

RESULTS	O
:	O
Histology	O
demonstrated	O
C	O
-	O
cell	O
hyperplasia	O
in	O
five	O
patients	O
(	O
aged	O
4	O
-	O
13	O
years	O
)	O
,	O
unilateral	O
medullary	O
microcarcinoma	O
in	O
six	O
(	O
aged	O
9	O
-	O
17	O
years	O
)	O
and	O
a	O
bilateral	O
medullary	O
microcarcinoma	O
in	O
three	O
cases	O
(	O
aged	O
17	O
-	O
24	O
years	O
)	O
.	O

One	O
9	O
-	O
year	O
-	O
old	O
boy	O
with	O
bilateral	O
microcarcinoma	O
already	O
had	O
a	O
lymph	O
node	O
metastasis	O
.	O

The	O
mean	O
baseline	O
calcitonin	O
level	O
correlated	O
with	O
the	O
histologic	O
findings	O
(	O
r	O
=	O
0	O
.	O
71	O
,	O
P	O
=	O
0	O
.	O
003	O
)	O
but	O
there	O
was	O
no	O
correlation	O
between	O
pentagastrin	O
-	O
stimulated	O
calcitonin	O
levels	O
and	O
histology	O
(	O
r	O
=	O
0	O
.	O
21	O
,	O
P	O
=	O
0	O
.	O
47	O
)	O
.	O

CONCLUSION	O
:	O
In	O
MEN	O
II	O
A	O
patients	O
undergoing	O
prophylactic	O
thyroidectomy	O
,	O
baseline	O
but	O
not	O
stimulated	O
calcitonin	O
levels	O
already	O
correlate	O
with	O
the	O
histologic	O
tumor	O
stage	O
at	O
the	O
stage	O
of	O
clinically	O
occult	O
C	O
-	O
cell	O
hyperplasia	O
or	O
medullary	O
microcarcinoma	O
.	O

However	O
,	O
biochemical	O
screening	O
can	O
not	O
reliably	O
discriminate	O
the	O
transition	O
from	O
C	O
-	O
cell	O
hyperplasia	O
to	O
invasive	O
microcarcinoma	O
.	O

Individuals	O
with	O
MEN	O
IIA	O
should	O
therefore	O
undergo	O
early	O
prophylactic	O
thyroidectomy	O
once	O
the	O
diagnosis	O
is	O
confirmed	O
by	O
molecular	O
genetic	O
testing	O
.	O

Induction	O
of	O
Ets	O
-	O
1	O
in	O
endothelial	O
cells	O
during	O
reendothelialization	O
after	O
denuding	O
injury	O
.	O

Ets	O
-	O
1	O
,	O
a	O
transcription	O
factor	O
,	O
is	O
induced	O
in	O
endothelial	O
cells	O
(	O
ECs	O
)	O
during	O
angiogenesis	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
Ets	O
-	O
1	O
during	O
reendothelialization	O
.	O

When	O
a	O
confluent	O
monolayer	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
line	O
,	O
ECV304	B
,	O
was	O
denuded	O
,	O
ECV304	B
at	O
the	O
wound	O
edge	O
expressed	O
Ets	O
-	O
1	O
.	O

An	O
immunohistochemical	O
analysis	O
revealed	O
that	O
Ets	O
-	O
1	O
accumulated	O
in	O
migrating	O
cells	O
at	O
the	O
wound	O
edge	O
and	O
returned	O
to	O
basal	O
level	O
when	O
reendothelialization	O
was	O
accomplished	O
.	O

This	O
induction	O
of	O
Ets	O
-	O
1	O
could	O
be	O
reproduced	O
in	O
in	O
vivo	O
denudation	O
of	O
rat	O
aortic	O
endothelium	O
by	O
a	O
balloon	O
catheter	O
.	O

The	O
induction	O
of	O
Ets	O
-	O
1	O
in	O
ECs	O
after	O
denudation	O
was	O
regulated	O
transcriptionally	O
,	O
and	O
humeral	O
factors	O
released	O
from	O
injured	O
ECs	O
might	O
not	O
be	O
responsible	O
.	O

Mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
activities	O
were	O
investigated	O
to	O
explore	O
the	O
mechanism	O
of	O
this	O
induction	O
.	O

Although	O
extracellular	O
signal	O
-	O
regulated	O
protein	O
kinase	O
1	O
/	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
,	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
1	O
(	O
JNK1	O
)	O
,	O
and	O
p38	O
were	O
activated	O
after	O
denudation	O
,	O
the	O
activation	O
of	O
ERK1	O
and	O
p38	O
was	O
more	O
rapid	O
and	O
prominent	O
.	O

PD98059	O
,	O
a	O
specific	O
MAPK	O
/	O
ERK	O
kinase	O
(	O
MEK	O
)	O
1	O
inhibitor	O
,	O
did	O
not	O
affect	O
the	O
induction	O
of	O
ets	O
-	O
1	O
mRNA	O
,	O
whereas	O
SB203580	O
,	O
a	O
specific	O
p38	O
inhibitor	O
,	O
almost	O
completely	O
abrogated	O
its	O
induction	O
.	O

These	O
results	O
indicate	O
that	O
Ets	O
-	O
1	O
is	O
induced	O
in	O
ECs	O
after	O
denudation	O
through	O
activation	O
of	O
p38	O
.	O

This	O
induction	O
of	O
Ets	O
-	O
1	O
may	O
be	O
relevant	O
for	O
reendothelialization	O
by	O
regulating	O
the	O
expression	O
of	O
certain	O
genes	O
.	O

SV40	O
Tag	O
transformation	O
of	O
the	O
normal	O
invasive	O
trophoblast	O
results	O
in	O
a	O
premalignant	O
phenotype	O
.	O

I	O
.	O

Mechanisms	O
responsible	O
for	O
hyperinvasiveness	O
and	O
resistance	O
to	O
anti	O
-	O
invasive	O
action	O
of	O
TGFbeta	O
.	O

Invasion	O
of	O
the	O
uterus	O
by	O
first	O
trimester	O
human	O
placental	O
extravillous	O
trophoblast	O
(	O
EVT	O
)	O
cells	O
depends	O
on	O
mechanisms	O
shared	O
by	O
malignant	O
cells	O
.	O

However	O
,	O
unlike	O
tumor	O
invasion	O
,	O
trophoblast	O
invasion	O
of	O
the	O
uterus	O
is	O
stringently	O
controlled	O
in	O
situ	O
by	O
local	O
molecules	O
such	O
as	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
beta	O
.	O

Since	O
EVT	O
cells	O
possess	O
active	O
invasion	O
-	O
associated	O
genes	O
but	O
are	O
nontumorigenic	O
,	O
our	O
objective	O
was	O
to	O
induce	O
premalignant	O
and	O
then	O
malignant	O
phenotype	O
into	O
a	O
normal	O
EVT	B
cell	O
line	O
in	O
order	O
to	O
identify	O
the	O
molecular	O
basis	O
of	O
tumor	O
progression	O
.	O

Simian	O
virus	O
40	O
large	O
T	O
antigen	O
(	O
SV40	O
Tag	O
)	O
was	O
introduced	O
into	O
a	O
normal	O
human	O
first	O
trimester	O
invasive	O
EVT	B
cell	O
line	O
,	O
HTR8	B
,	O
established	O
in	O
our	O
laboratory	O
.	O

Since	O
the	O
HTR8	B
line	O
has	O
a	O
limited	O
in	O
vitro	O
lifespan	O
of	O
12	O
-	O
15	O
passages	O
,	O
SV40	O
Tag	O
-	O
transformed	O
cells	O
were	O
selected	O
on	O
the	O
basis	O
of	O
extended	O
lifespan	O
.	O

A	O
long	O
-	O
lived	O
line	O
,	O
RSVT	B
-	I
2	I
,	O
was	O
produced	O
and	O
an	O
immortalized	O
subclone	O
,	O
RSVT2	B
/	I
C	I
,	O
was	O
further	O
derived	O
under	O
a	O
forced	O
crisis	O
regimen	O
.	O

We	O
examined	O
transformation	O
-	O
induced	O
alterations	O
in	O
proliferative	O
and	O
invasive	O
abilities	O
,	O
responses	O
to	O
the	O
invasion	O
and	O
proliferation	O
-	O
regulating	O
growth	O
factor	O
TGFbeta	O
and	O
changes	O
in	O
gene	O
expression	O
for	O
invasion	O
-	O
associated	O
enzymes	O
or	O
enzyme	O
inhibitors	O
.	O

RSVT	B
-	I
2	I
and	O
RSVT2	B
/	I
C	I
cell	O
lines	O
were	O
hyperproliferative	O
and	O
hyperinvasive	O
when	O
compared	O
with	O
the	O
parental	O
HTR8	B
cell	O
line	O
.	O

They	O
were	O
also	O
variably	O
resistant	O
to	O
the	O
anti	O
-	O
proliferative	O
and	O
anti	O
-	O
invasive	O
signals	O
from	O
TGFbeta	O
.	O

Since	O
both	O
cell	O
lines	O
remained	O
non	O
-	O
tumorigenic	O
in	O
nude	O
mice	O
,	O
these	O
properties	O
indicate	O
that	O
they	O
attained	O
a	O
premalignant	O
phenotype	O
.	O

Both	O
cell	O
lines	O
showed	O
reduced	O
expression	O
of	O
tissue	O
inhibitor	O
of	O
metalloproteases	O
(	O
TIMP	O
)	O
-	O
1	O
,	O
while	O
TIMP	O
-	O
2	O
and	O
plasminogen	O
activator	O
inhibitor	O
(	O
PAI	O
)	O
-	O
I	O
expression	O
was	O
was	O
also	O
reduced	O
in	O
RSVT2	B
/	I
C	I
cells	O
,	O
thus	O
contributing	O
to	O
their	O
hyperinvasiveness	O
.	O

Their	O
resistance	O
to	O
the	O
anti	O
-	O
invasive	O
action	O
of	O
TGFbeta	O
was	O
explained	O
by	O
the	O
failure	O
of	O
TGFbeta	O
to	O
upregulate	O
TIMPs	O
and	O
PAI	O
-	O
I	O
,	O
in	O
contrast	O
to	O
the	O
TGFbeta	O
-	O
induced	O
upregulation	O
noted	O
in	O
parental	O
HTR8	B
cells	O
.	O

Antisocial	O
patients	O
:	O
a	O
comparison	O
of	O
those	O
with	O
and	O
those	O
without	O
childhood	O
conduct	O
disorder	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
persons	O
with	O
antisocial	O
personality	O
disorder	O
(	O
ASP	O
)	O
with	O
those	O
who	O
meet	O
the	O
adult	O
criteria	O
for	O
ASP	O
but	O
fail	O
to	O
meet	O
the	O
criteria	O
for	O
childhood	O
conduct	O
disorder	O
.	O

Sociodemographic	O
data	O
,	O
medical	O
history	O
,	O
and	O
psychiatric	O
symptoms	O
exhibited	O
during	O
a	O
recent	O
hospital	O
admission	O
were	O
compared	O
in	O
the	O
two	O
groups	O
by	O
chart	O
review	O
.	O

The	O
two	O
groups	O
were	O
virtually	O
indistinguishable	O
,	O
except	O
that	O
patients	O
without	O
childhood	O
conduct	O
disorder	O
were	O
less	O
likely	O
to	O
smoke	O
or	O
consume	O
alcohol	O
,	O
were	O
less	O
likely	O
to	O
have	O
spent	O
time	O
in	O
a	O
training	O
school	O
/	O
boot	O
camp	O
as	O
a	O
child	O
or	O
adolescent	O
,	O
were	O
less	O
likely	O
to	O
have	O
been	O
admitted	O
for	O
a	O
recent	O
suicide	O
attempt	O
,	O
and	O
were	O
less	O
likely	O
to	O
have	O
conned	O
others	O
.	O

We	O
conclude	O
that	O
persons	O
meeting	O
the	O
adult	O
criteria	O
for	O
ASP	O
but	O
not	O
the	O
childhood	O
conduct	O
disorder	O
criteria	O
essentially	O
suffer	O
the	O
same	O
disorder	O
as	O
those	O
who	O
meet	O
full	O
ASP	O
criteria	O
but	O
are	O
less	O
severely	O
affected	O
.	O

Acylase	O
I	O
-	O
catalyzed	O
deacetylation	O
of	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
and	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
.	O

The	O
aminoacylase	O
that	O
catalyzes	O
the	O
hydrolysis	O
of	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
was	O
identified	O
as	O
acylase	O
I	O
after	O
purification	O
by	O
column	O
chromatography	O
and	O
electrophoretic	O
analysis	O
.	O

Rat	O
kidney	O
cytosol	O
was	O
fractionated	O
by	O
ammonium	O
sulfate	O
precipitation	O
,	O
and	O
the	O
proteins	O
were	O
separated	O
by	O
ion	O
-	O
exchange	O
column	O
chromatography	O
,	O
gel	O
-	O
filtration	O
column	O
chromatography	O
,	O
and	O
hydrophobic	O
interaction	O
column	O
chromatography	O
.	O

Acylase	O
activity	O
with	O
NAC	O
and	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
methionine	O
(	O
NAM	O
)	O
,	O
a	O
known	O
substrate	O
for	O
acylase	O
I	O
,	O
as	O
substrates	O
coeluted	O
during	O
all	O
chromatographic	O
steps	O
.	O

Sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
showed	O
that	O
the	O
protein	O
was	O
purified	O
to	O
near	O
homogeneity	O
and	O
had	O
a	O
subunit	O
Mr	O
of	O
43	O
000	O
,	O
which	O
is	O
identical	O
with	O
the	O
Mr	O
of	O
acylase	O
I	O
from	O
porcine	O
kidney	O
and	O
bovine	O
liver	O
.	O

n	O
-	O
Butylmalonic	O
acid	O
was	O
a	O
slow	O
-	O
binding	O
inhibitor	O
of	O
acylase	O
I	O
and	O
inhibited	O
the	O
deacetylation	O
of	O
NAC	O
with	O
a	O
Ki	O
of	O
192	O
+	O
/	O
-	O
27	O
microM	O
.	O

These	O
results	O
show	O
that	O
acylase	O
I	O
catalyzes	O
the	O
deacetylation	O
of	O
NAC	O
.	O

The	O
acylase	O
I	O
-	O
catalyzed	O
deacetylation	O
of	O
a	O
range	O
of	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
,	O
their	O
carbon	O
and	O
oxygen	O
analogues	O
,	O
and	O
the	O
selenium	O
analogue	O
of	O
NAM	O
was	O
also	O
studied	O
with	O
porcine	O
kidney	O
acylase	O
I	O
.	O

The	O
specific	O
activity	O
of	O
the	O
acylase	O
I	O
-	O
catalyzed	O
deacetylation	O
of	O
these	O
substrates	O
was	O
related	O
to	O
their	O
calculated	O
molar	O
volumes	O
and	O
log	O
P	O
values	O
.	O

The	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
with	O
short	O
(	O
C0	O
-	O
C3	O
)	O
and	O
unbranched	O
S	O
-	O
alkyl	O
substituents	O
were	O
good	O
acylase	O
I	O
substrates	O
,	O
whereas	O
the	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
with	O
long	O
(	O
>	O
C3	O
)	O
and	O
branched	O
S	O
-	O
alkyl	O
substituents	O
were	O
poLr	O
acylase	O
I	O
substrates	O
.	O

The	O
carbon	O
and	O
oxygen	O
analogues	O
of	O
S	O
-	O
methyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
and	O
the	O
carbon	O
analogue	O
of	O
S	O
-	O
ethyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
were	O
poor	O
acylase	O
I	O
substrates	O
,	O
whereas	O
the	O
selenium	O
analogue	O
of	O
NAM	O
was	O
a	O
good	O
acylase	O
I	O
substrate	O
.	O

Expression	O
of	O
two	O
type	O
II	O
-	O
like	O
tumor	O
hexokinase	O
RNA	O
transcripts	O
in	O
cancer	O
cell	O
lines	O
.	O

To	O
maintain	O
an	O
elevated	O
glycolytic	O
rate	O
,	O
cancerous	O
or	O
proliferating	O
cells	O
alter	O
the	O
expression	O
pattern	O
of	O
rate	O
limiting	O
glycolytic	O
enzymes	O
.	O

Since	O
glucose	O
phosphorylation	O
is	O
the	O
first	O
step	O
in	O
glycolysis	O
,	O
hexokinase	O
(	O
HK	O
)	O
,	O
the	O
first	O
rate	O
limiting	O
glycolytic	O
enzyme	O
,	O
can	O
play	O
a	O
key	O
regulatory	O
role	O
in	O
this	O
process	O
.	O

A	O
low	O
-	O
Km	O
,	O
mitochondrial	O
type	O
II	O
-	O
like	O
tumor	O
HK	O
is	O
described	O
as	O
the	O
predominant	O
form	O
in	O
hepatomas	O
.	O

However	O
,	O
recent	O
identification	O
of	O
a	O
high	O
-	O
Km	O
glucose	O
phosphorylating	O
activity	O
in	O
a	O
range	O
of	O
cancer	O
cells	O
prompted	O
us	O
to	O
characterize	O
glucose	O
phosphorylating	O
enzymes	O
of	O
cancer	O
cells	O
at	O
the	O
molecular	O
level	O
.	O

Highly	O
sensitive	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
identifies	O
an	O
induction	O
and	O
overexpression	O
of	O
a	O
type	O
II	O
-	O
like	O
tumor	O
HK	O
RNA	O
in	O
a	O
range	O
of	O
cancer	O
cell	O
lines	O
irrespective	O
of	O
tissue	O
origin	O
.	O

In	O
addition	O
,	O
we	O
report	O
here	O
the	O
identification	O
of	O
two	O
RNA	O
transcripts	O
of	O
type	O
II	O
-	O
like	O
tumor	O
HK	O
of	O
approximately	O
5	O
.	O
5	O
and	O
approximately	O
4	O
.	O
0	O
kb	O
in	O
these	O
cancer	O
cells	O
lines	O
,	O
including	O
muscle	O
-	O
derived	O
L6	B
myoblast	O
cells	O
.	O

Interestingly	O
,	O
under	O
normal	O
conditions	O
muscle	O
cells	O
express	O
only	O
a	O
approximately	O
5	O
.	O
5	O
-	O
kb	O
type	O
II	O
HK	O
RNA	O
transcript	O
.	O

A	O
significant	O
amount	O
of	O
type	O
I	O
HK	O
RNA	O
was	O
also	O
found	O
expressed	O
in	O
cancer	O
cell	O
lines	O
.	O

RNA	O
encoding	O
glucokinase	O
(	O
GK	O
)	O
,	O
the	O
high	O
-	O
Km	O
HK	O
isozyme	O
,	O
was	O
found	O
only	O
in	O
cancer	O
cells	O
originating	O
from	O
liver	O
and	O
pancreas	O
,	O
which	O
express	O
GK	O
under	O
normal	O
conditions	O
.	O

Homeobox	O
genes	O
in	O
hematopoiesis	O
and	O
leukemogenesis	O
.	O

Homeobox	O
genes	O
have	O
a	O
strikingly	O
conserved	O
61	O
-	O
amino	O
acid	O
sequence	O
,	O
encoding	O
DNA	O
-	O
binding	O
domain	O
.	O

Some	O
homeobox	O
genes	O
,	O
located	O
in	O
four	O
clusters	O
are	O
designated	O
HOX	O
A	O
through	O
D	O
,	O
while	O
others	O
are	O
known	O
as	O
divergent	O
homeobox	O
genes	O
.	O

Many	O
researchers	O
have	O
demonstrated	O
that	O
hematopoietic	O
cells	O
express	O
many	O
homeobox	O
genes	O
.	O

Induced	O
over	O
-	O
and	O
under	O
-	O
expression	O
of	O
these	O
genes	O
has	O
been	O
used	O
to	O
demonstrate	O
their	O
affect	O
on	O
some	O
aspects	O
of	O
hematopoiesis	O
and	O
leukemogenesis	O
.	O

Recently	O
,	O
knock	O
-	O
out	O
mice	O
of	O
homeobox	O
genes	O
by	O
targeted	O
disruption	O
have	O
also	O
been	O
used	O
to	O
examine	O
their	O
hematological	O
effect	O
.	O

There	O
are	O
examples	O
of	O
the	O
aberrant	O
expression	O
of	O
a	O
homeobox	O
gene	O
causing	O
leukemias	O
in	O
humans	O
.	O

In	O
pre	O
-	O
B	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
with	O
t	O
(	O
1	O
;	O
19	O
)	O
translocation	O
,	O
a	O
fusion	O
protein	O
is	O
created	O
between	O
E2A	O
and	O
a	O
homeobox	O
gene	O
PBX	O
.	O

In	O
T	O
-	O
cell	O
ALL	O
with	O
t	O
(	O
10	O
;	O
14	O
)	O
translocation	O
,	O
the	O
HOX	O
11	O
gene	O
is	O
deregulated	O
.	O

In	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
with	O
t	O
(	O
7	O
;	O
11	O
)	O
translocation	O
,	O
the	O
HOX	O
A9	O
gene	O
is	O
rearranged	O
.	O

In	O
this	O
review	O
article	O
,	O
many	O
functions	O
of	O
homeobox	O
genes	O
both	O
at	O
the	O
early	O
stem	O
cell	O
level	O
as	O
well	O
as	O
at	O
the	O
later	O
stages	O
of	O
hematopoietic	O
differentiation	O
,	O
and	O
the	O
leukemogenic	O
effect	O
of	O
altered	O
homeobox	O
genes	O
are	O
discussed	O
.	O

The	O
myoadipose	O
flap	O
:	O
a	O
new	O
composite	O
.	O

A	O
prefabricated	O
composite	O
fat	O
flap	O
consisting	O
of	O
muscle	O
woven	O
into	O
an	O
anatomically	O
distinct	O
fat	O
pad	O
was	O
studied	O
in	O
a	O
rabbit	O
model	O
.	O

In	O
17	O
rabbits	O
,	O
a	O
2	O
-	O
cm	O
strip	O
of	O
latissimus	O
dorsi	O
was	O
woven	O
into	O
the	O
parascapular	O
fat	O
pad	O
on	O
one	O
side	O
,	O
with	O
the	O
contralateral	O
fat	O
pad	O
serving	O
as	O
a	O
control	O
.	O

At	O
3	O
weeks	O
,	O
the	O
endogenous	O
blood	O
supply	O
of	O
both	O
the	O
control	O
and	O
the	O
experimental	O
fat	O
pads	O
was	O
isolated	O
and	O
ligated	O
,	O
and	O
the	O
composite	O
fat	O
/	O
muscle	O
flap	O
was	O
transferred	O
to	O
the	O
chest	O
wall	O
.	O

At	O
6	O
weeks	O
,	O
animals	O
were	O
killed	O
,	O
and	O
flaps	O
were	O
analyzed	O
for	O
length	O
,	O
width	O
,	O
and	O
weight	O
;	O
perfused	O
with	O
fluorescein	O
or	O
lead	O
oxide	O
;	O
and	O
examined	O
histologically	O
.	O

Significant	O
differences	O
were	O
found	O
between	O
the	O
control	O
and	O
experimental	O
fat	O
pads	O
with	O
regard	O
to	O
weight	O
and	O
length	O
.	O

Experimental	O
flaps	O
were	O
found	O
to	O
be	O
perfused	O
fully	O
with	O
fluorescein	O
and	O
lead	O
oxide	O
;	O
control	O
fat	O
pads	O
were	O
found	O
not	O
to	O
be	O
perfused	O
.	O

The	O
lead	O
oxide	O
group	O
revealed	O
extensive	O
growth	O
of	O
blood	O
vessels	O
from	O
the	O
latissimus	O
graft	O
into	O
the	O
experimental	O
fat	O
pad	O
.	O

No	O
vessels	O
were	O
visualized	O
in	O
the	O
controls	O
.	O

Finally	O
,	O
sections	O
of	O
the	O
control	O
and	O
experimental	O
flaps	O
were	O
analyzed	O
histologically	O
.	O

A	O
preponderance	O
of	O
viable	O
fat	O
,	O
with	O
evidence	O
of	O
neovascularization	O
,	O
was	O
found	O
in	O
experimental	O
flaps	O
,	O
compared	O
with	O
the	O
necrotic	O
fat	O
that	O
characterized	O
the	O
controls	O
.	O

We	O
conclude	O
that	O
prefabrication	O
of	O
a	O
fat	O
flap	O
is	O
possible	O
and	O
may	O
have	O
extensive	O
application	O
in	O
various	O
areas	O
of	O
plastic	O
surgery	O
.	O

Store	O
-	O
operated	O
calcium	O
entry	O
promotes	O
shape	O
change	O
in	O
pulmonary	O
endothelial	O
cells	O
expressing	O
Trp1	O
.	O

Activation	O
of	O
Ca2	O
+	O
entry	O
is	O
known	O
to	O
produce	O
endothelial	O
cell	O
shape	O
change	O
,	O
leading	O
to	O
increased	O
permeability	O
,	O
leukocyte	O
migration	O
,	O
and	O
initiation	O
of	O
angiogenesis	O
in	O
conduit	O
-	O
vessel	O
endothelial	O
cells	O
.	O

The	O
mode	O
of	O
Ca2	O
+	O
entry	O
regulating	O
cell	O
shape	O
is	O
unknown	O
.	O

We	O
hypothesized	O
that	O
activation	O
of	O
store	O
-	O
operated	O
Ca2	O
+	O
channels	O
(	O
SOCs	O
)	O
is	O
sufficient	O
to	O
promote	O
cell	O
shape	O
change	O
necessary	O
for	O
these	O
processes	O
.	O

SOC	O
activation	O
in	O
rat	O
pulmonary	O
arterial	O
endothelial	O
cells	O
increased	O
free	O
cytosolic	O
Ca2	O
+	O
that	O
was	O
dependent	O
on	O
a	O
membrane	O
current	O
having	O
a	O
net	O
inward	O
component	O
of	O
5	O
.	O
45	O
+	O
/	O
-	O
0	O
.	O
90	O
pA	O
/	O
pF	O
at	O
-	O
80	O
mV	O
.	O

Changes	O
in	O
endothelial	O
cell	O
shape	O
accompanied	O
SOC	O
activation	O
and	O
were	O
dependent	O
on	O
Ca2	O
+	O
entry	O
-	O
induced	O
reconfiguration	O
of	O
peripheral	O
(	O
cortical	O
)	O
filamentous	O
actin	O
(	O
F	O
-	O
actin	O
)	O
.	O

Because	O
the	O
identity	O
of	O
pulmonary	O
endothelial	O
SOCs	O
is	O
unknown	O
,	O
but	O
mammalian	O
homologues	O
of	O
the	O
Drosophila	O
melanogaster	O
transient	O
receptor	O
potential	O
(	O
trp	O
)	O
gene	O
have	O
been	O
proposed	O
to	O
form	O
Ca2	O
+	O
entry	O
channels	O
in	O
nonexcitable	O
cells	O
,	O
we	O
performed	O
RT	O
-	O
PCR	O
using	O
Trp	O
oligonucleotide	O
primers	O
in	O
both	O
rat	O
and	O
human	O
pulmonary	O
arterial	O
endothelial	O
cells	O
.	O

Both	O
cell	O
types	O
were	O
found	O
to	O
express	O
Trp1	O
,	O
but	O
neither	O
expressed	O
Trp3	O
nor	O
Trp6	O
.	O

Our	O
study	O
indicates	O
that	O
1	O
)	O
Ca2	O
+	O
entry	O
in	O
pulmonary	O
endothelial	O
cells	O
through	O
SOCs	O
produces	O
cell	O
shape	O
change	O
that	O
is	O
dependent	O
on	O
site	O
-	O
specific	O
rearrangement	O
of	O
the	O
microfilamentous	O
cytoskeleton	O
and	O
2	O
)	O
Trp1	O
may	O
be	O
a	O
component	O
of	O
pulmonary	O
endothelial	O
SOCs	O
.	O

Brainstem	O
auditory	O
-	O
evoked	O
potential	O
evaluation	O
in	O
children	O
with	O
meningitis	O
.	O

Brainstem	O
auditory	O
-	O
evoked	O
potential	O
(	O
BAEP	O
)	O
was	O
performed	O
on	O
101	O
children	O
with	O
meningitis	O
to	O
assess	O
the	O
incidence	O
of	O
hearing	O
impairment	O
.	O

Fifty	O
-	O
two	O
(	O
51	O
.	O
5	O
%	O
)	O
children	O
had	O
bacterial	O
meningitis	O
,	O
six	O
(	O
5	O
.	O
9	O
%	O
)	O
had	O
viral	O
meningitis	O
,	O
and	O
43	O
(	O
42	O
.	O
6	O
%	O
)	O
had	O
aseptic	O
meningitis	O
.	O

Fifty	O
-	O
one	O
(	O
50	O
.	O
5	O
%	O
)	O
patients	O
were	O
assessed	O
before	O
discharge	O
and	O
50	O
(	O
49	O
.	O
5	O
%	O
)	O
9	O
days	O
to	O
17	O
months	O
later	O
(	O
mean	O
=	O
4	O
months	O
)	O
.	O

BAEP	O
impairment	O
was	O
found	O
in	O
28	O
(	O
27	O
.	O
7	O
%	O
)	O
of	O
101	O
patients	O
;	O
24	O
had	O
sensorineural	O
and	O
four	O
had	O
conductive	O
type	O
of	O
hearing	O
loss	O
,	O
and	O
17	O
(	O
60	O
.	O
7	O
%	O
)	O
had	O
unilateral	O
and	O
11	O
(	O
39	O
.	O
3	O
%	O
)	O
had	O
bilateral	O
impairment	O
.	O

Hearing	O
threshold	O
was	O
elevated	O
in	O
22	O
(	O
21	O
.	O
8	O
%	O
)	O
patients	O
,	O
and	O
the	O
other	O
six	O
had	O
increased	O
latency	O
and	O
interpeak	O
latencies	O
with	O
normal	O
threshold	O
.	O

Frequency	O
of	O
BAEP	O
impairment	O
or	O
hearing	O
loss	O
associated	O
with	O
bacterial	O
meningitis	O
was	O
34	O
.	O
6	O
%	O
and	O
30	O
.	O
8	O
%	O
,	O
respectively	O
;	O
frequency	O
associated	O
with	O
aseptic	O
meningitis	O
was	O
20	O
.	O
9	O
%	O
and	O
13	O
.	O
9	O
%	O
,	O
respectively	O
.	O

One	O
child	O
with	O
viral	O
meningitis	O
(	O
coxsackie	O
virus	O
)	O
had	O
mild	O
BAEP	O
impairment	O
.	O

Most	O
of	O
the	O
BAEP	O
impairment	O
in	O
the	O
bacterial	O
meningitis	O
group	O
was	O
associated	O
with	O
H	O
.	O
influenzae	O
.	O

Prospective	O
BAEP	O
study	O
was	O
performed	O
in	O
20	O
patients	O
randomly	O
at	O
0	O
.	O
3	O
to	O
18	O
months	O
to	O
assess	O
hearing	O
status	O
after	O
antibiotic	O
treatment	O
,	O
10	O
with	O
normal	O
and	O
10	O
with	O
abnormal	O
BAEP	O
.	O

All	O
the	O
initially	O
normal	O
BAEP	O
patients	O
remained	O
normal	O
.	O

Of	O
the	O
10	O
patients	O
with	O
abnormal	O
BAEP	O
results	O
initially	O
,	O
four	O
returned	O
to	O
normal	O
,	O
two	O
improved	O
,	O
three	O
remained	O
unchanged	O
,	O
and	O
one	O
deteriorated	O
.	O

The	O
incidence	O
of	O
hearing	O
loss	O
after	O
bacterial	O
and	O
aseptic	O
meningitis	O
is	O
high	O
.	O

BAEP	O
is	O
useful	O
to	O
screen	O
for	O
possible	O
hearing	O
loss	O
in	O
children	O
with	O
meningitis	O
,	O
and	O
follow	O
-	O
up	O
BAEP	O
is	O
necessary	O
for	O
those	O
patients	O
with	O
initially	O
abnormal	O
BAEP	O
.	O

Hemispheric	O
control	O
of	O
motor	O
function	O
:	O
a	O
whole	O
brain	O
echo	O
planar	O
fMRI	O
study	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
whether	O
recruitment	O
of	O
the	O
ipsilateral	O
motor	O
cortex	O
during	O
non	O
-	O
dominant	O
motor	O
movement	O
reflects	O
left	O
hemispheric	O
control	O
of	O
motor	O
function	O
or	O
simply	O
the	O
greater	O
complexity	O
or	O
unfamiliarity	O
of	O
the	O
motor	O
task	O
.	O

BOLD	O
fMRI	O
was	O
performed	O
in	O
normal	O
right	O
-	O
handers	O
during	O
two	O
motor	O
tasks	O
:	O
(	O
1	O
)	O
sequential	O
finger	O
movements	O
(	O
SM	O
task	O
)	O
with	O
the	O
right	O
or	O
left	O
hand	O
;	O
and	O
(	O
2	O
)	O
random	O
finger	O
movements	O
(	O
RM	O
task	O
)	O
with	O
the	O
right	O
hand	O
.	O

In	O
all	O
subjects	O
,	O
activation	O
was	O
predominantly	O
in	O
the	O
contralateral	O
motor	O
areas	O
(	O
primary	O
sensorimotor	O
,	O
lateral	O
premotor	O
,	O
parietal	O
and	O
supplementary	O
motor	O
regions	O
)	O
and	O
ipsilateral	O
cerebellum	O
.	O

While	O
the	O
ipsilateral	O
motor	O
areas	O
were	O
also	O
activated	O
,	O
single	O
subject	O
analysis	O
revealed	O
these	O
areas	O
to	O
be	O
more	O
extensive	O
and	O
to	O
be	O
seen	O
in	O
more	O
subjects	O
during	O
the	O
non	O
-	O
dominant	O
hand	O
SM	O
task	O
and	O
dominant	O
hand	O
RM	O
task	O
than	O
during	O
the	O
more	O
familiar	O
dominant	O
hand	O
SM	O
task	O
.	O

Similarly	O
,	O
group	O
analysis	O
also	O
revealed	O
ipsilateral	O
activation	O
in	O
the	O
primary	O
sensorimotor	O
and	O
lateral	O
premotor	O
areas	O
,	O
but	O
only	O
during	O
the	O
non	O
-	O
dominant	O
SM	O
task	O
and	O
the	O
dominant	O
hand	O
RM	O
task	O
.	O

Non	O
-	O
dominant	O
hand	O
movements	O
,	O
perhaps	O
because	O
they	O
are	O
less	O
'	O
automatic	O
'	O
,	O
appear	O
to	O
require	O
more	O
cortical	O
activity	O
similar	O
to	O
complex	O
tasks	O
with	O
the	O
dominant	O
hand	O
,	O
and	O
result	O
in	O
greater	O
recruitment	O
of	O
ipsilateral	O
cortical	O
motor	O
areas	O
and	O
striatum	O
.	O

The	O
study	O
also	O
illustrates	O
how	O
potentially	O
meaningful	O
subtleties	O
seen	O
on	O
individual	O
maps	O
may	O
be	O
obscured	O
with	O
group	O
averaging	O
approaches	O
.	O

[	O
The	O
assessment	O
of	O
flow	O
velocity	O
in	O
carotid	O
and	O
intracranial	O
arteries	O
in	O
three	O
different	O
age	O
groups	O
]	O
.	O

In	O
this	O
report	O
we	O
assess	O
the	O
systolic	O
maximal	O
flow	O
velocity	O
in	O
carotid	O
and	O
intracranial	O
arteries	O
in	O
191	O
subjects	O
with	O
no	O
history	O
of	O
cerebral	O
vascular	O
disease	O
in	O
3	O
age	O
groups	O
:	O
20	O
-	O
40	O
years	O
(	O
1	O
group	O
)	O
,	O
41	O
-	O
60	O
years	O
(	O
2	O
group	O
)	O
,	O
and	O
above	O
60	O
years	O
(	O
3	O
group	O
)	O
.	O

The	O
subjects	O
were	O
assessed	O
using	O
Sonomed	O
Transcranial	O
Doppler	O
Spectrograph	O
according	O
to	O
generally	O
accepted	O
principles	O
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
establish	O
the	O
mean	O
value	O
of	O
maximal	O
flow	O
velocity	O
in	O
each	O
particular	O
artery	O
in	O
three	O
age	O
groups	O
,	O
and	O
to	O
observe	O
the	O
changes	O
in	O
this	O
parameter	O
with	O
age	O
.	O

The	O
results	O
were	O
analyzed	O
using	O
statistical	O
methods	O
and	O
a	O
significant	O
decrease	O
in	O
blood	O
flow	O
,	O
Vmax	O
,	O
was	O
found	O
in	O
all	O
investigated	O
arteries	O
.	O

A	O
mean	O
decrease	O
of	O
8	O
.	O
02	O
%	O
in	O
flow	O
velocity	O
Vmax	O
was	O
found	O
,	O
when	O
comparing	O
groups	O
2	O
and	O
1	O
,	O
and	O
difference	O
15	O
.	O
99	O
%	O
comparing	O
3	O
and	O
1	O
.	O

Lack	O
of	O
developmental	O
and	O
reproductive	O
toxicity	O
of	O
2	O
,	O
3	O
,	O
3	O
'	O
,	O
4	O
,	O
4	O
'	O
-	O
pentachlorobiphenyl	O
(	O
PCB	O
105	O
)	O
in	O
ring	O
-	O
necked	O
pheasants	O
.	O

Mono	O
-	O
ortho	O
PCBs	O
are	O
global	O
contaminants	O
of	O
wildlife	O
with	O
the	O
potential	O
to	O
produce	O
toxicity	O
by	O
an	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
-	O
mediated	O
mechanism	O
.	O

To	O
determine	O
the	O
potency	O
of	O
2	O
,	O
3	O
,	O
3	O
'	O
,	O
4	O
,	O
4	O
'	O
-	O
pentachlorobiphenyl	O
(	O
PCB	O
105	O
)	O
for	O
producing	O
reproductive	O
and	O
developmental	O
toxicity	O
,	O
adult	O
ring	O
-	O
necked	O
pheasant	O
hens	O
(	O
Phasianus	O
colchicus	O
)	O
were	O
orally	O
dosed	O
with	O
0	O
,	O
0	O
.	O
06	O
,	O
0	O
.	O
6	O
,	O
or	O
6	O
mg	O
PCB	O
105	O
/	O
kg	O
hen	O
/	O
week	O
for	O
10	O
weeks	O
to	O
achieve	O
cumulative	O
doses	O
of	O
0	O
,	O
0	O
.	O
6	O
,	O
6	O
,	O
or	O
60	O
mg	O
PCB	O
105	O
/	O
kg	O
hen	O
after	O
which	O
hens	O
were	O
bred	O
with	O
untreated	O
roosters	O
once	O
per	O
week	O
for	O
8	O
weeks	O
.	O

Except	O
at	O
week	O
6	O
of	O
the	O
egg	O
-	O
laying	O
period	O
when	O
cumulative	O
egg	O
production	O
in	O
the	O
6	O
mg	O
PCB	O
105	O
/	O
kg	O
hen	O
group	O
was	O
greater	O
than	O
controls	O
,	O
fertilized	O
egg	O
production	O
was	O
not	O
significantly	O
different	O
between	O
treatment	O
groups	O
.	O

Embryo	O
mortality	O
and	O
chick	O
mortality	O
were	O
not	O
significantly	O
different	O
between	O
treatment	O
groups	O
.	O

Total	O
body	O
and	O
heart	O
weights	O
of	O
all	O
chicks	O
1	O
day	O
posthatch	O
(	O
dph	O
)	O
were	O
not	O
different	O
between	O
groups	O
,	O
however	O
,	O
liver	O
weights	O
of	O
chicks	O
from	O
the	O
60	O
mg	O
/	O
kg	O
treatment	O
group	O
were	O
greater	O
than	O
controls	O
at	O
1	O
dph	O
.	O

The	O
first	O
chick	O
to	O
hatch	O
from	O
each	O
hen	O
was	O
reared	O
to	O
21	O
dph	O
and	O
among	O
these	O
birds	O
,	O
the	O
total	O
body	O
,	O
liver	O
,	O
and	O
heart	O
weights	O
were	O
not	O
different	O
between	O
groups	O
.	O

There	O
were	O
no	O
dose	O
-	O
related	O
malformations	O
of	O
the	O
beak	O
or	O
limbs	O
,	O
and	O
no	O
signs	O
of	O
subcutaneous	O
edema	O
,	O
ascites	O
,	O
or	O
pericardial	O
edema	O
in	O
chicks	O
at	O
1	O
or	O
21	O
dph	O
.	O

Hepatic	O
microsomal	O
monooxygenase	O
activities	O
[	O
ethoxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
EROD	O
)	O
,	O
benzyloxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
BROD	O
)	O
,	O
and	O
methyloxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
MROD	O
)	O
]	O
were	O
significantly	O
elevated	O
in	O
chicks	O
at	O
1	O
dph	O
from	O
hens	O
given	O
a	O
cumulative	O
PCB	O
105	O
dose	O
of	O
6	O
mg	O
/	O
kg	O
and	O
in	O
chicks	O
at	O
21	O
dph	O
from	O
hens	O
given	O
a	O
cumulative	O
PCB	O
dose	O
of	O
60	O
mg	O
/	O
kg	O
.	O

These	O
results	O
indicate	O
that	O
a	O
cumulative	O
PCB	O
105	O
dose	O
up	O
to	O
60	O
mg	O
/	O
kg	O
hen	O
does	O
not	O
decrease	O
the	O
production	O
of	O
fertilized	O
eggs	O
or	O
increase	O
embryo	O
or	O
chick	O
mortality	O
in	O
ring	O
-	O
necked	O
pheasants	O
,	O
but	O
does	O
increase	O
chick	O
hepatic	O
monooxygenase	O
activity	O
.	O

Glucose	O
and	O
lactate	O
metabolism	O
in	O
C6	B
glioma	O
cells	O
:	O
evidence	O
for	O
the	O
preferential	O
utilization	O
of	O
lactate	O
for	O
cell	O
oxidative	O
metabolism	O
.	O

13C	O
and	O
1H	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
(	O
NMR	O
)	O
was	O
used	O
to	O
investigate	O
the	O
metabolism	O
of	O
L	O
-	O
lactate	O
and	O
D	O
-	O
glucose	O
in	O
C6	B
glioma	O
cells	O
.	O

The	O
13C	O
enrichment	O
of	O
cell	O
metabolites	O
was	O
examined	O
after	O
a	O
4	O
-	O
h	O
incubation	O
in	O
media	O
containing	O
5	O
.	O
5	O
mM	O
glucose	O
and	O
11	O
mM	O
lactate	O
,	O
each	O
metabolite	O
being	O
alternatively	O
labelled	O
with	O
either	O
[	O
1	O
-	O
13C	O
]	O
D	O
-	O
glucose	O
or	O
[	O
3	O
-	O
13C	O
]	O
L	O
-	O
lactate	O
.	O

The	O
results	O
indicated	O
that	O
exogenous	O
lactate	O
was	O
the	O
major	O
substrate	O
for	O
oxidative	O
metabolism	O
.	O

They	O
were	O
consistent	O
with	O
the	O
concept	O
of	O
the	O
existence	O
of	O
2	O
pools	O
of	O
both	O
lactate	O
and	O
pyruvate	O
,	O
of	O
which	O
1	O
pool	O
was	O
closely	O
connected	O
with	O
exogenous	O
lactate	O
and	O
oxidative	O
metabolism	O
,	O
and	O
the	O
other	O
pool	O
was	O
closely	O
related	O
to	O
glycolysis	O
and	O
disconnected	O
from	O
oxidative	O
metabolism	O
.	O

The	O
molecular	O
basis	O
of	O
this	O
behaviour	O
could	O
be	O
related	O
to	O
different	O
locations	O
for	O
the	O
lactate	O
dehydrogenase	O
isoenzymes	O
,	O
as	O
suggested	O
by	O
their	O
immunohistochemical	O
labelling	O
.	O

Detection	O
of	O
total	O
assist	O
and	O
sucking	O
points	O
based	O
on	O
the	O
pulsatility	O
of	O
a	O
continuous	O
flow	O
artificial	O
heart	O
:	O
in	O
vivo	O
evaluation	O
.	O

Our	O
novel	O
control	O
strategy	O
for	O
a	O
continuous	O
flow	O
artificial	O
heart	O
by	O
detecting	O
the	O
total	O
assist	O
and	O
sucking	O
points	O
based	O
on	O
pump	O
pulsatility	O
was	O
evaluated	O
in	O
acute	O
animal	O
experiments	O
using	O
beagle	O
dogs	O
and	O
our	O
mixed	O
flow	O
pump	O
.	O

The	O
pump	O
was	O
installed	O
as	O
a	O
left	O
ventricular	O
(	O
LV	O
)	O
bypass	O
through	O
a	O
left	O
thoracotomy	O
.	O

To	O
change	O
LV	O
contractility	O
,	O
the	O
left	O
coronary	O
arteries	O
were	O
occluded	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
120	O
min	O
reperfusion	O
.	O

To	O
change	O
LV	O
end	O
diastolic	O
pressure	O
(	O
LVEDP	O
)	O
,	O
dextran	O
solution	O
was	O
rapidly	O
infused	O
.	O

To	O
estimate	O
the	O
pump	O
pulsatility	O
without	O
any	O
specific	O
sensor	O
,	O
we	O
calculated	O
the	O
index	O
of	O
current	O
amplitude	O
(	O
ICA	O
)	O
,	O
which	O
was	O
obtained	O
from	O
the	O
amplitude	O
of	O
the	O
motor	O
current	O
waveform	O
divided	O
by	O
the	O
simultaneous	O
mean	O
value	O
.	O

To	O
investigate	O
the	O
basic	O
characteristics	O
of	O
the	O
ICA	O
,	O
the	O
pump	O
speed	O
was	O
changed	O
temporarily	O
from	O
2	O
,	O
300	O
rpm	O
to	O
5	O
,	O
000	O
rpm	O
.	O

In	O
92	O
%	O
of	O
all	O
measurements	O
,	O
the	O
ICA	O
plotted	O
against	O
the	O
pump	O
speed	O
had	O
a	O
peak	O
point	O
(	O
t	O
-	O
point	O
)	O
that	O
corresponded	O
highly	O
with	O
the	O
turning	O
point	O
from	O
partial	O
to	O
total	O
assistance	O
.	O

The	O
ICA	O
also	O
had	O
a	O
trough	O
(	O
s	O
-	O
point	O
)	O
that	O
corresponded	O
with	O
the	O
beginning	O
of	O
severe	O
sucking	O
in	O
most	O
cases	O
.	O

Only	O
preload	O
significantly	O
influenced	O
pump	O
flow	O
rate	O
at	O
the	O
t	O
-	O
point	O
from	O
among	O
preload	O
(	O
LVEDP	O
)	O
,	O
afterload	O
(	O
SAoP	O
)	O
,	O
and	O
contractility	O
(	O
max	O
LV	O
dP	O
/	O
dt	O
)	O
,	O
by	O
which	O
we	O
can	O
simulate	O
Starling	O
'	O
s	O
law	O
of	O
the	O
natural	O
heart	O
.	O

We	O
concluded	O
that	O
a	O
continuous	O
flow	O
artificial	O
heart	O
could	O
be	O
well	O
controlled	O
by	O
detecting	O
the	O
t	O
-	O
point	O
and	O
s	O
-	O
point	O
.	O

Tumors	O
of	O
the	O
retinal	O
pigment	O
epithelium	O
metastasize	O
to	O
inguinal	O
lymph	O
nodes	O
and	O
spleen	O
in	O
tyrosinase	O
-	O
related	O
protein	O
1	O
/	O
SV40	O
T	O
antigen	O
transgenic	O
mice	O
.	O

The	O
pigment	O
epithelium	O
of	O
the	O
retina	O
(	O
RPE	O
)	O
is	O
derived	O
from	O
the	O
optic	O
cup	O
and	O
is	O
essential	O
for	O
function	O
and	O
development	O
of	O
the	O
eye	O
.	O

We	O
produced	O
a	O
transgenic	O
mouse	O
line	O
that	O
expresses	O
simian	O
virus	O
(	O
SV40	O
)	O
transforming	O
sequences	O
under	O
control	O
of	O
the	O
1	O
.	O
4	O
kb	O
tyrosinase	O
-	O
related	O
protein	O
1	O
(	O
TRP	O
-	O
1	O
)	O
promoter	O
,	O
targeting	O
expression	O
of	O
T	O
antigen	O
(	O
Tag	O
)	O
to	O
the	O
RPE	O
.	O

In	O
transgenic	O
embryos	O
,	O
RPE	O
cells	O
proliferated	O
in	O
the	O
anterior	O
part	O
of	O
the	O
eye	O
and	O
near	O
the	O
optic	O
nerve	O
.	O

This	O
resulted	O
in	O
formation	O
of	O
tumors	O
,	O
which	O
were	O
pigmented	O
and	O
of	O
epithelial	O
origin	O
.	O

In	O
3	O
months	O
-	O
old	O
mice	O
,	O
pigmented	O
cells	O
were	O
detected	O
in	O
spleen	O
and	O
inguinal	O
lymph	O
nodes	O
.	O

In	O
spleen	O
,	O
tyrosinase	O
,	O
TRP	O
-	O
1	O
and	O
SV40	O
Tag	O
were	O
expressed	O
and	O
tyrosinase	O
was	O
enzymatically	O
active	O
.	O

Pigmented	O
regions	O
were	O
positive	O
for	O
an	O
epithelial	O
marker	O
,	O
cytokeratin	O
.	O

Cell	O
lines	O
were	O
established	O
from	O
tumor	O
and	O
metastases	O
and	O
kept	O
in	O
culture	O
for	O
more	O
than	O
2	O
months	O
.	O

These	O
were	O
pigmented	O
,	O
and	O
maintained	O
expression	O
of	O
tyrosinase	O
,	O
TRP	O
-	O
1	O
,	O
cytokeratin	O
and	O
SV40	O
Tag	O
.	O

This	O
demonstrates	O
that	O
RPE	O
tumor	O
cells	O
metastasize	O
to	O
lymph	O
node	O
and	O
spleen	O
.	O

In	O
conclusion	O
,	O
the	O
metastasis	O
from	O
TRP	O
-	O
1	O
/	O
Tag	O
RPE	O
tumors	O
towards	O
spleen	O
and	O
lymph	O
nodes	O
serves	O
as	O
potential	O
tool	O
to	O
investigate	O
biology	O
and	O
metastasis	O
of	O
tumors	O
derived	O
from	O
the	O
pigment	O
epithelium	O
.	O

Glucagon	O
induces	O
suppression	O
of	O
ATP	O
-	O
sensitive	O
K	O
+	O
channel	O
activity	O
through	O
a	O
Ca2	O
+	O
/	O
calmodulin	O
-	O
dependent	O
pathway	O
in	O
mouse	O
pancreatic	O
beta	O
-	O
cells	O
.	O

Glucagon	O
is	O
known	O
to	O
increase	O
intracellular	O
cAMP	O
levels	O
and	O
enhance	O
glucose	O
-	O
induced	O
electrical	O
activity	O
and	O
insulin	O
secretion	O
in	O
pancreatic	O
beta	O
-	O
cell	O
perfused	O
with	O
Krebs	O
-	O
Ringer	O
bicarbonate	O
solution	O
.	O

The	O
present	O
experiments	O
were	O
aimed	O
at	O
evaluation	O
of	O
the	O
hypothesis	O
that	O
changes	O
in	O
beta	O
-	O
cells	O
ATP	O
-	O
sensitive	O
K	O
+	O
(	O
K	O
(	O
ATP	O
)	O
)	O
channel	O
activity	O
are	O
involved	O
in	O
the	O
glucagon	O
-	O
induced	O
enhancement	O
of	O
electrical	O
activity	O
.	O

Channel	O
activity	O
was	O
recorded	O
using	O
the	O
cell	O
-	O
attached	O
configuration	O
of	O
the	O
patch	O
-	O
clamp	O
technique	O
.	O

Addition	O
of	O
glucagon	O
(	O
2	O
.	O
9	O
x	O
10	O
(	O
-	O
7	O
)	O
m	O
)	O
in	O
the	O
presence	O
of	O
11	O
.	O
1	O
mm	O
glucose	O
caused	O
closure	O
of	O
K	O
(	O
ATP	O
)	O
channels	O
followed	O
by	O
an	O
increase	O
in	O
the	O
frequency	O
of	O
biphasic	O
current	O
transients	O
(	O
action	O
currents	O
)	O
due	O
to	O
action	O
potential	O
generation	O
in	O
the	O
cell	O
.	O

Three	O
calmodulin	O
-	O
antagonists	O
(	O
W	O
-	O
7	O
,	O
chlorpromazine	O
,	O
and	O
trifluoperazine	O
)	O
restored	O
with	O
similar	O
efficacy	O
K	O
(	O
ATP	O
)	O
channel	O
activity	O
in	O
cells	O
being	O
exposed	O
to	O
glucagon	O
.	O

At	O
2	O
.	O
8	O
mm	O
glucose	O
,	O
glucagon	O
did	O
not	O
affect	O
K	O
(	O
ATP	O
)	O
channel	O
activity	O
until	O
Ca2	O
+	O
was	O
released	O
from	O
Nitr	O
-	O
5	O
by	O
flash	O
photolysis	O
,	O
at	O
which	O
point	O
channel	O
activity	O
was	O
transiently	O
suppressed	O
.	O

Similar	O
effects	O
were	O
seen	O
when	O
db	O
-	O
cAMP	O
was	O
used	O
instead	O
of	O
glucagon	O
.	O

These	O
results	O
support	O
the	O
view	O
that	O
glucagon	O
and	O
other	O
cAMP	O
-	O
generating	O
agonists	O
enhance	O
glucose	O
-	O
induced	O
beta	O
-	O
cell	O
electrical	O
activity	O
through	O
a	O
Ca2	O
+	O
/	O
calmodulin	O
dependent	O
-	O
closure	O
of	O
K	O
(	O
ATP	O
)	O
channels	O
.	O

Requirement	O
of	O
estrogen	O
receptor	O
expression	O
and	O
function	O
for	O
[	O
12Val	O
]	O
K	O
-	O
Ras	O
-	O
mediated	O
NIH3T3	B
cell	O
transformation	O
.	O

We	O
investigated	O
the	O
biological	O
significance	O
of	O
estrogen	O
receptors	O
(	O
ERs	O
)	O
in	O
NIH3T3	B
cell	O
transformation	O
by	O
the	O
[	O
12Val	O
]	O
K	O
-	O
Ras	O
mutant	O
.	O

This	O
mutant	O
enhanced	O
the	O
steady	O
-	O
level	O
and	O
transcriptional	O
activity	O
of	O
ER	O
.	O

Coexpression	O
of	O
the	O
progesterone	O
receptor	O
with	O
mutant	O
K	O
-	O
Ras	O
led	O
to	O
suppression	O
of	O
tumorigenicity	O
and	O
inhibition	O
of	O
the	O
activation	O
of	O
ER	O
.	O

The	O
antisense	O
oligomers	O
complementary	O
to	O
the	O
ER	O
suppressed	O
proliferation	O
and	O
transformed	O
phenotypes	O
of	O
K12V	B
cells	O
.	O

These	O
observations	O
support	O
the	O
importance	O
of	O
ER	O
in	O
Ras	O
-	O
mediated	O
cell	O
transformation	O
.	O

Gene	O
therapy	O
for	O
gliomas	O
:	O
p53	O
and	O
E2F	O
-	O
1	O
proteins	O
and	O
the	O
target	O
of	O
apoptosis	O
.	O

Current	O
therapy	O
for	O
glioma	O
is	O
suboptimal	O
.	O

The	O
transfer	O
of	O
apoptosis	O
genes	O
to	O
tumors	O
constitutes	O
one	O
of	O
the	O
most	O
promising	O
strategies	O
for	O
cancer	O
gene	O
therapy	O
.	O

We	O
have	O
previously	O
shown	O
that	O
massive	O
apoptosis	O
occurs	O
when	O
wild	O
-	O
type	O
p53	O
or	O
E2F	O
-	O
1	O
expression	O
is	O
induced	O
in	O
glioma	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
action	O
and	O
the	O
efficiency	O
in	O
inducing	O
apoptosis	O
of	O
these	O
two	O
proteins	O
are	O
not	O
similar	O
.	O

Adenovirus	O
-	O
mediated	O
p53	O
gene	O
transfer	O
is	O
ineffective	O
in	O
causing	O
apoptosis	O
in	O
glioma	O
cells	O
that	O
retain	O
wild	O
-	O
type	O
p53	O
genotype	O
or	O
overexpress	O
the	O
p21	O
protein	O
.	O

The	O
p16	O
/	O
Rb	O
/	O
E2F	O
pathway	O
is	O
the	O
most	O
frequent	O
target	O
of	O
genetic	O
alterations	O
in	O
gliomas	O
,	O
and	O
therefore	O
constitutes	O
a	O
suitable	O
target	O
for	O
gene	O
therapy	O
strategies	O
.	O

However	O
,	O
the	O
transfer	O
of	O
either	O
the	O
p16	O
or	O
Rb	O
gene	O
to	O
glioma	O
cells	O
results	O
in	O
cytostatic	O
effect	O
.	O

The	O
E2F	O
-	O
1	O
protein	O
is	O
able	O
to	O
induce	O
generalized	O
apoptosis	O
in	O
gliomas	O
independently	O
of	O
the	O
p53	O
,	O
p16	O
or	O
Rb	O
status	O
.	O

In	O
addition	O
,	O
p21	O
-	O
or	O
p16	O
-	O
mediated	O
growth	O
arrest	O
did	O
not	O
protect	O
glioma	O
cells	O
from	O
E2F	O
-	O
1	O
-	O
mediated	O
apoptosis	O
.	O

The	O
apoptotic	O
molecule	O
bax	O
is	O
induced	O
in	O
p53	O
-	O
mediated	O
apoptosis	O
,	O
but	O
bax	O
is	O
not	O
induced	O
in	O
E2F	O
-	O
1	O
-	O
mediated	O
apoptosis	O
in	O
glioma	O
cells	O
.	O

Careful	O
selection	O
of	O
patients	O
may	O
be	O
necessary	O
before	O
designing	O
therapeutic	O
strategies	O
using	O
either	O
p53	O
or	O
E2F	O
-	O
1	O
as	O
a	O
therapeutic	O
tools	O
for	O
glioma	O
patients	O
.	O

Protective	O
function	O
of	O
von	O
Hippel	O
-	O
Lindau	O
protein	O
against	O
impaired	O
protein	O
processing	O
in	O
renal	O
carcinoma	O
cells	O
.	O

The	O
absence	O
of	O
functional	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
tumor	O
suppressor	O
gene	O
leads	O
to	O
the	O
development	O
of	O
neoplasias	O
characteristic	O
of	O
VHL	O
disease	O
,	O
including	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
.	O

Here	O
,	O
we	O
compared	O
the	O
sensitivity	O
of	O
RCC	O
cells	O
lacking	O
VHL	O
gene	O
function	O
with	O
that	O
of	O
RCC	O
cells	O
expressing	O
the	O
wild	O
-	O
type	O
VHL	O
gene	O
(	O
wtVHL	O
)	O
after	O
exposure	O
to	O
various	O
stresses	O
.	O

While	O
the	O
response	O
to	O
most	O
treatments	O
was	O
not	O
affected	O
by	O
the	O
VHL	O
gene	O
status	O
,	O
glucose	O
deprivation	O
was	O
found	O
to	O
be	O
much	O
more	O
cytotoxic	O
for	O
RCC	O
cells	O
lacking	O
VHL	O
gene	O
function	O
than	O
for	O
wtVHL	O
-	O
expressing	O
cells	O
.	O

The	O
heightened	O
sensitivity	O
of	O
VHL	O
-	O
deficient	O
cells	O
was	O
not	O
attributed	O
to	O
dissimilar	O
energy	O
requirements	O
or	O
to	O
differences	O
in	O
glucose	O
uptake	O
,	O
but	O
more	O
likely	O
reflects	O
a	O
lesser	O
ability	O
of	O
VHL	O
-	O
deficient	O
cells	O
to	O
handle	O
abnormally	O
processed	O
proteins	O
arising	O
from	O
impaired	O
glycosylation	O
.	O

In	O
support	O
of	O
this	O
hypothesis	O
,	O
other	O
treatments	O
which	O
act	O
through	O
different	O
mechanisms	O
to	O
interfere	O
with	O
protein	O
processing	O
(	O
i	O
.	O
e	O
.	O
,	O
tunicamycin	O
,	O
brefeldin	O
A	O
,	O
and	O
azetidine	O
)	O
were	O
also	O
found	O
to	O
be	O
much	O
more	O
toxic	O
for	O
VHL	O
-	O
deficient	O
cells	O
.	O

Furthermore	O
,	O
ubiquitination	O
of	O
cellular	O
proteins	O
was	O
elevated	O
in	O
VHL	O
-	O
deficient	O
cells	O
,	O
particularly	O
after	O
glucose	O
deprivation	O
,	O
supporting	O
a	O
role	O
for	O
the	O
VHL	O
gene	O
in	O
ubiquitin	O
-	O
mediated	O
proteolysis	O
.	O

Accordingly	O
,	O
the	O
rate	O
of	O
elimination	O
of	O
abnormal	O
proteins	O
was	O
lower	O
in	O
cells	O
lacking	O
a	O
functional	O
VHL	O
gene	O
than	O
in	O
wtVHL	O
-	O
expressing	O
cells	O
.	O

Thus	O
,	O
pVHL	O
appears	O
to	O
participate	O
in	O
the	O
elimination	O
of	O
misprocessed	O
proteins	O
,	O
such	O
as	O
those	O
arising	O
in	O
the	O
cell	O
due	O
to	O
the	O
unavailability	O
of	O
glucose	O
or	O
to	O
other	O
stresses	O
.	O

Effect	O
of	O
U	O
-	O
995	O
,	O
a	O
potent	O
shark	O
cartilage	O
-	O
derived	O
angiogenesis	O
inhibitor	O
,	O
on	O
anti	O
-	O
angiogenesis	O
and	O
anti	O
-	O
tumor	O
activities	O
.	O

BACKGROUND	O
:	O
A	O
potent	O
angiogenesis	O
inhibitor	O
,	O
U	O
-	O
995	O
,	O
has	O
been	O
purified	O
from	O
the	O
cartilage	O
of	O
the	O
blue	O
shark	O
(	O
Prionace	O
glauca	O
)	O
.	O

U	O
-	O
995	O
is	O
composed	O
of	O
two	O
single	O
peptides	O
with	O
molecular	O
mass	O
of	O
10	O
and	O
14	O
kDa	O
,	O
respectively	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
U	O
-	O
995	O
was	O
designed	O
to	O
study	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
(	O
HUVEC	O
)	O
migration	O
and	O
proliferation	O
in	O
vitro	O
and	O
angiogenesis	O
induced	O
by	O
TNF	O
alpha	O
in	O
chicken	O
chorioallantoic	O
membrane	O
(	O
CAM	O
)	O
.	O

Furthermore	O
,	O
we	O
determined	O
the	O
ability	O
of	O
U	O
-	O
995	O
to	O
inhibiting	O
tumor	O
cell	O
growth	O
and	O
metastasis	O
.	O

RESULTS	O
:	O
U	O
-	O
995	O
(	O
15	O
and	O
30	O
micrograms	O
/	O
ml	O
)	O
markedly	O
inhibited	O
HUVEC	O
migration	O
and	O
,	O
at	O
15	O
-	O
50	O
micrograms	O
/	O
ml	O
produced	O
a	O
dose	O
-	O
dependent	O
decline	O
in	O
[	O
3H	O
]	O
-	O
thymidine	O
incorporation	O
.	O

30	O
and	O
50	O
micrograms	O
/	O
ml	O
of	O
U	O
-	O
995	O
,	O
when	O
added	O
to	O
TNF	O
alpha	O
-	O
induced	O
angiogenesis	O
caused	O
discontinuous	O
and	O
disrupted	O
blood	O
vessels	O
.	O

Moreover	O
,	O
U	O
-	O
995	O
(	O
30	O
micrograms	O
/	O
ml	O
)	O
markedly	O
prevented	O
collagenase	O
-	O
induced	O
collagenolysis	O
.	O

In	O
addition	O
,	O
when	O
200	O
micrograms	O
U	O
-	O
995	O
was	O
injected	O
i	O
.	O
p	O
.	O
into	O
mice	O
it	O
suppressed	O
sarcoma	B
-	I
180	I
cell	O
growth	O
and	O
B16	B
-	I
F10	I
mouse	O
melanoma	O
cell	O
metastasis	O
in	O
vivo	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
the	O
anti	O
-	O
angiogenic	O
effects	O
of	O
U	O
-	O
995	O
may	O
be	O
be	O
due	O
to	O
interference	O
with	O
the	O
proliferation	O
and	O
migration	O
of	O
HUVECs	O
as	O
well	O
as	O
inhibition	O
of	O
collagenolysis	O
,	O
thereby	O
leading	O
to	O
inhibition	O
of	O
both	O
angiogenesis	O
and	O
tumor	O
cell	O
growth	O
.	O

Potential	O
roles	O
for	O
focal	O
adhesion	O
kinase	O
in	O
development	O
.	O

Focal	O
adhesion	O
kinase	O
(	O
pp125FAK	O
or	O
FAK	O
)	O
is	O
a	O
protein	O
tyrosine	O
kinase	O
which	O
is	O
associated	O
with	O
intracellular	O
signalling	O
cascades	O
which	O
are	O
initiated	O
when	O
the	O
integrin	O
family	O
of	O
cell	O
adhesion	O
molecules	O
engage	O
extracellular	O
matrix	O
molecules	O
.	O

In	O
cultured	O
cells	O
,	O
this	O
molecule	O
is	O
physically	O
associated	O
with	O
focal	O
adhesions	O
,	O
which	O
are	O
well	O
-	O
defined	O
regions	O
of	O
intimate	O
cell	O
-	O
to	O
-	O
substratum	O
adhesion	O
.	O

In	O
this	O
location	O
,	O
it	O
interacts	O
with	O
other	O
proteins	O
of	O
the	O
focal	O
adhesion	O
to	O
activate	O
intracellular	O
signalling	O
events	O
associated	O
with	O
cell	O
adhesion	O
.	O

The	O
in	O
vitro	O
expression	O
of	O
FAK	O
and	O
its	O
level	O
of	O
phosphorylation	O
appear	O
to	O
be	O
related	O
to	O
several	O
physiological	O
phenomena	O
,	O
including	O
cell	O
spreading	O
,	O
cell	O
differentiation	O
,	O
cell	O
locomotion	O
and	O
cell	O
death	O
.	O

Because	O
these	O
phenomena	O
are	O
all	O
of	O
critical	O
importance	O
during	O
morphogenesis	O
,	O
and	O
because	O
FAK	O
is	O
expressed	O
in	O
embryonic	O
cells	O
,	O
evidence	O
has	O
been	O
accumulating	O
to	O
indicate	O
that	O
FAK	O
may	O
be	O
an	O
important	O
modulator	O
of	O
developmental	O
processes	O
.	O

In	O
this	O
review	O
,	O
this	O
evidence	O
is	O
surveyed	O
together	O
with	O
evidence	O
from	O
analogous	O
situations	O
,	O
such	O
as	O
tumour	O
cell	O
migration	O
and	O
invasiveness	O
.	O

Although	O
evidence	O
suggesting	O
a	O
role	O
for	O
FAK	O
in	O
morphogenesis	O
is	O
accumulating	O
,	O
current	O
uncertainties	O
regarding	O
its	O
cytoplasmic	O
location	O
and	O
its	O
molecular	O
interactions	O
in	O
vivo	O
make	O
it	O
difficult	O
to	O
reach	O
definitive	O
conclusions	O
regarding	O
the	O
significance	O
of	O
its	O
contributions	O
to	O
developmental	O
processes	O
.	O

Selective	O
inhibition	O
of	O
the	O
renal	O
dopamine	O
subtype	O
D1A	O
receptor	O
induces	O
antinatriuresis	O
in	O
conscious	O
rats	O
.	O

Both	O
dopamine	O
D1	O
-	O
like	O
(	O
D1A	O
and	O
D1B	O
)	O
and	O
D2	O
-	O
like	O
(	O
D2	O
,	O
D3	O
,	O
and	O
D4	O
)	O
receptor	O
subfamilies	O
are	O
present	O
in	O
the	O
kidney	O
.	O

Blockade	O
of	O
the	O
intrarenal	O
D1	O
-	O
like	O
receptor	O
family	O
is	O
associated	O
with	O
natriuresis	O
and	O
diuresis	O
.	O

Because	O
the	O
D1A	O
and	O
D1B	O
receptor	O
subtypes	O
are	O
not	O
distinguishable	O
by	O
currently	O
available	O
dopaminergic	O
agents	O
,	O
their	O
functional	O
role	O
remains	O
undefined	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
selective	O
inhibition	O
of	O
the	O
renal	O
D1A	O
receptor	O
with	O
phosphorothioated	O
antisense	O
oligodeoxynucleotide	O
(	O
AS	O
-	O
ODN	O
)	O
was	O
investigated	O
in	O
conscious	O
uninephrectomized	O
rats	O
.	O

After	O
renal	O
interstitial	O
administration	O
of	O
Texas	O
red	O
-	O
labeled	O
D1A	O
receptor	O
AS	O
-	O
ODN	O
,	O
intense	O
fluorescent	O
signal	O
was	O
localized	O
in	O
the	O
renal	O
tubular	O
epithelium	O
and	O
vasculature	O
.	O

In	O
rats	O
on	O
normal	O
salt	O
intake	O
,	O
AS	O
-	O
ODN	O
injected	O
interstitially	O
into	O
the	O
kidney	O
reduced	O
daily	O
urinary	O
sodium	O
excretion	O
(	O
1	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
04	O
versus	O
0	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
2	O
mEq	O
/	O
d	O
,	O
n	O
=	O
5	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
urine	O
output	O
(	O
16	O
.	O
9	O
+	O
/	O
-	O
3	O
.	O
8	O
versus	O
12	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
6	O
mL	O
/	O
d	O
,	O
n	O
=	O
5	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
rats	O
on	O
high	O
sodium	O
intake	O
,	O
continuous	O
renal	O
interstitial	O
administration	O
of	O
D1A	O
receptor	O
AS	O
-	O
ODN	O
transiently	O
decreased	O
daily	O
urinary	O
sodium	O
excretion	O
(	O
5	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
5	O
versus	O
4	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
3	O
mEq	O
/	O
d	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
urine	O
output	O
(	O
27	O
.	O
6	O
+	O
/	O
-	O
4	O
.	O
5	O
versus	O
18	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
8	O
mL	O
/	O
d	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Neither	O
vehicle	O
nor	O
sense	O
oligodeoxynucleotide	O
had	O
significant	O
effects	O
.	O

Systolic	O
blood	O
pressure	O
remained	O
unchanged	O
.	O

The	O
renal	O
D1A	O
receptor	O
protein	O
was	O
significantly	O
decreased	O
by	O
35	O
%	O
and	O
46	O
%	O
at	O
the	O
end	O
of	O
the	O
study	O
in	O
AS	O
-	O
ODN	O
-	O
treated	O
rats	O
on	O
normal	O
and	O
high	O
salt	O
intake	O
,	O
respectively	O
,	O
whereas	O
the	O
D1B	O
receptor	O
and	O
beta	O
-	O
actin	O
were	O
not	O
affected	O
.	O

These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
the	O
renal	O
D1A	O
receptor	O
subtype	O
plays	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
sodium	O
excretion	O
.	O

